NCT03243760|ClinicalTrials.gov processed this data on October 10, 2017|2017-07-31|2017-08-04|||February 10, 2016|Actual|2016-02-10|August 2017|2017-08-01|August 20, 2016|Actual|2016-08-20|July 20, 2016|Actual|2016-07-20||Interventional|||Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients|A Double-blind (Sponsor Unblind), Randomized, Placebo-controlled, Single and Repeat Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CCI15106 Capsules for Inhalation in Healthy Subjects and Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD)|Terminated||Phase 1|60|Actual|GlaxoSmithKline||11||"The trial is terminated before investigation of repeat escalating doses as these will be   conducted with the new formulation instead."|f||||f||||||||||2017-10-10 20:48:40.295805|2017-10-10 20:48:40.295805
NCT03180762|ClinicalTrials.gov processed this data on October 10, 2017|2017-05-30|2017-09-22|||May 30, 2017|Actual|2017-05-30|September 2017|2017-09-01|November 13, 2017|Anticipated|2017-11-13|November 13, 2017|Anticipated|2017-11-13||Interventional|||A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants|A 3-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Subjects|Suspended||Phase 1|70|Anticipated|Janssen Research & Development, LLC||8||"Trial on hold: A SAE has occured. As a measure of precaution, the dosing of JNJ-64140284 has   been suspended for all subjects participating in the trial."|f||||f|f|f||||||||2017-10-10 20:58:02.588568|2017-10-10 20:58:02.588568
NCT03153618|ClinicalTrials.gov processed this data on October 10, 2017|2017-05-11|2017-09-12|||September 1, 2017|Anticipated|2017-09-01|September 2017|2017-09-01|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|VALIDATE||VALIDATE: Virtual Agent Linked Intelligent Disease Assessment Tool Engine|VALIDATE: Virtual Agent Linked Intelligent Disease Assessment Tool Engine|Withdrawn||N/A|0|Actual|Stanford University||2||Funding and proposal withdrawn|f||||f|f|f||||||||2017-10-10 21:04:03.843522|2017-10-10 21:04:03.843522
NCT03117621|ClinicalTrials.gov processed this data on October 10, 2017|2017-03-06|2017-06-09|||March 22, 2017|Actual|2017-03-22|June 2017|2017-06-01|February 22, 2022|Anticipated|2022-02-22|February 22, 2022|Anticipated|2022-02-22||Observational|||Observational Study of Blinatumomab|An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices|Recruiting||N/A|350|Anticipated|Amgen|||1||f||||f||f||||||Yes|Protocol, study status, and report(s) to be included in regulatory communications in line with the risk management plan, PSURs, and other regulatory requirements. Interim reports provided as part of PSURs, will include descriptive analyses and results for the primary and secondary objectives. Safety concerns identified during interim analyses will be immediately communicated to regulatory authorities in accordance with GVP. Final study report will be completed within a year of the end of data collection, and will be prepared whether the study is completed or prematurely terminated. Final study report will be submitted to the EMA and to the respective Competent Authorities as applicable. The summary of the final results will be provided to all participating HCPs. Any manuscript and/or abstract for scientific presentation(s) will be developed and submitted in accordance in with the 2012 Guideline on Good Pharmacovigilance Practice (GVP): Module VIII - Post-Authorisation Safety Studies|2017-10-10 21:09:51.374597|2017-10-10 21:09:51.374597
NCT03080428|ClinicalTrials.gov processed this data on October 10, 2017|2017-03-09|2017-08-25|||May 2017|Anticipated|2017-05-01|August 2017|2017-08-01|May 2023|Anticipated|2023-05-01|June 2018|Anticipated|2018-06-01||Interventional|OPTIGEN||Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer|Prospective Multicenter Randomized Study Assessing Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer With Uncertainty on the Indication of Chemotherapy Using Standard Assessments.|Withdrawn||N/A|0|Actual|UNICANCER||4||The study has been withdrawn because of lack of funding|f||||f|f|f||||||||2017-10-10 21:15:57.95489|2017-10-10 21:15:57.95489
NCT03072901|ClinicalTrials.gov processed this data on October 10, 2017|2017-01-19|2017-03-02|||December 2010||2010-12-01|March 2017|2017-03-01|February 2016|Actual|2016-02-01|December 2015|Actual|2015-12-01|12 Months|Observational [Patient Registry]|||Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity|Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity|Terminated||N/A|244|Actual|GI Dynamics|||1|GID terminated the Registry due to evolving registry requirements|f||||f|f|t|f|f|t|||No||2017-10-10 21:17:12.052143|2017-10-10 21:17:12.052143
NCT03070730|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-27|2017-04-13|2017-04-12||August 15, 2011|Actual|2011-08-15|April 2017|2017-04-01|July 28, 2014|Actual|2014-07-28|December 18, 2012|Actual|2012-12-18||Interventional||Participants that were enrolled in the study were not randomized. They did not meet eligibility criteria, or decided not to participate.|Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist|A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist|Terminated||Phase 1/Phase 2|8|Actual|Beth Israel Deaconess Medical Center|The trial was terminated early due to difficulties in the recruitment process. Subjects were found to be ineligible, or decided not to participate in the study.|3||Recruitment was slow and subjects declined participation after signing the ICF.|f||||f||||||||Yes|NIH Grant Policy on Sharing of Unique Research Resources including the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources.|2017-10-10 21:17:35.733685|2017-10-10 21:17:35.733685
NCT03065933|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-06|2017-03-15|2017-03-15||January 2012||2012-01-01|March 2017|2017-03-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional||No data besides region of enrollment was collected on these participants before the study terminated.|An Extended-Release Form of Clonidine as an Anti-Manic Agent: An Add-on, Open-Label Study|An Extended-Release Form of Clonidine as an Anti-Manic Agent: An Add-On, Open-Label Study|Terminated||Phase 4|5|Actual|Mclean Hospital||1|||f||||t|t|f|||f|||Yes|IPD to be shared via clinicaltrials.gov, publication, or personal request.|2017-10-10 21:18:25.344774|2017-10-10 21:18:25.344774
NCT03056742|ClinicalTrials.gov processed this data on October 10, 2017|2017-01-23|2017-04-05|||February 20, 2017|Anticipated|2017-02-20|April 2017|2017-04-01|October 2019|Anticipated|2019-10-01|April 2018|Anticipated|2018-04-01||Interventional|||A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease|A Single Arm, Open Label, Multicentric, Clinical Study Assessing the Efficacy and Safety of Stempeucel® (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With CLI Due to Buerger's Disease|Withdrawn||Phase 2|0|Actual|Stempeutics Research Pvt Ltd||1||"Form 46 from DCGI for the manufacturing & commercial marketing of Stempeucel® directs   Stempeutics to conduct PMS study. Hence this study is being terminated."|f||||t|f|f||||||No||2017-10-10 21:19:56.572367|2017-10-10 21:19:56.572367
NCT03028909|ClinicalTrials.gov processed this data on October 10, 2017|2016-12-06|2017-04-05|||July 24, 2017|Anticipated|2017-07-24|April 2017|2017-04-01|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Interventional|||Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.|A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Influenza Caused by Type A Strains|Withdrawn||Phase 2|0|Actual|MedImmune LLC||3||Study is withdrawn due to company decision.|f||||f||||||||||2017-10-10 21:26:10.234485|2017-10-10 21:26:10.234485
NCT03026803|ClinicalTrials.gov processed this data on October 10, 2017|2017-01-17|2017-03-16|2017-01-19||November 2006||2006-11-01|March 2017|2017-03-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional|||A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer|A Phase II Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer|Terminated||Phase 2|4|Actual|City of Hope Medical Center|Due to Sorafenib becoming a first line treatment for HCC, the designed treatment became less competitive. The company Sanofi decided not to continue support. Study was terminated after accrual of 4 of the 32 planned patients.|1||"Due to Sorafenib became first line treatment for HCC, the designed treatment became less   competitive. The company Sanofi decided not to continue to support"|f||||t||||||||||2017-10-10 21:26:28.454019|2017-10-10 21:26:28.454019
NCT03024177|ClinicalTrials.gov processed this data on October 10, 2017|2017-01-12|2017-04-21||||||April 2017|2017-04-01||||April 2017|Actual|2017-04-01||Interventional|||A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection|Withdrawn||Phase 2|0|Actual|Aviragen Therapeutics||2||Study is withdrawn due to company decision|f||||t||||||||||2017-10-10 21:26:52.822376|2017-10-10 21:26:52.822376
NCT03015519|ClinicalTrials.gov processed this data on October 10, 2017|2016-12-14|2017-09-13|||August 14, 2017|Anticipated|2017-08-14|September 2017|2017-09-01|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|||A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus|A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||6||The study was stopped as the asset will be withdrawn from the market prior to study end.|f||||t|t|f||||||||2017-10-10 21:28:17.883072|2017-10-10 21:28:17.883072
NCT03002454|ClinicalTrials.gov processed this data on October 10, 2017|2016-12-12|2017-05-03|2017-01-13||August 2016||2016-08-01|May 2017|2017-05-01|January 2017|Actual|2017-01-01|November 2016|Actual|2016-11-01||Interventional|||Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo|A Cross-over Comparison of the Diagnostic Accuracy of Technetium (99mTc) Medronate Injection Prepared With 99mTc Derived From Neutron-activation Produced 99Mo Versus the Current Reference Standard of 99mTc Derived From Fission-produced 99Mo|Terminated||Phase 3|4|Actual|University of Manitoba|Early termination. Despite a relatively comprehensive review of the first four subject's bone imaging scans a cause of an observed altered biodistribution is not apparent. As such study recruitment will be terminated.|1||Altered biodistribution in investigational images versus standard images.|f||||f||||||||No||2017-10-10 21:30:19.281187|2017-10-10 21:30:19.281187
NCT02965768|ClinicalTrials.gov processed this data on October 10, 2017|2016-11-14|2017-03-20|||January 2016||2016-01-01|March 2017|2017-03-01|August 2019|Anticipated|2019-08-01|August 2018|Anticipated|2018-08-01||Interventional|||Immune Effects of Low-dose Naltrexone in ME/CFS|The Immune Effects of Low-dose Naltrexone in People With Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS)|Suspended||N/A|30|Anticipated|University of Alabama at Birmingham||2||"Temporarily suspended to focus on other projects. At suspension, no participants were   determined eligible and none started the protocol."|f||||f||||||||No||2017-10-10 21:36:18.301986|2017-10-10 21:36:18.301986
NCT02925884|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-17|2016-10-04|||June 2013||2013-06-01|October 2016|2016-10-01|September 2013|Actual|2013-09-01|September 2013|Actual|2013-09-01||Interventional|||Effects of Gunnar Computer Glasses on Viewing Comfort and Performance|The Effect of Computer Eyewear on Viewing Comfort and Performance in Office Work|Terminated||N/A|34|Actual|Pacific University||2||The sponsor failed to provide financial support as promised.|f||||f||||||||No|All 34 subjects were recruited but data collection was early terminated. Data entry was not completed.|2017-10-10 21:43:01.604792|2017-10-10 21:43:01.604792
NCT02902744|ClinicalTrials.gov processed this data on October 10, 2017|2016-09-12|2017-08-21|||March 1, 2017|Actual|2017-03-01|August 2017|2017-08-01|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|FAD||Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study|Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||1||"The study was withdrawn due to difficult recruitment of patients for the study; No participants   were enrolled in the study."|f||||f|t|f|||f|||||2017-10-10 21:48:38.569985|2017-10-10 21:48:38.569985
NCT02894515|ClinicalTrials.gov processed this data on October 10, 2017|2016-09-05|2016-11-10|||September 2016||2016-09-01|November 2016|2016-11-01|September 2016|Actual|2016-09-01|September 2016|Actual|2016-09-01||Interventional|||Bioequivalence Study of Idalopirdine in Healthy Subjects|Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 10 mg Commercial Tablet (Test) to the 10 mg Clinical Tablet (Reference)|Withdrawn||Phase 1|0|Actual|H. Lundbeck A/S||2||The study was withdrawn based on new efficacy data from another study|f||||f||||||||||2017-10-10 21:49:54.707138|2017-10-10 21:49:54.707138
NCT02891941|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-19|2016-09-01|||June 2013||2013-06-01|September 2016|2016-09-01|June 2014|Actual|2014-06-01|January 2014|Actual|2014-01-01|6 Months|Observational [Patient Registry]|||Neuroimaging & Plasma Markers for Predicting Outcomes After Mild Traumatic Brain Injury|Neuroimaging & Plasma Markers for Predicting Outcomes After Mild Traumatic Brain Injury|Terminated||N/A|10|Actual|Johns Hopkins University|||1|Funding withdrawn|f||||t||||||Samples With DNA|"     whole blood, plasma   "|||2017-10-10 21:50:21.972285|2017-10-10 21:50:21.972285
NCT02876003|ClinicalTrials.gov processed this data on October 10, 2017|2016-08-18|2017-02-22|||September 2016||2016-09-01|February 2017|2017-02-01|October 2020|Anticipated|2020-10-01|October 2019|Anticipated|2019-10-01||Interventional|||Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma|An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With PSMA Positive Recurrent or Progressive Glioblastoma|Withdrawn||Phase 2|0|Actual|GenSpera, Inc.||1||This study has been withdrawn prior to enrollment.|f||||f||||||||No||2017-10-10 21:53:01.71828|2017-10-10 21:53:01.71828
NCT02869425|ClinicalTrials.gov processed this data on October 10, 2017|2016-08-03|2017-04-28|||July 2016||2016-07-01|April 2017|2017-04-01|January 2019|Anticipated|2019-01-01|October 2018|Anticipated|2018-10-01||Interventional|||To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS|A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis|Suspended||Phase 3|120|Anticipated|Osmotica Pharmaceutical US LLC||2||suspended due to inability to enroll subjects|f||||f||||||||No||2017-10-10 21:54:03.629698|2017-10-10 21:54:03.629698
NCT02855411|ClinicalTrials.gov processed this data on October 10, 2017|2016-07-27|2017-09-05|2017-07-28||August 2016|Actual|2016-08-01|September 2017|2017-09-01|September 26, 2016|Actual|2016-09-26|September 23, 2016|Actual|2016-09-23||Interventional||A total of 35 participants were screened. Study was terminated before any participants were treated.|A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)|A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)|Terminated||Phase 2|35|Actual|Pfizer|This study was terminated due to Pfizer portfolio prioritization. No participants had been randomized to receive study drug or placebo. There is no safety or efficacy data to report for this study.|3||"Terminated prematurely Sept 22, 2016 following an internal portfolio prioritization. It is not   due to any safety concern or change in benefit:risk assessment."|f||||t||||||||||2017-10-10 21:56:15.717479|2017-10-10 21:56:15.717479
NCT02845349|ClinicalTrials.gov processed this data on October 10, 2017|2016-07-18|2016-09-01|||October 2016||2016-10-01|September 2016|2016-09-01|October 2018|Anticipated|2018-10-01|October 2018|Anticipated|2018-10-01||Interventional|||Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)|Vortioxetine for the Treatment of Major Depression and Neuropsychiatric Co-morbidities After Traumatic Brain Injury (TBI)|Withdrawn||Phase 3|0|Actual|Johns Hopkins University||2||Funding withdrawn.|f||||t||||||||No|"Prior to the initiation of the study, a method will be developed for data collection. Each participant will have a study folder with a unique identifying number to contain the results of study tests and evaluations. Another folder will also be kept that will hold all consent forms and identifying demographic information. The folders will be reviewed monthly for inconsistencies. The data will be entered into a database maintained in the Neuropsychiatry Division of Johns Hopkins Bayview Medical Center, which is password protected and only the PI and her Research team will have access to the study folders and database.
NCT02835599|ClinicalTrials.gov processed this data on October 10, 2017|2016-07-08|2017-08-17|||November 1, 2016|Actual|2016-11-01|August 2017|2017-08-01|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06|5 Years|Observational [Patient Registry]|REVOLUTION||Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now|Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now|Terminated||N/A|23|Actual|AstraZeneca|||1|"The study sponsor requested the study be terminated as the existing study design did not meet   their needs."|f||||f||||||Samples With DNA|"     Archived residual specimens will be requested from appropriate institution for each patient     at consent. One block or 20 slides (if block is not available) will be requested for each     patient for molecular testing and sent as directed by the Lab Manual. Specimens will be     banked at the Carolinas HealthCare Biospecimen Repository (CHS BSR) specifically for this     protocol in their Clinical Trials Management System Biospecimen Module (CTMS BSM).   "|||2017-10-10 21:59:24.45672|2017-10-10 21:59:24.45672
NCT02835417|ClinicalTrials.gov processed this data on October 10, 2017|2016-07-13|2017-03-20|||January 2012||2012-01-01|March 2017|2017-03-01|December 2017|Anticipated|2017-12-01|December 2017|Anticipated|2017-12-01||Observational|FETUSES||Fetal Evaluation at Term Using Statistical ECG Signal Processing (FETUSES)|Fetal Evaluation at Term Using Statistical ECG Signal Processing (FETUSES)|Suspended||N/A|4500|Anticipated|Hospices Civils de Lyon|||1|"The recruitement is suspended because of problems wtih the society responsible of the data   base."|f||||f||||||||||2017-10-10 21:59:26.005441|2017-10-10 21:59:26.005441
NCT02823470|ClinicalTrials.gov processed this data on October 10, 2017|2016-07-01|2017-09-06|||June 2016||2016-06-01|September 2017|2017-09-01|August 2017|Actual|2017-08-01|August 2017|Actual|2017-08-01||Interventional|||A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation|A Phase 4, Open-label Treatment, Randomized, Multicenter, 2-arm, Parallel-group, Pilot Study of Adherence to Lumacaftor/Ivacaftor in CF Subjects Homozygous for the F508del CFTR Mutation|Terminated||Phase 4|24|Actual|Vertex Pharmaceuticals Incorporated||2||Study terminated early due to slow recruitment of patients.|f||||f||||||||||2017-10-10 22:01:25.66407|2017-10-10 22:01:25.66407
NCT02803476|ClinicalTrials.gov processed this data on October 10, 2017|2016-06-10|2016-06-16|||March 2016||2016-03-01|June 2016|2016-06-01|August 2016|Anticipated|2016-08-01|July 2016|Anticipated|2016-07-01||Observational|||Is There Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome?|Is There An Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome?|Recruiting||N/A|166|Anticipated|Ain Shams Maternity Hospital|||2||f||||t||||||Samples Without DNA|"     Overnight fasting venous blood samples will be withdrawn between the 2nd and 3rd day of     menstruation, and withdrawal bleeding following progesterone therapy for 5 days in amenorheic     women, centrifuged and frozen to -80 C until analyzed for the assessment of vitamin D levels,     Androgen levels, plasma Glucose and plasma Insulin, FSH and LH analogues.   "|Yes||2017-10-10 22:04:54.262308|2017-10-10 22:04:54.262308
NCT02802592|ClinicalTrials.gov processed this data on October 10, 2017|2016-06-03|2017-08-17|2017-08-17||May 2015||2015-05-01|August 2017|2017-08-01|February 27, 2017|Actual|2017-02-27|June 15, 2016|Actual|2016-06-15||Interventional|EPORT|This study was terminated due to loss of funding and those participants enrolled were not un-blinded to the study team members.|EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)|EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)|Terminated||Phase 1/Phase 2|4|Actual|Johns Hopkins University||2||Loss of funding|f||||f||||||||||2017-10-10 22:05:02.283264|2017-10-10 22:05:02.283264
NCT02797470|ClinicalTrials.gov processed this data on October 10, 2017|2016-06-08|2017-07-14|||May 2016||2016-05-01|December 2016|2016-12-01||||September 2019|Anticipated|2019-09-01||Interventional|||Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant|Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells|Suspended||Phase 1/Phase 2|18|Anticipated|AIDS Malignancy Consortium||1||Temporarily suspended due to manufacturing issues|f||||t||||||||||2017-10-10 22:05:56.555454|2017-10-10 22:05:56.555454
NCT02794519|ClinicalTrials.gov processed this data on October 10, 2017|2016-06-06|2017-10-02|||September 23, 2016|Actual|2016-09-23|October 2017|2017-10-01|August 13, 2018|Anticipated|2018-08-13|August 13, 2018|Anticipated|2018-08-13||Interventional|||A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma|205076: A Phase II, Multicenter, Randomized, Double-blind (Sponsor-unblind), Placebo- Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Severe, Poorly Controlled Asthma|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||This study has suspended participant recruitment.|f||||f||||||||||2017-10-10 22:06:27.320261|2017-10-10 22:06:27.320261
NCT02791555|ClinicalTrials.gov processed this data on October 10, 2017|2016-06-01|2017-04-10|||June 2016||2016-06-01|April 2017|2017-04-01|March 2017|Actual|2017-03-01|March 2017|Actual|2017-03-01||Observational|||Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers|Comparison of the Effects of the Direct Thrombin Inhibitor, Pradaxa, to That of Warfarin on Bone Mass and Bone Turnover Markers|Terminated||N/A|2|Actual|UConn Health|||2|Study was terminated early due to low enrollment numbers.|f||||f||||||Samples Without DNA|"     samples w/o DNA   "|Undecided||2017-10-10 22:07:02.254647|2017-10-10 22:07:02.254647
NCT02787421|ClinicalTrials.gov processed this data on October 10, 2017|2016-05-20|2017-06-13|||April 2016||2016-04-01|June 2017|2017-06-01|May 2017|Anticipated|2017-05-01|May 2017|Anticipated|2017-05-01||Interventional|||Nasal Dilator Strips for Rhinoplasty|Predictive Value of Nasal Dilator Strips for Evaluating Nasal Valve Obstruction as Measured by Post-Operative Rhinoplasty Outcomes|Withdrawn||N/A|0|Actual|Emory University||1||Study withdrawn - changing study design.|f||||f||||||||||2017-10-10 22:07:47.992231|2017-10-10 22:07:47.992231
NCT02758067|ClinicalTrials.gov processed this data on October 10, 2017|2016-04-29|2016-07-29|||June 2016||2016-06-01|July 2016|2016-07-01||||June 2016|Actual|2016-06-01||Interventional|TAILWIND||Comparison of the Effectiveness of Brexpiprazole With That of Risperidone|Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study to Compare the Effectiveness of Brexpiprazole to That of Risperidone in Adult Patients With Schizophrenia|Withdrawn||Phase 3|0|Actual|H. Lundbeck A/S||2||This study was withdrawn for administrative reasons. There were no safety concerns.|f||||f||||||||||2017-10-10 22:14:54.67131|2017-10-10 22:14:54.67131
NCT02752373|ClinicalTrials.gov processed this data on October 10, 2017|2016-03-28|2017-03-16|||May 2016||2016-05-01|March 2017|2017-03-01|February 2017|Actual|2017-02-01|January 2017|Actual|2017-01-01||Observational|||A Health Economic Study Evaluating the Brain Sentinel® GTC Seizure Detection and Information Systems Impact on Epilepsy and Healthcare Utilization|A Health Economic Study Evaluating the Brain Sentinel® GTC Seizure Detection and Information Systems Impact on Epilepsy and Healthcare Utilization|Terminated||N/A|5|Actual|Brain Sentinel|||1|This study was terminated due to low enrollment|f||||f||||||||No||2017-10-10 22:15:56.28254|2017-10-10 22:15:56.28254
NCT02739594|ClinicalTrials.gov processed this data on October 10, 2017|2016-04-12|2016-06-09|2016-06-09||February 2006||2006-02-01|June 2016|2016-06-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|COMPARE|Intent-to-Treat (ITT) Population: All participants who were randomized and received at least one dose of study medication and for whom at least one measurement of creatinine clearance (CrCl) was obtained.|Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma|COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma|Terminated||Phase 3|89|Actual|Hoffmann-La Roche|The Study was terminated as a result of slow recruitment. At the time of the decision to halt recruitment, the treatment duration was shortened to 40 weeks (instead of 92 weeks) for those participants who had not yet reached Week 48.|2||Slow recruitment|f||||||||||||||2017-10-10 22:18:17.699786|2017-10-10 22:18:17.699786
NCT02712437|ClinicalTrials.gov processed this data on October 10, 2017|2016-03-15|2017-09-05|||March 16, 2016|Actual|2016-03-16|September 2017|2017-09-01|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer|Prospective Study Evaluating the Use of PROSPECT, a Cognitive Behavioral Therapy-based Internet Module, to Reduce Insomnia in Patients With Early Stage Breast Cancer|Terminated||N/A|4|Actual|University of Michigan Cancer Center||1||The study was terminated because of low accrual.|f||||t||||||||||2017-10-10 22:23:04.785254|2017-10-10 22:23:04.785254
NCT02711462|ClinicalTrials.gov processed this data on October 10, 2017|2016-01-08|2016-11-04|||February 2016||2016-02-01|November 2016|2016-11-01|August 2016|Actual|2016-08-01|August 2016|Actual|2016-08-01||Interventional|||Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234|A Phase 1, Double Blind, Third-Party Open, Randomized, Placebo Controlled, Single And Multiple Dose, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-06687234 In Healthy Subjects|Terminated||Phase 1|10|Actual|Pfizer||11||"The study was prematurely terminated on 06 October 2016 due to the potential risk of further   dosing in healthy subjects"|f||||f||||||||||2017-10-10 22:23:16.273983|2017-10-10 22:23:16.273983
NCT02710929|ClinicalTrials.gov processed this data on October 10, 2017|2016-03-13|2016-10-17|||August 2015||2015-08-01|October 2016|2016-10-01|July 2018|Anticipated|2018-07-01|July 2018|Anticipated|2018-07-01||Observational|||A Genome-wide Association Study on the Endophenotype of Spatial Working Memory in ADHD|A Genome-wide Association Study on the Endophenotype of Spatial Working Memory in Attention Deficit Hyperactivity Disorder|Recruiting||N/A|232|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"     15 ml blood will be withdrawn from the subjects (one heparin-rinsed tube for cell culture,     one EDTA rinsed tube for DNA extraction)   "|No||2017-10-10 22:23:20.790431|2017-10-10 22:23:20.790431
NCT02699385|ClinicalTrials.gov processed this data on October 10, 2017|2016-02-15|2017-09-06|||December 7, 2015|Actual|2015-12-07|August 2017|2017-08-01|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects With Nausea and Vomiting Due to Acute Gastroenteritis|Terminated||Phase 3|292|Actual|Janssen-Cilag International NV||2||Study prematurely terminated upon recommendation of IDMC due to lack of efficacy.|f||||t|f|f||||||||2017-10-10 22:25:23.171679|2017-10-10 22:25:23.171679
NCT02698384|ClinicalTrials.gov processed this data on October 10, 2017|2016-02-26|2016-09-30|||January 2016||2016-01-01|September 2016|2016-09-01|June 2016|Actual|2016-06-01|January 2016|Actual|2016-01-01||Observational|ACRO-OPTIM||Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg|Optimisation of Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg|Terminated||N/A|4|Actual|Ipsen|||1|The study was terminated early due to insufficient potential for recruitment.|f||||f||||||||||2017-10-10 22:25:33.190578|2017-10-10 22:25:33.190578
NCT02678520|ClinicalTrials.gov processed this data on October 10, 2017|2016-01-06|2016-07-20|||December 2015||2015-12-01|July 2016|2016-07-01|February 2016|Actual|2016-02-01|February 2016|Actual|2016-02-01||Interventional|||Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients|Phase II Randomized Clinical Trial Comparing 3-D Conformal Radiation Therapy (RT) vs. Intensity Modulated Radiation Therapy in Post- Prostatectomy Prostate Cancer Patients|Withdrawn||Phase 2|0|Actual|University of Kansas Medical Center||2||PI no longer at institution. Study terminated prior to enrolling subjects.|f||||t||||||||Undecided||2017-10-10 22:29:02.39956|2017-10-10 22:29:02.39956
NCT02671331|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-29|2016-07-05|||January 2016||2016-01-01|July 2016|2016-07-01|July 2016|Actual|2016-07-01|May 2016|Actual|2016-05-01||Observational|||Loop Duodenal Switch Surgery in Morbidly Obese Patients|The Effect of Loop Duodenal Switch Surgery in Morbidly Obese Patients on Weight Loss at One Year|Terminated||N/A|1|Actual|Medical College of Wisconsin|||1|Principal investigator terminated study due to low enrollment.|f||||f||||||||No||2017-10-10 22:30:17.702071|2017-10-10 22:30:17.702071
NCT02667223|ClinicalTrials.gov processed this data on October 10, 2017|2016-01-06|2016-10-19|||February 2016||2016-02-01|October 2016|2016-10-01|July 2016|Actual|2016-07-01|July 2016|Actual|2016-07-01||Interventional|||Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase|A Phase 1, Open Label, Randomized, Single Dose, Dose Escalation Study To Assess The Subcutaneous Pharmacokinetics And Pharmacodynamics Of Bococizumab (pf 04950615) Alone And In Co Mixture With Recombinant Human Hyaluronidase (rhuph20, Pf 06744547) In Healthy And Hypercholesterolemic Adult Subjects|Terminated||Phase 1|60|Actual|Pfizer||5||"The study was terminated early on July 8, 2016 due to business priorities regarding study   execution."|f||||f||||||||||2017-10-10 22:31:01.965131|2017-10-10 22:31:01.965131
NCT02656849|ClinicalTrials.gov processed this data on October 10, 2017|2016-01-11|2016-06-29|||February 2016||2016-02-01|June 2016|2016-06-01|May 2023|Anticipated|2023-05-01|October 2019|Anticipated|2019-10-01||Interventional|||BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors|A Phase II Study of BAY 1000394 in MCL1-Amplified, MYC-Amplified, CCNE1-Amplified Tumors|Withdrawn||Phase 2|0|Actual|Dana-Farber Cancer Institute||1||Development of BAY1000394 has been terminated by Bayer.|f||||t||||||||||2017-10-10 22:32:57.135608|2017-10-10 22:32:57.135608
NCT02651090|ClinicalTrials.gov processed this data on October 10, 2017|2016-01-06|2017-09-12|||October 2017|Anticipated|2017-10-01|September 2017|2017-09-01|March 2018|Anticipated|2018-03-01|March 2018|Anticipated|2018-03-01||Interventional|||Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI|Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced Computed Tomography and/or Magnetic Resonance Imaging Using Sonazoid|Withdrawn||Phase 3|0|Actual|Northeastern Ohio Radiology Research and Education Fund||1||Sponsor terminated study before enrollment Sponsor terminated study before enrollment|f||||f|t|f||||||||2017-10-10 22:35:34.309118|2017-10-10 22:35:34.309118
NCT02649530|ClinicalTrials.gov processed this data on October 10, 2017|2016-01-05|2016-09-29||||||September 2016|2016-09-01||||July 2018|Anticipated|2018-07-01||Interventional|||A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma|An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma|Withdrawn||Phase 2|0|Actual|University of Michigan Cancer Center||1||funding withdrawn|f||||t||||||||||2017-10-10 22:35:48.914561|2017-10-10 22:35:48.914561
NCT02648633|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-16|2017-05-26|||May 24, 2016|Actual|2016-05-24|May 2017|2017-05-01|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|||Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma|A Pilot Study to Evaluate the Feasibility of the Combined Use of Stereotactic Radiosurgery With Nivolumab and Concurrent Valproate in Patients With Recurrent Glioblastoma|Terminated||Phase 1|4|Actual|University of Virginia||1||"The pharmaceutical company (BMS) would no longer provide nivolumab for the study, so the study   was terminated early."|f||||t||||||||No||2017-10-10 22:35:58.811829|2017-10-10 22:35:58.811829
NCT02647645|ClinicalTrials.gov processed this data on October 10, 2017|2016-01-05|2017-07-27|||September 2015||2015-09-01|July 2017|2017-07-01|December 2017|Anticipated|2017-12-01|October 2017|Anticipated|2017-10-01||Interventional|||Cognitive Training With and Without tDCS to Improve Cognition in HIV|Cognitive Training With and Without tDCS to Improve Cognition in HIV|Terminated||N/A|23|Actual|Nova Southeastern University||2||Pilot study protocol terminated to begin expanded study.|f||||f||||||||||2017-10-10 22:36:12.134952|2017-10-10 22:36:12.134952
NCT02647528|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-31|2016-12-05|||March 2016||2016-03-01|December 2016|2016-12-01|April 2016|Actual|2016-04-01|April 2016|Actual|2016-04-01||Interventional|Chromogenix||A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris|A Randomized, Blinded, Single-Centered, Placebo-Controlled Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris|Withdrawn||Phase 4|0|Actual|Sadick Research Group||2||funding withdrawn|f||||t||||||||No||2017-10-10 22:36:13.046404|2017-10-10 22:36:13.046404
NCT02639819|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-18|2017-07-05|||June 2016|Anticipated|2016-06-01|July 2017|2017-07-01|December 2017|Anticipated|2017-12-01|July 2017|Anticipated|2017-07-01||Interventional|MANICHAN-PILOT||Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study|A Pilot Study of Ultra-Early Intravenous ɛ-Aminocaproic Acid in Spontanteous Intracerebral Hemorrhage|Withdrawn||Phase 1|0|Actual|The University of Texas Health Science Center at San Antonio||1||Study was withdrawn from IRB review on 03/08/16|f||||t||||||||||2017-10-10 22:37:47.894518|2017-10-10 22:37:47.894518
NCT02638129|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-18|2017-02-21|2016-10-05||January 2016||2016-01-01|October 2016|2016-10-01|June 2016|Actual|2016-06-01|June 2016|Actual|2016-06-01||Interventional|||Naltrexone/Bupropion Cardiovascular Outcomes Study|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study to Assess the Effect of Naltrexone Hydrochloride and Bupropion Hydrochloride Extended Release Combination on the Occurrence of Major Adverse Cardiovascular Events in Overweight and Obese Subjects With Cardiovascular Disease|Terminated||Phase 4|67|Actual|Orexigen Therapeutics, Inc|As this study was prematurely terminated, analysis of the primary and secondary outcome measures was not performed and analysis of safety was limited in scope.|4|||f||||f||||||||||2017-10-10 22:38:07.109958|2017-10-10 22:38:07.109958
NCT02637375|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-17|2016-05-26|||May 2016||2016-05-01|May 2016|2016-05-01|December 2018|Anticipated|2018-12-01|December 2018|Anticipated|2018-12-01||Interventional|||A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer|A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer|Withdrawn||N/A|0|Actual|University of Chicago||1||Study never opened (terminated as study drug no longer available)|f||||f||||||||||2017-10-10 22:38:15.917113|2017-10-10 22:38:15.917113
NCT02630563|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-11|2016-04-19|2016-03-14||May 2003||2003-05-01|December 2015|2015-12-01|January 2005|Actual|2005-01-01|January 2005|Actual|2005-01-01||Interventional||All Patient Population included all participants who were enrolled in the trial|Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids|A Study of the Safety, Tolerability and Pharmacokinetics of Oral CellCept® (Mycophenolate Mofetil, MMF) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids|Terminated||Phase 2|9|Actual|Hoffmann-La Roche|Part I of the study was terminated early with 9 participants enrolled (8 of which were evaluable for PK), and Part II of the study was not performed due to extremely slow recruitment and the infrequent use of the combination of triple therapy.|1||"Due to extremely slow recruitment, infrequent use of combination triple therapy (MMF,   cyclosporine, steroids), study was discontinued; Part 2 was not conducted."|f||||||||||||||2017-10-10 22:39:34.475445|2017-10-10 22:39:34.475445
NCT02625922|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-03|2017-06-22|||February 5, 2016|Actual|2016-02-05|June 2017|2017-06-01|January 11, 2017|Actual|2017-01-11|January 11, 2017|Actual|2017-01-11||Interventional|RELAX-Cardio||Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure|A Multicenter, Randomized, Double-blind, Crossover Placebo-controlled Phase II Study to Assess the Effect of Serelaxin Versus Placebo on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure After Exercise When Used in Addition to Standard of Care|Terminated||Phase 2|24|Actual|Novartis||2||Study was terminated based on results from pivotal adult AHF study CRLX030A2301|f||||t|f|f||||||||2017-10-10 22:40:35.199378|2017-10-10 22:40:35.199378
NCT02625285|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-04|2017-10-05|||January 24, 2017|Actual|2017-01-24|October 2017|2017-10-01|December 2017|Anticipated|2017-12-01|December 2017|Anticipated|2017-12-01||Observational|Biosensors||Validation of New G6PD Point of Care Tests Against Gold Standard Quantitative|Validation of New G6PD Point of Care Tests (Biosensors) Against Gold Standard Quantitative Spectrophotometry and Genotyping|Recruiting||N/A|150|Anticipated|University of Oxford|||3||f||||f||||||Samples With DNA|"     Two blood samples will be withdrawn from participants; one sample will be taken by     finger-stick (200 µl) and one sample (0.5 ml) will be taken by arm venipuncture. The blood     from capillary sample will be used to assess G6PD activity using the POC tests, CBC and     laboratory based quantitative tests. The venous blood will be used for reference standard     quantitative G6PD assays, Hb typing analysis, CBC and buffy-coat will be stored for DNA     extraction for G6PD genotyping only; leftover blood will be discarded.   "|||2017-10-10 22:40:43.821335|2017-10-10 22:40:43.821335
NCT02623582|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-03|2017-06-08|||December 2015||2015-12-01|June 2017|2017-06-01|December 2018|Anticipated|2018-12-01|December 2018|Anticipated|2018-12-01||Interventional|||CD123 Redirected Autologous T Cells for AML|Pilot Study of RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD123 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Acute Myeloid Leukemia|Terminated||Early Phase 1|7|Actual|University of Pennsylvania||2||This study was terminated due to lack of funding.|f||||t||||||||Yes||2017-10-10 22:40:51.870478|2017-10-10 22:40:51.870478
NCT02624141|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-02|2016-11-01|||April 2006||2006-04-01|November 2016|2016-11-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Interventional|||A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy|Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels, of Patients With Anemia Reklated to Malignant Tumors, Treated With Erythropoietin B (Recormon) Using the Pre-Filled Syringe With 30,000 IU, as Well as to Quantify Teh Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment|Terminated||Phase 4|10|Actual|Hoffmann-La Roche||1||The study was terminated due to low recruitment|f||||||||||||||2017-10-10 22:40:58.368662|2017-10-10 22:40:58.368662
NCT02621099|ClinicalTrials.gov processed this data on October 10, 2017|2015-12-01|2017-05-02|||March 2016||2016-03-01|May 2017|2017-05-01|June 2017|Anticipated|2017-06-01|February 2017|Anticipated|2017-02-01||Observational|HICAM||Hybrid Gamma Camera in Breast Surgery|First Use of a Hybrid Gamma Camera for Sentinel Lymph Node Localisation in Patients Undergoing Surgery for Primary Breast Cancer|Withdrawn||N/A|0|Actual|University of Nottingham|||1|"The study was withdrawn due to the CE mark of the device was not yet granted during the   specified period."|f||||f||||||||||2017-10-10 22:41:29.376281|2017-10-10 22:41:29.376281
NCT02619812|ClinicalTrials.gov processed this data on October 10, 2017|2015-11-19|2017-05-17|2017-01-27||April 2016|Actual|2016-04-01|May 2017|2017-05-01|December 2016|Actual|2016-12-01|December 2016|Actual|2016-12-01||Interventional|||Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT|A Randomized, Placebo-Controlled, Pilot Study of Colesevelam and Serum-Derived Bovine Immunoglobulin/Protein Isolate to Manage Diarrhea in Patients With Multiple Myeloma Receiving Conditioning Chemotherapy for Autologous Stem Cell Transplantation (SCT)|Terminated||Phase 2|4|Actual|Mayo Clinic|This study was terminated early due to difficulty recruiting subjects; pill burden and nausea were barriers to study continuation for subjects accrued. Data were not collected.|4||Difficulty recruiting; pill burden and nausea were barriers|f||||f|t|f||||||No||2017-10-10 22:41:44.102763|2017-10-10 22:41:44.102763
NCT02613910|ClinicalTrials.gov processed this data on October 10, 2017|2015-11-23|2017-05-12|2017-03-16||December 23, 2015|Actual|2015-12-23|April 2017|2017-04-01|March 23, 2016|Actual|2016-03-23|March 23, 2016|Actual|2016-03-23||Interventional||Ofatumumab|Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris|OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris|Terminated||Phase 3|1|Actual|GlaxoSmithKline||1||"Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059   studies. This decision is not linked to any safety consideration."|f||||t|t|f||||||||2017-10-10 22:42:55.170104|2017-10-10 22:42:55.170104
NCT02608060|ClinicalTrials.gov processed this data on October 10, 2017|2015-11-16|2016-11-01|||September 2006||2006-09-01|November 2016|2016-11-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Interventional|||A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B|Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment|Terminated||Phase 4|4|Actual|Hoffmann-La Roche||1||Due to poor enrollment this study was terminated prematurely.|f||||||||||||||2017-10-10 22:44:06.7035|2017-10-10 22:44:06.7035
NCT02605473|ClinicalTrials.gov processed this data on October 10, 2017|2015-11-12|2015-11-13|||September 2008||2008-09-01|November 2015|2015-11-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional|||Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion|A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||"Study terminated following Phase I NCT00791271, no progression to Phase II due to toxicity and   lack of efficacy."|f||||t||||||||||2017-10-10 22:44:33.459323|2017-10-10 22:44:33.459323
NCT02604589|ClinicalTrials.gov processed this data on October 10, 2017|2015-11-02|2017-04-03|2017-01-19||March 2016||2016-03-01|April 2017|2017-04-01|November 2016|Actual|2016-11-01|November 2016|Actual|2016-11-01||Interventional|||Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures|"Prime Rib Time: Randomized Control Trial Evaluating the Use of Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures"|Terminated||N/A|10|Actual|William Beaumont Hospitals|Study terminated early due to lack of enrollment.|3||resource reallocation|f||||t||||||||No||2017-10-10 22:44:44.086419|2017-10-10 22:44:44.086419
NCT02603458|ClinicalTrials.gov processed this data on October 10, 2017|2015-11-09|2016-02-04||||||February 2016|2016-02-01||||August 2020|Anticipated|2020-08-01||Interventional|||NRX-1074 in Early Course Schizophrenia|A Placebo-controlled Two-dose Trial of NRX-1074 Early in the Course of Schizophrenia|Withdrawn||Phase 2|0|Actual|New York University School of Medicine||2||The study was withdrawn by the sponsor.|f||||t||||||||Undecided|The study has been withdrawn by the sponsor, so the plan to share data has not been discussed and is undecided.|2017-10-10 22:44:55.987194|2017-10-10 22:44:55.987194
NCT02603068|ClinicalTrials.gov processed this data on October 10, 2017|2015-11-10|2016-02-05|||February 2016||2016-02-01|February 2016|2016-02-01|July 2018|Anticipated|2018-07-01|April 2018|Anticipated|2018-04-01||Interventional|||Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis|Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis|Withdrawn||Phase 2|0|Actual|United Therapeutics||2||Study design was inadequate and would not achieve study endpoints|f||||f||||||||No|Study is withdrawn. There is no data to share.|2017-10-10 22:45:02.977811|2017-10-10 22:45:02.977811
NCT02593851|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-21|2017-04-12|||December 4, 2015|Actual|2015-12-04|April 2017|2017-04-01|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection|A Phase 1b, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With RSV Infection|Suspended||Phase 1|96|Anticipated|Janssen Sciences Ireland UC||16||Trial is suspended following HA feedback regarding the drug formulation.|f||||f|t|||||||||2017-10-10 22:46:59.395069|2017-10-10 22:46:59.395069
NCT02588456|ClinicalTrials.gov processed this data on October 10, 2017|2015-10-26|2017-06-08|||October 2015||2015-10-01|June 2017|2017-06-01|October 2018|Anticipated|2018-10-01|October 2018|Anticipated|2018-10-01||Interventional|||Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia|Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia|Terminated||Phase 1|15|Anticipated|University of Pennsylvania||1||This study was terminated due to lack of efficacy|f||||t||||||||||2017-10-10 22:47:58.216492|2017-10-10 22:47:58.216492
NCT02578836|ClinicalTrials.gov processed this data on October 10, 2017|2015-10-15|2017-08-29|||August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-01|November 2018|Anticipated|2018-11-01|March 2018|Anticipated|2018-03-01||Interventional|||Transoral Gastric Volume Reduction as an Intervention for Weight Management|Transoral Gastric Volume Reduction as an Intervention for Weight Management|Withdrawn||N/A|0|Actual|University of Miami||1||Study was withdrawn due to PI decision|f||||f|f|f||||||||2017-10-10 22:49:50.451693|2017-10-10 22:49:50.451693
NCT02576119|ClinicalTrials.gov processed this data on October 10, 2017|2015-10-13|2017-08-07|||October 19, 2015|Actual|2015-10-19|August 2017|2017-08-01|October 14, 2016|Actual|2016-10-14|February 26, 2016|Actual|2016-02-26||Interventional|||A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects|A Randomized, Double-Blind, Double-Dummy, Positive-Controlled, Crossover Study to Determine Electrocardiographic Effects of BMS-955176 in Healthy Subjects|Terminated||Phase 1|315|Actual|ViiV Healthcare||2||"This study was terminated early due to neuropsychiatric serious adverse events reported by 2   participants."|f||||f|t|f||||||||2017-10-10 22:50:30.061263|2017-10-10 22:50:30.061263
NCT02573220|ClinicalTrials.gov processed this data on October 10, 2017|2015-09-21|2016-12-08|||June 2015||2015-06-01|December 2016|2016-12-01|August 2016|Actual|2016-08-01|August 2016|Actual|2016-08-01||Interventional|||Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer|A UGT1A1 Genotype-Guided Dosing Study of Irinotecan Administered in Combination With 5-Fluorouracil/Leucovorin (FOLFIRI) and Cetuximab as First-Line Therapy in RAS Wild-Type Metastatic Colorectal Cancer Patients|Withdrawn||Phase 1|0|Actual|University of Chicago||1||Study terminated by PI due to inability to accrue.|f||||f||||||||||2017-10-10 22:51:03.44699|2017-10-10 22:51:03.44699
NCT02572206|ClinicalTrials.gov processed this data on October 10, 2017|2015-09-28|2016-09-26|||September 2015||2015-09-01|September 2016|2016-09-01|June 2016|Actual|2016-06-01|June 2016|Actual|2016-06-01||Interventional|||PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations|Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers|Terminated||Phase 1|4|Actual|New York State Psychiatric Institute||1||NIMH terminated study|f||||t||||||||||2017-10-10 22:51:15.566789|2017-10-10 22:51:15.566789
NCT02562820|ClinicalTrials.gov processed this data on October 10, 2017|2015-09-28|2017-08-28|||November 2015||2015-11-01|August 2017|2017-08-01|July 2017|Actual|2017-07-01|July 2017|Actual|2017-07-01||Interventional|||An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome|Ketamine for the Treatment of Rett Syndrome: An Exploratory Trial|Terminated||Phase 1|4|Actual|The Cleveland Clinic||2||Funding withdrawn|f||||t||||||||||2017-10-10 22:53:05.039168|2017-10-10 22:53:05.039168
NCT02561520|ClinicalTrials.gov processed this data on October 10, 2017|2015-09-17|2017-08-24|||December 2016||2016-12-01|August 2017|2017-08-01|September 2018|Anticipated|2018-09-01|September 2018|Anticipated|2018-09-01||Interventional|||Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD|Safety and Efficacy of Autologous Platelet Rich Plasma and Platelet Poor Plasma Eye Drops in the Treatment of Ocular Graft-Versus-Host Disease|Withdrawn||Phase 1|0|Actual|University of Pittsburgh||1||Study did not enroll participants is being withdrawn from the system.|f||||t||||||||||2017-10-10 22:53:24.699035|2017-10-10 22:53:24.699035
NCT02560363|ClinicalTrials.gov processed this data on October 10, 2017|2015-09-24|2016-01-08|||November 2015||2015-11-01|January 2016|2016-01-01|January 2016|Anticipated|2016-01-01|January 2016|Anticipated|2016-01-01||Interventional|||A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects|An Open-label, Randomized, Cross Over Single Oral Dose Study Comparing the Pharmacokinetics of Different Formulations of AZD9977 (Part A) and Influence of Food (Part B) in Healthy Male Subjects|Withdrawn||Phase 1|0|Actual|AstraZeneca||4||Has been terminated before FSFV.|f||||f||||||||||2017-10-10 22:53:37.947296|2017-10-10 22:53:37.947296
NCT02555085|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-27|2017-04-17|||September 30, 2015|Actual|2015-09-30|April 2017|2017-04-01|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Single Ascending Doses of BIIB063 in Healthy Volunteers|Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers|Terminated||Phase 1|29|Actual|Biogen||8||Clinical study terminated due to preclinical safety findings in non-human primates.|f||||f||||||||||2017-10-10 22:54:47.247496|2017-10-10 22:54:47.247496
NCT02554552|ClinicalTrials.gov processed this data on October 10, 2017|2015-09-15|2016-11-15|||September 2015||2015-09-01|November 2016|2016-11-01|October 2016|Actual|2016-10-01|October 2016|Actual|2016-10-01||Interventional|||Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee|A Multicenter, Randomized, Double-blinded, Parallel, Placebo-controlled, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular YY1201 Once in the Treatment of Patients With Osteoarthritis of the Knee|Withdrawn||Phase 1/Phase 2|0|Actual|Yooyoung Pharmaceutical Co.,Ltd.||4||This study has been withdrawn prior to enrollment.|f||||t||||||||Undecided||2017-10-10 22:54:57.777852|2017-10-10 22:54:57.777852
NCT02541357|ClinicalTrials.gov processed this data on October 10, 2017|2015-09-01|2017-05-23|||September 2015|Actual|2015-09-01|May 2017|2017-05-01|October 2016|Actual|2016-10-01|October 2016|Actual|2016-10-01||Interventional|MBM_Colo||Preoperative Relaxation and Intensified Patient Surgery Education in Patients Undergoing Colorectal Surgery|Effects of Preoperative Relaxation and Intensified Surgery Education on Preoperative Wellbeing and Postoperative Complaints in Patients Undergoing Colorectal Surgery - a Randomized Controlled Trial|Terminated||N/A|4|Actual|Universität Duisburg-Essen||4||Recruitment insufficient|f||||t||||||||No|Study has been terminated|2017-10-10 22:57:36.402458|2017-10-10 22:57:36.402458
NCT02541162|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-21|2017-02-20|||June 11, 2014|Actual|2014-06-11|February 2017|2017-02-01|October 15, 2017|Anticipated|2017-10-15|October 15, 2015|Actual|2015-10-15||Interventional|COUPLE||Cancer and Sexual Health : Early Information and Sexual Satisfaction of Couples in Oncology|Cancer and Sexual Health : Early Information and Sexual Satisfaction of Couples in Oncology|Suspended||N/A|60|Actual|Groupe Hospitalier Paris Saint Joseph||2||The study was suspended because the oncology service decided to adopt the procedure in routine|f||||f|f|f||||||Undecided||2017-10-10 22:57:38.495227|2017-10-10 22:57:38.495227
NCT02540356|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-24|2017-06-30|2017-05-22||November 2, 2015|Actual|2015-11-02|May 2017|2017-05-01|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional|||Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer|A Phase 1/2a, Open-Label, Parallel, Two-Arm Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects With Refractory Ovarian Cancer With Malignant Ascites|Terminated||Phase 1/Phase 2|2|Actual|Baxalta US Inc.|Study was terminated early with only 1 subject having been dosed. Therefore no statistical analysis was performed on the outcome measures. Only descriptive data for one subject are available.|2|||f||||f||||||||||2017-10-10 22:57:50.645922|2017-10-10 22:57:50.645922
NCT02536092|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-27|2017-01-30|||September 2015||2015-09-01|January 2017|2017-01-01|December 2016|Actual|2016-12-01|December 2016|Actual|2016-12-01||Interventional|||A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal|A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal|Terminated||N/A|50|Actual|Cutera Inc.||1||Sponsor terminated study|f||||f||||||||No|Study terminated|2017-10-10 22:58:46.386491|2017-10-10 22:58:46.386491
NCT02535247|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-26|2017-06-14|||January 5, 2016|Actual|2016-01-05|June 2017|2017-06-01|December 2018|Anticipated|2018-12-01|December 2017|Anticipated|2017-12-01||Interventional|||Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma|A Phase II Study to Determine Feasibility and Safety of Single Agent MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma|Suspended||Phase 2|24|Anticipated|Fox Chase Cancer Center||1||Study has been temporarily suspended for interim analyses|f||||t||||||||||2017-10-10 22:58:55.678272|2017-10-10 22:58:55.678272
NCT02534129|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-19|2017-10-04|2017-04-06||August 2015||2015-08-01|October 2017|2017-10-01|March 2016|Actual|2016-03-01|March 2016|Actual|2016-03-01||Interventional||The analysis population consisted of 13 breast cancer patients receiving radiation to a breast. Each breast was divided into two radiation fields, one defined as the Difinsa53 arm and the other as the Aquaphor Arm. Thus each participant contributed data from two fields.|Topical Use of Difinsa53™ to Prevent Radiation Dermatitis|Topical Use of a Silibin-based Cream, Difinsa53™, to Prevent Radiation Dermatitis in Patients With Breast Cancer: A Prospective Study|Terminated||Phase 1/Phase 2|13|Actual|ProTechSure Scientific, Inc.|This trial was terminated early, based on minimal radiation dermatitis (scores of 0-1 only in most fields evaluated) that precluded any meaningful analysis of any differing effect in the two treatment arms.|1||"Insufficient dermatitis was seen in the controls to allow any determination of protection by   Difinsa53"|f||||f||||||||||2017-10-10 22:59:08.939431|2017-10-10 22:59:08.939431
NCT02532101|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-10|2017-05-01|||December 2014||2014-12-01|May 2017|2017-05-01|December 2016|Actual|2016-12-01|December 2016|Actual|2016-12-01||Interventional|UNIDOPP||Modulating Effects of Oil Palm Phenolics in Uncontrolled Insulin-treated Type 2 Diabetes Mellitus|Modulating Effects of Oil Palm Phenolics in Uncontrolled Insulin-treated Type 2 Diabetes Mellitus|Terminated||N/A|8|Actual|University of Science Malaysia||1||Study was terminated due to futility.|f||||t||||||||No||2017-10-10 22:59:33.501711|2017-10-10 22:59:33.501711
NCT02531308|ClinicalTrials.gov processed this data on October 10, 2017|2015-07-27|2016-12-01|2016-12-01||July 2015||2015-07-01|December 2016|2016-12-01|July 2016|Actual|2016-07-01|July 2016|Actual|2016-07-01||Interventional|DLBCL||Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)|A Phase ll Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (RM-CHOP) for Previously Untreated Aggressive Diffuse Large B-cell Lymphoma|Terminated||Phase 2|5|Actual|Rush University Medical Center|Unable to report on endpoint of 2 year PFS as trial prematurely terminated|1||poor accrual|f||||t||||||||Undecided||2017-10-10 22:59:45.610488|2017-10-10 22:59:45.610488
NCT02530775|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-18|2015-12-15|||October 2015||2015-10-01|December 2015|2015-12-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional|||"Is Instrumentation Necessary for Static Degenerative Spondylolisthesis"|"Is Instrumentation Necessary for Static Degenerative Spondylolisthesis - A Prospective Randomized Clinical Study"|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||The study did not receive IRB approval and was withdrawn|f||||f||||||||||2017-10-10 22:59:51.265079|2017-10-10 22:59:51.265079
NCT02528331|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-17|2016-12-19|2016-11-29||March 2016||2016-03-01|November 2016|2016-11-01|August 2016|Actual|2016-08-01|July 2016|Actual|2016-07-01||Interventional|CBT-TMS||Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study|Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study|Terminated||N/A|2|Actual|Duke University|This trial was terminated early leading to small numbers of subjects analyzed.|1||PI has left Duke|f||||t||||||||||2017-10-10 23:00:17.748503|2017-10-10 23:00:17.748503
NCT02525913|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-13|2015-10-07|||September 2015||2015-09-01|October 2015|2015-10-01|September 2016|Anticipated|2016-09-01|September 2016|Anticipated|2016-09-01||Interventional|||Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue|Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue|Withdrawn||N/A|0|Actual|University of Arkansas||1||Study was withdrawn from the IRB and never opened. No subjects were enrolled.|f||||f||||||||||2017-10-10 23:00:45.926144|2017-10-10 23:00:45.926144
NCT02524288|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-10|2017-08-25|2017-08-25||August 31, 2015|Actual|2015-08-31|August 2017|2017-08-01|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Interventional|||Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)|A Phase 3, Single Arm, Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring in Healthy Women 18 Years of Age and Older, At Risk for Pregnancy|Terminated||Phase 3|1941|Actual|Merck Sharp & Dohme Corp.|Results for the Pearl Index should be interpreted with caution. Due to the discontinuation of product development and early trial termination, the number of “at risk” treatment cycles in the denominator is based on uncleaned diary data.|1||"This study was terminated by the Sponsor due to a business decision to discontinue product   development for reasons unrelated to safety or efficacy outcomes."|f||||f|t|f||||||||2017-10-10 23:02:36.236574|2017-10-10 23:02:36.236574
NCT02515539|ClinicalTrials.gov processed this data on October 10, 2017|2015-08-03|2016-03-29|||August 2015||2015-08-01|August 2015|2015-08-01|July 2021|Anticipated|2021-07-01|August 2016|Anticipated|2016-08-01||Interventional|||Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)|Early Feasibility Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transfemoral and Transapical Delivery Systems)|Withdrawn||N/A|0|Actual|Edwards Lifesciences||1||Edwards Lifesciences terminated the IDE associated with this study. No patients enrolled.|f||||t||||||||||2017-10-10 23:04:20.806136|2017-10-10 23:04:20.806136
NCT02496039|ClinicalTrials.gov processed this data on October 10, 2017|2015-07-08|2017-06-06|2017-04-18||September 2015||2015-09-01|June 2017|2017-06-01|May 2016|Actual|2016-05-01|May 2016|Actual|2016-05-01||Interventional|||Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)|A Study to Assess Effectiveness, Safety, and Health-related Outcomes of NUEDEXTA® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the Treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients|Terminated||Phase 4|5|Actual|Avanir Pharmaceuticals|The study was terminated prematurely because of difficulty with recruiting.|1||The study was terminated prematurely because of difficulty with recruiting.|f||||f||||||||||2017-10-10 23:08:12.914406|2017-10-10 23:08:12.914406
NCT02495233|ClinicalTrials.gov processed this data on October 10, 2017|2015-07-08|2017-09-14||2017-09-14|September 8, 2015|Actual|2015-09-08|August 2017|2017-08-01|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)|A Phase 1b/2 Study of ASP2215 in Combination With Erlotinib in Subjects With EGFR Activating Mutation-Positive (EGFRm+) Advanced NSCLC Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)|Terminated||Phase 1/Phase 2|10|Actual|Astellas Pharma Inc||2||Study terminated due to adverse events related to the combination therapy|f||||f||||||||||2017-10-10 23:08:26.21999|2017-10-10 23:08:26.21999
NCT02488746|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-26|2016-12-08|||March 2015||2015-03-01|December 2016|2016-12-01|September 2018|Anticipated|2018-09-01|September 2018|Anticipated|2018-09-01||Observational|||Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)|Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)|Terminated||N/A|5|Actual|Kliniken Ludwigsburg-Bietigheim gGmbH|||1|"According to study protocol the trial was terminated because the recruitment of trial   participants was insufficient."|f||||f||||||||||2017-10-10 23:09:51.336593|2017-10-10 23:09:51.336593
NCT02484703|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-16|2017-07-04|||October 28, 2015|Actual|2015-10-28|July 2017|2017-07-01|August 3, 2016|Actual|2016-08-03|August 3, 2016|Actual|2016-08-03||Interventional|||A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group 26-Week Dose-Investigating Study to Explore the Pharmacokinetics, Pharmacodynamic Effects, Efficacy, Safety and Tolerability of RO5186582 in Children With Down Syndrome Aged 6-11 Years|Terminated||Phase 2|45|Actual|Hoffmann-La Roche||4||"Study was terminated due to data from another study showing no efficacy. There were no safety   issues of concern."|f||||||||||||||2017-10-10 23:10:39.502066|2017-10-10 23:10:39.502066
NCT02480010|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-05|2015-08-18|2015-07-22||September 2003||2003-09-01|August 2015|2015-08-01|September 2005|Actual|2005-09-01|September 2005|Actual|2005-09-01||Interventional||Intent-to-Treat (ITT) population consisted of all participants enrolled and who received at least one dose of study medication.|A Study of Pertuzumab in Participants With Prostate Cancer|An Open Label, Phase II, Multicenter Study to Evaluate the Efficacy and Safety of a Recombinant Humanized Antibody to HER2 (Pertuzumab) Administered Every 3 Weeks to Patients With Hormone-Refractory Prostate Cancer Who Have Not Been Treated With Chemotherapy|Terminated||Phase 2|68|Actual|Hoffmann-La Roche|The study was terminated at the time of interim analysis since none of the participants showed a PSA response.|2||"The study was terminated at the time of interim analysis since none of the participants showed   a PSA response."|f||||||||||||||2017-10-10 23:11:34.283854|2017-10-10 23:11:34.283854
NCT02479204|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-17|2017-07-25|||April 28, 2015|Actual|2015-04-28|July 2017|2017-07-01|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Interventional|||Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441|Single-center, Open-label, Randomized, Multiple-dose, Parallel-group Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 Combined With Calcium-channel Blocker (Diltiazem) or Beta-blocker (Atenolol) Treatment in Healthy Subjects|Terminated||Phase 1|32|Anticipated|Actelion||4||"Based on results from the pilot phase, the study is terminated. No safety events leading to   discontinuation were reported"|f||||f||||||||||2017-10-10 23:11:43.390721|2017-10-10 23:11:43.390721
NCT02479009|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-19|2016-12-20|||June 2015||2015-06-01|December 2016|2016-12-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional|||Fluoroscopy vs. Computed Tomography for Diagnosis of Displacement and Instability of Acute Scaphoid Waist Fractures|Fluoroscopy vs. Computed Tomography for Diagnosis of Displacement and Instability of Acute Scaphoid Waist Fractures|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1||The investigator left the institution so the study was terminated.|f||||f||||||||||2017-10-10 23:11:45.447333|2017-10-10 23:11:45.447333
NCT02473523|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-03|2017-01-17|2017-01-17||June 2015||2015-06-01|January 2017|2017-01-01|December 2016|Actual|2016-12-01|December 2016|Actual|2016-12-01||Interventional|||Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia|Feasibility of Implementing Yoga Intervention for Adolescents at St. Jude Children's Research Hospital|Terminated||N/A|2|Actual|St. Jude Children's Research Hospital|The study was terminated because the principal investigator left the institution. One participant completed only 8 of 16 sessions and was not evaluable for study objectives.|1||The principal investigator left the institution.|f||||f||||||||||2017-10-10 23:12:49.239305|2017-10-10 23:12:49.239305
NCT02472977|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-12|2017-03-09|||July 2015||2015-07-01|August 2016|2016-08-01|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|CXCessoR4||Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors|A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors|Terminated||Phase 1/Phase 2|36|Actual|Bristol-Myers Squibb||2||Trial terminated because of lack of efficacy in the short term acute phase.|f||||t||||||||||2017-10-10 23:12:54.666331|2017-10-10 23:12:54.666331
NCT02472639|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-12|2017-09-08|2017-09-08||June 10, 2015|Actual|2015-06-10|September 2017|2017-09-01|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional||Study was prematurely terminated. Data was not collected or analyzed due to issue with study compliance.|Impact of Ostom-i Alert Sensor on Quality of Life in Patients With Ileostomy|Impact of Ostom-i Alert Sensor on Quality of Life in Patients With Ileostomy|Terminated||N/A|40|Actual|Cedars-Sinai Medical Center|"Study only accrued 7 patients. Due to non-compliance and issues with the device it was decided to terminate the study.
NCT02471599|ClinicalTrials.gov processed this data on October 10, 2017|2015-05-19|2015-06-10|||March 2011||2011-03-01|June 2015|2015-06-01|March 2023|Anticipated|2023-03-01|March 2023|Anticipated|2023-03-01||Interventional|||Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy|Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy :a Prospective,Randomized,Controlled Study.|Suspended||N/A|100|Anticipated|Sun Yat-sen University||2||This study was suspended because that few participants was enrolled.|f||||t||||||||||2017-10-10 23:13:11.837459|2017-10-10 23:13:11.837459
NCT02465294|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-01|2016-02-08|||February 2016||2016-02-01|February 2016|2016-02-01|February 2016|Actual|2016-02-01|February 2016|Actual|2016-02-01||Interventional|WLP||The Influence of Probiotics on Body Weight and Composition|The Influence of Probiotics With a Behavioral Life Style Intervention on Body Weight and Composition in Overweight Participants: A Randomized, Double-blinded, Placebo-controlled Study.|Withdrawn||N/A|0|Actual|University of Florida||3||study withdrawn due to funding|f||||f||||||||No||2017-10-10 23:14:27.387604|2017-10-10 23:14:27.387604
NCT02462473|ClinicalTrials.gov processed this data on October 10, 2017|2015-06-02|2017-02-22|2016-11-29||May 2015||2015-05-01|February 2017|2017-02-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional|||A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry|A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry|Terminated||Phase 2|9|Actual|Janssen Research & Development, LLC|Due to poor enrollment, the study was terminated early by the sponsor after enrolling only 9 participants in Cohort 1 and no participants were enrolled in Cohorts 2 and 3.|3||"Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment   in Cohorts 2 and 3."|f||||f||||||||||2017-10-10 23:15:01.648446|2017-10-10 23:15:01.648446
NCT02445092|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-08|2016-09-25|||January 2014||2014-01-01|September 2016|2016-09-01|September 2016|Actual|2016-09-01|July 2016|Actual|2016-07-01||Interventional|||The Effect of Pre-washing the Insemination Catheter on Pregnancy Outcome|Double Blind Randomized Controlled Trial on the Effect of Pre-washing the Insemination Catheter on Pregnancy Outcome|Terminated||N/A|450|Actual|McGill University Health Center||2||"After reviewing the interim analysis results the study was terminated as a bigger sample size   was needed to find a significant difference between the groups."|f||||t||||||||||2017-10-10 23:18:32.036234|2017-10-10 23:18:32.036234
NCT02444364|ClinicalTrials.gov processed this data on October 10, 2017|2015-05-11|2017-05-30|||May 2015||2015-05-01|May 2017|2017-05-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional|||Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus|Pilot Project Evaluation of the DPP-4 Inhibition With Sitagliptin on Calcium and Bone Metabolism in Patients With Type 2 Diabetes Mellitus|Withdrawn||Early Phase 1|0|Actual|University of Missouri-Columbia||1||Funding withdrawn; no participants enrolled.|f||||f||||||||No||2017-10-10 23:18:38.977169|2017-10-10 23:18:38.977169
NCT02442674|ClinicalTrials.gov processed this data on October 10, 2017|2015-05-08|2017-07-27|||November 2015||2015-11-01|July 2017|2017-07-01|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia|A Pilot Phase 3b,Multicenter,Randomized,Double-blind,Placebo-controlled Trial of the Safety,Efficacy,and Pharmacokinetics of Titrated Oral SAMSCA®(Tolvaptan) in Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia|Withdrawn||Phase 3|0|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2||Trial withdrawn due to inability to meet the trial objectives (Pilot).|f||||t||||||||||2017-10-10 23:18:59.269339|2017-10-10 23:18:59.269339
NCT02440646|ClinicalTrials.gov processed this data on October 10, 2017|2015-05-07|2015-12-26|||May 2015||2015-05-01|December 2015|2015-12-01|August 2020|Anticipated|2020-08-01|July 2018|Anticipated|2018-07-01|5 Years|Observational [Patient Registry]|REALITY||Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography|Natural History of Atherosclerosis Within the Concept of the Glagovian Artery Remodeling in REAL-world Chest Pain Population Underwent Computed Tomography Angiography and 3D Quantitative Coronary Angiography: Clinical potentIal and safeTY|Terminated||N/A|1080|Actual|Ural Medical University|||2|"The study was terminated under the political pressure of the Federal Security Service of the   Russian Federation (FSB) and the Russian Society of Cardiology"|f||||t||||||Samples Without DNA|"     Blood samples to examine level of thyroid hormones and kidney function   "|||2017-10-10 23:19:25.209132|2017-10-10 23:19:25.209132
NCT02439970|ClinicalTrials.gov processed this data on October 10, 2017|2015-05-07|2017-01-05|||September 2015||2015-09-01|January 2017|2017-01-01|September 2018|Anticipated|2018-09-01|September 2018|Anticipated|2018-09-01||Interventional|BCV CMV vGCV||SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients|SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipient|Terminated||Phase 3|750|Anticipated|Chimerix||2||Study was terminated early due to results from another CMX study|f||||t||||||||||2017-10-10 23:19:31.001274|2017-10-10 23:19:31.001274
NCT02439138|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-29|2016-11-14|2016-09-26||October 2015||2015-10-01|November 2016|2016-11-01|April 2016|Actual|2016-04-01|April 2016|Actual|2016-04-01||Interventional|||Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia|Phase II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia|Terminated||Phase 2|5|Actual|Dana-Farber Cancer Institute|This study was terminated early due to safety concerns from the previously untreated CLL experience. All participants who remained on study at that time were permanently removed from protocol therapy. The median time on protocol therapy was 1 cycle|1||Safety issues from trials in CLL|f||||t||||||||No||2017-10-10 23:19:39.612831|2017-10-10 23:19:39.612831
NCT02435836|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-15|2015-08-18|2015-07-01||April 1998||1998-04-01|August 2015|2015-08-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|||A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia|An Open-Label Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia|Terminated||Phase 3|631|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|The study was terminated prematurely by the sponsor. The protocol specified that the study would run until Abilify (aripiprazole) was commercially available in all site countries.|1||Study terminated when aripiprazole available commercially per protocol|f||||f||||||||||2017-10-10 23:20:21.258204|2017-10-10 23:20:21.258204
NCT02433600|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-27|2016-03-14|||August 2015||2015-08-01|March 2016|2016-03-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional|||The Effect of Feeding Infant Formula With Enriched Protein Fractions in the US|The Effect of Feeding Infant Formula With Enriched Protein Fractions|Terminated||N/A|2|Actual|Mead Johnson Nutrition||2||Study was terminated due to lack of enrollment|f||||f||||||||||2017-10-10 23:20:45.107883|2017-10-10 23:20:45.107883
NCT02433236|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-29|2015-10-21|||September 2015||2015-09-01|October 2015|2015-10-01||||September 2015|Actual|2015-09-01||Interventional|||Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy|A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050|Withdrawn||Phase 2|0|Actual|Rigel Pharmaceuticals||2||Study withdrawn prior to enrollment of first subject|f||||f||||||||||2017-10-10 23:20:56.494457|2017-10-10 23:20:56.494457
NCT02432664|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-02|2017-06-30|||April 14, 2015|Actual|2015-04-14|June 2017|2017-06-01|April 22, 2016|Actual|2016-04-22|April 22, 2016|Actual|2016-04-22||Interventional|FIMTRIP||Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single and Multiple Escalating Doses of ODM-108: A Single Centre Study in Healthy Male Volunteers|Terminated||Phase 1|85|Actual|Orion Corporation, Orion Pharma||6||"The study was terminated after the second cohort had completed Part II due complex PK results.   There were no safety concerns."|f||||t||||||||||2017-10-10 23:21:01.635092|2017-10-10 23:21:01.635092
NCT02431104|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-27|2016-07-25|||April 2015||2015-04-01|July 2016|2016-07-01|June 2017|Anticipated|2017-06-01|May 2017|Anticipated|2017-05-01||Interventional|||Clinical Evaluation of Tattoo Removal Using a Novel Dual-Wavelength, Dual-Pulse Duration Laser|"Clinical Evaluation of Tattoo Removal Using a Novel Dual-Wavelength, Dual-Pulse Duration Laser"|Terminated||N/A|10|Actual|Cutera Inc.||1||Sponsor terminated study.|f||||f||||||||Undecided||2017-10-10 23:21:19.042933|2017-10-10 23:21:19.042933
NCT02430532|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-27|2017-03-27|2016-12-12||May 2015||2015-05-01|March 2017|2017-03-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional|INSPIRE||BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis|Terminated||Phase 3|58|Actual|Biogen|The study was terminated early by the sponsor for business reasons. Efficacy, patient-reported outcomes, and pharmacodynamic data were not analyzed.|2||Sponsor Decision|f||||t||||||||||2017-10-10 23:21:27.276828|2017-10-10 23:21:27.276828
NCT02430389|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-25|2015-06-25|2015-05-21||July 2012||2012-07-01|June 2015|2015-06-01|December 2014|Actual|2014-12-01|November 2012|Actual|2012-11-01||Interventional|||Effect of Remifentanil on Hemodynamic Stability During Placement of a Mayfield Head Fixation Device for Craniotomy|Effect of Remifentanil Administration on Hemodynamic Stability During Placement of a Mayfield Head Fixation Device for Craniotomy|Terminated||N/A|20|Actual|Northwestern University|Study terminated early due to interim analysis with patients in placebo group having substantially higher systemic HTN requiring rescue meds compared to study drug group. Another limitation is difficulty defining baseline BP preoperatively.|2||A priori hypothesis confirmed with interim analysis.|f||||f||||||||||2017-10-10 23:21:28.611342|2017-10-10 23:21:28.611342
NCT02429401|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-13|2016-10-25|||August 2015||2015-08-01|October 2016|2016-10-01|May 2016|Actual|2016-05-01|May 2016|Actual|2016-05-01||Interventional|Project Valor||Culturally Adapted Brief Intervention for Heavy Drinking Hispanic Men|Culturally Adapted Brief Intervention for Heavy Drinking Hispanic Men: a Randomized Clinical Trial Among Injured Patients|Terminated||N/A|87|Actual|University of Texas, El Paso||2||Study terminated due to low recruitment (funding agency halted study).|f||||f||||||||||2017-10-10 23:21:37.199353|2017-10-10 23:21:37.199353
NCT02420080|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-09|2017-01-05|||February 2015||2015-02-01|January 2017|2017-01-01|September 2016|Actual|2016-09-01|June 2016|Actual|2016-06-01||Observational|||A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304|A Multicenter Non-Interventional Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304|Terminated||N/A|100|Actual|Chimerix|||2|Study was terminated early due to results from previous CMX study|f||||f||||||||||2017-10-10 23:23:16.322875|2017-10-10 23:23:16.322875
NCT02417532|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-11|2016-12-26|2016-12-26||May 2015||2015-05-01|December 2016|2016-12-01|December 2016|Actual|2016-12-01|December 2016|Actual|2016-12-01||Interventional|SAFE RAPPER||Safety and Feasibility Evaluation of Robot Assisted Physiotherapy Exercises With REX|Safety and Feasibility Evaluation of Robot Assisted Physiotherapy Exercises With REX|Terminated||N/A|57|Actual|Rex Bionics Plc|Trial was terminated early. PI determined that after 57 subjects with successful results and no AE's, remaining subjects would add not statistical relevance to trial success.|1||PI determined additional subjects would not change outcome|f||||f||||||||No||2017-10-10 23:23:43.218872|2017-10-10 23:23:43.218872
NCT02413489|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-07|2017-06-29|||September 2, 2015|Actual|2015-09-02|June 2017|2017-06-01|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma|An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma|Terminated||Phase 2|42|Actual|Janssen Research & Development, LLC||1||"DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL   cohort was terminated due to slow recruitment and aggressive disease."|f||||f||f||||||||2017-10-10 23:24:36.298802|2017-10-10 23:24:36.298802
NCT02409433|ClinicalTrials.gov processed this data on October 10, 2017|2015-04-01|2016-01-05|||August 2014||2014-08-01|January 2016|2016-01-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional|||Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management|Prospective, Randomized, Single-blinded Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management|Terminated||Phase 4|3|Actual|Lawson Health Research Institute||2||due to slow recruitment and budgetary restraints study was prematurely terminated|f||||f||||||||||2017-10-10 23:25:22.668836|2017-10-10 23:25:22.668836
NCT02398942|ClinicalTrials.gov processed this data on October 10, 2017|2015-03-04|2016-12-20|||March 2015||2015-03-01|December 2016|2016-12-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Observational|||Proximal Pole Fractures of the Scaphoid|A Prospective Study of Proximal Pole Fractures of the Scaphoid|Withdrawn||N/A|0|Actual|Massachusetts General Hospital|||1|The investigator left the institution so the study was terminated.|f||||f||||||||||2017-10-10 23:27:18.68451|2017-10-10 23:27:18.68451
NCT02395302|ClinicalTrials.gov processed this data on October 10, 2017|2015-03-10|2017-02-23|2017-01-03||December 2014||2014-12-01|February 2017|2017-02-01|November 2015|Actual|2015-11-01|September 2015|Actual|2015-09-01||Interventional||Demographic information for 27 of the 28 study subjects was collected. One study subject was withdrawn from the study before demographic information was collected.|Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers (VLUs)|Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort in Patients With Venous Leg Ulcers|Completed||N/A|28|Actual|Tactile Medical||1|||f||||f||||||||No||2017-10-10 23:27:56.210101|2017-10-10 23:27:56.210101
NCT02394665|ClinicalTrials.gov processed this data on October 10, 2017|2015-03-16|2016-11-08|2016-11-08||March 2015||2015-03-01|November 2016|2016-11-01|September 2016|Actual|2016-09-01|September 2016|Actual|2016-09-01||Interventional||Data were not analyzed due to insufficient number of evaluable subjects. Only one subject enrolled who was later withdrawn by the Investigator prior to assignment to any treatment group or receiving any protocol therapy.|Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma|Phase II Study of Dose Escalated, Targeted Radiation Therapy Using 3D Magnetic Resonance Spectroscopy Imaging (MRSI) in Newly Diagnosed Glioblastoma|Terminated||Phase 2|1|Actual|University of Miami|Data were not analyzed due to insufficient number of evaluable subjects. Only one subject enrolled who was later withdrawn by the Investigator prior to assignment to any treatment group or receiving any protocol therapy.|2||Lack of Accrual/Enrollment|f||||t||||||||||2017-10-10 23:28:05.937065|2017-10-10 23:28:05.937065
NCT02392156|ClinicalTrials.gov processed this data on October 10, 2017|2015-03-12|2017-02-27|||July 2015||2015-07-01|February 2017|2017-02-01|January 2020|Anticipated|2020-01-01|January 2020|Anticipated|2020-01-01||Observational|FORWARD||Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes|A Global, Multicenter, Observational Study Evaluating the Impact of rFVIIIFc and rFIXFc on Patient-reported Treatment Burden and Health Economic Outcomes|Terminated||N/A|3|Actual|Bioverativ Therapeutics Inc.|||4|Study terminated due to recruitment challenges.|f||||f||||||||||2017-10-10 23:30:00.281863|2017-10-10 23:30:00.281863
NCT02391038|ClinicalTrials.gov processed this data on October 10, 2017|2014-11-28|2017-02-08|2016-11-04||December 2014||2014-12-01|February 2017|2017-02-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional||Safety population included all participants who received any amount of study drug.|MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C|A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC)|Terminated||Phase 1|12|Actual|Takeda||1||"The study was terminated because preliminary PK and overall clinical data demonstrated   compelling similarity between Western and Asian participant populations."|f||||f||||||||||2017-10-10 23:30:12.381363|2017-10-10 23:30:12.381363
NCT02388971|ClinicalTrials.gov processed this data on October 10, 2017|2015-02-23|2015-12-08|||April 2016||2016-04-01|December 2015|2015-12-01|April 2016|Anticipated|2016-04-01|April 2016|Anticipated|2016-04-01||Interventional|||Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease|A Randomized, Double-Blind Placebo- Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects With Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging|Withdrawn||Phase 2|0|Actual|Takeda||2||Study has withdrawn.|f||||f||||||||||2017-10-10 23:30:38.53335|2017-10-10 23:30:38.53335
NCT02380937|ClinicalTrials.gov processed this data on October 10, 2017|2015-02-16|2015-11-14|||January 2015||2015-01-01|November 2015|2015-11-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional|||Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking|Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking: Pilot Study Using a Combination Imricor and Philips Interventional System|Terminated||N/A|8|Actual|Heartcenter Leipzig GmbH||1||"The study was terminated prematurely on 05May 2015 because of the unavailability of study   devices."|f||||f||||||||||2017-10-10 23:32:05.921168|2017-10-10 23:32:05.921168
NCT02380209|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-09|2016-10-25|||August 2014||2014-08-01|October 2016|2016-10-01|August 2016|Actual|2016-08-01|August 2016|Actual|2016-08-01||Interventional|||An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer|An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer|Terminated||Early Phase 1|8|Actual|University of Arizona||1||"PI has terminated study as the sequencing on patients and volunteers didn't yield the results   expected. PI has no plans for scholarly/scientific presentations."|f||||t||||||||||2017-10-10 23:32:13.667098|2017-10-10 23:32:13.667098
NCT02374723|ClinicalTrials.gov processed this data on October 10, 2017|2015-02-23|2016-04-14|||June 2015||2015-06-01|April 2016|2016-04-01|April 2016|Actual|2016-04-01|April 2016|Actual|2016-04-01||Interventional|||Evaluation of Biosynthetic Constructs to Replace Donor Corneas|Evaluation of Biosynthetic Constructs as Replacement for Donor Corneas as Graft Material for Corneal Transplantation|Withdrawn||Phase 1|0|Actual|Region Östergötland||2||This study was withdrawn to be replaced with a multi-site Phase I trial.|f||||t||||||||||2017-10-10 23:33:08.486451|2017-10-10 23:33:08.486451
NCT02373397|ClinicalTrials.gov processed this data on October 10, 2017|2015-02-16|2017-04-25|||March 2015||2015-03-01|April 2017|2017-04-01|December 2017|Anticipated|2017-12-01|December 2017|Anticipated|2017-12-01||Interventional|CACICOL-PTK||Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy|Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy of the Anterior Cornea: A Randomized Double-Blinded Placebo-Controlled Study|Terminated||Phase 4|40|Actual|Region Östergötland||2||Study terminated due to poor patient recruitment|f||||f||||||||||2017-10-10 23:33:22.482605|2017-10-10 23:33:22.482605
NCT02372578|ClinicalTrials.gov processed this data on October 10, 2017|2015-02-21|2017-05-10||2017-05-10|May 27, 2015|Actual|2015-05-27|April 2017|2017-04-01|May 20, 2016|Actual|2016-05-20|May 20, 2016|Actual|2016-05-20||Interventional|||Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy|A Phase 2a Randomized, Double-Blind, Multicenter, Placebo and Active Controlled Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy|Terminated||Phase 2|116|Actual|Astellas Pharma Inc||3||The study was terminated due to futility analysis.|f||||t||||||||Undecided||2017-10-10 23:33:29.168629|2017-10-10 23:33:29.168629
NCT02371577|ClinicalTrials.gov processed this data on October 10, 2017|2015-02-13|2017-04-26|||February 1, 2017|Anticipated|2017-02-01|April 2017|2017-04-01|December 2020|Anticipated|2020-12-01|December 2018|Anticipated|2018-12-01||Interventional|Revlimid||Evaluation of the Immune Restoration Potential Of Lenalidomide|A Phase 2 Clinical Trial To Evaluate The Immune Restoration Potential Of Lenalidomide For Patients With CLL-Associated Immunodeficiency|Withdrawn||Phase 2|0|Actual|University of California, San Diego||1||withdrawn|f||||t|t|f||||||||2017-10-10 23:33:42.651975|2017-10-10 23:33:42.651975
NCT02368639|ClinicalTrials.gov processed this data on October 10, 2017|2015-02-08|2017-08-09|||January 2015|Actual|2015-01-01|August 2017|2017-08-01|March 2016|Actual|2016-03-01|March 2016|Actual|2016-03-01||Interventional|||Feasibility of a Modified Positive Airway Pressure Device to Treat Sleep Disordered Breathing|Feasibility of a Modified Positive Airway Pressure Device to Treat Sleep Disordered Breathing|Terminated||N/A|14|Actual|Fisher and Paykel Healthcare||1||The study was terminated due to recruitment slower than anticipated|f||||f||||||||||2017-10-10 23:34:15.267016|2017-10-10 23:34:15.267016
NCT02366637|ClinicalTrials.gov processed this data on October 10, 2017|2014-09-02|2016-05-24|2016-03-03||January 2015||2015-01-01|May 2016|2016-05-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional|||An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Placebo-controlled 2-way Crossover Study To Evaluate The Efficacy, Safety And Tolerability Of Pf-03715455 Administered Twice Daily By Inhalation For 4 Weeks In Subjects With Moderate To Severe Chronic Obstructive Pulmonary Disease (Copd)|Terminated||Phase 2|13|Actual|Pfizer|As this study was prematurely terminated by the sponsor for business reasons, no formal safety or efficacy conclusions can be drawn due to insufficient participant numbers. In addition, PK analysis was not conducted.|2||"Study terminated on 7 April 2015 for business reasons. No safety and/or efficacy concerns   contributed to the termination of the study"|f||||t||||||||||2017-10-10 23:34:42.560655|2017-10-10 23:34:42.560655
NCT02366234|ClinicalTrials.gov processed this data on October 10, 2017|2015-02-06|2016-12-20|||January 2015||2015-01-01|December 2016|2016-12-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Observational|||Symptomatic Treatment of Distal Tubercle Fractures of the Scaphoid|Symptomatic Treatment of Distal Tubercle Fractures of the Scaphoid|Withdrawn||N/A|0|Actual|Massachusetts General Hospital|||1|The investigator left the institution so the study was terminated.|f||||f||||||||||2017-10-10 23:34:46.204649|2017-10-10 23:34:46.204649
NCT02365688|ClinicalTrials.gov processed this data on October 10, 2017|2014-09-09|2017-06-20|2016-03-07||September 2014||2014-09-01|June 2017|2017-06-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional||Self hemodynamic baseline before surgical incision.|Hemodynamic Response During Goal Directed Fluid Therapy in the OR|Correlation of Multiple Invasive and Non-Invasive Hemodynamic Monitored Modalities to Support Goal Directed Fluid Therapy During Open Abdominal Surgery|Terminated||N/A|18|Actual|Medtronic - MITG|Reference devices did not agree so trial terminated.|1||Lack of consistent reference devices|f||||f||||||||No|Data collected for new algorithm development|2017-10-10 23:34:51.348719|2017-10-10 23:34:51.348719
NCT02355431|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-30|2015-11-16|||December 2014||2014-12-01|November 2015|2015-11-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional|||INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations|A Randomized, Double-blind Phase 2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB/ IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Activating Mutations|Withdrawn||Phase 2|0|Actual|Incyte Corporation||2||Study withdrawn before enrolling first patient|f||||t||||||||||2017-10-10 23:36:42.993804|2017-10-10 23:36:42.993804
NCT02353572|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-28|2015-02-23|2015-02-23||November 2009||2009-11-01|January 2015|2015-01-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional||Based on the annual number of referrals made to the Myeloma and Amyloidosis Program, expected accrual to this study was about 20 patients per year.|Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase I-II Study of Infusional Melphalan + Bortezomib for Myeloablative Therapy Prior to Autologous Transplant for Patients With Multiple Myeloma|Terminated||Phase 1/Phase 2|3|Actual|University of Colorado, Denver|This study was terminated due to the investigator's departure from the institution.|1||Principle investigator left the institution|f||||t||||||||||2017-10-10 23:37:02.56278|2017-10-10 23:37:02.56278
NCT02353468|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-28|2015-02-23|2015-02-23||December 2009||2009-12-01|January 2015|2015-01-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional||The study had planned to enroll sixty-two patients in order to achieve sufficient power, 81% to detect an improvement in 3-year event-free survival.|Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant|Phase II Study: Therapy With Bortezomib + Lenalidomide + Dexamethasone With Lenalidomide + Dexamethasone as Post Transplant Consolidation and Maintenance for Patients With Symptomatic Multiple Myeloma Following Autologous Transplantation|Terminated||Phase 2|3|Actual|University of Colorado, Denver|This study was terminated due to the investigator's departure from the institution.|1||Principle investigator left the institution|f||||t||||||||||2017-10-10 23:37:03.360882|2017-10-10 23:37:03.360882
NCT02349659|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-09|2017-01-30|||December 2014||2014-12-01|January 2017|2017-01-01|October 2017|Anticipated|2017-10-01|July 2017|Anticipated|2017-07-01||Interventional|SMASHING||A Multi-Centre RCT of the Axium® Neurostimulator for the Treatment of Chronic Inguinal Pain Following Surgery|A Randomised Controlled Trial to Evaluate the Efficacy of the Spinal Modulation Axium® NeuroStimulator THerapy as a Treatment for Persistent INGuinal Pain Following Surgical Intervention: SMASHING|Terminated||N/A|18|Actual|Maxima Medical Center||2||Sponsor withdrawn due to low inclusion rate|f||||f||||||||||2017-10-10 23:37:43.207364|2017-10-10 23:37:43.207364
NCT02346422|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-15|2017-01-30||2017-01-30|April 2015||2015-04-01|January 2017|2017-01-01||||June 26, 2015|Actual|2015-06-26||Interventional|||A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure|A Phase 1/2 Study of the Safety and Preliminary Activity of MYDICAR® at a Dose of 2.5 x 10^13 DNase Resistant Particles (DRP) in Subjects With Advanced Heart Failure Divided Into 2 Phases: Phase 1 Open-label and Phase 2 Randomized, Double-blind, Placebo-controlled|Terminated||Phase 1/Phase 2|9|Actual|Celladon Corporation||2||Sponsor has suspended clinical development of MYDICAR for heart failure.|f||||t||||||||||2017-10-10 23:38:19.471059|2017-10-10 23:38:19.471059
NCT02345538|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-20|2016-06-17||||||June 2016|2016-06-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Observational|||Use of a Perineometer to Assess Pelvic Muscle Tone|Use of a Perineometer to Assess Resting Pelvic Muscle Tone in Patients With Pelvic Pain|Withdrawn||N/A|0|Actual|Duke University|||2|"Investigator did not start the project in time; study team decided it was not feasible to begin   study as resident was soon graduating. No patients enrolled."|f||||f||||||||No|study withdrawn|2017-10-10 23:38:29.823882|2017-10-10 23:38:29.823882
NCT02342548|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-15|2017-03-09|||February 25, 2015|Actual|2015-02-25|March 2017|2017-03-01|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021|An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021|Terminated||Phase 2|188|Actual|Pfizer||2||"Study terminated on 15DEC2016 due to study A8241021 showing no significant difference on   primary endpoint between PF-02545920 & placebo. No safety concerns."|f||||t||||||||||2017-10-10 23:39:02.230649|2017-10-10 23:39:02.230649
NCT02336425|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-08|2017-08-07|2017-02-21||September 2015||2015-09-01|August 2017|2017-08-01|March 2016|Actual|2016-03-01|March 2016|Actual|2016-03-01||Interventional|||Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma|A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of 52 Weeks Treatment With QGE031 Subcutaneous (s.c). in Asthma Patients Not Adequately Controlled by Medium- or High-dose Inhaled Corticosteroid (ICS) Plus Long Acting β2-agonist (LABA) With or Without Oral Corticosteroid (OCS)|Terminated||Phase 2|10|Actual|Novartis|Study was terminated due to the efficacy results from the Phase II study CQGE031B2201 (NCT01716754). Data analyses were not performed due to the very limited dataset (only 10 participants received study medication of the 440 participants planned).|4||"This study was terminated due to the efficacy results from an interim analysis (at the end of   treatment epoch) of the Phase II study CQGE031B2201 (NCT01716754)."|f||||t||||||||||2017-10-10 23:40:14.26307|2017-10-10 23:40:14.26307
NCT02335489|ClinicalTrials.gov processed this data on October 10, 2017|2015-01-07|2017-08-28|2017-04-24||March 2013||2013-03-01|August 2017|2017-08-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Observational|||A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg|A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg|Terminated||N/A|10|Actual|St. Jude Medical|||1|"A significant local issue has to led to the suspension of recruitment, this study will be   terminated in the coming months"|f||||f||||||||||2017-10-10 23:40:23.364647|2017-10-10 23:40:23.364647
NCT02327182|ClinicalTrials.gov processed this data on October 10, 2017|2014-12-23|2015-11-12|||December 2014||2014-12-01|November 2015|2015-11-01|October 2015|Actual|2015-10-01|September 2015|Actual|2015-09-01||Interventional|||Safety Study of MT-4666 in Subjects With Alzheimer's Disease|A Long-Term Safety Study of MT-4666 in Patients With Mild to Moderate Alzheimer's Disease (AD)|Terminated||Phase 3|117|Actual|Mitsubishi Tanabe Pharma Corporation||2||This study was terminated due to the benefit-risk balance of MT-4666.|f||||f||||||||||2017-10-10 23:41:55.413802|2017-10-10 23:41:55.413802
NCT02323269|ClinicalTrials.gov processed this data on October 10, 2017|2014-12-18|2016-04-07|||May 2015||2015-05-01|April 2016|2016-04-01|March 2016|Actual|2016-03-01|March 2016|Actual|2016-03-01||Observational|IMPROVE||Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)|A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing-Remitting Multiple Sclerosis, Who Are Either Treatment-Naïve or Switching From an Interferon or Glatiramer Acetate After Suboptimal Response (ImPROve)|Terminated||N/A|24|Actual|Biogen|||2|"109MS415 ImPROve study was terminated due to patient enrollment challenges and feasibility .   The decision was not a result of safety concerns."|f||||f||||||||||2017-10-10 23:42:40.89627|2017-10-10 23:42:40.89627
NCT02322541|ClinicalTrials.gov processed this data on October 10, 2017|2014-12-08|2017-06-02|||September 2016||2016-09-01|June 2017|2017-06-01|December 2016|Anticipated|2016-12-01|December 2016|Anticipated|2016-12-01||Interventional|||Dietary Absorption of Garlic Metabolites Following Garlic Consumption||Withdrawn||N/A|0|Actual|USDA Beltsville Human Nutrition Research Center||1||This study was suspended due to additional time needed for method development.|f||||f||||||||||2017-10-10 23:42:51.84421|2017-10-10 23:42:51.84421
NCT02317419|ClinicalTrials.gov processed this data on October 10, 2017|2014-12-11|2016-07-22|||December 2014||2014-12-01|July 2016|2016-07-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional|||A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors|PHASE IA/IB, OPEN-LABEL, MULTICENTER, MULTIPLE ASCENDING DOSE STUDY FOLLOWED BY AN EXTENSION PHASE TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ACTIVITY OF RO6927005, AN ANTI-MESOTHELIN (MSLN) RECOMBINANT CYTOLYTIC FUSION PROTEIN (cFP), ADMINISTERED EITHER ALONE (PART A) OR IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL (PART B) IN PATIENTS WITH MESOTHELIN-POSITIVE METASTATIC AND/OR LOCALLY ADVANCED MALIGNANT SOLID TUMORS|Terminated||Phase 1|15|Actual|Hoffmann-La Roche||5||"The study was prematurely terminated because the emerging benefit:risk ratio did not justify   continuing dosing patients."|f||||||||||||||2017-10-10 23:43:53.34037|2017-10-10 23:43:53.34037
NCT02314793|ClinicalTrials.gov processed this data on October 10, 2017|2014-12-08|2016-06-17|||November 2014||2014-11-01|June 2016|2016-06-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205|A Phase 1 Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of ASP2205|Terminated||Phase 1|93|Actual|Astellas Pharma Inc||7||The study has been terminated because of operational reasons.|f||||f||||||||||2017-10-10 23:44:26.001087|2017-10-10 23:44:26.001087
NCT02311491|ClinicalTrials.gov processed this data on October 10, 2017|2014-12-04|2017-08-25|||December 2016||2016-12-01|August 2017|2017-08-01|August 2017|Anticipated|2017-08-01|December 2016|Anticipated|2016-12-01||Interventional|||Nano-Crystalline Ceramic Coating of Orthodontic Archwires|Nano-Crystalline Ceramic Coating for the Reduction of Sliding Resistance of Orthodontic Archwires|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2||Funding terminated|f||||f||||||||||2017-10-10 23:45:09.6718|2017-10-10 23:45:09.6718
NCT02310971|ClinicalTrials.gov processed this data on October 10, 2017|2014-11-15|2015-04-01|||February 2015||2015-02-01|March 2015|2015-03-01|March 2015|Actual|2015-03-01|March 2015|Actual|2015-03-01||Interventional|||Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas|A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas|Withdrawn||Phase 2|0|Actual|Prima BioMed Ltd||1||"The trial has been terminated per Sponsor direction due to longer than expected clinical and   regulatory approvals."|f||||t||||||||||2017-10-10 23:45:13.546232|2017-10-10 23:45:13.546232
NCT02310581|ClinicalTrials.gov processed this data on October 10, 2017|2014-12-01|2017-08-03|2017-06-01|2015-12-07|February 24, 2015|Actual|2015-02-24|June 2017|2017-06-01|March 19, 2015|Actual|2015-03-19|March 19, 2015|Actual|2015-03-19||Interventional||All participants who were randomized.|Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain|A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain|Terminated||Phase 3|40|Actual|INSYS Therapeutics Inc|This study was terminated early by the sponsor due to business reasons (40 participants enrolled out of 312 planned). Due to this early termination 10 outcome measures originally registered as pre-specified secondary are no longer secondaries.|4||Business decision|f||||f||||||||||2017-10-10 23:45:25.240751|2017-10-10 23:45:25.240751
NCT02310568|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-24|2016-11-16|2016-09-26||November 2014||2014-11-01|September 2016|2016-09-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional|||POC Study in Partially Responsive Generalized Anxiety Disorder|An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder|Terminated||Phase 2|90|Actual|Pfizer|All 34 centres who enrolled subjects were terminated due to internal sponsor portfolio prioritization. The decision to terminate the study was not due to any safety concern or change in the benefit:risk assessment of PF-06372865|5||"Study recruitment was terminated on 24 June 2015, due to a Pfizer business decision. This study   was not terminated for reasons of safety or efficacy"|f||||t||||||||||2017-10-10 23:45:26.305942|2017-10-10 23:45:26.305942
NCT02306876|ClinicalTrials.gov processed this data on October 10, 2017|2014-11-20|2017-08-14|||January 19, 2015|Actual|2015-01-19|August 2017|2017-08-01|June 14, 2016|Actual|2016-06-14|June 14, 2016|Actual|2016-06-14||Interventional|||A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males|A Randomized,Subject And Investigator Blind, Sponsor Open Placebo Controlled, Parallel Phase 1b Study To Examine The Safety, Pharmacokinetics, And Pharmacodynamic Effects Of Pf‑06412562 On Cognitive And Reward/Motivation Domains In Healthy Male Volunteers Selected By Cognitive Phenotype|Terminated||Phase 1|77|Actual|Pfizer||3||"Study recruitment was terminated on 14 June 2016 due to a Pfizer business decision. This study   was not terminated for reasons of safety."|f||||f|t|f||||||||2017-10-10 23:46:10.320197|2017-10-10 23:46:10.320197
NCT02300935|ClinicalTrials.gov processed this data on October 10, 2017|2014-11-21|2016-01-14|||January 2016||2016-01-01|January 2016|2016-01-01|November 2018|Anticipated|2018-11-01|March 2018|Anticipated|2018-03-01||Interventional|||Study of Trametinib and Nab-paclitaxel in Patients With Melanoma|Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma|Withdrawn||Phase 1|0|Actual|SCRI Development Innovations, LLC||1||Study concept was terminated.|f||||f||||||||||2017-10-10 23:47:16.130965|2017-10-10 23:47:16.130965
NCT02299635|ClinicalTrials.gov processed this data on October 10, 2017|2014-11-20|2016-11-17|2016-11-17||February 2015||2015-02-01|November 2016|2016-11-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional|||A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations|Phase 2 Study Of Single-agent Pf-03084014 In Patients With Advanced Triple-negative Breast Cancer With Or Without Genomic Alterations In Notch Receptors|Terminated||Phase 2|19|Actual|Pfizer|This study was terminated prematurely based on project re-prioritization by the Sponsor and was not due to any safety concerns or regulatory actions.|1||"The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014   development. There were no safety/efficacy concerns behind the decision."|f||||f||||||||||2017-10-10 23:47:30.681278|2017-10-10 23:47:30.681278
NCT02293720|ClinicalTrials.gov processed this data on October 10, 2017|2014-11-11|2016-09-13|||April 2015||2015-04-01|November 2014|2014-11-01|July 2016|Actual|2016-07-01|July 2016|Actual|2016-07-01||Interventional|OLE||An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System|An Open-Label Extension to Protocol 09-1, Multi-Center, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects|Withdrawn||N/A|0|Actual|GI Dynamics||1||This was the cross over study for 09-1 which was terminated early|f||||t||||||||No||2017-10-10 23:48:50.453408|2017-10-10 23:48:50.453408
NCT02293525|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-27|2016-01-20||||||January 2016|2016-01-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional|||Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain|Investigational Plan for the Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain|Withdrawn||N/A|0|Actual|Vital 5, LLC||2||No subjects were enrolled and the sponsor suspended support at this time|f||||f||||||||||2017-10-10 23:48:53.758386|2017-10-10 23:48:53.758386
NCT02289482|ClinicalTrials.gov processed this data on October 10, 2017|2014-11-10|2017-05-12|||November 17, 2014|Actual|2014-11-17|May 2017|2017-05-01|March 10, 2015|Actual|2015-03-10|March 10, 2015|Actual|2015-03-10||Interventional|||A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects|A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 With and Without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects|Terminated||Phase 1|20|Actual|GlaxoSmithKline||2||Study prematurely terminated due to safety concerns leading to clinical hold|f||||f||||||||||2017-10-10 23:49:40.226325|2017-10-10 23:49:40.226325
NCT02286882|ClinicalTrials.gov processed this data on October 10, 2017|2014-11-06|2015-07-16|||November 2014||2014-11-01|July 2015|2015-07-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|||A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06409577 In Healthy Adult Subjects|Terminated||Phase 1|39|Actual|Pfizer||9||"The trial was terminated prematurely on June 19, 2015 for business reasons. There were no   safety concerns in the study which led to the decision."|f||||f||||||||||2017-10-10 23:50:15.17444|2017-10-10 23:50:15.17444
NCT02286258|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-29|2017-08-28|||October 2014|Actual|2014-10-01|August 2017|2017-08-01|October 2017|Anticipated|2017-10-01|October 2017|Anticipated|2017-10-01||Interventional|MultiGFR||Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)|MultiGFR: Equivalency Study of Different Methods of Measuring Glomerular Filtration Rate|Suspended||Phase 1/Phase 2|350|Anticipated|Assistance Publique - Hôpitaux de Paris||2||The study was suspended after a suspected unexpected serious adverse event.|f||||f||||||||||2017-10-10 23:50:24.812249|2017-10-10 23:50:24.812249
NCT02285465|ClinicalTrials.gov processed this data on October 10, 2017|2014-11-05|2015-01-09|||November 2014||2014-11-01|January 2015|2015-01-01|November 2014|Actual|2014-11-01|November 2014|Actual|2014-11-01||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects|A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of ASP3700 in Healthy Subjects|Withdrawn||Phase 1|0|Actual|Astellas Pharma Inc||2||Study terminated due to sponsor decision|f||||f||||||||||2017-10-10 23:50:33.349176|2017-10-10 23:50:33.349176
NCT02276560|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-21|2017-03-29|2017-03-29||January 2015||2015-01-01|March 2017|2017-03-01|June 2016|Actual|2016-06-01|June 2016|Actual|2016-06-01||Interventional|LCCC1407||Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC|Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|1|Actual|UNC Lineberger Comprehensive Cancer Center||3||This study was terminated due to lack of funding.|f||||t||||||||No||2017-10-10 23:52:21.555246|2017-10-10 23:52:21.555246
NCT02275481|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-23|2017-09-28|2017-09-05||November 2014|Actual|2014-11-01|September 2017|2017-09-01|September 14, 2016|Actual|2016-09-14|September 14, 2016|Actual|2016-09-14||Interventional||full analysis set|A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects|A Comparative Effectiveness and Safety Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects|Terminated||Phase 4|66|Actual|Sunovion|study was terminated early due to lack of enrollment|2||lack of enrollment|f||||f||||||||||2017-10-10 23:52:36.01991|2017-10-10 23:52:36.01991
NCT02274077|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-08|2016-07-06|||January 2016||2016-01-01|July 2016|2016-07-01|June 2017|Anticipated|2017-06-01|March 2017|Anticipated|2017-03-01||Interventional|||Transverse Abdominal Plane Anesthesia for Abdominal Wall Reconstruction|Abdominal Wall Reconstruction: Postoperative Outcomes Using Transverse Abdominal Plane Anesthesia|Withdrawn||Phase 4|0|Actual|University of Rochester||2||funding for the study was terminated|f||||t||||||||||2017-10-10 23:52:53.922781|2017-10-10 23:52:53.922781
NCT02273856|ClinicalTrials.gov processed this data on October 10, 2017|2014-09-02|2016-06-17|||January 2015||2015-01-01|May 2016|2016-05-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Observational|NADIR||Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)|Prospective Multicentre Observational Registry Of Treatments And Outcomes In Patients With Chronic Lymphocytic Leukaemia Or Indolent Non Hodgkin's Lymphoma|Terminated||N/A|25|Actual|Astellas Pharma Inc|||4|The study was terminated due to insufficient subject enrollment and very slow enrollment.|f||||f||||||||||2017-10-10 23:52:56.720333|2017-10-10 23:52:56.720333
NCT02263677|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-01|2016-10-03|||March 2014||2014-03-01|October 2016|2016-10-01|January 2016|Actual|2016-01-01|December 2015|Anticipated|2015-12-01||Interventional|||Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI|Pilot Project Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI|Withdrawn||Phase 4|0|Actual|University of Missouri-Columbia||1||Technical difficulties have caused this study to be terminated|f||||f||||||||No||2017-10-10 23:54:46.662851|2017-10-10 23:54:46.662851
NCT02261805|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-07|2017-07-10|||October 2014|Actual|2014-10-01|October 2016|2016-10-01|October 2016|Actual|2016-10-01|October 2016|Actual|2016-10-01||Interventional|||A Phase I/II Study of Ganetespib in Combination With Doxorubicin|A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)|Terminated||Phase 1/Phase 2|10|Actual|Georgetown University||1||Company terminated drug support|f||||t||||||||||2017-10-10 23:56:28.278553|2017-10-10 23:56:28.278553
NCT02260882|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-06|2017-03-13|2016-01-19||October 2014||2014-10-01|March 2017|2017-03-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional||One participant in the Primary Vaccination Group was withdrawn from the study before vaccination because of a protocol violation. Baseline Characteristics are based on the Full Analysis Set: participants who received at least one vaccination.|Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)|A Study Evaluating the Safety and Immunogenicity of Revaccination With 23-Valent Pneumococcal Polysaccharide Vaccine in Older Japanese Adults|Completed||Phase 4|243|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT02259348|ClinicalTrials.gov processed this data on October 10, 2017|2014-10-03|2017-04-24|2016-03-10||October 2014||2014-10-01|September 2016|2016-09-01|March 2016|Actual|2016-03-01|April 2015|Actual|2015-04-01||Interventional|||Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation|CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation|Terminated||Phase 2|12|Actual|St. Jude Children's Research Hospital|The trial was terminated early due to investigator's decision.|1||Investigator's decision.|f||||f||||||||||2017-10-10 23:56:57.216823|2017-10-10 23:56:57.216823
NCT02246114|ClinicalTrials.gov processed this data on October 10, 2017|2014-09-15|2016-11-21|2016-09-29||September 2014||2014-09-01|November 2016|2016-11-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional|||Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women|Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women|Terminated||N/A|1|Actual|Milton S. Hershey Medical Center|The study closed early due to lack of recruitment. Only 1 subject enrolled in the study and she terminated after the baseline visit due to a miscarriage at 9 weeks. Therefore no analysis has been performed.|2||Lack of Recruitment|f||||f||||||||||2017-10-10 23:59:44.587424|2017-10-10 23:59:44.587424
Baseline participants less than participant flow as no abdominal pain within 3 weeks following randomization were withdrawn."|Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort|A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Hyoscine Butylbromide Capsule 10mg, to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets 10 mg (20mg, 3 Times Daily, Orally) Over a Period of 3 Days for the Treatment of Occasional or Recurrent Episodes of Self-reported Gastric or Intestinal Spasm-like Pain|Completed||Phase 3|302|Actual|Boehringer Ingelheim||2|||f||||||||||||||2017-10-11 00:00:38.577192|2017-10-11 00:00:38.577192
NCT02241798|ClinicalTrials.gov processed this data on October 10, 2017|2014-09-12|2017-03-10|||August 2013||2013-08-01|March 2017|2017-03-01|March 2016|Actual|2016-03-01|August 2014|Actual|2014-08-01||Interventional|||Pre-oxygenation and Measures of Gas Exchanges During Seizures in the Epilepsy Monitoring Unit|Effects of Pre-oxygenation on Indicators of Gas Exchange and Autonomic Function During Seizures in the Epilepsy Unit|Terminated||N/A|5|Actual|New York University School of Medicine||2||Investigator is leaving the institution and has terminated the study.|f||||f||||||||||2017-10-11 00:00:43.673842|2017-10-11 00:00:43.673842
NCT02241486|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-12|2017-06-30|2017-05-05||September 2013||2013-09-01|June 2017|2017-06-01|March 2015|Actual|2015-03-01|September 2014|Actual|2014-09-01||Interventional||Only two patients were initially enrolled in this trial, which was terminated prematurely.|Sublingual Fentanyl and Procedural Burn Pain|A Randomized, Double-blind, Placebo-controlled, Cross-over Trial of Sublingual Fentanyl Spray (Subsys) and Oral Morphine for Procedural Wound Care in Adult Patients With Burn Injury Pain|Terminated||Phase 3|2|Actual|Loyola University|This trial was terminated prematurely due to a lack of study funding.|1||No funding source.|f||||f||||||||||2017-10-11 00:00:46.685235|2017-10-11 00:00:46.685235
NCT02240355|ClinicalTrials.gov processed this data on October 10, 2017|2014-09-11|2016-12-20|||November 2014||2014-11-01|December 2016|2016-12-01|July 2015|Actual|2015-07-01|July 2015|Actual|2015-07-01||Interventional|||A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)|A Multicenter, Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6885247 Following 12 Weeks of Treatment in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH).|Terminated||Phase 1|9|Actual|Hoffmann-La Roche||3||"There was an unexpected toxicology finding observed in the 39 week monkey study. Dosing was   suspended, the study was put on hold and eventually terminated."|f||||||||||||||2017-10-11 00:01:01.301015|2017-10-11 00:01:01.301015
NCT02239926|ClinicalTrials.gov processed this data on October 10, 2017|2014-09-11|2016-02-16|2016-01-05||September 2014||2014-09-01|February 2016|2016-02-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional|Ranolazine||Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D|Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)|Terminated||Phase 2/Phase 3|5|Actual|Mayo Clinic|The study was terminated early due to enrollment issues.|2||Difficulty in enrolling subjects|f||||f||||||||||2017-10-11 00:01:06.610287|2017-10-11 00:01:06.610287
NCT02227368|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-19|2017-06-21|2017-05-19||October 20, 2014|Actual|2014-10-20|June 2017|2017-06-01|May 23, 2016|Actual|2016-05-23|May 23, 2016|Actual|2016-05-23||Interventional|TI-PAD EVR|All randomised subjects with the exception of one subject who did not undergo EVR.|Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR|A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR|Terminated||Phase 2|40|Actual|AstraZeneca|This study was terminated early for low enrolment. Less than 25% of anticipated number of subjects were enroled and there was an imbanlance between groups. Therefore, the results should be interpreted with caution.|2|||f||||f||||||||||2017-10-11 00:03:53.80288|2017-10-11 00:03:53.80288
NCT02227108|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-21|2017-03-09|2016-08-04||August 2014||2014-08-01|March 2017|2017-03-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional||The intent-to-treat (ITT) population included all participants who entered the study.|Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma|A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin|Terminated||Phase 2|37|Actual|MedImmune LLC|The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled.|1||"The study was terminated prior to a planned interim analysis based on lack of required efficacy   in the first 32 participants enrolled."|f||||t||||||||||2017-10-11 00:03:59.562274|2017-10-11 00:03:59.562274
NCT02224859|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-28|2015-03-23|||March 2014||2014-03-01|March 2015|2015-03-01|January 2015|Anticipated|2015-01-01|January 2015|Anticipated|2015-01-01||Interventional|INV-CS-001||Invictus Medical, Medical Cranial Support Device (CSD) is a Device Safety Study in Infants at Risk of Head Ulcers.|Clinical Safety and Utility of the Invictus Cranial Support Device (CSD)|Withdrawn||N/A|0|Actual|Invictus Medical, Inc.||1||Organization has withdrawn their 510k submission and stopped the study|f||||t||||||||||2017-10-11 00:04:26.042419|2017-10-11 00:04:26.042419
NCT02223975|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-21|2017-08-03|||August 2014||2014-08-01|August 2017|2017-08-01|August 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|Vulval VS||Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease|Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease|Suspended||N/A|200|Anticipated|Gloucestershire Hospitals NHS Foundation Trust|||1|Study suspended pending further funding|f||||f||||||Samples With DNA|"     Histological sections of vulval and lymph node tissue.   "|||2017-10-11 00:04:44.322792|2017-10-11 00:04:44.322792
NCT02222207|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-20|2016-07-25|2016-06-11|2015-10-12|October 2014||2014-10-01|July 2016|2016-07-01|June 2015|Actual|2015-06-01|May 2015|Actual|2015-05-01||Interventional|DREAM||Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration|A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration|Terminated||Phase 2|52|Actual|Bayer|As the study was prematurely terminated since pre-defined proof of concept (PoC) criteria were not met in Part A, hence part B was not initiated. Part B related end points and data were not reported since it is not conducted.|8|||f||||t||||||||||2017-10-11 00:05:08.230956|2017-10-11 00:05:08.230956
NCT02221648|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-01|2016-07-18|2015-09-07||December 2012||2012-12-01|July 2016|2016-07-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional|||Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain|Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain|Terminated||Phase 2|43|Actual|Yale University|This study was terminated due to relocation of the PI. The initial goal was enrolling 90 patients. The number enrolled at the time of termination was 43, with 37 completed the study. Results may not provide enough statistical power.|2||PI retired and moved- funding sponsor contacted and Oked|f||||f||||||||||2017-10-11 00:05:17.317024|2017-10-11 00:05:17.317024
NCT02218216|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-13|2017-06-22|2017-04-27||September 2014||2014-09-01|June 2017|2017-06-01|November 2015|Actual|2015-11-01|May 2015|Actual|2015-05-01||Interventional|||TBI MR Study 3 Houston Methodist|Advanced MRI Applications for Mild Traumatic Brain Injury - Study 3|Terminated||N/A|16|Actual|GE Healthcare|Early termination due to limited enrollment|2||Sponsor terminated study early to start a larger feasability study|f||||f||||||||No||2017-10-11 00:06:11.01969|2017-10-11 00:06:11.01969
NCT02217202|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-12|2014-08-13|||April 2014||2014-04-01|August 2014|2014-08-01|September 2014|Anticipated|2014-09-01|July 2014|Anticipated|2014-07-01||Observational|||Study of AQUACEL™ Ag Surgical Cover Dressing Following Total Knee Replacement|Prospective Cohort Study of the AQUACEL™ Ag SURGICAL Cover Dressing in Total Knee Replacement Surgery|Withdrawn||N/A|0|Actual|Golden Jubilee National Hospital|||1|Funding withdrawn before ethical approval granted|f||||f||||||||||2017-10-11 00:06:23.535037|2017-10-11 00:06:23.535037
NCT02216201|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-07|2014-11-07|||December 2014||2014-12-01|November 2014|2014-11-01||||December 2015|Anticipated|2015-12-01||Observational|||Clinical Utility of SUDOSCAN in the Pediatric Population|Clinical Utility of SUDOSCAN in the Pediatric Population|Withdrawn||N/A|0|Actual|Impeto Medical|||1|Sponsor terminated study|f||||||||||||||2017-10-11 00:06:36.258661|2017-10-11 00:06:36.258661
NCT02216097|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-12|2016-05-26|2016-03-10||October 2014||2014-10-01|May 2016|2016-05-01|March 2015|Actual|2015-03-01|March 2015|Actual|2015-03-01||Interventional|||A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder|A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase 2 Study To Assess Effects Of Pf 04457845 On Bold Functional Mri In Subjects With Ptsd|Terminated||Phase 2|14|Actual|Pfizer|There were no efficacy evaluations done in this study because of a change in the planned analysis after the study was prematurely terminated due to GCP non-compliance that resulted in data integrity and quality issues.|2||"The study stopped based on Pfizer portfolio prioritization and not due to safety and/or   efficacy concern or change in benefit:risk assessment of PF-04457845."|f||||f||||||||||2017-10-11 00:06:37.338733|2017-10-11 00:06:37.338733
NCT02211508|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-06|2016-08-05||2015-07-27|July 2014||2014-07-01|August 2016|2016-08-01|February 2015|Actual|2015-02-01|February 2015|Actual|2015-02-01||Interventional|PERRFECT-301||Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301|A Double-Blinded, Randomized, Sham-Controlled, Pivotal Study of the NeuroPoint Device for the Treatment of Pain Associated With Fibromyalgia|Terminated||N/A|236|Actual|Cerephex Corporation||2||"Trial terminated Feb '15. Interim analysis results missed primary endpoint, intended signal not   delivered in Tx arm, sham results as expected. No safety issues."|f||||f||||||||||2017-10-11 00:07:40.823909|2017-10-11 00:07:40.823909
NCT02210676|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-05|2016-12-20|||June 2014||2014-06-01|December 2016|2016-12-01||||January 2016|Actual|2016-01-01||Interventional|||Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger|Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1||Due to the investigator leaving the institution, the study was terminated|f||||f||||||||||2017-10-11 00:07:51.716698|2017-10-11 00:07:51.716698
NCT02208349|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-18|2017-10-03|||April 2014||2014-04-01|October 2017|2017-10-01|April 2017|Actual|2017-04-01|December 2016|Actual|2016-12-01||Interventional|||King Video Laryngoscope Versus Direct Laryngoscopy for Prehospital Intubation: A Randomized Controlled Trial|King Video Laryngoscope Versus Direct Laryngoscopy for Prehospital Intubation: A Randomized Controlled Trial|Terminated||N/A|83|Actual|Saint Vincent Hospital, Pennsylvania||2||"We ran an interim analysis and found that additional enrollment would not alter our current   findings so terminated the trial."|f||||t||||||||||2017-10-11 00:08:24.089197|2017-10-11 00:08:24.089197
NCT02208310|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-01|2017-08-31|2017-03-19||April 2015||2015-04-01|August 2017|2017-08-01|April 2016|Actual|2016-04-01|April 2016|Actual|2016-04-01||Interventional|RODIN-CD||Trial of High Dose Vitamin D in Patient's With Crohn's Disease|A Randomized Controlled Trial of High-Dose Vitamin D in Crohn's Disease|Terminated||Phase 4|11|Actual|University of Michigan|Very few patients with inactive disease had low vitamin D levels, so most patients screened were ineligible. This made recruitment very slow, and the project was terminated.Suggests low vitamin D could be a marker of activity, rather than a cause|2||Unable to enroll at rate anticipated, insufft low vitamin D in clin rem @ 5 sites|f||||f||||||||||2017-10-11 00:08:24.436001|2017-10-11 00:08:24.436001
NCT02208258|ClinicalTrials.gov processed this data on October 10, 2017|2014-08-01|2016-01-28|||September 2014||2014-09-01|January 2016|2016-01-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional|||Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.||Withdrawn||N/A|0|Actual|Consure Medical Pvt. Ltd.||1||Hospital had initiated a conflicting study, hence the study was terminated.|f||||f||||||||||2017-10-11 00:08:25.364989|2017-10-11 00:08:25.364989
NCT02205476|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-29|2015-12-21|2015-12-21||December 2014||2014-12-01|December 2015|2015-12-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Interventional||Enrolled analysis set included all participants who signed an informed consent and for whom data were collected for Part A of this trial.|A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study|A Long-term Efficacy Assessment Following Initial Scar Revision Surgery And Phase 2 Open-label Study To Evaluate Safety Of Re-treatment With Pf-06473871|Terminated||Phase 2|10|Actual|Pfizer|The study was prematurely terminated at the discretion of sponsor as study B5301001 did not meet its pre-defined efficacy endpoints for the dosing regimens evaluated.|2||"B5301001 study did not meet its predefined efficacy endpoints, the long term follow up study   B5301012 was terminated in 1/6/2015. No safety concerns identified."|f||||f||||||||||2017-10-11 00:09:04.767291|2017-10-11 00:09:04.767291
NCT02205463|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-29|2014-07-31|||December 2014||2014-12-01|July 2014|2014-07-01|July 2017|Anticipated|2017-07-01|July 2017|Anticipated|2017-07-01||Interventional|||KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer|A Phase Ib Study of KD019 Plus Trastuzumab in Patients With HER2 Overexpressed or Amplified Metastatic or Unresectable Adenocarcinoma of Esophagus, Gastroesophageal Junction and Stomach|Withdrawn||Phase 1|0|Actual|New York University School of Medicine||1||IND application withdrawn|f||||t||||||||||2017-10-11 00:09:05.249554|2017-10-11 00:09:05.249554
NCT02205333|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-18|2017-06-01|2017-03-27||August 13, 2014|Actual|2014-08-13|June 2017|2017-06-01|April 8, 2016|Actual|2016-04-08|April 8, 2016|Actual|2016-04-08||Interventional|MEDI6469||A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies|A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas|Terminated||Phase 1/Phase 2|48|Actual|MedImmune LLC|The study was terminated early at the Sponsor’s discretion.|9||The study was terminated early at the sponsor's discretion.|f||||f||||||||||2017-10-11 00:09:07.185533|2017-10-11 00:09:07.185533
NCT02204371|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-28|2017-06-06|2017-04-20||February 25, 2015|Actual|2015-02-25|April 2017|2017-04-01|February 10, 2016|Actual|2016-02-10|February 10, 2016|Actual|2016-02-10||Interventional|||Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia|A Phase II Study to Evaluate the Effects of up to 12 Weeks of Pazopanib Dosing on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia|Terminated||Phase 2|7|Actual|GlaxoSmithKline||2||"The study was terminated as the asset was sold to another company who decided not to pursue   this indication with this drug."|f||||f||||||||||2017-10-11 00:09:23.163888|2017-10-11 00:09:23.163888
NCT02202434|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-21|2017-03-23|||September 22, 2014|Actual|2014-09-22|March 2017|2017-03-01|February 2023|Anticipated|2023-02-01|March 8, 2017|Actual|2017-03-08||Interventional|REPRISE III||Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement|REPRISE III: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Randomized Clinical Evaluation|Suspended||N/A|2092|Anticipated|Boston Scientific Corporation||7||Continued Access Study cohort enrollment voluntarily suspended due to field action|f||||t||||||||||2017-10-11 00:09:58.086217|2017-10-11 00:09:58.086217
NCT02201524|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-24|2016-08-11|2016-08-11||November 2014||2014-11-01|August 2016|2016-08-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional||The full analysis set (FAS) included all randomized participants who received at least 1 dose of the randomized study drug (PF-04965842 or placebo).|Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis|A Phase 2, Randomized, Double-blind, Placebo-controlled Study To Evaluate Safety And Efficacy Of Pf-04965842 In Subjects With Moderate To Severe Psoriasis|Terminated||Phase 2|59|Actual|Pfizer|The study was terminated early due to changes in the prioritization of the drug development portfolio and the early termination was not safety related.|4||"Study terminated 26 June 2015 due to changes in the drug development portfolio. This study was   not terminated for reasons of safety and/or efficacy"|f||||f||||||||||2017-10-11 00:10:19.816247|2017-10-11 00:10:19.816247
NCT02195817|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-17|2017-02-27|||August 2014|Actual|2014-08-01|February 2017|2017-02-01|February 2016|Actual|2016-02-01|February 2016|Actual|2016-02-01||Interventional|||Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care|Interventional, Open-label Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care|Terminated||Phase 4|378|Actual|H. Lundbeck A/S||2||The study was terminated due to enrolment challenges|f||||f||||||||||2017-10-11 00:11:42.666447|2017-10-11 00:11:42.666447
NCT02187809|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-09|2017-02-22|2016-10-28||March 2015||2015-03-01|February 2017|2017-02-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional||At the time of study termination, one patient had had been treated|Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Terminated||Phase 3|3|Actual|H. Lundbeck A/S|Early termination leading to small numbers of subjects treated and no analysis. One patient was treated for 33 days.|1||The study was terminated due to recruitment challenges|f||||t||||||||||2017-10-11 00:13:52.382722|2017-10-11 00:13:52.382722
NCT02187276|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-05|2014-09-10|||June 2009||2009-06-01|September 2014|2014-09-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Observational|||The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia|The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer Disease and Mixed Dementia: a Naturalistic Study|Completed||N/A|129|Actual|Federal University of Minas Gerais|||1||f||||t||||||Samples With DNA|"     Genetic and biochemical analyzes A blood sample (5 mL) was withdrawn from all patients on the     first consultation for DNA extraction and APOE genotyping in its different allelic forms (Ɛ2,     Ɛ3, Ɛ4). An additional blood sample (10 mL) was withdrawn from patients who took donepezil     (51 patients) and was kept in a tube with heparin and frozen at - 70 ° C. In this group of     patients, we genotyped the APOE and assessed the polymorphism of CYP 2D6 (*3,*4,*5,*6     and*10). This procedure was done when they came at 3, 6 and 12 months consultation,     respectively.   "|||2017-10-11 00:13:59.121456|2017-10-11 00:13:59.121456
NCT02186665|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-08|2017-03-31|2017-02-15||July 2014||2014-07-01|March 2017|2017-03-01|January 2016|Actual|2016-01-01|November 2015|Actual|2015-11-01||Interventional|||Plaque Psoriasis Study in Pediatric Subjects|A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis|Completed||Phase 4|19|Actual|Galderma|Study terminated early due to slow enrollment.|2|||f||||||||||||||2017-10-11 00:14:11.980604|2017-10-11 00:14:11.980604
NCT02184871|ClinicalTrials.gov processed this data on October 10, 2017|2014-07-03|2014-07-08|||May 2014||2014-05-01|July 2014|2014-07-01|May 2017|Anticipated|2017-05-01|May 2016|Anticipated|2016-05-01||Observational|EtherBil||Next Generation Sequencing in Intrahepatic Cholangiocarcinoma|Next Generation Sequencing in Intrahepatic Cholangiocarcinoma (ICC) According to the Stratification of the Risk Factors|Unknown status|Recruiting|N/A|45|Anticipated|University of Bologna|||1||f||||f||||||Samples With DNA|"     Tumor tissue samples will be immediately collected after surgery: one part will be suspended     in RNAlater to prevent RNA degradation and stored at -20°C, the other will be formalin-fixed     and paraffin-embedded for histopathology examination and evaluation of asbestos fibers. For     each patient enrolled, peripheral blood will be also collected and stored at -20°C. Total RNA     and genomic DNA will be extracted from tumor tissue and peripheral blood and stored at -80°C     until use.   "|||2017-10-11 00:14:34.100408|2017-10-11 00:14:34.100408
NCT02180139|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-30|2017-09-29|||September 2017|Anticipated|2017-09-01|September 2017|2017-09-01|December 2017|Anticipated|2017-12-01|September 2017|Anticipated|2017-09-01||Interventional|||tDCS in Cervical Dystonia|Optimizing tDCS in Cervical Dystonia|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||4||Study was withdrawn due to lack of funding and staff availability.|f||||f|f|t|f|f|f|||||2017-10-11 00:15:29.381697|2017-10-11 00:15:29.381697
NCT02177266|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-18|2017-05-24|2017-05-24||May 2015||2015-05-01|May 2017|2017-05-01|November 2016|Actual|2016-11-01|November 2016|Actual|2016-11-01||Interventional|||Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation|Colchicine Versus Placebo in Post-Cardiac Surgery Patients to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation|Terminated||Phase 3|2|Actual|Mayo Clinic|The data were not analyzed because the 2 subjects enrolled withdrew before completing the study; the study was terminated early due to the difficulty in enrolling subjects.|2||Difficulty in recruiting patients|f||||t|t|f|||t|||No||2017-10-11 00:16:08.313039|2017-10-11 00:16:08.313039
NCT02174094|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-02|2015-09-23|||March 2015||2015-03-01|September 2015|2015-09-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional|||Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Multi-site, Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, Interventional Study to Evaluate the Efficacy, Safety, and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Withdrawn||Phase 3|0|Actual|H. Lundbeck A/S||2||The study was terminated due to recruitment challenges|f||||t||||||||||2017-10-11 00:16:54.490738|2017-10-11 00:16:54.490738
NCT02170012|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-19|2015-03-16|||July 2014||2014-07-01|March 2015|2015-03-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional|||A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649|A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses Of Pf-06743649 In Healthy Elderly Subjects|Terminated||Phase 1|24|Actual|Pfizer||5||The study was prematurely terminated on 17th December 2014 due to safety concerns.|f||||f||||||||||2017-10-11 00:17:53.700608|2017-10-11 00:17:53.700608
NCT02169336|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-17|2015-11-06|2015-10-06||June 2014||2014-06-01|November 2015|2015-11-01|October 2014|Actual|2014-10-01|September 2014|Actual|2014-09-01||Interventional|||Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy, Safety, and Pharmacokinetics of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy|Terminated||Phase 2|95|Actual|Recro Pharma, Inc.|An interim analysis was performed that focused on the primary efficacy endpoint (SPID48). Observed effect size was determined for purposes of final sample size determination. The study was terminated following the interim analysis.|3||Lack of observed efficacy|f||||f||||||||||2017-10-11 00:18:04.200279|2017-10-11 00:18:04.200279
NCT02169076|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-18|2017-01-03|||September 2014||2014-09-01|January 2017|2017-01-01|May 2016|Actual|2016-05-01|May 2016|Actual|2016-05-01||Interventional|CRT-LVAD||Impact of Cardiac Resynchronization Therapy on Right Ventricular Function in Left Ventricular Assist Device Patients|Cardiac Resynchronization Therapy in Patients With Left Ventricular Assist Devices|Withdrawn||N/A|0|Actual|University of Louisville||2||IRB Approval withdrawn|f||||t||||||||||2017-10-11 00:18:07.330292|2017-10-11 00:18:07.330292
NCT02166918|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-19|2016-11-23|||June 2013||2013-06-01|November 2016|2016-11-01|July 2016|Actual|2016-07-01|July 2014|Actual|2014-07-01||Observational|PRIN2014||Factors Influencing Social Functioning of People With Schizophrenia|Multicenter Study on Factors Influencing Real-life Social Functioning of People With a Diagnosis of Schizophrenia|Completed||N/A|587|Actual|"University of Campania Luigi Vanvitelli"|||3||f||||t||||||Samples With DNA|"     In all subjects a blood sample of 20 ml will be withdrawn from a peripheral vein for genetic     analyses.   "|No||2017-10-11 00:18:32.051739|2017-10-11 00:18:32.051739
NCT02162641|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-11|2015-06-02|||September 2014||2014-09-01|June 2015|2015-06-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Observational|R-SeNSAR||Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer|R-SeNSAR Feasibility Study: The Role of Sentinel Node Biopsy in Patients With Anal Cancer|Withdrawn||N/A|0|Actual|The Christie NHS Foundation Trust|||1|The study was terminated early as it failed to recruit.|f||||t||||||||||2017-10-11 00:19:43.511195|2017-10-11 00:19:43.511195
NCT02162628|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-11|2015-12-11|||August 2014||2014-08-01|December 2015|2015-12-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Observational|||Exair® Versus Native Tissue Repair for Prolapse|Exair® Prolapse Repair System Versus Native Tissue Repair for Treatment of Pelvic Organ Prolapse, Exair 522 Study|Terminated||N/A|79|Actual|Coloplast A/S|||2|Device voluntarily withdrawn from commercial use by manufacturer|f||||f||||||||||2017-10-11 00:19:43.606551|2017-10-11 00:19:43.606551
NCT02161185|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-09|2017-09-19||2016-06-15|May 2014||2014-05-01|June 2016|2016-06-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional|||A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters|An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters|Terminated||Phase 3|7|Actual|Proximagen, LLC||1||Study terminated due to slow enrollment. There were no safety concerns.|f||||f||||||||||2017-10-11 00:20:00.36617|2017-10-11 00:20:00.36617
NCT02159040|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-05|2017-03-06|2016-06-16||September 11, 2014|Actual|2014-09-11|March 2017|2017-03-01|June 26, 2015|Actual|2015-06-26|June 26, 2015|Actual|2015-06-26||Interventional|||Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.|A 2-year, Multi-center, Phase II, Open-label, Fixed-dose, Randomized Comparative Trial of Azacitidine, With or Without Deferasirox in Patients With Higher Risk Myelodysplastic Syndromes|Terminated||Phase 2|1|Actual|Novartis|No conclusion pertaining to efficacy and/or safety was drawn, only one patient was randomized to the study and their study participation was terminated prematurely due to fatal outcome of SAE.Only one patient in trial.No analysis will ever be done.|2|||f||||t||||||||||2017-10-11 00:20:28.102386|2017-10-11 00:20:28.102386
NCT02157623|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-02|2017-05-01|2017-05-01||February 1, 2016|Actual|2016-02-01|May 2017|2017-05-01|December 1, 2016|Actual|2016-12-01|September 1, 2016|Actual|2016-09-01||Interventional||study was terminated, no data|Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome|Pilot Trial Comparing Two Different Wavelengths of Light (Blue Versus Red) During Levulan™-Based Photodynamic Therapy of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome|Completed||N/A|7|Actual|The Cleveland Clinic||2|||f||||t||||||||Undecided||2017-10-11 00:20:49.558146|2017-10-11 00:20:49.558146
NCT02155634|ClinicalTrials.gov processed this data on October 10, 2017|2014-06-02|2015-01-05|||July 2014||2014-07-01|January 2015|2015-01-01|March 2021|Anticipated|2021-03-01|April 2017|Anticipated|2017-04-01||Interventional|||Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma|Phase 3b, Randomized Trial of Continuous Revlimid® (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst® or Thalomid® in Newly Diagnosed Multiple Myeloma|Withdrawn||Phase 3|0|Actual|Celgene||2||"The study was terminated due to poor feasibility and lack of interest at the participating   sites."|f||||t||||||||||2017-10-11 00:21:20.580409|2017-10-11 00:21:20.580409
NCT02145650|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-21|2015-11-02|||May 2014||2014-05-01|November 2015|2015-11-01|August 2015|Anticipated|2015-08-01|August 2015|Anticipated|2015-08-01||Observational|STRETCh||Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs||Withdrawn||N/A|0|Actual|Allergan|||1|Study suspended due to company decision prior to enrollment.|f||||f||||||||||2017-10-11 00:23:40.328494|2017-10-11 00:23:40.328494
NCT02148107|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-19|2016-02-01|2015-11-11||May 2014||2014-05-01|February 2016|2016-02-01|August 2014|Actual|2014-08-01|July 2014|Actual|2014-07-01||Interventional||Treated set which included all subjects who received at least one dose of study drug.|Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects|Terminated||Phase 1|18|Actual|Boehringer Ingelheim|The trial was terminated prematurely because the sponsor decided to discontinue the development of BI 691751, also no PK blood samples were analysed because of the trial termination.|7|||f||||||||||||||2017-10-11 00:23:08.909983|2017-10-11 00:23:08.909983
NCT02147873|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-13|2016-10-18|||June 2014||2014-06-01|October 2016|2016-10-01|June 2016|Actual|2016-06-01|January 2016|Actual|2016-01-01||Interventional|||Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia|Terminated||Phase 2|118|Actual|TetraLogic Pharmaceuticals||2||Study terminated due to lack of efficacy|f||||t||||||||||2017-10-11 00:23:11.771388|2017-10-11 00:23:11.771388
NCT02145689|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-21|2014-08-12|||August 2014||2014-08-01|August 2014|2014-08-01|May 2017|Anticipated|2017-05-01|May 2017|Anticipated|2017-05-01||Interventional|||Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity||Withdrawn||Phase 3|0|Actual|Allergan||2||The study was withdrawn prior to enrollment due to corporate decision.|f||||t||||||||||2017-10-11 00:23:39.598407|2017-10-11 00:23:39.598407
NCT02145299|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-19|2016-09-15|2016-07-11||May 2014||2014-05-01|September 2016|2016-09-01|June 2015|Actual|2015-06-01|March 2015|Actual|2015-03-01||Interventional||Only 8 subjects were recruited and enrolled overall- study was terminated.|The Lumen Study: Comparing Devices for Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)|A Prospective, Multicenter, Open Label Randomized Study to Evaluate the Safety, Performance and Intraluminal Crossing of the TruePath™ CTO Device Versus The Crosser System in Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)|Terminated||Phase 2|8|Actual|Yale University||2||The study was stopped due to insufficient numbers of subjects to meet study design objectives.|f||||f||||||||||2017-10-11 00:23:50.590051|2017-10-11 00:23:50.590051
NCT02141360|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-12|2017-06-22|2017-04-27||July 2014||2014-07-01|June 2017|2017-06-01|November 2015|Actual|2015-11-01|May 2015|Actual|2015-05-01||Interventional|TBI-2||Advanced MRI Applications for Mild Traumatic Brain Injury - UCSF|Advanced MRI Applications for Mild Traumatic Brain Injury - UCSF|Terminated||N/A|17|Actual|GE Healthcare|Early termination of study due to limited recruitment|2||Sponser terminated early to start a larger feasability study|f||||f||||||||No||2017-10-11 00:24:52.111113|2017-10-11 00:24:52.111113
NCT02140788|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-14|2014-11-06|2014-11-06||May 2011||2011-05-01|May 2014|2014-05-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional||Subjects who signed a consent form|Effects of Metformin and Fish Oil on Treatment With Clozapine|A Comparison Of The Effects Of Added Metformin (Versus No Added Metformin) On Psychopathology, Lipids, And Measures of Inflammation During The Initiation Or Re-Institution Of Treatment With Clozapine In Patients With Schizophrenia Or Schizoaffective Disorder|Terminated||Phase 4|34|Actual|Duke University|Patients were not randomized per protocol and the study was terminated. Data analysis was not performed.|4||PI left institution|f||||||||||||||2017-10-11 00:24:58.146011|2017-10-11 00:24:58.146011
NCT02140684|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-14|2014-05-14|||March 2012||2012-03-01|May 2014|2014-05-01|January 2015|Anticipated|2015-01-01|January 2015|Anticipated|2015-01-01||Observational|||Exhaled Nitric Oxide in Asthma Management|Exhaled Nitric Oxide in Asthma Management: a Retrospective Real-life Observational Evaluation of the Use of Exhaled Nitric Oxide Measurements for Asthma Management in a UK Primary Care Population|Suspended||N/A|400|Anticipated|Research in Real-Life Ltd|||2|suspended due to lack of data.|f||||||||||||||2017-10-11 00:24:59.780715|2017-10-11 00:24:59.780715
NCT02140138|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-07|2016-06-10|||June 2014||2014-06-01|June 2016|2016-06-01|April 2016|Actual|2016-04-01|April 2016|Actual|2016-04-01||Interventional|||An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer|An Open Label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer|Terminated||Phase 2|35|Actual|CureVac AG||3||"Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for   administrative reasons."|f||||f||||||||||2017-10-11 00:25:06.77173|2017-10-11 00:25:06.77173
NCT02139384|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-08|2017-04-24|||August 2012||2012-08-01|April 2017|2017-04-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Observational|||Clinical Pediatric Pneumonia Score in Critically Ill Children|Development of a Clinical Pediatric Pneumonia Score in Critically Ill Children Admitted With Acute Respiratory Failure|Withdrawn||N/A|0|Actual|Loma Linda University|||1|The study was withdrawn due to inability to enroll patients in a timely fashion.|f||||f||||||||||2017-10-11 00:25:18.958979|2017-10-11 00:25:18.958979
NCT02138825|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-15|2017-05-03|2017-05-03||June 4, 2014|Actual|2014-06-04|May 2017|2017-05-01|September 14, 2016|Actual|2016-09-14|May 5, 2016|Actual|2016-05-05||Interventional|RISE-IIP||Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)|A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).|Terminated||Phase 2|147|Actual|Bayer|The study was prematurely terminated following a recommendation from the independent data safety monitoring committee (DMC) and steering committee (SC).|2||"Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include   4-month safety follow-up for patients after withdrawal of riociguat."|f||||t|t|||||||||2017-10-11 00:25:30.397667|2017-10-11 00:25:30.397667
NCT02138175|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-12|2015-02-03|||January 2016||2016-01-01|February 2015|2015-02-01|January 2017|Anticipated|2017-01-01|December 2016|Anticipated|2016-12-01||Observational|||Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective|Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective|Withdrawn||N/A|0|Actual|Carolinas Healthcare System|||1|Sponsor (Masimo) suspended trial due to change in corporate ownership|f||||t||||||||||2017-10-11 00:25:39.876037|2017-10-11 00:25:39.876037
NCT02137889|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-29|2014-05-12|||July 2012||2012-07-01|May 2014|2014-05-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Interventional|VAY736Y||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients|A Phase 1, Muticenter, Open-label, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 When Administered Intravenously in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients|Terminated||Phase 1|3|Actual|Novartis||2||"Study terminated on 04Oct2013 for business reasons after being on hold for 10 months. Early   termination was not due to safety concerns."|f||||f||||||||||2017-10-11 00:25:47.772243|2017-10-11 00:25:47.772243
NCT02137343|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-28|2016-03-04||2015-10-28|July 2014||2014-07-01|March 2016|2016-03-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|RILOMET-2||A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma|Terminated||Phase 3|34|Actual|Amgen||2||"All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data   Monitoring Committee safety review of study 20070622."|f||||t||||||||||2017-10-11 00:25:57.932196|2017-10-11 00:25:57.932196
NCT02136537|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-09|2016-04-14|||August 2014||2014-08-01|November 2015|2015-11-01||||December 2016|Anticipated|2016-12-01||Interventional|PAD||Electrical Stimulation in Peripheral Arterial Disease|Electrical Stimulation in Peripheral Arterial Disease|Terminated||N/A|40|Actual|Imperial College London||2||Member of staff moved on to training post. Trial halted and terminated|f||||t||||||||||2017-10-11 00:26:07.440102|2017-10-11 00:26:07.440102
NCT02131272|ClinicalTrials.gov processed this data on October 10, 2017|2014-05-02|2017-08-02|2017-05-31||June 11, 2014|Actual|2014-06-11|July 2017|2017-07-01|June 14, 2016|Actual|2016-06-14|June 14, 2016|Actual|2016-06-14||Interventional|||A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin|A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin|Terminated||Phase 3|42|Actual|Novo Nordisk A/S|The trial was terminated earlier than planned due to a very slow recruitment rate. Based on the low number of subjects, the conclusions should be interpreted with caution.|2|||f||||t||||||||||2017-10-11 00:28:44.046762|2017-10-11 00:28:44.046762
NCT02125266|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-24|2016-12-07||2016-12-07|April 2014||2014-04-01|December 2016|2016-12-01|March 2015|Actual|2015-03-01|October 2014|Actual|2014-10-01||Interventional|||Safety and Preliminary Efficacy Study of V404 PDS in Uveitis|A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis|Terminated||Phase 1/Phase 2|7|Actual|Forsight Vision4||2||Study terminated due to unacceptable frequency of drug related adverse events|f||||f||||||||No||2017-10-11 00:30:21.114814|2017-10-11 00:30:21.114814
NCT02120417|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-18|2017-07-10|2017-02-06||May 2014|Actual|2014-05-01|July 2017|2017-07-01|January 2017|Actual|2017-01-01|February 2016|Actual|2016-02-01||Interventional||The Intent-to-Treat (ITT) population consisted of all participants randomized to the study.|A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer|A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer|Terminated||Phase 2|149|Actual|Incyte Corporation||2||"The study was terminated as other related studies of ruxolitinib did not provide sufficient   efficacy to warrant continuation."|f||||f||||||||||2017-10-11 00:31:28.809436|2017-10-11 00:31:28.809436
NCT02119676|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-17|2017-05-12|2017-02-10||March 2014||2014-03-01|May 2017|2017-05-01|December 2016|Actual|2016-12-01|February 2016|Actual|2016-02-01||Interventional||The intent-to-treat (ITT) population consisted of participants that were randomized in the study.|Study of Ruxolitinib in Colorectal Cancer Patients|A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer|Terminated||Phase 2|396|Actual|Incyte Corporation|Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.|2||"Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per   sponsor decision."|f||||t||||||||||2017-10-11 00:31:40.071272|2017-10-11 00:31:40.071272
NCT02119663|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-17|2017-05-10|2017-02-06||June 2014|Actual|2014-06-01|May 2017|2017-05-01|October 2016|Actual|2016-10-01|February 2016|Actual|2016-02-01||Interventional||The intent-to-treat (ITT) population consisted of all participants randomized to the study.|A Study of Ruxolitinib in Pancreatic Cancer Patients|A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)|Terminated||Phase 3|86|Actual|Incyte Corporation|The study was terminated prior to the final analysis at the recommendation of the Data Monitoring Committee based on the review of efficacy in the 18424-362 (JANUS 1).|2||"The safety committee found no safety issues but recommended halting the study based on a lack   of efficacy in a similar trial. The sponsor terminated the trial."|f||||t||||||||||2017-10-11 00:31:42.391018|2017-10-11 00:31:42.391018
NCT02119650|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-17|2017-08-18|2017-02-10||February 11, 2014|Actual|2014-02-11|August 2017|2017-08-01|June 21, 2016|Actual|2016-06-21|February 11, 2016|Actual|2016-02-11||Interventional||The intent-to-treat (ITT) population consisted of participants that were randomized in the study.|Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer|A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent|Terminated||Phase 2|76|Actual|Incyte Corporation|The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.|2||"The study was terminated as other related studies of ruxolitinib did not provide sufficient   efficacy to warrant continuation."|f||||t||||||||||2017-10-11 00:31:43.651758|2017-10-11 00:31:43.651758
NCT02118597|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-16|2016-10-18|2016-06-15||May 2014||2014-05-01|October 2016|2016-10-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Observational||Analysis was performed on all enrolled participants.|An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients|Non-interventional Study to Observe Triple Combination Therapy With Boceprevir or Simeprevir Plus Peginterferon Alfa-2a Plus Ribavirin for Re-treatment of Chronic Hepatitis C in Hungary (IMPERIAL)|Terminated||N/A|19|Actual|Hoffmann-La Roche|||1|Study terminated due to the Sponsor's decision.|f||||||||||Samples Without DNA|"     Blood serum used to analyze levels of hepatitic c virus (HCV) ribonucleic acid (RNA)   "|||2017-10-11 00:32:10.513524|2017-10-11 00:32:10.513524
NCT02118493|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-08|2015-12-02|||December 2015||2015-12-01|December 2015|2015-12-01|May 2017|Anticipated|2017-05-01|July 2016|Anticipated|2016-07-01||Interventional|||Endo-biliary Laser Excision of Biliary Stenoses|Endo-biliary Laser Excision of Biliary Stenoses: Initial Experience and Feasibility|Withdrawn||N/A|0|Actual|University of Florida||1||The protocol has been withdrawn for re-evaluation.|f||||f||||||||||2017-10-11 00:32:14.049915|2017-10-11 00:32:14.049915
NCT02117479|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-16|2017-06-09|2017-02-09||March 2014|Actual|2014-03-01|June 2017|2017-06-01|December 2016|Actual|2016-12-01|February 2016|Actual|2016-02-01||Interventional||The intent-to-treat (ITT) population consisted of all participants randomized to the study.|Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)|A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)|Terminated||Phase 3|321|Actual|Incyte Corporation|The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation at the recommendation of the Data Monitoring Committee.|2||The study was terminated early based on the results of the planned interim analysis.|f||||t||||||||||2017-10-11 00:32:30.59389|2017-10-11 00:32:30.59389
NCT02117050|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-15|2016-11-28|2016-11-28||June 2014||2014-06-01|November 2016|2016-11-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional|RESOunD||RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate|RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera™ to Rebif® 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)|Terminated||Phase 4|1|Actual|EMD Serono|The study was prematurely terminated due to enrollment issues. Only 1 subject was enrolled in this study, but did not receive any dose. Neither efficacy nor safety analysis was done for the study.|1||recruitment challenges|f||||||||||||||2017-10-11 00:32:39.661055|2017-10-11 00:32:39.661055
NCT02111486|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-09|2016-10-17|||October 2015||2015-10-01|October 2016|2016-10-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional|||Effect of Certain Breakfasts on Appetite Control|A Randomized, Controlled, Cross-over Study of the Effect of Certain Breakfasts on Appetite Control.|Withdrawn||N/A|0|Actual|St. Boniface General Hospital Research Centre||3||Funding withdrawn|f||||f||||||||||2017-10-11 00:34:03.355035|2017-10-11 00:34:03.355035
NCT02111863|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-09|2017-08-21|2017-07-21||February 21, 2014|Actual|2014-02-21|August 2017|2017-08-01|July 21, 2016|Actual|2016-07-21|July 21, 2016|Actual|2016-07-21||Interventional|||Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma|A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen|Terminated||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1||Study terminated due to low accrual and change in research focus.|f||||t|t|f||||||||2017-10-11 00:33:52.529654|2017-10-11 00:33:52.529654
NCT02109445|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-02|2017-05-08|2017-03-24|2015-12-07|September 3, 2014|Actual|2014-09-03|May 2017|2017-05-01|November 6, 2014|Actual|2014-11-06|November 6, 2014|Actual|2014-11-06||Interventional|||Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies|Phase 1/2 Study Of Pf-03084014 In Combination With Gemcitabine And Nab-paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma|Terminated||Phase 2|3|Actual|Pfizer|Due to early termination of the study, only 3 participants were enrolled. Phase 2 was not carried out. As such, there is limited data for Phase 1 and no data for Phase 2.|3||"The study was terminated on 24JUN15 due to change in strategy of PF-03084014 development.No   safety/efficacy concerns were behind the reason of trial termination"|f||||t||||||||||2017-10-11 00:34:25.737831|2017-10-11 00:34:25.737831
NCT02109198|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-07|2015-05-29|||June 2015||2015-06-01|May 2015|2015-05-01|August 2016|Anticipated|2016-08-01|August 2016|Anticipated|2016-08-01||Interventional|||Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Trial)|Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Phase)|Withdrawn||N/A|0|Actual|U.S. Army Medical Research and Materiel Command||2||protocol withdrawn|f||||f||||||||||2017-10-11 00:34:28.236702|2017-10-11 00:34:28.236702
NCT02107560|ClinicalTrials.gov processed this data on October 10, 2017|2014-04-03|2016-05-23|||April 2014||2014-04-01|April 2014|2014-04-01|March 2016|Actual|2016-03-01|March 2016|Actual|2016-03-01||Observational|||Results of Bile and Blood Culture in Patients With Acute Cholangitis|A Comparison of Results With Bile and Blood Culture in Patients With Acute Cholangitis According to Severity|Terminated||N/A|3|Actual|Seoul National University Hospital|||1|Because of small number of enrolled patients, we terminated this study.|f||||t||||||||||2017-10-11 00:34:59.369807|2017-10-11 00:34:59.369807
NCT02106689|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-18|2016-05-30|||February 2014||2014-02-01|May 2016|2016-05-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional|||Needle-Free Injections of Gonadotropins for Superovulation|Needle Free Injections of Gonadotropins for Patients Undergoing Superovulation - A Randomized, Pilot Study|Terminated||N/A|2|Actual|University of British Columbia||2||This study is terminated due to an inability to recruit a sufficient number of participants.|f||||f||||||||||2017-10-11 00:35:14.479998|2017-10-11 00:35:14.479998
NCT02102386|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-29|2015-01-27|||February 2014||2014-02-01|January 2015|2015-01-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Observational|CerOx||Monitoring Brain Perfusion and Cerebral Oximetry in Carotid Endarterectomy Surgeries|Monitoring Brain Perfusion and Cerebral Oximetry in Carotid Endarterectomy Surgeries|Terminated||N/A|13|Actual|Washington University School of Medicine|||1|Technical issues with the device under study. Sponsor terminated.|f||||f||||||||||2017-10-11 00:36:26.334111|2017-10-11 00:36:26.334111
NCT02097576|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-24|2014-07-17|||May 2014||2014-05-01|July 2014|2014-07-01|December 2015|Anticipated|2015-12-01|December 2015|Anticipated|2015-12-01||Interventional|||Manuka Honey Nasal Rinse Study|Effectiveness of Manuka Honey/Saline Nasal Rinses as an Adjunct to Standard Medical Therapy for Chronic Rhinosinusitis: A Prospective Clinical Trial|Withdrawn||N/A|0|Actual|University of Florida||2||Funding withdrawn.|f||||f||||||||||2017-10-11 00:37:43.787391|2017-10-11 00:37:43.787391
NCT02095639|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-20|2017-07-20|||August 2012|Actual|2012-08-01|July 2017|2017-07-01|May 2017|Actual|2017-05-01|March 2017|Actual|2017-03-01||Observational|||Inflammation and Electroconvulsive Therapy|Does Electroconvulsive Therapy Cause Neuroinflammation? An [18F]FEPPA Positron Emission Tomography Study in Treatment Resistant Depression|Terminated||N/A|5|Actual|Centre for Addiction and Mental Health|||1|The study was terminated|f||||t||||||Samples With DNA|"     Whole blood, plasma and serum samples will be kept for analysis of genotype, peripheral     inflammatory markers and protein binding.   "|||2017-10-11 00:38:13.840708|2017-10-11 00:38:13.840708
NCT02095015|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-20|2015-06-24|||March 2014||2014-03-01|June 2015|2015-06-01|September 2018|Anticipated|2018-09-01|August 2018|Anticipated|2018-08-01||Observational|||Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)|Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric Ear, Nose and Throat (ENT) Surgery (Adenoidectomy and/or Tonsillectomy and/or Tympanostomy) (The HATT Project)|Terminated||N/A|160|Actual|Shire|||1|terminated for not meeting enrollment goals|f||||f||||||||||2017-10-11 00:38:20.183873|2017-10-11 00:38:20.183873
NCT02092389|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-18|2017-01-05|2016-09-22||July 2014||2014-07-01|January 2017|2017-01-01|March 2016|Actual|2016-03-01|October 2015|Actual|2015-10-01||Observational|AdaProQuo|All enrolled participants with demographic and baseline data available.|Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo|Fecal Calprotectin Levels, Quality of Life and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo|Terminated||N/A|10|Actual|AbbVie|The study was terminated due to low enrollment; therefore, safety and efficacy data should be interpreted with caution because of the small number of participants and incomplete data.||1|Recruitment below expectation|f||||f||||||||||2017-10-11 00:39:05.684464|2017-10-11 00:39:05.684464
NCT02091752|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-06|2016-02-24|2016-01-05||September 2014||2014-09-01|February 2016|2016-02-01|February 2015|Actual|2015-02-01|February 2015|Actual|2015-02-01||Interventional|||A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)|The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.|Terminated||Phase 2|3|Actual|Novartis||1||The study was terminated due to low enrollment.|f||||f||||||||||2017-10-11 00:39:16.895142|2017-10-11 00:39:16.895142
NCT02090517|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-04|2017-06-27|||June 2014|Actual|2014-06-01|June 2017|2017-06-01|February 2016|Actual|2016-02-01|February 2016|Actual|2016-02-01||Interventional|||Laser Therapy Versus Electrosurgery For Nasal Telangiectasias|Evaluation of Laser Therapy Vs Electrosurgery For Nasal Telangiectasias Using A Novel Vascular Imaging Device|Withdrawn||N/A|0|Actual|University of California, Davis||5||Study was withdrawn because the university wanted to bill study patients for use of the laser.|f||||f||||||||||2017-10-11 00:39:28.422086|2017-10-11 00:39:28.422086
NCT02090348|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-14|2015-09-03|||June 2015||2015-06-01|September 2015|2015-09-01|October 2017|Anticipated|2017-10-01|October 2017|Anticipated|2017-10-01||Interventional|TECNERGY||Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate|A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY)|Withdrawn||Phase 4|0|Actual|Biogen||1||"The study was withdrawn for business reasons. The decision to stop the TECNERGY study was not a   result of any safety or efficacy concerns."|f||||f||||||||||2017-10-11 00:39:33.914921|2017-10-11 00:39:33.914921
NCT02087241|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-06|2017-02-10|2016-04-26||March 2014||2014-03-01|February 2017|2017-02-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|||Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer|A Phase II Study of AZD1775 Plus Pemetrexed and Carboplatin Followed by a Randomised Comparison of Pemetrexed and Carboplatin With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer|Terminated||Phase 2|22|Actual|AstraZeneca|The study was terminated on June 1, 2015 by the sponsor. The Primary Outcome Measure (Progression Free Survival) was not assessed and the randomised portion of the study was not done.|2||The sponsor decided to terminate the study.|f||||f||||||||||2017-10-11 00:40:07.464138|2017-10-11 00:40:07.464138
NCT02087176|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-07|2016-05-06|2016-03-22||March 2014||2014-03-01|April 2016|2016-04-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional|||A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer|A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients|Terminated||Phase 2|48|Actual|AstraZeneca|The sponsor terminated the study early. The study was closed on May 12, 2015. Part B of the study was not done.|2||The study was terminated early by the sponsor.|f||||f||||||||||2017-10-11 00:40:09.096532|2017-10-11 00:40:09.096532
NCT02086487|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-27|2017-03-06|||March 2013||2013-03-01|March 2017|2017-03-01|August 2016|Actual|2016-08-01|August 2016|Actual|2016-08-01||Interventional|NISRI||Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy|Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy (NISRI)|Terminated||Phase 4|98|Actual|King Abdullah International Medical Research Center||1||Because of many unseen obstacles resulted in poor accrual, study is terminated.|f||||t||||||||Undecided||2017-10-11 00:40:16.864452|2017-10-11 00:40:16.864452
NCT02081183|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-05|2014-06-17|2014-06-17||March 2006||2006-03-01|June 2014|2014-06-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional||No baseline analysis was performed because the study was terminated early.|A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis|A Study to Evaluate the Efficacy of CellCept, Administered in a Sequential Treatment Scheme, in Delaying Progressive Renal Damage in Patients With Lupus Nephritis|Terminated||Phase 3|16|Actual|Hoffmann-La Roche|Data were not analyzed because the study was terminated early.|2|||f||||||||||||||2017-10-11 00:41:23.346409|2017-10-11 00:41:23.346409
NCT02080416|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-04|2016-06-08|||July 2014||2014-07-01|June 2016|2016-06-01|February 2016|Actual|2016-02-01|February 2016|Actual|2016-02-01||Interventional|||Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors|A Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related Tumors|Terminated||Early Phase 1|1|Actual|Sidney Kimmel Comprehensive Cancer Center||1||"Very slow accrual; terminated to allow resources to be utilized more effectively on other   studies. No data analysis completed, nor any conclusions reached."|f||||t||||||||No|Study terminated; no data analysis completed|2017-10-11 00:41:36.128371|2017-10-11 00:41:36.128371
NCT02079220|ClinicalTrials.gov processed this data on October 10, 2017|2014-03-03|2017-07-26|||March 2014||2014-03-01|July 2017|2017-07-01|March 2018|Anticipated|2018-03-01|March 2018|Anticipated|2018-03-01||Interventional|||A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer|A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||2||Funding for the study was withdrawn, no participants were ever recruited.|f||||t||||||||||2017-10-11 00:41:53.938846|2017-10-11 00:41:53.938846
NCT02078895|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-26|2017-05-23|||February 2014||2014-02-01|May 2017|2017-05-01|February 2017|Actual|2017-02-01|February 2017|Actual|2017-02-01||Interventional|||Randomization of Botox for Stent Pain and Irritative Voiding Symptoms|Prospective Randomized Evaluation of Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A for the Treatment of Ureteral Stent Related Pain and Irritative Voiding Symptoms|Terminated||Phase 3|15|Actual|University of California, Irvine||2||The study was terminated due to low enrollment|f||||f||||||||No||2017-10-11 00:41:57.303682|2017-10-11 00:41:57.303682
NCT02077296|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-26|2016-09-08|||March 2014||2014-03-01|September 2016|2016-09-01|August 2016|Actual|2016-08-01|August 2016|Actual|2016-08-01||Observational|CYTORECT||The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer|The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer|Completed||N/A|34|Actual|St. Antonius Hospital|||1||f||||t||||||Samples Without DNA|"     An extra ethylene diamine tetra acetic acid blood tube of 4 ml will be withdrawn from the     patient during a regular venapuncture or after administration of an intravenous needle     specifically before, during and just after preoperative CRT, 1 day before and 2 days after     surgery and 6 weeks after surgery. Blood samples for determination of cytokines are directly     processed.      As standard medical treatment surgery will be performed and biopsies of resection specimen     will be collected by the department of pathology, frozen, and further examined. For this     study 4 extra biopsies will be taken from resection tissue for cytokine measurements. Two     from tumour tissue and 2 from normal mucosa of each patient. These biopsies will be     snap-frozen in liquid nitrogen. Subsequently, the frozen biopsies will be grinded with a     mortar and pestle, which were cooled in liquid nitrogen, and resuspended in 100 μl ice-cold     PBS containing 10 μl/ml of a cocktail of protease inhibitors.   "|Yes||2017-10-11 00:42:14.463706|2017-10-11 00:42:14.463706
NCT02075034|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-27|2017-06-22|||May 2014||2014-05-01|June 2017|2017-06-01|October 2018|Anticipated|2018-10-01|April 2018|Anticipated|2018-04-01||Interventional|||Three Dosing Schedules of Oral Rigosertib in MDS Patients|A Randomized Phase I Study to Assess the Pharmacokinetics, Tolerability, Efficacy and Pharmacodynamics of Three Dosing Schedules of Oral Rigosertib in Transfusion-dependent, Low, Intermediate 1, or Intermediate-2 Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System|Suspended||Phase 1|36|Anticipated|Onconova Therapeutics, Inc.||3||"Study suspended before enrollment and treatment of any patients; study potentially will resume   after evaluation of results from other studies"|f||||f||||||||||2017-10-11 00:42:50.440442|2017-10-11 00:42:50.440442
NCT02075008|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-27|2017-08-07|2017-03-14||March 27, 2014|Actual|2014-03-27|August 2017|2017-08-01|March 22, 2016|Actual|2016-03-22|March 22, 2016|Actual|2016-03-22||Interventional|||Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201|An Open-label, Multi-center, Extension Study to Evaluate the Long-term Safety of Subcutaneous 240mg QGE031 Given Every 4 Weeks for 52 Weeks in Allergic Asthma Patients Who Completed Study CQGE031B2201|Terminated||Phase 2|270|Actual|Novartis||1||"The study was prematurely terminated after core study CQGE031B2201 failed to meet the primary   objective of demonstrating superiority for QGE031 versus placebo."|f||||f||||||||||2017-10-11 00:42:50.764769|2017-10-11 00:42:50.764769
NCT02074995|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-27|2016-03-03|2015-12-08||February 2014||2014-02-01|March 2016|2016-03-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Interventional|||Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects|Multiple Ascending, Sequential, Placebo-controlled, Double-blind Study to Assess Safety, Tolerability and Efficacy of BVS857 in Severe Burn Subjects|Terminated||Phase 2|1|Actual|Novartis|Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided|3||The study was prematurely terminated due to recruitment issues|f||||t||||||||||2017-10-11 00:42:51.218832|2017-10-11 00:42:51.218832
NCT02074410|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-21|2015-04-20|||January 2014||2014-01-01|October 2014|2014-10-01|March 2016|Anticipated|2016-03-01|March 2016|Anticipated|2016-03-01||Interventional|||Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease|Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease|Suspended||Phase 2|36|Anticipated|Omeros Corporation||4||Enrollment has been suspended in this study.|f||||f||||||||||2017-10-11 00:43:01.054224|2017-10-11 00:43:01.054224
NCT02072226|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-24|2017-07-05|||May 31, 2014|Actual|2014-05-31|July 2017|2017-07-01|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|PRISMS||A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke|A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)|Terminated||Phase 3|313|Actual|Genentech, Inc.||2||The study was terminated due to slow enrollment.|f|||||t|f||||||||2017-10-11 00:43:31.729878|2017-10-11 00:43:31.729878
NCT02072096|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-24|2016-10-04|2016-10-04||February 2014||2014-02-01|October 2016|2016-10-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional|IMPERIUM|All randomized participants.|A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)|An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM)|Terminated||Phase 4|192|Actual|Eli Lilly and Company|The trial was terminated per protocol due to lack of feasibility. All participants completed the first 24 weeks of the study. Some participants continued into the Core study. Data was assessed from Baseline to last participant visit, up to 72 weeks.|2||The trial was terminated per protocol because of lack of feasibility.|f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
NCT02070588|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-18|2017-06-22|2017-04-28||February 2014||2014-02-01|June 2017|2017-06-01|November 2015|Actual|2015-11-01|June 2015|Actual|2015-06-01||Interventional|TBI||Advanced MRI Applications for Mild Traumatic Brain Injury|Advanced MRI Applications for Mild Traumatic Brain Injury|Terminated||N/A|112|Actual|GE Healthcare||2||Sponsor terminated early as moving to a new larger study program|f||||f||||||||No||2017-10-11 00:43:53.957074|2017-10-11 00:43:53.957074
NCT02065401|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-10|2014-08-07|||February 2014||2014-02-01|August 2014|2014-08-01|March 2014|Anticipated|2014-03-01|March 2014|Anticipated|2014-03-01||Interventional|||Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)|A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt), Each Administered as a Single Oral Dose|Withdrawn||Phase 1|0|Actual|Shire||3||This study was withdrawn until the evaluation of the nonclinical rat findings is complete.|f||||||||||||||2017-10-11 00:44:56.058252|2017-10-11 00:44:56.058252
NCT02064868|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-14|2017-07-12|||January 31, 2014|Actual|2014-01-31|July 2017|2017-07-01|April 25, 2017|Actual|2017-04-25|March 26, 2017|Actual|2017-03-26||Interventional|RELAX-AHF-EU||Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients|A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients|Terminated||Phase 3|2653|Actual|Novartis||2||Study was terminated based on results from pivotal adult AHF study CRLX030A2301|f||||t||||||||||2017-10-11 00:45:04.742362|2017-10-11 00:45:04.742362
NCT02060084|ClinicalTrials.gov processed this data on October 10, 2017|2014-02-02|2016-09-04|||January 2014||2014-01-01|January 2014|2014-01-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|||Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm|Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm|Completed||Phase 4|60|Actual|Kunshan First People's Hospital Affiliated to Jiangsu University||2|||f||||t||||||||No|The patients were randomly assigned to either a control group or a probiotic-supplemented group in the following manner. The randomization schedule was made available only to the pharmacist who supervised the quality, transport and storage of LCB. Infants were followed up until they were discharged from the hospital or died. They were withdrawn from the trial if severe adverse effects developed, or parents withdrew consent. The probiotic-supplemented group were orally administered LCB (Bifico, Shanghai Xinyi Pharmaceutical Inc. Shanghai), and the control group was fed with the same dose of luke warm water); both the preparations were supplied in identical containers. LCB was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live>0.5*107CFU), twice per day, for 2 weeks.|2017-10-11 00:46:19.895721|2017-10-11 00:46:19.895721
NCT02057276|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-05|2017-02-02|2015-07-30||September 2012||2012-09-01|February 2017|2017-02-01|June 2016|Actual|2016-06-01|June 2015|Actual|2015-06-01||Interventional||After signing consent forms, two separate participants did not proceed with the study. The study was then terminated.|Repetitive TMS and Occupational Therapy in Children and Young Adults With Chronic Hemiparesis|Motor Control Enhancement Through Repetitive Transcranial Magnetic Stimulation Plus Rehabilitation in Hemiparetic Cerebral Palsy and Stroke|Terminated||N/A|2|Actual|Children's Hospital Medical Center, Cincinnati||2||Study was terminated due to low recruitment.|f||||t||||||||||2017-10-11 00:47:07.993694|2017-10-11 00:47:07.993694
NCT02053116|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-30|2016-03-29||2016-03-29|March 2014||2014-03-01|May 2014|2014-05-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin|A 6-week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 Administered With Canagliflozin In Adult Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|8|Actual|Pfizer||2||"On 25April2014, study was terminated before any dosing due to an AE of safety concern that   occurred in protocol B1731003 with the same drug."|f||||f||||||||||2017-10-11 00:48:06.65598|2017-10-11 00:48:06.65598
NCT02053103|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-30|2016-03-29||2016-03-29|March 2014||2014-03-01|May 2014|2014-05-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin|A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 In Adult Subjects With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin|Terminated||Phase 2|13|Actual|Pfizer||2||"On 25April2014, study was terminated before any dosing due to an AE of safety concern that   occurred in protocol B1731003 with the same drug."|f||||f||||||||||2017-10-11 00:48:06.751667|2017-10-11 00:48:06.751667
NCT02052635|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-14|2016-04-28|2016-03-08||September 2014||2014-09-01|April 2016|2016-04-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional|NSTE-ACS||Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.|A Phase IV, Randomised, Multi-Centre, Open Label Study, Comparing Ticagrelor Versus Clopidogrel in Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Patients Undergoing Percutaneous Coronary Intervention (PCI) With Bivalirudin|Terminated||Phase 4|34|Actual|AstraZeneca|The target sample size for this study was 100 patients. But due to recruitment challenges and low enrolment,the study was terminated early with only 13 pateints randomized. No formal statistical analyses were performed.|2||"Patient recruitment challenges, low enrolment, and a forecasted inability to complete the study   in an acceptable timeframe"|f||||f||||||||||2017-10-11 00:48:11.971178|2017-10-11 00:48:11.971178
NCT02050048|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-27|2016-06-13|2016-03-29||January 2014||2014-01-01|June 2016|2016-06-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional||Those randomized to either the high or low volume group|High Volume Lactated Ringer's Solution and Pancreatitis|Perioperative Intravenous Administration of High Volume Lactated Ringer's Solution and the Risk of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|Terminated||Phase 2/Phase 3|26|Actual|NorthShore University HealthSystem|Due to low study enrollment, the study was terminated early. Beacuse only 26 subjects were enrolled, the study results may not be statistically significant.|2||Study was closed prematurely due to low enrollment numbers.|f||||t||||||||||2017-10-11 00:48:41.058438|2017-10-11 00:48:41.058438
NCT02049151|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-27|2017-07-24|2016-06-30||March 2014||2014-03-01|July 2017|2017-07-01|July 2015|Actual|2015-07-01|July 2015|Actual|2015-07-01||Interventional|START2|Safety Analysis Set included all subjects who had taken at least one dose of trial treatment (tecemotide [L-BLP25] or placebo), including cyclophosphamide or saline.|Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 3|35|Actual|EMD Serono|Sponsor discontinued development of tecemotide (L-BLP25) in NSCLC, hence the study was terminated.|2||"The study is terminated prematurely as the sponsor decided to discontinue program with   Tecemotide in NSCLC"|f||||t||||||||||2017-10-11 00:48:53.183039|2017-10-11 00:48:53.183039
NCT02048904|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-27|2017-07-11|2017-05-01||January 2014||2014-01-01|June 2017|2017-06-01|June 2016|Actual|2016-06-01|January 2016|Actual|2016-01-01||Interventional||Total enrollment was 142 participants, with 65 completing, 7 withdrew voluntarily, and 70 were found to be ineligible. However, data was not analyzed and results are unavailable as investigator and study coordinator no longer work at the institution and did not make information available. Study was terminated prematurely.|Use of Sitagliptin to Decrease Microalbuminuria|Clinical Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Urinary Albumin to Creatinine Ratio in Patients With Overt Kidney Disease|Terminated||Phase 4|142|Actual|University of Missouri-Columbia|Study was terminated during the enrollment period due to difficulties at the study site. 65 participants had completed study by time of study termination.No data were collected or analyzed.|2||Original Principal Investigator left institution. No data analyzed.|f||||f||||||||||2017-10-11 00:48:56.477851|2017-10-11 00:48:56.477851
NCT02048111|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-14|2016-08-19|||March 2014||2014-03-01|August 2016|2016-08-01|November 2015|Anticipated|2015-11-01|October 2015|Anticipated|2015-10-01||Interventional|||Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B|Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B|Withdrawn||Phase 3|0|Actual|Cangene Corporation||1||The study was withdrawn from the IND.|f||||t||||||||||2017-10-11 00:49:08.606931|2017-10-11 00:49:08.606931
NCT02046538|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-23|2017-01-23|||February 2014||2014-02-01|January 2017|2017-01-01|February 2018|Anticipated|2018-02-01|February 2016|Anticipated|2016-02-01||Interventional|||Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer|Phase II Study of Preoperative Chemotherapy With Ziv-aflibercept (Zaltrap) Followed by Postoperative Chemotherapy With or Without Ziv-aflibercept (Zaltrap) in Patients With Advanced Resectable Colorectal Cancer|Withdrawn||Phase 2|0|Actual|Weill Medical College of Cornell University||2||Investigator terminated due to funding issues|f||||t||||||||No||2017-10-11 00:49:27.883286|2017-10-11 00:49:27.883286
NCT02045732|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-22|2016-11-18|2016-11-18||September 2014||2014-09-01|November 2016|2016-11-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional|||A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)|A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms)|Terminated||Phase 1|4|Actual|Pfizer|Due to the early termination of the study, the small enrollment number and minimal data, no statistical analyses were performed.|4||"This study terminated on April 8, 2015 due to a corporate decision and not related to the   safety or efficacy of the protocol."|f||||f||||||||||2017-10-11 00:49:43.718114|2017-10-11 00:49:43.718114
NCT02044991|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-17|2017-08-04|2017-04-03||October 24, 2013|Actual|2013-10-24|August 2017|2017-08-01|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional||The baseline analysis population comprises all participants who signed an informed consent document to participate in the trial.|Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain|The Efficacy of Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain: A Randomized Controlled Trial|Terminated||Phase 2|2|Actual|Loyola University|The trial was terminated in February 2017 due to poor recruitment|2||The study was halted prematurely due to poor recruitment|f||||t|t|f||||||||2017-10-11 00:49:53.96977|2017-10-11 00:49:53.96977
NCT02044848|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-22|2016-01-19|2015-09-09||February 2014||2014-02-01|January 2016|2016-01-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional|||Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus|A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)|Terminated||Phase 2|5|Actual|Novartis||2||This study was terminated prematurely by the Sponsor for business reasons only.|f||||f||||||||||2017-10-11 00:49:55.512519|2017-10-11 00:49:55.512519
NCT02044302|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-21|2017-04-06|2016-08-26||April 2014||2014-04-01|February 2017|2017-02-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional||Only two subjects were enrolled into 1 of the 2 blinded arms and then the study was terminated.|A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction|A Prospective Randomized Double Blind Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction|Terminated||Phase 2|2|Actual|Yale University||4|||f||||f||||||||||2017-10-11 00:50:01.86234|2017-10-11 00:50:01.86234
NCT02040311|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-07|2014-01-16|||August 2000||2000-08-01|January 2014|2014-01-01|June 2002|Actual|2002-06-01|June 2002|Actual|2002-06-01||Interventional|TOBES||Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in Obese Subjects|A Multicenter Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in Weight Loss Maintenance in Obese Subjects Following Participation in an Intensive, Non-pharmacologic Weight Loss Program|Terminated||Phase 4|701|Actual|University of Copenhagen||3||Study was terminated early as sponsor wanted to develop an improved formulation.|f||||f||||||||||2017-10-11 00:50:54.980464|2017-10-11 00:50:54.980464
NCT02037607|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-14|2017-03-14|2017-03-14||September 2012||2012-09-01|March 2017|2017-03-01|July 2015|Actual|2015-07-01|July 2015|Actual|2015-07-01||Observational||91 subjects received study procedures and were analyzed. 9 additional subjects were consented but withdrawn prior to completion of study procedures.|Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures|Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures|Completed||N/A|100|Actual|Indiana University|||1||f||||f||||||||||2017-10-11 00:51:34.266415|2017-10-11 00:51:34.266415
NCT02036307|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-13|2017-02-28|||April 2013||2013-04-01|February 2017|2017-02-01|January 2015|Actual|2015-01-01|May 2013|Actual|2013-05-01||Interventional|SOMA||Supplementation With Omega-3: Mechanism of Action|Supplementation With Omega-3: Mechanism of Action|Terminated||Phase 2|13|Actual|Johns Hopkins University||2||This study was suspended because there is no more funds to complete the study.|f||||f||||||||No|We do not plan to share the individual patient data.|2017-10-11 00:51:52.615963|2017-10-11 00:51:52.615963
NCT02035124|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-10|2016-02-10|||April 2014||2014-04-01|February 2016|2016-02-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Interventional|||Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel|Cabazitaxel With BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer Following Treatment With Docetaxel: Phase II Study With Safety Lead-in Cohort|Withdrawn||Phase 2|0|Actual|SCRI Development Innovations, LLC||1||Study withdrawn due to slow accrual. No patients were enrolled.|f||||f||||||||||2017-10-11 00:52:06.407311|2017-10-11 00:52:06.407311
NCT02033317|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-09|2016-01-25|2015-11-11|2014-10-30|August 2008||2008-08-01|January 2016|2016-01-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis|An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Hemodialysis Patients|Terminated||Phase 2|6|Actual|Relypsa, Inc.|The initial intent was to enroll 12-24 adult male and female participants on hemodialysis into the study. Due to significant recruitment challenges, the study was discontinued after six participants were enrolled in the study.|1||Study terminated due to slow enrollment|f||||f||||||||||2017-10-11 00:52:28.600357|2017-10-11 00:52:28.600357
NCT02031406|ClinicalTrials.gov processed this data on October 10, 2017|2014-01-07|2017-08-14|||January 2014||2014-01-01|August 2017|2017-08-01|July 2018|Anticipated|2018-07-01|February 2014|Actual|2014-02-01||Interventional|||Impact of Pharmacist Post-discharge Phone Calls on Hospital Readmission and Patient Medication Literacy and Adherence|Impact of Pharmacist Post-discharge Phone Calls on Hospital Readmission and Patient Medication Literacy and Adherence|Terminated||N/A|155|Actual|Cedars-Sinai Medical Center||2||"This trial was started, but data collection was inadequate. Analysis was thus terminated.   Further exploration of this research question is being planned."|f||||||||||||||2017-10-11 00:53:03.916376|2017-10-11 00:53:03.916376
NCT02030574|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-20|2016-07-25|2015-10-27||July 2014||2014-07-01|July 2016|2016-07-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|||Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin|BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin|Terminated||Phase 2|2|Actual|Brown University|The study has been terminated secondary to low accrual and an interest in opening up a different trial; more tailored to Physician interests and patient need.|1||"The study is being closed to accrual secondary to low accrual and an interest in opening up a   different trial."|f||||t||||||||||2017-10-11 00:53:11.851665|2017-10-11 00:53:11.851665
NCT02029469|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-25|2014-08-15|||October 2007||2007-10-01|August 2014|2014-08-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||Ascension® Humeral Resurfacing Arthroplasty Follow-Up Study|Ascension® Humeral Resurfacing Arthroplasty Follow-Up Study|Terminated||N/A|59|Actual|Ascension Orthopedics, Inc.||1||Study was terminated due to PI leaving the institution|f||||f||||||||||2017-10-11 00:53:30.701981|2017-10-11 00:53:30.701981
NCT02025569|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-24|2013-12-30|||January 2008||2008-01-01|December 2013|2013-12-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||The Effect of Strain-counterstrain on Ankle Instability|The Effectiveness of Strain Counterstrain in the Treatment of Patients With Chronic Ankle Instability: a Randomized Clinical Trial|Terminated||N/A|27|Actual|Long Island University||2||Data collection was terminated due to unavailability of additional participants.|f||||f||||||||||2017-10-11 00:54:19.633904|2017-10-11 00:54:19.633904
NCT02024074|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-23|2015-02-05|||November 2013||2013-11-01|February 2015|2015-02-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Interventional|||Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients|Performance of Tc99m Sestamibi Molecular Breast Imaging (Tc-MBI) Versus Magnetic Resonance Imaging in the Diagnosis of Breast Carcinoma: A Pilot Study|Terminated||Phase 1|1|Actual|Emory University||1||Study terminated by the Sponsor due to slow enrollment|f||||t||||||||||2017-10-11 00:54:39.675224|2017-10-11 00:54:39.675224
NCT02020031|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-18|2016-10-04|2016-10-04||December 2013||2013-12-01|October 2016|2016-10-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|VIDACARE|Although 22 subjects were enrolled, 2 subjects were withdrawn from the study following an intra-operative decision not to proceed with a full revision. Baseline demographics are provided for the subjects who completed the study.|Regional Prophylactic Vancomycin in Revision Total Knee Replacement|Regional Prophylactic Vancomycin in Revision Total Knee Replacement|Completed||Phase 2/Phase 3|22|Actual|Mayo Clinic||2|||f||||f||||||||Undecided||2017-10-11 00:55:31.436118|2017-10-11 00:55:31.436118
NCT02018341|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-20|2013-12-20|||June 2013||2013-06-01|December 2013|2013-12-01|February 2014|Anticipated|2014-02-01|October 2013|Anticipated|2013-10-01||Interventional|||The Homeogenomic Trial|"A Randomized Double-blind Placebo Controlled Homeopathic Pathogenetic Trial (HPT) on Healthy Volunteers Proving XX in the Potency of 30C, The Homeogenomic Trial"|Withdrawn||N/A|0|Actual|University of Washington||2||Funding withdrawn|f||||f||||||||||2017-10-11 00:55:51.490821|2017-10-11 00:55:51.490821
NCT02016066|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-14|2017-02-03|||December 2013||2013-12-01|November 2016|2016-11-01|April 2014|Anticipated|2014-04-01|January 2014|Actual|2014-01-01||Interventional|||A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants|A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Japanese Subjects to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 Following Single Intravenous Administration|Withdrawn||Phase 1|0|Actual|Janssen Pharmaceutical K.K.||2||Study terminated due to business decision|f||||f||||||||||2017-10-11 00:56:22.262732|2017-10-11 00:56:22.262732
NCT02015195|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-04|2015-04-10|2015-01-26||June 2013||2013-06-01|April 2015|2015-04-01|August 2013|Actual|2013-08-01|August 2013|Actual|2013-08-01||Interventional||one patient treated with ammonia - adverse local skin reaction - this treatment arm therefore withdrawn from study|Effective Treatments for Jellyfish Stings|Efficacy of Topical Agents in the Treatment of Chrysaora Chinensis Stings|Completed||N/A|97|Actual|Stanford University||7|||f||||f||||||||||2017-10-11 00:56:34.2953|2017-10-11 00:56:34.2953
NCT02013765|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-03|2014-09-22|2014-07-24||January 2001||2001-01-01|September 2014|2014-09-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional||Full analysis set (FAS) includes all participants who received study treatment.|A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer|An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression|Terminated||Phase 2|5|Actual|Hoffmann-La Roche||1||Trial was terminated prematurely because of recruitment difficulties.|f||||||||||||||2017-10-11 00:57:01.140569|2017-10-11 00:57:01.140569
NCT02011230|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-03|2016-08-10|||August 2013||2013-08-01|August 2016|2016-08-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||Measuring Pain and Hydration After Tonsillectomy|Pain Control as a Function of Hydration Status in the Post Tonsillectomy Patient.|Terminated||N/A|57|Actual|TriHealth Inc.||2||IRB closed study: irregularities in documentation of informed consent, HIPAA|f||||t||||||||No|Study terminated|2017-10-11 00:57:41.501745|2017-10-11 00:57:41.501745
NCT02008617|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-06|2017-03-08|2017-03-08||December 2013|Actual|2013-12-01|March 2017|2017-03-01|December 2015|Actual|2015-12-01|November 2015|Actual|2015-11-01||Interventional|||Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing ACL Reconstruction|Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction|Terminated||Phase 4|18|Actual|Northwestern University|Early termination leading to small numbers of subjects analyzed|2||The study was terminated due to lack of subject recruitment|f||||f||||||||No||2017-10-11 00:58:25.37026|2017-10-11 00:58:25.37026
NCT02008539|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-28|2017-03-23|||October 2013|Actual|2013-10-01|March 2017|2017-03-01|September 7, 2016|Actual|2016-09-07|September 7, 2016|Actual|2016-09-07||Interventional|TREAT-ME 1||Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101|Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101|Terminated||Phase 1/Phase 2|13|Actual|Apceth GmbH & Co. KG||1||"Enrollment terminated after 13 patients (14 planned); further patients did not meet eligibility   criteria to receive autologous IMP"|f||||t||||||||||2017-10-11 00:58:26.262149|2017-10-11 00:58:26.262149
NCT02008513|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-30|2015-06-23|||June 2013||2013-06-01|June 2015|2015-06-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional|||Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006|A Randomized, Controlled, Parallel Group, Double-blind, Multi-centre, Phase IIb Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in the AFFITOPE® AD02 Phase II Study AFF006.|Terminated||Phase 2|194|Actual|Affiris AG||2||Study AFF006A was early terminated by the sponsor based on the results of study AFF006.|f||||t||||||||||2017-10-11 00:58:26.942024|2017-10-11 00:58:26.942024
NCT02008409|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-22|2015-08-03|||November 2011||2011-11-01|August 2015|2015-08-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|||Evaluation of Safety and Efficacy of the EndoLift Liver Retractor|Evaluation of Safety and Efficacy of the EndoLift Liver Retractor: a Pilot Study of a New Internal Laparoscopic Liver Retraction Device|Withdrawn||N/A|0|Actual|Duke University||1||"The study was terminated. Six subjects were consented & all were withdrawn before any study   activities took place."|f||||f||||||||||2017-10-11 00:58:28.011813|2017-10-11 00:58:28.011813
NCT02008019|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-06|2017-08-04|||August 14, 2014|Actual|2014-08-14|August 2017|2017-08-01|August 2019|Anticipated|2019-08-01|August 2018|Anticipated|2018-08-01||Interventional|CHONRAD||A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas|A Randomized Prospective, Multicentric, Open Label, Phase II Study Aiming to Evaluate the Efficacity and Safety of EVEROLIMUS as Neo-adjuvant Therapy in Patients With Primary or Relapsed Chondrosarcomas|Suspended||Phase 2|57|Anticipated|Centre Leon Berard||3||The study was suspended since july 27th 2016 because of unavailability of Everolimus|f||||t||||||||||2017-10-11 00:58:42.173583|2017-10-11 00:58:42.173583
NCT02007720|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-20|2017-07-05|||March 12, 2014|Actual|2014-03-12|July 2017|2017-07-01|June 16, 2017|Actual|2017-06-16|March 27, 2017|Actual|2017-03-27||Interventional|RELAX-AHF-ASIA||Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF|A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients|Terminated||Phase 3|872|Actual|Novartis||2||Study was terminated based on results from pivotal adult AHF study CRLX030A2301|f||||t|f|||||||||2017-10-11 00:58:45.666448|2017-10-11 00:58:45.666448
NCT02005484|ClinicalTrials.gov processed this data on October 10, 2017|2013-12-04|2014-07-23|2014-06-09||January 2004||2004-01-01|July 2014|2014-07-01|February 2008|Actual|2008-02-01|February 2008|Actual|2008-02-01||Interventional||Intent-to-treat (ITT) population: all participants who signed informed consent for the study.|A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression|An Open-label Pilot Study of Herceptin Monotherapy on Objective Treatment Response in Patients With Metastatic or Locally Advanced Gastric Cancer Who Had Disease Progression During Platinum-based or 5-fluoropyrimidine-based Chemotherapy|Terminated||Phase 2|6|Actual|Hoffmann-La Roche|Due to slow patient recruitment, the study was prematurely terminated.|1||Study terminated due to slow patient recruitment.|f||||||||||||||2017-10-11 00:59:23.94426|2017-10-11 00:59:23.94426
NCT02004392|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-27|2016-05-02|||June 2014||2014-06-01|September 2015|2015-09-01|August 2017|Anticipated|2017-08-01|August 2017|Anticipated|2017-08-01||Interventional|||Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025|A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication|Terminated||Phase 3|348|Actual|FORUM Pharmaceuticals Inc||2||Study has been suspended due to clinical hold.|f||||t||||||||||2017-10-11 00:59:38.73085|2017-10-11 00:59:38.73085
NCT02002234|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-07|2014-02-16|||January 2002||2002-01-01|February 2014|2014-02-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Interventional|HeMMI||Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI): A Single Center Randomized Controlled Clinical Trial|Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI): A Single Center Randomized Controlled Clinical Trial|Terminated||Phase 3|29|Actual|University of the Philippines||2||Recruitment for the study was terminated due to slow recruitment|f||||||||||||||2017-10-11 01:01:30.942597|2017-10-11 01:01:30.942597
NCT02000596|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-21|2016-03-01|||January 2014||2014-01-01|March 2016|2016-03-01|January 2025|Anticipated|2025-01-01|January 2024|Anticipated|2024-01-01||Interventional|||1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.|1303GCC: Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma|Terminated||Phase 2|2|Actual|University of Maryland||3||funding withdrawn by sponsor|f||||t||||||||||2017-10-11 01:01:53.055333|2017-10-11 01:01:53.055333
NCT02000466|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-27|2014-10-23|||November 2013||2013-11-01|October 2014|2014-10-01|May 2018|Anticipated|2018-05-01|May 2018|Anticipated|2018-05-01||Observational|||FluLaval® Quadrivalent Pregnancy Registry|FluLaval® Quadrivalent Pregnancy Registry: a Prospective, Exploratory, Cohort Study to Detect and Describe Any Abnormal Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With FluLaval® Quadrivalent During Pregnancy or Within 28 Days Preceding Conception|Withdrawn||N/A|0|Actual|GlaxoSmithKline|||1|"GSK has merged all individual pregnancy registries, which are terminated, for its seasonal   influenza vaccines into one combined registry, EPI-FLU-039 VS US PR."|f||||||||||||||2017-10-11 01:01:55.597214|2017-10-11 01:01:55.597214
NCT01999192|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-17|2017-07-25|2017-03-16||October 2013||2013-10-01|July 2017|2017-07-01|July 2015|Actual|2015-07-01|July 2015|Actual|2015-07-01||Interventional|986|8 subjects of 321 who had no post-baseline assessment were excluded from the Full Analysis Set (FAS), (one subject [1.3%] in the placebo group, three subjects [3.6%] in Dose Level 1 Tregalizumab group, two subjects [2.5%] in Dose Level 2 Tregalizumab group, and two subjects [2.6%] in Dose Level 3 Tregalizumab group).|Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis|A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)|Terminated||Phase 2|321|Actual|Biotest|Due to the lack of efficacy the Extension Phase of the study was terminated early.|4||Lack of efficacy|f||||t||||||||||2017-10-11 01:02:13.506668|2017-10-11 01:02:13.506668
NCT01997450|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-06|2017-09-20|||December 2, 2013|Actual|2013-12-02|September 2017|2017-09-01|April 13, 2018|Anticipated|2018-04-13|April 13, 2018|Anticipated|2018-04-13||Observational|ICICLE||A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age|A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age|Suspended||N/A|8760|Anticipated|MedImmune LLC|||2|Study recruitment has been suspended.|f||||f||||||Samples With DNA|"     A nasal swab specimen will be collected and tested for influenza and other viral pathogens.   "|||2017-10-11 01:02:42.253094|2017-10-11 01:02:42.253094
NCT01994447|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-19|2016-10-24|||November 2013||2013-11-01|October 2016|2016-10-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|TRAIN||The Train Study: Parental Understanding of Informed Consent|"Traditional Research Nurses Versus an Innovative Undergraduate Research Assistant Program: Parental Understanding of Informed Consent  (the TRAIN Study)"|Terminated||N/A|12|Actual|University of Calgary||2||Change in study consent process at study site so that study had to be terminated|f||||f||||||||||2017-10-11 01:03:30.4057|2017-10-11 01:03:30.4057
NCT01994122|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-13|2016-06-16|||August 2014||2014-08-01|June 2016|2016-06-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Observational|||Mental Health and Resilience in Emerging Adulthood|Mental Health and Resilience in Emerging Adulthood|Terminated||N/A|14|Actual|University of Tromso|||2|The study has been terminated because of recruitment difficulties and lack of further funding|f||||f||||||||||2017-10-11 01:03:35.077918|2017-10-11 01:03:35.077918
NCT01993654|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-19|2016-08-12|||September 2011||2011-09-01|August 2016|2016-08-01|July 2015|Actual|2015-07-01|July 2015|Actual|2015-07-01||Observational|||In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions|In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions|Terminated||N/A|17|Actual|Massachusetts Eye and Ear Infirmary|||5|Study was terminated due to low recruitment.|f||||f||||||||No|Study data was not analyzed due to sample size and no statistical power.|2017-10-11 01:03:43.559853|2017-10-11 01:03:43.559853
NCT01989052|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-21|2016-08-02|||May 2014||2014-05-01|August 2016|2016-08-01|February 2016|Actual|2016-02-01|March 2015|Actual|2015-03-01||Interventional|||Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma|A Phase 1/2 Unblinded Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Lomustine for Bevacizumab-Naïve Adult Patients With Recurrent Malignant Glioma|Terminated||Phase 1|9|Actual|Duke University||4||This study was terminated early due to funding issues prior to completion of phase I|f||||f||||||||||2017-10-11 01:05:03.08705|2017-10-11 01:05:03.08705
NCT01987960|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-13|2017-01-23|2016-10-28||December 2013||2013-12-01|January 2017|2017-01-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional||The all-patients-treated set (APTS) comprises all randomized patients who took at least one dose of brexpiprazole or placebo.|Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Study of Brexpiprazole as Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)|Terminated||Phase 3|417|Actual|H. Lundbeck A/S|As the study was terminated limited efficacy and safety data were collected from the randomized patients. The data are descriptive and the primary and key secondary efficacy analyses were not done.|2||"The study was terminated due to challenges with patient eligibility; the decision to terminate   was not based on any safety concerns"|f||||f||||||||||2017-10-11 01:05:17.406121|2017-10-11 01:05:17.406121
NCT01987908|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-29|2017-02-03|2016-06-21||October 2013||2013-10-01|November 2016|2016-11-01|March 2015|Actual|2015-03-01|March 2015|Actual|2015-03-01||Interventional||Out of the participants who enrolled in the study, only participants who passed the screen and were randomized were entered in the Placebo Lead-in Period.|Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease|A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Two Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease|Terminated||Phase 2|35|Actual|Baxalta US Inc.|PK data not determined as the assay collection method was found to be faulty rendering all samples unevaluable. Study was terminated early by the Sponsor due to unblinding between study drug and placebo groups at the subject, site and Sponsor levels.|4||"Study was terminated early by the Sponsor due to unblinding between study drug and placebo   groups at the subject, site and Sponsor levels."|f||||f||||||||||2017-10-11 01:05:18.655982|2017-10-11 01:05:18.655982
NCT01986946|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-03|2017-01-10|2016-09-23||October 2013||2013-10-01|January 2017|2017-01-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional|||Epidural Analgesia Versus IV Analgesia in Lumbar Spine Fusions|A Comparison of Epidural Analgesia With Standard Care Following Lumbar Spinal Fusion: A Prospective Randomized Study|Terminated||Phase 3|17|Actual|Duke University|Enrollment was terminated when co-PI/coordinator left Duke. No surgical collaborators would enroll subjects. Low enrollment of the study significantly affected the analysis, as both study arms were expected to have 100 participants each.|2||Lack of recruitment.|f||||f||||||||||2017-10-11 01:05:37.827484|2017-10-11 01:05:37.827484
NCT01981811|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-22|2015-04-27|||March 2014||2014-03-01|April 2015|2015-04-01|December 2014|Anticipated|2014-12-01|May 2014|Actual|2014-05-01||Interventional|||Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder|A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole|Withdrawn||Phase 2|0|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1||"The trial was terminated because it was determined that the usability of the MIND1 System in   the intended population was necessary before conducting this trial."|f||||f||||||||||2017-10-11 01:06:52.581665|2017-10-11 01:06:52.581665
NCT01981499|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-05|2014-05-06|||January 2014||2014-01-01|May 2014|2014-05-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults|A Phase 1, Placebo-Controlled, Crossover, Subject- And Investigator-Blind, Sponsor-Open Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of A Modified-Release Formulation Of PF-05180999 In Healthy Adult Subjects|Terminated||Phase 1|31|Actual|Pfizer||6||The trial was prematurely terminated on 01April2014 due to safety concerns.|f||||f||||||||||2017-10-11 01:06:55.576159|2017-10-11 01:06:55.576159
NCT01980875|ClinicalTrials.gov processed this data on October 10, 2017|2013-11-05|2017-05-26|2017-03-30||April 21, 2015|Actual|2015-04-21|May 2017|2017-05-01|May 13, 2016|Actual|2016-05-13|May 13, 2016|Actual|2016-05-13||Interventional||Intent-to-Treat Analysis Set: participants who were randomized regardless of whether participants received any study drug(s), or received a different regimen from the regimen to which they were randomized.|Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia|A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia|Terminated||Phase 3|57|Actual|Gilead Sciences|The study was terminated in agreement with the FDA due to urgent safety measures. Complete data were not collected for any participant.|3|||f||||t|t|f||||||||2017-10-11 01:07:04.99639|2017-10-11 01:07:04.99639
NCT01975844|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-13|2014-03-21|||July 2013||2013-07-01|March 2014|2014-03-01||||March 2014|Actual|2014-03-01||Interventional|||The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability|The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability|Terminated||Phase 4|48|Actual|Baystate Medical Center||1||Study has been terminated due to lack of financial support|f||||t||||||||||2017-10-11 01:08:25.596861|2017-10-11 01:08:25.596861
NCT01973608|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-25|2016-09-14|2016-06-30||January 2014||2014-01-01|September 2016|2016-09-01|June 2015|Actual|2015-06-01|April 2015|Actual|2015-04-01||Interventional||Safety analyst set included all subjects who signed informed consent, were enrolled into the study and received at least 1 dose of MSB0010445.|MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma|A Safety Study for MSB0010445 in Combination With Stereotactic Body Radiation in Advanced Melanoma Subjects Following Prior Treatment With Ipilimumab|Terminated||Phase 2|12|Actual|EMD Serono|The study was terminated early due to sponsor’s decision to discontinue the development of MSB0010445. The decision to discontinue development of MSB0010445 was not related to any safety or efficacy concerns.|4||"The study is terminated prematurely as the sponsor decided to discontinue program of NHS-IL2   [MSB0010445]"|f||||||||||||||2017-10-11 01:09:08.217728|2017-10-11 01:09:08.217728
NCT01972776|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-24|2016-02-24|2016-01-22||November 2013||2013-11-01|February 2016|2016-02-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional|||A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.|A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD|Terminated||Phase 2|48|Actual|Novartis|Part 2 was terminated after 21 patients were enrolled. Three of the 21 patients experienced moderate to severe (up to 17-fold) asymptomatic and reversible elevation of liver transaminase levels after 3 weeks of treatment with QBM076 150 mg bid.|6||Part 1 was completed. Part 2 was terminated for safety reasons.|f||||t||||||||||2017-10-11 01:09:22.817377|2017-10-11 01:09:22.817377
NCT01969136|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-21|2016-05-02|||October 2013||2013-10-01|September 2015|2015-09-01|January 2017|Anticipated|2017-01-01|January 2017|Anticipated|2017-01-01||Interventional|||Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication|Terminated||Phase 3|403|Actual|FORUM Pharmaceuticals Inc||3||Study has been suspended due to clinical hold.|f||||||||||||||2017-10-11 01:10:20.798964|2017-10-11 01:10:20.798964
NCT01969123|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-21|2016-05-02|||October 2013||2013-10-01|September 2015|2015-09-01|January 2017|Anticipated|2017-01-01|January 2017|Anticipated|2017-01-01||Interventional|||Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication|Terminated||Phase 3|474|Actual|FORUM Pharmaceuticals Inc||3||Study has been suspended due to clinical hold.|f||||||||||||||2017-10-11 01:10:21.095632|2017-10-11 01:10:21.095632
PK population = 58 => 41 in Group 1 (2 withdrawn + 1 excluded due to major protocol deviation), 17 in Group 2 (1 withdrawn)."|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes and Nicotine Nasal Spray|Completed||N/A|64|Actual|Philip Morris Products S.A.||4|||f||||f||||||||No||2017-10-11 01:10:52.814166|2017-10-11 01:10:52.814166
61 completers: 43 in Group 1 (1 withdrawn subject), 18 in Group 2."|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes and Nicotine Gum.|Completed||N/A|73|Actual|Philip Morris Products S.A.||4|||f||||f||||||||||2017-10-11 01:10:53.215514|2017-10-11 01:10:53.215514
NCT01963611|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-11|2016-04-05|2016-04-05||October 2013||2013-10-01|April 2016|2016-04-01|March 2015|Actual|2015-03-01|March 2015|Actual|2015-03-01||Interventional||Safety Analysis Set (SAF) includes all randomized subjects who had received at least 1 dose of investigational medicinal product (IMP).|Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)|A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis|Terminated||Phase 2|255|Actual|EMD Serono|Based on Sponsor decision to discontinue the clinical development program of plovamer acetate therapy for multiple sclerosis the trial was prematurely terminated|5||Study was terminated based on sponsor discretion.|f||||t||||||||||2017-10-11 01:12:16.977482|2017-10-11 01:12:16.977482
60 completers: 42 in Group 1 (2 withdrawn subjects), 18 in Group 2."|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of THS 2.2 Following Single Use in Healthy Smokers Compared to Conventional Cigarettes and Nicotine Gum|Completed||N/A|65|Actual|Philip Morris Products S.A.||4|||f||||f||||||||||2017-10-11 01:13:20.677353|2017-10-11 01:13:20.677353
NCT01958060|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-01|2015-07-02|2015-07-02||October 2013||2013-10-01|July 2015|2015-07-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional||Treated set (TS):This subject set included all subjects who were dispensed study medication and were documented to have received 1 dose of trial medication.|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)|Terminated||Phase 1|35|Actual|Boehringer Ingelheim|Due to a drug-related Serious Adverse event in the first subject of 100 mg BI 1034020 single iv dose group, the trial was prematurely terminated. No further iv dosing was performed and no planned sc dosing scheme was performed in this trial.|2|||f||||||||||||||2017-10-11 01:13:44.539801|2017-10-11 01:13:44.539801
NCT01957657|ClinicalTrials.gov processed this data on October 10, 2017|2013-10-01|2016-03-16|2016-01-21||October 2013||2013-10-01|March 2016|2016-03-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional||Treated Set, (TS) included all enrolled subjects, who had taken at least one dose of trial medication.|Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients|Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Single Center, Open-label, Parallel-group, Phase I Trial|Terminated||Phase 1|4|Actual|Boehringer Ingelheim|The sponsor decided to stop the development of Hepatitis C treatments and terminated the trial prematurely on 27 Dec 2013. Due to the small sample size the pharmacokinetic endpoints were not determined.|4|||f||||||||||||||2017-10-11 01:13:51.279335|2017-10-11 01:13:51.279335
NCT01957501|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-10|2017-04-06|||July 2013||2013-07-01|April 2017|2017-04-01|March 2016|Actual|2016-03-01|July 2015|Actual|2015-07-01||Observational|||Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel|Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel|Terminated||N/A|75|Actual|University of Utah|||3|Funding has been terminated for this study.|f||||f||||||||||2017-10-11 01:13:54.000178|2017-10-11 01:13:54.000178
NCT01957410|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-30|2016-12-05|2016-09-21||February 2014||2014-02-01|December 2016|2016-12-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional||Baseline analysis population included all participants who were received at least one dose of study drug.|A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder|An Open-Label and Double-Blind Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Subjects With Major Depressive Disorder|Terminated||Phase 2|13|Actual|Janssen Research & Development, LLC|Study was planned as open label treatment phase (Cohort 1) and double blind treatment phase (Cohort 2). However, study was terminated after completion of Cohort 1.|2||"Clinical Team decision to terminate the study after the results from Cohort 1 did not support   conducting Cohort 2."|f||||f||||||||||2017-10-11 01:13:55.983696|2017-10-11 01:13:55.983696
NCT01954745|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-24|2016-12-12|2016-12-12||September 2013||2013-09-01|December 2016|2016-12-01|June 2016|Actual|2016-06-01|June 2015|Actual|2015-06-01||Interventional|||Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma|A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy|Completed||Phase 2|19|Actual|Massachusetts General Hospital|After 12 patients failed to be progression-free at 16 weeks, the study was terminated as it was determined that the criterion for proceeding to stage 2 could not be met. (i.e. 9 of 20 patients needed to be progression free at 4 months.)|1|||f||||t||||||||No||2017-10-11 01:14:41.914609|2017-10-11 01:14:41.914609
NCT01954160|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-24|2015-12-30|2015-12-30||December 2013||2013-12-01|December 2015|2015-12-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|PRESERVE|All patients were required to have suitable anatomy per renal ultrasound. One randomized subject did not have suitable anatomy to proceed to renal denervaton.|Study of Renal Denervation in Patients With Heart Failure|Promotion of Renal Sodium Excretion by Renal Sympathetic Denervation in Congestive Heart Failure|Terminated||Phase 2|5|Actual|Duke University|Data Safety Monitoring Board (DSMB) terminated trial based upon noted lack of efficacy in manufacturers pivotal trials. Endpoint data not collected or analyzed.|2||DSMB decision based upon noted lack of efficacy in manufacturers pivotal trials.|f||||t||||||||||2017-10-11 01:14:51.782278|2017-10-11 01:14:51.782278
NCT01954082|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-26|2017-09-22|||April 2014||2014-04-01|September 2017|2017-09-01|April 30, 2018|Anticipated|2018-04-30|December 31, 2016|Actual|2016-12-31||Interventional|INS-3||Inositol to Reduce Retinopathy of Prematurity|INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants|Terminated||Phase 3|638|Actual|NICHD Neonatal Research Network||2||Study terminated due to safety concerns; participant follow up will continue until March 2018|f||||t|t|f||||||||2017-10-11 01:14:54.797141|2017-10-11 01:14:54.797141
NCT01954030|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-26|2016-02-17|||October 2013||2013-10-01|February 2016|2016-02-01|July 2015|Actual|2015-07-01|July 2015|Actual|2015-07-01||Interventional|||Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure|A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure|Terminated||Phase 1|17|Actual|Duke University||3||Study terminated early due to funding reasons prior to completing Phase 1|f||||f||||||||||2017-10-11 01:14:55.421688|2017-10-11 01:14:55.421688
NCT01953354|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-24|2017-02-09|2016-12-16||November 2013||2013-11-01|February 2017|2017-02-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional||The Randomized population included all subjects who were randomized to receive either TSO 7500 or placebo.|Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis|A Prospective, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study of Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis and Its Effects on Mucosal Immune State and Microbiota|Terminated||Phase 2|16|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Recruitment was slower than anticipated. The study was ultimately terminated when the manufacturer decided to discontinue study product production.|2||MFR's business decision to d/c TSO production -unrelated to any safety concern.|f||||t||||||||||2017-10-11 01:15:06.092145|2017-10-11 01:15:06.092145
NCT01947946|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-11|2015-11-23|2015-07-21||November 2013||2013-11-01|October 2015|2015-10-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||The number of participants for analysis will be from the full analysis set. The full analysis set consists of all patients randomized and receiving any investigational product, irrespective of their protocol adherence and continued participation in the study.|Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma|A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma|Terminated||Phase 3|13|Actual|AstraZeneca||3||Study terminated due to sponsor decision|f||||f||||||||||2017-10-11 01:16:43.694417|2017-10-11 01:16:43.694417
NCT01946542|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-17|2015-11-10|2015-09-28||February 2014||2014-02-01|November 2015|2015-11-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional|||Acute Effects of Beet Juice Consumption on Exercise Capacity in Heart Failure|Acute Effects of Beet Juice Consumption on Exercise Capacity in Heart Failure|Terminated||Phase 1/Phase 2|2|Actual|Duke University|The study was terminated due to low enrollment.|2||Low enrollment|f||||f||||||||||2017-10-11 01:17:02.607403|2017-10-11 01:17:02.607403
NCT01944969|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-13|2016-02-04|2015-08-17||October 2013||2013-10-01|February 2016|2016-02-01||||May 2014|Actual|2014-05-01||Interventional|||Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder|Interventional, Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder|Terminated||Phase 3|26|Actual|H. Lundbeck A/S|Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.|1||"The study was terminated because the lead-in study (14571A) in elderly was terminated; see   Detailed Description."|f||||f||||||||||2017-10-11 01:17:37.243238|2017-10-11 01:17:37.243238
NCT01944618|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-13|2016-09-12|||October 2013||2013-10-01|September 2016|2016-09-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Observational|forREAL||forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)|forREAL: FORXIGA (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) PRESCRIPTION EVENT MONITORING PROGRAM|Terminated||N/A|5000|Anticipated|AstraZeneca|||1|"Participant Data obtained to 30Sep2015:    Baseline data: 447 6 month data: 253 Program terminated: recruitment target not met. No   analysis will be provided."|f||||f||||||||||2017-10-11 01:17:43.862447|2017-10-11 01:17:43.862447
NCT01944306|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-10|2015-04-15|||August 2013||2013-08-01|April 2015|2015-04-01|December 2015|Anticipated|2015-12-01|April 2015|Actual|2015-04-01||Observational|||Obesity and Oral Contraceptive Failure|Prenatal Growth Programs Oral Contraceptive Metabolism and Effectiveness|Terminated||N/A|40|Anticipated|Oregon Health and Science University|||4|"Due to lack of funds, the study has been terminated upon recruiting less than desired number of   subjects"|f||||f||||||Samples With DNA|"     Blood, Plasma, and Urine will be collected for the analaysis of drug levels and genotyping of     various genes that could explain pharmacokinetics of oral contraceptives.   "|||2017-10-11 01:17:47.243044|2017-10-11 01:17:47.243044
NCT01941277|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-06|2016-07-14|||August 2014||2014-08-01|July 2016|2016-07-01|March 2015|Actual|2015-03-01|March 2015|Actual|2015-03-01||Interventional|EFFORT||Effect of Exercise on Insulin Resistance|Effect of Exercise on Insulin Resistance|Terminated||N/A|3|Actual|Alere San Diego||2||funding withdrawn|f||||f||||||||||2017-10-11 01:18:31.395078|2017-10-11 01:18:31.395078
NCT01939548|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-09|2016-07-12|2015-10-16||October 2013||2013-10-01|July 2016|2016-07-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional||All participants who received study treatment were included in the baseline characteristics summary.|An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia|A 12-week , Randomized, Phase 2, Double-blind, Parallel-group Study Of Two Dose Levels Of Pf-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-optimally Controlled Symptoms Of Schizophrenia|Terminated||Phase 2|240|Actual|Pfizer|The study was terminated prematurely as a pre-planned interim analysis indicated the study was unlikely to meet the pre-specified efficacy criteria. The decision was not based on any safety concerns.|3||"A pre-planned interim analysis indicated the trial was unlikely to meet the pre-specified   efficacy criteria. The decision was not based on any safety concerns."|f||||t||||||||||2017-10-11 01:18:59.137338|2017-10-11 01:18:59.137338
NCT01939067|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-30|2015-09-14|||March 2014||2014-03-01|September 2015|2015-09-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP|Pulmonary Mechanics in Preterm Infants Treated With Heated Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure.|Withdrawn||Phase 1|0|Actual|Children's Hospital of Philadelphia||2||Application for regulatory approval withdrawn|f||||f||||||||||2017-10-11 01:19:10.844485|2017-10-11 01:19:10.844485
NCT01937715|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-27|2016-07-08|2016-07-08|2015-12-15|February 2014||2014-02-01|July 2016|2016-07-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional||The baseline analysis population included all participants who received at least 1 dose of study treatment.|A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer|An Open-Label, Multi-Center, Randomized Phase 1b/2 Study Of PF-05212384 Plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer|Terminated||Phase 1/Phase 2|18|Actual|Pfizer|As this study was terminated due to Pfizer portfolio prioritization prior to the Phase 2 portion, there are no efficacy evaluations for Phase 2.|2||"B2151007 was prematurely discontinued due to Pfizer's change in prioritization for the   portfolio and is not due to any safety concerns or regulatory interaction"|f||||f||||||||||2017-10-11 01:19:41.753521|2017-10-11 01:19:41.753521
NCT01937130|ClinicalTrials.gov processed this data on October 10, 2017|2013-09-04|2016-03-28|2016-02-26||September 2013||2013-09-01|March 2016|2016-03-01|February 2015|Actual|2015-02-01|January 2015|Actual|2015-01-01||Interventional||Subjects with acute-on-Chronic liver failure (ACLF)|Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF|A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure|Terminated||Phase 2|23|Actual|Conatus Pharmaceuticals Inc.|Study was terminated early.|4||Data needs met|f||||t||||||||||2017-10-11 01:19:52.009012|2017-10-11 01:19:52.009012
NCT01934894|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-27|2017-06-01|2017-02-01||May 2014|Actual|2014-05-01|June 2017|2017-06-01|April 2017|Actual|2017-04-01|February 2016|Actual|2016-02-01||Interventional||Includes participants that received at least one dose of study treatment.|Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases|Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases|Terminated||Phase 2|11|Actual|SCRI Development Innovations, LLC|Early termination of study resulted in small number of subjects analyzed.|1||Study was terminated due to lack of significant signal of efficacy|f||||f||||||||||2017-10-11 01:20:20.508578|2017-10-11 01:20:20.508578
NCT01931631|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-26|2017-04-11|||January 2014||2014-01-01|April 2017|2017-04-01|January 2018|Anticipated|2018-01-01|January 2018|Anticipated|2018-01-01||Interventional|WCCR-DIAB2||Plant-Based Dietary Intervention in Type 2 Diabetes-2|A Practice-Based, Nutrition Intervention in Type 2 Diabetes|Suspended||N/A|60|Anticipated|Physicians Committee for Responsible Medicine||2||Erroneously duplicated study|f||||t||||||||Undecided|This study has been suspended|2017-10-11 01:21:24.440293|2017-10-11 01:21:24.440293
NCT01930890|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-26|2016-11-22|2016-11-22||November 2013||2013-11-01|November 2016|2016-11-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional|||BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis|A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis|Terminated||Phase 2|87|Actual|Biogen|Study was terminated based on the pre-specified, blinded futility analysis of Study 211LE201 (NCT01499355), which did not demonstrate sufficient efficacy to warrant continuation of the studies. Study was not terminated based on safety considerations.|2||"Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate   sufficient efficacy to warrant continuation of the study"|f||||t||||||||||2017-10-11 01:21:33.949115|2017-10-11 01:21:33.949115
NCT01928693|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-20|2015-08-11|2015-08-11||July 2013||2013-07-01|August 2015|2015-08-01|May 2014|Actual|2014-05-01|May 2014|Actual|2014-05-01||Interventional|Eye02||A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.|A Single-site, Single Masked, Prospective Comparison of Three Fluoroquinolone Topical Therapies (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%) in the Treatment of Infectious Corneal Ulcers.|Terminated||Phase 2|2|Actual|Cornea Consultants Of Nashville|The study was terminated due to slow enrollment.|3||study terminated due to slow accrual|f||||f||||||||||2017-10-11 01:22:16.172967|2017-10-11 01:22:16.172967
NCT01927952|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-19|2013-12-03|||September 2013||2013-09-01|December 2013|2013-12-01|December 2016|Anticipated|2016-12-01|December 2015|Anticipated|2015-12-01||Interventional|||A Prospective Randomized Comparison of Three Methods for Fixation of Hammertoes|A Prospective Randomized Comparison of Three Methods for Fixation of Hammertoes|Withdrawn||Phase 4|0|Actual|Milton S. Hershey Medical Center||3||Study withdrawn from IRB approval process by PI|f||||f||||||||||2017-10-11 01:22:30.469345|2017-10-11 01:22:30.469345
NCT01927913|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-20|2015-05-06|||July 2014||2014-07-01|May 2015|2015-05-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||Treatment of Iron Overload Requiring Chelation Therapy|A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan® (R2) Magnetic Resonance Imaging in B-thalassemia Subjects Administered SPD602 (SSP-004184AQ) or Exjade® (Deferasirox) for Treatment of Chronic Transfusional Iron Overload|Withdrawn||Phase 2|0|Actual|Shire||2||This study was withdrawn until the evaluation of the nonclinical rat findings is complete.|f||||t||||||||||2017-10-11 01:22:31.083199|2017-10-11 01:22:31.083199
NCT01927055|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-16|2015-12-04|2015-11-02||November 2013||2013-11-01|December 2015|2015-12-01|February 2015|Actual|2015-02-01|February 2015|Actual|2015-02-01||Interventional|||A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy|A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy|Terminated||Phase 3|61|Actual|Chelsea Therapeutics|The study was prematurely terminated; the limited sample size precludes meaningful conclusions on the efficacy or safety of droxidopa in this study.|2||Due to potential competition with a post-marketing study requested by FDA|f||||f||||||||||2017-10-11 01:22:42.707006|2017-10-11 01:22:42.707006
NCT01925274|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-15|2017-04-28|2017-01-09||November 2013||2013-11-01|April 2017|2017-04-01|April 2016|Actual|2016-04-01|April 2016|Actual|2016-04-01||Interventional||The baseline analysis population included all enrolled participants who received the study drug.|A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer|A Randomized Phase 2 Study Of Pf-05212384 Plus Irinotecan Versus Cetuximab Plus Irinotecan In Patients With Kras And Nras Wild Type Metastatic Colorectal Cancer|Terminated||Phase 2|19|Actual|Pfizer|This study was terminated by sponsor due to strategic reasons and not due to any safety or efficacy concerns with treatment of PF-05212384.|2||"Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no   safety or efficacy issues that contributed to this decision."|f||||f||||||||||2017-10-11 01:23:08.616993|2017-10-11 01:23:08.616993
NCT01924858|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-15|2017-05-05|||August 19, 2013|Actual|2013-08-19|May 2017|2017-05-01|March 3, 2014|Actual|2014-03-03|March 3, 2014|Actual|2014-03-03||Interventional|||A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.|An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects|Terminated||Phase 1|4|Actual|GlaxoSmithKline||1||Study objectives met so study concluded earlier than planned hence we terminated the study.|f||||f||||||||||2017-10-11 01:23:19.415937|2017-10-11 01:23:19.415937
NCT01923805|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-26|2017-05-05|2017-01-18||April 2013||2013-04-01|May 2017|2017-05-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||Vitagel Revision Total Knee Arthroplasty|A Prospective Randomized Evaluation of a Collagen/Thrombin Autologous Platelet Hemostatic Agent During Revision Knee Arthroplasty|Terminated||N/A|8|Actual|The Cleveland Clinic||2||Difficulty enrolling patients|f||||f||||||||No|Study terminated early|2017-10-11 01:23:33.401292|2017-10-11 01:23:33.401292
NCT01923389|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-30|2014-09-08|2014-09-08||September 2013||2013-09-01|September 2014|2014-09-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional||All participants who received at least 1 dose of study medication (PF-05231023 or placebo).|Multiple Dose Study Of PF-05231023 In Obese Adult Subjects|A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-05231023 In Obese Adult Subjects|Terminated||Phase 1|4|Actual|Pfizer||2||"The study was terminated on December 19th, 2013 due to a business decision by the Sponsor. No   safety concerns have been observed in this study."|f||||f||||||||||2017-10-11 01:23:42.220825|2017-10-11 01:23:42.220825
NCT01921998|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-09|2015-02-03|||October 2013||2013-10-01|February 2015|2015-02-01||||November 2015|Anticipated|2015-11-01||Observational|BioACT||Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy|Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy|Suspended||N/A|50|Anticipated|The Christie NHS Foundation Trust|||1|Trial has been suspended due to lack of resource and staff|f||||f||||||Samples With DNA|"     Blood samples will be collected to analyse for biomarkers CK18 and FLT 3 Ligand.   "|||2017-10-11 01:24:06.785184|2017-10-11 01:24:06.785184
NCT01921296|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-08|2016-03-21|2014-11-12||August 2013||2013-08-01|March 2016|2016-03-01|April 2015|Actual|2015-04-01|May 2014|Actual|2014-05-01||Interventional|||Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients|UMCC 2013.051: Prospective Pilot Study Evaluating the Use of Cyclobenzaprine for Treatment of Sleep Disturbance, Fatigue, and Musculoskeletal Symptoms in Aromatase Inhibitor-treated Breast Cancer Patients|Terminated||Phase 2|2|Actual|University of Michigan Cancer Center|The study was closed early for futility. The primary endpoint was not analyzed.|1||Accrual terminated early because of poor accrual|f||||t||||||||||2017-10-11 01:24:16.28157|2017-10-11 01:24:16.28157
NCT01920178|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-07|2017-04-18|2016-07-15||April 2013||2013-04-01|July 2016|2016-07-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional|||Evaluation Study for the Efficacy and Safety of PinPointe FootLaser in Treatment for Onychomycosis|A Placebo Controlled, Randomized, Prospective Study to Evaluate the Efficacy and Safety of PinPointe FootLaser in Patients Who Have Failed Oral Terbinafine Treatment for Onychomycosis|Terminated||N/A|7|Actual|Cambridge Health Alliance|Withdrawal of financial support by Nuvolase, Inc in June, 2014 with very small enrollment of only 7 subjects ( 40 originally anticipated) led to loss of vital Primary and Secondary Outcome Measures with no reliable or interpretable data produced.|2||"Financial support of the Study withdrawn by Nuvolase, Inc ( PinPointe FootLaser) due to delayed   start of the Study and inadequate subjects enrolled"|f||||f||||||||No||2017-10-11 01:24:39.055116|2017-10-11 01:24:39.055116
NCT01919996|ClinicalTrials.gov processed this data on October 10, 2017|2013-08-07|2016-07-06|2016-03-28||December 2013||2013-12-01|July 2016|2016-07-01|November 2015|Actual|2015-11-01|October 2015|Actual|2015-10-01||Interventional||The safety population included all enrolled participants that took at least one dose of study medication.|PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients|Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/Tonsillitis|Terminated||Phase 2|8|Actual|Pfizer|The study was terminated after the FDA released the Sponsor from the PMC. The FDA deemed the study as impracticable, given the azithromycin dose studied in the PMC was not used and the available data did not identify a signal for ocular toxicity.|1||See Termination Statement in the Detailed Description below|f||||f||||||||||2017-10-11 01:24:40.969096|2017-10-11 01:24:40.969096
NCT01914679|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-23|2017-03-07|2017-01-04||July 2013||2013-07-01|March 2017|2017-03-01|February 2015|Actual|2015-02-01|February 2015|Actual|2015-02-01||Interventional|PERRFECT-UM||A Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - University of Michigan|A Phase 2 Clinical Trial Evaluating Use of the NeuroPoint Medical Device as a Treatment for Fibromyalgia.|Terminated||N/A|17|Actual|University of Michigan|This mechanistic study wasn’t powered to show statistically significant clinical improvement, even as originally planned. Sponsor terminated study early when they realized the devices were not delivering enough current to be of therapeutic benefit.|1||Sponsor terminated the study|f||||f||||||||||2017-10-11 01:25:56.388232|2017-10-11 01:25:56.388232
NCT01913535|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-30|2017-05-31|2017-04-17||September 12, 2013|Actual|2013-09-12|May 2017|2017-05-01|January 22, 2016|Actual|2016-01-22|January 22, 2016|Actual|2016-01-22||Interventional|RAPID KOR|Only 8 participants were randomized because the study terminated early due to slow enrollment.|Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression|Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)|Terminated||Phase 2|8|Actual|Massachusetts General Hospital||5||slow enrollment|f||||t||||||||||2017-10-11 01:26:10.819209|2017-10-11 01:26:10.819209
NCT01912404|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-29|2016-09-16|2016-07-29||July 2013||2013-07-01|September 2016|2016-09-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional|AH|Study in patients with alcoholic hepatitis who were contraindicated to receive corticosteroid therapy.|Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy|A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy|Terminated||Phase 2|5|Actual|Conatus Pharmaceuticals Inc.|Since the study was stopped early, no conclusions regarding efficacy can be made.|2||Due to concern for high systemic drug levels that could exceed levels in toxicology studies.|f||||t||||||||No|Study was terminated early with insufficient subjects for meaningful analysis.|2017-10-11 01:26:25.440693|2017-10-11 01:26:25.440693
NCT01911793|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-26|2017-05-26|2017-02-13||July 2013||2013-07-01|May 2017|2017-05-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||Data were not collected and no data was analyzed study was terminated due to issues with study enrollment and study administrative coverage.|Stoma Tube Decompression and Postoperative Ileus After Major Colorectal Surgery|Stoma Tube Decompression and Postoperative Ileus After Major Colorectal Surgery|Terminated||N/A|6|Actual|Cedars-Sinai Medical Center|"Study only accrued 6 patients. Due to poor enrollment and issues with administrative coverage for study it was decided to terminate the study.
NCT01911403|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-14|2015-02-26|2015-02-26||December 2010||2010-12-01|February 2015|2015-02-01|September 2014|Actual|2014-09-01|August 2014|Actual|2014-08-01||Interventional|AGIR||AGIR Study: Angio-Seal in Interventional Radiology|Efficacy Superiority of Angio-Seal™ vs. Manual Compression in Interventional Radiology|Terminated||Phase 4|123|Actual|St. Jude Medical|This study has been early terminated on 15 May 2014 due to low enrollment rate and the publication of other larger studies about closure device versus manual compression.This lead to small number of subjects analyzed.|2||Low enrollment rate.|f||||f||||||||||2017-10-11 01:26:41.459435|2017-10-11 01:26:41.459435
NCT01911273|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-26|2015-10-06|2015-06-09||October 2013||2013-10-01|October 2015|2015-10-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer|A Phase 2, Randomized, Double Blind Study To Evaluate The Efficacy, Safety, Pharmacodynamics And Pharmacokinetics Of The Anti-alk-1 Monoclonal Antibody Pf-03446962 In Combination With Best Supportive Care Vs. Placebo Plus Best Supportive Care In Adult Patients With Advanced Hepatocellular Carcinoma Following Failure Of Sorafenib|Terminated||Phase 2|3|Actual|Pfizer|This study was prematurely terminated due to a Sponsor decision not to pursue the clinical development of PF-03446962 as monotherapy in second-line hepatocellular carcinoma.|2||See termination reason in detailed description.|f||||t||||||||||2017-10-11 01:26:43.531537|2017-10-11 01:26:43.531537
NCT01910441|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-25|2015-09-22|2015-09-22||July 2013||2013-07-01|September 2015|2015-09-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional|VARIABLE||Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients|A Comparative Study to Assess the Effect of Vildagliptin Versus Glimepiride on Glucose Variability in Type 2 Diabetic Patients Uncontrolled on Metformin Alone|Terminated||Phase 4|95|Actual|Novartis||2||"The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors   (CGMS) which were required to assess the primary end-point."|f||||f||||||||||2017-10-11 01:26:53.643664|2017-10-11 01:26:53.643664
NCT01910389|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-25|2015-04-16|2015-04-16||November 2013||2013-11-01|January 2014|2014-01-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|PITCH-HF||Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure|Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure|Terminated||Phase 3|23|Actual|New England Research Institutes|Early termination leading to small numbers of subjects. Outcome measure data not obtained.|2||terminated by funding agency|f||||t||||||||||2017-10-11 01:26:59.163208|2017-10-11 01:26:59.163208
NCT01910298|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-22|2017-03-13|||July 2013||2013-07-01|March 2017|2017-03-01|September 2017|Anticipated|2017-09-01|August 2016|Actual|2016-08-01||Interventional|ESSBR||Efficacy of Single Stage Breast Reconstruction|A Prospective, Multicenter, Controlled Study of Implant-based Breast Reconstruction, Measuring the Safety, Efficacy and Outcomes, of Immediate Single Stage Breast Reconstruction With Strattice™ Reconstructive Tissue Matrix Versus Immediate Two Stage Breast Reconstruction Without Strattice™ TM .|Terminated||N/A|127|Actual|LifeCell||2||The study is being terminated due to no enrollment in over one year in the control arm|f||||t||||||||||2017-10-11 01:27:00.799683|2017-10-11 01:27:00.799683
NCT01908387|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-23|2015-07-24|||July 2013||2013-07-01|July 2015|2015-07-01|July 2015|Actual|2015-07-01|July 2015|Actual|2015-07-01||Interventional|||Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms|A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral Azacitidine (CC-486) in Japanese Subjects With Hematological Neoplasms|Terminated||Phase 1|2|Actual|Celgene||1||Due to Slow Accrual study was terminated.|f||||t||||||||||2017-10-11 01:27:37.649406|2017-10-11 01:27:37.649406
NCT01905605|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-18|2017-03-03|||September 2013|Anticipated|2013-09-01|March 2017|2017-03-01|January 2017|Actual|2017-01-01|January 2017|Actual|2017-01-01||Interventional|||Phosphatidylcholine Supplementation in Infants|Phosphatidylcholine Supplementation in Infants With Diminished Sensory Gating|Withdrawn||Phase 1/Phase 2|0|Actual|University of Colorado, Denver||2||Funding not secured. IRB approval has been withdrawn as of January 2017.|f||||t||||||||||2017-10-11 01:28:13.241453|2017-10-11 01:28:13.241453
NCT01905527|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-18|2015-01-30|||July 2013||2013-07-01|January 2015|2015-01-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Observational|||Adherence Trial With MS LifeLines ® Services|A Prospective, Parallel Group, Phase IV Study of Three Levels of MS LifeLines ® Support Services Provided to Patients Prescribed Rebif ® for Newly Diagnosed or First-switch Relapsing Remitting Multiple Sclerosis (RRMS)|Terminated||N/A|306|Actual|EMD Serono|||3|The study was terminated as per the Sponsor's decision.|f||||f||||||||||2017-10-11 01:28:16.498708|2017-10-11 01:28:16.498708
NCT01901341|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-09|2015-10-16|2015-04-19||July 2013||2013-07-01|October 2015|2015-10-01|April 2014|Actual|2014-04-01|February 2014|Actual|2014-02-01||Interventional||All participants randomized to treatment who received ≥ 1 dose of double-blind study medication.|The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain|Terminated||Phase 3|44|Actual|Cubist Pharmaceuticals LLC|Due to difficulties with enrollment, the study was terminated early.|2||Due to difficulties with enrollment, the study was terminated early.|f||||t||||||||||2017-10-11 01:29:17.289516|2017-10-11 01:29:17.289516
NCT01901328|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-09|2016-01-05|2015-04-19||August 2013||2013-08-01|January 2016|2016-01-01|April 2014|Actual|2014-04-01|February 2014|Actual|2014-02-01||Interventional||All participants randomized to treatment who received ≥ 1 dose of double-blind study medication.|Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain|Terminated||Phase 3|49|Actual|Cubist Pharmaceuticals LLC|Due to difficulties with enrollment, this study was terminated early.|2||Sponsor decision due to lack of enrollment.|f||||t||||||||||2017-10-11 01:29:18.053959|2017-10-11 01:29:18.053959
NCT01901302|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-09|2016-01-05|2015-04-19||July 2013||2013-07-01|January 2016|2016-01-01|April 2014|Actual|2014-04-01|January 2014|Actual|2014-01-01||Interventional||All participants randomized to treatment who received ≥ 1 dose of double-blind study medication.|Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain|Terminated||Phase 3|61|Actual|Cubist Pharmaceuticals LLC|Due to difficulties with enrollment, this study was terminated early.|2||Sponsor decision due to lack of enrollment.|f||||t||||||||||2017-10-11 01:29:18.750862|2017-10-11 01:29:18.750862
NCT01899690|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-11|2017-02-22|||June 2016|Anticipated|2016-06-01|February 2017|2017-02-01|December 2017|Anticipated|2017-12-01|August 2017|Anticipated|2017-08-01||Interventional|||Antibiotics and Tissue Expanders in Breast Reconstruction|Impact of Prophylactic Perioperative Antibiotic Administration on Surgical Site Infections Following Implant-based Breast Reconstruction.|Withdrawn||Phase 4|0|Actual|Emory University||2||The study was withdrawn prior to IRB approval.|f||||f||||||||||2017-10-11 01:29:49.902849|2017-10-11 01:29:49.902849
NCT01899508|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-26|2017-01-31|||January 2015|Actual|2015-01-01|January 2017|2017-01-01|December 2019|Anticipated|2019-12-01|December 2019|Anticipated|2019-12-01||Interventional|VROA||Virtual Reality for Osteoarthritis Knee Pain Pilot|Virtual Reality for Osteoarthritis Knee Pain Pilot|Suspended||N/A|30|Anticipated|Duke University||1||The study has been suspended, due to technically difficulties.|f||||f||||||||||2017-10-11 01:29:53.59751|2017-10-11 01:29:53.59751
NCT01898286|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-10|2016-04-19|2015-11-16||October 2013||2013-10-01|April 2016|2016-04-01|December 2014|Actual|2014-12-01|September 2014|Actual|2014-09-01||Interventional|DIA-AID 2||Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®|Open-Label Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277® in Subjects Who Have Completed Study 1001 (NCT01103284)|Terminated||Phase 3|38|Actual|Andromeda Biotech Ltd.|The objectives of this study were to evaluate the safety and tolerability of long term treatment with DiaPep277. The study was terminated by the Sponsor on 08Sep14; hence many of the protocol-specified objectives could not be adequately assessed|1||A corporate decision to suspend development of DiaPep277®|f||||t||||||||||2017-10-11 01:30:09.418581|2017-10-11 01:30:09.418581
NCT01897792|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-09|2017-02-08|2015-10-27||May 2013||2013-05-01|February 2017|2017-02-01|February 2015|Actual|2015-02-01|February 2015|Actual|2015-02-01||Interventional|||Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma|Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma|Terminated||Phase 2|11|Actual|University of Alabama at Birmingham|Study terminated--inability to recruit patient that met inclusion criteria.|2||Inability to recruit patients that meet inclusion criteria.|f||||t||||||||||2017-10-11 01:30:17.855856|2017-10-11 01:30:17.855856
NCT01897077|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-08|2017-03-21|||November 2012|Actual|2012-11-01|March 2017|2017-03-01|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy|The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy|Suspended||Phase 1/Phase 2|15|Anticipated|Johns Hopkins University||2||Study product manufacturing suspended|f||||t||||||||||2017-10-11 01:30:27.803349|2017-10-11 01:30:27.803349
NCT01895400|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-05|2016-02-14|||July 2013||2013-07-01|February 2016|2016-02-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional|REREV||Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy|A Single-center, Prospective, Randomized, Parallel Group, Placebo-controlled Exploratory Study on the Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy|Terminated||Phase 3|26|Actual|Asan Medical Center||2||Participant enrollment is much delayed. The whole design needs to be revised.|f||||f||||||||Undecided|This study is decided to be terminated. Among 26 participants, 15 finished medication according to the protocol. I am not sure that these data can be analyzed because data is still unblinded.|2017-10-11 01:30:53.5963|2017-10-11 01:30:53.5963
NCT01894984|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-03|2014-04-22|2013-09-05||January 2007||2007-01-01|April 2014|2014-04-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Observational||"N (number of participants analyzed) signifies the participants evaluable for this measure."|An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia|Clinical Observation of the Efficacy and Safety of Risperidone Long-Acting Injection (Risperdal Consta) in the Treatment of Schizophrenia in China|Terminated||Phase 4|640|Actual|Xian-Janssen Pharmaceutical Ltd.|||2|The study was terminated because of high dropout rate.|f||||f||||||||||2017-10-11 01:31:03.10572|2017-10-11 01:31:03.10572
NCT01894633|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-29|2017-03-02|||May 2011||2011-05-01|March 2017|2017-03-01|January 2013|Actual|2013-01-01|April 2012|Actual|2012-04-01||Interventional|CLQ||Study of Whole-brain Irradiation With Chloroquine for Brain Metastases|Phase II Randomized, Double Blind, Placebo Controlled Study of Whole-brain Irradiation With Concomitant Daily-dose Chloroquine for Brain Metastases.|Terminated||Phase 2|73|Actual|Instituto Nacional de Cancerologia de Mexico||2||terminated|f||||f||||||||||2017-10-11 01:31:08.025519|2017-10-11 01:31:08.025519
NCT01892267|ClinicalTrials.gov processed this data on October 10, 2017|2013-07-01|2017-04-13|2016-08-19||September 6, 2013|Actual|2013-09-06|April 2017|2017-04-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|||Self-Propelled Versus Standard Percutaneous Endoscopic Gastrojejunostomy(PEG-J); RCT|Comparison Outcomes and Complications of Self-Propelled vs. Standard Percutaneous Endoscopic Gastrojejunostomy (PEG-J); a Randomized Single Blind Clinical Trial|Terminated||Phase 2|19|Actual|Johns Hopkins University||2||Study was terminated prematurely as costs incurred were more than the available funds.|f||||t||||||||||2017-10-11 01:31:42.032658|2017-10-11 01:31:42.032658
NCT01891890|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-28|2017-08-20|2017-07-14||August 2013||2013-08-01|July 2017|2017-07-01|October 23, 2015|Actual|2015-10-23|October 23, 2015|Actual|2015-10-23||Interventional|COPE|Patients who were eligible to participate and were randomized to a study arm are included in the baseline description.|Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)|Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)|Terminated||Phase 3|72|Actual|Emory University|The study was terminated early due to inability to meet enrollment goals.|3||Poor recruitment|f||||f|t|f||||||||2017-10-11 01:31:50.010061|2017-10-11 01:31:50.010061
NCT01891669|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-10|2016-05-17|2016-05-17||August 2013||2013-08-01|May 2016|2016-05-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|||A Study Of PF-06263507 In Patients With Advanced Solid Tumors|A Phase 1, Dose Escalation Study Of PF-06263507 In Patients With Advanced Solid Tumors|Terminated||Phase 1|26|Actual|Pfizer|This study was terminated prematurely before treatment in Part 2 started due to a business-related decision.|1||"The study was terminated on June 23, 2015 due to the company's change in prioritization for the   portfolio and is not due to any safety concerns."|f||||f||||||||||2017-10-11 01:31:54.656304|2017-10-11 01:31:54.656304
NCT01890577|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-18|2016-06-08|2015-03-31||April 2013||2013-04-01|June 2016|2016-06-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Observational||The Full Analysis Set (FAS) consists of all patients enrolled into the study after commencing Aranesp® therapy amd with reported data|Study of South African Dialysis Patients|An Observational Study of South African Dialysis Patients Treated With Aranesp|Terminated||N/A|28|Actual|Amgen|||1|"Study was terminated due to slow enrolment with no reasonable expectation of attaining a   meaningful sample size"|f||||f||||||||||2017-10-11 01:32:17.296176|2017-10-11 01:32:17.296176
NCT01887132|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-22|2017-09-21|2017-08-14||June 2013||2013-06-01|September 2017|2017-09-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional|||A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism|A Randomized Controlled Trial of Donepezil for REM Enhancement and Behavioral Change in Autism|Terminated||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)|Study terminated due to lack of recruitment. No conclusions regarding the use of donepezil can be drawn from small sample size data collection.|3|||f||||||||||||||2017-10-11 01:33:01.853994|2017-10-11 01:33:01.853994
NCT01887002|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-24|2016-01-26||2016-01-26|June 2013||2013-06-01|January 2016|2016-01-01||||January 2015|Actual|2015-01-01||Interventional|RESTORE||Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)|Terminated||Phase 2|39|Actual|Ono Pharmaceutical Co. Ltd||2||The study was terminated due to slow accrual of subjects.|f||||f||||||||||2017-10-11 01:33:03.244173|2017-10-11 01:33:03.244173
NCT01883908|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-13|2015-09-03|2015-04-21||December 2012||2012-12-01|September 2015|2015-09-01|February 2015|Actual|2015-02-01|June 2014|Actual|2014-06-01||Interventional|GCC1229||Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer|A Pilot Randomized Controlled Trial to Evaluate the Efficacy and Explore the Mechanism of Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer.|Terminated||N/A|4|Actual|University of Maryland|The PI left the institution before the end of the study; therefore the study was withdrawn in clinicaltrials.gov and IRB closed.|2||"The project is terminated due to that fact that the PI has moved to another institution and   there are no resources to keep the study open in either institution."|f||||t||||||||||2017-10-11 01:33:42.569065|2017-10-11 01:33:42.569065
NCT01883011|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-18|2013-08-28|||August 1998||1998-08-01|August 2013|2013-08-01|July 2001|Actual|2001-07-01|July 2001|Actual|2001-07-01||Interventional|||A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke|Randomized, Double Blind, Placebo Controlled, Two Parallel Group Study to Evaluate the Efficacy and Safety of Piracetam, 12 g Intravenous (IV) Infusion Within 7 Hour (h) Post Stroke Onset, Followed by 12 g/d for 4 Weeks (IV Ampoules, Oral Solution) and 4.8 g/d for 8 Weeks (Tablets) in Adult Subjects With an Acute Ischemic Middle Cerebral Artery Stroke|Terminated||Phase 4|571|Actual|UCB Pharma||2||"This study was terminated after a pre-specified interim analysis. Please see Detailed Study   Description for further information."|f||||t||||||||||2017-10-11 01:33:52.697813|2017-10-11 01:33:52.697813
NCT01882114|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-24|2016-09-06|||November 2007||2007-11-01|September 2016|2016-09-01|December 2020|Anticipated|2020-12-01|December 2020|Anticipated|2020-12-01||Observational|||Atherosclerosis in Atrial Fibrillation|Study of Atherosclerotic Risk Factors and Oxidative Stress in Atrial Fibrillation. Relation to Cardiovascular Events|Recruiting||N/A|3000|Anticipated|University of Roma La Sapienza|||1||f||||t||||||Samples With DNA|"     After overnight fasting and supine rest for at least 10 minutes, blood was withdrawn from the     antecubital vein. Serum was divided into aliquots and stored at -80°C.   "|Undecided||2017-10-11 01:34:06.533882|2017-10-11 01:34:06.533882
NCT01881932|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-13|2015-09-03|2015-04-21||February 2013||2013-02-01|September 2015|2015-09-01|April 2015|Actual|2015-04-01|June 2014|Actual|2014-06-01||Interventional|||Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)|Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients|Terminated||N/A|19|Actual|University of Maryland|The PI left the institution before the end of the study; therefore the study was withdrawn in clinicaltrials.gov and IRB closed.|3||"The PI has moved to another institution, which resulted in significant changes in the study   design and study title."|f||||t||||||||||2017-10-11 01:34:09.875345|2017-10-11 01:34:09.875345
NCT01880437|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-11|2015-11-11|2015-11-11||September 2013||2013-09-01|November 2015|2015-11-01|November 2014|Actual|2014-11-01|November 2014|Actual|2014-11-01||Interventional||Included all enrolled participants who received at least 1 dose of study drug.|A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome|A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)|Terminated||Phase 2|38|Actual|Hoffmann-La Roche|This study was prematurely terminated because of lower-than-expected efficacy observed in interim data analyses.|1|||f||||||||||||||2017-10-11 01:34:26.357747|2017-10-11 01:34:26.357747
NCT01878578|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-12|2014-02-26|||November 2002||2002-11-01|February 2014|2014-02-01|March 2003|Actual|2003-03-01|March 2003|Actual|2003-03-01||Interventional|||The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients||Terminated||Phase 1|4|Actual|Bial - Portela C S.A.||3||"prematurely terminated due to impossibility of recruiting the planned number of patients by the   study centre."|f||||f||||||||||2017-10-11 01:34:58.11672|2017-10-11 01:34:58.11672
NCT01877343|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-15|2016-02-09|2015-02-20||June 2013||2013-06-01|February 2016|2016-02-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Interventional|||Developing a Non-invasive Cardiac Functional Health Status Measurement Device|Developing a Non-invasive Cardiac Functional Health Status Measurement Device to be Used in a Critical Population of Adults and Children With Heart Failure.|Terminated||N/A|10|Actual|University of Florida|Early termination due concerns for severity of stress test on high risk patients. Only control and post-transplant groups had enrollment. Statistical analysis cannot be performed.|1||Challenges associated with study enrollment due to stress test, study terminated|f||||f||||||||||2017-10-11 01:35:27.658403|2017-10-11 01:35:27.658403
NCT01875874|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-05|2015-10-20|||October 2014||2014-10-01|October 2015|2015-10-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional|||Safety and Efficacy of ELAD to Treat Acute Liver Failure (ALF)|An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF)|Terminated||Phase 2|8|Actual|Vital Therapies, Inc.||1||"Due to results from the 1st pivotal study, the ELAD clinical plan is being re-evaluated, and   the VTI-212 study has been terminated."|f||||t||||||||||2017-10-11 01:35:48.491986|2017-10-11 01:35:48.491986
NCT01874340|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-28|2015-05-14|2015-04-13||June 2013||2013-06-01|May 2015|2015-05-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis|A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis|Terminated||Phase 2|28|Actual|Novartis|Due to early termination this trial was not powered for efficacy no statistical analysis was performed|4||"Study terminated early based upon development of another anti-IL17 fully human monoclonal   antibody with better potential for treating MS patients"|f||||t||||||||||2017-10-11 01:36:06.581159|2017-10-11 01:36:06.581159
NCT01873651|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-05|2014-08-08|||October 2013||2013-10-01|August 2014|2014-08-01|March 2014|Anticipated|2014-03-01|December 2013|Anticipated|2013-12-01||Interventional|||Longterm Outcome of the Delta III Inverse Prosthesis|The Reverse Delta III Total Shoulder Prosthesis - Longerm Results in 98 Patients|Withdrawn||Phase 4|0|Actual|Schulthess Klinik||1||The study has been withdrawn due to too few patients|f||||f||||||||||2017-10-11 01:36:17.968998|2017-10-11 01:36:17.968998
NCT01871532|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-04|2016-06-30|2016-04-18||July 2013||2013-07-01|June 2016|2016-06-01|November 2014|Actual|2014-11-01|March 2014|Actual|2014-03-01||Interventional|LoGo|Intent-to-Treat (ITT) included all subjects randomized and that had received at least 1 Gonal-f injection and had number of follicles measured at any point.|Low-dose Gonal-f® in Ovulation Induction|A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction|Terminated||Phase 4|24|Actual|Merck KGaA|Study was terminated because of delays in sourcing replacement Investigational Medicinal Product (IMP) for the study due to manufacturing delays hence the outcome measure was not assessed.|2||"Study was terminated because of delays in sourcing replacement Investigational Medicinal   Product for the study due to manufacturing delays."|f||||f||||||||||2017-10-11 01:37:54.808709|2017-10-11 01:37:54.808709
NCT01869478|ClinicalTrials.gov processed this data on October 10, 2017|2013-06-01|2016-08-12|2016-08-12||January 2013||2013-01-01|August 2016|2016-08-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional|EARLY||Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke|Endovascular Arterial Reperfusion vs. Intravenous ThromboLYsis for Acute Ischemic Stroke (EARLY): A Randomized Pilot Study of Ultra-early (<2 Hours) and Early (2-4.5 Hours) Reperfusion Therapy|Terminated||Phase 2|1|Actual|Mayo Clinic|This study was terminated due to difficulty in recruiting subjects.|2||Poor recruitment|f||||f||||||||No||2017-10-11 01:38:30.34545|2017-10-11 01:38:30.34545
NCT01867645|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-23|2013-05-29|||December 2004||2004-12-01|May 2013|2013-05-01|April 2011|Actual|2011-04-01|April 2009|Actual|2009-04-01||Interventional|CIPNM||The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis|The Impact of Early Treatment With IgM-enriched IVIG on Critical Illness Polyneuropathy and/or Myopathy in Patients With Multiple Organ Failure and SIRS/Sepsis: A Prospective, Randomized, Placebo-controlled, Double-blinded Trial|Terminated||Phase 1|38|Actual|Medical University of Vienna||2||The trial was terminated early due to futility in reaching the primary endpoint.|f||||f||||||||||2017-10-11 01:38:56.305841|2017-10-11 01:38:56.305841
NCT01866904|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-29|2017-05-29|||June 19, 2013|Actual|2013-06-19|May 2017|2017-05-01|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|TIGRIS||Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients|TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients|Terminated||N/A|9284|Actual|AstraZeneca|||1|"Study was terminated in order to secure the data quality of the study in terms of follow-up   rates and data completeness."|f||||f||||||||||2017-10-11 01:39:05.921295|2017-10-11 01:39:05.921295
NCT01866423|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-28|2017-07-31|2017-07-03||October 25, 2013|Actual|2013-10-25|June 2017|2017-06-01|July 26, 2016|Actual|2016-07-26|July 23, 2015|Actual|2015-07-23||Interventional|||Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Phase 2 Trial of TAK-700 (Also Known as Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer|Terminated||Phase 2|4|Actual|University of Southern California|The trial was terminated early due to the discontinuation of the development program for the study drug, TAK-700 (orteronel) for prostate cancer.|1||Not progressing toward scientific goals|f||||t||||||||||2017-10-11 01:39:12.998542|2017-10-11 01:39:12.998542
NCT01865084|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-24|2017-01-10|2016-09-30||September 2013||2013-09-01|January 2017|2017-01-01|March 2016|Actual|2016-03-01|December 2015|Actual|2015-12-01||Interventional||All participants who were randomized to study drug.|A Study of Tadalafil for Duchenne Muscular Dystrophy|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy|Terminated||Phase 3|331|Actual|Eli Lilly and Company|The Sponsor concluded that the efficacy results do not provide sufficient justification for continuance of the open-label extension (OLE) period of the study, where all participants were receiving daily treatment with tadalafil.|3||The study is being terminated for lack of efficacy|f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
NCT01863667|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-23|2017-06-05|2015-09-29||July 8, 2013|Actual|2013-07-08|June 2017|2017-06-01|April 3, 2014|Actual|2014-04-03|April 3, 2014|Actual|2014-04-03||Interventional|||A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)|A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappropriate Due to Intolerance or Contraindication|Terminated||Phase 3|65|Actual|Merck Sharp & Dohme Corp.|The study was terminated based on business decisions only, and not due to any unexpected safety or efficacy concerns.|2|||f||||t||||||||||2017-10-11 01:39:52.790397|2017-10-11 01:39:52.790397
NCT01861249|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-21|2016-07-12||2015-11-03|July 2013||2013-07-01|July 2016|2016-07-01|April 2016|Actual|2016-04-01|May 2014|Actual|2014-05-01||Interventional|||Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)|A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)|Terminated||Phase 2|6|Actual|Sanofi||1||Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.|f||||t||||||||||2017-10-11 01:40:27.981919|2017-10-11 01:40:27.981919
No patient was excluded of any of the populations. Results presented for SAF."|Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia|Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia|Terminated||Phase 4|6|Actual|Sandoz|This was an Additional Pharmacovigilance Activity (MEA005). Based on interim study data, complemented with clinical data from continued global development & extensive post-marketing experience MEA005 was considered fulfilled and the study terminated.|1||Additional pharmacovigilance activity was considered as fulfilled by the EMA.|f||||f||||||||Yes|Since there are only six patients enrolled, all the patient data is already provided in the registry.|2017-10-11 01:40:53.16059|2017-10-11 01:40:53.16059
NCT01859351|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-23|2014-05-15|||July 2013||2013-07-01|May 2014|2014-05-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours|A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors|Terminated||Phase 1|13|Actual|Wilex||2||Study terminated for business reasons|f||||f||||||||||2017-10-11 01:40:57.847537|2017-10-11 01:40:57.847537
NCT01858480|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-09|2016-07-12|||July 2013||2013-07-01|July 2016|2016-07-01|November 2013|Actual|2013-11-01|November 2013|Actual|2013-11-01||Interventional|||Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure|Randomized, Double-Blind, Placebo-Controlled Study To Evaluate D-Ribose For The Treatment Of Congestive Heart Failure|Withdrawn||Phase 2|0|Actual|RiboCor, Inc.||2||Terminated due to slow enrollment|f||||f||||||||No|Study terminated due to slow enrollment|2017-10-11 01:41:14.86334|2017-10-11 01:41:14.86334
NCT01856881|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-25|2015-11-05|||March 2013||2013-03-01|November 2015|2015-11-01|March 2015|Actual|2015-03-01|November 2014|Actual|2014-11-01||Interventional|||Multiple Ascending Dose Study in Subjects With Type 2 Diabetes|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 876 in Subjects With Type 2 Diabetes|Terminated||Phase 1|86|Actual|Amgen||2||"This study was terminated on August 29th, 2014 due to a business decision by the Sponsor. The   study was not terminated due to a safety reason."|f||||f||||||||||2017-10-11 01:41:38.438072|2017-10-11 01:41:38.438072
NCT01853982|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-13|2016-01-06|2015-04-19||July 2013||2013-07-01|January 2016|2016-01-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|||Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia|A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia|Terminated||Phase 3|4|Actual|Cubist Pharmaceuticals LLC|This study was electively terminated to focus on a larger registrational study, which was also part of the clinical development program for nosocomial pneumonia.|2||Terminated to focus on a larger study within the clinical development program.|f||||f||||||||||2017-10-11 01:42:41.497964|2017-10-11 01:42:41.497964
NCT01853241|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-10|2013-05-13|||May 2010||2010-05-01|May 2013|2013-05-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Observational|||Prospective Randomized Trial of Anterograde Single Balloon Versus Spirus Enteroscopy|Prospective Randomized Trial of Anterograde Single Balloon Versus Spirus Enteroscopy in Patients With Suspected Small Bowel Disease|Terminated||N/A|30|Actual|Johns Hopkins University|||2|SE system by Spirus Medical withdrawn from market in 2011|f||||f||||||||||2017-10-11 01:42:53.487286|2017-10-11 01:42:53.487286
NCT01853176|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-10|2014-10-29|2014-10-29||May 2013||2013-05-01|October 2014|2014-10-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||Did not meet target accrual before study terminated.|Exparel vs. Standard Bupivicaine for Abdominoplasty|Is Liposomal Injection Bupivacaine (Exparel) Superior to Standard Bupivacaine for Abdominoplasty? A Randomized Controlled Trial|Terminated||Phase 4|4|Actual|Emory University|Trial terminated prior to any meaningful patient accrual so no analysis performed.|2||required documentation too onerous|f||||f||||||||||2017-10-11 01:42:54.26451|2017-10-11 01:42:54.26451
NCT01850459|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-07|2017-04-17|||January 2013||2013-01-01|April 2017|2017-04-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Observational|ERK||Extracellular Signal-Related Kinase Biomarker Development in Autism|Extracellular Signal-Related Kinase Biomarker Development in Autism|Completed||N/A|213|Actual|Children's Hospital Medical Center, Cincinnati|||4||f||||f||||||Samples Without DNA|"     For the ERK activation assay, about 5 mL of whole blood is layered onto 3 mL Histopaque in a     15 mL centrifuge tube, and centrifuged. The lymphocyte-containing cell layer is removed and     transferred for washing. After a second wash, cells are resuspended and rested. They are then     stimulated by addition of phorbol myristate acetate and sample aliquots are removed at short     intervals, fixed and permeabilized. Fixed, permeabilized cells are stained by addition of     Alexafluor488-labeled monoclonal antibody to phospho-ERK in the dark for 30 min. Washed,     resuspended cells are analyzed in a Coulter flow cytometer.   "|||2017-10-11 01:43:36.610998|2017-10-11 01:43:36.610998
NCT01849588|ClinicalTrials.gov processed this data on October 10, 2017|2013-05-06|2017-03-22|2017-01-23||May 2013||2013-05-01|March 2017|2017-03-01|January 2017|Actual|2017-01-01|December 2016|Actual|2016-12-01||Interventional|||HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)|A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C|Terminated||Phase 4|3|Actual|Massachusetts General Hospital|Study was terminated early due to slow accrual, therefore a small number of participants were analyzed and the data are not statistically significant.|1||Slow Accrual|f||||f||||||||No||2017-10-11 01:43:51.081261|2017-10-11 01:43:51.081261
NCT01846104|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-30|2016-11-22|2015-12-10||June 2013||2013-06-01|November 2016|2016-11-01|March 2014|Actual|2014-03-01|February 2014|Actual|2014-02-01||Interventional|RVEc||Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults|Safety and Immunogenicity of a Booster Dose (50 µg) of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Previously Vaccinated Healthy Adults|Completed||Phase 1|4|Actual|U.S. Army Medical Research and Materiel Command|Four subjects were enrolled and vaccinated. Three subject completed the study and one was withdrawn due to relocation.|1|||f||||f||||||||||2017-10-11 01:44:50.303531|2017-10-11 01:44:50.303531
NCT01842633|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-25|2017-08-02|2016-06-02||April 1, 2013|Actual|2013-04-01|August 2017|2017-08-01|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional||Demography data is available for 157 Participants only (safety Population).|Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache|A Study to Assess Efficacy Over Placebo and Speed of Onset of Pain Relief of New Paracetamol and Caffeine Tablets as Compared to Ibuprofen in Episodic Tension Type Headache|Terminated||Phase 3|365|Actual|GlaxoSmithKline|Enrollment into the trial was terminated after randomization of 62% of the plan resulting in a significant reduction in study power. The originally planned inferential statistics (p-values) were therefore not presented in tables summarizing results.|3|||f||||f||||||||||2017-10-11 01:45:56.38655|2017-10-11 01:45:56.38655
NCT01841021|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-24|2016-11-22|2016-11-22||April 2014||2014-04-01|November 2016|2016-11-01|June 2016|Actual|2016-06-01|May 2016|Actual|2016-05-01||Interventional||All participants.|Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30|Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Receptor|Terminated||N/A|1|Actual|H. Lee Moffitt Cancer Center and Research Institute|Planned accrual: 20. Sponsor withdrew support soon after one enrollment. Accrual was terminated; analysis unable to be performed. Participant stopped treatment after 14 cycles due to progressive lymphadenopathy; entered another clinical trial.|1||Slow accrual, loss of sponsor support|f||||f||||||||No||2017-10-11 01:46:22.117207|2017-10-11 01:46:22.117207
NCT01840943|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-18|2015-11-17|2015-05-22||June 2013||2013-06-01|November 2015|2015-11-01|August 2014|Actual|2014-08-01|May 2014|Actual|2014-05-01||Interventional||The modified intent-to-treat population included (mITT) included all randomized participants.|A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy|A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYX® Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy|Terminated||Phase 3|32|Actual|Xian-Janssen Pharmaceutical Ltd.|The study was terminated early as the total number of participants treated in this study was low and only descriptive analysis was used for efficacy and safety evaluation.|2||the study was terminated due to medication supply issue from current manufacturer|f||||f||||||||||2017-10-11 01:46:22.832431|2017-10-11 01:46:22.832431
NCT01838499|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-19|2016-07-21|2015-10-13||May 2013||2013-05-01|July 2016|2016-07-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional||Full Analysis Set|Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa|A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa|Terminated||Phase 2|224|Actual|AstraZeneca|The trial terminated early due to lack of efficacy. An interim analysis was conducted after the first 61 subjects at 12 weeks and showed no evidence of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.|2||"At the planned IA for decision making, no evidence was demonstrated of MEDI8968 activity in   reducing (HS) severity or pain over that seen with placebo."|f||||f||||||||||2017-10-11 01:47:02.130399|2017-10-11 01:47:02.130399
NCT01838057|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-15|2015-04-15|||June 2013||2013-06-01|April 2015|2015-04-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Observational|||Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting|Evaluation of the Clinical and Economic Impact of Pfizer's painPRIMER Program in the Treatment of Low Back Pain in a Primary Care Setting|Terminated||N/A|103|Actual|Pfizer|||2|"The study was terminated on 02-Jun-2014 due to slow enrollment. The study was not terminated   for reasons of either safety or efficacy."|f||||f||||||||||2017-10-11 01:47:06.982361|2017-10-11 01:47:06.982361
NCT01838044|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-15|2016-07-20|2016-05-12||October 2013||2013-10-01|July 2016|2016-07-01|June 2015|Actual|2015-06-01|May 2015|Actual|2015-05-01||Interventional||Safety population was composed of all participants who took at least one dose of study medication (either pregabalin or celecoxib).|Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component|A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Concomitant Administration Of Celecoxib And Pregabalin Compared With Celecoxib Monotherapy, In Patients With Chronic Low Back Pain Having A Neuropathic Component|Terminated||Phase 4|180|Actual|Pfizer|The study was terminated as it had been determined that it was no longer operationally feasible to continue the trial. The study termination was not due to a safety issue or finding.|2||"Recruitment terminated on 3Apr2015 due to slow recruitment rate and lack of operational   feasibility. Study was not terminated for reasons of safety/efficacy."|f||||t||||||||||2017-10-11 01:47:07.140726|2017-10-11 01:47:07.140726
NCT01837797|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-04|2016-02-04|2015-08-17||April 2013||2013-04-01|February 2016|2016-02-01||||May 2014|Actual|2014-05-01||Interventional|||Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Terminated||Phase 3|129|Actual|H. Lundbeck A/S|Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.|3||The study was terminated because of recruitment challenges|f||||f||||||||||2017-10-11 01:47:10.906828|2017-10-11 01:47:10.906828
NCT01834183|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-12|2013-06-17|||June 2013||2013-06-01|June 2013|2013-06-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||Tivozanib + Gemcitabine in Metastatic RCC|A Phase II and Biomarker Study of Tivozanib With Gemcitabine Addition Upon Progression in Patients With Metastatic Refractory Renal Cell Carcinoma|Withdrawn||Phase 2|0|Actual|Dana-Farber Cancer Institute||1||Sponsor Aveo has withdrawn support for this trial.|f||||t||||||||||2017-10-11 01:48:08.850918|2017-10-11 01:48:08.850918
NCT01833845|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-15|2014-08-27|2014-07-30||April 2013||2013-04-01|August 2014|2014-08-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional||40 subjects were planned to be included in the study; however, due to the Sponsor's decision, the study was terminated prematurely after 4 subjects had completed the study, due to failure to recruit subjects|Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C|An Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C|Terminated||Phase 1/Phase 2|4|Actual|BioLineRx, Ltd.||1||due to failure to recruit subjects|f||||f||||||||||2017-10-11 01:48:14.163132|2017-10-11 01:48:14.163132
NCT01833338|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-04|2014-09-10|||June 2011||2011-06-01|September 2014|2014-09-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional|||Non-invasive and Invasive Plaque Characterisation|Coronary Artery Plaque Characterisation With Non-invasive Multi-Slice Computed Tomography and Invasive Intravascular Ultrasound and Optical Coherence Tomography in Patients With Acute Coronary Syndromes Without ST-segment Elevation|Terminated||N/A|30|Actual|University Medical Center Groningen||1||The study was terminated based on an included stopping rule in the study protocol|f||||f||||||||||2017-10-11 01:48:21.404218|2017-10-11 01:48:21.404218
NCT01833130|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-12|2015-09-18|2015-09-18||April 2013||2013-04-01|September 2015|2015-09-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional||Intent-to-Treat Population: all randomized patients (7 patients were withdrawn from the study due to a randomization error and excluded from the Intent-to-Treat population)|Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)||Completed||Phase 4|52|Actual|Allergan||2|||f||||f||||||||||2017-10-11 01:48:23.740702|2017-10-11 01:48:23.740702
NCT01830790|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-10|2015-05-27|2015-04-29||March 2013||2013-03-01|April 2015|2015-04-01|May 2014|Actual|2014-05-01|May 2014|Actual|2014-05-01||Interventional|||Effects of Sildenafil on Choroidal Thickness in AMD|Effects of Sildenafil on Choroidal Thickness in Age-Related Macular Degeneration|Terminated||Phase 2|10|Actual|Duke University|Study was terminated early due to inadequate support to complete recruitment/data analysis.|2||Inadequate support to complete recruitment/data analysis.|f||||t||||||||||2017-10-11 01:49:07.112787|2017-10-11 01:49:07.112787
NCT01829347|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-08|2015-10-20|||April 2014||2014-04-01|October 2015|2015-10-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional|||Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure|A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure|Terminated||Phase 3|18|Actual|Vital Therapies, Inc.||2||"Due to results from the 1st pivotal study, the ELAD clinical plan is being re-evaluated, and   the VTI-210 study has been terminated."|f||||t||||||||||2017-10-11 01:49:31.835962|2017-10-11 01:49:31.835962
NCT01826175|ClinicalTrials.gov processed this data on October 10, 2017|2013-04-01|2016-12-19|||May 2013||2013-05-01|December 2016|2016-12-01|May 2014|Actual|2014-05-01|May 2014|Actual|2014-05-01||Interventional|||Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study|Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During Percutaneous Coronary Intervention: an Optical Coherence Tomography Study|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2||Study terminated mutually by sponsor & PI due to no enrollment|f||||f||||||||No||2017-10-11 01:50:25.686487|2017-10-11 01:50:25.686487
NCT01824303|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-31|2015-12-16|2015-10-23||March 2013||2013-03-01|December 2015|2015-12-01|December 2014|Actual|2014-12-01|November 2014|Actual|2014-11-01||Interventional|||Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis|A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension|Terminated||Phase 2|31|Actual|Allergan|Due to technical issues with the patient electronic diary used for the collection of the outcome measures data, as well as the small evaluable sample size and large variability, the efficacy data should be interpreted with caution.|2||This study was terminated early due to company decision.|f||||t||||||||||2017-10-11 01:50:48.475069|2017-10-11 01:50:48.475069
NCT01821963|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-27|2015-02-23|2015-02-23||April 2013||2013-04-01|February 2015|2015-02-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional||Study terminated with one participant, no analysis performed.|Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)|Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation|Terminated||Phase 3|1|Actual|M.D. Anderson Cancer Center||1||Low referral rate due to new therapeutic options.|f||||f||||||||||2017-10-11 01:51:21.607709|2017-10-11 01:51:21.607709
NCT01820468|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-25|2015-01-09|||July 2013||2013-07-01|December 2014|2014-12-01|March 2016|Anticipated|2016-03-01|December 2014|Anticipated|2014-12-01||Interventional|||Adapting a Model for Veterans on a Psychiatric Inpatient Unit|Adapting a Critical Time Intervention Model for Veterans on a Psychiatric Inpatient Unit|Withdrawn||N/A|0|Actual|VA Connecticut Healthcare System||2||"This study was terminated before any participants were enrolled due to unforseen problems with   participant enrollment and study design."|f||||t||||||||||2017-10-11 01:51:41.953362|2017-10-11 01:51:41.953362
NCT01820364|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-25|2016-11-10|2016-04-13||November 2013||2013-11-01|November 2016|2016-11-01|March 2015|Actual|2015-03-01|March 2015|Actual|2015-03-01||Interventional|LOGIC|The analysis population for Baseline Demographics is composed of the Full Analysis Set, which consists of all patients who received at least one dose of LGX818.|LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma|Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma|Terminated||Phase 2|15|Actual|Array BioPharma|Recruitment halted on 26-Jul-2014, which led to small numbers of subjects analyzed. This recruitment halt was not a consequence of any safety concern and patients who were ongoing in the study continued to be treated as per protocol.|1||Study was withdrawn due to scientific and business considerations.|f||||||||||||||2017-10-11 01:51:42.932942|2017-10-11 01:51:42.932942
NCT01818687|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-18|2015-05-25|||August 2013||2013-08-01|May 2015|2015-05-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|||Safety and Tolerability Study of MCI-196|A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Chronic Kidney Disease Stages 3b to 5 and With Hyperphosphataemia Not on Dialysis|Terminated||Phase 3|4|Actual|Mitsubishi Tanabe Pharma Corporation||1||This study has been terminated because of insufficient patient recruitment.|f||||t||||||||||2017-10-11 01:52:07.502915|2017-10-11 01:52:07.502915
NCT01818648|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-28|2014-01-10|||March 2013||2013-03-01|January 2014|2014-01-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome|Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition|Withdrawn||Phase 4|0|Actual|Mayo Clinic||2||Study was withdrawn by PI due to decision to study a different medication.|f||||f||||||||||2017-10-11 01:52:07.851249|2017-10-11 01:52:07.851249
NCT01818479|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-14|2017-08-07|||July 2013||2013-07-01|August 2017|2017-08-01|July 2020|Anticipated|2020-07-01|July 2020|Anticipated|2020-07-01||Interventional|||Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells With Myeloablative Conditioning for High Risk Hematologic Malignancies|Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells With Myeloablative Conditioning for High Risk Hematologic Malignancies|Suspended||Phase 1/Phase 2|24|Anticipated|University of Utah||1||Study suspended due to GVHD Assessments|f||||t||||||||||2017-10-11 01:52:10.943046|2017-10-11 01:52:10.943046
NCT01814917|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-18|2015-05-25|||August 2013||2013-08-01|May 2015|2015-05-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|||Long-term Extension Study of MCI-196|A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Hyperphosphataemia and With Either Chronic Kidney Disease Stage 5 on Dialysis or Chronic Kidney Disease Stages 3b to 5 Not on Dialysis|Terminated||Phase 3|6|Actual|Mitsubishi Tanabe Pharma Corporation||2||This study has been terminated because of insufficient patient recruitment.|f||||t||||||||||2017-10-11 01:53:02.929227|2017-10-11 01:53:02.929227
NCT01814904|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-18|2015-05-25|||April 2014||2014-04-01|May 2015|2015-05-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Interventional|||Dose-finding Study of MCI-196|A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy With a Calcium-based Phosphate Binder, in Paediatric Subjects With Chronic Kidney Disease Stage 5 on Dialysis and With Hyperphosphataemia|Terminated||Phase 3|10|Actual|Mitsubishi Tanabe Pharma Corporation||4||This study has been terminated because of insufficient patient recruitment.|f||||t||||||||||2017-10-11 01:53:03.071155|2017-10-11 01:53:03.071155
NCT01814722|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-18|2017-03-23|2014-10-06||November 9, 2012|Actual|2012-11-09|March 2017|2017-03-01|October 31, 2013|Actual|2013-10-31|October 31, 2013|Actual|2013-10-31||Observational||Gender and Age data for one participant from the Raltegravir, and two participants from the NNRTI groups were missing, resulting in a n = 60.|Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)|Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens|Terminated||N/A|63|Actual|Merck Sharp & Dohme Corp.|||3|The trial was terminated early due to slow recruitment.|f||||f||||||||||2017-10-11 01:53:10.455825|2017-10-11 01:53:10.455825
NCT01813019|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-14|2016-11-15|2015-11-10||November 2013||2013-11-01|November 2016|2016-11-01|November 2014|Actual|2014-11-01|November 2014|Actual|2014-11-01||Interventional|||Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy|A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof of Concept Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy|Terminated||Phase 2|50|Actual|Novartis||2||"Study was prematurely terminated at the time of the first Interim Analysis (IA) as the study   did not meet its primary efficacy objective."|f||||t||||||||||2017-10-11 01:53:36.621976|2017-10-11 01:53:36.621976
NCT01810302|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-11|2014-08-18|2014-08-18||August 2013||2013-08-01|August 2014|2014-08-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Safety Study of Nicardipine to Treat Cerebral Vasospasm|Intraventricular Nicardipine for the Treatment of Cerebral Vasospasm: Prospective Pilot Study|Terminated||Phase 2|2|Actual|University of Florida|This single center study was terminated early due to inability to maintain an adequate drug supply; therefore, statistical analysis of the 2 participants was not done.|2||Unable to secure drug.|f||||t||||||||||2017-10-11 01:54:20.850275|2017-10-11 01:54:20.850275
NCT01808261|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-14|2017-09-29|2017-06-09|2016-03-21|May 18, 2013|Actual|2013-05-18|August 2017|2017-08-01|July 28, 2014|Actual|2014-07-28|July 28, 2014|Actual|2014-07-28||Interventional|||Proof of Concept (POC) in Patients With Ischaemic Stroke|Study MAG104615, a Proof of Concept Study for GSK249320 Versus Placebo in Stroke Patients|Terminated||Phase 2|134|Actual|GlaxoSmithKline|The study was terminated early, on 27 May 2014, at the planned interim analysis for futility.|2||This study was terminated for futility.|f||||t||||||||||2017-10-11 01:54:59.691028|2017-10-11 01:54:59.691028
NCT01805180|ClinicalTrials.gov processed this data on October 10, 2017|2013-03-01|2015-02-27|2014-06-27||February 2013||2013-02-01|February 2015|2015-02-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|PMNC|Subjects in the Full Set Analysis (n=32) were randomized to either Arm 1 or Arm 2 and completed both procedures as assigned. Subjects who did not complete the collection (withdrawn n=10) did not have data and could not be included in the full set analysis.|Evaluation of the Spectra Optia PMN Cell Collection Procedure|A Controlled Evaluation of the Spectra Optia® Apheresis System's Granulocyte / Polymorphonuclear (PMN) Cell Collection Procedure|Completed||N/A|42|Actual|Terumo BCT|The Full Analysis Set included 32 subjects who completed both procedures of the cross-over study design presented here. Two subjects did not meet pre-defined criteria for evaluable and 30 subjects were included in the Evaluable Analysis Population.|2|||f||||f||||||||||2017-10-11 01:55:59.378845|2017-10-11 01:55:59.378845
NCT01802515|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-27|2016-10-13|2016-07-07||December 2012||2012-12-01|July 2016|2016-07-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment|Atomoxetine Treatment for Opioid Maintained Cocaine Users|Terminated||N/A|14|Actual|Yale University|Study terminated after 14 subjects enrolled. 11 completers. 3 subjects dropped out in treatment week 7. There were no serious adverse events. Only descriptive statistics were computed.|3||No funding stopped recruitment march 2014 with only 14 enrolled|f||||t||||||||No||2017-10-11 01:56:39.917934|2017-10-11 01:56:39.917934
NCT01801358|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-21|2016-08-29|2016-05-12|2016-02-11|August 2013||2013-08-01|August 2016|2016-08-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional||Baseline Demographics data represents the Full Analysis Set (FAS), which includes all patients who received at least one full or partial dose of sotrastaurin or binimetinib.|A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma|A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma|Terminated||Phase 1/Phase 2|38|Actual|Array BioPharma|Due to an enrollment halt, the Phase II part of the study was not conducted. The sponsor decided to permanently stop recruitment for the study prior to MTD determination.|2||The trial was terminated for scientific reasons.|f||||f||||||||||2017-10-11 01:56:55.290508|2017-10-11 01:56:55.290508
NCT01799057|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-22|2016-02-07|||July 2013||2013-07-01|February 2016|2016-02-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|||The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication|Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of Metformin for the Assessment of Changes in Functional Capacity, Endothelial Function, and Hemodynamics in Individuals With Peripheral Artery Disease-Related Intermittent Claudication|Terminated||Phase 4|2|Actual|Baker IDI Heart and Diabetes Institute||2||The trial has been terminated due to difficulties with recruitment.|f||||f||||||||||2017-10-11 01:57:31.136214|2017-10-11 01:57:31.136214
NCT01797380|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-20|2013-05-17|2013-02-25||January 2008||2008-01-01|March 2013|2013-03-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional||Terminated study. Study terminated prior to interventions|A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women|A Double-Blind, Placebo-Controlled Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women|Terminated||Phase 4|5|Actual|Duke University||2||Failure to recruit.|f||||f||||||||||2017-10-11 01:58:00.837723|2017-10-11 01:58:00.837723
NCT01794000|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-14|2016-06-15|2016-06-15||April 2013||2013-04-01|June 2016|2016-06-01|December 2015|Actual|2015-12-01|July 2015|Actual|2015-07-01||Interventional||All randomized participants.|A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)|A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.|Terminated||Phase 3|341|Actual|Eli Lilly and Company|The study was stopped following Submission Database Lock, the topline information indicated that the primary and secondary efficacy endpoints were not met.|2||The study is being terminated for lack of efficacy.|f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
NCT01792635|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-20|2016-12-22|2016-01-11||December 2012||2012-12-01|December 2016|2016-12-01|May 2014|Actual|2014-05-01|May 2014|Actual|2014-05-01||Interventional|||A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus|A 6-week Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral Pf-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|19|Actual|Pfizer|Part B of the study was terminated due to the safety issue. Due to the low number of participants who completed the study, there are no conclusions for PK or PD in Part B. The prioritization of Part A endpoints was done by inputs from team.|2||The study was terminated prematurely on 16 May 2014 due to a safety concern.|f||||f||||||||||2017-10-11 01:59:04.590805|2017-10-11 01:59:04.590805
NCT01791465|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-11|2017-01-20|2016-05-05||March 2013||2013-03-01|January 2017|2017-01-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|||Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults|Pilot Study of Extended-release Exenatide to Improve Glucose Control and Reduce Systemic Inflammation in Diabetic, HIV-infected Adults on Antiretroviral Therapy|Terminated||Phase 4|6|Actual|Vanderbilt University Medical Center|Trial terminated after only 6 individuals enrolled due to lack of interest in participation from patients and expiration of funding. Results are not considered reliable due to low number of observations|1||This study was terminated after 6 patients due to loss of funding|f||||f||||||||No|Individual participant data is protected by HIPPA and Vanderbilt University research regulations. Summary de-identified data is available if requested|2017-10-11 01:59:21.243088|2017-10-11 01:59:21.243088
NCT01790763|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-13|2015-05-12|||April 2015||2015-04-01|May 2015|2015-05-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional|||Compare the Efficacy of Mepilex and Keramatrix in Second Degree Burn Wounds|Prospective,Randomized, Parallel Study to Compare the Efficacy of Mepilex and Keramatrix in Promoting Healing of Second Degree Burn Wounds|Withdrawn||Phase 2/Phase 3|0|Actual|The University of Texas Medical Branch, Galveston||2||Due to lack of funding from the sponsor this study is being withdrawn.|f||||t||||||||||2017-10-11 01:59:34.723359|2017-10-11 01:59:34.723359
NCT01788475|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-07|2015-09-01|||December 2012||2012-12-01|September 2015|2015-09-01|November 2014|Actual|2014-11-01|November 2014|Actual|2014-11-01||Interventional|||Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery|A Randomized, Pilot Study of the Efficacy and Safety of Ozurdex Steroid Implants in Post-Vitrectomized Eyes in Patients With Diabetic Macular Edema|Withdrawn||N/A|0|Actual|Lahey Clinic||3||Unable to recruit study participants, study withdrawn by Investigator|f||||f||||||||||2017-10-11 02:00:05.827803|2017-10-11 02:00:05.827803
NCT01787214|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-01|2014-03-17|||June 2013||2013-06-01|March 2014|2014-03-01|September 2013|Actual|2013-09-01|September 2013|Actual|2013-09-01||Interventional|||Walnuts and Glucose Variability|The Effect of Walnuts on Glucose Variability in Adults With Type-2 Diabetes Mellitus: a Dose-response Metabolic Feeding Study|Terminated||N/A|18|Actual|Loma Linda University||3||Funding withdrawn|f||||t||||||||||2017-10-11 02:00:32.174881|2017-10-11 02:00:32.174881
NCT01784666|ClinicalTrials.gov processed this data on October 10, 2017|2013-02-04|2017-04-18|2016-11-30||February 2013||2013-02-01|April 2017|2017-04-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|Isradipine||Adjunctive Isradipine for the Treatment of Bipolar Depression|Adjunctive Isradipine for the Treatment of Bipolar Depression|Terminated||Phase 2|2|Actual|Massachusetts General Hospital|The study was terminated early by the investigator because delays in study initiation and insufficient recruitment. Our statisticians have advised that this analysis is uninformative.|3||Lack of Enrollment|f||||t||||||||||2017-10-11 02:01:22.012687|2017-10-11 02:01:22.012687
NCT01783431|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-25|2015-10-01|||October 2012||2012-10-01|May 2014|2014-05-01|November 2013|Actual|2013-11-01|July 2013|Actual|2013-07-01||Interventional|||Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells|A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic and/or Unresectable Melanoma|Terminated||Phase 1|1|Actual|Medical University of South Carolina||1||The study was terminated early due to low accrual.|f||||t||||||||||2017-10-11 02:01:44.37629|2017-10-11 02:01:44.37629
NCT01783054|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-10|2016-02-08|2015-10-07||July 2012||2012-07-01|October 2015|2015-10-01||||October 2015|Actual|2015-10-01||Interventional|||Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas|Pilot Study of Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas|Terminated||Early Phase 1|2|Actual|Medical University of South Carolina||1||Study terminated due to low accrual|f||||t||||||||||2017-10-11 02:01:48.291658|2017-10-11 02:01:48.291658
NCT01783015|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-31|2015-12-01|2015-05-12||September 2013||2013-09-01|December 2015|2015-12-01|August 2014|Actual|2014-08-01|August 2014|Actual|2014-08-01||Interventional|SERUM||Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate|A Randomized, Double-blind, Placebo-controlled Study Of The Safety And Efficacy Of Etanercept In Subjects With Rheumatoid Arthritis Who Have Had An Inadequate Response To Adalimumab Or Infliximab Plus Methotrexate|Terminated||Phase 4|16|Actual|Pfizer|This study was prematurely terminated on June 25, 2014. This termination was due to delays in achieving the enrolment target and not due to any safety concerns. No statistical analyses were done since there were a small number of participants.|4||This study was prematurely terminated on June 25, 2014 due to lack of enrollment.|f||||f||||||||||2017-10-11 02:01:48.990732|2017-10-11 02:01:48.990732
NCT01781962|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-30|2014-07-30|2014-06-16||January 2013||2013-01-01|July 2014|2014-07-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Observational|||A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension||Terminated||N/A|206|Actual|Allergan|||1|Study terminated due to corporate decision.|f||||f||||||||||2017-10-11 02:02:11.048871|2017-10-11 02:02:11.048871
NCT01780935|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-29|2017-07-04|2016-07-08||June 3, 2013|Actual|2013-06-03|July 2017|2017-07-01|July 9, 2015|Actual|2015-07-09|July 9, 2015|Actual|2015-07-09||Interventional|OCTAVE||Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration|A 24-month, Phase IIIb, Randomized, Double-masked, Multicenter Study Assessing the Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration|Completed||Phase 3|671|Actual|Novartis|Use of optical coherence tomography guided therapy in the treatment of neovascular age related macular degeneration became standard of care by HA & Ophth. community during the time this trial was conducted.Novartis terminated this trial.|2|||f||||f|f|f||||||||2017-10-11 02:02:30.66869|2017-10-11 02:02:30.66869
NCT01780584|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-28|2013-02-02|2013-02-02||April 2010||2010-04-01|February 2013|2013-02-01|October 2010|Actual|2010-10-01|September 2010|Actual|2010-09-01||Interventional||One subject in in oral T3 low dose group with hypertension due to unrecognized coarctation and one subject in oral T3 high dose group with inability to attain enteral feeds were withdrawn from the treatment protocol. Therefore there were 43 subjects included in the final analysis.|Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?|Oral Triiodothyronine Normalizes T3 Levels After Surgery For Pediatric Congenital Heart Disease|Completed||Phase 2|45|Actual|National Cardiovascular Center Harapan Kita Hospital Indonesia|The lack of power to detect differences in clinical outcomes. There was also insufficient power to detect potentially subtle adverse effects of T3 supplementation.|3|||f||||t||||||||||2017-10-11 02:02:38.356522|2017-10-11 02:02:38.356522
NCT01780389|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-29|2015-01-20|2013-06-18||October 2010||2010-10-01|January 2015|2015-01-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional||5 patients enrolled, 4 completed, 1 terminated due to adverse event.|Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)|Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)|Completed||Phase 4|5|Actual|Duke University|Limitations include this was a small open label pilot study.|1|||f||||f||||||||||2017-10-11 02:02:42.975867|2017-10-11 02:02:42.975867
NCT01778530|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-26|2015-10-06|2014-04-10||December 2012||2012-12-01|October 2015|2015-10-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|||TRC105 for Recurrent Glioblastoma|A Phase 2 Study of TRC105 in Patients With Recurrent Glioblastoma (GBM)|Terminated||Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)||1||Study was terminated due to poor accrual.|f||||f||||||||||2017-10-11 02:03:05.742747|2017-10-11 02:03:05.742747
NCT01777776|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-22|2016-07-27|2016-04-13|2016-02-11|July 2013||2013-07-01|July 2016|2016-07-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional||Baseline data is comprised of the Full Analysis Set (FAS), which is all patients who received at least one dose of LGX818 or LEE011.|Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.|A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.|Terminated||Phase 1/Phase 2|28|Actual|Array BioPharma|Study recruitment was halted on 07-Aug-2014 during the Phase Ib part of the study. The Phase II part of the study was not performed. Early termination of the study was not due to any safety concerns.|4||Study was withdrawn due to scientific and business considerations.|f||||f||||||||||2017-10-11 02:03:17.448357|2017-10-11 02:03:17.448357
NCT01777724|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-14|2014-07-16|||January 2013||2013-01-01|July 2014|2014-07-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|HAPPY||Evaluation of a Parenting and Stress Management Programmme|Evaluation of a Parenting and Stress Management Programme: An Exploratory Randomised Controlled Trial of Triple P-Positive Parenting Program and Stress Control|Terminated||N/A|14|Actual|Medical Research Council||2||"The study was terminated due to time constraints and the withdrawal of Stress Control from the   NHS Greater Glasgow and Clyde services."|f||||f||||||||||2017-10-11 02:03:21.795171|2017-10-11 02:03:21.795171
NCT01775397|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-08|2014-06-02|||November 2012||2012-11-01|June 2014|2014-06-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|FREEDOM||A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System|A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy|Terminated||Phase 4|12|Actual|Astellas Pharma Inc||2||Study terminated due to difficulty in enrollment|f||||t||||||||||2017-10-11 02:04:03.022513|2017-10-11 02:04:03.022513
NCT01774851|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-10|2017-06-19|2017-05-10||January 2013||2013-01-01|June 2017|2017-06-01|December 2015|Actual|2015-12-01|July 2015|Actual|2015-07-01||Interventional|||A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach|Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy|Terminated||Phase 2|84|Actual|Merrimack Pharmaceuticals|Following the recommendation of the data monitoring committee, this study was terminated prior to enrollment being completed due to lack of efficacy.|2||DSMB recommendation due to lack of efficacy. There were no safety signals.|f||||t||||||||||2017-10-11 02:04:19.29815|2017-10-11 02:04:19.29815
NCT01774747|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-08|2014-06-17|||December 2012||2012-12-01|June 2014|2014-06-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|MAD||A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of DSP-1053 in Healthy Subjects and in Subjects With Major Depressive Disorder|Terminated||Phase 1|47|Actual|Sunovion||2||This program was terminated for financial reasons|f||||f||||||||||2017-10-11 02:04:22.306567|2017-10-11 02:04:22.306567
NCT01774604|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-21|2016-09-28|2016-07-29||January 2013||2013-01-01|September 2016|2016-09-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional||All patient randomized to receive rectal indomethacin or placebo|Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|Rectal Indomethacin to Prevent Post-ERCP Pancreatitis|Terminated||Phase 3|449|Actual|Dartmouth-Hitchcock Medical Center|The study was terminated due to indomethacin's lack of efficacy after 449 patients had been enrolled. Thus the study may be underpowered to draw conclusions about the role of indomethacin in preventing post ERCP pancreatitis|2||Futility|f||||t||||||||||2017-10-11 02:04:24.079189|2017-10-11 02:04:24.079189
NCT01773460|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-15|2016-02-09|||July 2013||2013-07-01|February 2016|2016-02-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|Evelyn||Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane|A Multicenter Randomized, Double Blind, Placebo- Controlled, Phase II Study to Compare Endocrine Treatment Alone Versus Endocrine Treatment With Everolimus in Patients With HR+/HER2- Metastatic Breast Cancer and Progression After Previous Treatment With Exemestane and Everolimus|Terminated||Phase 3|3|Actual|German Breast Group||2||Study was stopped terminated early due to low recruitment.|f||||t||||||||||2017-10-11 02:04:43.624068|2017-10-11 02:04:43.624068
NCT01770379|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-16|2016-06-09|2016-05-03||October 2012||2012-10-01|June 2016|2016-06-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional|REASSURE2||Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.|A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents|Terminated||Phase 3|242|Actual|Novartis|The study was terminated early due to the decision (unrelated to safety) to discontinue the clinical development program for secukinumab in Rheumatoid Arthritis, with last patient last visit (LPLV) on 11-May-2015.|3|||f||||t||||||||||2017-10-11 02:05:28.891173|2017-10-11 02:05:28.891173
NCT01769443|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-14|2015-10-14|2015-10-13||June 2013||2013-06-01|October 2015|2015-10-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||All enrolled|Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation|A Prospective, Randomized, Multicenter, Two-Parallel Arm Study Evaluating the Overall Efficacy and Safety of Desensitization Therapy on Selected Patients Awaiting Heart Transplantation|Terminated||Phase 2|2|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Study was terminated by the study sponsor, with agreement from the investigators. Reason: very slow rate of accrual and inability to meet the accrual goal within the funding period. (N=2 enrolled. Aim was 80 participants).|2||Inability to enroll within funding period|f||||t||||||||||2017-10-11 02:05:40.135866|2017-10-11 02:05:40.135866
NCT01769196|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-14|2017-04-28|2017-02-22||January 31, 2013|Actual|2013-01-31|April 2017|2017-04-01|February 23, 2016|Actual|2016-02-23|February 23, 2016|Actual|2016-02-23||Interventional|RAINIER|Intent-to-Treat (ITT) Analysis Set included all participants who were randomized into the study, and were analyzed according to treatment randomized.|Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Terminated||Phase 2|544|Actual|Gilead Sciences||2||The Study was terminated due to lack of efficacy.|f||||t|t|f||||||||2017-10-11 02:05:49.861501|2017-10-11 02:05:49.861501
NCT01767987|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-28|2017-08-16|2014-09-09||November 2012||2012-11-01|August 2017|2017-08-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||Ranolazine Cardioprotection in PCI|Ranolazine Cardioprotection in PCI|Terminated||Phase 2|6|Actual|Kettering Health Network||2||Sponsor terminated study due to lack of enrollment|f||||f||||||||||2017-10-11 02:06:11.284219|2017-10-11 02:06:11.284219
NCT01766440|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-09|2017-04-19|2017-02-15||March 2013||2013-03-01|April 2017|2017-04-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional|||PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis|Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis|Completed||Phase 4|18|Actual|Galderma|Study was terminated early due to slow enrollment.|1|||f||||f||||||||||2017-10-11 02:06:36.899079|2017-10-11 02:06:36.899079
NCT01765582|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-09|2017-08-18|2017-06-02||January 23, 2013|Actual|2013-01-23|August 2017|2017-08-01|March 14, 2016|Actual|2016-03-14|March 14, 2016|Actual|2016-03-14||Interventional|STEAM|Intent to Treat (ITT) population was defined as all randomized participants regardless of whether they received any dose of study treatment.|Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer|Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer|Terminated||Phase 2|280|Actual|Hoffmann-La Roche|This trial was terminated on 12 November 2015, because the primary objective was not met.|3|||f|||||t|f||||||||2017-10-11 02:06:52.980417|2017-10-11 02:06:52.980417
NCT01764997|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-08|2017-06-28|2017-05-23|2015-10-07|April 2013||2013-04-01|June 2017|2017-06-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Interventional|RA-COMPARE|All participants who included in open label run-in period, randomized treatment and sub-study.|An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate|A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX|Terminated||Phase 3|776|Actual|Sanofi|The study was prematurely terminated due to small number of participants entering randomization.|5||Due to small number of participants entering randomization. Not a safety issue.|f||||t||||||||||2017-10-11 02:07:06.164533|2017-10-11 02:07:06.164533
NCT01764685|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-04|2016-02-16|2015-08-07||January 2013||2013-01-01|February 2016|2016-02-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers|Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers|Terminated||Phase 2|4|Actual|University of Pennsylvania|We closed our enrollment before meeting recruitment goals, due to difficulties with recruitment. We didn't analyze our data, due to a sample size of 4, that were all randomized to placebo group and only 3 of the 4 completed the study procedures.|2||We terminated the study due to problems recruiting alcoholic subjects with HIV.|f||||f||||||||||2017-10-11 02:07:16.373806|2017-10-11 02:07:16.373806
NCT01762644|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-02|2016-04-15|||August 2015||2015-08-01|July 2015|2015-07-01|August 2016|Anticipated|2016-08-01|May 2016|Anticipated|2016-05-01||Interventional|IIT||The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients|A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.|Withdrawn||Phase 3|0|Actual|Perle Bioscience, Inc.||2||This study was withdrawn prior to enrollment.|f||||f||||||||||2017-10-11 02:08:15.730569|2017-10-11 02:08:15.730569
NCT01761565|ClinicalTrials.gov processed this data on October 10, 2017|2013-01-03|2015-09-16|2014-12-15||January 2013||2013-01-01|September 2015|2015-09-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional||One patient was withdrawn after Period 1 due to non-compliance|Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab|Single- and Multiple-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab® PCA System (Zalviso™) in Healthy Subjects|Completed||Phase 1|40|Actual|AcelRx Pharmaceuticals, Inc.||1|||f||||f||||||||||2017-10-11 02:08:28.735786|2017-10-11 02:08:28.735786
NCT01759550|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-31|2015-06-09|||September 2011||2011-09-01|June 2015|2015-06-01|June 2014|Actual|2014-06-01|June 2014|Actual|2014-06-01||Observational|||Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip|Prospective Case-Series of LigaSure Advance Pistol Grip and LigaSure Blunt Tip in Gastric Procedures|Terminated||N/A|51|Actual|Duke University|||1|The Sponsor terminated the study.|f||||t||||||||||2017-10-11 02:08:54.898986|2017-10-11 02:08:54.898986
NCT01759511|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-15|2017-02-17|2017-02-17||October 18, 2012|Actual|2012-10-18|February 2017|2017-02-01|February 19, 2016|Actual|2016-02-19|February 19, 2016|Actual|2016-02-19||Interventional|ATLAS|Safety Analysis Set: all participants who received at least 1 dose of study drug|Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Terminated||Phase 2|34|Actual|Gilead Sciences||1||The Study was terminated due to lack of efficacy.|f||||f|t|f||||||||2017-10-11 02:08:55.225661|2017-10-11 02:08:55.225661
NCT01756924|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-18|2014-11-18||2014-11-06|December 2012||2012-12-01|November 2014|2014-11-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection||Terminated||Phase 2|14|Actual|Cempra Inc||2||"This study has been terminated; alternative study designs are being considered. Fusidic acid   remains available under an Expanded Access Protocol."|f||||f||||||||||2017-10-11 02:09:30.4131|2017-10-11 02:09:30.4131
NCT01756053|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-19|2014-10-23|2014-09-23||March 2013||2013-03-01|February 2014|2014-02-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Effects of ABT-089 on Smoking Abstinence Symptoms and Reward|A Pilot Feasibility Study of the Effects of ABT-089 on Smoking Abstinence Symptoms and Reward|Terminated||Phase 2|17|Actual|University of Pennsylvania|The study was terminated early due to the results of an interim futility analysis.|2||Trial discontinued based on the results of an interim futility analysis.|f||||t||||||||||2017-10-11 02:09:43.806485|2017-10-11 02:09:43.806485
NCT01755702|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-23|2015-03-12|2014-01-16||July 2009||2009-07-01|November 2014|2014-11-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||Paracetamol With Caffeine to Treat Episodic Tension Type Headache|A Study to Assess the Efficacy of Paracetamol Taken in Combination With Caffeine for the Treatment of Episodic Tension Type Headache|Terminated||Phase 2/Phase 3|66|Actual|GlaxoSmithKline||4||"Study was terminated due to unforeseen difficulties with subject recruitment. No safety issues   were identified in the study with this new formulation."|f||||f||||||||||2017-10-11 02:09:47.700444|2017-10-11 02:09:47.700444
NCT01754623|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-18|2015-08-06|2015-06-17||February 2013||2013-02-01|June 2015|2015-06-01|October 2014|Actual|2014-10-01|September 2014|Actual|2014-09-01||Interventional||All participants|GTX-RT in Borderline Resectable Pancreatic Cancer|Validation of a Radiation Response Signature in Borderline Resectable Pancreatic Cancer Patients Treated With Induction Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT)|Terminated||Phase 2|9|Actual|H. Lee Moffitt Cancer Center and Research Institute|The study only accrued 9 (of planned 35) participants. It was not possible to collect adequate pre-treatment tissue for radiosensitivity index (RSI) analysis, pre-treatment. The study was terminated before planned completion.|1||Lack of pre-treatment tissue to make the study plan feasible.|f||||f||||||||||2017-10-11 02:10:07.161839|2017-10-11 02:10:07.161839
NCT01754519|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-23|2017-06-07|2017-05-15||May 2013||2013-05-01|June 2017|2017-06-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional||All treated and eligible patients|Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery|Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer|Terminated||Phase 2|1|Actual|Roswell Park Cancer Institute|The study was terminated early by the IRB due to the fact that an IDE (Investigational Device Exemption) was never submitted. No outcome measure data was collected.|1||IDE not submitted|f||||t||||||||||2017-10-11 02:10:08.498899|2017-10-11 02:10:08.498899
NCT01754376|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-16|2017-03-14|2017-01-18||January 2013||2013-01-01|January 2017|2017-01-01|March 2016|Actual|2016-03-01|February 2015|Actual|2015-02-01||Interventional|||Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma|COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma|Terminated||Phase 2|6|Actual|Massachusetts General Hospital|The protocol terminated early due to a dramatic change in the treatment landscape for treating BRAF mutant melanoma (e.g. one BRAF/MEK inhibitor combination and two anti-PD1 antibodies were approved by the FDA while this study was open).|1||changes in available treatments for melanoma|f||||t||||||||Yes|All raw analytic data on tumor and blood samples will be shared, upon acceptance of manuscript.|2017-10-11 02:10:13.686934|2017-10-11 02:10:13.686934
NCT01753830|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-12|2016-07-15||2016-07-15|December 2012||2012-12-01|July 2016|2016-07-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|||Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis|A Multi Center, Randomized, Double Blind, Saline Controlled Study of a Single Injection of Durolane® Versus a Single Injection of Phosphate Buffered Saline (PBS) to Treat Pain Associated With Osteoarthritis of the Knee|Terminated||N/A|75|Actual|Q-Med AB||2||Study terminated early due to decision by sponsor|f||||t||||||||||2017-10-11 02:10:23.644825|2017-10-11 02:10:23.644825
NCT01751802|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-14|2015-10-05|2015-10-05||December 2012||2012-12-01|October 2015|2015-10-01|December 2014|Actual|2014-12-01|December 2013|Actual|2013-12-01||Interventional|||Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease|An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease|Terminated||Phase 3|9|Actual|Psyadon Pharma||2||Study terminated for commercial reasons|f||||t||||||||||2017-10-11 02:10:57.353729|2017-10-11 02:10:57.353729
NCT01749735|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-06|2017-03-30|2015-03-09||July 2011||2011-07-01|March 2017|2017-03-01|September 2013|Actual|2013-09-01|September 2013|Actual|2013-09-01||Interventional|||Transcranial Direct Current Stimulation (tDCS) and Motor Training for Traumatic Brain Injury (TBI) Survivors|The Effect of Transcranial Direct Current Stimulation Combined With Functional Task Training on Motor Recovery in Traumatic Brain Injury Survivors|Terminated||N/A|2|Actual|Spaulding Rehabilitation Hospital|Patient 1 did not finish study (stopped in follow up week 2). Patient 2 missed 2 training sessions. Both patients received the intervention (tDCS group) according to the confidential patient log. There was no control group available for comparison.|2||The study was terminated because of lack of funding.|f||||f||||||||No||2017-10-11 02:11:37.876128|2017-10-11 02:11:37.876128
NCT01748045|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-20|2017-06-20|2016-06-17||March 2013||2013-03-01|June 2017|2017-06-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants|The Use of Inhaled Nitric Oxide to Improve Respiratory Outcomes in Late Preterm Infants|Terminated||Phase 2/Phase 3|3|Actual|Tufts Medical Center||2||Enrollenment has been suspended due to poor enrollment|f||||t||||||||||2017-10-11 02:11:59.423348|2017-10-11 02:11:59.423348
NCT01747382|ClinicalTrials.gov processed this data on October 10, 2017|2012-12-09|2017-04-27|||April 2012||2012-04-01|April 2017|2017-04-01|September 2017|Anticipated|2017-09-01|September 2015|Actual|2015-09-01||Expanded Access|||Renal Denervation for Treatment of Resistant Hypertension in Patients With Chronic Kidney Disease|Catheter-based Renal Sympathetic Nerve Ablation for Treatment-resistant Hypertension in Patients With Chronic Kidney Disease|No longer available||N/A|||Singapore General Hospital||||Symplicity HTN-3 trial showed no benefit, hence trial was terminated|f||||||||||||||2017-10-11 02:12:13.799093|2017-10-11 02:12:13.799093
NCT01740089|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-30|2015-07-22|2015-03-01||November 2011||2011-11-01|July 2015|2015-07-01|December 2013|Actual|2013-12-01|July 2012|Actual|2012-07-01||Interventional||During randomization, patients were stratified by gender, age, viral load, and HCV genotype. The mITT-analysis included all randomized patients received at least one dose of investigational products, who were not withdrawn from the study at its beginning due to serious violations of the inclusion/non-inclusion criteria.|Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C|Multicenter Open-label Randomized Prospective Clinical Study of Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b) in Comparison With PegIntron (Peginterferon Alfa-2b) in the Combined Treatment of Chronic Hepatitis C|Completed||Phase 2/Phase 3|150|Actual|Biocad||3|||f||||f||||||||||2017-10-11 02:15:16.801908|2017-10-11 02:15:16.801908
NCT01737762|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-20|2017-06-27|2017-06-27||November 2012||2012-11-01|September 2016|2016-09-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional|||Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2|A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2|Completed||Phase 3|155|Actual|Healthpoint|The trial was terminated due to the failure of the Phase 3 study|2|||f||||t||||||||Yes|Results summaries have been sent to each site for distribution to participants|2017-10-11 02:15:47.639696|2017-10-11 02:15:47.639696
NCT01737541|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-21|2014-08-20|||November 2012||2012-11-01|August 2014|2014-08-01|August 2014|Actual|2014-08-01|August 2014|Actual|2014-08-01||Interventional|FMRICH||Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage|Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): a Randomised Placebo-controlled Trial|Terminated||Phase 3|32|Actual|Universidad Autónoma de Aguascalientes||2||Study recruitment was suspended due to lack of funding|f||||t||||||||||2017-10-11 02:15:51.59219|2017-10-11 02:15:51.59219
NCT01736878|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-23|2013-05-16|||October 2012||2012-10-01|May 2013|2013-05-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|SUMMIT||Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma|Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma|Withdrawn||Phase 2|0|Actual|Eanm Research Ltd||2||Study was withdrawn due to unanticipated hassle in patient recruitment.|f||||t||||||||||2017-10-11 02:15:57.863049|2017-10-11 02:15:57.863049
NCT01736579|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-27|2016-11-28|2016-07-13||November 2012||2012-11-01|October 2016|2016-10-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||Long-Term Study of IGIV, 10% in Alzheimer´s Disease|A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease|Terminated||Phase 3|6|Actual|Baxalta US Inc.|This study was an extension of study 160701 and was stopped early due to lack of evidence of clinical benefit of IGIV treatment in Alzheimer's Disease patients in Baxalta study 160701. Summary tables available for safety data only.|2||"The study was terminated because the first Phase 3 did not demonstrate efficacy on the   co-primary endpoints. The known safety profile remained unchanged."|f||||t||||||||||2017-10-11 02:16:04.348827|2017-10-11 02:16:04.348827
NCT01736215|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-26|2014-03-28|2013-03-29||November 2010||2010-11-01|March 2014|2014-03-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Observational||Number of participants analyzed for this baseline characteristic included all the participants who received erythropoietin treatment and had sufficient data to perform statistical evaluation.|An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy|Prediction of Response to Erythropoietin Treatment in Cancer Related Anemia Patients Receiving Chemotherapy|Terminated||Phase 4|33|Actual|Janssen-Cilag Ltd.,Thailand|||1|This study was terminated regarding to slow enrollment.|f||||f||||||Samples Without DNA|"     Blood samples will be collected for hematological analysis.   "|||2017-10-11 02:16:11.284506|2017-10-11 02:16:11.284506
NCT01735916|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-15|2014-10-01|2014-09-12||December 2012||2012-12-01|October 2014|2014-10-01|December 2018|Anticipated|2018-12-01|December 2017|Anticipated|2017-12-01||Interventional|MIRACLE EF||MIRACLE EF Clinical Study|MIRACLE EF Clinical Study|Terminated||N/A|44|Actual|Medtronic Cardiac Rhythm and Heart Failure||2||The study was terminated early due to low enrollment.|f||||t||||||||||2017-10-11 02:16:17.306377|2017-10-11 02:16:17.306377
NCT01733355|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-25|2013-07-18|||July 2012||2012-07-01|July 2013|2013-07-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|||A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807|A Phase 0, Open Label, Non-randomized, Multi-center Exploratory and Safety Study of [F-18]T807|Terminated||Early Phase 1|11|Actual|Avid Radiopharmaceuticals||1||Study was terminated in anticipation of transfer of ownership to Avid Radiopharmaceuticals.|f||||f||||||||||2017-10-11 02:16:51.174184|2017-10-11 02:16:51.174184
NCT01732549|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-24|2016-08-09|2016-04-29||January 2013||2013-01-01|August 2016|2016-08-01|May 2015|Actual|2015-05-01|February 2015|Actual|2015-02-01||Interventional||ITT population: All randomised patients. Patients were allocated to the treatment they were randomised to. Patients randomised that have been actually dead before randomisation were not retained in the intention to treat (ITT) population|A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy|A Randomised, Double-Blind, Placebo-Controlled Proof Of Concept Study Of Maintenance Therapy With Tasquinimod In Patients With Metastatic Castrate-Resistant Prostate Cancer Who Are Not Progressing After A First Line Docetaxel Based Chemotherapy|Terminated||Phase 2|144|Actual|Ipsen|The study was terminated early due to the stop of the project as decided by sponsor. The trial included number of planned patients & number of events(PFS)were met to draw conclusions. Only follow-up of patients were discontinued earlier than planned.|2||Development of tasquinimod in prostate cancer discontinued|f||||t||||||||||2017-10-11 02:17:09.518758|2017-10-11 02:17:09.518758
NCT01731990|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-18|2017-08-29|2017-07-21||October 30, 2012|Actual|2012-10-30|July 2017|2017-07-01|August 4, 2016|Actual|2016-08-04|August 4, 2016|Actual|2016-08-04||Interventional||safety analysis set: All patients that received any study drug were included in the safety analysis set|Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Effects on Arterial Structure and Function of ACZ885 in Patients With Intermittent Claudication.|Terminated||Phase 2|38|Actual|Novartis|Study was terminated after the third interim analysis based on result from primary outcome analysis.|2||The study got terminated based on result from primary endpoint analysis|f||||f|t|f||||||||2017-10-11 02:17:18.586315|2017-10-11 02:17:18.586315
NCT01731587|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-11|2017-02-27|||January 2001||2001-01-01|February 2017|2017-02-01||||||||Interventional|FINGERPRINT||Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer|Phase Ib, Single-arm, Proof-of-principle Trial Investigating the Cytokine Profile and Specific T Cell Response in Peripheral Blood of Non-small Cell Lung Cancer (NSCLC) Subjects With Unresected Stage III Disease Treated With L-BLP25|Withdrawn||Phase 1|0|Actual|Merck KGaA||1||"The objectives of this trial are no longer deemed appropriate for the clinical development of   L-BLP25 therefore this trial is withdrawn"|f||||f||||||||||2017-10-11 02:17:22.757555|2017-10-11 02:17:22.757555
NCT01725854|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-09|2016-10-31|||July 2012||2012-07-01|October 2016|2016-10-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Interventional|RR||Relaxation Response Training for PTSD Prevention in US Military Personnel|"Relaxation Response (RR) Training for PTSD Prevention in Soldiers a.k.a. SPIRIT SMART (Stemming PTSD, Increasing Resilience and Impeding Trauma in Service Members: Assessing Relaxation Response Training)"|Terminated||N/A|8|Actual|William Beaumont Army Medical Center||2||Loss of staff for completion|f||||t||||||||Undecided|Study terminated|2017-10-11 02:18:51.536909|2017-10-11 02:18:51.536909
NCT01723488|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-01|2013-07-18|||July 2012||2012-07-01|July 2013|2013-07-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|T808||A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808|A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808|Terminated||Early Phase 1|12|Actual|Avid Radiopharmaceuticals||1||Study was terminated in anticipation of transfer of ownership to Avid Radiopharmaceuticals.|f||||f||||||||||2017-10-11 02:19:24.236969|2017-10-11 02:19:24.236969
NCT01721707|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-02|2014-12-10|||December 2012||2012-12-01|December 2014|2014-12-01|June 2013|Anticipated|2013-06-01|March 2013|Anticipated|2013-03-01||Interventional|||Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH|Safety and Efficacy to Reduce the IOP of the Fixed Association of Latanoprost 0.005% (50 μg/mL)/ Brinzolamide 1% (10mg/mL) Drops, Compared to Latanoprost 0.005% (50 μg/mL) Drops, in Patients With Open Angle Glaucoma or Ocular Hypertension|Withdrawn||Phase 3|0|Actual|Adapt Produtos Oftalmológicos Ltda.||2||withdrawn by industry|f||||f||||||||||2017-10-11 02:20:00.690854|2017-10-11 02:20:00.690854
NCT01721694|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-02|2014-12-10|||December 2012||2012-12-01|December 2014|2014-12-01|May 2013|Anticipated|2013-05-01|March 2013|Anticipated|2013-03-01||Interventional|||Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection|Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection|Withdrawn||Phase 3|0|Actual|Adapt Produtos Oftalmológicos Ltda.||2||withdrawn by industry|f||||f||||||||||2017-10-11 02:20:00.799134|2017-10-11 02:20:00.799134
NCT01721330|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-30|2016-04-27|2016-03-14||November 2012||2012-11-01|April 2016|2016-04-01|February 2015|Actual|2015-02-01|February 2015|Actual|2015-02-01||Interventional|||A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder|A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder|Terminated||Phase 4|3|Actual|Massachusetts General Hospital|The study was terminated prior to completion due to competing studies. Therefore, only one subject in each group was analyzed.|2||Competing studies|f||||f||||||||Undecided||2017-10-11 02:20:04.178182|2017-10-11 02:20:04.178182
NCT01721135|ClinicalTrials.gov processed this data on October 10, 2017|2012-11-01|2013-08-20|||September 2010||2010-09-01|August 2013|2013-08-01|December 2014|Anticipated|2014-12-01|December 2014|Anticipated|2014-12-01||Interventional|||A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.|A Randomised, Placebo Controlled, Four-way Cross-over Study to Assess Cardiac Re-polarisation Following Repeat Dosing With GSK2190915 and Placebo for Five Days, With Moxifloxacin as a Positive Control, in Healthy Male and Female Subjects.|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||4||"Study was terminated due to toxicology findings after screening started but before first   subject first dose."|f||||f||||||||||2017-10-11 02:20:07.847364|2017-10-11 02:20:07.847364
NCT01719861|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-29|2017-03-02|2017-01-12||October 2012||2012-10-01|March 2017|2017-03-01|May 2015|Actual|2015-05-01|May 2014|Actual|2014-05-01||Interventional|||Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors|A Phase 2a Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors|Terminated||Phase 2|6|Actual|Stanford University|This study had to be terminated early because patients with small cell lung cancer were not able to tolerate clinically relevant doses of desipramine, and no clinical activity was observed in the first enrolled patients.|1||Lack of efficacy|f||||t||||||||No||2017-10-11 02:20:29.954363|2017-10-11 02:20:29.954363
NCT01716234|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-25|2017-03-31|2016-03-15||April 17, 2008|Actual|2008-04-17|March 2017|2017-03-01|April 1, 2015|Actual|2015-04-01|April 1, 2015|Actual|2015-04-01||Interventional|||A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)|Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia (P03579)|Terminated||Phase 1|142|Actual|Merck Sharp & Dohme Corp.|Only 1 participant was enrolled in the POS 12 TID 3 months to <2 years group, limiting conclusions that may be drawn for pharmacokinetics or safety.|7||"Study was terminated early (10 July 2015) based on preliminary analysis of pharmacokinetic   data."|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT01715311|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-24|2017-04-19|||November 2012||2012-11-01|February 2013|2013-02-01|September 2013|Anticipated|2013-09-01|September 2013|Anticipated|2013-09-01||Interventional|INITIATE||Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control|A Randomized, Double-blind Placebo-controlled Study to Compare the Efficacy of Indacaterol With That of Placebo in Patients With COPD Who Have Not Previously Received Maintenance COPD Medication, Using Blinded Tiotropium as Active Control|Withdrawn||Phase 4|0|Actual|Novartis||3||withdrawn prior to patient recruitment|f||||f||||||||||2017-10-11 02:21:54.780387|2017-10-11 02:21:54.780387
NCT01712399|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-19|2017-05-30|2017-02-28||January 28, 2013||2013-01-28|May 2017|2017-05-01|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Interventional||The As-treated Population included participants who received at least one dose of mavrilimumab 100 mg every 2 weeks (Q2W).|A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis|An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis|Terminated||Phase 2|409|Actual|MedImmune LLC|The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations.|1||"The study was terminated after approximately 3 years due to future clinical development plans,   including ethical considerations."|f||||t||||||||||2017-10-11 02:22:40.30389|2017-10-11 02:22:40.30389
NCT01712074|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-19|2017-01-30|2016-08-26||November 2012||2012-11-01|January 2017|2017-01-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional||One (1) of participant randomized but not treated appeared under placebo run-in including his/her discontinued and safety information|Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil|A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil|Terminated||Phase 2|186|Actual|Pfizer||2||"The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria   were met. The termination was not due to safety concerns."|f||||t||||||||||2017-10-11 02:22:46.374326|2017-10-11 02:22:46.374326
NCT01709474|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-16|2015-12-15|2015-10-20||June 2013||2013-06-01|December 2015|2015-12-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||The population included all subjects who were randomized to receive either Vitamin D3 6000 IU daily or 400 IU daily.|Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus|Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE)|Terminated||Phase 2|7|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study terminated early due to recruitment feasibility issues. Seven subjects were enrolled and received treatment in contrast to the planned number of 78 subjects for randomization/receipt of treatment. No mechanistic analyses were performed.|2||Due to slow enrollment|f||||t||||||||||2017-10-11 02:23:45.804141|2017-10-11 02:23:45.804141
NCT01709396|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-12|2017-01-10|||January 2012||2012-01-01|January 2017|2017-01-01|January 2018|Anticipated|2018-01-01|January 2016|Actual|2016-01-01||Interventional|ED-TBI||ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS|Extended Dose - Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory Acute Leukemia And Advanced Myelodysplastic Syndrome|Suspended||Phase 2|20|Anticipated|Ottawa Hospital Research Institute||1||initial on hold due to space but now permanently suspended due to futility.|f||||t||||||||Undecided||2017-10-11 02:23:48.604391|2017-10-11 02:23:48.604391
NCT01709201|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-15|2017-06-19|||July 2013||2013-07-01|June 2017|2017-06-01|June 2015|Anticipated|2015-06-01|December 2014|Anticipated|2014-12-01||Interventional|||Reducing Problematic Substance Use in Youth With Chronic Medical Conditions|Reducing Problematic Substance Use in Youth With Chronic Medical Conditions|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||2||Study did not receive funding and was administratively withdrawn.|f||||f||||||||||2017-10-11 02:23:53.889336|2017-10-11 02:23:53.889336
NCT01709162|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-12|2015-10-27|2015-09-17||March 2013||2013-03-01|September 2015|2015-09-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||All participants who were randomized|Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma|A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment Versus Chemotherapy for Subjects With Advanced Melanoma Who Progressed After Initially Achieving Disease Control With Ipilimumab Therapy|Terminated||Phase 2|31|Actual|Bristol-Myers Squibb|As planned, accrual of participants was to be completed within 21 months. However, current projections showed that 4 to 5 years were needed. The study was terminated early because the scientific objective could not be met in the predefined timeframe.|2||Discontinued early due to enrollment challenges and changes in treatment standards|f||||f||||||||||2017-10-11 02:23:54.23717|2017-10-11 02:23:54.23717
NCT01707758|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-12|2013-05-15|||October 2012||2012-10-01|May 2013|2013-05-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Observational|||Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence|Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence|Withdrawn||N/A|0|Actual|University of Kansas Medical Center|||1|Trial terminated - Nanoscale Company out of business|f||||t||||||Samples Without DNA|"     Approximately 1 tablespoon of blood will be collected from each subject.   "|||2017-10-11 02:24:21.820196|2017-10-11 02:24:21.820196
NCT01706159|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-09|2014-09-22|2014-07-10|2013-11-07|October 2012||2012-10-01|September 2014|2014-09-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional||The demographics and baseline characteristics are presented for the Full analysis set (FAS) which included all randomised and treated subjects.|A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis|A Multicenter, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis|Terminated||Phase 2|20|Actual|Novo Nordisk A/S|The trial was terminated earlier than planned as the hypothesis of a correlation between low levels of FXIII and disease activity of UC could not be confirmed.|2||Trial screening data did not support the medical hypothesis|f||||f||||||||||2017-10-11 02:24:49.385949|2017-10-11 02:24:49.385949
NCT01705509|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-10|2017-04-05|||September 2012|Actual|2012-09-01|April 2017|2017-04-01|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|ERIC||The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)|The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)|Terminated||N/A|15|Actual|Cardiovascular Institute of the South Clinical Research Corporation||1||Study terminated due to lack of resources.|f||||f||||||||||2017-10-11 02:24:59.326801|2017-10-11 02:24:59.326801
NCT01703208|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-05|2017-04-05|||October 5, 2012|Actual|2012-10-05|April 2017|2017-04-01|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|||A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 3|4202|Actual|Merck Sharp & Dohme Corp.||2||"The study was terminated for business reasons and not due to any safety or efficacy concerns   related to omarigliptin"|f||||t||||||||||2017-10-11 02:25:46.97586|2017-10-11 02:25:46.97586
NCT01702350|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-20|2017-06-27|||October 21, 2011|Actual|2011-10-21|June 2017|2017-06-01|December 8, 2011|Actual|2011-12-08|December 8, 2011|Actual|2011-12-08||Interventional|Relative Bio||A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study|A Study to Evaluate the Relative Bioavailability of Five Different Oral Formulations of GSK2251052 and the Multiple-dose, Safety, Tolerability, and Pharmacokinetics of GSK2251052 With and Without Food in Male and Female, Young and Elderly Healthy Volunteers|Terminated||Phase 1|24|Actual|GlaxoSmithKline||5||"Study was terminated in March 2012 due to lack of eficacy in a seperate Phase II study in   patients."|f||||f||||||||||2017-10-11 02:26:04.294743|2017-10-11 02:26:04.294743
NCT01701843|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-11|2013-03-06|||October 2012||2012-10-01|March 2013|2013-03-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional|||Cromoglicate in Mastocytosis|A Phase II Exploratory Study Evaluating the Efficacy of Topical Cromoglicate Solution Compared to Topical Solution Vehicle in the Treatment of Mastocytosis|Terminated||Phase 2|7|Actual|LEO Pharma||2||prematurely terminated because of low recruitment|f||||f||||||||||2017-10-11 02:26:14.209036|2017-10-11 02:26:14.209036
NCT01701063|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-27|2016-06-07|2016-04-18||January 2013||2013-01-01|April 2016|2016-04-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional||Full analysis set (FAS) included all enrolled participants who received at least 1 dose of study drug.|An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus|A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus|Terminated||Phase 1/Phase 2|42|Actual|Vertex Pharmaceuticals Incorporated|Study was terminated early because it was determined that telaprevir/Peg-IFN/RBV regimen did not present a meaningful therapeutic treatment over existing interferon-free regimens and was unlikely to be used for participants aged 3 to 17 years.|1|||f||||t||||||||||2017-10-11 02:26:29.752454|2017-10-11 02:26:29.752454
Large number of protocol deviations encountered"|2||"Study terminated by sponsor due to low accrual, and high number of protocol deviations due in   part to the impact of Hurricane Sandy on protocol compliance."|f||||f||||||||||2017-10-11 02:26:43.38641|2017-10-11 02:26:43.38641
NCT01698944|ClinicalTrials.gov processed this data on October 10, 2017|2012-10-01|2017-02-23|||May 16, 2001|Actual|2001-05-16|February 2017|2017-02-01|November 18, 2002|Actual|2002-11-18|November 18, 2002|Actual|2002-11-18||Interventional|||Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency|Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency|Terminated||Phase 4|7|Actual|Novo Nordisk A/S||1||The trial was prematurely terminated due to low recruitment|f||||f||||||||||2017-10-11 02:27:04.69585|2017-10-11 02:27:04.69585
NCT01697072|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-26|2016-01-18||2015-10-22|October 2012||2012-10-01|January 2016|2016-01-01|August 2015|Actual|2015-08-01|November 2014|Actual|2014-11-01||Interventional|RILOMET-1||First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma|Terminated||Phase 3|609|Actual|Amgen||2||"All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data   Monitoring Committee safety review of study 20070622."|f||||t||||||||||2017-10-11 02:27:35.801396|2017-10-11 02:27:35.801396
NCT01693367|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-20|2016-08-04|2016-04-08||September 2012||2012-09-01|August 2016|2016-08-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional||Study was stopped|Dynamic Locking Screws 5.0 vs. Standard Locking Screws in Fracture of Distal Femur Treated With Locked Plate Fixation|A Multi-Center Randomized Controlled Pilot Study of Dynamic Locking Screws 5.0 vs. Standard Locking Screws in Fracture of Distal Femur Treated With Locked Plate Fixation|Terminated||Phase 4|5|Actual|AO Clinical Investigation and Documentation||2||The medical device has been withdrawn from the market due to technical issues.|f||||f||||||||||2017-10-11 02:28:38.098578|2017-10-11 02:28:38.098578
NCT01691014|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-12|2016-11-01|2016-11-01||April 2013||2013-04-01|November 2016|2016-11-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Observational||Effectiveness analysis set (EAS) included all participants that provided at least 1 post-baseline assessment.|Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents|Formation Of Antibodies And Subsequent Prediction Of Clinical Response In Patients With Rheumatoid Arthritis Treated With Four Tnf Blocking Agents|Terminated||N/A|79|Actual|Pfizer|Due to premature termination of the study, the primary objective and few of the secondary objectives for the study were not met.||4|"The study was terminated on 10DEC2014 due to the inability to enroll the planned number of   patients. There were no safety concerns."|f||||f||||||||||2017-10-11 02:29:17.142125|2017-10-11 02:29:17.142125
NCT01689337|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-17|2017-01-12|2015-07-08||April 2013||2013-04-01|January 2017|2017-01-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional||Intention-to-treat (ITT) analysis set included all participants randomly allocated to treatment.|A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Trial to Investigate the Efficacy and Safety of 30 mcg and 100 mcg AS902330 Given as One Cycle of Three Intra-articular Knee Injections Once a Week for Three Weeks as an Adjunct Treatment to Patients Following Microfracture Surgery for Cartilage Injury of the Knee.|Terminated||Phase 2|1|Actual|EMD Serono|Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.|3||The study was discontinued due to low recruitment.|f||||f||||||||||2017-10-11 02:29:46.245002|2017-10-11 02:29:46.245002
NCT01688882|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-17|2016-03-28|2016-03-28||January 2013||2013-01-01|March 2016|2016-03-01|March 2015|Actual|2015-03-01|March 2015|Actual|2015-03-01||Interventional|||Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment|Terminated||Phase 2|20|Actual|Novartis||3||"This study was stopped after Part 1 completed and was terminated because the predefined   criteria of efficacy was not reached ( >50% better then placebo)"|f||||t||||||||||2017-10-11 02:29:55.384515|2017-10-11 02:29:55.384515
NCT01685255|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-04|2017-06-06||2015-11-04|August 2012||2012-08-01|June 2017|2017-06-01|October 23, 2014|Actual|2014-10-23|October 23, 2014|Actual|2014-10-23||Interventional|||A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy|A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy|Terminated||Phase 2|83|Actual|Incyte Corporation||2||Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.|f||||t||||||||Undecided||2017-10-11 02:31:00.724048|2017-10-11 02:31:00.724048
NCT01684410|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-06|2016-01-11|2015-08-10||August 2012||2012-08-01|January 2016|2016-01-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional||Intent-To-Treat (ITT) Population: included all subjects who were randomized (included those withdrawn from treatment for any reason).|Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis|A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis.|Completed||Phase 2|30|Actual|Grifols Therapeutics Inc.||3|||f||||t||||||||||2017-10-11 02:31:16.955653|2017-10-11 02:31:16.955653
NCT01681368|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-05|2017-04-24|2015-01-21||August 15, 2012|Actual|2012-08-15|April 2017|2017-04-01|April 30, 2014|Actual|2014-04-30|December 9, 2013|Actual|2013-12-09||Interventional|||Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer|Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal|Terminated||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||1||Accrual was terminated for lack of a clinical benefit.|f||||f|t|f||||||No||2017-10-11 02:32:20.016335|2017-10-11 02:32:20.016335
NCT01680757|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-28|2013-02-21|||September 2012||2012-09-01|February 2013|2013-02-01|March 2014|Anticipated|2014-03-01|March 2014|Anticipated|2014-03-01||Interventional|PLACE III||Study of Left Atrial Appendage Closure in Patients With Atrial Fibrillation - III|Multicenter Registry of Permanent Ligation Approximation Closure Exclusion of the Left Atrial Appendage in Patients With Atrial Fibrillation III (PLACE III)|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||1||This study has been withdrawn prior to enrollment|f||||f||||||||||2017-10-11 02:32:33.52918|2017-10-11 02:32:33.52918
NCT01680172|ClinicalTrials.gov processed this data on October 10, 2017|2012-09-04|2016-01-29|2016-01-29||August 2012||2012-08-01|January 2016|2016-01-01|February 2015|Actual|2015-02-01|February 2015|Actual|2015-02-01||Interventional|||Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer|Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer|Terminated||Phase 2|5|Actual|Mayo Clinic|The study was terminated due to slow accrual rate. Data analysis limited to 5 participants.|2||Slow enrollment|f||||f||||||||No||2017-10-11 02:32:45.226481|2017-10-11 02:32:45.226481
NCT01678911|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-31|2015-06-26|2015-05-20||August 2012||2012-08-01|June 2015|2015-06-01|June 2014|Actual|2014-06-01|March 2014|Actual|2014-03-01||Interventional|||Efficacy of Gralise® for Chronic Pelvic Pain|Efficacy of Gralise® for Chronic Pelvic Pain|Terminated||Phase 4|11|Actual|Shirley Ryan AbilityLab|This study was terminated early due to low recruitment. Therefore, the data presented represents a very small sample, with low 'n's in each group. The data tables represent all available data for the small sample.|2||Study ended due to difficulties in recruitment and low enrollment.|f||||t||||||||||2017-10-11 02:33:02.770013|2017-10-11 02:33:02.770013
NCT01678820|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-31|2017-04-06|2014-10-16||October 10, 2012|Actual|2012-10-10|April 2017|2017-04-01|November 1, 2013|Actual|2013-11-01|November 1, 2013|Actual|2013-11-01||Interventional||All participants randomized population. Study specific baseline characteristics include all randomized participants with data.|A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)|A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy|Terminated||Phase 3|299|Actual|Merck Sharp & Dohme Corp.|Study was terminated for business reasons in November 2013.|3||Merck terminated the study for business reasons in November 2013.|f||||f||||||||||2017-10-11 02:33:04.07757|2017-10-11 02:33:04.07757
NCT01677988|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-29|2015-12-11|2015-10-28||July 2012||2012-07-01|July 2015|2015-07-01||||October 2015|Actual|2015-10-01||Interventional|||Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma|Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Capecitabine With Concurrent Limited Field Radiation Therapy in Patients With Localized Pancreatic Head Adenocarcinoma|Terminated||Phase 2|3|Actual|Medical University of South Carolina||1||Study was terminated due to low accrual.|f||||t||||||||||2017-10-11 02:33:16.564424|2017-10-11 02:33:16.564424
NCT01676766|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-23|2016-11-04|||September 2012||2012-09-01|November 2016|2016-11-01|October 2016|Actual|2016-10-01|October 2016|Actual|2016-10-01||Observational|||Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease|Novel Quantification Methods for Fundus Flavoprotein Fluorescence and Lipofuscin Fluorescence to Detect Progression in Stargardt Disease|Terminated||N/A|2|Actual|University of Michigan|||1|"Flavoprotein fluorescence machine for the trial is not working so the trial was terminated. No   study data was collected prior to termination."|f||||f||||||||||2017-10-11 02:33:41.673997|2017-10-11 02:33:41.673997
NCT01675674|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-23|2013-05-23|||September 2011||2011-09-01|May 2013|2013-05-01|March 2014|Anticipated|2014-03-01|March 2014|Anticipated|2014-03-01||Observational|||Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics|Unrecognized Mucopolysaccharidosis I, II, IVA, and VI in the Pediatric Rheumatology Population|Terminated||N/A|3000|Anticipated|National MPS Society|||1|Funding withdrawn due to insufficient enrollment rate|f||||t||||||||||2017-10-11 02:33:54.017108|2017-10-11 02:33:54.017108
NCT01675011|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-25|2016-02-10|2015-01-28||August 2012||2012-08-01|February 2016|2016-02-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|||Embozene Microspheres for Uterine Fibroid Embolization (UFE)|Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization Compared to Embosphere for Symptomatic Relief From Uterine Fibroids|Terminated||N/A|4|Actual|Boston Scientific Corporation|The trial was terminated early due to insufficient enrollment, therefore formal statistical analyses were not possible.|2||Inadequate enrollment|f||||t||||||||||2017-10-11 02:34:33.100762|2017-10-11 02:34:33.100762
NCT01671111|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-16|2015-07-10|2015-07-10||August 2012||2012-08-01|August 2014|2014-08-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||Safety set included all participants who had taken at least 1 dose of investigational product.|Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)|A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)|Terminated||Phase 2|30|Actual|Shire|This study was terminated early due to non-clinical safety results. Not all participants completed the study. The available efficacy data were analyzed as specified in the statistical analysis plan; however, no efficacy conclusions were drawn.|1||"This study was terminated due to treatment stop resulting in an inability to draw conclusions   from the data. Evaluation of nonclinical rat findings is ongoing."|f||||||||||||||2017-10-11 02:35:49.799959|2017-10-11 02:35:49.799959
NCT01670071|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-17|2016-04-12|||January 2013||2013-01-01|April 2016|2016-04-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|||A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia|A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia|Terminated||Phase 4|17|Actual|Johnson & Johnson Taiwan Ltd||2||The study was terminated due to insufficient sample size and protocol compliance issue.|f||||f||||||||||2017-10-11 02:36:04.819411|2017-10-11 02:36:04.819411
NCT01669187|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-20|2014-04-09|||December 2011||2011-12-01|April 2014|2014-04-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|||The Effects of Pre-operative Physical Therapy Education|Phase 1 of the The Effects of Pre-operative Physical Therapy Education and Exercise on Patient Outcomes Post Breast Cancer Surgery: a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Oakland University||2||Study withdrawn.|f||||f||||||||||2017-10-11 02:36:17.877644|2017-10-11 02:36:17.877644
NCT01668654|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-17|2016-11-18|2014-07-10||September 2012||2012-09-01|November 2016|2016-11-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS|RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects With Partial Onset Seizures (>= 12 Years Old) and Subjects With Lennox-Gastaut Syndrome (>=12 Years Old)|Terminated||Phase 3|4|Actual|GlaxoSmithKline|This study was terminated early and only 4 of the planned 500 participants were enrolled. Due to the early study termination and small sample size, many planned analyses were not completed therefore lmiited results data were available.|1||"FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in   subjects; early termination allows for timely reporting of results."|f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2017-10-11 02:36:33.246738|2017-10-11 02:36:33.246738
NCT01667913|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-15|2013-11-13|||September 2012||2012-09-01|November 2013|2013-11-01|August 2013|Actual|2013-08-01|August 2013|Actual|2013-08-01||Interventional|||Reliability of 6-Minutes Walking Test in Hip Fracture Patients|The Relative and Absolute Reliability of 6-Minutes Walking Test in Hip Fracture Patients|Terminated||N/A|20|Actual|Lolland Community, Denmark||1||Due to low inclusion rate we terminated this study with n=20 participants instead of n=50.|f||||f||||||||||2017-10-11 02:36:44.649211|2017-10-11 02:36:44.649211
NCT01667107|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-14|2017-03-03|2014-12-22||January 2013||2013-01-01|March 2017|2017-03-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|PAPAL||A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)|A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients|Terminated||Phase 4|26|Actual|Merck Sharp & Dohme Corp.||2||Study terminated due to an unfavorable risk-benefit analysis|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT01665950|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-09|2017-04-03|2016-11-30||August 2012||2012-08-01|April 2017|2017-04-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional|||Simvastatin Augmentation of Lithium Treatment in Bipolar Depression|Simvastatin Augmentation of Lithium Treatment in Bipolar Depression|Terminated||Phase 2|4|Actual|Massachusetts General Hospital|The study was terminated early because delays in study initiation and insufficient recruitment. Our statisticians have advised us that this analysis is uninformative as it represents the change for one individual in 2 of the three arms of the study.|3||Lack of enrollment|f||||t||||||||||2017-10-11 02:37:13.914052|2017-10-11 02:37:13.914052
NCT01664273|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-16|2014-06-19|||July 2012||2012-07-01|June 2014|2014-06-01|May 2015|Anticipated|2015-05-01|May 2015|Anticipated|2015-05-01||Interventional|||Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer|Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer|Terminated||Phase 1|7|Actual|Copenhagen University Hospital at Herlev||1||Production of the IMP (plasmid AMEP) has been terminated by the supplier (BioAlliance Pharma)|f||||t||||||||||2017-10-11 02:37:41.52947|2017-10-11 02:37:41.52947
NCT01663285|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-24|2015-11-04|2014-09-11||September 2012||2012-09-01|November 2015|2015-11-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)|Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)|Terminated||Phase 2|1|Actual|University of Michigan Cancer Center|The study was terminated prematurely due to poor patient accrual. Study objectives were not analyzed.|1||Low study participant enrollment.|f||||t||||||||||2017-10-11 02:38:07.915276|2017-10-11 02:38:07.915276
NCT01662115|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-07|2017-08-21|2017-04-13||August 2012||2012-08-01|August 2017|2017-08-01|June 2014|Actual|2014-06-01|June 2014|Actual|2014-06-01||Interventional|||Nicotine Gum Recovery After Colorectal Surgery|Does Nicotine Gum Enhance Bowel Recovery After Colorectal Surgery?|Terminated||Phase 4|4|Actual|The Cleveland Clinic|Principal Investigator decided for an early termination of the enrollment period due to small numbers of subjects consented, with limited data to make conclusions.|3||"Study has been terminated due linability to recruit the targeted participants. Aimed for 300   participants and only 4 were enrolled after 1 year."|f||||f||||||||||2017-10-11 02:38:30.739666|2017-10-11 02:38:30.739666
NCT01660243|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-02|2016-02-18||2015-10-20|September 2012||2012-09-01|February 2016|2016-02-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis|A Phase 2, Randomized, Double-blind, Placebo-controlled, Fixed-dose, Parallel-group, Multicenter, Efficacy, and Safety Study of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis|Terminated||Phase 2|45|Actual|Toray Industries, Inc||4||This study has been terminated because of insufficient patient recruitment.|f||||f||||||||||2017-10-11 02:39:03.646431|2017-10-11 02:39:03.646431
NCT01659138|ClinicalTrials.gov processed this data on October 10, 2017|2012-08-03|2016-07-12||2015-11-03|August 2012||2012-08-01|July 2016|2016-07-01|April 2016|Actual|2016-04-01|June 2014|Actual|2014-06-01||Interventional|FUSCIA||Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients With Active Moderate to Severe Ulcerative Colitis (UC)|Terminated||Phase 2|28|Actual|Sanofi||2||Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.|f||||t||||||||||2017-10-11 02:39:29.280229|2017-10-11 02:39:29.280229
NCT01658605|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-24|2013-06-20|||February 2013||2013-02-01|June 2013|2013-06-01|December 2014|Anticipated|2014-12-01|February 2013|Actual|2013-02-01||Interventional|||A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis|A Phase II, 20-week, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Proof of Concept Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||"Study CCX115383 has been terminated prior to enrolment of any patients. A decision was made by   GSK to delay pursuit of this indication as the biology evolves."|f||||||||||||||2017-10-11 02:39:35.97934|2017-10-11 02:39:35.97934
NCT01658527|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-27|2016-06-09|||January 2014||2014-01-01|June 2016|2016-06-01|January 2017|Anticipated|2017-01-01|January 2016|Anticipated|2016-01-01||Interventional|||TAK-700 in Castration Resistant Prostate Cancer|Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration.|Withdrawn||Phase 2|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||Pharmaceutical company has terminated orteronel (TAK-700) development for Prostate Cancer|f||||t||||||||||2017-10-11 02:39:37.510821|2017-10-11 02:39:37.510821
NCT01657149|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-15|2016-04-05|||December 2015||2015-12-01|August 2015|2015-08-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional|||Influence of Manual Lymph Drainage During Hospitalization on Swelling, Function and Pain in Patients After Total Knee Replacement|Influence of Manual Lymph Drainage During Hospitalization on Swelling, Function and Pain in Patients After Total Knee Replacement - Randomized Control Trial.|Terminated||N/A|20|Actual|Rabin Medical Center||2||a cardinal member of The research team withdrawn from study, the study has beem terminated.|f||||t||||||||||2017-10-11 02:39:58.685939|2017-10-11 02:39:58.685939
NCT01656967|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-30|2016-11-29|2016-03-22||July 2010||2010-07-01|November 2016|2016-11-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional||All enrolled patients, except for one in the Ambu group who was withdrawn due to a faulty monitor|AMBU AScope2 Fiberoptic Intubation Versus Fastrach Intubating LMA|Flexible Optical Intubation Via the AMBU Aura-I Versus Blind Intubation Via the Fastrach Single Use Intubating LMA - A Prospective Randomized Clinical Trial|Completed||N/A|66|Actual|The University of Texas Health Science Center, Houston|Experience of the residents, some only had 6 months experience When using AScope, there were secretions and no suctioning capability Sample size ILMA is a straightforward attempt; whereas, AScope needs to maneuver and go all the way to carina|2|||f||||f||||||||Undecided||2017-10-11 02:40:01.833632|2017-10-11 02:40:01.833632
NCT01654562|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-27|2014-10-14|||December 2012||2012-12-01|September 2013|2013-09-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|||The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia|A Repeated Measures Study of Simvastatin on Choroideremia: Simvastatin Intervention and Reversal in Choroideremia Patients and Age-matched Controls.|Terminated||Phase 1/Phase 2|2|Actual|University of Alberta||2||The study has been terminated due to limited participant enrollment.|f||||f||||||||||2017-10-11 02:40:44.468985|2017-10-11 02:40:44.468985
NCT01651936|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-25|2017-01-03|2017-01-03||August 2012||2012-08-01|December 2016|2016-12-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional||All randomized participants|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Subjects With Active Rheumatoid Arthritis and an Inadequate Response or Intolerance to Anti-TNF-α Therapy|Terminated||Phase 2|56|Actual|Merck Sharp & Dohme Corp.|This study was terminated early (12 September 2013) based on preliminary analysis of data. The results of this study need to be interpreted with caution given the small sample size (56 participants) resulting from early termination of the study.|3|||f||||f||||||||||2017-10-11 02:41:37.62551|2017-10-11 02:41:37.62551
NCT01650805|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-18|2014-11-05|2014-10-15||June 2012||2012-06-01|October 2014|2014-10-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional||ITT Population|Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)|A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase|Terminated||Phase 3|307|Actual|Ariad Pharmaceuticals|Trial was discontinued early.|2||Study terminated based on evaluation of safety data.|t||||t||||||||||2017-10-11 02:41:49.755401|2017-10-11 02:41:49.755401
NCT01648699|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-20|2013-10-01|2013-03-15||April 2010||2010-04-01|October 2013|2013-10-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional|||Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain|Study on the Effectiveness and Safety of OROS Hydromorphone in Pain Management Among Patients With Cancer Pain|Terminated||Phase 4|20|Actual|Janssen Pharmaceutica|The study was prematurely terminated due to administrative reason.|1||the study was stopped due to non-availability of 4mg|f||||f||||||||||2017-10-11 02:42:25.62521|2017-10-11 02:42:25.62521
NCT01648101|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-28|2017-01-31|2014-08-14||August 2012||2012-08-01|January 2017|2017-01-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|||Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.|Terminated||Phase 3|76|Actual|GlaxoSmithKline|RTG114855 was designed for registration of retigabine as add-on treatment of drug-resistant POS in South Korea/Taiwan/ Vietnam. GSK decided not to pursue registration in these countries and terminated the study early based on new safety information.|3||Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2017-10-11 02:42:45.876657|2017-10-11 02:42:45.876657
NCT01647308|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-19|2014-07-11|||July 2012||2012-07-01|July 2014|2014-07-01|March 2014|Actual|2014-03-01|January 2014|Actual|2014-01-01||Interventional|||Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes|A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|15|Actual|Ionis Pharmaceuticals, Inc.||2||"The study was terminated for business planning purposes. Assessments of APOCIIIRx in this   population will be explored in a larger efficacy study"|f||||f||||||||||2017-10-11 02:42:58.070765|2017-10-11 02:42:58.070765
NCT01645709|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-17|2014-08-26|2014-08-26||April 2012||2012-04-01|August 2014|2014-08-01||||February 2013|Actual|2013-02-01||Interventional||Study was terminated and no data is available|Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee|CS-201: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intra-Articular Verapamil in the Treatment of JoinT Pain in Subjects With Osteoarthritis of the Knee|Terminated||Phase 1/Phase 2|81|Actual|Calosyn Pharma, Inc.||2||Sponsor decision to terminate study|f||||f||||||||||2017-10-11 02:43:28.545966|2017-10-11 02:43:28.545966
NCT01643252|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-16|2017-06-20|||July 2012||2012-07-01|June 2017|2017-06-01||||||||Interventional|||Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery|Withdrawn||Phase 3|0|Actual|Avedro, Inc.||2||This study was withdrawn for business reasons.|f||||f||||||||||2017-10-11 02:44:21.91259|2017-10-11 02:44:21.91259
NCT01642732|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-24|2017-05-24|2014-11-13||October 2012||2012-10-01|May 2017|2017-05-01|August 2014|Actual|2014-08-01|August 2014|Actual|2014-08-01||Interventional|||Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer|A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer|Terminated||Phase 1|1|Actual|University of Michigan Cancer Center|Only one patient was enrolled to the trial and consent was withdrawn prior to treatment therefore the primary objective could not be analyzed.|1||Lack of accrual and funding expires in June, 2014.|f||||t||||||||||2017-10-11 02:44:27.944506|2017-10-11 02:44:27.944506
NCT01641939|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-13|2017-05-05|2016-06-30||September 3, 2012|Actual|2012-09-03|May 2017|2017-05-01|April 30, 2016|Actual|2016-04-30|June 30, 2015|Actual|2015-06-30||Interventional||Intent to treat (ITT) analysis population included all randomized participants; participants grouped according to the therapy they were randomized to receive.|A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer|A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction|Terminated||Phase 2/Phase 3|415|Actual|Hoffmann-La Roche|The study was terminated by the Sponsor as the primary analysis results did not meet the primary endpoint.|3|||f||||||||||||||2017-10-11 02:44:50.321923|2017-10-11 02:44:50.321923
NCT01641926|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-11|2017-03-10|2016-11-16||November 2012||2012-11-01|March 2017|2017-03-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Interventional||All Participants as Treated (APaT: all randomized participants who received ≥1 dose of study medication|A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)|A Multicenter Open-label Study to Evaluate the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Subjects With HBeAg Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B Protocol No. MK-4031-376-00 (Also Known as SCH 054031, P08450)|Terminated||Phase 3|402|Actual|Merck Sharp & Dohme Corp.||4||This study was terminated early due to poor recruitment|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT01641575|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-09|2014-03-08|||July 2012||2012-07-01|March 2014|2014-03-01|June 2013|Actual|2013-06-01|May 2013|Actual|2013-05-01||Interventional|||A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin|A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.|Terminated||Phase 1|8|Actual|Clovis Oncology, Inc.||1||"Registrational study did not meet endpoint so entire program (including CO-101-011) was   terminated."|f||||f||||||||||2017-10-11 02:45:04.078333|2017-10-11 02:45:04.078333
NCT01636960|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-05|2017-05-19|2015-01-26||December 25, 2012|Actual|2012-12-25|May 2017|2017-05-01|November 4, 2015|Actual|2015-11-04|March 26, 2014|Actual|2014-03-26||Interventional|||A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)|An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (Protocol No. MK-4031 370 Also Known as SCH 54031, P08556)|Terminated||Phase 1|9|Actual|Merck Sharp & Dohme Corp.|The study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan.|1||"The study was terminated after 118 weeks from the study start, during the maintenance phase,   due to regulatory approval in Japan."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT01636414|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-14|2016-07-21|2016-03-23||May 2012||2012-05-01|July 2016|2016-07-01|October 2015|Actual|2015-10-01|June 2014|Actual|2014-06-01||Interventional||All patients who completed the study are included in the reported results. Patients that were withdrawn from the study did not receive treatment.|Reinfusion Drains vs Tranexamic Acid in Total Joint Arthroplasty||Completed||Phase 4|204|Actual|OrthoCarolina Research Institute, Inc.||3|||f||||t||||||||||2017-10-11 02:46:27.485708|2017-10-11 02:46:27.485708
NCT01635621|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-03|2012-10-29|||June 2012||2012-06-01|October 2012|2012-10-01|August 2013|Anticipated|2013-08-01|August 2013|Anticipated|2013-08-01||Interventional|||A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Olokizumab Administered Subcutaneously to Subjects With Moderate to Severe Crohn's Disease|Withdrawn||Phase 2|0|Actual|UCB Pharma||4||"Study was withdrawn due to delay in timelines. There were no safety concerns regarding the   study or the compound in the decision to withdraw the trial."|f||||f||||||||||2017-10-11 02:46:42.915268|2017-10-11 02:46:42.915268
NCT01635543|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-27|2013-10-16|||October 2011||2011-10-01|October 2013|2013-10-01|October 2013|Anticipated|2013-10-01|June 2013|Anticipated|2013-06-01||Observational|||Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas|Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas|Withdrawn||N/A|0|Actual|University of British Columbia|||1|This study was terminated due to some challenges in recruitment process|f||||t||||||||||2017-10-11 02:46:43.52638|2017-10-11 02:46:43.52638
NCT01634789|ClinicalTrials.gov processed this data on October 10, 2017|2012-07-03|2013-01-17|||August 2012||2012-08-01|January 2013|2013-01-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Interventional|||A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women|A Phase 1, Open-label, Single-dose, Randomized, 4-treatment, 4- Period, Crossover, Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene (Bza) Compared With A Reference Tablet Formulation of Bza/Conjugated Estrogens (ce) in Healthy Postmenopausal Women|Terminated||Phase 1|2|Actual|Pfizer||4||"This study was terminated on 10 December 2012 due to low enrollment. The decision to terminate   the study was not based on safety or efficacy issues."|f||||f||||||||||2017-10-11 02:46:52.356939|2017-10-11 02:46:52.356939
NCT01633814|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-25|2017-07-11|2017-05-01||September 2011|Actual|2011-09-01|June 2017|2017-06-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional||Total enrollment was 4 women. Study was terminated prematurely early due to poor enrollment and the fact that the PI was moving to another institution. No data was analyzed.|Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women|Influence of Hormone Replacement on Neural Cardiovascular Control in Postmenopausal Women|Terminated||N/A|4|Actual|University of Missouri-Columbia|Total enrollment was 4 women. Study was terminated prematurely early due to poor enrollment and the fact that the PI was moving to another institution. No data was analyzed.|2||PI left institution prior to completion of study. Data unavailable..|f||||t||||||||||2017-10-11 02:47:12.325925|2017-10-11 02:47:12.325925
NCT01632306|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-28|2016-03-28||2016-03-28|March 2013||2013-03-01|March 2016|2016-03-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|||A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer|Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy|Terminated||Phase 1/Phase 2|13|Actual|Eli Lilly and Company||3||Study has been terminated due to slow enrollment.|f||||f||||||||||2017-10-11 02:47:32.870027|2017-10-11 02:47:32.870027
NCT01631630|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-27|2017-01-27|2016-10-21||May 2012||2012-05-01|January 2017|2017-01-01|September 2015|Actual|2015-09-01|September 2015|Actual|2015-09-01||Interventional|||Role of Proinflammatory Signaling in Alcohol Craving|Role of Proinflammatory Signaling in Alcohol Craving|Terminated||Phase 2|16|Actual|National Institutes of Health Clinical Center (CC)|This study was terminated early, so the number of subjects analyzed is small.|2||The study was closed to recruitment due to feasibility problems.|f||||t||||||||No||2017-10-11 02:47:45.699057|2017-10-11 02:47:45.699057
NCT01631409|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-24|2014-04-07|||September 2013||2013-09-01|April 2014|2014-04-01|September 2021|Anticipated|2021-09-01|September 2021|Anticipated|2021-09-01||Observational|CSWTSPB40||Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy|Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy in the General System of Noninvasive, Invasive, and Surgical Treatment of Ischemic Heart Disease in the Conditions of a Large General City Hospital|Withdrawn||N/A|0|Actual|City Hospital No 40, Saint Petersburg, Russia|||7|The study has been withdrawn due to organizational problems|f||||t||||||||||2017-10-11 02:47:49.145559|2017-10-11 02:47:49.145559
NCT01629667|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-12|2017-04-28|2017-01-19||October 2012||2012-10-01|April 2017|2017-04-01|January 2016|Actual|2016-01-01|May 2015|Actual|2015-05-01||Interventional||The intent-to-treat (ITT) population is all randomized participants who receive any study investigational product and participants were analysed according to the randomization.|A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis|A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis|Terminated||Phase 2|409|Actual|MedImmune LLC|Study was early terminated due to lack of efficacy.|3||Early termination of the study due to lack of efficacy.|f||||t||||||||||2017-10-11 02:48:11.908637|2017-10-11 02:48:11.908637
NCT01628913|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-25|2016-03-09|2015-08-19||October 2012||2012-10-01|March 2016|2016-03-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional|||Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors|Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors|Terminated||Phase 2|62|Actual|Novartis|Trial terminated based on the results of a pre-planned interim analysis of the primary OM ( which demonstrated BEX235 not having improved PFS (progression free survival) vs everolimus)..The secondary OM analyses were not conducted|2||"This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a   progression free survival advantage to everolimus treatment."|f||||f||||||||||2017-10-11 02:48:22.781278|2017-10-11 02:48:22.781278
NCT01627353|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-19|2014-06-18|||January 2012||2012-01-01|June 2014|2014-06-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||Post Hysterectomy Pain Prevention: Pre-op Wound Infiltration With Anesthetic Protocol Versus Standard of Care|Post Hysterectomy Pain Prevention: Randomized Clinical Trial of High Volume Preoperative Wound Infiltration and Pain Specific Anesthetic Protocol Versus Standard of Care (no Wound Infiltration and Routine Anesthetic Protocol)|Terminated||Phase 4|16|Actual|University of Calgary||2||Funding withdrawn|f||||f||||||||||2017-10-11 02:48:47.249969|2017-10-11 02:48:47.249969
NCT01627002|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-12|2013-07-18|2013-07-18||May 2012||2012-05-01|July 2013|2013-07-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|||A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401|A Phase 1, FIH, Double-blind, Randomised Placebo-controlled Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of PA401, and the Effects of PA401 Following LPS Challenge, in Healthy Subjects|Terminated||Phase 1|49|Actual|ProtAffin Biotechnologie AG|Part B of the study was terminated early which led to a small number of subjects analyzed. Pharmacokinetic parameters were not calculated for Part A 0.3mg and 10 mg PA401|2|||f||||f||||||||||2017-10-11 02:48:53.378595|2017-10-11 02:48:53.378595
NCT01626391|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-20|2014-06-10|2014-04-28||September 2012||2012-09-01|June 2014|2014-06-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional||Safety Population|Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease|A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy|Terminated||Phase 2|9|Actual|TauRx Therapeutics Ltd|Early termination leading to small numbers of subjects analyzed|2||This study has been terminated for administrative reasons only.|f||||t||||||||||2017-10-11 02:49:04.323702|2017-10-11 02:49:04.323702
NCT01621477|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-08|2016-12-28|2016-10-17||August 2012||2012-08-01|December 2016|2016-12-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional|||T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant|T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant|Terminated||Phase 2|34|Actual|St. Jude Children's Research Hospital||1||Study was terminated in August 2016 due to replacement by a new study.|f||||f||||||||||2017-10-11 02:50:19.923846|2017-10-11 02:50:19.923846
NCT01621243|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-22|2017-01-04|||May 2012||2012-05-01|January 2017|2017-01-01|December 2016|Actual|2016-12-01|December 2016|Actual|2016-12-01||Interventional|||M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer|A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer|Terminated||Phase 1/Phase 2|128|Actual|Momenta Pharmaceuticals, Inc.||2||"The study was terminated after a pre-planned futility analyses showed an insufficient level of   efficacy in the study population to warrant continuation."|f||||f||||||||||2017-10-11 02:50:22.419894|2017-10-11 02:50:22.419894
NCT01619800|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-12|2017-04-15|2015-02-17||March 2012||2012-03-01|April 2017|2017-04-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional|ABSOLVE CI||The Effect of Blended Sensor Efficiency on Relieving the Heart's Inability to Increase Its Rate During Exercise|The impAct of Blended Sensor Optimization on resoLVing Chronotropic Incompetence: ABSOLVE CI|Terminated||N/A|2|Actual|Icahn School of Medicine at Mount Sinai|2 subjects enrolled, unable to meet goal of 38 enrollments. Data not analyzed.|2||The study was terminated due to poor enrollment.|f||||t||||||||No||2017-10-11 02:50:47.259405|2017-10-11 02:50:47.259405
NCT01615484|ClinicalTrials.gov processed this data on October 10, 2017|2012-06-06|2016-07-08|||September 2013||2013-09-01|July 2016|2016-07-01|July 2018|Anticipated|2018-07-01|July 2017|Anticipated|2017-07-01||Interventional|||Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability|Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability|Suspended||Phase 2|10|Anticipated|University of North Carolina, Chapel Hill||2||Funding suspended, currently seeking other funding source(s).|f||||t||||||||Yes|De-identified individual clinical outcome data will be made available upon request|2017-10-11 02:51:58.41175|2017-10-11 02:51:58.41175
NCT01615016|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-30|2017-08-19|||July 2012||2012-07-01|August 2017|2017-08-01|August 19, 2017|Actual|2017-08-19|August 19, 2017|Actual|2017-08-19||Interventional|MIsurf||MISurf Versus InSurE. A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants|Feasibility Study of A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants|Terminated||Phase 2|4|Actual|Hamilton Health Sciences Corporation||2||Delay due to infrastructural reasons. Funding withdrawn|f||||t||||||||||2017-10-11 02:52:07.348206|2017-10-11 02:52:07.348206
NCT01612299|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-30|2017-08-04|||May 2012||2012-05-01|August 2017|2017-08-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|||Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients|Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients|Withdrawn||N/A|0|Actual|University of Kentucky||2||Funding was withdrawn for this study by the sponsor.|f||||t||||||||||2017-10-11 02:52:52.870173|2017-10-11 02:52:52.870173
NCT01610765|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-30|2016-06-06|||January 2016||2016-01-01|June 2016|2016-06-01|June 2017|Anticipated|2017-06-01|June 2017|Anticipated|2017-06-01||Interventional|||A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)|A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)|Withdrawn||Phase 1/Phase 2|0|Actual|University of Alabama at Birmingham||2||Study terminated because unable to obtain access to study drug for study population.|f||||t||||||||||2017-10-11 02:53:15.633878|2017-10-11 02:53:15.633878
NCT01607645|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-25|2017-02-14|2016-10-13||July 2012||2012-07-01|February 2017|2017-02-01|September 2013|Actual|2013-09-01|July 2013|Actual|2013-07-01||Interventional|||Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS|Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML.|Terminated||Phase 2|7|Actual|Fred Hutchinson Cancer Research Center|Early termination due to similar competing protocol, which made statistical evaluation of primary endpoint and any meaningful evaluation of secondary time points not feasible.|2||The study was terminated early because there were other competing protocols.|f||||f||||||||Yes||2017-10-11 02:55:27.800421|2017-10-11 02:55:27.800421
NCT01607346|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-17|2017-08-28|2017-07-11||March 27, 2013|Actual|2013-03-27|August 2017|2017-08-01|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|||An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures|An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures|Terminated||Phase 4|10|Actual|GlaxoSmithKline|The study was terminated after 10 of 100 subjects had been enrolled. Statistical analyses were not performed as the sample size enrolled was too small to allow for these analyses to be meaningful. The data are presented as summary statistics only.|1|||f||||f||||||||||2017-10-11 02:55:33.999935|2017-10-11 02:55:33.999935
NCT01606800|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-24|2017-03-10|2016-01-26||January 2013||2013-01-01|March 2017|2017-03-01|January 2015|Actual|2015-01-01|January 2015|Actual|2015-01-01||Interventional|START 4|All Treated Population, which included all participants who received at least one dose of study medication after RVR.|Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)|Randomized Open Label Study to Assess the Efficacy and Safety of Short Course Therapy (24 Weeks) With Peginterferon Alpha-2b and Ribavirin for Chronic Hepatitis C (Genotype 4) Patients Who Achieve a Rapid Virological Response (HCV -RNA Undetectable at Week 4 of Treatment)|Terminated||Phase 4|45|Actual|Merck Sharp & Dohme Corp.|This Trial was prematurely terminated due to the availability of more promising treatment for HCV participants and the change in treatment guidelines, which will offer the patient a better treatment opportunity.|2||The trial was terminated due to change in new standard of therapy during the study period.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT01605942|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-23|2015-06-11|2015-06-11||June 2012||2012-06-01|June 2015|2015-06-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Interventional|||A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery||Terminated||Phase 1|8|Actual|Allergan||2||Study terminated due to corporate decision.|f||||f||||||||||2017-10-11 02:56:03.304305|2017-10-11 02:56:03.304305
NCT01605929|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-16|2015-12-04|||July 2012||2012-07-01|December 2015|2015-12-01|September 2013|Anticipated|2013-09-01|September 2013|Anticipated|2013-09-01||Interventional|||Clinical Evaluation of the Ultrasound-Guided Retroclavicular Brachial Plexus Block|Clinical Evaluation of the Ultrasound-Guided Retroclavicular Brachial Plexus Block|Withdrawn||N/A|0|Actual|Brigham and Women's Hospital||1||withdrawn before IRB approval|f||||f||||||||||2017-10-11 02:56:03.760556|2017-10-11 02:56:03.760556
NCT01605617|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-03|2013-12-16|2013-09-24||June 2012||2012-06-01|December 2013|2013-12-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|||Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate|Prospective Randomized Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate|Terminated||Phase 4|4|Actual|Mayo Clinic|The study was terminated due to a low recruitment rate prior to subjects completing treatment.|2||Low recruitment rate, and study patients were removed prior to completion|f||||f||||||||||2017-10-11 02:56:10.851803|2017-10-11 02:56:10.851803
NCT01605370|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-22|2014-05-08|2014-04-04||June 2012||2012-06-01|May 2014|2014-05-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|Inapprop|The study was terminated early due to the difficulty in identifying subjects satisfying the inclusion criteria. Only 1 subject was enrolled.|Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?|Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?|Terminated||Phase 4|1|Actual|Mayo Clinic|The study was terminated early due to the difficulty in identifying subjects satisfying the inclusion criteria. Only 1 subject was enrolled.|2||Difficulty in identifying subjects satisfying the inclusion criteria.|f||||f||||||||||2017-10-11 02:56:16.693368|2017-10-11 02:56:16.693368
NCT01605344|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-22|2014-02-26|||April 2012||2012-04-01|February 2014|2014-02-01|July 2014|Anticipated|2014-07-01|July 2013|Anticipated|2013-07-01||Interventional|||Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI|A Prospective, Randomized, Crossover Evaluation of the Effect of Atorvastatin on the Pharmacokinetics of Irinotecan in Colorectal Cancer Patients Receiving FOLFIRI|Withdrawn||Phase 1|0|Actual|UNC Lineberger Comprehensive Cancer Center||2||Study was withdrawn due to lack of patient enrollment.|f||||t||||||||||2017-10-11 02:56:17.26826|2017-10-11 02:56:17.26826
NCT01604941|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-22|2015-07-22|2015-06-04||September 2012||2012-09-01|August 2014|2014-08-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||Safety Set, defined as all participants who had taken at least 1 BID dose of investigational product.|Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy|A Phase 2, 24 Week, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSP-004184 (SPD602) in the Treatment of Chronic Iron Overload Requiring Chelation Therapy|Terminated||Phase 2|32|Actual|Shire|This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.|1||"This study was terminated due to treatment stop resulting in an inability to draw conclusions   from the data. Evaluation of nonclinical rat findings is ongoing."|f||||t||||||||||2017-10-11 02:56:22.051158|2017-10-11 02:56:22.051158
NCT01604863|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-23|2012-10-29|||June 2012||2012-06-01|October 2012|2012-10-01|July 2014|Anticipated|2014-07-01|June 2014|Anticipated|2014-06-01||Interventional|||A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies|Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies|Suspended||Phase 1|54|Anticipated|GlaxoSmithKline||3||Study suspended prior to enrollment|f||||f||||||||||2017-10-11 02:56:23.85992|2017-10-11 02:56:23.85992
NCT01604252|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-21|2017-07-25|||June 20, 2012|Actual|2012-06-20|June 2017|2017-06-01|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Observational|||An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)|A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients|Terminated||N/A|503|Actual|Genentech, Inc.|||1|"The study was terminated early by the Sponsor due to the high rate of discontinuation of   subjects unrelated to patient safety."|f||||||||||Samples With DNA|"     optional blood sample   "|||2017-10-11 02:56:32.459079|2017-10-11 02:56:32.459079
NCT01602471|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-14|2013-07-26|2013-07-26||May 2012||2012-05-01|July 2013|2013-07-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional||Five participants enrolled, four complete and one withdrawal prior to receiving the investigational prodcut. Study was terminated early by the sponsor.|[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis|An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis|Terminated||Phase 2|5|Actual|Siemens Molecular Imaging||1||Sponsor decided to develop the product in collaboration|f||||f||||||||||2017-10-11 02:57:06.300342|2017-10-11 02:57:06.300342
NCT01602016|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-15|2017-01-05|2016-11-04||May 2012||2012-05-01|January 2017|2017-01-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional||The study sponsor (UAMS) was unable to completely monitor the study or resolve outstanding queries. The study data cannot be fully validated by the sponsor. The study was placed on Full Clinical Hold by the FDA and terminated by the sponsor as a result of investigator non-compliance.|A Folinic Acid Intervention for Autism Spectrum Disorders|A Folinic Acid Intervention for ASD: Links to Folate Receptor-alpha Autoimmunity & Redox Metabolism|Terminated||Phase 2|99|Actual|University of Arkansas||3||Non-compliance|f||||f||||||||||2017-10-11 02:57:14.956312|2017-10-11 02:57:14.956312
NCT01601782|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-01|2014-08-18|2013-12-10||August 2009||2009-08-01|August 2014|2014-08-01|May 2010|Actual|2010-05-01|March 2010|Actual|2010-03-01||Interventional||Patients were randomly evaluated without pre-selection of gender or race|Impact of Volume Imaging Using Diagnostic Ultrasound|Impact of Volume Imaging With Ultrasound|Terminated||N/A|16|Actual|University of Michigan|16 patients were studied as part of a pilot project to determine if 3D ultrasound offers any benefit over routine standard ultrasound imaging of the extremity. The study was terminated after evaluating 16 subjects.|1||It was determined that the volume imaging was not working.|f||||f||||||||||2017-10-11 02:57:18.250315|2017-10-11 02:57:18.250315
NCT01601704|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-14|2017-02-24|2016-12-11||June 2012||2012-06-01|April 2016|2016-04-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional|||Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR|Terminated||Phase 3|8910|Actual|Orexigen Therapeutics, Inc|The study was terminated early. Outcome measures data is based on the 50% interim analysis, designated as the primary analysis. Safety data is based on all available data at the time of database lock, which occurred after the 50% interim analysis.|2|||f||||t||||||||||2017-10-11 02:57:19.042419|2017-10-11 02:57:19.042419
NCT01601236|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-15|2017-07-21|2017-05-18||May 2012||2012-05-01|July 2017|2017-07-01|March 2016|Actual|2016-03-01|January 2016|Actual|2016-01-01||Interventional||All randomized subjects|Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.|Completed||Phase 2|34|Actual|Mallinckrodt|Groups 5 & 6 were closed when 2 of the 1st 4 subjects met predefined tolerability criteria. Enrollment terminated early at 34/40 subjects due to slow recruitment.16 of 34 subjects discontinued prior to collecting primary endpoint data at week 36.|6|||f||||||||||||||2017-10-11 02:57:27.603583|2017-10-11 02:57:27.603583
NCT01600807|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-08|2013-06-25||||||June 2013|2013-06-01||||||||Interventional|||OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas|Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas|Withdrawn||Phase 1/Phase 2|0|Actual|Dana-Farber Cancer Institute||2||"Study was pending major changes and was on hold, pending activation; administratively   withdrawn; will be submitted as a new protocol if study is revised."|f||||t||||||||||2017-10-11 02:57:35.02918|2017-10-11 02:57:35.02918
NCT01600677|ClinicalTrials.gov processed this data on October 10, 2017|2012-05-14|2016-08-18|2016-01-14||May 2012||2012-05-01|August 2016|2016-08-01|May 2013|Actual|2013-05-01|February 2013|Actual|2013-02-01||Interventional|EMMA-RCT||Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions|Determining the Impact of a Medication Delivery Unit on Medication Adherence Immediately Following Hospitalization of Adults With Common Cardiac Conditions|Terminated||N/A|11|Actual|University of Pittsburgh|We terminated the study early after exhausting all possible approaches to increasing participant enrollment.|2||Terminated on 2/28/13, low enrollment; last participant med visit 5/13/13.|f||||t||||||||||2017-10-11 02:57:37.580923|2017-10-11 02:57:37.580923
NCT01598987|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-01|2017-04-13|2016-11-30||October 2012||2012-10-01|April 2017|2017-04-01|June 2016|Actual|2016-06-01|June 2016|Actual|2016-06-01||Interventional||Full analysis set (FAS): consisted of all patients enrolled into the study, including patients who did not receive any everolimus, but were followed beyond baseline.|Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.|A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.|Completed||Phase 3|56|Actual|Novartis|Based on DMC recommendation, enrolment was terminated and patients below 7 years were converted form study medication to local standard of care but patients were followed up until Month 24.|1|||f||||t||||||||||2017-10-11 02:58:12.753421|2017-10-11 02:58:12.753421
NCT01592201|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-10|2014-06-24|||July 2012||2012-07-01|June 2014|2014-06-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug|An Open-label, Prospective, Randomized and Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug|Terminated||Phase 4|13|Actual|Janssen Korea, Ltd., Korea||2||This study was early terminated due to insufficient enrollment required for hypothesis testing.|f||||f||||||||||2017-10-11 03:00:15.959744|2017-10-11 03:00:15.959744
NCT01590979|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-27|2017-02-01|2016-09-08||April 2012||2012-04-01|February 2017|2017-02-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|||Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation|Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation Rates in Post-Operative Cardiac Surgery Patients|Terminated||N/A|54|Actual|Northwell Health|Due to insufficient accrual rate the study was stopped before the recruitment total was met. Thus, a major limitation is small sample size.|2||The study was terminated due to slow rate of accrual resulting in a sample size.|f||||t||||||||No||2017-10-11 03:00:35.990032|2017-10-11 03:00:35.990032
NCT01589705|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-30|2012-07-29|||January 2012||2012-01-01|July 2012|2012-07-01|April 2012|Actual|2012-04-01|April 2012|Actual|2012-04-01||Observational|||The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease|Endothelial Dysfunction in Patients With Polycystic Kidney Disease|Terminated||N/A|150|Actual|TC Erciyes University|||1|Patients recruitment and analysis were terminated|f||||f||||||||||2017-10-11 03:00:59.158761|2017-10-11 03:00:59.158761
NCT01587508|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-24|2016-04-29|||May 2013||2013-05-01|April 2012|2012-04-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional|||Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago|A Phase III, Randomized, Single-Blind, Superiority Study Comparing The Efficacy And Tolerability Of A New Drug Containing The Combination Meloxicam And Cyclobenzaprine And The Same Components Alone In The Treatment Of Acute Lumbago|Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||3||"The comparator product was withdrawn from the brazilian market not being possible to conduct   the design regarding initially planned."|f||||f||||||||||2017-10-11 03:01:35.980216|2017-10-11 03:01:35.980216
NCT01587495|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-05|2015-05-19|||March 2012||2012-03-01|May 2015|2015-05-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Pharmacokinetics and Safety of Ertapenem in the Postpartum Period|Pharmacokinetics and Safety of Ertapenem in the Postpartum Period|Terminated||Phase 1|3|Actual|Duke University||1||study terminated due to low subject accrual|f||||f||||||||||2017-10-11 03:01:36.094711|2017-10-11 03:01:36.094711
NCT01586026|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-25|2016-07-13|2014-07-10||April 2012||2012-04-01|July 2016|2016-07-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Observational|DISTAL|Post-infusional chemotherapy subjects that had Bard implanted ports with distally valved catheters.|Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters|A Retrospective Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters|Terminated||N/A|171|Actual|C. R. Bard|||3|Insufficient number of adverse events|f||||f||||||||No|Study was terminated due to limited number of adverse events recorded.|2017-10-11 03:01:57.795132|2017-10-11 03:01:57.795132
NCT01585441|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-24|2014-11-25|2014-10-29||April 2012||2012-04-01|November 2014|2014-11-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|||Finasteride for Chronic Central Serous Chorioretinopathy|Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy|Terminated||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)|This study was terminated early due to lack of enrollment.|2||This study was terminated early due to lack of enrollment.|f||||t||||||||||2017-10-11 03:02:10.295815|2017-10-11 03:02:10.295815
NCT01582100|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-19|2014-11-05|2014-11-05||March 2012||2012-03-01|July 2014|2014-07-01|November 2013|Actual|2013-11-01|November 2013|Actual|2013-11-01||Interventional||two subjects with GERD and nausea|Reletex for Nausea in GERD Patients|Reletex ™ Band as an Adjunct to Standard Therapy in Patients With GERD, Nausea With or Without Vomiting- A Pilot Study|Terminated||N/A|2|Actual|Northwestern University|The study was terminated due to low enrollment. One subject withdrew due to minor wrist discomfort and the other withdrew after determining the study schedule was undesirable.|1||study was terminated by investigator due to low enrollment|f||||f||||||||||2017-10-11 03:03:10.25641|2017-10-11 03:03:10.25641
NCT01581060|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-28|2014-05-15|||March 2012||2012-03-01|May 2014|2014-05-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours|A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours|Terminated||Phase 1/Phase 2|41|Actual|Wilex||1||Study terminated for business reasons|f||||f||||||||||2017-10-11 03:03:27.455686|2017-10-11 03:03:27.455686
NCT01577745|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-05|2017-03-21|2017-01-23||April 2012||2012-04-01|March 2017|2017-03-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional||Safety Population included all participants who received at least one dose of MEDI0639.|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors|A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Adult Subjects With Advanced Solid Tumors|Completed||Phase 1|58|Actual|MedImmune LLC|OMs relationship modulation of DLL4-Notch signaling pathway in tumor and clinical response analysis was not conducted due to low number of evaluable tumor samples and low response rate. Study was terminated early due to lack of clinical activity.|6|||f||||f||||||||||2017-10-11 03:04:21.285265|2017-10-11 03:04:21.285265
NCT01577381|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-11|2016-02-16|2015-12-09|2015-11-06|August 2012||2012-08-01|February 2016|2016-02-01|October 2013|Actual|2013-10-01|September 2013|Actual|2013-09-01||Interventional|||Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration|A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration|Terminated||Phase 2|10|Actual|Pfizer|The study was terminated early due to an organizational decision, which was not based on safety or efficacy concerns. As only 10 participants enrolled at the time of termination, there were not enough subjects or data to perform meaningful analyses.|2||See termination reason in detailed description.|f||||t||||||||||2017-10-11 03:04:28.816958|2017-10-11 03:04:28.816958
NCT01576146|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-05|2017-03-01|2017-03-01|2015-07-21|March 2012||2012-03-01|March 2017|2017-03-01|May 1, 2014|Actual|2014-05-01|May 1, 2014|Actual|2014-05-01||Interventional||Baseline was defined as the baseline of the parent study, 20120331.|Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism|A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (Also Known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients With Secondary Hyperparathyroidism|Terminated||Phase 2|30|Actual|KAI Pharmaceuticals||1||Study was terminated early to allow subjects to roll over to study NCT02102204.|f||||f|t|f||||||||2017-10-11 03:04:49.871714|2017-10-11 03:04:49.871714
NCT01575769|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-10|2015-12-03|2015-08-17||March 2012||2012-03-01|December 2015|2015-12-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional||Safety Population included all participants who entered the study, took at least one dose of study drug, and with at least one safety follow-up, regardless of premature withdrawal.|An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis|Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From Poland and Russia Who Completed the Global, Multinational Trial (WA19977).|Terminated||Phase 3|41|Actual|Hoffmann-La Roche|The study was terminated prior to the planned final on-treatment efficacy assessments due to commercial availability of tocilizumab in Russia and Poland.|1|||f||||||||||||||2017-10-11 03:04:57.249795|2017-10-11 03:04:57.249795
NCT01570634|ClinicalTrials.gov processed this data on October 10, 2017|2012-04-01|2013-02-03|2012-12-29||March 2012||2012-03-01|February 2013|2013-02-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Interventional|||Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection|Proof-of-Concept, CASAD for Treatment of Clostridium Difficile Infection|Terminated||Phase 2|2|Actual|Salient Pharmaceuticals Incorporated|This study was terminated early for slow enrollment. Only 2 patients were enrolled during the open period. One of the two took less than 50% of the prescribed study drug. The results are not meaningful.|1||Study was stopped for slow enrollment - only 2 patients, no evaluable results|f||||t||||||||||2017-10-11 03:06:24.919741|2017-10-11 03:06:24.919741
NCT01569152|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-30|2017-03-14|2017-01-19||May 2012||2012-05-01|March 2017|2017-03-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional||All randomized participants|Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial With a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Terminated||Phase 2|82|Actual|Merck Sharp & Dohme Corp.|This study was terminated early (12 September 2013) based on preliminary analysis of data. The results of this study need to be interpreted with caution given the small sample size (82 participants) resulting from the early termination of the study.|3|||f||||f||||||||||2017-10-11 03:06:45.95405|2017-10-11 03:06:45.95405
NCT01567553|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-24|2015-10-27|||April 2009||2009-04-01|January 2015|2015-01-01|June 2015|Actual|2015-06-01|June 2014|Actual|2014-06-01||Observational|USPIO-CIS||The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.|Early Neuroinflammatory Changes as a Prognostic Marker in Clinically Isolated Syndromes Patients.|Terminated||N/A|37|Actual|Rennes University Hospital|||2|terminated ( Halted prematurely,expiration of investigationnal product)|f||||f||||||||||2017-10-11 03:07:19.405789|2017-10-11 03:07:19.405789
NCT01566630|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-27|2015-10-12|2015-08-06||May 2013||2013-05-01|October 2015|2015-10-01|August 2014|Actual|2014-08-01|August 2014|Actual|2014-08-01||Interventional|||Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia|An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia|Terminated||Phase 2|3|Actual|Novartis||2||Novartis terminated this study due to internal, strategic decisions.|f||||||||||||||2017-10-11 03:07:36.475004|2017-10-11 03:07:36.475004
NCT01564563|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-23|2017-02-23|||June 28, 2002|Actual|2002-06-28|February 2017|2017-02-01|October 27, 2003|Actual|2003-10-27|October 27, 2003|Actual|2003-10-27||Interventional|||Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation|A Multi-center, Randomized, Double-blind, Parallel Groups, Placebo-controlled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation (HSCT)|Terminated||Phase 2|11|Actual|Novo Nordisk A/S||3||Trial enrollment was prematurely terminated due to excessively slow patient recruitment|f||||f||||||||||2017-10-11 03:08:19.454276|2017-10-11 03:08:19.454276
NCT01564316|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-11|2016-04-14|||May 2005||2005-05-01|March 2016|2016-03-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Observational|||Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients|Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients|Terminated||Early Phase 1|22|Actual|Seoul National University Hospital|||1|The study has been terminated due to difficulties in gathering the patient samples.|f||||t||||||Samples With DNA|"     serum:10ml      WHO: neurodegeneration patients and control group include dementia patients visited the part     of neurology.   "|||2017-10-11 03:08:25.201659|2017-10-11 03:08:25.201659
NCT01562899|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-22|2017-02-14||2017-02-14|August 2012||2012-08-01|February 2017|2017-02-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional|||A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors|A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors|Terminated||Phase 2|77|Actual|Array BioPharma||4||Study was withdrawn due to scientific and business considerations.|f||||||||||||||2017-10-11 03:08:47.605412|2017-10-11 03:08:47.605412
NCT01561430|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-21|2014-01-07||2014-01-07|March 2012||2012-03-01|January 2014|2014-01-01|August 2013|Actual|2013-08-01|August 2013|Actual|2013-08-01||Interventional|||Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease|Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease|Terminated||Phase 1/Phase 2|128|Anticipated|Eli Lilly and Company||4||Study terminated due to abnormal liver biochemical tests in some participants.|f||||f||||||||||2017-10-11 03:09:17.154515|2017-10-11 03:09:17.154515
NCT01558674|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-16|2017-03-27|2017-01-11||May 2014||2014-05-01|March 2017|2017-03-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|||A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)|A Two Part, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7145 in Patients With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II)|Terminated||Phase 1|11|Actual|Merck Sharp & Dohme Corp.|Study terminated early due to lack of efficacy.|7||Lack of efficacy|f||||t||||||||||2017-10-11 03:10:00.843186|2017-10-11 03:10:00.843186
NCT01558232|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-06|2012-07-05|||March 2012||2012-03-01|July 2012|2012-07-01|August 2012|Anticipated|2012-08-01|August 2012|Anticipated|2012-08-01||Interventional|Acute Effects||A Prospective Study to Evaluate Use of the Tibion Bionic Leg in Sub-Acute Post-stroke Patients|A Prospective, Experimental ABA Study to Evaluate Use of the Tibion Bionic Leg in Subacute Post-stroke Patients Undergoing Physical Therapy|Terminated||N/A|10|Actual|Tibion Bionics, Inc.||1||Study was terminated base on Sponsor's decision.|f||||f||||||||||2017-10-11 03:10:08.151407|2017-10-11 03:10:08.151407
NCT01557842|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-16|2017-05-13|2014-12-19||June 1, 2012|Actual|2012-06-01|May 2017|2017-05-01|March 19, 2014|Actual|2014-03-19|March 19, 2014|Actual|2014-03-19||Interventional|ASPIRE|All enrolled subjects|Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators|Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators|Terminated||Phase 4|15|Actual|Biosense Webster, Inc.|Please note that this study was terminated early and only 15 subjects were enrolled. As a result the reported results might be unreliable (unmonitored) and limited.|2|||f||||f||||||||||2017-10-11 03:10:15.595383|2017-10-11 03:10:15.595383
NCT01556633|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-15|2016-05-26|2015-11-30||March 2012||2012-03-01|May 2016|2016-05-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional||Safety population: All participants who received the study drug, whether prematurely withdrawn from the study or not, were included.|A Single Dose Study of Tamiflu in Volunteers in Dialysis And in Volunteers With Reduced Creatinine Clearance|An Open Label, Prospective, Single Oral Dose Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Oseltamivir in Adult Subjects on Peritoneal Dialysis (PD) Using a Rapid Cycle Regimen to Simulate APD and in Adult Subjects With Creatinine Clearance From 10 to 30 mL/Min Not on Dialysis|Completed||Phase 1|16|Actual|Hoffmann-La Roche||2|||f||||||||||||||2017-10-11 03:10:36.904125|2017-10-11 03:10:36.904125
NCT01556568|ClinicalTrials.gov processed this data on October 10, 2017|2012-03-15|2015-12-28|||February 2012||2012-02-01|December 2015|2015-12-01||||May 2017|Anticipated|2017-05-01||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy|An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy|Withdrawn||Phase 2|0|Actual|Array BioPharma||1||Study was withdrawn due to scientific and business considerations.|f||||f||||||||||2017-10-11 03:10:38.417255|2017-10-11 03:10:38.417255
NCT01551693|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-29|2017-03-01|2016-12-21||September 2011||2011-09-01|January 2017|2017-01-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Interventional||The analysis dataset is comprised of all treated patients.|STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma|This Trial is an Open Label, Parallel Cohort, Phase II Study Evaluating the Efficacy of the Heat Shock Protein 90 (Hsp90) Inhibitor STA-9090 in Patients With Unresectable Stage III or Stage IV Melanoma Who Were Intolerant of, or Progressed on, Prior Tyrosine Kinase Inhibitor Treatment. Two Cohorts Will Enroll Concurrently. One Cohort Will be Composed of Patients With Melanoma Expressing a Mutation in the Protein BRAF and the Other Cohort Will be Composed of Patients With Melanoma Expressing Wild-type BRAF.|Terminated||Phase 2|3|Actual|Dana-Farber Cancer Institute|The study was terminated early due to weak accrual.|2||due to weak accrual|f||||t|t|f||||||No||2017-10-11 03:11:58.559194|2017-10-11 03:11:58.559194
NCT01549613|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-08|2014-07-07|2014-07-07||May 2012||2012-05-01|July 2014|2014-07-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional||161 patients were screened;104 were initially enrolled. 3 patients were withdrawn prior to randomization; 1 patient was transferred to OR, 1 patient was admitted prior to randomization, 1 patient was prescribed a different antibiotic;1 patient was withdrawn not meet inclusion criteria. 39 patients in each treatment group completed follow-up.|Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections|Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections|Completed||Phase 4|104|Actual|University of Cincinnati||2|||f||||t||||||||||2017-10-11 03:12:29.099158|2017-10-11 03:12:29.099158
NCT01547728|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-07|2015-07-13|2015-04-21||February 2012||2012-02-01|July 2015|2015-07-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|||Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery|Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery|Terminated||Phase 4|42|Actual|Mayo Clinic|The study was terminated because there were too many barriers to enroll participants.|1||Too many barriers to enroll participants.|f||||f||||||||||2017-10-11 03:13:00.039248|2017-10-11 03:13:00.039248
NCT01545518|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-30|2014-08-21|2014-08-21||November 2011||2011-11-01|August 2014|2014-08-01|August 2013|Actual|2013-08-01|June 2013|Actual|2013-06-01||Interventional||18-50 years of age, both male and female|IVIG Treatment for Refractory Immune-Related Adult Epilepsy|IVIG Treatment for Refractory Immune-Related Adult Epilepsy|Terminated||Phase 2|20|Actual|Emory University|Study was terminated early. Subject eligibility for phase 2 not available.|1||Futility criteria, unable for Phase 2 of study, & phase 1 was terminated.|f||||f||||||||||2017-10-11 03:13:38.987295|2017-10-11 03:13:38.987295
NCT01544504|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-15|2012-05-25|||March 2012||2012-03-01|May 2012|2012-05-01|May 2012|Actual|2012-05-01|May 2012|Actual|2012-05-01||Interventional|||Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy|Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy|Withdrawn||Phase 1/Phase 2|0|Actual|ProCertus BioPharm, Inc||1||"The principal investigator withdrew from the study. The study was withdrawn because a qualified   replacement was not available."|f||||f||||||||||2017-10-11 03:13:53.588409|2017-10-11 03:13:53.588409
NCT01542255|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-17|2014-09-08|2014-08-28||June 2010||2010-06-01|September 2014|2014-09-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional||patients with metastatic melanoma|Metronomic Therapy in Patients With Metastatic Melanoma|Metronomic Therapy in Patients With Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine|Terminated||Phase 2|7|Actual|Dartmouth-Hitchcock Medical Center|terminated early due to difficulty with scheduling three times per week office treatment|1||Low accrual not allowing to support statistical endpoints|f||||t||||||||||2017-10-11 03:14:41.317938|2017-10-11 03:14:41.317938
NCT01536067|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-10|2016-05-03|2016-05-03||April 2012||2012-04-01|May 2016|2016-05-01||||April 2014|Actual|2014-04-01||Interventional||All treated and eligible patients|Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia|A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia|Terminated||Phase 2|3|Actual|Roswell Park Cancer Institute||1||funding was withdrawn|f||||t||||||||||2017-10-11 03:16:25.753978|2017-10-11 03:16:25.753978
NCT01534351|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-13|2017-05-26|2015-10-29||August 1, 2013|Actual|2013-08-01|May 2017|2017-05-01|November 18, 2013|Actual|2013-11-18|November 18, 2013|Actual|2013-11-18||Interventional|||Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)|A Phase III, Randomized Clinical Trial to Study the Safety and Efficacy of MK-906 (Finasteride) and Tamsulosin Administered Either Alone or Concomitantly in Patients With Benign Prostatic Hyperplasia (BPH)|Terminated||Phase 3|1|Actual|Merck Sharp & Dohme Corp.|The trial was terminated for business reasons.|3||Business Reasons|f||||t||||||||||2017-10-11 03:16:56.632088|2017-10-11 03:16:56.632088
NCT01533753|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-10|2014-09-10|2014-08-25||February 2012||2012-02-01|September 2014|2014-09-01|May 2014|Actual|2014-05-01|January 2014|Actual|2014-01-01||Interventional|||Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer|Randomized, Open-Label Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer|Terminated||Phase 2|5|Actual|University of Wisconsin, Madison|The study was terminated due to slow accrual. The data was uninterpretable due to the small numbers of subjects analyzed.|2||Slow accrual|f||||||||||||||2017-10-11 03:17:08.279676|2017-10-11 03:17:08.279676
NCT01532908|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-10|2017-04-24||2016-07-13|May 2012||2012-05-01|April 2017|2017-04-01|August 27, 2015|Actual|2015-08-27|August 27, 2015|Actual|2015-08-27||Interventional|MBL-HCV1||Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C|A Phase II Open-Label Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) Combined With Oral Direct-Acting Antivirals in Hepatitis C Infected Patients Undergoing Liver Transplantation|Terminated||Phase 2|10|Actual|MassBiologics||2||The study was terminated due to funding constraints|f||||f||||||||||2017-10-11 03:17:29.090324|2017-10-11 03:17:29.090324
NCT01532635|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-06|2016-10-19|2014-11-03||March 2012||2012-03-01|October 2016|2016-10-01|May 2013|Actual|2013-05-01|February 2013|Actual|2013-02-01||Interventional|||A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using Two Related Donors|Terminated||Phase 2|4|Actual|Thomas Jefferson University|Study was terminated due to poor accrual. No reportable data has been collected.|1||Slow accrual|f||||t||||||||||2017-10-11 03:17:34.016146|2017-10-11 03:17:34.016146
NCT01532453|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-09|2015-12-03|2015-07-16||November 2010||2010-11-01|December 2015|2015-12-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients|Open, Multicentre, Randomised, Comparative, Prospective Trial With MD-3511356 Versus Standard Sun Protection Measures in Immunosuppressed Solid Organ Transplanted Patients for Prevention of UV-induced Carcinogenic Skin Alterations|Terminated||Phase 3|244|Actual|Spirig Pharma Ltd.|Trial was terminated early for futility reasons (outcome would not be changed, if trial pursued up completion) and potential “loss of chance” (which could neither be confirmed nor rejected at the time) for patients included in the MD 3511356 group.|2||"For futility reasons and potential loss of chance for MD 3511356 group"|f||||t||||||||||2017-10-11 03:17:38.87797|2017-10-11 03:17:38.87797
NCT01528293|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-27|2016-12-21|2015-04-14||July 2012||2012-07-01|December 2016|2016-12-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations|A Prospective, Randomized, Comparative Effectiveness Trial of the ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations|Terminated||N/A|2|Actual|Georgetown University|Enrollment was insufficient to support statistical analyses. Three subjects were screened and only one completed the study. The study was terminated due to insufficient enrollment.|2||slow recruitment - unable to meet enrollment goals|f||||f||||||||No||2017-10-11 03:18:43.319293|2017-10-11 03:18:43.319293
NCT01527019|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-31|2015-07-24|||October 2012||2012-10-01|February 2012|2012-02-01||||October 2012|Actual|2012-10-01||Interventional|CECI||Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)|A Phase III Non-Inferiority Open-label Multicenter Randomized Clinical Trial to Compare CEPHALOSPORIN to NORFLOXACIN in the Treatment of Acute Cystitis|Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||3||the company suspended the persecution of this combination|f||||t||||||||||2017-10-11 03:18:59.45609|2017-10-11 03:18:59.45609
NCT01525927|ClinicalTrials.gov processed this data on October 10, 2017|2012-02-01|2016-01-29|2015-08-28||August 2010||2010-08-01|January 2016|2016-01-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional||data was not collected for Baseline Characteristics due to premature termination of this study|Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity|Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders|Terminated||Phase 2|2|Actual|Northwell Health|Study terminated , PI left the institution, no data analyzed|2||Principal Investigator left institution. IRB approval lapsed.|f||||t||||||||||2017-10-11 03:19:16.58045|2017-10-11 03:19:16.58045
NCT01524887|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-20|2015-06-26|2015-02-03||January 2012||2012-01-01|February 2015|2015-02-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional||The baseline analysis population comprises treated subjects (=safety analysis set).|Phase 3 IGIV, 10% in Alzheimer´s Disease|A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease|Terminated||Phase 3|508|Actual|Baxalta US Inc.|The primary and secondary outcome measures were originally planned to be assessed at 18 months. However, as the study was terminated early, an analysis was completed at 9 months instead, in a subset of subjects who had received 9 months of treatment.|3||"The study was terminated because the first Phase 3 did not demonstrate efficacy on the   co-primary endpoints. The known safety profile remained unchanged."|f||||t||||||||||2017-10-11 03:19:45.807243|2017-10-11 03:19:45.807243
NCT01522378|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-27|2017-04-24|||February 2012||2012-02-01|April 2017|2017-04-01|February 2016|Actual|2016-02-01|February 2016|Actual|2016-02-01||Interventional|||Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging|Cardiac Resynchronization and MIBG Imaging|Terminated||Phase 1|14|Actual|Mayo Clinic||1||The study was terminated because the funding was withdrawn.|f||||f|t|f|||t|||No||2017-10-11 03:20:28.260884|2017-10-11 03:20:28.260884
NCT01521780|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-16|2015-10-30|2013-08-14||April 2012||2012-04-01|October 2015|2015-10-01|November 2012|Actual|2012-11-01|September 2012|Actual|2012-09-01||Interventional|||Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)|A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials|Terminated||Phase 1|12|Actual|Merck Sharp & Dohme Corp.|The study was terminated early.|3|||f||||f||||||||||2017-10-11 03:20:40.258006|2017-10-11 03:20:40.258006
Part B - Safety population: All randomized participants who received at least 1 dose of Cvac (Cvac group) or were evaluated at least once (observational standard of care group)."|Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment|A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-glutathione S-transferase] Coupled to Oxidized Polymannose) as Maintenance Treatment in Patients With Epithelial Ovarian Cancer (EOC) in Complete Remission Following First-line Chemotherapy (A) and Patients With EOC in Second Remission (B)|Terminated||Phase 2|91|Actual|Prima BioMed Ltd||4||"The study was terminated due to company restructuring and changes in drug development   priorities."|f||||t||||||||||2017-10-11 03:20:48.209181|2017-10-11 03:20:48.209181
NCT01519427|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-25|2014-05-16|2013-11-27||January 2012||2012-01-01|January 2014|2014-01-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional||2 consented patients were not eligible for the trial|Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib|A Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600-Mutant Advanced Melanoma Whose Disease Has Progressed on Prior Therapy With a Selective BRAF Inhibitor (i.e., Vemurafenib, Dabrafenib, LGX818)|Terminated||Phase 2|2|Actual|National Cancer Institute (NCI)|Because this study terminated early due to slow accrual, data were available for only the two eligible patients that enrolled before study closure.|1||Study terminated due to slow accrual|f||||t||||||||||2017-10-11 03:21:31.733569|2017-10-11 03:21:31.733569
NCT01519323|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-16|2016-08-25|2016-06-17||January 2013||2013-01-01|August 2016|2016-08-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional|||BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations|An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of Vemurafenib (RO5185426) in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations|Terminated||Phase 1|6|Actual|Hoffmann-La Roche|The study was prematurely terminated on 18 December 2015 by the Sponsor due to recruitment challenges and therefore low enrollment.|1||Study was terminated due to low enrollment.|f||||t||||||||||2017-10-11 03:21:33.034246|2017-10-11 03:21:33.034246
NCT01517763|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-17|2014-09-28|||January 2012||2012-01-01|September 2014|2014-09-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional|||Comparison Study of the ICON™ Auto Series With and Without SensAwake™ and ThermoSmart™ and Conventional Continuous Positive Airway Pressure in Obstructive Sleep Apnea Patients||Terminated||N/A|25|Actual|Fisher and Paykel Healthcare||3||The site closed down, therefore the study has been terminated.|f||||f||||||||||2017-10-11 03:21:59.707385|2017-10-11 03:21:59.707385
NCT01514864|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-18|2015-11-02|2015-07-23||May 2012||2012-05-01|November 2015|2015-11-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||All participants who received at least 1 dose of study drug|Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation|Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation|Terminated||Phase 2|19|Actual|Bristol-Myers Squibb|The study was terminated due to lack of efficacy and slow enrollment of patients.|2||Lack of efficacy and slow accrual|f||||f||||||||||2017-10-11 03:23:06.998564|2017-10-11 03:23:06.998564
NCT01513148|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-09|2013-07-10|2012-06-11||June 2006||2006-06-01|July 2013|2013-07-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||Effects of Light Emitting Diode Irradiation on the Conduction Parameters of the Superficial Radial Nerve|The Effect of Light Therapy on Superficial Radial Nerve Conduction Using a Clustered Array of Infrared Super Luminous and Red Light Emitting Diodes|Completed||N/A|32|Actual|Shenandoah University|4 subjects were terminated early in the project, two from the light therapy group and two from the sham therapy group. All cases, we were unable to achieve an appropriate baseline temperature of 30 degrees celsius to allow continued participation|2|||f||||f||||||||||2017-10-11 03:23:39.275298|2017-10-11 03:23:39.275298
NCT01512160|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-30|2013-05-23|2013-03-14||October 2011||2011-10-01|May 2013|2013-05-01|May 2012|Actual|2012-05-01|March 2012|Actual|2012-03-01||Interventional|||Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain|A Randomized, Double-Blind Third Party Open, Double-Dummy, Parallel Group, Placebo Controlled Study Assessing The Efficacy Of Single Doses Of Pf-04531083 For The Treatment Of Post-Surgical Dental Pain Using Ibuprofen 400 Mg As A Positive Control|Terminated||Phase 2|90|Actual|Pfizer|Study was terminated for futility based on results of interim analysis.|4||See termination reason in detailed description.|f||||t||||||||||2017-10-11 03:23:52.562121|2017-10-11 03:23:52.562121
NCT01511107|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-10|2017-10-05|2016-09-30||January 2012||2012-01-01|October 2017|2017-10-01|October 2015|Actual|2015-10-01|September 2015|Actual|2015-09-01||Interventional||520 children underwent randomization; 260 were randomized to the amoxicillin-clavulante 10 days group and 260 to the amoxicillin-clavulante 5 days, placebo 5 days group. 3 and 2, respectively, were found ineligible after randomization and were withdrawn by the PI. The remaining 257 and 258 participants, respectively, were the basis for analysis.|Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance|A Phase 2b, Multicenter, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Short-Course Antimicrobial Therapy for Young Children With Acute Otitis Media (AOM) and Impact on Antimicrobial Resistance|Terminated||Phase 2|520|Actual|University of Pittsburgh||2||The primary objective of the study was met.|f||||t||||||||||2017-10-11 03:24:11.689787|2017-10-11 03:24:11.689787
NCT01511055|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-12|2015-06-03|||January 2012||2012-01-01|June 2015|2015-06-01|June 2014|Actual|2014-06-01|June 2014|Actual|2014-06-01||Interventional|||Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand|Phase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand|Terminated||Phase 2|21|Actual|Mayo Clinic||1||"Accrual temporarily suspended, followed by study closure due to technical problems with   investigational camera."|f||||t||||||||||2017-10-11 03:24:13.64142|2017-10-11 03:24:13.64142
NCT01510288|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-04|2012-01-10|||November 2004||2004-11-01|January 2012|2012-01-01|November 2011|Actual|2011-11-01|December 2007|Actual|2007-12-01||Interventional|||Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer|A Phase 1 Dose Escalation Trial of Ipilimumab in Combination With CG1940 and CG8711 in Patients With Metastatic Hormone-Refractory Prostate Cancer|Terminated||Phase 1|28|Actual|VU University Medical Center||1||The study was terminated because Cell Genesys stopped all activities for GVAX.|f||||t||||||||||2017-10-11 03:24:25.513193|2017-10-11 03:24:25.513193
NCT01508910|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-10|2016-12-22|2016-12-22||April 2012||2012-04-01|December 2016|2016-12-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional|RENEW|Arms for baseline characteristics based on the Safety population as randomized i.e. randomized participants prior to treatment.|Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina|A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia|Completed||Phase 3|291|Actual|Baxalta US Inc.|Study terminated early due to business considerations. Participants in Treatment or Active Control arms who did not have injection of target cells/placebo assigned to Not Injected Arm. Not included in efficacy analysis but in safety follow-up.|3|||f||||t||||||||||2017-10-11 03:24:48.672841|2017-10-11 03:24:48.672841
NCT01507935|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-05|2012-09-04|||January 2012||2012-01-01|September 2012|2012-09-01|November 2012|Anticipated|2012-11-01|November 2012|Anticipated|2012-11-01||Interventional|ColoR||Colonisation Resistance Study|Randomised, Controlled, Double-blind Exploratory Study to Investigate the Effect of Specific Prebiotic Oligosaccharides on Gut Microbiota Composition in Healthy Infants|Withdrawn||Phase 2|0|Actual|Danone Asia Pacific Holdings Pte, Ltd.||4||The study was withdrawn due to change of the study product formulation.|f||||f||||||||||2017-10-11 03:25:06.622211|2017-10-11 03:25:06.622211
NCT01506232|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-05|2013-10-24|||March 2011||2011-03-01|October 2013|2013-10-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Observational|||Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study|Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study|Terminated||N/A|1|Actual|Massachusetts General Hospital|||4|Due to slow enrollment and lack of funding the study was terminated prior to completion.|f||||f||||||||||2017-10-11 03:25:40.098418|2017-10-11 03:25:40.098418
NCT01505881|ClinicalTrials.gov processed this data on October 10, 2017|2012-01-05|2014-07-10|2014-06-06||December 2011||2011-12-01|July 2014|2014-07-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional||Treated set (TRT): The TRT comprised all patients who were documented to have taken at least 1 dose of study drug|Follow on Study From RE-ALIGN|Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve|Terminated||Phase 2|158|Actual|Boehringer Ingelheim|This study was terminated prematurely due to safety concerns arising during conduct of the trial.|2|||f||||||||||||||2017-10-11 03:25:45.354499|2017-10-11 03:25:45.354499
NCT01502761|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-22|2017-07-26|2017-06-30||March 2012||2012-03-01|July 2017|2017-07-01|May 2016|Actual|2016-05-01|May 2016|Actual|2016-05-01||Interventional||4 patients were enrolled (regional intra-arterial Magnesium 0.75g) before the study was stopped (not due to safety concerns). They were all enrolled in the first group|Intra-arterial Magnesium Administration for Acute Stroke|Intra-arterial Magnesium Therapy: A Novel Platorm for Neuroprotectant Delivery in Acute Stroke|Terminated||Phase 1/Phase 2|4|Actual|University of Southern California|The trial was terminated early (with enrollment only in the first arm) by the investigators due to low enrollment (given results of relevant studies at the time) . There were no safety concerns with the trial or the agent.|4||No safety issues. Low enrollment secondary to negative stroke studies 2013|f||||t||||||||||2017-10-11 03:26:27.23351|2017-10-11 03:26:27.23351
NCT01500382|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-22|2016-08-02|2016-08-02||February 2012||2012-02-01|August 2016|2016-08-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional|||A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)|A Placebo and Active-Comparator Controlled Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of MK-4618 in Patients With Overactive Bladder|Terminated||Phase 1|4|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to insufficient recruitment. Only four participants in total participated in the study with three completing and one discontinuation.|4||This study was terminated early due to insufficient recruitment.|f||||f||||||||||2017-10-11 03:26:58.707702|2017-10-11 03:26:58.707702
NCT01499667|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-18|2014-08-06|2013-11-25||September 2011||2011-09-01|August 2014|2014-08-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Interventional|TOFIINGO|Randomized set includes all subjects who receive a randomization number, regardless of whether or not they receive study medication.|Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod|A 32-week, Patient- and Rater-blinded, Randomized, Multi-center, Parallel-group Study to Evaluate Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis Transferred From Previous Treatment With Natalizumab to Fingolimod (FTY720)|Terminated||Phase 3|142|Actual|Novartis|Study was terminated due to new data on nataluzimab washout prior to treatment with other disease modifying treatments. The power to detect statistically significant differences between the washout groups based on the (-)binomial is estimated 30-40%.|3||"Based on recent publications, determination of natalizumub washout period was no longer   relevant."|f||||f||||||||||2017-10-11 03:27:15.694354|2017-10-11 03:27:15.694354
NCT01499355|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-23|2016-11-22|2016-11-22||July 2012||2012-07-01|November 2016|2016-11-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional|ATLAS||BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis|Terminated||Phase 2|276|Actual|Biogen|Study was terminated based on the review of results following the prespecified, blinded futility analysis, which did not demonstrate sufficient efficacy to warrant continuation of the study. Study was not terminated based on safety considerations.|3||"Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant   continuation of the study."|f||||t||||||||||2017-10-11 03:27:19.994075|2017-10-11 03:27:19.994075
NCT01498705|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-20|2014-01-31|||December 2011||2011-12-01|January 2014|2014-01-01|December 2012|Anticipated|2012-12-01|June 2012|Anticipated|2012-06-01||Observational|||The Natural History of Procalcitonin in Hemorrhagic Stroke|The Natural History of Procalcitonin in Hemorrhagic Stroke|Withdrawn||N/A|0|Actual|CAMC Health System|||1|Anticipated grant was withdrawn and additional funding was unable to be obtained|f||||f||||||Samples Without DNA|"     3 mL of blood will be obtained for each PCT sample and will be sent to the Virology lab at     CAMC Memorial hospital where the serum will be frozen until all samples are collected. After     all samples from each of the 30 patients are obtained, the specimens will be analyzed for the     PCT value and then discarded.   "|||2017-10-11 03:27:39.893407|2017-10-11 03:27:39.893407
NCT01497626|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-20|2016-02-15|||September 2011||2011-09-01|September 2015|2015-09-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional|||Lapatinib and Bortezomib in Patients With Advanced Malignancies|A Phase I Study of the HER1, HER2 Dual Kinase Inhibitor, Lapatinib Plus the Proteosomal Inhibitor Bortezomib in Patients With Advanced Malignancies|Terminated||Phase 1|15|Actual|Georgetown University||1||Drug support withdrawn|f||||t||||||||||2017-10-11 03:28:02.479033|2017-10-11 03:28:02.479033
NCT01497197|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-20|2015-10-12|2015-06-15||May 2012||2012-05-01|October 2015|2015-10-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional||Baseline analysis population included all the subjects randomized in the study.|A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique|A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART)|Terminated||Phase 3|174|Actual|Merck KGaA|Study was terminated as per sponsor's decision.|2||Study was terminated as per sponsor's decision|f||||f||||||||||2017-10-11 03:28:08.154548|2017-10-11 03:28:08.154548
NCT01497119|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-20|2015-11-30|||October 2011||2011-10-01|November 2015|2015-11-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Interventional|||A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-39758979 in Adult Japanese Subjects With Moderate Atopic Dermatitis|Terminated||Phase 2|88|Actual|Janssen Pharmaceutical K.K.||3||This study was terminated prematurely due to 2 cases of agranulocytosis.|f||||f||||||||||2017-10-11 03:28:09.214062|2017-10-11 03:28:09.214062
NCT01496560|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-19|2015-11-16|||November 2015||2015-11-01|November 2015|2015-11-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01|1 Day|Observational [Patient Registry]|||Open Prospective Study for Determination of Predictive Measures for Pain During Colonoscopy|Comparison of Procedural Sequence in Same Day Consecutive Bidirectional Endoscopy Using Moderate Sedation: A Prospective Randomized Study|Withdrawn||N/A|0|Actual|Sheba Medical Center|||1|study terminated due toTechnical issue pre -recruiting|f||||f||||||||||2017-10-11 03:28:17.505578|2017-10-11 03:28:17.505578
NCT01495988|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-09|2017-05-30|2017-05-30||August 2013||2013-08-01|May 2017|2017-05-01|June 2016|Actual|2016-06-01|January 2016|Actual|2016-01-01||Interventional|||Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma|Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma|Terminated||Phase 2|10|Actual|Melanoma Research Foundation Breakthrough Consortium|The study was terminated prematurely on June 13, 2016. No further accrual to the study will occur.|2||Slow accrual; toxicity; change in priorities|f||||t||||||||||2017-10-11 03:28:28.486004|2017-10-11 03:28:28.486004
NCT01493882|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-15|2012-05-10|||March 2012||2012-03-01|May 2012|2012-05-01|June 2015|Anticipated|2015-06-01|June 2015|Anticipated|2015-06-01||Interventional|||Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, 2-Part Study of JNJ-39758979 in Symptomatic Adult Subjects With Uncontrolled, Persistent Asthma|Withdrawn||Phase 2|0|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4||"Study was withdrawn due to 2 cases of agranulocytosis in a different clinical trial with this   same drug."|f||||t||||||||||2017-10-11 03:29:15.360062|2017-10-11 03:29:15.360062
NCT01492894|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-09|2016-12-08|||January 2008||2008-01-01|December 2016|2016-12-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|KADWORC||Kidney Allograft Dysfunction Without Reversible Causes|A Randomized Controlled Trial of Reducing Calcineruin Inhibitor Target Level by 50% Versus Converting to Rapamycin in Chronic Kidney Dysfunction Without Reversible Causes|Withdrawn||Phase 4|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||study terminated due to low enrollment|f||||f||||||||||2017-10-11 03:29:31.251819|2017-10-11 03:29:31.251819
NCT01492322|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-02|2015-10-07|||November 2011||2011-11-01|December 2011|2011-12-01|October 2014|Actual|2014-10-01|July 2013|Actual|2013-07-01||Observational|DDAT||SPECT Imaging of DAT Genotype|Use of SPECT (Single-photon Emission Computed Tomography) to Examine the Role of DAT (Dopamine Transporter) Genotype in Motivated Smoking Behavior|Terminated||Phase 1|14|Actual|University of Pennsylvania|||1|UPenn suspended production of the ligand necessary to produce the tracer TRODAT.|f||||f||||||||||2017-10-11 03:29:42.620068|2017-10-11 03:29:42.620068
NCT01489956|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-01|2016-03-11|2015-12-24||December 2011||2011-12-01|March 2016|2016-03-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional||Enrolled Sample|A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)|Pilot Study to Determine the Immunogenicity of Immucothel® and Oral Tolerance Induction With Biosyn Native KLH in Healthy Subjects (ITN047AI)|Terminated||Early Phase 1|19|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Data from 4 of the 5 evaluable subjects in Part B was negative for tolerance to KLH as defined by a stimulation index <3 on day 42 after booster immunization. The study was terminated. Data were not collected and no analyses were performed.|3||Due to futility, identified after 5 subjects completed treatment in Part B|f||||t||||||||||2017-10-11 03:30:34.449123|2017-10-11 03:30:34.449123
NCT01488877|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-06|2013-09-24|2013-07-18||January 2012||2012-01-01|September 2013|2013-09-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional|||A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy|A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria|Terminated||Phase 1|6|Actual|Pfizer|Study was terminated prematurely; this was based on a strategic decision by the sponsor to terminate further development of this compound for proposed indication. The study was not terminated for safety or lack of efficacy reasons.|3||See termination reason in detailed description.|f||||f||||||||||2017-10-11 03:30:57.284013|2017-10-11 03:30:57.284013
NCT01488110|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-02|2013-06-17|||January 2012||2012-01-01|June 2013|2013-06-01||||||||Interventional|||Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine|Undersökning av ny Behandlingsmetod Vid migränanfall (Evaluation of a New Treatment for Migraine Attacks)|Terminated||N/A|40|Anticipated|Karolinska University Hospital||2||"Too slow recruitment rate. The study has been terminated and will be re-started with an   improved and more suitable study design."|f||||f||||||||||2017-10-11 03:31:09.592023|2017-10-11 03:31:09.592023
NCT01487746|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-05|2011-12-06|||December 2011||2011-12-01|December 2011|2011-12-01|September 2012|Anticipated|2012-09-01|March 2012|Anticipated|2012-03-01||Observational|||Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls|Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls.|Unknown status|Not yet recruiting|N/A|207|Anticipated|Meir Medical Center|||2||f||||f||||||Samples Without DNA|"     Serum samples of Stroke patients withdrawned within 36 hrs since stroke evoked. Healthy     controls   "|||2017-10-11 03:31:17.780189|2017-10-11 03:31:17.780189
NCT01486966|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-05|2017-02-09|2013-04-22||November 2011||2011-11-01|February 2017|2017-02-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes|A 2-week, Randomised, Controlled, Open-label, Two-group Parallel, Multi-centre Trial Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin Both in a Basal Bolus Regimen With or Without Metformin in Chinese Inpatients With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment|Terminated||Phase 4|58|Actual|Novo Nordisk A/S|The size of population analysed in study was smaller than that planned in the protocol. Therefore, the superiority of experimental products to comparator could not be concluded with sufficient statistical power.|2||Trial terminated prematurely due to slow recruitment.|f||||f||||||||||2017-10-11 03:31:26.468147|2017-10-11 03:31:26.468147
NCT01486043|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-30|2015-01-20|2015-01-13||December 2011||2011-12-01|January 2015|2015-01-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional|||Metformin and Transient Hyperglycemia|Metformin as an Adjunctive Therapy For Transient Hyperglycemia in Patients With Acute Lymphoblastic Leukemia During Induction Chemotherapy|Terminated||N/A|4|Actual|Children's Hospital Los Angeles|Early termination leading to small numbers of subjects analyzed.|1||"The research project was terminated due to lower than projected patient recruitment within the   period of time allowed for the study."|f||||t||||||||||2017-10-11 03:31:39.759296|2017-10-11 03:31:39.759296
NCT01485874|ClinicalTrials.gov processed this data on October 10, 2017|2011-12-02|2016-08-04|||November 2011||2011-11-01|August 2016|2016-08-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional|||Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer|A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149|Terminated||Phase 1|11|Actual|Hoosier Cancer Research Network||1||Funding withdrawn due to drug unavailability|f||||t||||||||||2017-10-11 03:31:43.328662|2017-10-11 03:31:43.328662
NCT01485536|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-29|2016-11-28|2016-11-28||August 2012||2012-08-01|December 2015|2015-12-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional|||A Study of the HSP90 Inhibitor AUY922|A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma|Terminated||Phase 2|21|Actual|M.D. Anderson Cancer Center|Although the study surpassed the first futility endpoint for DLBCL cohort, it was terminated early due to limited responses and significant toxicities witnessed in the entire cohort of the study.|1||Study halted early due to limited response.|f||||f||||||||||2017-10-11 03:31:47.514345|2017-10-11 03:31:47.514345
NCT01485094|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-05|2014-09-30|2014-09-16||February 2012||2012-02-01|September 2014|2014-09-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional||Intention-to-treat|A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain|Evaluation of the Efficacy, Tolerability, and Safety of 7 Days of Treatment With GRT6010 or Pregabalin in Comparison to Placebo in Subjects With Peripheral Neuropathic Pain.|Terminated||Phase 2|114|Actual|Grünenthal GmbH||3||"The trial was early terminated after it was concluded that there was no added benefit from   exposing further participants after an unblinded interim analysis."|f||||f||||||||||2017-10-11 03:31:56.698378|2017-10-11 03:31:56.698378
NCT01484314|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-30|2017-02-01|2016-09-23||April 2012|Actual|2012-04-01|February 2017|2017-02-01|September 2015|Actual|2015-09-01|September 2014|Actual|2014-09-01||Interventional|||Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma|A Phase II Study of Eltrombopag for the Treatment of Thrombocytopenia in Patients Undergoing Therapy for Relapsed Multiple Myeloma|Terminated||Phase 2|1|Actual|Dana-Farber Cancer Institute|The study is limited because it terminated early with only 1 patient enrolled.|1||Low accrual.|f||||t|t|f||||||No||2017-10-11 03:32:11.301139|2017-10-11 03:32:11.301139
NCT01483183|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-29|2017-02-24|2016-10-04||November 2011||2011-11-01|February 2017|2017-02-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional|CADENCE 215||Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation|A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects With Paroxysmal and Persistent Atrial Fibrillation|Terminated||Phase 1|40|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|The trial was terminated after Part 1 enrollment completed. It did not progress due to many factors including slow enrollment, limited site activity in pre-screening, absence of reproducible efficacy signal and increased costs.|4||Enrollment Difficulty|f||||f||||||||||2017-10-11 03:32:34.329976|2017-10-11 03:32:34.329976
NCT01482325|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-28|2016-08-08|2015-07-06||November 2011||2011-11-01|August 2016|2016-08-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|SNIPE|No analysis was performed, study prematurely terminated.|SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement|SNIPE:SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement|Terminated||N/A|31|Actual|GE Healthcare||1||The business decided not to pursue the study at this time.|f||||f||||||||||2017-10-11 03:32:51.072605|2017-10-11 03:32:51.072605
NCT01481012|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-07|2011-11-23|||January 2006||2006-01-01|November 2011|2011-11-01|July 2007|Actual|2007-07-01|July 2007|Actual|2007-07-01||Observational|||The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices|The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices|Terminated||N/A|94|Actual|Icahn School of Medicine at Mount Sinai|||4|Slow enrollment - terminated for futility.|f||||t||||||Samples Without DNA|"     Blood for the following markers of thrombin generation and platelet function will be drawn,     spun, aliquoted and stored for later batched analysis: - Thrombo-antithrombin complex (TAT);     - Prothrombin Fragment 1+2 (F1.2); - Thromboelastrograph (TEG) (performed at the clinical     site when available); - Additional markers of coagulation and platelet activation (for future     consideration) - 4ml of plasma frozen in 1ml aliquots.   "|||2017-10-11 03:33:13.215037|2017-10-11 03:33:13.215037
NCT01480388|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-23|2016-11-30|||December 2011||2011-12-01|November 2016|2016-11-01|March 2014|Anticipated|2014-03-01|March 2014|Anticipated|2014-03-01||Interventional|||A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate|A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ-39758979 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy|Withdrawn||Phase 2|0|Actual|Janssen Research & Development, LLC||5||"Study was terminated prematurely due to 2 cases of agranulocytosis in a different clinical   trial with this same drug."|f||||t||||||||||2017-10-11 03:33:21.770051|2017-10-11 03:33:21.770051
NCT01479309|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-21|2011-11-23|||September 2006||2006-09-01|November 2011|2011-11-01|February 2010|Actual|2010-02-01|February 2010|Actual|2010-02-01||Interventional|||Study to Evaluate Sodium Stibogluconate With Interferon Alpha-2b|A Phase IIa, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination With Interferon Alpha-2b for Patients With Advanced Malignancies|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Pharmaceutical sponsor terminated study.|f||||f||||||||||2017-10-11 03:33:51.605115|2017-10-11 03:33:51.605115
NCT01479231|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-22|2012-04-18|||March 2012||2012-03-01|April 2012|2012-04-01|March 2012|Actual|2012-03-01|March 2012|Actual|2012-03-01||Interventional|||Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis|Predictors of PPI Response in Eosinophilic Esophagitis|Withdrawn||Phase 1/Phase 2|0|Actual|Mayo Clinic||1||Souces of funding have been terminated|f||||t||||||||||2017-10-11 03:33:52.97814|2017-10-11 03:33:52.97814
NCT01478386|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-21|2013-07-22|||December 2011||2011-12-01|July 2013|2013-07-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|||Effectiveness of a Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis|Randomized Trail to Assess the Effectiveness of an Off-Loading Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis|Terminated||N/A|11|Actual|OAD Orthopaedics||3||The study was terminated due to poor enrollment|f||||f||||||||||2017-10-11 03:35:07.927856|2017-10-11 03:35:07.927856
NCT01478087|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-07|2013-02-12|2013-01-08||November 2011||2011-11-01|February 2013|2013-02-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)|Pilot Study of Immunoadsorption Therapy for Patients With Chronic Non-Ischemic Dilated Cardiomyopathy|Terminated||N/A|2|Actual|Asahi Kasei Medical Co., Ltd.||1||Sponsor terminated due to business reasons|f||||t||||||||||2017-10-11 03:35:11.616131|2017-10-11 03:35:11.616131
NCT01477853|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-19|2017-05-25|2016-06-21||October 24, 2011|Actual|2011-10-24|May 2017|2017-05-01|December 4, 2012|Actual|2012-12-04|December 4, 2012|Actual|2012-12-04||Interventional|||A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)|A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy|Terminated||Phase 3|166|Actual|Merck Sharp & Dohme Corp.|The study was terminated early by the Sponsor for business reasons. Due to the small number of participants included in the FAS, the results for Phase A and for the overall study should be interpreted with caution.|3||The study was terminated early by the Sponsor for business reasons.|f||||f||||||||||2017-10-11 03:35:15.102052|2017-10-11 03:35:15.102052
NCT01476085|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-01|2013-06-27|||July 2011||2011-07-01|June 2013|2013-06-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|||Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)|An Open-label Study to Evaluate the Utility of the Apoptosis Imaging Biomarker 18F]ML10 to Assess the Response to Chemotherapy in Patients With Non-Hodgkin's Lymphoma(NHL).|Terminated||Phase 1|1|Actual|GlaxoSmithKline||1||"Study terminated as ongoing analysis suggested objectives not practical to achieve with study   as implemented"|f||||f||||||||||2017-10-11 03:35:37.461949|2017-10-11 03:35:37.461949
NCT01475305|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-14|2017-07-20|2017-04-05||October 20, 2011|Actual|2011-10-20|July 2017|2017-07-01|December 13, 2012|Actual|2012-12-13|December 3, 2011|Actual|2011-12-03||Interventional||The Intent-to-treat (ITT) population included all participants who were randomized into the study.|Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)|A Phase 1 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of MEDI-557 in Healthy Adults Intranasally Challenged With Respiratory Syncytial Virus (RSV)|Terminated||Phase 1|7|Actual|MedImmune LLC|The study was terminated before an adequate number of subjects were enrolled.|2||"The study was terminated as it was determined to not be feasible to complete enrollment and the   study within the required timeline and budget."|f||||f||||||||||2017-10-11 03:36:03.064951|2017-10-11 03:36:03.064951
NCT01475253|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-03|2015-08-19|2014-08-05||November 2011||2011-11-01|August 2015|2015-08-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|||Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis|A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® in Women With Interstitial Cystitis Followed by an Open Label Extension|Terminated||Phase 2|104|Actual|Allergan|As per protocol, efficacy analyses were not performed for the Sham Cytoscopic Procedure-Randomized Study Arm/Group. Only safety analyses were completed.|3||This study was not enrolled completely and was terminated.|f||||t||||||||||2017-10-11 03:36:04.538357|2017-10-11 03:36:04.538357
NCT01474434|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-09|2016-03-16|2015-06-04||December 2011||2011-12-01|March 2016|2016-03-01|June 2014|Actual|2014-06-01|June 2014|Actual|2014-06-01||Interventional||The safety analysis set included all patients who received at least one dose of study drug.|Efficacy of LCQ908 on Cardiovascular Risk|A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of LCQ908 on Cardiovascular Risk|Terminated||Phase 2|41|Actual|Novartis|The study was terminated based on the interim analysis on Part A, Cohort 1 after patients completed Part A. Part B was not conducted. Not all the planned assessments were completed due to the termination|2||The study was terminated based on interim analysis. See detailed description.|f||||||||||||||2017-10-11 03:36:27.918728|2017-10-11 03:36:27.918728
NCT01474200|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-11|2017-04-04|2015-07-23||January 2012||2012-01-01|April 2017|2017-04-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|AVOID-HF|3 patients in the IV Loop Diuretics (LD) arm were randomized, but withdrawn from the study prior to beginning study treatment. These patients are excluded from the number of baseline participants (analysis population).|Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment|Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure (AVOID-HF)|Terminated||N/A|224|Actual|Baxter Healthcare Corporation|Due to patient recruitment challenges, the study was terminated early. At that time, no interim analyses of the data had been completed; therefore the decision to close the study was not related to any underlying concerns about safety or futility.|2||"Closed due to patient recruitment challenges. No interim analyses were completed; study closure   was not related to any concerns about safety or futility."|f||||t||||||||||2017-10-11 03:36:35.235589|2017-10-11 03:36:35.235589
NCT01471379|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-10|2017-03-15|2013-07-03||April 2012||2012-04-01|March 2017|2017-03-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional||The study was terminated early resulting in a small number of subjects enrolled leaving the ability to analyze only certain categories.|Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Milnacipran in the Treatment of Irritable Bowel Syndrome|Terminated||Phase 2|2|Actual|University of North Carolina, Chapel Hill||3||Due to recruitment difficulties the study is terminated.|f||||f||||||||||2017-10-11 03:37:35.386416|2017-10-11 03:37:35.386416
NCT01468623|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-01|2013-01-29|||September 2011||2011-09-01|January 2013|2013-01-01|December 2016|Anticipated|2016-12-01|September 2016|Anticipated|2016-09-01||Interventional|PROFUSE||Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6|A Prospective, Randomized, Open-label Trial Comparing OnDose® AUC Optimized 5-FU Based Administration Versus Standard Body Surface Area (BSA) Dosing in Metastatic Colorectal Cancer Patients (mCRC) Treated With mFOLFOX6|Terminated||Phase 4|51|Actual|Myriad Genetic Laboratories, Inc.||2||Study terminated due to slow enrollment.|f||||t||||||||||2017-10-11 03:38:23.781112|2017-10-11 03:38:23.781112
NCT01467505|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-03|2015-06-01|2015-05-02||February 2012||2012-02-01|June 2015|2015-06-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional||Full analysis set included all participants who received at least 1 dose of study drug.|An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients|A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation|Terminated||Phase 2|61|Actual|Vertex Pharmaceuticals Incorporated|It was decided by Sponsor on 13 January 2014 to terminate the study early at the primary efficacy endpoint (SVR12) as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.|2||"The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify   the drug development plan."|f||||f||||||||||2017-10-11 03:38:48.734199|2017-10-11 03:38:48.734199
NCT01467414|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-31|2013-11-26|||October 2011||2011-10-01|November 2013|2013-11-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1250 in Japanese Subjects With Type 2 Diabetes|Terminated||Phase 1|1|Actual|Novo Nordisk A/S||1||This trial was terminated due to low recruitment|f||||f||||||||||2017-10-11 03:38:56.617751|2017-10-11 03:38:56.617751
NCT01466764|ClinicalTrials.gov processed this data on October 10, 2017|2011-11-01|2017-07-10|2017-06-06||October 2011||2011-10-01|July 2017|2017-07-01|June 2013|Actual|2013-06-01|May 2013|Actual|2013-05-01||Interventional|||Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain|Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain|Terminated||N/A|13|Actual|Stanford University|The trial terminated early. We did not expect to see an effect in such a small number of subjects.|2||Due to inability to demonstrate benefit in this patient population.|f||||t||||||||||2017-10-11 03:39:05.613687|2017-10-11 03:39:05.613687
NCT01464021|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-31|2014-02-03|2013-12-11||December 2011||2011-12-01|February 2014|2014-02-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Observational|||A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China|A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China|Terminated||N/A|26|Actual|AbbVie|The study was terminated early due to low enrollment and high drop-out rate. Only serious adverse events and events leading to discontinuation were collected.||1|This study was prematurely terminated due to low enrollment|f||||f||||||Samples Without DNA|"     Whole blood, serum   "|||2017-10-11 03:39:58.711833|2017-10-11 03:39:58.711833
NCT01459913|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-24|2015-05-14|2015-01-26||November 2011||2011-11-01|May 2015|2015-05-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|CONCISE|Full Analysis (FA) Set included all subjects who received at least 1 dose of study drug and fulfilled all relevant inclusion criteria. One subject from “Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)” was excluded from the FA Set due to having HCV Genotype 6.|Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype|A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype|Terminated||Phase 3|239|Actual|Vertex Pharmaceuticals Incorporated|The study was terminated early at the primary efficacy endpoint (SVR12), by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.|4||"The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify   the drug development plan."|f||||f||||||||||2017-10-11 03:41:15.353368|2017-10-11 03:41:15.353368
NCT01459159|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-11|2013-11-20|||October 2011||2011-10-01|November 2013|2013-11-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional|||Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome|Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome|Terminated||Phase 2|162|Anticipated|Telik||1||Study TLK199.2108 was terminated for business reasons.|f||||f||||||||||2017-10-11 03:41:33.634372|2017-10-11 03:41:33.634372
NCT01458561|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-07|2015-04-29|2013-07-05||October 2010||2010-10-01|April 2015|2015-04-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Interventional|BARRIER||Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery|An Investigational Plan Evaluating the Operative Management of Parenchymal Bleeding By Means of an Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery|Terminated||Phase 3|1|Actual|CryoLife, Inc.|Early termination leading to small number of subjects evaluated (n=1).|2||Sponsor terminated due to signif. difficulty with pilot investigation enrollment|f||||t||||||||||2017-10-11 03:41:45.661062|2017-10-11 03:41:45.661062
NCT01453387|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-09|2017-03-27|2016-04-08||September 2011||2011-09-01|March 2017|2017-03-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional||Safety analysis set included all subjects who received at least one administration of the trial medication.|MSC2015103B in Solid Tumors|A Phase I Dose-Escalation First-In-Human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral MEK Inhibitor MSC2015103B Administered With Two Different Treatment Schedules in Subjects With Advanced Solid Tumors|Terminated||Phase 1|28|Actual|EMD Serono|The study was terminated early during Part 1 of the trial due to administrative reason. Pharmacodynamics evaluations were not performed due to early termination.|2||Due to an administrative reason|f||||f||||||||||2017-10-11 03:43:29.376489|2017-10-11 03:43:29.376489
NCT01452347|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-11|2014-07-11|2014-05-23||October 2011||2011-10-01|July 2014|2014-07-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|RE-ALIGN|Treated Set (TRT): The set of patients who received at least 1 dose of study medication|Dabigatran Etexilate in Patients With Mechanical Heart Valves|A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt|Terminated||Phase 2|328|Actual|Boehringer Ingelheim|This study was terminated prematurely due to safety concerns arising during conduct of the trial.|2|||f||||||||||||||2017-10-11 03:43:49.640512|2017-10-11 03:43:49.640512
NCT01452152|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-10|2016-05-19|2016-02-18||February 2012||2012-02-01|March 2016|2016-03-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|PAPI-2||Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study|Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy|Terminated||Phase 4|9|Actual|University of Maryland|The study was terminated early by the sponsor due to low enrollment.|3||Terminated by study sponsor.|f||||t||||||||||2017-10-11 03:43:51.779213|2017-10-11 03:43:51.779213
NCT01451437|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-11|2017-05-18|2016-02-05||November 18, 2011|Actual|2011-11-18|May 2017|2017-05-01|September 5, 2014|Actual|2014-09-05|September 5, 2014|Actual|2014-09-05||Interventional|||Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)|A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination With Chemotherapy in Subjects With Refractory or Recurrent Acute Myelogenous Leukemia (Protocol No. P07649 (005))|Terminated||Phase 1|26|Actual|Merck Sharp & Dohme Corp.||9||The study was terminated early due to business reasons.|f||||f||||||||||2017-10-11 03:44:06.968899|2017-10-11 03:44:06.968899
NCT01450410|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-07|2013-01-28|||July 2012||2012-07-01|November 2011|2011-11-01|May 2013|Anticipated|2013-05-01|March 2013|Anticipated|2013-03-01||Interventional|11MSP011||Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL|Efecto Del ácido nicotínico Sobre la composición de Las lipoproteínas de Alta Densidad (HDL) y la función Del Endotelio Arterial en Los Pacientes Con cardiopatía isquémica Prematura y Concentraciones Elevadas de Colesterol-HDL|Terminated||Phase 4|12|Actual|Hospital Universitari de Bellvitge||2||Study terminated (halted prematurely) as recomended by the drug supplier and medical agencies|f||||t||||||||||2017-10-11 03:44:28.866883|2017-10-11 03:44:28.866883
NCT01449539|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-06|2015-02-20|2014-11-21||February 2012||2012-02-01|February 2015|2015-02-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization|Pilot Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization|Terminated||N/A|8|Actual|University of Arkansas|Study was terminated early because the site that administered the hyperbaric oxygen treatment closed and an alternative site could not be identified. Only four subjects completed the trial.|1||"Study was terminated early because the site that administered the hyperbaric oxygen treatment   closed and an alternative site could not be identified."|f||||t||||||||||2017-10-11 03:44:42.962896|2017-10-11 03:44:42.962896
NCT01448629|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-18|2012-02-06|||May 2011||2011-05-01|February 2012|2012-02-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional|||Safety and Performance of a New 1-piece Ostomy Product Compared to Standard Care Ostomy Products in Subjects Ileostomy|An Open-labelled, Randomised, Controlled, Comparative, Explorative, Cross-over Study Investigating Safety and Performance of a New 1-piece Ostomy Product Compared Standard Care Ostomy Products in Subjects With Ileostomy|Withdrawn||N/A|0|Actual|Coloplast A/S||2||The study was withdrawn because of problems found with the baseplate|f||||f||||||||||2017-10-11 03:45:20.649946|2017-10-11 03:45:20.649946
NCT01448486|ClinicalTrials.gov processed this data on October 10, 2017|2011-10-05|2016-05-19|2013-11-13||October 2011||2011-10-01|May 2016|2016-05-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional|HANDral||A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV|A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Raltegravir in HIV Virally Suppressed Patients With Cognitive Impairment|Terminated||Phase 4|6|Actual|St Vincent's Hospital, Sydney|Early termination leading to incomplete dataset with sample size too small to produce any meaningful statistical analysis.|2||Funding withdrawn based on unacceptably slow recruitment rate.|f||||t||||||||||2017-10-11 03:45:22.44885|2017-10-11 03:45:22.44885
NCT01446796|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-14|2015-02-19|2013-06-21||September 2011||2011-09-01|February 2015|2015-02-01|October 2012|Actual|2012-10-01|May 2012|Actual|2012-05-01||Interventional||Study terminated early|Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)|Hemodynamic and Clinical Effects of Continuous Right Ventricular Pacing in the Early Post-operative Period After Left Ventricular Assist Device Implantation|Terminated||Phase 4|3|Actual|Duke University||2||Recruitment futility|f||||t||||||||||2017-10-11 03:45:53.658229|2017-10-11 03:45:53.658229
NCT01442337|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-16|2014-06-17||2014-06-17|December 2011||2011-12-01|June 2014|2014-06-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|||A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients|A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de Novo Kidney Transplant Recipients|Terminated||Phase 2/Phase 3|21|Actual|Astellas Pharma Inc||4||Study was terminated by sponsor decision|f||||t||||||||||2017-10-11 03:47:07.75236|2017-10-11 03:47:07.75236
NCT01441765|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-22|2016-12-15|2016-07-28||November 2011||2011-11-01|December 2016|2016-12-01|July 2016|Actual|2016-07-01|July 2016|Actual|2016-07-01||Interventional|||PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine|Phase II Study of PD-1 Blockade Alone or In Conjunction With the Dendritic Cell (DC)/Renal Cell Carcinoma (RCC) Fusion Cell Vaccination|Terminated||Phase 2|11|Actual|Dana-Farber Cancer Institute|Due to lack of funding, the study was terminated early without completing enrollment.|2||Funding|f||||t||||||||||2017-10-11 03:47:23.942783|2017-10-11 03:47:23.942783
NCT01441414|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-26|2015-12-11|2015-03-27|2014-04-30|November 2011||2011-11-01|December 2015|2015-12-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional||The full analysis (FA) set was the primary population for evaluating all safety and efficacy endpoints per the treatment randomization as well as participant characteristics.|PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma|A Phase II Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (ANG-2) Inhibitor In Combination With AG-013736 (Axitinib) In Patients With Previously Treated Metastatic Renal Cell Carcinoma|Terminated||Phase 2|18|Actual|Pfizer|On 06 Nov 2012, based on Part I safety findings and due to strategic considerations, Pfizer decided not to open enrolment onto Part II of the study and terminated the study. For primary OM, AEs reported in ≥2 participants overall are presented.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 03:47:29.887189|2017-10-11 03:47:29.887189
NCT01441193|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-26|2016-03-03|||September 2011||2011-09-01|March 2016|2016-03-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|||A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)|A Phase I, Open Label, Safety and Immunogenicity Vaccine Trial Based on the Association of Recombinant HIV-1 Biologically Active Tat and V2-deleted Env Proteins in HIV Uninfected Healthy Adult Volunteers.|Terminated||Phase 1|11|Actual|Istituto Superiore di Sanità||4||"Enrollments were suspended due to delta-V2 Env unavailability, following the   EMA/CHMP/BWP/534898/2008 guideline, not allowing the use of a retest date"|f||||t||||||||||2017-10-11 03:47:34.41012|2017-10-11 03:47:34.41012
NCT01439958|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-22|2015-04-13|||February 2012||2012-02-01|April 2015|2015-04-01|December 2014|Actual|2014-12-01|July 2013|Actual|2013-07-01||Interventional|||Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)|A Long-term Safety Follow-up Study of L-CsA Therapy for Patients Who Participated in Study 12011.201 and Volunteered to Continue or to Cross-over to L-CsA Inhalation Therapy|Terminated||Phase 3|14|Actual|Pari Pharma GmbH||1||Core study 12011.201 was terminated.|f||||f||||||||||2017-10-11 03:48:06.720853|2017-10-11 03:48:06.720853
NCT01438372|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-14|2014-01-04|||November 2011||2011-11-01|September 2011|2011-09-01|March 2012|Anticipated|2012-03-01|February 2012|Anticipated|2012-02-01||Interventional|||IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD|Intravenous Iron Sucrose Versus Oral Ferrous Sulfate in Treating Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease|Withdrawn||Phase 2|0|Actual|Wayne State University||2||"The study was terminated prior to enrolling patients as we were unable to secure enough funding   to complete the study."|f||||t||||||||||2017-10-11 03:48:40.759563|2017-10-11 03:48:40.759563
NCT01438151|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-20|2014-03-04|2014-01-06||December 2011||2011-12-01|March 2014|2014-03-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|||Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease|Association of Serum Infliximab and Antibodies Toward Infliximab (ATI) to Clinical Outcomes in Crohn's Disease|Terminated||N/A|11|Actual|Icahn School of Medicine at Mount Sinai|Study was terminated without completion due to poor enrollment.|1||terminated due to poor enrollment|f||||f||||||||||2017-10-11 03:48:44.508731|2017-10-11 03:48:44.508731
NCT01437943|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-20|2017-03-21|2017-01-15||April 2010||2010-04-01|March 2017|2017-03-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients|P-MR Spectroscopy Evaluation of the Effect of Short-Term Treatment With Aliskiren on Kidney β-ATP/Pi Level in Kidney Transplant Patients|Terminated||Phase 4|10|Actual|Brigham and Women's Hospital|In December 2011, all studies involving Aliskiren were terminated by Novartis after interim analysis of the ALTITUDE trial.|2||"Novartis has have decided to terminate all clinical investigator-initiated research projects   involving aliskiren"|f||||f||||||||||2017-10-11 03:48:51.328889|2017-10-11 03:48:51.328889
NCT01436643|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-16|2014-09-24|2014-09-01||November 2011||2011-11-01|September 2014|2014-09-01|September 2013|Actual|2013-09-01|September 2013|Actual|2013-09-01||Interventional|REGAIN|The safety set was used for analysis, which consists of 54 patients, of whom 2 patients did not start treatment with any antidepressant|Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression|A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression|Terminated||Phase 4|54|Actual|Novartis||3||Due to slow enrollment the study was terminated early|f||||||||||||||2017-10-11 03:49:14.855656|2017-10-11 03:49:14.855656
NCT01436175|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-15|2015-02-05|2015-02-05||February 2012||2012-02-01|March 2014|2014-03-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional||Safety analysis set included all participants who took at least 1 dose of investigational product and had at least 1 post-Visit 0 (Week 0) safety assessment in this study.|SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study|A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant|Terminated||Phase 3|1570|Actual|Shire|The study was terminated on 11 Feb 2014. SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.|1||"SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination   was not related to any new safety findings."|f||||||||||||||2017-10-11 03:49:26.72432|2017-10-11 03:49:26.72432
NCT01436123|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-14|2015-05-17|||December 2010||2010-12-01|May 2015|2015-05-01|October 2012|Actual|2012-10-01|July 2012|Actual|2012-07-01||Interventional|NANOM PCI||Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting|Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis With The Use of Gold Nanoparticles With Iron Oxide-Silica Shells Versus Stenting|Terminated||Phase 1|62|Actual|Ural Medical University||2||"The study was terminated under the political pressure of the Federal Security Service of the   Russian Federation (FSB) and the Russian Society of Cardiology"|f||||t||||||||||2017-10-11 03:49:30.310666|2017-10-11 03:49:30.310666
NCT01434511|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-13|2015-06-26|2014-12-11||August 2011||2011-08-01|December 2014|2014-12-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional||This study was terminated early and only enrolled one participant. Due to concerns that the participant would be at risk of being re-identified, study results are not posted. The decision to terminate this study was not related to any safety and/or efficacy concern of OBI-1 in the indication described within this study (Congenital Hemophilia A).|Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A|Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients With Congenital Hemophilia A With Factor VIII Inhibitors|Terminated||Phase 3|1|Actual|Baxalta US Inc.||1|||f||||t||||||||||2017-10-11 03:50:00.177137|2017-10-11 03:50:00.177137
NCT01432106|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-08|2013-11-14|||February 2011||2011-02-01|November 2013|2013-11-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|SAAVE||The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome|A Randomized, Double Blind, Active Comparator, Parallel-group Study to Determine Whether the Combination of Valsartan and Aliskiren Provides Cardioprotection in African American Patients With Hypertension and Elements of the Metabolic Syndrome|Withdrawn||Phase 1|0|Actual|University of Michigan||2||"Novartis terminated all projects involving aliskiren. Findings of the DMC overseeing the   ALTITUDE clinical trial found a higher incidence of adverse events."|f||||f||||||||||2017-10-11 03:50:42.194384|2017-10-11 03:50:42.194384
NCT01430988|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-07|2012-05-02|||September 2011||2011-09-01|May 2012|2012-05-01|April 2012|Actual|2012-04-01|April 2012|Actual|2012-04-01||Observational|||Observational Study of the BrainScope® Ahead™ M-100 in UK Emergency Department Patients With Head Injury|An Observational Clinical Study of the BrainScope® Ahead™ M-100 Hand Held Electroencephalogram in Emergency Department Patients With Head Injury (B-AHEAD UK Trial)|Terminated||N/A|318|Actual|BrainScope Company, Inc.|||3|"The trial was terminated prematurely following a suspected data processing concern in the study   device. The concern did not pose a patient safety issue."|f||||f||||||||||2017-10-11 03:51:16.827271|2017-10-11 03:51:16.827271
NCT01430585|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-18|2014-07-18|2014-07-18||March 2012||2012-03-01|July 2014|2014-07-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|||Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer|An Open-Label, Randomised Phase 1b/2 Study Of PF-04691502 In Combination With Letrozole Compared With Letrozole Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Early Breast Cancer|Terminated||Phase 2|14|Actual|Pfizer|Study was prematurely terminated due to PF-04691502 tolerability findings that prompted Sponsor to re-evaluate strategic goals of program. Unexpected frequency of severe skin toxicity was observed and no participant was enrolled in phase 2 of study.|3||See termination reason in detailed description.|f||||f||||||||||2017-10-11 03:51:22.286347|2017-10-11 03:51:22.286347
NCT01428505|ClinicalTrials.gov processed this data on October 10, 2017|2011-09-01|2016-02-04|||July 2011||2011-07-01|February 2016|2016-02-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|||[18F]PBR111 and Microglial Activation in Multiple Sclerosis|A Study to Characterize the Novel TSPO PET Radioligand [18F]PBR111 as an in Vivo Marker of Microglial Activation in Multiple Sclerosis|Terminated||Phase 2|50|Actual|GlaxoSmithKline||1||The Study was terminated because there was insufficient data to complete the study objectives|f||||f||||||||||2017-10-11 03:51:56.104227|2017-10-11 03:51:56.104227
NCT01426113|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-29|2015-09-02|2015-06-29||September 2011||2011-09-01|September 2015|2015-09-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional|||A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma||Terminated||Phase 3|6|Actual|Allergan||2||Study terminated due to corporate decision.|f||||t||||||||||2017-10-11 03:52:43.808861|2017-10-11 03:52:43.808861
NCT01426035|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-09|2013-03-01|||September 2014||2014-09-01|March 2013|2013-03-01|February 2015|Anticipated|2015-02-01|December 2014|Anticipated|2014-12-01||Interventional|||Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate Cream In The Superficial Varicose Veins Treatment|Phase III of Safety and Efficacy Study of Topic Mucopolysaccharide Polysulfate Cream 5mg/g in the Superficial Varicose Veins Treatment|Suspended||Phase 3|76|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2017-10-11 03:52:44.593448|2017-10-11 03:52:44.593448
NCT01425294|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-19|2017-02-17|||August 2011||2011-08-01|February 2017|2017-02-01|January 2016|Actual|2016-01-01|January 2016|Actual|2016-01-01||Observational|||Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment|A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice|Terminated||N/A|231|Actual|AstraZeneca|||1|"The study has been decided to be early terminated for the FAS 500 mg has launched in 2015. The   use mothod of 250mg per month in clinical practice is off-label."|f||||t||||||||||2017-10-11 03:52:59.221502|2017-10-11 03:52:59.221502
NCT01425190|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-26|2017-03-09|2014-10-03||January 2012||2012-01-01|March 2017|2017-03-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional||The Baseline Population includes all participants in Cohort 1 that received boceprevir. The trial was terminated prior to enrolling participants in either Cohorts 2 or 3.|Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)|Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (Phase 1b); Protocol No. P07614|Terminated||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||3||"The US FDA and the EU CHMP provided guidance indicating preference for intereferon-free   regimens in pediatric studies of HCV infection."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT01424657|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-23|2011-08-26|||October 1997||1997-10-01|August 2011|2011-08-01|July 2002|Actual|2002-07-01|July 2002|Actual|2002-07-01||Interventional|||Magnetic Resonance Cholangiopancreatography Versus Endoscopic Retrograde Cholangiopancreatography in the Approach to Patients With Suspected Biliary Obstruction||Terminated||Phase 3|378|Actual|McGill University Health Center||2||The study was terminated before reaching the estimated sample size because of trial fatigue.|f||||f||||||||||2017-10-11 03:53:08.749251|2017-10-11 03:53:08.749251
NCT01424501|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-25|2016-11-29|2016-11-29|2014-05-29|November 2011||2011-11-01|December 2015|2015-12-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease|Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease|Terminated||Phase 2|142|Actual|GlaxoSmithKline|Due to a safety signal found at a planned interim safety review, further conduct of this safety study is not recommended hence the study was terminated.|6||"Due to a safety signal found at a planned interim safety review, further conduct of this safety   study is not recommended hence the study was terminated."|f||||||||||||||2017-10-11 03:53:14.604283|2017-10-11 03:53:14.604283
NCT01424033|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-24|2017-02-22|2016-01-14||December 2011||2011-12-01|February 2017|2017-02-01||||February 2013|Actual|2013-02-01||Interventional|||A Clinical Trial for CTD-ILD Treatment|Clinical Trial of Oral Medication for CTD-ILD Treatment|Terminated||Phase 2/Phase 3|5|Actual|University of Michigan|Five subjects were consented. Study was terminated prior to conclusion due to departure of PI.|1||Departure of study team|f||||t||||||||||2017-10-11 03:53:25.635459|2017-10-11 03:53:25.635459
NCT01423760|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-23|2016-08-10|2016-06-02||January 2012||2012-01-01|August 2016|2016-08-01|August 2015|Actual|2015-08-01|July 2015|Actual|2015-07-01||Interventional||Screening analysis set included all the subjects included in the trial.|Common Safety Follow-up Trial of Tecemotide (L-BLP25)|An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials|Terminated||N/A|27|Actual|Merck KGaA|The study was terminated prematurely as the sponsor decided to discontinue program with Tecemotide in non-small cell lung cancer (NSCLC).|2||"The study is terminated prematurely as the sponsor decided to discontinue program with   Tecemotide in NSCLC."|f||||f||||||||||2017-10-11 03:53:29.310897|2017-10-11 03:53:29.310897
NCT01423539|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-24|2016-11-01|||October 2011||2011-10-01|November 2016|2016-11-01|February 2014|Anticipated|2014-02-01|February 2014|Anticipated|2014-02-01||Interventional|||A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)|A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma|Withdrawn||Phase 2|0|Actual|Genentech, Inc.||2||The NAVIGATE study has been terminated due to non-safety related reasons.|f||||||||||||||2017-10-11 03:53:33.171897|2017-10-11 03:53:33.171897
NCT01422486|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-18|2013-11-20|||October 2011||2011-10-01|November 2013|2013-11-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional|||Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome|Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome|Terminated||Phase 2|2|Actual|Telik||1||Study TLK199.2107 was terminated for business reasons.|f||||f||||||||||2017-10-11 03:53:49.023166|2017-10-11 03:53:49.023166
NCT01420666|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-16|2016-01-04||||||January 2016|2016-01-01||||||||Interventional|||Maxi-Analgesic Osteoarthritis (OA) Study|Maxi-Analgesic OA Study: Multicentre, Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Effects of Maxigesic 325 With Acetaminophen or Ibuprofen on Patients With Pain From Osteoarthritis|Withdrawn||Phase 3|0|Actual|AFT Pharmaceuticals, Ltd.||4||The study was withdrawn for administrative reason|f||||f||||||||||2017-10-11 03:54:30.24831|2017-10-11 03:54:30.24831
NCT01418781|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-15|2016-03-14|||January 2008||2008-01-01|March 2016|2016-03-01|March 2010||2010-03-01|March 2010|Actual|2010-03-01||Observational|||CLinical Prediction Rule Score in Veterans|Development of CLinical Prediction Rule Score in Veterans: A Study of Impact of Gout on Health Care Utilization and Costs|Withdrawn||N/A|0|Actual|Minneapolis Veterans Affairs Medical Center|||4|Funding withdrawn by the funding agency; study could not be performed.|f||||f||||||||||2017-10-11 03:55:03.553954|2017-10-11 03:55:03.553954
NCT01417988|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-25|2014-02-14|||August 2011||2011-08-01|February 2014|2014-02-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|PrOMPT||Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment|Prevention of Early Mortality by Presumptive TB Treatment in HIV-infected Patients Initiating Antiretroviral Therapy|Terminated||Phase 4|44|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2||Study was terminated prematurely due to insufficient enrolment.|f||||t||||||||||2017-10-11 03:55:14.06738|2017-10-11 03:55:14.06738
NCT01416558|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-11|2013-05-21|||July 2011||2011-07-01|May 2013|2013-05-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)|A Multicenter Non-randomized Phase II Study to Evaluate Nab-paclitaxel in Metastatic Brest Cancer Patients Failing a Solvent Based Taxane as (Neo-)Adjuvant Treatment (Tiffany)|Terminated||Phase 2|66|Anticipated|German Breast Group||1||Study was terminated because of extrem low recruitment|f||||t||||||||||2017-10-11 03:55:31.950879|2017-10-11 03:55:31.950879
NCT01416272|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-11|2014-11-18|2014-11-18||April 2011||2011-04-01|November 2014|2014-11-01|February 2013|Actual|2013-02-01|December 2012|Actual|2012-12-01||Interventional|||Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses|Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses|Terminated||N/A|12|Actual|Bausch & Lomb Incorporated||1||Study was terminated due to a business decision to cancel the entire project.|f||||f||||||||||2017-10-11 03:55:34.5583|2017-10-11 03:55:34.5583
NCT01415908|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-10|2016-01-20|2015-09-25||July 2011||2011-07-01|January 2016|2016-01-01|January 2015|Actual|2015-01-01|September 2014|Actual|2014-09-01||Interventional|TLIF||INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine|A Prospective, Multi-center, Pivotal Trial for INFUSE® Bone Graft With CAPSTONE® Spinal System and Posterior Supplemental Fixation to Treat 1- or 2-level Advanced Degenerative Disease of the Lumbosacral Spine For a TLIF Approach|Terminated||Phase 3|15|Actual|Medtronic Spinal and Biologics|A total of 534 ± 10 subjects were planned for enrollment. However, this study was terminated early with only 15 enrolled patients, leading to small numbers of subjects analyzed.|2||"Due to study design challenges including DMC enrollment suspension as required by the protocol   stopping rules and recommended changes to the surgical technique"|f||||t||||||||||2017-10-11 03:55:43.674968|2017-10-11 03:55:43.674968
NCT01415453|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-25|2013-03-01|2012-06-21||July 2011||2011-07-01|March 2013|2013-03-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Evoked Retinal Response|Evoked Visual Response Using Pulsed Ultrasound|Terminated||N/A|1|Actual|Columbia University|Difficulty in recruiting appropriate volunteers. Study terminated due to poor enrollment.|1||Poor enrollment.|f||||f||||||||||2017-10-11 03:55:52.293647|2017-10-11 03:55:52.293647
NCT01413750|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-05|2015-07-22|2015-06-05||November 2010||2010-11-01|September 2013|2013-09-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|||Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer|Terminated||Phase 1/Phase 2|23|Actual|National Cancer Institute (NCI)|Study was terminated early by NCI due to slow accrual.|2||Slow Accrual|f||||||||||||||2017-10-11 03:56:20.987392|2017-10-11 03:56:20.987392
NCT01413581|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-08|2015-07-29|||May 2011||2011-05-01|July 2015|2015-07-01|August 2014|Actual|2014-08-01|July 2013|Actual|2013-07-01||Interventional|LAIF||Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants|A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 32 of Gestational Age|Terminated||Phase 3|415|Actual|Swedish Orphan Biovitrum||2||Primary endpoint showed no stat significant difference. FU > M12 terminated.|f||||t||||||||||2017-10-11 03:56:23.126474|2017-10-11 03:56:23.126474
NCT01409837|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-02|2013-09-21|2013-06-22||March 1998||1998-03-01|September 2013|2013-09-01|December 2006|Actual|2006-12-01|December 2006|Actual|2006-12-01||Interventional|||The Effect and Safety of Lisinopril in Non-hypertensive Men With Infertility From Low Sperm Count|A 5-year Prospective, Placebo-controlled, Crossover Evaluation of the Efficacy and Tolerability of Low-dose Lisinopril in Normotensives With Idiopathic Oligospermic Infertility|Completed||Phase 2|33|Actual|University Of Nigeria Teaching Hospital|The sample size of the study is small thereby limiting the reliability of generalizing the findings. In addition, three subjects who started the study terminated prematurely and it is difficult to assess how this fact has affected the study results.|2|||f||||t||||||||||2017-10-11 03:57:32.866402|2017-10-11 03:57:32.866402
NCT01408745|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-19|2015-04-13|||June 2008||2008-06-01|April 2015|2015-04-01|November 2012|Actual|2012-11-01|August 2012|Actual|2012-08-01||Interventional|STEPHIX||Sternal Closure With STERNUMFIX in Patients With High Risk|Multicenter Controlled Study on the Safety and Efficacy of Sternal Closure With STERNUMFIX in Patients With High Risk|Terminated||Phase 4|166|Actual|Aesculap AG||2||terminatedd due to insufficient recruitment|f||||f||||||||||2017-10-11 03:57:48.558848|2017-10-11 03:57:48.558848
NCT01408095|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-01|2011-08-23|||September 2011||2011-09-01|August 2011|2011-08-01|September 2012|Anticipated|2012-09-01|September 2012|Anticipated|2012-09-01||Interventional|||A Study in Patients With Type 2 Diabetes|A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2608204 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus|Withdrawn||Phase 2|240|Anticipated|Eli Lilly and Company||2||Trial terminated no patients were screened or enrolled|f||||f||||||||||2017-10-11 03:57:59.114452|2017-10-11 03:57:59.114452
NCT01408069|ClinicalTrials.gov processed this data on October 10, 2017|2011-08-01|2013-03-25|||March 2014||2014-03-01|March 2013|2013-03-01|December 2014|Anticipated|2014-12-01|October 2014|Anticipated|2014-10-01||Interventional|||Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia|Multicentric, Randomizade, Double Blind, Double Dummy To Non-Inferiority Comparison Of Migrane® Versus Parcel ® For Treatment Of Tensional Cephaleia|Suspended||Phase 3|108|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2017-10-11 03:57:59.639453|2017-10-11 03:57:59.639453
NCT01407991|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-25|2015-11-09|||July 2011||2011-07-01|November 2015|2015-11-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional|||Nasogastric/Oral Gastric Tube Placement in Infants: Comparing 2 Measurement Methods|Placement of NG or OG Tube in Infants by Length Versus Traditional Measuring Methods|Terminated||Phase 2|9|Actual|Children's Hospital of Philadelphia||2||"Study terminated due to change in clinical practice affecting recruitment. For majority of   patients, NJ tubes are now used instead of NG tubes."|f||||f||||||||||2017-10-11 03:58:01.663928|2017-10-11 03:58:01.663928
NCT01406639|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-29|2013-04-26|||July 2011||2011-07-01|April 2013|2013-04-01|May 2012|Actual|2012-05-01|May 2012|Actual|2012-05-01||Interventional|||Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Ranibizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Withdrawn||Phase 1|0|Actual|University of California, San Diego||1||Study withdrawn due to lack of study population.|f||||f||||||||||2017-10-11 03:58:24.49722|2017-10-11 03:58:24.49722
NCT01404351|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-25|2013-01-03|||May 2011||2011-05-01|January 2013|2013-01-01|November 2011|Actual|2011-11-01|October 2011|Actual|2011-10-01||Interventional|||Use of the PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction|A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade® 4.0 in Bilateral Breast Reduction|Withdrawn||N/A|0|Actual|Medtronic Surgical Technologies||2||Study terminated due to the acquisition of PEAK Surgical by Medtronic|f||||f||||||||||2017-10-11 03:58:56.884427|2017-10-11 03:58:56.884427
NCT01402869|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-25|2014-03-25|2013-10-15||August 2011||2011-08-01|March 2014|2014-03-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional||1 subject was withdrawn from the no local anesthetic group as the subject required 1 or more dental tooth extractions and required local anesthetic|Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics|Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Prilocaine Versus Lidocaine|Completed||N/A|91|Actual|Loma Linda University|Did not compare locals anesthetics with equivalent concentrations of epinephrine; unable to control length of time methemoglobin blood levels were monitored as all subjects varied in extent of restorative dental procedures needed.|3|||f||||f||||||||||2017-10-11 03:59:20.750735|2017-10-11 03:59:20.750735
NCT01402739|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-25|2015-06-12|||August 2011||2011-08-01|June 2015|2015-06-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|HEART-PoC||Algorithm-Guided Transfusions in Cardiac Surgery Patients for Reduction of Drainage Blood Losses|Monocentric Pilot Study of Algorithm-Guided Transfusions in Cardiac Surgery Patients for Reduction of Drainage Blood Losses|Terminated||N/A|100|Actual|Charite University, Berlin, Germany||2||Study terminated prematurely due to futility|f||||f||||||||||2017-10-11 03:59:22.271653|2017-10-11 03:59:22.271653
NCT01402440|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-05|2015-01-06|||November 2011||2011-11-01|January 2015|2015-01-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma|An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma|Terminated||Phase 1|15|Actual|Novartis||1||"Study terminated due to enrolment challenges and availability of other options for DLBCL   patients. The termination is not a consequence of any safety concern."|f||||||||||||||2017-10-11 03:59:26.460106|2017-10-11 03:59:26.460106
NCT01400763|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-20|2011-07-21|||May 2011||2011-05-01|July 2011|2011-07-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional|METC-11/07||Lutein Bioavailability From Fresh and Dried Beverages|Bioavailability of Lutein From a Lutein-enriched Egg-yolk-beverage and Its Dried Re-suspended Versions.|Completed||N/A|103|Actual|Wageningen University||1|||f||||t||||||||||2017-10-11 03:59:55.834144|2017-10-11 03:59:55.834144
NCT01400451|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-21|2014-12-10|2014-04-21||November 2011||2011-11-01|December 2014|2014-12-01|December 2013|Actual|2013-12-01|April 2013|Actual|2013-04-01||Interventional||All participants who received at least one dose of study drug.|Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)|A Phase I Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma|Terminated||Phase 1|18|Actual|Bristol-Myers Squibb|In Phase 1 of the study, MTD was not reached because more than 2 of 6 treated participants experienced DLTs with the combination therapy. Enrollments in Phase 1 were terminated and Phase 2 was not started so only overall safety was summarized.|1||More than 2 of 6 patients treated experienced dose limiting toxicities.|f||||f||||||||||2017-10-11 04:00:00.274707|2017-10-11 04:00:00.274707
NCT01398995|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-20|2011-07-20|||May 2011||2011-05-01|July 2011|2011-07-01|September 2011|Anticipated|2011-09-01|September 2011|Anticipated|2011-09-01||Interventional|||Managing Insulin Pumps for Exercise (Study 2)|To Consider the Effect of the Timing of a Reduction in Basal Insulin Infusion Rate to 50% of Normal Prior to Exercise on Glycaemic Control in People With Type 1 Diabetes Treated With CSII|Terminated||N/A|6|Actual|Buckinghamshire Healthcare NHS Trust||4||Recruitment was terminated due to elevated levels of hypoglycaemia|f||||f||||||||||2017-10-11 04:00:25.484545|2017-10-11 04:00:25.484545
NCT01397630|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-07|2015-06-23|||April 2012||2012-04-01|June 2015|2015-06-01|November 2013|Actual|2013-11-01|October 2013|Actual|2013-10-01||Interventional|ACTION||Accelerated Titration of Oxytocin for Nulliparous Patients With Labour Dystocia: ACTION Pilot Study|Accelerate Versus Gradual Titration of Oxytocin Dose for Labour Dystocia: A Pilot Study|Terminated||Phase 3|79|Actual|Ottawa Hospital Research Institute||2||"Due to budgetary concerns, the TSC decided it best to adjust sample size as there was   sufficient data to assess feasibility. Recruitment was terminated early."|f||||t||||||||||2017-10-11 04:00:44.727154|2017-10-11 04:00:44.727154
NCT01395953|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-14|2015-04-06|||November 2011||2011-11-01|April 2015|2015-04-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|||Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||2||This study was withdrawn due to competing research interests and slow recruitment.|f||||f||||||||||2017-10-11 04:01:15.48684|2017-10-11 04:01:15.48684
NCT01394913|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-12|2013-03-01|||August 2013||2013-08-01|March 2013|2013-03-01|June 2014|Anticipated|2014-06-01|March 2014|Anticipated|2014-03-01||Interventional|||Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis|A Prospective, Double-blind, Randomized Study to Compare Efficacy of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis|Suspended||Phase 3|216|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2017-10-11 04:01:33.411645|2017-10-11 04:01:33.411645
NCT01391377|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-05|2013-02-25|||July 2011||2011-07-01|February 2013|2013-02-01|December 2014|Anticipated|2014-12-01|December 2014|Anticipated|2014-12-01||Interventional|||Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease|The Effects of Chronic High-density Lipoprotein (HDL) Elevation With Extended Release Niacin on Peripheral Arterial Disease|Terminated||N/A|7|Actual|Bayside Health||2||Tredaptive has been suspended worldwide|f||||f||||||||||2017-10-11 04:02:49.68428|2017-10-11 04:02:49.68428
NCT01390441|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-07|2016-06-08|2016-03-24||July 2011||2011-07-01|May 2016|2016-05-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)|A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With EU-approved MabThera® and US-licensed Rituxan® in Patients With Rheumatoid Arthritis (RA)|Terminated||Phase 1|100|Actual|Merck Sharp & Dohme Corp.||5||The study was terminated early by the Sponsor for business reasons.|f||||f||||||||||2017-10-11 04:03:17.289042|2017-10-11 04:03:17.289042
NCT01388920|ClinicalTrials.gov processed this data on October 10, 2017|2011-07-05|2014-04-04|2014-04-04||September 2011||2011-09-01|April 2014|2014-04-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Tesamorelin in Stable Ambulatory COPD Subjects With Muscle Wasting|Terminated||Phase 2|3|Actual|Theratechnologies||3||The study was terminated based on a non-safety related corporate decision.|f||||f||||||||||2017-10-11 04:03:42.160454|2017-10-11 04:03:42.160454
NCT01387659|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-08|2013-09-30|||March 2011||2011-03-01|September 2013|2013-09-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations|Study to Evaluate Tolerability of Myfortic With Simulect Induction and Tacrolimus Without Steroids in Three Patient Populations; 1: Kidney/Pancreas Transplants,2: Diabetic Kidney Transplants, and 3: Non-diabetic Kidney Transplants|Terminated||Phase 4|2|Actual|The University of Texas Medical Branch, Galveston||1||Study terminated due to slow enrollment|f||||t||||||||||2017-10-11 04:04:00.767237|2017-10-11 04:04:00.767237
NCT01386879|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-27|2015-05-12|||July 2011||2011-07-01|May 2015|2015-05-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Evaluation of Above the Cuff Suctioning During General Anesthesia|Evaluation of Microaspiration and Efficacy of Above the Cuff Suctioning During General Anesthesia: A Comparison of Two Endotracheal Tubes With Suction Above Cuff With a Standard Endotracheal Tube|Terminated||Phase 4|60|Actual|Thomas Jefferson University||3||The study was terminated because of slower than anticipated enrollment|f||||f||||||||||2017-10-11 04:04:14.031774|2017-10-11 04:04:14.031774
NCT01386008|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-22|2014-02-04|2013-11-01||May 2011||2011-05-01|February 2014|2014-02-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|||Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens||Terminated||N/A|28|Actual|Coopervision, Inc.|Incomplete data sets / Data not analyzed / Not all subjects completed the study measures at each outcome measurement time frame before the study was terminated. 20 participants completed V1 and only 1 participant completed the V2 follow-up.|1||unexpected adverse events|f||||f||||||||||2017-10-11 04:04:26.315384|2017-10-11 04:04:26.315384
NCT01381003|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-23|2012-06-01|||November 2011||2011-11-01|June 2012|2012-06-01|November 2016|Anticipated|2016-11-01|November 2016|Anticipated|2016-11-01||Interventional|||Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD)|Phase I/II Gene Therapy Protocol for X-Linked Chronic Granulomatous Disease|Withdrawn||Phase 1/Phase 2|0|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||1||"Study is withdrawn before recruting participants, new trial will be multi centre, sponsored by   different organisation."|f||||f||||||||||2017-10-11 04:05:46.192135|2017-10-11 04:05:46.192135
NCT01379521|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-01|2017-04-13|2016-06-09||June 2011||2011-06-01|April 2017|2017-04-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|TRACER||Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC|A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitor®) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study|Terminated||Phase 2|65|Actual|Novartis||2||"The study was terminated due to low enrollment. This resulted in the study being underpowered   and inconclusive."|f||||t||||||||||2017-10-11 04:06:22.793767|2017-10-11 04:06:22.793767
NCT01377532|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-13|2014-12-23|||August 2009||2009-08-01|December 2014|2014-12-01|August 2021|Anticipated|2021-08-01|August 2020|Anticipated|2020-08-01||Expanded Access|||Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma|Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma|Available||N/A|||University of California, San Francisco||||Study has been suspended after the event of an serious adverse event.|||||t||||||||||2017-10-11 04:06:47.513634|2017-10-11 04:06:47.513634
NCT01374789|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-30|2015-06-02|||July 2010||2010-07-01|June 2015|2015-06-01|March 2012|Actual|2012-03-01|March 2012|Actual|2012-03-01||Interventional|PURO||PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer|PURO - An Open-label, Randomised, Multicentre, Phase II Study to Evaluate the Efficacy of Chemotherapy With Gemcitabine and Cisplatin in Combination With the EGF Receptor Antibody Panitumumab (GemCisP) Versus GemCis in the First-line Therapy of Locally Advanced/Metastatic Urothelial Carcinoma in Patients With Wild-type HRAS|Terminated||Phase 2|2|Actual|WiSP Wissenschaftlicher Service Pharma GmbH||2||The study was terminated due to insufficient recruitment.|f||||t||||||||||2017-10-11 04:07:36.540208|2017-10-11 04:07:36.540208
NCT01374555|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-14|2013-02-20|||August 2010||2010-08-01|February 2013|2013-02-01|December 2013|Anticipated|2013-12-01|December 2013|Anticipated|2013-12-01||Observational|||Evaluation of the CardioSond Electronic Stethoscope in the Detection of Coronary Artery Disease|Validation of the CardioSond Sonospectrographic Digital Electronic Stethoscope in Diagnosing Coronary Artery Disease Versus CT Angiography|Suspended||N/A|200|Anticipated|SonoMedica, Inc.|||1|Phase II cohort recruitment suspended until analysis of Phase I cohort completed|f||||f||||||||||2017-10-11 04:07:41.915515|2017-10-11 04:07:41.915515
NCT01374451|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-14|2016-10-26|2016-02-16||June 2011||2011-06-01|October 2016|2016-10-01|February 2015|Actual|2015-02-01|February 2015|Actual|2015-02-01||Interventional|COOPERATE-2|Full analysis set (FAS) was defined according to the intention to treat principle. The FAS consisted of all randomized patients. Following the intention to treat principle patients were analyzed according to the treatment (and stratum) they were assigned to at randomization.|Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET|A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study|Terminated||Phase 2|160|Actual|Novartis|A planned primary analysis was completed with data cut of 02-Apr-2014. The study did not meet its primary objective, which was based on progression-free survival as per local radiology assessment and was prematurely terminated.|2||The study was stopped for not meeting the primary endpoint for PFS.|f||||t||||||||||2017-10-11 04:07:42.953909|2017-10-11 04:07:42.953909
NCT01373918|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-06|2016-05-10|2016-02-22||December 2010||2010-12-01|May 2016|2016-05-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders|Low Dose Parenteral Fat for the Prevention of Parenteral Nutrition Associated Cholestasis in Neonates With Congenital/Acquired Gastrointestinal Disorders|Terminated||Phase 4|41|Actual|University of California, Los Angeles|Early termination leading to small number of subjects analyzed.|2||The study was terminated due to slow enrollment.|f||||t||||||||No||2017-10-11 04:07:54.991358|2017-10-11 04:07:54.991358
NCT01372813|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-11|2015-10-02|2011-12-19||December 2007||2007-12-01|October 2015|2015-10-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||Vandetanib to Treat Advanced Kidney Cancer|A Phase II Study of ZD6474 (Vandetanib) in Subjects With Advanced Clear Cell Renal Carcinoma|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)|Study was designed to accrue up to 37 patients but only 3 were enrolled. Study was terminated due to low accrual.|1||Terminated for insufficient accrual.|f||||f||||||||||2017-10-11 04:08:10.916948|2017-10-11 04:08:10.916948
NCT01371747|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-09|2017-04-24|2015-11-11|2014-10-30|June 2011||2011-06-01|April 2017|2017-04-01|June 2013|Actual|2013-06-01|May 2013|Actual|2013-05-01||Interventional|AMETHYST-DN|306 participants were randomized and stratified by baseline serum potassium (2 randomized participants in Stratum 1 did not receive any study drug: 1 participant withdrew consent and 1 participant was randomized in error and was withdrawn from the study); 304 participants were analyzed for safety.|Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)|A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone|Completed||Phase 2|324|Actual|Relypsa, Inc.||6|||f||||f||||||||||2017-10-11 04:08:30.442915|2017-10-11 04:08:30.442915
NCT01370863|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-31|2014-06-25|2013-04-15||December 2010||2010-12-01|April 2014|2014-04-01|May 2012|Actual|2012-05-01|May 2012|Actual|2012-05-01||Interventional||The Safety Population was used defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).|An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients|An Explorative, Randomized, Placebo-controlled, DB, Parallel-group Trial, to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Subjects With GERD & With Persistent Symptoms Despite Taking a Stable Dose of PPIs|Terminated||Phase 2|67|Actual|Shire|Results data should be interpreted with caution since the study’s early termination affects the statistical power to detect true differences between treatment groups.|2||This study was terminated early due to recruitment difficulties. There were no safety concerns.|f||||f||||||||||2017-10-11 04:08:46.542469|2017-10-11 04:08:46.542469
NCT01370694|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-18|2017-06-06|2015-10-23||August 19, 2011|Actual|2011-08-19|June 2017|2017-06-01|December 1, 2014|Actual|2014-12-01|December 1, 2014|Actual|2014-12-01||Interventional|||Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)|An Open-Label, Single Arm Study of MK-8808 in Patients With Advanced CD20-Positive Follicular Lymphoma|Terminated||Phase 1|7|Actual|Merck Sharp & Dohme Corp.|The study was terminated for business reasons. Not all planned analyses were performed|1||The study was terminated for business reasons.|f||||f||||||||||2017-10-11 04:08:49.319667|2017-10-11 04:08:49.319667
NCT01369641|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-07|2016-10-19|2014-01-24||August 2011||2011-08-01|October 2016|2016-10-01|August 2017|Anticipated|2017-08-01|March 2012|Actual|2012-03-01||Interventional|||The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy|A Pilot, Randomized, Self-controlled Study of the Effects of Intratympanic Sodium Thiosulfate on the Degree of Hearing Loss in Patients Receiving Cisplatin Therapy|Terminated||N/A|1|Actual|Thomas Jefferson University|Study terminated due to poor accrual, prior to subjects being analyzed.|2||Poor accrual|f||||t||||||||||2017-10-11 04:09:13.076281|2017-10-11 04:09:13.076281
NCT01367990|ClinicalTrials.gov processed this data on October 10, 2017|2011-06-05|2012-03-22|||July 2011||2011-07-01|March 2012|2012-03-01|April 2012|Anticipated|2012-04-01|February 2012|Actual|2012-02-01||Interventional|||Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy|Alopecia Prevention Trial of Topical Vasoconstrictor Therapy in Head and Neck Cancer Patients Treated With Intensity Modulated Radiotherapy (IMRT)|Terminated||Phase 1|3|Actual|ProCertus BioPharm, Inc||1||Study site has terminated the study due to the complexity of the study|f||||f||||||||||2017-10-11 04:09:51.57261|2017-10-11 04:09:51.57261
NCT01366651|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-14|2013-12-04|||March 2012||2012-03-01|December 2013|2013-12-01|June 2012|Actual|2012-06-01|May 2012|Actual|2012-05-01||Interventional|||A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age|An Open-Label Study to Evaluate the Penetration of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Subjects Less Than 1 Year Chronological Age|Terminated||Phase 1|1|Actual|Janssen Research & Development, LLC||1||Trial terminated early per business decision.|f||||f||||||||||2017-10-11 04:10:17.981928|2017-10-11 04:10:17.981928
NCT01365468|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-27|2016-05-10|2016-03-15||April 2012||2012-04-01|May 2016|2016-05-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional|||Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)|A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1)|Terminated||Phase 2|9|Actual|Novartis|Study got terminated because of poor patient's accrual.|1||Poor patients' accrual|f||||||||||||||2017-10-11 04:10:41.421961|2017-10-11 04:10:41.421961
NCT01363986|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-31|2014-07-23|2014-05-07||September 2011||2011-09-01|July 2014|2014-07-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional||Intent to treat (ITT) population included all consented participants who received study treatment.|A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer|A Multicenter, Open Label Study to Assess the Effect of Trastuzumab + Whole Brain Radiotherapy (WBRT) on Brain Metastases From HER-2 Positive Breast Cancer. (bHERt-2)|Terminated||Phase 2|3|Actual|Hoffmann-La Roche||1||"Study was prematurely terminated due to difficulties experienced in recruiting patients in a   reasonable timeframe."|f||||||||||||||2017-10-11 04:11:09.127597|2017-10-11 04:11:09.127597
NCT01363908|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-30|2015-05-27|2015-05-06||August 2011||2011-08-01|August 2014|2014-08-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||The Safety Analysis Set, defined as all participants who had taken at least 1 dose of investigational product.|Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload|A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload|Terminated||Phase 2|30|Actual|Shire|This study was terminated early because of non-clinical safety results. As such, not all subjects completed the study. The available efficacy data were summarized and analyzed as specified in the SAP; however, no efficacy conclusions could be drawn.|3||"This study was terminated due to treatment stop resulting in an inability to draw conclusions   from the data. Evaluation of nonclinical rat findings is ongoing."|f||||t||||||||||2017-10-11 04:11:10.045242|2017-10-11 04:11:10.045242
NCT01363154|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-27|2013-06-02|||November 2010||2010-11-01|June 2013|2013-06-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional|||Prevention of Photoparoxysmal Abnormalities by Mozart K448|Prevention of Photoparoxysmal Abnormalities Through Patterned Auditory Stimulation|Terminated||N/A|10|Actual|Medical University of South Carolina||3||terminated|f||||t||||||||||2017-10-11 04:11:30.934453|2017-10-11 04:11:30.934453
NCT01362608|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-24|2017-06-07|2016-05-19||June 20, 2011|Actual|2011-06-20|June 2017|2017-06-01|May 19, 2015|Actual|2015-05-19|May 19, 2015|Actual|2015-05-19||Interventional|||Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective|A Randomized, Double-blind, Double-dummy, Active Controlled Study of Canakinumab (ACZ885) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective|Terminated||Phase 3|136|Actual|Novartis|This study was terminated early. The decision to terminate study was not out of concerns for efficacy or safety of canakinumab|2|||f||||||||||||||2017-10-11 04:11:40.285091|2017-10-11 04:11:40.285091
NCT01361464|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-24|2015-03-19|2013-11-15||May 2011||2011-05-01|February 2015|2015-02-01|November 2014|Actual|2014-11-01|November 2014|Actual|2014-11-01||Interventional|||Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia|Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)|Due to trial not meeting primary endpoint of at least 3 CR/CRi after 2 cycles, accrual was suspended. 1 year survival was not calculated, not relevant in the setting of a median survival of 6.6 months and with study not meeting its primary endpoint.|1|||f||||||||||||||2017-10-11 04:12:11.692827|2017-10-11 04:12:11.692827
NCT01360827|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-24|2014-06-16|||August 2010||2010-08-01|June 2014|2014-06-01||||April 2011|Actual|2011-04-01||Interventional|||EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase Ib Trial of Multiple-ascending Doses of EMD 1201081 in Combination With 5-FU/Cisplatin and Cetuximab in First-line Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1|13|Actual|Merck KGaA||2||Study terminated due to potential safety concerns in combination with platinum-based therapies|f||||f||||||||||2017-10-11 04:12:23.903274|2017-10-11 04:12:23.903274
NCT01359072|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-20|2012-08-21|||June 2011||2011-06-01|August 2012|2012-08-01|August 2012|Actual|2012-08-01|August 2012|Actual|2012-08-01||Interventional|||Enhancing Coping Skills in Patients With Cancer|Enhancing Coping Skills in Patients With Cancer - a Randomized Controlled Study|Terminated||N/A|1|Actual|McGill University Health Center||2||This study is currently terminated due to low recruitment rate.|f||||f||||||||||2017-10-11 04:13:00.454072|2017-10-11 04:13:00.454072
NCT01357863|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-19|2017-05-23|||July 2010||2010-07-01|May 2017|2017-05-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Observational|(TYCO1)||Role of Early Versus Late Switch to Lapatinib-Capecitabine|Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO1) - Brazil|Terminated||N/A|3|Actual|GlaxoSmithKline|||2|This study was terminated because the National Ethics Committee has not approved the protocol.|f||||f||||||||||2017-10-11 04:13:36.057038|2017-10-11 04:13:36.057038
NCT01355861|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-14|2015-06-25|||June 2011||2011-06-01|June 2015|2015-06-01|June 2014|Anticipated|2014-06-01|June 2014|Anticipated|2014-06-01||Interventional|REPAiRS||Resistance Exercise for the Prevention of Age-related Sarcopenia|Negative Work Exercise as a Novel Treatment for Sarcopenia in Older Men|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||Project has been withdrawn from funding consideration|f||||f||||||||||2017-10-11 04:14:06.411481|2017-10-11 04:14:06.411481
NCT01355302|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-16|2017-04-07|2017-01-19|2013-05-21|November 2011||2011-11-01|March 2017|2017-03-01|July 2013|Actual|2013-07-01|April 2013|Actual|2013-04-01||Interventional|||E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer|Terminated||Phase 1/Phase 2|7|Actual|Eisai Inc.|The study was terminated prior to enrollment in Phase 2.|2||Sites not recruiting|f||||f||||||||||2017-10-11 04:14:16.629951|2017-10-11 04:14:16.629951
NCT01353859|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-13|2014-05-08|2014-04-22||March 2011||2011-03-01|May 2014|2014-05-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional||Intent to treat (ITT) population: all participants included in the study who received at least one dose of study medication. Participants prematurely withdrawn from the study will be considered as nonresponders at the end of the study in all analyses of treatment response variables.|A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs|An Open Label, Local, Multicenter , Phase IIIb Interventional Study to Assess the Efficacy of Tocilizumab (TCZ) in Combination With Methotrexate (MTX) in Indonesian Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs|Completed||Phase 3|39|Actual|Hoffmann-La Roche||1|||f||||||||||||||2017-10-11 04:14:45.536727|2017-10-11 04:14:45.536727
NCT01353482|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-11|2012-03-21||||||March 2012|2012-03-01||||||||Interventional|MESO-02||A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma|A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma|Withdrawn||Phase 1/Phase 2|0|Actual|University College, London||2||"UCL CTC were informed by Merck Sharp & Dohme on 22.08.11 that support for the trial had been   withdrawn in light of results from another trial with trial drug."|f||||||||||||||2017-10-11 04:14:52.447809|2017-10-11 04:14:52.447809
NCT01352702|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-11|2015-02-04|||May 2011||2011-05-01|February 2015|2015-02-01|May 2014|Actual|2014-05-01|May 2014|Actual|2014-05-01||Interventional|Dabi-ADP-2||Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Terminated||Phase 4|46|Actual|Deutsches Herzzentrum Muenchen||2||Slow recruitment; Study was terminated for futility reasons|f||||f||||||||||2017-10-11 04:15:14.127031|2017-10-11 04:15:14.127031
NCT01352416|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-04|2016-11-08|2016-06-14||September 2010||2010-09-01|November 2016|2016-11-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Interventional||Subjects scheduled/undergoing cardiac surgery.|Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery|Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery|Terminated||Phase 3|15|Actual|William Beaumont Hospitals|Early termination due to lack of enrollment. 15 pts enrolled, 6 withdrawn due breathing tube not removed by 10 pm day of surgery. 1 withdrawn after day 3 as he was in afib and placed on amio. All pts were male.|4||lack of enrollment|f||||t||||||||Undecided||2017-10-11 04:15:18.345961|2017-10-11 04:15:18.345961
NCT01350544|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-06|2017-04-07|2016-05-19||April 2013||2013-04-01|April 2017|2017-04-01|December 2015|Actual|2015-12-01|July 2015|Actual|2015-07-01||Interventional|TA|One participant was administratively withdrawn from the intervention condition because it was found that she was ineligible (not on medications) after being randomized to the intervention.|Treatment Advocacy Intervention for HIV-Positive African Americans|Treatment Advocacy Intervention for HIV-Positive African Americans|Completed||N/A|216|Actual|Boston Children’s Hospital|We did not assess long-term effects, as the 6-month follow-up assessment occurred immediately after the last booster session. In addition, we did not assess the effects of the intervention on viral suppression.|2|||f||||f||||||||No||2017-10-11 04:15:49.497651|2017-10-11 04:15:49.497651
NCT01350258|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-04|2016-11-28|2014-10-21||April 2011||2011-04-01|October 2016|2016-10-01|August 2012|Actual|2012-08-01|May 2012|Actual|2012-05-01||Interventional|||Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps|A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Using Melphalan for T-Cell Tolerization|Terminated||Phase 1/Phase 2|8|Actual|Thomas Jefferson University|Study was terminated due to extreme toxicity. The study was closed before any data could be collected.|1||Poor accrual|f||||t||||||||||2017-10-11 04:15:54.845177|2017-10-11 04:15:54.845177
NCT01350232|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-04|2016-10-19|2014-11-13||September 2009||2009-09-01|October 2016|2016-10-01|August 2011|Actual|2011-08-01|August 2011|Actual|2011-08-01||Interventional|||Treatment of Sickle Cell Anemia With Stem Cell Transplant|Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors|Terminated||N/A|2|Actual|Thomas Jefferson University|Study was terminated due to poor accrual. No reportable data has been collected.|1||Poor accrual|f||||t||||||||||2017-10-11 04:15:56.139228|2017-10-11 04:15:56.139228
NCT01349556|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-05|2014-04-21|||May 2011||2011-05-01|April 2014|2014-04-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream|Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin|Withdrawn||N/A|0|Actual|Johns Hopkins University||1||Study withdrawn due to volunteer disinterest in participating.|f||||||||||||||2017-10-11 04:16:14.37509|2017-10-11 04:16:14.37509
NCT01348165|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-03|2016-08-04|2014-03-12||May 2011||2011-05-01|August 2016|2016-08-01||||August 2011|Actual|2011-08-01||Interventional||Treated Set which included all subjects who received one dose of trial medication|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers (A Randomised, Single-blind, Placebo-controlled Phase I Study)|Terminated||Phase 1|40|Actual|Boehringer Ingelheim|The trial was put on hold due to a serious adverse event (post-treatment period) which was evaluated to be not drug related and the trial was subsequently terminated.|10|||f||||||||||||||2017-10-11 04:16:30.568986|2017-10-11 04:16:30.568986
NCT01347840|ClinicalTrials.gov processed this data on October 10, 2017|2011-05-03|2012-04-19|2012-04-19||April 2011||2011-04-01|April 2012|2012-04-01|March 2012|Actual|2012-03-01|March 2012|Actual|2012-03-01||Observational|Cassini||Metabolic Factors of Outcomes From Gastric Bypass Surgery|Metabolic Factors of Outcomes From Gastric Bypass Surgery|Terminated||N/A|1|Actual|Ethicon Endo-Surgery|Trial termination due to business needs. One subject enrolled and withdrew consent. Zero subjects completed study. No subject data analyzed.||1|Study was terminated for business reasons.|f||||f||||||||||2017-10-11 04:16:38.910073|2017-10-11 04:16:38.910073
NCT00000372|ClinicalTrials.gov processed this data on October 10, 2017|1999-11-02|2014-06-11|||March 1998||1998-03-01|June 2014|2014-06-01|November 2005|Actual|2005-11-01|November 2005|Actual|2005-11-01||Interventional|||Glycine and D-Cycloserine in Schizophrenia|A Placebo Controlled Trial of Glycine Added to Clozapine in Schizophrenia|Withdrawn||Phase 3|0|Actual|Massachusetts General Hospital||3||"Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients with   Schizophrenia, so the study was suspended."|f||||||||||||||2017-10-11 04:17:51.024311|2017-10-11 04:17:51.024311
NCT00002874|ClinicalTrials.gov processed this data on October 10, 2017|1999-11-01|2017-07-18|2017-06-06||February 1998||1998-02-01|July 2017|2017-07-01||||August 2015|Actual|2015-08-01||Interventional||Eligible patients who have not withdrawn|Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy|A PHASE III TRIAL OF RADIATION THERAPY WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY FOR pT3N0 CARCINOMA OF THE PROSTATE|Active, not recruiting||Phase 3|840|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2017-10-11 04:22:03.395249|2017-10-11 04:22:03.395249
NCT00002934|ClinicalTrials.gov processed this data on October 10, 2017|1999-11-01|2015-10-06|||April 1997||1997-04-01|October 2015|2015-10-01|October 2012|Actual|2012-10-01|December 2007|Actual|2007-12-01||Interventional|||Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ|Local Excision Alone for Selected Patients With DCIS of the Breast|Terminated||Phase 2|711|Actual|Eastern Cooperative Oncology Group||1||"This study was terminated when the accrual goal for the low/intermediate grade stratum was   reached. The high grade stratum was closed due to slow accrual."|f||||f||||||||||2017-10-11 04:22:11.845439|2017-10-11 04:22:11.845439
NCT00003056|ClinicalTrials.gov processed this data on October 10, 2017|1999-11-01|2015-06-26|||April 1997||1997-04-01|May 2013|2013-05-01|June 2003||2003-06-01|June 2003||2003-06-01||Interventional|||Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation|Peripheral Blood Stem Cell Transplantation in Patients With Advanced Malignancies Eligible for Allogeneic Transplantation From Matched Related Donors: A Randomized Study of Cyclosporine/Methotrexate or Cyclosporine/T-Cell Depletion (CD34 Cell Selection) for GVHD Prophylaxis|Terminated||Phase 3|105|Actual|Baxalta US Inc.||2||Interim analysis indicated study should be terminated|||||t||||||||||2017-10-11 04:22:26.101683|2017-10-11 04:22:26.101683
NCT00003564|ClinicalTrials.gov processed this data on October 10, 2017|1999-11-01|2012-02-17||||||February 2012|2012-02-01||||||||Interventional|||Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas|Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas|Withdrawn||Phase 3|0|Actual|M.D. Anderson Cancer Center||2||Study withdrawn.|f||||f||||||||||2017-10-11 04:23:35.854136|2017-10-11 04:23:35.854136
NCT00003843|ClinicalTrials.gov processed this data on October 10, 2017|1999-11-01|2015-02-13|||October 1998||1998-10-01|September 2013|2013-09-01|February 2001|Actual|2001-02-01|February 2001|Actual|2001-02-01||Observational|||Irinotecan in Treating Patients With Colorectal Cancer|UGT1A1 Polymorphism in Patients With Colorectal Cancer Treated With CPT-11 (Irinotecan)|Terminated||Phase 2|28|Anticipated|California Cancer Consortium||||Study terminated due to poor accrual|||||||||||||||2017-10-11 04:24:17.473753|2017-10-11 04:24:17.473753
NCT00005097|ClinicalTrials.gov processed this data on October 10, 2017|2000-04-06|2014-04-17|||August 1999||1999-08-01|April 2014|2014-04-01|August 2002|Actual|2002-08-01|August 2002|Actual|2002-08-01||Interventional|||Green Tea Extract in Treating Patients With Actinic Keratosis|A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology|Terminated||Phase 2|88|Actual|University of California, Irvine||1||terminated due to the low conditional power for a positive study|f||||t||||||||||2017-10-11 04:26:26.881535|2017-10-11 04:26:26.881535
NCT00005812|ClinicalTrials.gov processed this data on October 10, 2017|2000-06-02|2013-05-13|||January 2000||2000-01-01|May 2013|2013-05-01|May 2004|Actual|2004-05-01|May 2004|Actual|2004-05-01||Interventional|||Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma|A Pilot Phase II Trial of Temozolomide in Leptomeningeal Metastases|Terminated||Phase 2|12|Actual|Dartmouth-Hitchcock Medical Center||1||No objective response documented, protocol terminated after 12 patients.|f||||t||||||||||2017-10-11 04:27:30.023711|2017-10-11 04:27:30.023711
NCT00005969|ClinicalTrials.gov processed this data on October 10, 2017|2000-07-05|2012-02-17|||September 1999||1999-09-01|February 2012|2012-02-01||||January 2001|Actual|2001-01-01||Interventional|||Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease|Phase II Study of ATRAGEN (Liposomal Tretinoin) in Patients With Relapsed or Refractory Hodgkin's Disease|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Study withdrawn.|f||||f||||||||||2017-10-11 04:27:51.861422|2017-10-11 04:27:51.861422
NCT00005984|ClinicalTrials.gov processed this data on October 10, 2017|2000-07-05|2011-05-25|||August 2000||2000-08-01|May 2011|2011-05-01|September 2005|Actual|2005-09-01|September 2005|Actual|2005-09-01||Interventional|||Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia|Autologous Marrow Transplantation for Chronic Myelogenous Leukemia Using Stem Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming|Terminated||Phase 2|22|Actual|Masonic Cancer Center, University of Minnesota||1||Study terminated as principal investigator [PI] left the university.|f||||t||||||||||2017-10-11 04:27:54.857361|2017-10-11 04:27:54.857361
NCT00012675|ClinicalTrials.gov processed this data on October 10, 2017|2001-03-14|2012-05-23||||||May 2012|2012-05-01|December 2003|Actual|2003-12-01|||||Observational|||Developing and Implementing a Quality Measure for Glycemic Control|Developing and Implementing a Quality Measure for Glycemic Control|Withdrawn||N/A|0|Actual|VA Office of Research and Development|||1|This study was withdrawn prior to enrollment.|f||||f||||||||||2017-10-11 04:29:26.824097|2017-10-11 04:29:26.824097
NCT00021229|ClinicalTrials.gov processed this data on October 10, 2017|2001-07-11|2014-07-25|2010-02-09||May 2001||2001-05-01|February 2013|2013-02-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|||Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma|A Phase I/II Trial Of STI571 In Children With Newly Diagnosed Poor Prognosis Brainstem Gliomas And Recurrent Intracranial Malignant Gliomas|Terminated||Phase 1/Phase 2|85|Actual|National Cancer Institute (NCI)|The phase II component of the trial was terminated because of poor accrual. Only one patient enrolled to the phase II component and did not receive the investigational drug.|1||Poor accrual|f||||t||||||||||2017-10-11 04:31:46.270736|2017-10-11 04:31:46.270736
NCT00022490|ClinicalTrials.gov processed this data on October 10, 2017|2001-08-10|2015-12-08|2012-06-06||June 2001||2001-06-01|December 2015|2015-12-01|July 2011|Actual|2011-07-01|May 2011|Actual|2011-05-01||Interventional|||Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia|A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase|Terminated||Phase 2|24|Actual|OHSU Knight Cancer Institute|Study was terminated, therefore the 12 month response data was not analyzed.|1|||f||||t||||||||||2017-10-11 04:32:06.587491|2017-10-11 04:32:06.587491
NCT00024674|ClinicalTrials.gov processed this data on October 10, 2017|2001-09-24|2014-11-13|||February 2001||2001-02-01|November 2014|2014-11-01||||||||Interventional|||Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days||Withdrawn||Phase 1|0|Actual|INSYS Therapeutics Inc||||Support withdrawn - Study continued by NCI - see record NCT00006981|||||||||||||||2017-10-11 04:32:51.166706|2017-10-11 04:32:51.166706
NCT00024687|ClinicalTrials.gov processed this data on October 10, 2017|2001-09-24|2014-11-13|||November 2000||2000-11-01|November 2014|2014-11-01||||||||Interventional|||Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses||Withdrawn||Phase 1|0|Actual|INSYS Therapeutics Inc||||Support withdrawn - Study continued by NCI - see record NCT00006981|||||||||||||||2017-10-11 04:32:51.268997|2017-10-11 04:32:51.268997
NCT00027521|ClinicalTrials.gov processed this data on October 10, 2017|2001-12-07|2012-09-17|||December 2000||2000-12-01|September 2012|2012-09-01||||||||Interventional|||Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer|Phase I Study: Electroporation Therapy With Bleomycin For The Treatment Of Pancreatic Cancer|Withdrawn||Phase 1|0|Actual|Ichor Medical Systems Incorporated||||Program terminated|f||||||||||||||2017-10-11 04:33:26.234247|2017-10-11 04:33:26.234247
NCT00032643|ClinicalTrials.gov processed this data on October 10, 2017|2002-03-27|2013-11-04|||June 2004||2004-06-01|November 2013|2013-11-01|December 2006|Actual|2006-12-01|December 2006|Actual|2006-12-01||Interventional|||A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)|CSP #526 - A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)|Terminated||Phase 2|150|Anticipated|VA Office of Research and Development||1||Funding support withdrawn (much slower than expected enrollment)|f||||f||||||||||2017-10-11 04:34:12.368774|2017-10-11 04:34:12.368774
NCT00033371|ClinicalTrials.gov processed this data on October 10, 2017|2002-04-09|2016-12-28|2015-01-26||December 2001||2001-12-01|December 2016|2016-12-01|December 2014|Actual|2014-12-01|April 2009|Actual|2009-04-01||Interventional||According to the protocol, a patient needed to receive at least 80% of intended overall dose AND at least 80% dose during the final 60 days of the study to qualify as evaluable. One participant was randomized to Arm II but withdrew prior to receiving any treatment.|Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis|A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients|Terminated||Phase 2|112|Actual|National Cancer Institute (NCI)|Following reports of COX-2 inhibitor-associated cardiovascular toxicities, trial suspended from December 17, 2004 to March 18, 2005 pending reevaluation of cardiovascular risks, only two sites resumed the trial.|2||Slow recruitment.|f||||t||||||||||2017-10-11 04:34:19.788837|2017-10-11 04:34:19.788837
NCT00031590|ClinicalTrials.gov processed this data on October 10, 2017|2002-03-08|2015-09-30|||April 2001||2001-04-01|September 2015|2015-09-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Interventional|||Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma|Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma)|Terminated||Phase 2|30|Actual|Children's Hospital of Philadelphia||1||The study was terminated prematurely due to slow accrual.|f||||t||||||||||2017-10-11 04:35:54.12639|2017-10-11 04:35:54.12639
NCT00038038|ClinicalTrials.gov processed this data on October 10, 2017|2002-05-24|2012-07-31|||January 1994||1994-01-01|July 2012|2012-07-01|June 2003|Actual|2003-06-01|June 2003|Actual|2003-06-01||Interventional|||Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole|Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||1||No participants enrolled, study terminated.|f||||f||||||||||2017-10-11 04:35:58.267842|2017-10-11 04:35:58.267842
NCT00048074|ClinicalTrials.gov processed this data on October 10, 2017|2002-10-24|2016-01-04|2016-01-04||June 2002||2002-06-01|January 2016|2016-01-01|May 2005|Actual|2005-05-01|May 2005|Actual|2005-05-01||Interventional||Safety Population: All participants who were randomized and had at least one dose of study drug, whether withdrawn prematurely or not, and who had at least one follow-up data point were included.|DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis|A Randomized, Double-blind Study Comparing the Effect of Different Treatment Regimens of Intravenous Bonviva on Lumbar Bone Mineral Density in Women With Osteoporosis|Completed||Phase 3|1395|Actual|Hoffmann-La Roche||3|||f||||||||||||||2017-10-11 04:37:24.539193|2017-10-11 04:37:24.539193
NCT00046163|ClinicalTrials.gov processed this data on October 10, 2017|2002-09-20|2007-11-02|||September 2002||2002-09-01|November 2007|2007-11-01|August 2003|Actual|2003-08-01|||||Interventional|||A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension|A Phase IV, Multi-Center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled Study to Assess the Clinical Benefit of Three Doses of Midodrine Hydrochloride (ProAmatine®) in Subjects With Neurogenic Orthostatic Hypotension|Terminated||Phase 4|150||Shire||||Study was terminated due to poor enrollment|||||||||||||||2017-10-11 04:40:35.701134|2017-10-11 04:40:35.701134
NCT00058214|ClinicalTrials.gov processed this data on October 10, 2017|2003-04-07|2015-02-09|2015-02-09||March 2003||2003-03-01|February 2013|2013-02-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|||Perifosine in Treating Patients With Recurrent Prostate Cancer|A Phase II Trial of Perifosine (IND 58,156; NSC# 639966) in Biochemically Recurrent, Hormone Sensitive Prostate Cancer|Terminated||Phase 2|25|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.|1||Did not meet interim stopping criteria for continuation to the second stage.|f||||||||||||||2017-10-11 04:41:00.54256|2017-10-11 04:41:00.54256
NCT00058448|ClinicalTrials.gov processed this data on October 10, 2017|2003-04-07|2013-04-16|||October 2004||2004-10-01|April 2013|2013-04-01|November 2005|Actual|2005-11-01|November 2005|Actual|2005-11-01||Interventional|||S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)|Phase II Study Of Weekly Docetaxel In Patients With Advanced Epidermoid Carcinoma Of The Penis|Terminated||Phase 2|1|Actual|Southwest Oncology Group||1||Study terminated due to poor patient recruitment.|f||||f||||||||||2017-10-11 04:41:02.885647|2017-10-11 04:41:02.885647
NCT00061646|ClinicalTrials.gov processed this data on October 10, 2017|2003-06-02|2007-08-10|||March 2003||2003-03-01|August 2007|2007-08-01||||||||Interventional|||Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)|A Phase II Single-Arm Study Evaluating the Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|25|Actual|Abbott||1||"Enrollment suspended based upon interim analysis; subjects allowed to stay on study until   disease progression."|f||||f||||||||||2017-10-11 04:42:00.733678|2017-10-11 04:42:00.733678
NCT00062751|ClinicalTrials.gov processed this data on October 10, 2017|2003-06-12|2011-04-13|2010-10-27||December 2002||2002-12-01|April 2011|2011-04-01|October 2009|Actual|2009-10-01|April 2005|Actual|2005-04-01||Interventional|||Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms|A Phase 2 Randomized Open-Label Study Of Letrozole In Combination With Two Dose Levels And Schedules Of Oral Temsirolimus (CCI-779), Or Letrozole Alone, In Postmenopausal Women With Locally Advanced Or Metastatic Breast Cancer|Completed||Phase 2|108|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|Clinical development of oral temsirolimus for treatment of locally advanced or metastatic breast cancer was terminated by Wyeth based on the results of a phase 3 clinical study with the combination temsirolimus and letrozole.|3|||f||||f||||||||||2017-10-11 04:42:19.09017|2017-10-11 04:42:19.09017
NCT00062972|ClinicalTrials.gov processed this data on October 10, 2017|2003-06-18|2017-04-21|||September 1999||1999-09-01|May 2011|2011-05-01|August 2002||2002-08-01|||||Interventional|||Improving Memory in Patients With Multiple Sclerosis|Interventions to Improve Memory in Patients With Multiple Sclerosis|Withdrawn||Phase 3|0|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||||Study terminated/withdrawn|f||||||||||||||2017-10-11 04:42:25.743812|2017-10-11 04:42:25.743812
NCT00063258|ClinicalTrials.gov processed this data on October 10, 2017|2003-06-24|2016-04-05|2010-08-25||June 2003||2003-06-01|April 2016|2016-04-01|April 2008|Actual|2008-04-01|April 2008|Actual|2008-04-01||Interventional|||Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer|Phase II Randomized Open-Label Trial of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Tarceva™) in Combination With Paclitaxel and Carboplatin Prior to Surgery in Resectable Stage IIIA (N2) and IIIB (T4 N2) NSCLC: A Clinical Outcome and Biological Endpoint Trial|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center|Despite active study recruitment and screening for this study, only 5 subjects were enrolled out of the planned 40 subjects. Of the 5 subjects enrolled, only 1 patient was evaluable for response assessment. The study was subsequently terminated.|2||Low accrual rate|f||||t||||||||||2017-10-11 04:42:28.729561|2017-10-11 04:42:28.729561
NCT00066417|ClinicalTrials.gov processed this data on October 10, 2017|2003-08-06|2013-04-30||||||November 2006|2006-11-01|January 2007|Actual|2007-01-01|||||Interventional|||Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia|Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia|Terminated||Phase 2|51|Anticipated|National Cancer Institute (NCI)||||Trial was withdrawn for drug availability issues.|f||||||||||||||2017-10-11 04:44:14.22212|2017-10-11 04:44:14.22212
NCT00066807|ClinicalTrials.gov processed this data on October 10, 2017|2003-08-06|2016-09-26|2016-03-11||August 2003||2003-08-01|September 2016|2016-09-01|December 2006|Actual|2006-12-01|December 2006|Actual|2006-12-01||Interventional|PERCHE||Premenopausal Endocrine Responsive Chemotherapy Trial|A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy|Terminated||Phase 3|29|Actual|International Breast Cancer Study Group|Trial terminated early due to poor accrual. Adverse event data is available ONLY for selected Grade 3-5 AEs for chemotherapy arm. 25 of 29 patients were co-enrolled in TEXT (IBCSG 25-02), which reports AEs and outcomes of endocrine therapy.|2||Poor accrual, patients were followed until completion of 5 yrs treatment|f||||t||||||||||2017-10-11 04:44:25.510002|2017-10-11 04:44:25.510002
NCT00054704|ClinicalTrials.gov processed this data on October 10, 2017|2003-02-06|2016-05-17|2015-12-10||February 2003||2003-02-01|May 2016|2016-05-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional||All participants randomized.|Riluzole to Treat Depression in Bipolar Disorder|An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression|Terminated||Phase 2|20|Actual|National Institutes of Health Clinical Center (CC)|The study was terminated due to results suggesting the active drug was leading to worse outcomes than placebo.|2||Placebo was better than active drug.|f||||t||||||||No||2017-10-11 04:44:55.127846|2017-10-11 04:44:55.127846
NCT00055198|ClinicalTrials.gov processed this data on October 10, 2017|2003-02-20|2017-06-12|||December 19, 2002|Actual|2002-12-19|June 2017|2017-06-01|January 26, 2004|Actual|2004-01-26|January 26, 2004|Actual|2004-01-26||Interventional|||Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria|A Compassionate Use Protocol for Intravenous Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria That Cannot be Adequately Treated With Currently Available Therapy|Terminated||Phase 3|75||Cubist Pharmaceuticals LLC||||Study terminated due to low enrollment|||||||||||||||2017-10-11 04:45:10.487082|2017-10-11 04:45:10.487082
NCT00072189|ClinicalTrials.gov processed this data on October 10, 2017|2003-11-04|2015-02-17|2015-02-17||November 2003||2003-11-01|October 2013|2013-10-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||A Phase II Study of UCN-01 in Metastatic Melanoma|A Phase II Study of UCN-01 in Metastatic Melanoma|Terminated||Phase 2|17|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results|1||Early termination for discouraging results|f||||||||||||||2017-10-11 04:46:16.389305|2017-10-11 04:46:16.389305
NCT00072449|ClinicalTrials.gov processed this data on October 10, 2017|2003-11-04|2013-06-14|2013-06-14||May 2004||2004-05-01|June 2013|2013-06-01|June 2010|Actual|2010-06-01|March 2009|Actual|2009-03-01||Interventional|||Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma|A Phase II Study Of Anti-CD20 Monoclonal Antibody (Rituximab) Therapy For Patients With Refractory Or Relapsed Primary CNS Lymphoma (PCNSL)|Terminated||Phase 2|12|Actual|Sidney Kimmel Comprehensive Cancer Center|Study terminated early due to slow accrual and lack of resources and priority due to NCI mandate of combining two consortia. Unable to fully analyze the data, or objectives, not enough patients. Not able to do statistics|1||slow accrual and lack of resources and priority due to combining 2 consortia|f||||||||||||||2017-10-11 04:46:30.116063|2017-10-11 04:46:30.116063
NCT00078806|ClinicalTrials.gov processed this data on October 10, 2017|2004-03-05|2009-04-30|||June 2001||2001-06-01|April 2009|2009-04-01|May 2004|Actual|2004-05-01|May 2004|Actual|2004-05-01||Interventional|||Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis|Phase 3 Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis|Terminated||Phase 3|75|Anticipated|Amgen||2||the study was terminated because of slow enrollment|f||||||||||||||2017-10-11 04:49:26.375193|2017-10-11 04:49:26.375193
NCT00079274|ClinicalTrials.gov processed this data on October 10, 2017|2004-03-08|2015-01-23|2013-12-05||February 2004||2004-02-01|October 2014|2014-10-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Interventional|||Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer|A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer|Completed||Phase 3|3397|Actual|National Cancer Institute (NCI)|Accrual to arms A and D terminated early based on the results of the planned 2nd interim analysis. Sample sizes limit statistical conclusions for data from the irinotecan treated patients as those treatment arms were discontinued early in the study.|7|||f||||t||||||||||2017-10-11 04:49:36.642488|2017-10-11 04:49:36.642488
NCT00081900|ClinicalTrials.gov processed this data on October 10, 2017|2004-04-26|2015-04-09|||March 2004||2004-03-01|April 2015|2015-04-01|November 2007|Actual|2007-11-01|July 2007|Actual|2007-07-01||Interventional|||A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care|A Phase 1/2 Study of DENSPM (N1, N11-diethylnorspermine) in Patients With Unresectable Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|38|Actual|Sanofi||1||"This study was terminated early by Genzyme because there were insufficient data to support   clinical benefit to HCC patients on the study."|f||||t||||||||||2017-10-11 04:50:28.087462|2017-10-11 04:50:28.087462
NCT00082017|ClinicalTrials.gov processed this data on October 10, 2017|2004-04-28|2017-05-01|2012-06-06||April 5, 2004|Actual|2004-04-05|May 2017|2017-05-01|September 27, 2011|Actual|2011-09-27|September 27, 2011|Actual|2011-09-27||Interventional|||UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas|Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas|Terminated||Phase 2|20|Actual|National Institutes of Health Clinical Center (CC)||2||IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND.|f||||f|t|f|||t|||No||2017-10-11 04:50:30.025935|2017-10-11 04:50:30.025935
NCT00082095|ClinicalTrials.gov processed this data on October 10, 2017|2004-04-29|2014-10-08|||April 2004||2004-04-01|October 2014|2014-10-01|December 2005|Actual|2005-12-01|December 2005|Actual|2005-12-01||Interventional|||To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older|A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer in Women 60 Years and Older|Terminated||Phase 3|62|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||"The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in   20 months"|f||||f||||||||||2017-10-11 04:50:30.982775|2017-10-11 04:50:30.982775
NCT00083447|ClinicalTrials.gov processed this data on October 10, 2017|2004-05-24|2009-01-06|||May 2004||2004-05-01|January 2008|2008-01-01|June 2007|Anticipated|2007-06-01|March 2006|Actual|2006-03-01||Interventional|||Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme|A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID™ Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme|Withdrawn||Phase 3|323||Xenova Biomedix||||This study has been withdrawn because the drug would not meet trial criteria for efficacy|f||||||||||||||2017-10-11 04:50:52.764549|2017-10-11 04:50:52.764549
NCT00083759|ClinicalTrials.gov processed this data on October 10, 2017|2004-06-01|2016-07-14|2009-01-27||May 2004||2004-05-01|April 2009|2009-04-01||||February 2005|Actual|2005-02-01||Interventional|||Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate|A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)|Terminated||Phase 2|299|Actual|Biogen|The study was terminated prematurely on 28 February 2005. The biological effect seen with natalizumab was not sufficient to warrant further development in RA.|2||"The biological effect seen with natalizumab was not sufficient to warrant further development   in RA."|||||||||||||||2017-10-11 04:50:58.218392|2017-10-11 04:50:58.218392
NCT00077610|ClinicalTrials.gov processed this data on October 10, 2017|2004-02-10|2016-11-23|2016-01-29||February 2004||2004-02-01|September 2016|2016-09-01|August 2005|Actual|2005-08-01|August 2005|Actual|2005-08-01||Interventional||The safety population included all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not.|A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients|A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.|Completed||Phase 3|673|Actual|Hoffmann-La Roche||3|||f||||||||||||||2017-10-11 04:51:34.42825|2017-10-11 04:51:34.42825
NCT00077766|ClinicalTrials.gov processed this data on October 10, 2017|2004-02-12|2016-09-16|2016-07-27||March 2004||2004-03-01|November 2015|2015-11-01|August 2005|Actual|2005-08-01|August 2005|Actual|2005-08-01||Interventional||The safety population was defined as all participants who received at least one dose of RO0503821 or darbepoetin alfa and had a safety follow-up, whether withdrawn prematurely or not. There were 4 participants who were excluded from the safety population as they did not receive the study medication.|A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.|A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.|Completed||Phase 3|313|Actual|Hoffmann-La Roche||2|||f||||||||||||||2017-10-11 04:51:46.346381|2017-10-11 04:51:46.346381
NCT00088985|ClinicalTrials.gov processed this data on October 10, 2017|2004-08-04|2017-05-26|2017-03-28||January 2004||2004-01-01|May 2017|2017-05-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional|||Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer|Phase II Trial Evaluating The Efficacy Of A Multiepitope Dendritic Cell Vaccine Given With Trastuzumab And Vinorelbine For The Treatment Of Women With Metastatic Breast Cancer That Express HLA-A0201|Terminated||Phase 2|56|Actual|UNC Lineberger Comprehensive Cancer Center|Study was terminated due to unavailable funding.|1||Funding unavailable|f||||t||||||||||2017-10-11 04:52:20.952437|2017-10-11 04:52:20.952437
NCT00089414|ClinicalTrials.gov processed this data on October 10, 2017|2004-08-04|2017-07-26|2013-01-14||July 2004||2004-07-01|July 2017|2017-07-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives|The Treatment of Menstrually-Related Mood Disorders With Extended Versus Interrupted Oral Contraceptives|Terminated||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)|Protocol terminated after receiving information from manufacturer (Pharma) that CDB-2914 crosses the blood-brain barrier, invalidating Arm #3 due to potential CNS effect of the compound on behavior.|3||"Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of   protocol."|f||||f||||||||||2017-10-11 04:52:26.489495|2017-10-11 04:52:26.489495
NCT00090532|ClinicalTrials.gov processed this data on October 10, 2017|2004-08-26|2011-05-26|||January 2004||2004-01-01|May 2011|2011-05-01|August 2006|Actual|2006-08-01|||||Interventional|||A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration|A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety an Efficacy of AG-013958 in Subjects With Subfoveal Choroidal Neovascularization Associated With Age-related Macular Degeneration|Terminated||Phase 1/Phase 2|155||Pfizer||||This study was terminated due to a lack of efficacy.|||||||||||||||2017-10-11 04:53:29.176963|2017-10-11 04:53:29.176963
NCT00090688|ClinicalTrials.gov processed this data on October 10, 2017|2004-09-02|2016-12-27|||August 2004||2004-08-01|January 2006|2006-01-01||||||||Interventional|||Phase 1 meCS6 + LT(R192G) Vaccine Study|Safety and Immunogenicity of Oral Microencapsulated CS6 Vaccine and LT(R192G) Adjuvant in Volunteers|Withdrawn||Phase 1|0|Actual|U.S. Army Medical Research and Materiel Command||||IND was terminated for being inactive for more than five years|||||||||||||||2017-10-11 04:53:32.903669|2017-10-11 04:53:32.903669
NCT00085423|ClinicalTrials.gov processed this data on October 10, 2017|2004-06-10|2013-04-09|2012-01-26||February 2004||2004-02-01|April 2013|2013-04-01|February 2010|Actual|2010-02-01|December 2008|Actual|2008-12-01||Interventional|||Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma|"High Dose Interleukin-2 (IL-2) Therapy In Lymphodepleted Primed Patients With Metastatic Melanoma"|Completed||Phase 2|20|Actual|Dartmouth-Hitchcock Medical Center|This was the first stage of a two-stage phase II study and continuation to next stage required 4 of 18 particpant having an objective response. Only 3 objective responses were noted and the study was terminated at stage 1.|1|||f||||t||||||||||2017-10-11 04:55:28.203273|2017-10-11 04:55:28.203273
NCT00085540|ClinicalTrials.gov processed this data on October 10, 2017|2004-06-10|2016-11-15|2016-09-23||January 2005||2005-01-01|November 2016|2016-11-01|March 2009|Actual|2009-03-01|December 2008|Actual|2008-12-01||Interventional||two patients were removed from the analysis due to one withdrawing consent and one was deemed ineligible.|FR901228 in Treating Patients With Recurrent High-Grade Gliomas|A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas|Completed||Phase 1/Phase 2|50|Actual|National Cancer Institute (NCI)|Dose escalation was terminated after 2 dose levels because PK parameters of romidepsin in pts receiving EIAEDs were similar to those reported in Adults not receiving CYP34A inducing drugs, we wanted to avoid the expected dose limiting toxicity.|2|||f||||t||||||||No||2017-10-11 04:55:31.174756|2017-10-11 04:55:31.174756
NCT00087464|ClinicalTrials.gov processed this data on October 10, 2017|2004-07-08|2012-05-17||||||May 2012|2012-05-01||||||||Interventional|||Three Month Course of Anti-HIV Medications for People Recently Infected With HIV|Tenofovir, Emtricitabine, and Nevirapine for Recently HIV-Infected Subjects: Can Short-Course, Once Daily Therapy Reduce the Viral Load at 12 Months From Estimated Date of Infection?|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||||study was withdrawn before any participants were recruited and enrolled|||||||||||||||2017-10-11 04:56:17.420675|2017-10-11 04:56:17.420675
NCT00097370|ClinicalTrials.gov processed this data on October 10, 2017|2004-11-22|2017-06-07|2015-11-09|2012-03-15|September 30, 2004|Actual|2004-09-30|June 2017|2017-06-01|September 29, 2010|Actual|2010-09-29|September 29, 2010|Actual|2010-09-29||Interventional|||Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome|An Open Label Extension Study to Evaluate Safety and Efficacy of Mepolizumab in Patients With Hypereosinophilic Syndromes|Terminated||Phase 3|78|Actual|GlaxoSmithKline||1||"Study terminated by sponsor (29 Sep 2010). Subjects eligible to continue mepolizumab treatment   were transferred into the compassionate use program (MHE104317)"|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2017-10-11 04:56:41.278154|2017-10-11 04:56:41.278154
NCT00100347|ClinicalTrials.gov processed this data on October 10, 2017|2004-12-29|2007-07-23|||December 2004||2004-12-01|July 2007|2007-07-01|July 2007|Actual|2007-07-01|||||Interventional|||Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors|A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors|Terminated||Phase 1|45|Actual|PRAECIS Pharmaceuticals Inc.||1||terminated due to corporate transaction.|f||||f||||||||||2017-10-11 05:00:02.935414|2017-10-11 05:00:02.935414
NCT00100971|ClinicalTrials.gov processed this data on October 10, 2017|2005-01-07|2013-01-03|||April 2004||2004-04-01|January 2013|2013-01-01|March 2007|Actual|2007-03-01|March 2007|Actual|2007-03-01||Interventional|||Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia|Dendritic/Leukemic Fusion Cell Vaccine Therapy For AML Patients In First Remission; A Phase I Clinical Trial|Terminated||Phase 1|9||Boston Medical Center||||Protocol is withdrawn due to inadequate accrual|f||||||||||||||2017-10-11 05:00:15.79298|2017-10-11 05:00:15.79298
NCT00101361|ClinicalTrials.gov processed this data on October 10, 2017|2005-01-07|2013-11-26|2013-06-27||August 2005||2005-08-01|November 2013|2013-11-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional||overall baseline participants were determined by number of participants that were eligible after screening based on a pressure ulcer that is defined as hard-to-heal or worsening at randomization.|Oxandrolone to Heal Pressure Ulcers|CSP #535 - Anabolic Steroid Therapy on Pressure Ulcer Healing in Persons With Spinal Cord Injury|Terminated||Phase 3|212|Actual|VA Office of Research and Development|Selection of severe wounds may have reduced treatment response. The study was terminated after a futility analysis showed a low probability of detecting a significant difference between groups.|2||futility analysis showed low probability of detecting a significant difference|f||||t||||||||||2017-10-11 05:00:23.476078|2017-10-11 05:00:23.476078
NCT00101907|ClinicalTrials.gov processed this data on October 10, 2017|2005-01-18|2014-02-03|2010-08-13||December 2004||2004-12-01|February 2014|2014-02-01|April 2008|Actual|2008-04-01|June 2007|Actual|2007-06-01||Interventional|||Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer|An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer|Terminated||Phase 1|41|Actual|Amgen||6||Study terminated per recommendation of Data Review Team|f||||||||||||||2017-10-11 05:00:43.252295|2017-10-11 05:00:43.252295
NCT00091611|ClinicalTrials.gov processed this data on October 10, 2017|2004-09-11|2012-10-25|||September 2004||2004-09-01|October 2012|2012-10-01|March 2008|Actual|2008-03-01|April 2006|Actual|2006-04-01||Interventional|||Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer|Phase II Study in Metastatic Renal Cell Cancer Using Cultured, Tumor-Reactive Lymphocytes and Interleukin-2|Terminated||Phase 1|3|Actual|National Institutes of Health Clinical Center (CC)||||This study was terminated due to low accrual.|f||||||||||||||2017-10-11 05:01:16.419737|2017-10-11 05:01:16.419737
NCT00103519|ClinicalTrials.gov processed this data on October 10, 2017|2005-02-09|2013-03-27|||December 2004||2004-12-01|November 2006|2006-11-01|December 2006|Actual|2006-12-01|December 2006|Actual|2006-12-01||Interventional|||Study of DITPA in Patients With Congestive Heart Failure|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DITPA in Patients With NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T3 Levels|Terminated||Phase 2|86|Actual|Titan Pharmaceuticals||3||Study terminated for reasons unrelated to safety or efficacy.|f||||||||||||||2017-10-11 05:01:35.705934|2017-10-11 05:01:35.705934
NCT00108433|ClinicalTrials.gov processed this data on October 10, 2017|2005-04-15|2012-06-28|2012-06-28||September 2005||2005-09-01|June 2012|2012-06-01|September 2006|Actual|2006-09-01|||||Interventional|||Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections|Linezolid vs Vancomycin/Cefazolin in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections|Terminated||Phase 3|61|Actual|Pfizer|Efficacy results were not reported because the study was prematurely terminated.|||See Detailed Description|f||||||||||||||2017-10-11 05:03:03.795677|2017-10-11 05:03:03.795677
NCT00113386|ClinicalTrials.gov processed this data on October 10, 2017|2005-06-07|2013-06-21|2012-11-27||April 2005||2005-04-01|June 2013|2013-06-01||||February 2009|Actual|2009-02-01||Interventional|||Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer|Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer|Terminated||Phase 3|19|Actual|Radiation Therapy Oncology Group|This study terminated early with 19 out of 574 subjects accrued. Therefore no analysis was performed.|2||This study terminated early due to low accrual.|f||||t||||||||||2017-10-11 05:04:19.40788|2017-10-11 05:04:19.40788
NCT00113399|ClinicalTrials.gov processed this data on October 10, 2017|2005-06-07|2013-06-26|2012-11-27||April 2005||2005-04-01|June 2013|2013-06-01||||February 2009|Actual|2009-02-01||Interventional|||Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery|A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy Versus Chemotherapy Alone|Terminated||Phase 3|15|Actual|Radiation Therapy Oncology Group|This study terminated early with 15 subjects out of 240 subjects accrued, therefore no analysis was performed.|2||Terminated early due to low accrual.|f||||t||||||||||2017-10-11 05:04:20.288223|2017-10-11 05:04:20.288223
NCT00104884|ClinicalTrials.gov processed this data on October 10, 2017|2005-03-03|2016-02-01|2015-12-15||January 2005||2005-01-01|February 2016|2016-02-01|March 2009|Actual|2009-03-01|May 2006|Actual|2006-05-01||Interventional||All enrolled patients|FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma|Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma|Terminated||Phase 2|4|Actual|Eastern Cooperative Oncology Group||1||The study was terminated on May 17, 2006 due to slow accrual.|f||||f||||||||No||2017-10-11 05:04:56.782492|2017-10-11 05:04:56.782492
NCT00108953|ClinicalTrials.gov processed this data on October 10, 2017|2005-04-21|2014-10-24|2009-04-23||April 2005||2005-04-01|October 2014|2014-10-01|April 2008|Actual|2008-04-01|April 2008|Actual|2008-04-01||Interventional|||A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma|A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.|Completed||Phase 2|96|Actual|Bayer|The study had been prematurely terminated by the sponsor because positive results were obtained in another Nexavar trial (Phase 3 study 100554 NCT00105443). NCI-CTC was translated to MedDRA for SOCs only.|2|||f||||f||||||||||2017-10-11 05:06:38.591588|2017-10-11 05:06:38.591588
NCT00109304|ClinicalTrials.gov processed this data on October 10, 2017|2005-04-27|2015-09-17|||July 2005||2005-07-01|September 2015|2015-09-01|December 2006||2006-12-01|||||Interventional|||Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine|Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine VEE IA/B V3526 in VEE-Naive Healthy Volunteers After Single Dose Subcutaneous Administration|Withdrawn||Phase 1|0|Actual|DynPort Vaccine Company LLC, A CSC Company||1||Funding withdrawn|f||||t||||||||||2017-10-11 05:06:46.830587|2017-10-11 05:06:46.830587
NCT00117312|ClinicalTrials.gov processed this data on October 10, 2017|2005-06-30|2011-05-18|2009-01-22||October 2002||2002-10-01|May 2011|2011-05-01|November 2005|Actual|2005-11-01|November 2005|Actual|2005-11-01||Interventional|||Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients|An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients|Terminated||Phase 2|37|Actual|Ferring Pharmaceuticals||4||After 190 weeks [7 patients left] it was terminated for administrative reasons|f||||t||||||||||2017-10-11 05:07:50.267828|2017-10-11 05:07:50.267828
NCT00119028|ClinicalTrials.gov processed this data on October 10, 2017|2005-07-01|2012-04-23|||April 2005||2005-04-01|April 2012|2012-04-01|October 2009|Actual|2009-10-01|December 2008|Actual|2008-12-01||Interventional|ReTIDES||Expanding and Testing VA Collaborative Care Models for Depression|Expanding and Testing VA Collaborative Care Models for Depression|Withdrawn||N/A|0|Actual|VA Office of Research and Development||1||This study was withdrawn prior to enrollment.|f||||f||||||||||2017-10-11 05:08:44.505247|2017-10-11 05:08:44.505247
NCT00119184|ClinicalTrials.gov processed this data on October 10, 2017|2005-07-03|2008-06-05|||October 2002||2002-10-01|May 2008|2008-05-01|May 2008|Actual|2008-05-01|March 2006|Actual|2006-03-01||Interventional|||Spinal Analgesia Versus No Analgesia: Study for External Cephalic Version|A Prospective Randomized Study to Examine the Success Rate of External Cephalic Version for Breech Presentation at Term Presentation: Spinal Analgesia Versus No Analgesia|Terminated||Phase 1|140|Anticipated|Hadassah Medical Organization||2||"Multiparas study terminated due to poor recruitment. Randomization revealed only after decision   recorded on clinicaltrials.gov"|f||||f||||||||||2017-10-11 05:08:46.347098|2017-10-11 05:08:46.347098
NCT00121537|ClinicalTrials.gov processed this data on October 10, 2017|2005-07-13|2015-10-07|||July 2005||2005-07-01|October 2015|2015-10-01|October 2006|Actual|2006-10-01|||||Interventional|||Study to Determine the Utility of Wound Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes|A Prospective Study to Determine the Utility of Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes With Regards to Lower Extremity Fasciotomy Wound Healing, Complications, Cost and Patient and Nursing Satisfaction|Terminated||N/A|30||The University of Texas Health Science Center at San Antonio||||terminated, due to lack enrollment,|f||||||||||||||2017-10-11 05:09:09.881359|2017-10-11 05:09:09.881359
NCT00123890|ClinicalTrials.gov processed this data on October 10, 2017|2005-07-22|2011-03-28|||June 2005||2005-06-01|March 2011|2011-03-01|October 2005|Actual|2005-10-01|October 2005|Actual|2005-10-01||Interventional|||Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140|A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 Infected, Treatment-experienced Subjects With Drug-resistant Virus or an Observational Study.|Terminated||Phase 3|0|Actual|GlaxoSmithKline||1||The study was terminated due to hepatoxicity of compound|||||||||||||||2017-10-11 05:10:26.716887|2017-10-11 05:10:26.716887
NCT00124930|ClinicalTrials.gov processed this data on October 10, 2017|2005-07-27|2012-01-18|||May 2005||2005-05-01|January 2012|2012-01-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional|||Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer|A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer|Terminated||Phase 3|80|Anticipated|AHS Cancer Control Alberta||||Study suspended due to low enrollment|f||||||||||||||2017-10-11 05:10:42.733903|2017-10-11 05:10:42.733903
NCT00125268|ClinicalTrials.gov processed this data on October 10, 2017|2005-07-27|2012-08-02|2012-08-02||July 2005||2005-07-01|August 2012|2012-08-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|||Near Infrared Light for the Treatment of Painful Peripheral Neuropathy|A Phase III, Double Blind, Randomized, Placebo-controlled Study to Assess the Efficacy of Adjunct Monochromatic Near-infrared Photoenergy (MIRE) in Patients With Painful Axonal Peripheral Neuropathy|Terminated||Phase 3|30|Actual|Mayo Clinic|This study was terminated early because the study was unable to enroll enough patients.|2||Unable to enroll enough patients|f||||t||||||||||2017-10-11 05:10:56.889469|2017-10-11 05:10:56.889469
NCT00125645|ClinicalTrials.gov processed this data on October 10, 2017|2005-07-29|2011-08-15|||March 2005||2005-03-01|April 2007|2007-04-01|September 2011|Anticipated|2011-09-01|September 2011|Anticipated|2011-09-01||Interventional|||Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)|Global Left Ventricular Function After Acute Myocardial Infarction. Treatment With the Angiotensin 2-Receptor Blocker Irbesartan|Suspended||Phase 4|200|Anticipated|University of Southern Denmark||1||Study terminated due to lack of patients|f||||||||||||||2017-10-11 05:11:01.468869|2017-10-11 05:11:01.468869
NCT00127374|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-04|2016-11-07|||January 2005||2005-01-01|November 2016|2016-11-01|September 2006|Actual|2006-09-01|September 2006|Actual|2006-09-01||Observational|||Mood and Behavior Changes Among Overweight Adolescent Females|Mood and Behavior Changes Among Overweight Adolescent Females|Withdrawn||N/A|0|Actual|University of Kentucky||||withdrawn due to non-response. PI left university|f||||||||||||||2017-10-11 05:11:52.397657|2017-10-11 05:11:52.397657
NCT00128557|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-09|2007-04-09|||January 2004||2004-01-01|April 2007|2007-04-01|December 2006|Actual|2006-12-01|||||Interventional|||Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh|A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh|Terminated||Phase 3|25000||Johns Hopkins Bloomberg School of Public Health||||Study terminated based on DSMB recommendation in December 2006|f||||t||||||||||2017-10-11 05:12:21.914842|2017-10-11 05:12:21.914842
NCT00128921|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-08|2012-04-25|2011-04-15||April 2006||2006-04-01|April 2012|2012-04-01|February 2008|Actual|2008-02-01|February 2008|Actual|2008-02-01||Interventional|||Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma|A Phase II Dose-Response Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 2|18|Actual|University of Arkansas|Early termination due to difficulty in accruing participants.|3||study terminated due to low accrual|f||||t||||||||||2017-10-11 05:12:29.313436|2017-10-11 05:12:29.313436
NCT00129623|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-11|2015-12-05|2015-12-05||December 2005||2005-12-01|December 2015|2015-12-01|December 2007|Actual|2007-12-01|December 2007|Actual|2007-12-01||Interventional||Baseline characteristics are presented for the safety population which included participants who had at least one dose of the trial medication documented in the case report form (CRF) whether withdrawn prematurely or not.|A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia|Double-blind, Placebo-controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of Oral Ibandronate Once Monthly in Postmenopausal Women With Osteopenia|Completed||Phase 4|160|Actual|Hoffmann-La Roche||2|||f||||||||||||||2017-10-11 05:12:51.240037|2017-10-11 05:12:51.240037
NCT00130390|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-12|2012-05-30|||August 2005||2005-08-01|May 2012|2012-05-01|July 2008|Actual|2008-07-01|December 2007|Actual|2007-12-01||Interventional|||Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease|Multi-center, Randomized, Double-Blind, Placebo-Controlled Trial of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease in Adults|Terminated||Phase 2|98|Actual|Romark Laboratories L.C.||2||terminated due to slow recruitment|f||||f||||||||||2017-10-11 05:13:10.178565|2017-10-11 05:13:10.178565
NCT00131508|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-17|2017-04-24|2010-02-19||May 2004||2004-05-01|March 2010|2010-03-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||Trial of Oral Glutamine in Patients With Sickle Cell Anemia|A Randomized Controlled Trial of Oral Glutamine Supplementation Versus a Placebo Supplement in Children With Sickle Cell Anemia|Terminated||Phase 2|27|Actual|St. Jude Children's Research Hospital|The study was designed to enroll 46 participants (23 per arm). Due to slow accrual the study was terminated after enrolling 27 participants. Of the 27 participants enrolled, 2 dropped out of the study prior to randomization.|2||Due to slow participant accrual|f||||t||||||||||2017-10-11 05:13:28.796285|2017-10-11 05:13:28.796285
NCT00131664|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-17|2013-04-15|2012-01-28||September 2005||2005-09-01|April 2013|2013-04-01|January 2008|Actual|2008-01-01|January 2008|Actual|2008-01-01||Interventional|AVALANCHE||Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)|Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin: A 48-week Randomized, Open-label, Multicentre Phase IIIB Study to Compare the Effectiveness of Combination Therapy to Monotherapy in Type 2 Diabetes Mellitus Patients|Completed||Phase 3|391|Actual|Canadian Heart Research Centre|The LOCF used in the ITT population for withdrawn subjects or missing values was analyzed as per protocol. The 3 treatment groups used throughout the results section were the numbers where the patients were originally randomized to.|3|||f||||t||||||||||2017-10-11 05:13:30.782496|2017-10-11 05:13:30.782496
NCT00132002|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-16|2015-03-06|2015-03-06||June 2005||2005-06-01|February 2013|2013-02-01|January 2008|Actual|2008-01-01|January 2008|Actual|2008-01-01||Interventional|||Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer|Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer|Terminated||Phase 2|14|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results|1||Early termination for discouraging results|f||||||||||||||2017-10-11 05:13:35.62137|2017-10-11 05:13:35.62137
NCT00132730|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-03|2017-03-24|2014-03-17||June 1, 2004|Actual|2004-06-01|March 2017|2017-03-01|August 17, 2005|Actual|2005-08-17|August 17, 2005|Actual|2005-08-17||Interventional|||An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK-0873 in Patients With COPD|Terminated||Phase 2|604|Actual|Merck Sharp & Dohme Corp.|The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.|6|||f||||f||||||||||2017-10-11 05:13:46.310988|2017-10-11 05:13:46.310988
NCT00137501|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-29|2013-07-18|||May 2003||2003-05-01|July 2013|2013-07-01|June 2009|Actual|2009-06-01|January 2009|Actual|2009-01-01||Interventional|||Two Dose Regimens of Nifedipine for the Management of Preterm Labor|Study of Different Doses of Nifedipine to Treat Preterm Labor|Terminated||Phase 3|102|Actual|American University of Beirut Medical Center||2||The trial was terminated because of difficulties in recruitement.|f||||f||||||||||2017-10-11 05:14:15.263557|2017-10-11 05:14:15.263557
NCT00138073|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-26|2014-05-29|2014-03-24||December 2005||2005-12-01|May 2014|2014-05-01|April 2012|Actual|2012-04-01|April 2012|Actual|2012-04-01||Interventional|||Effectiveness of a Computer Application in Improving Pulmonary Artery Catheter Waveform Interpretation|Effectiveness of a Web-Based Computer Application in Improving Pulmonary Artery Catheter Waveform Interpretation Among Nurses and Physicians|Terminated||N/A|55|Actual|Massachusetts General Hospital|Study not completed.|1||The study was terminated because of lack of resources to complete it.|f||||t||||||||||2017-10-11 05:14:21.287597|2017-10-11 05:14:21.287597
NCT00138125|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-29|2016-01-28|2013-01-08||April 2005||2005-04-01|January 2013|2013-01-01|December 2009|Actual|2009-12-01|September 2009|Actual|2009-09-01||Interventional|||Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer|Phase II Randomized Trial of Faslodex and Herceptin, Alone and Combined, in the First - Line Treatment of Hormone Receptor-Positive, HER-2/Neu-Overexpressing Metastatic Breast Cancer|Terminated||Phase 2|2|Actual|Translational Oncology Research International|Trial terminated due to slow patient accrual.Study closed with two subjects enrolled to treatment phase.Slow accrual was due to specific requirements of study population limiting enrollment and possibly due to availability of study drugs in clinic.|1||Due to low accrual|f||||t||||||||||2017-10-11 05:14:21.853954|2017-10-11 05:14:21.853954
NCT00138671|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-26|2010-01-25|2009-09-02||January 2003||2003-01-01|August 2009|2009-08-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD|Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial|Terminated||Phase 3|105|Actual|Pfizer|This study was terminated due to Pfizer's decision to stop marketing Exubera®. Due to inconsistency in concomitant medication data entry, interpretation of the event rates for non-severe exacerbations may be of limited clinical value.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 05:14:34.340434|2017-10-11 05:14:34.340434
NCT00139074|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-29|2013-01-25|||July 2005||2005-07-01|January 2013|2013-01-01|June 2006|Actual|2006-06-01|June 2006|Actual|2006-06-01||Interventional|||Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients|Phase IV Study to Investigate if Valproate Add-on Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients|Terminated||Phase 4|17|Actual|AstraZeneca||2||terminated due to very low recruitment rate (27 June 2006)|f||||f||||||||||2017-10-11 05:14:40.030021|2017-10-11 05:14:40.030021
NCT00142974|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-31|2012-04-19|||May 2004||2004-05-01|April 2012|2012-04-01|April 2005|Actual|2005-04-01|April 2005|Actual|2005-04-01||Interventional|||Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy|Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy|Terminated||Phase 2|120||Novartis||||This study was terminated early in April 2005 due to low patient enrollment|||||||||||||||2017-10-11 05:14:43.623973|2017-10-11 05:14:43.623973
NCT00143247|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-31|2010-04-10|2009-01-16||March 2003||2003-03-01|July 2009|2009-07-01|January 2008|Actual|2008-01-01|January 2008|Actual|2008-01-01||Interventional|||Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus|An Open-Label, Phase 2, Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus Participating in Extension Protocols 217-102, 103, or 104|Terminated||Phase 2|173|Actual|Pfizer|Study terminated early due to business and operational issues. All subjects who were treated with inhaled insulin in parent protocols(217-102,-103,or-104) or in extension protocols (217-102E,-103E,-104E,or A2171036)are included in safety evaluation.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 05:14:46.771646|2017-10-11 05:14:46.771646
NCT00148109|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-02|2013-01-15|2011-04-12||June 2005||2005-06-01|January 2013|2013-01-01|December 2009|Actual|2009-12-01|July 2008|Actual|2008-07-01||Interventional|||Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas|Phase II Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas|Completed||Phase 2|36|Actual|University of Michigan Cancer Center|accrual to EGFR + cohort suspended after first step for lack of efficacy of cetuximab.|2|||f||||t||||||||||2017-10-11 05:17:11.609737|2017-10-11 05:17:11.609737
NCT00141037|ClinicalTrials.gov processed this data on October 10, 2017|2005-08-01|2016-10-19|2013-05-21||March 2004||2004-03-01|October 2016|2016-10-01|November 2010|Actual|2010-11-01|September 2006|Actual|2006-09-01||Interventional|||Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation|Randomized, Multi-Center Comparative Trial of Tacrolimus w/Steroids and Standard Daclizumab Induction vs a Novel Steroid-Free Tacrolimus Based Immunosuppression Protocol w/ Extended Daclizumab Induction in Pediatric Renal Transplantation|Completed||Phase 1/Phase 2|130|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|"The results cannot be generalized and daclizumab has since been withdrawn from the United States market (business-related, not due to any safety issues).
NCT00142168|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-01|2016-03-23|2012-12-19||September 2004||2004-09-01|March 2016|2016-03-01|April 2008|Actual|2008-04-01|May 2006|Actual|2006-05-01||Interventional|||CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia|Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia|Terminated||Phase 2|16|Actual|Dana-Farber Cancer Institute|Due to toxicity, study was terminated.|1||Toxicity|f||||t||||||||||2017-10-11 05:18:24.075629|2017-10-11 05:18:24.075629
NCT00142727|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-01|2017-01-11|||January 2004||2004-01-01|July 2007|2007-07-01|February 2006||2006-02-01|||||Interventional|||Opioid Agonist and Antagonist Effects on Opioid Dependence|The Variability of Agonist and Antagonist Effects as a Function of Level of Physical Dependence|Terminated||Phase 2|16|Anticipated|National Institute on Drug Abuse (NIDA)||1||Study terminated due to halt in funding; may resume recruiting in future|f||||f||||||||||2017-10-11 05:18:35.735572|2017-10-11 05:18:35.735572
NCT00149357|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-06|2017-03-21|||July 2005||2005-07-01|March 2017|2017-03-01|December 2008|Actual|2008-12-01|February 2008|Actual|2008-02-01||Observational|||Fetal Loss in Women With Unprovoked Thromboembolism (FLUTE)|Determining the Risk of Fetal Loss in Women With Unprovoked Venous Thromboembolism (VTE) Who Do NOT Have Identifiable Inherited Thrombophilia Compared With Women Who Have the Diagnosis of VTE Excluded|Terminated||N/A|239|Actual|McMaster University|||1|Funding withdrawn due to low enrollment|f||||t||||||||||2017-10-11 05:18:38.952403|2017-10-11 05:18:38.952403
NCT00146406|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-02|2012-09-10|||January 2005||2005-01-01|September 2012|2012-09-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Multi-level Interventions for STD Prevention Among Adolescents|Integrated Multi-level Interventions to Improve Adolescent Health Through the Prevention of STD, Including HIV, and Teen Pregnancy|Terminated||N/A|36502|Actual|Centers for Disease Control and Prevention||||IRB terminated due to no continuation request.|f||||||||||||||2017-10-11 05:20:02.908302|2017-10-11 05:20:02.908302
NCT00154427|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-09|2017-01-11|||August 2004||2004-08-01|January 2017|2017-01-01|November 2007|Actual|2007-11-01|November 2007|Actual|2007-11-01||Interventional|||Use of Activated Recombinant Human Factor VII in Cardiac Surgery|A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass|Terminated||Phase 2|172|Actual|Novo Nordisk A/S||||"Trial terminated after recruiting 172 patients but without proceeding to the highest dosing   cohort as this no longer reflects common clinical practice"|f||||f||||||||||2017-10-11 05:20:34.313561|2017-10-11 05:20:34.313561
NCT00162097|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-09|2010-09-07|2010-07-28||November 2004||2004-11-01|September 2010|2010-09-01|March 2008|Actual|2008-03-01|March 2008|Actual|2008-03-01||Interventional|||Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment|Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects With Hepatic Impairment.|Completed||Phase 1|21|Actual|Bristol-Myers Squibb|The study was terminated early leading to a small number of participants treated and analyzed. Due to the small sample size, no conclusion could be made for participants with Child-Pugh scores B and C (moderate and severe hepatic impairment).|4|||f||||f||||||||||2017-10-11 05:23:09.460896|2017-10-11 05:23:09.460896
NCT00165503|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2016-07-25|2014-04-23||April 2004||2004-04-01|July 2016|2016-07-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|||Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate|A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin|Terminated||Phase 2|16|Actual|Dana-Farber Cancer Institute|This trial was terminated due to low accrual and feasibility.|1||lack of acurral|f||||t||||||||No||2017-10-11 05:24:05.677128|2017-10-11 05:24:05.677128
NCT00167661|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-11|2015-10-09|||June 2004||2004-06-01|October 2015|2015-10-01|May 2012|Actual|2012-05-01|December 2011|Actual|2011-12-01||Interventional|||Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation|Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation|Terminated||Phase 1/Phase 2|50|Anticipated|University of Wisconsin, Madison||1||Enrollment suspended pending protocol revision to change study to observational|f||||t||||||||||2017-10-11 05:24:45.88187|2017-10-11 05:24:45.88187
NCT00169221|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2011-11-14|||September 2005||2005-09-01|November 2011|2011-11-01|July 2011|Actual|2011-07-01|July 2009|Actual|2009-07-01||Interventional|||Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas|CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) in Upper Aerodigestive Tract Carcinomas|Terminated||Phase 2|54|Actual|Groupe Oncologie Radiotherapie Tete et Cou||2||"Toxicity in an independent study IMEX. The trial was subsequently terminated (54 pts instead of   140) despite safety analyses showing no excess of toxicity"|f||||||||||||||2017-10-11 05:25:18.155055|2017-10-11 05:25:18.155055
NCT00169949|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-09|2009-09-24|||January 2004||2004-01-01|April 2007|2007-04-01|May 2006|Actual|2006-05-01|||||Interventional|||Aripiprazole Treatment of the Prodrome|Open-Label Study of Aripiprazole in Individuals at Risk for Chronic Mental Illness|Terminated||N/A|30||Northwell Health||||The study was terminated due to low enrollment.|f||||t||||||||||2017-10-11 05:25:28.226953|2017-10-11 05:25:28.226953
NCT00171925|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2012-04-05|2011-01-20||August 2000||2000-08-01|April 2012|2012-04-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional|||Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I|Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I|Terminated||Phase 3|143|Actual|Novartis|Only exploratory analyses were performed as the trial was terminated early due to lack of obtaining the required sample size. Secondary Outcomes for Quality of Life and Bone Markers not posted due to sparse data.|2||Recruitment in study could not be reached after 8 yrs of recruiting|f||||||||||||||2017-10-11 05:25:48.301268|2017-10-11 05:25:48.301268
NCT00172367|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2008-09-25|||January 2006||2006-01-01|November 2004|2004-11-01||||||||Interventional|||Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma||Withdrawn||Phase 2|80|Anticipated|National Taiwan University Hospital||||"This study was for National Science Council project. The study was not funded, so the study was   withdrawn."|f||||||||||||||2017-10-11 05:25:55.426808|2017-10-11 05:25:55.426808
NCT00174187|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-09|2012-11-05|2012-09-11||September 2000||2000-09-01|November 2012|2012-11-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional|||Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy|Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety.|Terminated||Phase 3|30|Actual|Pfizer|Results for secondary and other pre-specified endpoints (except IGF-1) are reported for only up to 3 years because data beyond Year 3 was not summarized as the study was terminated due to Good Clinical Practice (GCP) non-compliance issues.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 05:26:21.336452|2017-10-11 05:26:21.336452
NCT00174291|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-09|2012-10-26|2012-10-26||March 2002||2002-03-01|October 2012|2012-10-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|||Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy|Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor Genotonorm (Registered) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-term Corticosteroid Therapy. Extension of the Study Beyond Three Years|Terminated||Phase 3|21|Actual|Pfizer|Data for bone mineral density (BMD), bone mineral content (BMC) and IGFBP3 were not analyzed because of change in planned analysis after the study was prematurely terminated due to Good Clinical Practice (GCP) non-compliance issues.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 05:26:24.913595|2017-10-11 05:26:24.913595
NCT00176683|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2017-01-26|||July 2005||2005-07-01|January 2017|2017-01-01|January 2009|Actual|2009-01-01|September 2008|Actual|2008-09-01||Observational|||The Use of Capnography as a Guide for Oral Intubation|Assessing the Use of Capnography as a Guide for Endotracheal Intubation|Terminated||N/A|20|Actual|Rutgers, The State University of New Jersey|||1|study was suspended because of difficluty maintaining equipment|f||||f||||||||||2017-10-11 05:26:44.75073|2017-10-11 05:26:44.75073
NCT00177138|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2013-02-05|||July 2004||2004-07-01|February 2013|2013-02-01|November 2006|Actual|2006-11-01|||||Interventional|||Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation|Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation|Terminated||Phase 4|9|Actual|University of Minnesota - Clinical and Translational Science Institute||2||The clinical use of Campath for transplant patients was temporarily suspended.|f||||f||||||||||2017-10-11 05:26:50.90743|2017-10-11 05:26:50.90743
NCT00177255|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2016-01-10|2016-01-10||April 2005||2005-04-01|January 2016|2016-01-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers|A Phase II Study of Weekly Docetaxel (Taxotere®) in Combination With Capecitabine (Xeloda) in Advanced Gastric and Gastro-Esophageal Adenocarcinomas.|Terminated||Phase 2|40|Actual|University of Pittsburgh||1||Roche has withdrawn support|f||||t||||||||||2017-10-11 05:26:52.454166|2017-10-11 05:26:52.454166
NCT00177853|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2010-07-01|||December 2006||2006-12-01|July 2010|2010-07-01|July 2010|Actual|2010-07-01|December 2006|Actual|2006-12-01||Interventional|||Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer|A Phase I Study of Celecoxib, Irinotecan and Concurrent Radiotherapy in the Preoperative Treatment of Pancreatic Cancer|Terminated||Phase 1|23|Anticipated|University of Pittsburgh||1||terminated|f||||t||||||||||2017-10-11 05:26:57.768851|2017-10-11 05:26:57.768851
NCT00170950|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-10|2011-04-19|2011-01-13||October 2003||2003-10-01|April 2011|2011-04-01|May 2008|Actual|2008-05-01|January 2008|Actual|2008-01-01||Interventional|ACCOMPLISH||Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension|A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension|Terminated||Phase 3|11506|Actual|Novartis|Study was stopped early, as recommended by the Data Monitoring Committee, due to positive efficacy results.|2||"The study was terminated early because of significant efficacy results for the primary endpoint   in favor of benazepril/amlodipine treatment."|f||||||||||||||2017-10-11 05:27:09.121705|2017-10-11 05:27:09.121705
NCT00171431|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2012-04-19|||November 2004||2004-11-01|April 2012|2012-04-01|May 2006|Actual|2006-05-01|May 2006|Actual|2006-05-01||Interventional|||The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)|The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)|Terminated||Phase 3|20||Novartis||||This study was terminated early in May 2006 due to low patient enrollment|f||||||||||||||2017-10-11 05:27:23.160265|2017-10-11 05:27:23.160265
NCT00178282|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2011-11-02|||June 2005||2005-06-01|November 2011|2011-11-01|October 2007|Actual|2007-10-01|January 2007|Actual|2007-01-01||Interventional|||Low-Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence|Pilot Study: Low Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence|Terminated||N/A|23|Actual|University of Rochester||1||The study was terminated early due to poor subject enrollment.|f||||f||||||||||2017-10-11 05:27:24.468302|2017-10-11 05:27:24.468302
NCT00180388|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2016-08-31|||May 2004||2004-05-01|March 2007|2007-03-01|June 2006|Actual|2006-06-01|June 2006|Actual|2006-06-01||Interventional|||VENEK: Healing in Different Vein Harvesting Methods During Aortocoronary Coronary Artery Bypass Graft Surgery (CABG)|Comparison of Clinical and Economical Parameters of Healing in Different Vein Harvesting Methods During Aortocoronary CABG|Terminated||Phase 4|300|Anticipated|Boston Scientific Corporation||2||terminated for logistical reasons|f||||||||||||||2017-10-11 05:27:33.42612|2017-10-11 05:27:33.42612
NCT00181753|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2017-01-12|||November 2009||2009-11-01|January 2017|2017-01-01|October 2010|Anticipated|2010-10-01|October 2010|Anticipated|2010-10-01||Interventional|||Study of Glutamate and Glutamine Metabolism in Burn Patients Receiving Enteral or Parenteral Nutrition|Study of Glutamate and Glutamine Metabolism in Burn Patients Receiving Enteral or Parenteral Nutrition|Withdrawn||N/A|0|Actual|National Institute of General Medical Sciences (NIGMS)||4||"State of Mass. tightened regulations for making intravenous solutions for research subjects.   Study was withdrawn and no participants were enrolled."|f||||t||||||||||2017-10-11 05:27:45.975239|2017-10-11 05:27:45.975239
NCT00181896|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2011-07-14|||January 2005||2005-01-01|July 2011|2011-07-01||||February 2007|Actual|2007-02-01||Interventional|||Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder|Open-Label Study of Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar and Bipolar Spectrum Disorder|Terminated||Phase 4|1|Actual|Massachusetts General Hospital||1||Study was terminated due to lack of recruitment|f||||t||||||||||2017-10-11 05:27:47.671819|2017-10-11 05:27:47.671819
NCT00182039|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-09|2008-04-10|||October 2002||2002-10-01|January 2008|2008-01-01|August 2007|Actual|2007-08-01|July 2007|Actual|2007-07-01||Interventional|POISE||POISE Trial: Perioperative Ischemic Evaluation Study|Perioperative Ischemic Evaluation Study (POISE) Trial|Terminated||Phase 3|8351|Actual|McMaster University||2||Please see detailed description for reason why study was terminated.|f||||t||||||||||2017-10-11 05:27:48.735366|2017-10-11 05:27:48.735366
NCT00174811|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2009-04-02|||June 2005||2005-06-01|April 2009|2009-04-01|June 2006|Actual|2006-06-01|June 2006|Actual|2006-06-01||Interventional|||Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections|Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of Telithromycin 25 mg/kg Given Once Daily for 5 or 10 Days Depending on Age and Previous Treatment History Versus Cefuroxime Axetil 15 mg/kg, Given Twice Daily for 10 Days, in Children With Acute Otitis Media|Terminated||Phase 3|639|Actual|Sanofi||||Pediatric development program terminated by sponsor|f||||||||||||||2017-10-11 05:28:07.216682|2017-10-11 05:28:07.216682
NCT00184366|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2012-01-18|||May 2005||2005-05-01|January 2012|2012-01-01|July 2008|Actual|2008-07-01|May 2008|Actual|2008-05-01||Observational|||Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis|Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab|Terminated||Phase 4|96|Actual|Norwegian University of Science and Technology|||1|efalizumab was withdrawn from market; full 2 years follow-up only 14 patients|f||||f||||||||||2017-10-11 05:28:32.639533|2017-10-11 05:28:32.639533
NCT00184548|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-09|2014-06-13|2009-09-04||October 2005||2005-10-01|June 2014|2014-06-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|CONTROL||Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/NiaStase®) in Severely Injured Trauma Patients With Bleeding Refractory to Standard Treatment|Terminated||Phase 3|554|Actual|Novo Nordisk A/S|Trial was terminated after planned interim analysis for futility showed a lower than expected conditional power for showing superiority (11.2% [actual] vs. 50% [required]). 554 of 1502 planned patients were included in the intent-to-treat population.|4||See termination reason in detailed description|f||||f||||||||||2017-10-11 05:28:35.630065|2017-10-11 05:28:35.630065
NCT00190151|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2012-09-17|||September 2004||2004-09-01|September 2005|2005-09-01|July 2005|Actual|2005-07-01|July 2005|Actual|2005-07-01||Interventional|||Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora|Pharmacokinetic/Pharmacodynamic Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora|Terminated||N/A|48|Actual|Assistance Publique - Hôpitaux de Paris||1||terminated|f||||f||||||||||2017-10-11 05:29:35.661584|2017-10-11 05:29:35.661584
NCT00190216|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2007-11-06|||December 2001||2001-12-01|July 2005|2005-07-01|October 2007|Actual|2007-10-01|||||Interventional|||Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS)|Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression|Terminated||Phase 3|60|Actual|Assistance Publique - Hôpitaux de Paris||1||terminated|f||||f||||||||||2017-10-11 05:29:36.019946|2017-10-11 05:29:36.019946
NCT00191308|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2011-10-13|2010-03-16||May 2005||2005-05-01|October 2011|2011-10-01|December 2010|Actual|2010-12-01|July 2008|Actual|2008-07-01||Interventional|||Molecular Profiling in Lung Cancer Patients|Molecular Profiling and Safety Study of Operable Lung Cancer Patients Treated With Alimta Combined With Cisplatin as Neoadjuvant Chemotherapy|Completed||Phase 2|30|Actual|Eli Lilly and Company|Trial enrollment was terminated early due to lack of eligible participants.|1|||f||||f||||||||||2017-10-11 05:30:07.338096|2017-10-11 05:30:07.338096
NCT00194974|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2017-01-27|||July 2004||2004-07-01|January 2017|2017-01-01|March 2005|Actual|2005-03-01|March 2005|Actual|2005-03-01||Interventional|||Treatment Targets for Chronic Hypertension in Pregnancy|Treatment Targets for Chronic Hypertension in Pregnancy|Withdrawn||Phase 1/Phase 2|0|Actual|Weill Medical College of Cornell University||||Lack of funding|f||||f||||||||No|Study terminated|2017-10-11 05:31:16.235555|2017-10-11 05:31:16.235555
NCT00187135|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2017-04-03|2009-10-13||March 2002||2002-03-01|March 2010|2010-03-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|||Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration|Fentanyl-Propofol-EMLA or L.M.X4™ Technique for Bone Marrow Aspiration in Pediatric Patients - A Phase III Study|Terminated||Phase 3|168|Actual|St. Jude Children's Research Hospital|All 162 participants were expected to receive three treatments. Not all participants received all three treatments. Therefore, analysis required the identification of subsets of treated participants. The trial terminated early due to slow accrual.|3||The study was terminated due to slow accrual.|f||||f||||||||||2017-10-11 05:32:38.530629|2017-10-11 05:32:38.530629
NCT00201656|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2014-12-17|||November 2004||2004-11-01|December 2014|2014-12-01|April 2014|Actual|2014-04-01|November 2013|Actual|2013-11-01||Interventional|PROMCerclage||Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)|Removal Versus Retention of Cervical Cerclage in Preterm Premature Rupture of Membranes-A Multicenter Randomized Clinical Trial|Terminated||Phase 4|58|Actual|Mednax Center for Research, Education and Quality||2||"This trial was terminated following a futility analysis confirming futility of continuing the   study"|f||||t||||||||||2017-10-11 05:32:43.84708|2017-10-11 05:32:43.84708
NCT00203281|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2016-10-19|||February 2003||2003-02-01|October 2016|2016-10-01|September 2009|Anticipated|2009-09-01|September 2009|Anticipated|2009-09-01||Observational|||Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis|Pharmacokinetic Evaluation of Plasmapheresis in Cross Match Positive or ABO Incompatible Kidney Allograft Recipients|Withdrawn||Phase 4|0|Actual|Thomas Jefferson University|||1|funding withdrawn|f||||f||||||||||2017-10-11 05:32:52.929363|2017-10-11 05:32:52.929363
NCT00203307|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2011-08-23|2011-05-24||May 2004||2004-05-01|August 2011|2011-08-01|June 2006|Actual|2006-06-01|March 2006|Actual|2006-03-01||Interventional|||A Research Study Examining the Use of Olanzapine for the Prevention of Migraine|A Single-Site, Double-Blind, Placebo-Controlled Cross-Over Trial Examining the Safety and Efficacy of Olanzapine Taken Daily for the Prevention of Episodic Migraine.|Terminated||N/A|3|Actual|Thomas Jefferson University||2||Study terminated by sponsor|f||||||||||||||2017-10-11 05:32:53.394435|2017-10-11 05:32:53.394435
NCT00205049|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2014-04-10|2011-08-04||March 2005||2005-03-01|April 2014|2014-04-01|November 2006|Actual|2006-11-01|November 2006|Actual|2006-11-01||Interventional|||Pentoxifylline for Acute Alcoholic Hepatitis (AAH)|A Pilot Study of Pentoxifylline-Therapy for Acute Alcoholic Hepatitis|Terminated||Phase 1|4|Actual|University of Wisconsin, Madison|Study was terminated before any data was gathered/analyzed.|1||lack of funding|f||||f||||||||||2017-10-11 05:33:09.537706|2017-10-11 05:33:09.537706
NCT00196677|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2009-03-10|||September 2005||2005-09-01|March 2009|2009-03-01|October 2008|Actual|2008-10-01|July 2008|Actual|2008-07-01||Interventional|||Study of Glaucoma Treatment With Food Additives|Treatment of Glaucomatous Neuropathy With Food Additives|Terminated||Phase 1/Phase 2|25|Anticipated|Future Products Management||||The trial was terminated due to investigator's decision|f||||||||||||||2017-10-11 05:33:15.247234|2017-10-11 05:33:15.247234
NCT00197197|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2011-03-28|||July 2005||2005-07-01|March 2011|2011-03-01|October 2005|Actual|2005-10-01|October 2005|Actual|2005-10-01||Interventional|||Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.|Terminated||Phase 3|18|Actual|GlaxoSmithKline||1||The study was terminated due to hepatoxicity of compound|||||||||||||||2017-10-11 05:33:31.862238|2017-10-11 05:33:31.862238
NCT00206063|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2010-11-10|||August 1999||1999-08-01|November 2010|2010-11-01|April 2006|Actual|2006-04-01|June 2004|Actual|2004-06-01||Interventional|||Long Term Open Follow-up With H376/95 vs. Warfarin|Long-Term Treatment With the Oral Direct Thrombin Inhibitor Ximelagatran, Compared to Warfarin, as Stroke Prophylaxis in Patients With Atrial Fibrillation. A Long Term Follow-Up Study|Terminated||Phase 2|220||AstraZeneca||||"Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006   in the interest of patient safety."|f||||||||||||||2017-10-11 05:34:12.944783|2017-10-11 05:34:12.944783
NCT00206089|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2010-11-11|||September 2005||2005-09-01|November 2010|2010-11-01|August 2006|Actual|2006-08-01|August 2006|Actual|2006-08-01||Interventional|EXTEND||Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events|"The EXTEND Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery."|Terminated||Phase 3|3300||AstraZeneca||||"Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006   in the interest of patient safety."|f||||||||||||||2017-10-11 05:34:13.388048|2017-10-11 05:34:13.388048
NCT00208325|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2016-08-01|2015-06-05||May 2000||2000-05-01|August 2016|2016-08-01|September 2010|Actual|2010-09-01|January 2009|Actual|2009-01-01||Interventional||All participants who received treatment and were not mis-randomized.|PFC Sigma Fixed and Mobile Knee Study|Clinical Evaluation of the P.F.C. Sigma (Fixed Bearing) and P.F.C. Sigma RP (Mobile Bearing) Total Knee Systems|Terminated||Phase 4|754|Actual|DePuy International||4||"The study was terminated at the point the primary endpoint and early milestones were reached   and because long term outcomes were available from other sources"|f||||f||||||||||2017-10-11 05:36:20.947636|2017-10-11 05:36:20.947636
NCT00208364|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2016-10-06|||April 2004||2004-04-01|September 2016|2016-09-01|September 2016|Actual|2016-09-01|October 2014|Actual|2014-10-01||Interventional|||A Two Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Metal-on-Metal Bearing in Primary Total Hip Replacement|Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle Acetabular Cup Prosthesis With a Metal on Metal Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement|Terminated||Phase 4|163|Actual|DePuy International||1||Study terminated early due to business reasons|f||||f||||||||||2017-10-11 05:36:25.088178|2017-10-11 05:36:25.088178
NCT00209560|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2014-12-22|2012-03-01||October 2004||2004-10-01|July 2014|2014-07-01|March 2005||2005-03-01|||||Interventional|||A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures|A Phase III, Randomized, Open-label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Minor Surgical Procedures|Terminated||Phase 3|168|Actual|Eisai Inc.|Analysis of results from a previous fospropofol study (3000-0410) completed during the enrollment of this study indicated that the dosing regimen needed to be re-evaluated. The study was prematurely terminated after 168 subjects were randomized.||||f||||||||||||||2017-10-11 05:36:29.766255|2017-10-11 05:36:29.766255
NCT00214565|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-20|2010-11-17|||August 2004||2004-08-01|November 2010|2010-11-01|October 2006|Actual|2006-10-01|October 2006|Actual|2006-10-01||Interventional|||GALLANT 6 Tesaglitazar vs. Pioglitazone|A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (Pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes|Terminated||Phase 3|1450||AstraZeneca||||The development program has been terminated|||||||||||||||2017-10-11 05:37:17.489515|2017-10-11 05:37:17.489515
NCT00214591|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-20|2010-11-18|||August 2004||2004-08-01|November 2010|2010-11-01|December 2006|Actual|2006-12-01|December 2006|Actual|2006-12-01||Interventional|||GALLANT 5 Tesaglitazar Versus Metformin|A 52-wk Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes|Terminated||Phase 3|580||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:37:18.103508|2017-10-11 05:37:18.103508
NCT00209131|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-14|2013-09-23|2012-06-05||April 2005||2005-04-01|September 2013|2013-09-01|February 2009|Actual|2009-02-01|February 2009|Actual|2009-02-01||Interventional|||Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy|Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy|Terminated||N/A|24|Actual|Emory University|Study was terminated due to turnovers of personnel to assist with recruitment and execution of the study.Recruitment was strained and patients recruited could not be followed up in a timely fashion to adhere to protocol. Thus, no data was generated.|2||Due to frequent turnover of research coordinators and thus poor study accrual.|f||||f||||||||||2017-10-11 05:37:31.379696|2017-10-11 05:37:31.379696
NCT00216086|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-09|2016-04-27|2016-01-05||May 2005||2005-05-01|April 2016|2016-04-01|May 2008|Actual|2008-05-01|May 2008|Actual|2008-05-01||Interventional|||Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer|A Phase II Trial of Preoperative Capecitabine Plus Irinotecan Followed by Combined Modality Capecitabine and Radiation for Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53|Terminated||Phase 2|22|Actual|Hoosier Cancer Research Network||1||Funding withdrawn|f||||t||||||||No||2017-10-11 05:37:56.645159|2017-10-11 05:37:56.645159
NCT00216151|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2011-04-28|||June 2005||2005-06-01|April 2011|2011-04-01|March 2007|Actual|2007-03-01|March 2007|Actual|2007-03-01||Interventional|||Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma|A Randomized Phase II Study of Bisphosphonate: Zoledronic Acid (Zometa) in the Management of Asymptomatic/Early Stage Multiple Myeloma: Hoosier Oncology Group MM02-35|Terminated||Phase 2|3|Actual|Hoosier Cancer Research Network||2||Study terminated due to low patient enrollment.|f||||t||||||||||2017-10-11 05:37:59.456396|2017-10-11 05:37:59.456396
NCT00216164|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2011-04-28|||April 2005||2005-04-01|April 2011|2011-04-01|March 2007|Actual|2007-03-01|March 2007|Actual|2007-03-01||Interventional|||Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Phase II Study of Rituximab and Gemcitabine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Hoosier Oncology Group LYM03-64|Terminated||Phase 2|8|Actual|Hoosier Cancer Research Network||1||Study terminated due to lack of response at the first efficacy analysis|f||||t||||||||||2017-10-11 05:37:59.587773|2017-10-11 05:37:59.587773
NCT00216983|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-20|2017-01-12|||September 1997||1997-09-01|January 2017|2017-01-01|January 2010|Anticipated|2010-01-01|January 2010|Anticipated|2010-01-01||Observational|||Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding|Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding.|Withdrawn||N/A|0|Actual|National Institute of General Medical Sciences (NIGMS)|||3|"State of Mass. tightened regulations for making intravenous solutions for research subjects.   Study was withdrawn and no participants were enrolled."|f||||t||||||||||2017-10-11 05:38:09.142872|2017-10-11 05:38:09.142872
NCT00216996|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-20|2016-11-15||||||November 2016|2016-11-01||||||||Observational|||Effect of Glutamine Supplemented Nutrition Support on Protein and Glutamine Metabolism in Burns|Study on the Effect of Glutamine Supplemented Nutrition Support on Protein and Glutamine Metabolism in Severely Burned Patients|Withdrawn||N/A|0|Actual|Massachusetts General Hospital|||1|This study was withdrawn (see NCT00181753).|f||||t||||||||Yes|Published data will be shared in our publications and directly with an individual researcher when requested.|2017-10-11 05:38:09.27655|2017-10-11 05:38:09.27655
NCT00217035|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-19|2017-01-12|||August 1997||1997-08-01|January 2017|2017-01-01|January 2010|Anticipated|2010-01-01|January 2010|Anticipated|2010-01-01||Observational|||Glutamine Enriched Total Parenteral Feeding and Proline Metabolism in Severely Burned Patients|Glutamine Enriched Total Parenteral Feeding and Proline Metabolism in Severely Burned Patients.|Withdrawn||N/A|0|Actual|National Institute of General Medical Sciences (NIGMS)||||"State of Mass. tightened regulations for making intravenous solutions for research subjects.   Study was withdrawn and no participants were enrolled."|f||||t||||||||||2017-10-11 05:38:09.744907|2017-10-11 05:38:09.744907
NCT00224328|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2007-09-11|||August 2005||2005-08-01|September 2007|2007-09-01|January 2007|Actual|2007-01-01|||||Observational|||Measurement of Tissue Oxygen Saturation in Chronic Critical Limb Ischemia|Measurement of Tissue Oxygen Saturation in Chronic Critical Limb Ischemia: A Phase Iia, Non-Randomized Study Using the ODISsey Tissue Oximeter to Evaluate the Correlation Between Tissue Oxygen Saturation and Symptom Resolution in Patients With Chronic Critical Limb Ischemia Undergoing Treatment Interventions|Terminated||Phase 2|100|Anticipated|ViOptix Canada||||The results were not able to be consistantly reproduced. Thus the trial was terminated|f||||||||||||||2017-10-11 05:39:49.312789|2017-10-11 05:39:49.312789
NCT00224419|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-21|2014-07-18|||June 2003||2003-06-01|April 2009|2009-04-01||||August 2006|Actual|2006-08-01||Interventional|||Testing Pharmacological Therapies for Pregnant Smokers|Testing Pharmacological Therapies for Pregnant Smokers|Terminated||Phase 4|181|Actual|Duke University||2||was terminated due to meeting a priori stopping rule set by DSMB|f||||t||||||||||2017-10-11 05:39:50.12116|2017-10-11 05:39:50.12116
NCT00225992|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-22|2012-10-10|||February 2004||2004-02-01|October 2012|2012-10-01|November 2007|Actual|2007-11-01|November 2007|Actual|2007-11-01||Interventional|||Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)|A Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)|Terminated||Phase 2|||Oncology Specialties, Alabama||||terminated due to lack of accrual.|f||||f||||||||||2017-10-11 05:40:12.344705|2017-10-11 05:40:12.344705
NCT00226330|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-23|2010-11-18|||March 2005||2005-03-01|November 2010|2010-11-01|December 2006|Actual|2006-12-01|December 2006|Actual|2006-12-01||Interventional|||GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Multi-Centre, Active-Controlled (15, 30, and 45 mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Tesaglitazar (0.5 and 1 mg) in Patients With Type 2 Diabetes Mellitus (GALLEX 6)|Terminated||Phase 3|1100||AstraZeneca||||The development program has been terminated|||||||||||||||2017-10-11 05:40:15.465478|2017-10-11 05:40:15.465478
NCT00227344|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-15|2016-03-10|2014-05-27||December 2004||2004-12-01|March 2016|2016-03-01|May 2009|Actual|2009-05-01|October 2008|Actual|2008-10-01||Interventional|CACAF-2||CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation|Catheter Ablation for Cure of Atrial Fibrillation|Terminated||Phase 4|129|Actual|Biosense Webster, Inc.|The study was terminated early due to randomization imbalance. The relatively small number of subjects enrolled limited the amount of data available for analysis. Because the study did not reach its targeted enrollment, the study is underpowered.|2||Study prematurely terminated due to randomization imbalance.|f||||f||||||||||2017-10-11 05:40:28.633444|2017-10-11 05:40:28.633444
NCT00229684|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-28|2011-08-29|||September 2004||2004-09-01|August 2011|2011-08-01|June 2006|Actual|2006-06-01|June 2006|Actual|2006-06-01||Interventional|||ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)|A 24-week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus|Terminated||Phase 2|100||AstraZeneca||||The development program has been terminated|||||||||||||||2017-10-11 05:40:54.862802|2017-10-11 05:40:54.862802
NCT00229710|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-28|2010-11-18|||February 2005||2005-02-01|November 2010|2010-11-01|December 2006|Actual|2006-12-01|December 2006|Actual|2006-12-01||Interventional|||GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes|An Open-Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 0.5mg When Added to Insulin Therapy in Patients With Type 2 Diabetes Mellitus (GALLEX 9)|Terminated||Phase 3|270||AstraZeneca||||The development program has been terminated|||||||||||||||2017-10-11 05:40:55.277897|2017-10-11 05:40:55.277897
NCT00229814|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2012-09-20|||August 2005||2005-08-01|September 2012|2012-09-01|December 2007|Actual|2007-12-01|December 2007|Actual|2007-12-01||Observational|||Study of Brain Tumors (Tectal Tumors) Using Magnetic Resonance Imaging|Magnetic Resonance Spectroscopic Analysis of Pediatric Tectal Tumors: Insight Into Pathology and Behavior|Withdrawn||N/A|0|Actual|Children's Healthcare of Atlanta|||1|There were technical difficulties and the study was terminated in 2008|f||||||||||||||2017-10-11 05:40:59.936503|2017-10-11 05:40:59.936503
NCT00234559|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-05|2013-08-19|||September 2005||2005-09-01|August 2013|2013-08-01|August 2007|Actual|2007-08-01|August 2007|Actual|2007-08-01||Interventional|||Trial of Vacuum Assisted Closure® Therapy Versus Control Therapy in Angiogenesis|A Randomized Controlled Study Comparing Vacuum Assisted Closure® Therapy to Moist Wound Therapy in Angiogenesis|Withdrawn||N/A|0|Actual|KCI USA, Inc.||||Study terminated due to no subject enrollment.|f||||||||||||||2017-10-11 05:41:27.788795|2017-10-11 05:41:27.788795
NCT00235235|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-06|2015-12-08|||September 2005||2005-09-01|December 2015|2015-12-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Observational|||A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer|Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01|Terminated||N/A|80|Actual|Hoosier Cancer Research Network|||4|Funding terminated|f||||t||||||Samples With DNA|"     core biopsy, serum, urine   "|||2017-10-11 05:41:45.40899|2017-10-11 05:41:45.40899
NCT00236301|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-11|2008-01-16|||March 2004||2004-03-01|October 2005|2005-10-01|January 2007|Actual|2007-01-01|June 2006|Actual|2006-06-01||Interventional|THS||Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers|Pro-Inflammatory Effects of Two Different Doses of 17 Beta Estradiol in Menopausal Women|Terminated||Phase 3|99|Actual|Assistance Publique - Hôpitaux de Paris||3||terminated|f||||f||||||||||2017-10-11 05:42:16.097457|2017-10-11 05:42:16.097457
NCT00236405|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-07|2011-06-08|||March 2005||2005-03-01|March 2010|2010-03-01|October 2005|Actual|2005-10-01|||||Interventional|||PROCRIT and Short-Term Outcomes in Orthopedic Surgery|A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of of PROCRIT� (Epoetin Alfa) on Short-Term Outcomes in Orthopedic Subjects Undergoing Primary Unilateral Knee Arthroplasty|Terminated||Phase 2|6|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||The study was terminated due to poor enrollment.|||||f||||||||||2017-10-11 05:42:16.962173|2017-10-11 05:42:16.962173
NCT00236678|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-07|2011-06-08|||July 2004||2004-07-01|March 2010|2010-03-01|January 2006|Actual|2006-01-01|||||Interventional|||Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT|A Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis Receiving PROCRIT� (Epoetin Alfa)|Terminated||Phase 2|29|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"This study was terminated due to slow enrollment, despite protocol amendments to change the   entrance criteria."|||||t||||||||||2017-10-11 05:42:18.759968|2017-10-11 05:42:18.759968
NCT00236912|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-07|2011-06-08|||July 2003||2003-07-01|April 2010|2010-04-01|September 2004|Actual|2004-09-01|||||Interventional|||A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus Piperacillin/Tazobactam in Treating Complicated Appendicitis|A Multi-center, Open-label, Randomized Study to Compare the Safety and Efficacy of Once Daily Levofloxacin Along With Once Daily Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Appendicitis|Terminated||Phase 4|139|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1||This study was terminated due to low enrollment.|||||f||||||||||2017-10-11 05:42:23.292084|2017-10-11 05:42:23.292084
NCT00232206|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-30|2011-05-17|||May 2005||2005-05-01|May 2011|2011-05-01|November 2007||2007-11-01|April 2007|Actual|2007-04-01||Interventional|||Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer|A Phase II Study of Cisplatin Plus Docetaxel as Neoadjuvant Therapy for Stages IB Through Selected IIIA NSCLC|Terminated||Phase 2|40|Anticipated|Providence Health & Services||||study terminated due to slow accrual|f||||||||||||||2017-10-11 05:43:30.069877|2017-10-11 05:43:30.069877
NCT00232349|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-30|2008-07-30|||February 2005||2005-02-01|July 2008|2008-07-01|June 2007|Actual|2007-06-01|June 2007|Actual|2007-06-01||Interventional|||Efficacy of Galantamine to Treat Schizophrenia|An Open-Label Trial of Adjunctive Galantamine Maintenance Therapy to Treat Functional Impairments in Chronic Outpatients With Schizophrenia|Terminated||Phase 4|21|Actual|Seattle Institute for Biomedical and Clinical Research||1||Study terminated due to no apparent benefit.|f||||t||||||||||2017-10-11 05:43:31.150554|2017-10-11 05:43:31.150554
NCT00233090|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-03|2016-03-16|2013-08-07||July 2005||2005-07-01|March 2016|2016-03-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||Post-Traumatic Brain Injury (Post-TBI) Fatigue and Its Treatment|Post-TBI Fatigue and Its Treatment|Terminated||Phase 2|21|Actual|Icahn School of Medicine at Mount Sinai|Study was terminated due to insufficient recruitment. Data analysis not available.|2||Insufficient recruitment|f||||||||||||||2017-10-11 05:43:43.901378|2017-10-11 05:43:43.901378
NCT00233558|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-13|2007-04-23|||June 2005||2005-06-01|April 2007|2007-04-01||||||||Interventional|||Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis|Multicentre, Randomised, Open Label Study Comparing a “Scheduled Steroid Reduction Strategy” Versus a Free Steroid Reduction Strategy (Physician’s Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 Months|Terminated||Phase 4|160||Abbott||||Study terminated due to low subject enrollment. Safety results consistent with product label.|f||||||||||||||2017-10-11 05:43:50.011875|2017-10-11 05:43:50.011875
NCT00233948|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-05|2015-03-30|2015-02-02||March 2006||2006-03-01|March 2015|2015-03-01||||July 2013|Actual|2013-07-01||Interventional|||Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma|A Phase I/II Study of Nelfinavir in Liposarcoma|Terminated||Phase 1/Phase 2|29|Actual|City of Hope Medical Center|After 12 patients were accrued to the Phase II portion, the study was terminated…protocol objectives for the Phase II portion not met. Closed prematurely due to drug availability issues.|1||Drug availability issues|f||||t||||||||||2017-10-11 05:43:55.252562|2017-10-11 05:43:55.252562
NCT00240227|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-13|2016-03-11|2013-11-25||April 2004||2004-04-01|March 2016|2016-03-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|||Prazosin for ETOH or Cocaine Craving|The Role of the Alpha 1-adrenergic Antagonist, Prazosin, in the Reduction of Craving and Relapse in Alcohol and Cocaine-dependent Individuals: a Double-blind, Randomized, Controlled Clinical Trial|Terminated||N/A|8|Actual|VA Office of Research and Development|The study procedure intended to induce substance craving failed to induce craving. Thus, any difference between placebo and active medication conditions could not be measured and so the study was terminated.|2||"Experimental procedure did not induce sufficient craving to determine any possible effect of   medication."|f||||f||||||||||2017-10-11 05:44:09.665809|2017-10-11 05:44:09.665809
NCT00242372|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-19|2009-04-21|||August 2004||2004-08-01|April 2009|2009-04-01|March 2006|Actual|2006-03-01|||||Interventional|||GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin|A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin|Terminated||Phase 3|370||AstraZeneca||||The development program has been terminated|||||||||||||||2017-10-11 05:44:15.351439|2017-10-11 05:44:15.351439
NCT00242580|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-19|2016-03-03|2011-01-24||September 2005||2005-09-01|March 2016|2016-03-01||||January 2008|Actual|2008-01-01||Interventional|VERITAS||A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib|A 24-month Randomized, Double-masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin (Visudyne®) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) Versus Visudyne® Plus Intravitreal Pegaptanib(Macugen®) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Completed||Phase 3|111|Actual|Novartis|Secondary outcome measures were to be assessed at Month 6 and at 24 months. However, this study was not completed but terminated after all patients completed 12 months. Original safety was COSTART now mapped to SOC MedDRA.|3|||f||||||||||||||2017-10-11 05:44:24.419109|2017-10-11 05:44:24.419109
NCT00242645|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-19|2010-08-24|||June 2004||2004-06-01|August 2010|2010-08-01|June 2007|Actual|2007-06-01|June 2007|Actual|2007-06-01||Interventional|||Computer-Assisted Cancer Risk Behavior Counseling|Computer-Assisted Cancer Risk Behavior Counseling|Terminated||Phase 1|200|Actual|Thomas Jefferson University||||Administratively terminated.|f||||f||||||||||2017-10-11 05:44:26.091512|2017-10-11 05:44:26.091512
NCT00243009|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-20|2012-05-24|||June 2005||2005-06-01|June 2010|2010-06-01|April 2006|Actual|2006-04-01|April 2006|Actual|2006-04-01||Interventional|||Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery|Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Metastatic Renal Cell Carcinoma|Terminated||Phase 2|1|Actual|OHSU Knight Cancer Institute||1||Due to a lack of a referal base, study was terminated.|f||||t||||||||||2017-10-11 05:44:34.222609|2017-10-11 05:44:34.222609
NCT00244010|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-24|2017-04-24|2012-02-02||October 2005||2005-10-01|February 2009|2009-02-01|February 2009|Actual|2009-02-01|November 2008|Actual|2008-11-01||Interventional|||Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias|Hematopoietic Stem Cell Transplantation (HSCT) From Partially Matched Family Donors for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias: A Pilot Study|Completed||N/A|4|Actual|St. Jude Children's Research Hospital|This study has terminated due to the PI leaving the institution. An insufficient number of subjects were enrolled to answer the primary objective.|1|||f||||f||||||||||2017-10-11 05:44:54.873657|2017-10-11 05:44:54.873657
NCT00244257|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-25|2015-04-08|||August 2005||2005-08-01|April 2015|2015-04-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Interventional|||Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)|Phase I, Open-Label, Multi-center, Single-Dose, Dose-Escalating, Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamic Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)|Terminated||Phase 1|10|Actual|Sanofi||5||Study terminated due to low enrollment.|f||||t||||||||||2017-10-11 05:44:57.491704|2017-10-11 05:44:57.491704
NCT00231621|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-30|2011-06-06|||May 2001||2001-05-01|April 2010|2010-04-01|June 2002|Actual|2002-06-01|||||Interventional|||A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, One-year Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Subjects With Dyslipidemia|Terminated||Phase 3|179|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"The study was terminated prior to completion to focus on the development of a controlled   release formulation."|f||||f||||||||||2017-10-11 05:45:02.261564|2017-10-11 05:45:02.261564
NCT00245505|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-26|2012-03-09|||February 2009||2009-02-01|March 2012|2012-03-01|July 2009|Actual|2009-07-01|June 2009|Actual|2009-06-01||Interventional|||"The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active Drug: Crohn's Disease"|The Effect on Mucosal Healing With Pentasa Sachet 4g in Mild to Moderate Active Small Bowel Crohn´s Disease, Evaluated by Video Capsule Endoscopy After 6 and 12 Weeks Treatment. A Pilot Study|Terminated||Phase 3|3|Actual|Ferring Pharmaceuticals||1||Study terminated due to lack of eligible patients|f||||f||||||||||2017-10-11 05:45:21.081175|2017-10-11 05:45:21.081175
NCT00247936|ClinicalTrials.gov processed this data on October 10, 2017|2005-10-31|2009-11-04|||May 2004||2004-05-01|November 2009|2009-11-01|April 2010|Anticipated|2010-04-01|April 2010|Anticipated|2010-04-01||Interventional|||Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial.|Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial.|Withdrawn||N/A|40|Anticipated|University of California, Irvine||2||Prior to recruitment, study terminated lack of recruitment interest.|f||||f||||||||||2017-10-11 05:46:40.04941|2017-10-11 05:46:40.04941
NCT00250861|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-07|2008-04-17|||October 2005||2005-10-01|April 2008|2008-04-01|August 2007|Actual|2007-08-01|August 2007|Actual|2007-08-01||Interventional|||Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma|A Randomized Phase II Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy With Autologous PBSC Rescue|Terminated||Phase 2|110||US Oncology Research||||Study terminated due to lack of enrollment.|f||||||||||||||2017-10-11 05:47:14.386413|2017-10-11 05:47:14.386413
NCT00251511|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-08|2012-05-09|||August 2004||2004-08-01|May 2012|2012-05-01|May 2007|Actual|2007-05-01|January 2006|Actual|2006-01-01||Interventional|||A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome|A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome|Terminated||Phase 2|60|Actual|Veeda Oncology||1||Sponsor terminated trial|f||||f||||||||||2017-10-11 05:47:25.505419|2017-10-11 05:47:25.505419
NCT00251589|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-07|2015-02-17|2008-10-27||January 2006||2006-01-01|February 2015|2015-02-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Interventional|||A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)|A Phase I/II Clinical Trial of Oral Vorinostat (MK0683) in Combination With Erlotinib in Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer|Terminated||Phase 1/Phase 2|23|Actual|Merck Sharp & Dohme Corp.|Due to the slow pace of patient accrual, failure to observe meaningful efficacy in treated patients, and overall intolerance of the combination regimen, the study was terminated prematurely on 12-Oct-2007.|4||"This trial is being closed based on lack of substantive efficacy, slow accrual and overall   tolerance in patients treated to date."|f||||f||||||||||2017-10-11 05:47:26.052323|2017-10-11 05:47:26.052323
NCT00251940|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-09|2008-03-14|||July 2004||2004-07-01|March 2008|2008-03-01|March 2006|Actual|2006-03-01|||||Interventional|||GALLANT 7 Tesaglitazar Add-on to Sulphonylurea|A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Sulphonylurea Alone|Terminated||Phase 3|555||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:47:55.610218|2017-10-11 05:47:55.610218
NCT00251953|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-09|2009-04-21|||July 2004||2004-07-01|April 2009|2009-04-01|March 2006|Actual|2006-03-01|||||Interventional|||GALLANT 8 Tesaglitazar Add-on to Metformin|A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Metformin Alone|Terminated||Phase 3|555||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:47:55.961552|2017-10-11 05:47:55.961552
NCT00252876|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-10|2008-03-14|||March 2005||2005-03-01|March 2008|2008-03-01|January 2007|Actual|2007-01-01|||||Interventional|||GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes|An Open-Label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 1 mg in Patients With Type 2 Diabetes Mellitus.|Terminated||Phase 3|2000||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:48:05.740567|2017-10-11 05:48:05.740567
NCT00247988|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-01|2007-04-20|||October 2003||2003-10-01|April 2007|2007-04-01|April 2007|Actual|2007-04-01|||||Interventional|||Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers|Phase II Study of Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers|Terminated||Phase 2|38||University of Saskatchewan||||"Regulatory issues(trial temporarily suspended December 28, 2005. Permanently suspended January   19, 2007. Institutional Reveiw Board informed April 18, 2007"|f||||||||||||||2017-10-11 05:48:52.215811|2017-10-11 05:48:52.215811
NCT00255541|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-17|2008-03-14|||September 2004||2004-09-01|March 2008|2008-03-01|December 2006|Actual|2006-12-01|||||Interventional|||GALLANT 4 Tesaglitazar vs. Glibenclamide|A 52-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes|Terminated||Phase 3|580||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:49:17.06438|2017-10-11 05:49:17.06438
NCT00255645|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-18|2008-03-14|||September 2005||2005-09-01|March 2008|2008-03-01|December 2006|Actual|2006-12-01|||||Observational|||G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)|A Long-Term, Post-Treatment, Safety Follow-Up, Multi-Center Study in Patients With Type 2 Diabetes Mellitus From the GALLANT, GALLEX or ARMOR Studies.|Terminated||Phase 3|4500||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:49:19.584466|2017-10-11 05:49:19.584466
NCT00260208|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-30|2011-12-02|2011-09-14||January 2006||2006-01-01|December 2011|2011-12-01||||September 2010|Actual|2010-09-01||Interventional|||Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus|A Multicenter, Randomized, Open-label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Cyclosporine Microemulsion or Tacrolimus|Terminated||Phase 4|361|Actual|Novartis|This study was prematurely discontinued due to poor recruitment. Since only a small patient group could be analyzed for primary outcome measure, robust conclusions on the effect of the two calcineurin inhibitors on the fibrosis score cannot be drawn.|2||Study was prematurely terminated due to poor recruitment.|f||||||||||||||2017-10-11 05:49:53.350716|2017-10-11 05:49:53.350716
NCT00252772|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-10|2009-04-21|||September 2004||2004-09-01|April 2009|2009-04-01|November 2006|Actual|2006-11-01|||||Interventional|||GALLANT 2 Tesaglitazar vs. Placebo|A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes|Terminated||Phase 3|80||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:50:14.916904|2017-10-11 05:50:14.916904
NCT00252837|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-10|2008-03-14|||April 2005||2005-04-01|March 2008|2008-03-01|December 2006|Actual|2006-12-01|||||Interventional|||GALLANT 22 Tesaglitazar vs. Placebo|A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes|Terminated||Phase 3|475||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:50:15.674958|2017-10-11 05:50:15.674958
NCT00263965|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-09|2008-03-14|||August 2005||2005-08-01|March 2008|2008-03-01|July 2006|Actual|2006-07-01|||||Interventional|||ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity|A 16-Week Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo- and Active- (Metformin) Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes|Terminated||Phase 2|105||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:50:21.009304|2017-10-11 05:50:21.009304
NCT00264498|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-12|2009-06-11|2009-06-11||October 2004||2004-10-01|June 2009|2009-06-01|June 2008|Actual|2008-06-01|||||Interventional|||Phase II Iressa & Carbo/Gem in NSCLC|A Randomized, Open-Label Phase II Study Of ZD1839 (IRESSA™) Versus Gemcitabine And Carboplatin In Chemotherapy-Naive Patients With Advanced (Stage IIIB OR IV) Non-Small Cell Lung Cancer And ECOG Performance Status 2|Completed||Phase 2|38|Actual|AstraZeneca|"No analysis of the efficacy results was performed as the study was prematurely terminated with only 35 out of the planned 122 subjects randomized.
NCT00264810|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-09|2013-08-23|2013-08-23|2012-01-17|December 2005||2005-12-01|August 2013|2013-08-01|May 2011|Actual|2011-05-01|October 2009|Actual|2009-10-01||Interventional||Baseline characteristics and primary endpoints were calculated using the Intent-to-Treat population, which includes all subjects that underwent RNS® System implantation (191 subjects). Individuals that did not undergo initial implant (49 subjects) were withdrawn from the study and are considered screen failures.|RNS® System Pivotal Study|RNS® System Pivotal-A Clinical Investigation|Completed||Phase 3|240|Actual|NeuroPace||2|||f||||t||||||||||2017-10-11 05:50:41.39538|2017-10-11 05:50:41.39538
NCT00256997|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-18|2013-11-12|2013-02-27||January 2006||2006-01-01|November 2013|2013-11-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional||Out of a total of 167 participants, Baseline data was available for only 165 participants who were included in intent to treat (ITT) population.|A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication|Pragmatic Randomized Trial of Risperdal Consta Versus Oral Atypical Antipsychotics in Poorly Adherent Subjects With Schizophrenia in a Routine Care Setting|Terminated||Phase 4|167|Actual|Janssen-Ortho Inc., Canada|The study was terminated due to futility.|2||Inability to recruit number of planned patients|f||||f||||||||||2017-10-11 05:51:51.412872|2017-10-11 05:51:51.412872
NCT00257335|ClinicalTrials.gov processed this data on October 10, 2017|2005-11-21|2017-07-26|||October 14, 2004||2004-10-14|July 2017|2017-07-01|June 12, 2007|Actual|2007-06-12|June 12, 2007|Actual|2007-06-12||Interventional|||Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer|A Phase II Protocol of Intensity-Modulated Radiotherapy for Treatment of Previously Irradiated Recurrent Head and Neck Cancer|Withdrawn||Phase 2|0|Actual|University of California, Irvine||||Due to no patient enrollment this study was withdrawn/closed|f||||||||||||||2017-10-11 05:51:59.998028|2017-10-11 05:51:59.998028
NCT00267683|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-20|2016-03-03|||December 2005||2005-12-01|March 2016|2016-03-01|April 2006|Actual|2006-04-01|April 2006|Actual|2006-04-01||Interventional|||Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes|A Clinical Trial to Study the Efficacy and Safety of Insulin Aspart Three Times Per Day Compared to Glibenclamide Once or Twice Daily in Type 2 Diabetes by Comparison of Ability to Control Blood Glucose|Terminated||Phase 3|9|Actual|Novo Nordisk A/S||||This trial was terminated due to low recruitment|f||||f||||||||||2017-10-11 05:52:26.731518|2017-10-11 05:52:26.731518
NCT00268151|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-20|2013-05-02|||February 2005||2005-02-01|May 2013|2013-05-01||||February 2007|Actual|2007-02-01||Interventional|||Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer|Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer|Terminated||Phase 1|24||James Graham Brown Cancer Center||||Study was terminated due to lack of funding.|f||||||||||||||2017-10-11 05:52:38.2702|2017-10-11 05:52:38.2702
NCT00268242|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-20|2015-08-30|2015-06-03||January 2006||2006-01-01|August 2015|2015-08-01|July 2011|Actual|2011-07-01|August 2010|Actual|2010-08-01||Interventional|||Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia|A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse|Terminated||Phase 2|24|Actual|The Cleveland Clinic|If </= 5 of 1st 18 pts had a CR, study would stop (otherwise, another 22 pts would be accrued). Study would stop if >4 of 1st 10 or 10 of 1st 25 pts had unacceptable toxicity per protocol & Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0|1||"If </= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients (21%)   of 24 enrolled patients had a CR so the study was terminated."|f||||f||||||||||2017-10-11 05:52:41.749984|2017-10-11 05:52:41.749984
NCT00268463|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-20|2013-05-10|2013-02-05||January 2006||2006-01-01|May 2013|2013-05-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional|||Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer|A Phase III Clinical Trial Comparing Oxaliplatin, Capecitabine and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capecitabine in Patients With Resected or Ablated Liver Metastases From Colorectal Cancer|Terminated||Phase 3|22|Actual|NSABP Foundation Inc||2||The study was terminated due to low accrual.|f||||t||||||||||2017-10-11 05:52:44.851215|2017-10-11 05:52:44.851215
NCT00261352|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-01|2009-04-21|||March 2005||2005-03-01|April 2009|2009-04-01|December 2006|Actual|2006-12-01|||||Interventional|||GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate|A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined With Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients With Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy With a Statin|Terminated||Phase 3|1000||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:53:16.638672|2017-10-11 05:53:16.638672
NCT00261417|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-01|2009-04-21|||May 2004||2004-05-01|April 2009|2009-04-01|October 2005|Actual|2005-10-01|||||Interventional|||Dose Response Study in Japanese Patients|A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Dose-Response and Safety of Tesaglitazar Therapy in Japanese Subjects With Type 2 Diabetes|Terminated||Phase 2|250||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 05:53:17.562235|2017-10-11 05:53:17.562235
NCT00261898|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-04|2015-11-03|||November 2005||2005-11-01|November 2015|2015-11-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity|Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity|Terminated||Phase 2|239|Actual|National Institutes of Health Clinical Center (CC)||1||"This study has been terminated. (Interim analysis of preliminary results indicated the need for   protocol re-design)."|f||||||||||||||2017-10-11 05:53:50.503183|2017-10-11 05:53:50.503183
NCT00261989|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-02|2011-07-05|||November 2005||2005-11-01|September 2007|2007-09-01|September 2007|Actual|2007-09-01|||||Observational|||Pulse Oximetry Readings and Hourly Variation in Oximetry Readings With CHD|The Retrospective Analysis of Presenting Pulse Oximetry Readings and Hourly Variation in Oximetry Readings in Patients With Known Congenital Heart Disease|Terminated||N/A|1000|Actual|Children's Healthcare of Atlanta|||1|data insignificant, study terminated|f||||f||||||||||2017-10-11 05:53:52.714012|2017-10-11 05:53:52.714012
NCT00262509|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-02|2014-01-14|2013-09-17||September 2008||2008-09-01|January 2014|2014-01-01|April 2009|Actual|2009-04-01|December 2008|Actual|2008-12-01||Interventional||Includes groups randomized to do either baseline tests first or Intervention tests first|Emergency Egress and Information System for Persons With Vision Loss|Emergency Egress and Information System for Persons With Vision Loss|Terminated||N/A|17|Actual|VA Office of Research and Development|Trials were terminated early with just 17 Participants of the planned 24, as the intervention was NOT providing measurable benefit.|2||Intervention worsened performance for first 17 of 24 planned participants.|f||||f||||||||||2017-10-11 05:54:08.513233|2017-10-11 05:54:08.513233
NCT00271947|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-02|2014-02-10|2013-05-08||April 2005||2005-04-01|February 2014|2014-02-01|April 2013|Actual|2013-04-01|April 2012|Actual|2012-04-01||Interventional|||Crohn's Disease Stem Cell Transplantation|Crohn's Disease Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation (CDNST) Versus Standard Therapy|Terminated||Phase 2|1|Actual|Northwestern University|Potential participants refused to be randomized. Just one participant was enrolled on study, the study is terminated early.|1||The PI, who was sponsor got retired|f||||t||||||||||2017-10-11 05:55:19.88245|2017-10-11 05:55:19.88245
NCT00273858|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-04|2011-09-08|2011-06-30||March 2006||2006-03-01|September 2011|2011-09-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Observational|||Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis|Open Label Study To Evaluate The Safety Profile And The Quality Of Life In Patients Receiving Etanercept For The Treatment Of Rheumatoid Arthritis, Ankylosing Spondylitis And Psoriatic Arthritis|Terminated||N/A|880|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1|"The study was terminated because at least one year follow-up was achieved for each patient and   the achievement of 965 exposure years to the drug."|f||||f||||||||||2017-10-11 05:56:17.369939|2017-10-11 05:56:17.369939
NCT00276419|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-11|2012-12-13|2012-11-16||June 2005||2005-06-01|December 2012|2012-12-01|May 2009|Actual|2009-05-01|May 2009|Actual|2009-05-01||Interventional|||Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin|Topical Diclofenac for the Treatment of Noncyclic Breast Pain|Terminated||Phase 2/Phase 3|25|Actual|Mayo Clinic|This study was terminated early due to lack of funds; the FDA approved a topical form of diclofenac during study, therefore there was no need to continue study of pharmacy-compounded drug.|2||"Lack of funds; FDA approved a topical form of diclofenac during study, no need to continue   study of pharmacy-compounded drug."|f||||f||||||||||2017-10-11 05:56:30.461272|2017-10-11 05:56:30.461272
NCT00277290|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-12|2010-02-18|||January 2006||2006-01-01|February 2010|2010-02-01|November 2006|Actual|2006-11-01|November 2006|Actual|2006-11-01||Interventional|||Study of XL999 in Patients With Previously Treated Ovarian Cancer|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer|Terminated||Phase 2|24|Actual|Symphony Evolution, Inc.||1||Study was terminated due to cardiac toxicities in the subjects|t||||t||||||||||2017-10-11 05:56:47.256042|2017-10-11 05:56:47.256042
NCT00277303|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-12|2010-02-18|||December 2005||2005-12-01|February 2010|2010-02-01|February 2007|Actual|2007-02-01|August 2006|Actual|2006-08-01||Interventional|||Study of XL999 in Patients With Metastatic Colorectal Cancer|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Colorectal Cancer|Terminated||Phase 2|17|Actual|Symphony Evolution, Inc.||1||Study was terminated due to cardiac toxicities in the subjects|f||||t||||||||||2017-10-11 05:56:47.362373|2017-10-11 05:56:47.362373
NCT00277329|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-12|2010-02-18|||December 2005||2005-12-01|February 2010|2010-02-01|July 2008|Actual|2008-07-01|August 2007|Actual|2007-08-01||Interventional|||Study of XL999 in Patients With Non-small Cell Lung Cancer|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer|Terminated||Phase 2|9|Actual|Symphony Evolution, Inc.||1||Study was terminated due to cardiac toxicities in the subejcts|f||||t||||||||||2017-10-11 05:56:47.620296|2017-10-11 05:56:47.620296
NCT00277979|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-13|2012-03-14|||January 2005||2005-01-01|December 2007|2007-12-01|February 2007|Actual|2007-02-01|February 2007|Actual|2007-02-01||Observational|||3D Echocardiography Managing Infantile Pompe's Disease|Utilization of 3D Echocardiography in the Management of Infantile Pompe's Disease: Two Case Reports|Terminated||N/A|2|Actual|Children's Healthcare of Atlanta|||1|project withdrawn|f||||f||||||||||2017-10-11 05:56:57.159456|2017-10-11 05:56:57.159456
NCT00270725|ClinicalTrials.gov processed this data on October 10, 2017|2005-12-27|2017-02-26|||July 1, 2005|Actual|2005-07-01|February 2017|2017-02-01|July 1, 2005|Actual|2005-07-01|July 1, 2005|Actual|2005-07-01||Observational|||Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa|The Effectiveness of Antiretroviral Therapy in Reducing the Costs of HIV/AIDS|Withdrawn||N/A|0|Actual|Boston University|||1|Enrollment never initiated, study withdrawn.|f||||||||||||||2017-10-11 05:57:03.791989|2017-10-11 05:57:03.791989
NCT00282438|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-24|2017-01-03|2016-09-12||December 2003||2003-12-01|September 2016|2016-09-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional|||Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis|Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial|Terminated||Phase 1/Phase 2|2|Actual|Northwestern University|Two patients had been enrolled on trial. One underwent autologous HSCT and relapsed early after the transplant. The second participant underwent allogeneic HSCT and died 70 days after the transplant and the study has been terminated.|2||No plan to continue enrollment|f||||f||||||||Undecided||2017-10-11 05:57:34.693115|2017-10-11 05:57:34.693115
NCT00282971|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-26|2009-09-11|2009-02-11||March 2006||2006-03-01|July 2009|2009-07-01|February 2008|Actual|2008-02-01|February 2008|Actual|2008-02-01||Interventional|||A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus|A Six Month, Open-Label Outpatient, Parallel Group Trial Assessing The Impact Of Inhaled Insulin (Exubera) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On Two Oral Anti-Diabetic Agents.|Terminated||Phase 3|354|Actual|Pfizer|Study terminated prematurely since the sponsor stopped marketing and manufacturing of EXUBERA and withdrew Market Authorization in Europe in September 2008. No efficacy, safety, or quality reason was associated with the premature halt of this study.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 05:57:47.052388|2017-10-11 05:57:47.052388
NCT00283049|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-26|2011-01-07|2009-12-16||February 2006||2006-02-01|January 2011|2011-01-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional|||Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control|Safety and Efficacy of Insulin Glargine Injection [rDNA Origin] Treatment in Place of the TZD or the Sulfonylurea or Metformin in Triple Agent Therapy for T2DM Adult Subjects With Unsatisfactory Control|Terminated||Phase 4|390|Actual|Sanofi|The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.|3||Due to technical issues relating to the Electronic diary data.|f||||||||||||||2017-10-11 05:57:49.326791|2017-10-11 05:57:49.326791
NCT00275262|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-09|2010-04-09|2010-02-05||February 2006||2006-02-01|April 2010|2010-04-01||||February 2009|Actual|2009-02-01||Interventional|||A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation|Leuprolide Acetate to Enhance Immune Function Post-Autologous Stem Cell Transplantation|Terminated||Phase 2|25|Actual|Abbott|The study was terminated early because of slow enrollment. For the primary endpoint, changes from baseline within each treatment group were analyzed. Between treatment group comparisons were not performed because the sample size was too small.|2|||f||||f||||||||||2017-10-11 05:58:44.994369|2017-10-11 05:58:44.994369
NCT00285779|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-31|2015-02-16|2015-01-28||August 2006||2006-08-01|February 2015|2015-02-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|||Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus|A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus|Terminated||Phase 2|27|Actual|Stanford University|Trial was terminated early due to low recruitment rates.|2||Slow recruitment|f||||t||||||||||2017-10-11 05:59:00.908765|2017-10-11 05:59:00.908765
NCT00286013|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-01|2007-12-19|||May 2004||2004-05-01|December 2007|2007-12-01||||||||Interventional|||Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma|Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma|Suspended||Phase 2|30||University Hospital, Ghent||||Study suspended because of safety reasons|f||||f||||||||||2017-10-11 05:59:03.362392|2017-10-11 05:59:03.362392
NCT00286195|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-02|2015-05-12|||December 2004||2004-12-01|May 2015|2015-05-01|December 2006||2006-12-01|December 2006|Actual|2006-12-01||Interventional|||Frontier Registry II Bifurcation Stent System Registry|The Abbott Vascular MULTI -LINK FRONTIER Coronary Bifurcation Stent System Registry II|Withdrawn||Phase 4|0|Actual|Abbott Vascular||1||Study was withdrawn due to a business decision.|f||||||||||||||2017-10-11 05:59:11.315166|2017-10-11 05:59:11.315166
NCT00286403|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-01|2016-03-25|||August 2008||2008-08-01|March 2016|2016-03-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|||Vasodilators and Anti-Oxidant Therapy in Early ATN|Combination Fenoldopam Mesylate and Intravenous MESNA (2-mercaptoethane Sulphonate)in Early Acute Kidney Injury (AKD): A Randomized, Double-Blind Placebo Controlled Clinical Trial|Withdrawn||Phase 2/Phase 3|0|Actual|Southeast Renal Research Institute||||The study was terminated due to logistics at a local hospital.|f||||t||||||||||2017-10-11 05:59:14.375893|2017-10-11 05:59:14.375893
NCT00287326|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-03|2016-04-15|||January 2006||2006-01-01|June 2009|2009-06-01|June 2006|Actual|2006-06-01|||||Interventional|||Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone|Comparison of Epidural Bupivacaine-Clonidine With Intravenous Morphine Versus Intravenous Morphine Alone for Post-Operative Pain Relief in Pediatric Patients Undergoing Lower Extremity or Pelvic Osteotomy.|Terminated||Phase 3|40|Anticipated|University of North Carolina, Chapel Hill||||terminated by PI|f||||||||||||||2017-10-11 05:59:40.715586|2017-10-11 05:59:40.715586
NCT00279461|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-17|2015-07-31|||May 2009||2009-05-01|July 2015|2015-07-01|May 2011|Anticipated|2011-05-01|May 2011|Anticipated|2011-05-01||Interventional|||Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis|Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis: Clinical Trial and Investigations on Dendritic Cells|Withdrawn||Phase 2|0|Actual|Indiana University||2||"Dr. Levy terminated from IU in December 2009. Indiana University has no record that this study   was initiated prior to his termination."|f||||f||||||||||2017-10-11 05:59:45.876593|2017-10-11 05:59:45.876593
NCT00279565|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-17|2012-11-21|||August 2005||2005-08-01|February 2007|2007-02-01|February 2007|Actual|2007-02-01|February 2007|Actual|2007-02-01||Interventional|||Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)|Randomized, Controlled Study of Buprenorphine and Methadone in Hepatitis C Patients in Need of Treatment|Terminated||Phase 4|128||Indivior Inc.||||The trial was terminated because of deviations from the protocol.|f||||f||||||||||2017-10-11 05:59:46.462262|2017-10-11 05:59:46.462262
NCT00279669|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-17|2008-05-07|||December 2004||2004-12-01|May 2008|2008-05-01|July 2008|Anticipated|2008-07-01|||||Observational|||Ultrasound to Detect Evidence for Retinal Detachment in Retinopathy of Prematurity|Ultrasound to Detect Evidence for Retinal Detachment in Retinopathy of Prematurity|Suspended||N/A|30|Anticipated|Weill Medical College of Cornell University|||1|Studies are suspended until a new ultrasound scanner is acquired.|f||||f||||||||||2017-10-11 05:59:47.476677|2017-10-11 05:59:47.476677
NCT00281658|ClinicalTrials.gov processed this data on October 10, 2017|2006-01-23|2017-06-06|2011-05-05||January 2, 2006|Actual|2006-01-02|June 2017|2017-06-01|December 31, 2019|Anticipated|2019-12-31|June 18, 2010|Actual|2010-06-18||Interventional|||Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer|Active, not recruiting||Phase 3|443|Actual|Novartis|Some participants (PAR) are captured as withdrawing from the study due to death. Per protocol, PAR who died were considered to be study completers and did not withdraw from the study; for the purposes of this report, they are classified as withdrawn.|3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
NCT00289601|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-08|2007-07-19|||March 2006||2006-03-01|July 2007|2007-07-01|December 2007||2007-12-01|||||Interventional|||Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty|Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance|Terminated||Phase 4|1200|Anticipated|Brigham and Women's Hospital||||Sponsor support withdrawn|f||||t||||||||||2017-10-11 06:01:08.447522|2017-10-11 06:01:08.447522
NCT00290407|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-09|2013-05-03|2013-05-03||March 2006||2006-03-01|May 2013|2013-05-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|||Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)|Phase II Study of Rituximab Plus B-Glucan in Patients With Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)|Terminated||Phase 2|2|Actual|James Graham Brown Cancer Center|Study terminated, results data not available|1||terminated due to lack of accrual|f||||t||||||||||2017-10-11 06:01:31.473095|2017-10-11 06:01:31.473095
NCT00294723|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-20|2017-01-24|2010-02-23|2009-11-09|February 2006||2006-02-01|January 2017|2017-01-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional|LEAD-3||To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c|Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes|Terminated||Phase 3|746|Actual|Novo Nordisk A/S|Trial terminated due to an insufficient number of subjects remaining to obtain reasonable statistical power. Efficacy data was not analysed after week 156. Safety data was collected through week 195. No data was available from week 195 to 260|4||"The trial was terminated at week 195 due to an insufficient number of subjects remaining to   obtain reasonable statistical power"|f||||f||||||||||2017-10-11 06:02:16.789854|2017-10-11 06:02:16.789854
NCT00295880|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-23|2012-11-06|2009-03-25||June 2005||2005-06-01|November 2012|2012-11-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|||Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer|A Phase I/II Study of Double Unit Umbilical Cord Blood (UCB) Transplantation Utilizing Graft Administration Via Intra-Bone Marrow Injection (Companion Protocol to MT2000-25)|Terminated||Phase 1/Phase 2|12|Actual|Masonic Cancer Center, University of Minnesota|This study was terminated early based on interim statistical analysis that indicated time to engraftment will not be improved compared to historical controls. While safe, lack of faster marrow recovery supports early discontinuation.|1||Time to engraftment would not be improved compared to historical controls.|f||||t||||||||||2017-10-11 06:02:37.406304|2017-10-11 06:02:37.406304
NCT00296556|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-24|2009-04-27|||February 2006||2006-02-01|April 2009|2009-04-01|March 2008|Actual|2008-03-01|December 2007|Anticipated|2007-12-01||Interventional|||Therapeutic Study of ONO-4819CD for Ulcerative Colitis|A Randomized, Placebo-Controlled Trial of ONO-4819CD for Treatment of Mild to Moderate Ulcerative Colitis.|Terminated||Phase 2|7|Actual|Kyoto University, Graduate School of Medicine||1||terminated|f||||t||||||||||2017-10-11 06:03:08.776549|2017-10-11 06:03:08.776549
NCT00288080|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-06|2016-11-28|2016-11-28||December 2005||2005-12-01|November 2016|2016-11-01||||April 2014|Actual|2014-04-01||Interventional||Eligible patients who have not withdrawn consent.|Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer|A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer|Active, not recruiting||Phase 3|612|Actual|Radiation Therapy Oncology Group|Due to insufficient number of events, local control analysis was not conducted.|2|||f||||t||||||||||2017-10-11 06:03:15.714719|2017-10-11 06:03:15.714719
NCT00298805|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-01|2013-08-08|||January 2006||2006-01-01|August 2013|2013-08-01|April 2013|Actual|2013-04-01|June 2009|Actual|2009-06-01||Observational|||A Quality of Life Study in Patients With Migraines|Dysphoric-like Disorder of Epilepsy, Is It Unique?|Terminated||N/A|52|Actual|Northwell Health|||1|Study terminated due to expiration of IRB approval|f||||f||||||||||2017-10-11 06:03:41.51779|2017-10-11 06:03:41.51779
NCT00300105|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-07|2008-03-14|||October 2005||2005-10-01|March 2008|2008-03-01|December 2006|Actual|2006-12-01|||||Interventional|||GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes|A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar Therapy in Patients With Type 2 Diabetes|Terminated||Phase 3|400||AstraZeneca||||The development program has been terminated|f||||||||||||||2017-10-11 06:04:05.863035|2017-10-11 06:04:05.863035
NCT00300300|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-06|2015-09-09|||September 2009||2009-09-01|September 2015|2015-09-01|January 2029|Anticipated|2029-01-01|January 2028|Anticipated|2028-01-01||Interventional|||Anterior Cruciate Ligament (ACL) Reconstruction Using Different Grafts and Surgical Techniques|Anterior Cruciate Ligament Reconstruction: Comparison of Patellar With Hamstring Tendon Using a Computer-assisted Versus a Conventional Surgical Technique.|Terminated||Phase 4|125|Actual|Queen's University||4||Study temporarily suspended until funding can be secured.|f||||f||||||||||2017-10-11 06:04:12.225449|2017-10-11 06:04:12.225449
NCT00292500|ClinicalTrials.gov processed this data on October 10, 2017|2006-02-14|2013-08-19|||January 2006||2006-01-01|August 2013|2013-08-01|December 2009|Actual|2009-12-01|October 2008|Actual|2008-10-01||Interventional|||Efficacy of Automated Distal Vascular Anastomosis in Coronary Surgery: Phase II|Efficacy of Automated Distal Vascular Anastomosis in Coronary Surgery: Phase II|Terminated||N/A|170|Actual|Cardica, Inc||1||Cardica has terminated the development of the product for Business Reason.|f||||f||||||||||2017-10-11 06:04:42.487302|2017-10-11 06:04:42.487302
NCT00300885|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-08|2014-10-28|2009-11-04||February 2006||2006-02-01|October 2014|2014-10-01|February 2009|Actual|2009-02-01|October 2007|Actual|2007-10-01||Interventional|||A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)|A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 3|926|Actual|Bayer|Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early. The planned biomarker analysis was suspended due to early termination.|2||"Based on the results of the interim analysis, it was determined that the study would not meet   its primary efficacy endpoint and the study was terminated early."|f||||f||||||||||2017-10-11 06:05:20.804049|2017-10-11 06:05:20.804049
NCT00304590|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-16|2010-02-18|||February 2006||2006-02-01|February 2010|2010-02-01|May 2007|Actual|2007-05-01|December 2006|Actual|2006-12-01||Interventional|||Study of XL999 in Patients With Multiple Myeloma|A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 2|4|Actual|Symphony Evolution, Inc.||1||Study was terminated due to cardiac toxicities in the subjects|f||||t||||||||||2017-10-11 06:05:30.339453|2017-10-11 06:05:30.339453
NCT00305292|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-17|2011-03-23|||March 2006||2006-03-01|March 2011|2011-03-01|August 2006||2006-08-01|||||Interventional|||Modafinil-Alcohol Interactions in Healthy Volunteers|"Modafinil-Alcohol Interactions Assessed Using Tests of Thermal Stimulation, Cognition, Mood, and Motor Function in Healthy Volunteers"|Terminated||N/A|32||University of California, San Francisco||||"This study should be terminated as the study closed prior to 2007 and the investigator has   since retired. No records are available."|f||||||||||||||2017-10-11 06:05:39.747831|2017-10-11 06:05:39.747831
NCT00306020|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-21|2012-07-03|||January 2006||2006-01-01|July 2012|2012-07-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Analgesia and Wound Healing Assessment Following Topical Morphine Applied to Patients With Cutaneous Cancer Related Pain|Analgesia and Wound Healing Assessment Following Topical Morphine Applied to Patients With Cutaneous Cancer Related Pain|Withdrawn||N/A|0|Actual|Soroka University Medical Center||||"The study was withdrawn due to difficulties in recruiting appropriate patients in community   clinic setting"|f||||||||||||||2017-10-11 06:05:55.638761|2017-10-11 06:05:55.638761
NCT00306670|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-23|2016-12-20|2016-12-20||April 2006||2006-04-01|December 2016|2016-12-01|August 2011|Actual|2011-08-01|January 2011|Actual|2011-01-01||Interventional||Patients diagnosed with acquired FVIII inhibitors were to be randomized to Rituximab versus oral cyclophosphamide to evaluate efficacy of inhibitor eradication and safety|Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A|A Prospective, Phase II/III Randomized, Mult-institutional Controlled, Open-label, Phase II Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Patients With Acquired Hemophilia A|Terminated||Phase 2/Phase 3|2|Actual|Georgetown University|Sponsor terminated study prior to patient receiving first dose of study drug.|2||Sponsor no longer funding study.|f||||f||||||||||2017-10-11 06:06:13.052|2017-10-11 06:06:13.052
NCT00306826|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-23|2010-02-01||||||June 2008|2008-06-01|May 2009||2009-05-01|||||Interventional|||Pioglitazone in Impaired Glucose Tolerance|Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance|Withdrawn||Phase 4|120||University of Leipzig||||financial support withdrawn|f||||||||||||||2017-10-11 06:06:35.875029|2017-10-11 06:06:35.875029
NCT00312221|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-06|2012-09-05|2010-07-15||April 2004||2004-04-01|September 2012|2012-09-01|August 2005|Actual|2005-08-01|July 2005|Actual|2005-07-01||Interventional|||Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain|Randomized, Double-blind, Multicenter Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release (OxyIR) Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain|Terminated||Phase 3|418|Actual|Purdue Pharma LP|This study was terminated early for administrative reasons not related to safety or efficacy. Low enrollment at termination led to reduced power.|3||terminated early for administrative reasons unrelated to safety or efficacy|f||||f||||||||||2017-10-11 06:07:01.990324|2017-10-11 06:07:01.990324
NCT00313014|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-10|2012-08-27|2010-07-28||February 2004||2004-02-01|August 2012|2012-08-01|September 2005|Actual|2005-09-01|September 2005|Actual|2005-09-01||Interventional|||Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain|A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-release Versus BTDS 5 in Subjects With Moderate to Severe Low Back Pain|Terminated||Phase 3|660|Actual|Purdue Pharma LP|BUP3015 was terminated early due to administrative reasons unrelated to efficacy or safety.|3||Terminated early due to administrative reasons unrelated to efficacy or safety.|f||||f||||||||||2017-10-11 06:07:19.716558|2017-10-11 06:07:19.716558
NCT00313144|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-10|2015-06-26|2011-03-04||June 2006||2006-06-01|August 2011|2011-08-01|May 2009|Actual|2009-05-01|December 2008|Actual|2008-12-01||Interventional|||Aralast alpha1-proteinase Inhibitor Surveillance Study|ARALAST alpha1-proteinase Inhibitor (α1-PI) Surveillance Study|Terminated||Phase 4|127|Actual|Baxalta US Inc.|Study was terminated early due to Aralast being phased out of the market.|1||Study terminated early due to Aralast being phased out of the market.|f||||f||||||||||2017-10-11 06:07:22.373816|2017-10-11 06:07:22.373816
NCT00301886|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-09|2013-11-11|||May 2006||2006-05-01|November 2013|2013-11-01|May 2006|Actual|2006-05-01|May 2006|Actual|2006-05-01||Interventional|||S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone|A Phase III Randomized, Multicenter Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate Versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients With Metastatic Breast Cancer|Withdrawn||Phase 3|0|Actual|Southwest Oncology Group||2||withdrawn support for study|f||||t||||||||||2017-10-11 06:07:39.916719|2017-10-11 06:07:39.916719
NCT00302770|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-13|2011-01-25|||June 2006||2006-06-01|January 2011|2011-01-01|December 2006|Actual|2006-12-01|December 2006|Actual|2006-12-01||Interventional|||Efficacy of Quetiapine in Generalised Social Anxiety Disorder|Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a Double-blind, Placebo-controlled Study|Terminated||Phase 3|50|Anticipated|AstraZeneca||||This study was terminated due to poor enrollment|f||||||||||||||2017-10-11 06:07:56.3482|2017-10-11 06:07:56.3482
NCT00303628|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-15|2016-07-13|2016-01-28||February 2006||2006-02-01|July 2016|2016-07-01|April 2019|Anticipated|2019-04-01|April 2015|Actual|2015-04-01||Interventional||All randomized patients (intent-to-treat population)|Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer|Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation|Terminated||Phase 3|355|Actual|Eastern Cooperative Oncology Group||2||The study was terminated before reaching its accrual goal due to slow accrual.|f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2017-10-11 06:08:20.039723|2017-10-11 06:08:20.039723
NCT00317018|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-19|2014-04-25|||May 2008||2008-05-01|April 2014|2014-04-01|September 2009|Actual|2009-09-01|June 2009|Actual|2009-06-01||Interventional|||Implementing Telemedicine-Based Collaborative Care for MDD in Contract CBOCs|Implementing Telemedicine-Based Collaborative Care for MDD in Contract CBOCs|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||This study was withdrawn prior to enrollment.|f||||f||||||||||2017-10-11 06:08:49.628556|2017-10-11 06:08:49.628556
NCT00307125|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-23|2015-03-11|2015-02-27||March 2006||2006-03-01|March 2015|2015-03-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional||Intent-to-treat|Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies|B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection|Completed||Phase 2|757|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Slow accrual. In order to ensure the study was completed within the time frame allotted, randomization to the control arm (Pilot Phase-Placebo plus immunosuppression) was suspended. Enrollment continued to lag. The study was stopped early.|2|||f||||t||||||||||2017-10-11 06:09:52.866898|2017-10-11 06:09:52.866898
NCT00307151|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-24|2017-03-15|2011-07-05||December 2005||2005-12-01|March 2017|2017-03-01|December 2016|Actual|2016-12-01|December 2010|Actual|2010-12-01||Interventional|P1060||Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV|Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-to-Child HIV Transmission|Completed||Phase 2|452|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Accrual to Cohort I was terminated early by the Data Safety Monitoring Committee after enrollment of 164 of the planned 288 subjects.|4|||f||||t||||||||||2017-10-11 06:09:53.661197|2017-10-11 06:09:53.661197
NCT00308594|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-28|2011-04-27|||November 2006||2006-11-01|April 2011|2011-04-01|November 2007|Actual|2007-11-01|November 2007|Actual|2007-11-01||Interventional|||Oral Dexamethasone for the Treatment of Cervical Radiculopathy|Oral Dexamethasone for the Treatment of Cervical Radiculopathy: A Double Blinded, Randomized, Placebo Controlled Trial|Terminated||Phase 2|100||University of Manitoba||||Study terminated due to withdrawl of participating co-investigators.|f||||f||||||||||2017-10-11 06:10:02.629181|2017-10-11 06:10:02.629181
NCT00310765|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-31|2012-09-04|||March 2006||2006-03-01|September 2012|2012-09-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|||Pregabalin for Abdominal Pain From Adhesions|Pregabalin for the Treatment of Abdominal Pain From Adhesions: Placebo Controlled Trial|Terminated||Phase 4|18|Actual|Henry Ford Health System||2||Study was terminated by the sponsor due to low accrual.|f||||f||||||||||2017-10-11 06:10:49.873456|2017-10-11 06:10:49.873456
NCT00319631|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-27|2017-01-27|||January 2006|Actual|2006-01-01|January 2017|2017-01-01|January 2017|Actual|2017-01-01|January 2017|Actual|2017-01-01||Observational|||Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)|Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)|Withdrawn||N/A|0|Actual|Weill Medical College of Cornell University|||1|Under the discretion of the PI the study has been withdrawn.|f||||t||||||||Undecided||2017-10-11 06:11:04.000325|2017-10-11 06:11:04.000325
NCT00322348|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-03|2010-12-22|2010-11-11||April 2006||2006-04-01|December 2010|2010-12-01|November 2009|Actual|2009-11-01|||||Interventional|||Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women|An Open-label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer|Completed||Phase 2|98|Actual|AstraZeneca|The criteria for non-inferiority were not met for the primary efficacy endpoint (PFS at Week 24). However, since recruitment was terminated prematurely, the study was no longer adequately powered to detect non-inferiority.|2|||f||||||||||||||2017-10-11 06:11:33.476598|2017-10-11 06:11:33.476598
NCT00322673|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-04|2010-02-18|||May 2006||2006-05-01|February 2010|2010-02-01|May 2007|Actual|2007-05-01|November 2006|Actual|2006-11-01||Interventional|||Study of XL999 in Patients With Acute Myeloid Leukemia (AML)|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia|Terminated||Phase 2|14|Actual|Symphony Evolution, Inc.||1||Study was terminated due to cardiac toxicities|f||||t||||||||||2017-10-11 06:11:48.314737|2017-10-11 06:11:48.314737
NCT00322829|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-04|2008-09-18|||May 2006||2006-05-01|September 2008|2008-09-01|February 2009|Anticipated|2009-02-01|||||Observational|||Development and Optimization of a GBS Diagnostic Test|Development and Optimization of a GBS Micro Total Analysis System (µTAS) Prototype for the Direct Detection of Group B Streptococci in Vaginal/Anal Specimens From Intrapartum Maternity Patients|Suspended||N/A|320|Anticipated|Laval University|||1|Temporarily suspended in between validating test systems.|f||||t||||||Samples With DNA|"     Vaginal/anal swab samples taken from pregnant women admitted for delivery to the Centre     Hospitalier Universitaire de Québec (CHUQ).   "|||2017-10-11 06:11:50.205139|2017-10-11 06:11:50.205139
NCT00322881|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-05|2017-03-22|2015-01-06||April 2006||2006-04-01|March 2017|2017-03-01|April 2010|Actual|2010-04-01|April 2008|Actual|2008-04-01||Interventional|||Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer|A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer|Terminated||Phase 2|12|Actual|Dana-Farber Cancer Institute|This study terminated early due to 3 deaths on study and consequently results are limited.|1||Early closure based on audit by study investigators after 3 patients died on study.|f||||t||||||||||2017-10-11 06:11:51.312348|2017-10-11 06:11:51.312348
NCT00307931|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-24|2011-08-30|2009-09-08||April 2007||2007-04-01|December 2009|2009-12-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|||Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab|Certolizumab Pegol in the Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Have Been Previously Treated Successfully With Infliximab But Who Have Subsequently Lost Response or Developed Intolerance to Infliximab|Terminated||Phase 3|16|Actual|UCB Pharma|This study was terminated early due to slow recruitment, namely only 17 subjects were recruited although the sample size had planned for approximately 50 subjects. As a consequence, the majority of secondary outcome measures were not summarized.|1||Study was terminated early because of slow recruitment|f||||f||||||||||2017-10-11 06:12:37.762794|2017-10-11 06:12:37.762794
NCT00315003|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-13|2009-04-02|||January 2006||2006-01-01|April 2009|2009-04-01|July 2006|Actual|2006-07-01|July 2006|Actual|2006-07-01||Interventional|||TELI COM - Telithromycin in Children With Otitis Media|Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 mg/kg od for 4 Days, in Children With Acute Otitis Media|Terminated||Phase 3|1500||Sanofi||||Pediatric development program terminated by sponsor|f||||||||||||||2017-10-11 06:12:48.41303|2017-10-11 06:12:48.41303
NCT00315042|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-13|2009-04-02|||March 2006||2006-03-01|April 2009|2009-04-01|August 2006|Actual|2006-08-01|August 2006|Actual|2006-08-01||Interventional|||TELI TON - Telithromycin in Tonsillitis|Multinational, Randomized, Double-Blind, Double Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 10 Days Penicillin V 13.3 mg/kg Tid in Children 6 Months to Less Than 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis|Terminated||Phase 3|314|Actual|Sanofi||||Pediatric development program terminated by sponsor|f||||||||||||||2017-10-11 06:12:48.791995|2017-10-11 06:12:48.791995
NCT00315458|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-17|2012-08-27|2010-07-28||December 2003||2003-12-01|August 2012|2012-08-01|March 2005|Actual|2005-03-01|March 2005|Actual|2005-03-01||Interventional|||Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.|Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Determine Efficacy and Safety of Buprenorphine Transdermal System in Subjects With Moderate To Severe Osteoarthritis Pain Requiring Daily Treatment With Opioids|Terminated||Phase 3|107|Actual|Purdue Pharma LP|This study was terminated early for administrative reasons. The efficacy data are not presented since the primary objective of this study was changed identifying it as a safety study.|2||Administrative reasons.|f||||||||||||||2017-10-11 06:12:59.877713|2017-10-11 06:12:59.877713
NCT00315549|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-14|2009-04-02|||February 2006||2006-02-01|April 2009|2009-04-01|September 2006|Actual|2006-09-01|September 2006|Actual|2006-09-01||Interventional|||TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults|Multinational, Randomized, Double Blind, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 800 mg od Versus 10 Days Penicillin V 500 mg Tid in Adolescent and Adult Subjects Equal to or Over 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis|Terminated||Phase 3|233|Actual|Sanofi||||Pediatric development program terminated by sponsor|f||||||||||||||2017-10-11 06:13:01.176013|2017-10-11 06:13:01.176013
NCT00315601|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-14|2009-02-12|||January 2006||2006-01-01|February 2009|2009-02-01|November 2006|Actual|2006-11-01|November 2006|Actual|2006-11-01||Interventional|||Intrapulmonary Pharmacokinetics of Antibiotics|Comparison of the Intrapulmonary and Plasma Concentrations of Telithromycin and Azithromycin in Healthy Adult Subjects|Terminated||Phase 4|35|Actual|University of Illinois at Chicago||1||Sanofi-Aventis wanted the study terminated.|f||||f||||||||||2017-10-11 06:13:01.902071|2017-10-11 06:13:01.902071
NCT00315822|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-17|2017-02-22|2016-11-29||May 2006||2006-05-01|February 2017|2017-02-01|January 2009|Actual|2009-01-01|December 2008|Actual|2008-12-01||Interventional|||Supplemental Postoperative Oxygen and Wound Infection in Morbidly Obese Patients|Supplemental Postoperative Oxygen & Wound Infection in Morbidly Obese Patients|Terminated||N/A|400|Actual|The Cleveland Clinic||2||Study was terminated due to futility|f||||f||||||||||2017-10-11 06:13:11.331166|2017-10-11 06:13:11.331166
NCT00316134|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-18|2011-11-07|||March 2006||2006-03-01|November 2011|2011-11-01|February 2008|Actual|2008-02-01|||||Observational|||Multiple Biomarkers in Undiagnosed Pleural Effusion|Evaluation of Multiple Biomarkers in Serum and Pleural Fluid to Estimate the Probability of Cancer in Patients Presenting With an Undiagnosed Pleural Effusion|Terminated||N/A|200|Actual|Fujirebio Diagnostics, Inc.|||1|The study was terminated on completion of the Pilot Study phase.|f||||f||||||Samples Without DNA|"     Serum and pleural fluids   "|||2017-10-11 06:13:18.304164|2017-10-11 06:13:18.304164
NCT00326196|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-12|2014-04-07|2013-07-01||July 2006||2006-07-01|April 2014|2014-04-01|August 2012|Actual|2012-08-01|August 2012|Actual|2012-08-01||Interventional|VA CARDS||Coronary Artery Revascularization in Diabetes|CSP #557 - Coronary Artery Revascularization in Diabetes (VA CARDS)|Terminated||Phase 4|198|Actual|VA Office of Research and Development|Low participant recruitment led to the study being terminated early.|2||Lack of participant enrollment|f||||t||||||||||2017-10-11 06:13:55.166172|2017-10-11 06:13:55.166172
NCT00320190|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-01|2013-10-01|2011-06-06||August 2006||2006-08-01|July 2011|2011-07-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|||Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib|An Open-label, Randomized Study of Dasatinib vs High-dose (800-mg) Imatinib in the Treatment of Subjects With Chronic Phase Chronic Myeloid Leukemia Who Have Had a Suboptimal Response After at Least 3 Months of Therapy With 400 mg Imatinib|Terminated||Phase 2|52|Actual|Bristol-Myers Squibb|Enrollment terminated prematurely on September 5, 2008, due to slow accrual. Only 32 of 156 planned participants were randomized from August 2, 2006. Per BMS standards, findings were reported in a synopsis format, with only safety results included.|2||Terminated due to slow participant accrual|f||||f||||||||||2017-10-11 06:14:55.623227|2017-10-11 06:14:55.623227
NCT00320801|ClinicalTrials.gov processed this data on October 10, 2017|2006-04-28|2012-08-27|2010-07-28||January 2004||2004-01-01|August 2012|2012-08-01|March 2005|Actual|2005-03-01|March 2005|Actual|2005-03-01||Interventional|||Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.|A Randomized, Double-Blind, Multicenter Study Evaluating The Safety and Efficacy of BTDS in Subjects With Moderate to Severe Osteoarthritis Pain. Includes a 52-Week Extension Phase.|Terminated||Phase 3|188|Actual|Purdue Pharma LP|Study terminated due to administrative reasons. The primary objective was changed to a safety study prior to unblinding.|2||This study was terminated early due to administrative reasons.|f||||t||||||||||2017-10-11 06:15:21.205602|2017-10-11 06:15:21.205602
NCT00329108|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-05|2009-04-01|2008-12-22||November 2006||2006-11-01|April 2009|2009-04-01|January 2008|Actual|2008-01-01|July 2007|Actual|2007-07-01||Interventional|ZOOM||Ziprasidone And Olanzapine's Outcomes In Mania|A Multicenter, Randomized, Double-Blind, Parallel Group Study, Comparing The Efficacy And Tolerability Of Ziprasidone (Zeldox, Geodon) vs. Olanzapine (Zyprexa) In The Treatment And Maintenance Of Response In Patients With Acute Mania|Terminated||Phase 4|29|Actual|Pfizer|The study was terminated due to poor recruitment. No efficacy data were summarized due to very low sample size. Only safety data were summarized.|2||Please see Brief Summary for Termination Reason.|f||||f||||||||||2017-10-11 06:15:51.757644|2017-10-11 06:15:51.757644
NCT00329316|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-23|2008-06-26||||||June 2007|2007-06-01||||||||Interventional|||Prevention of Recurrent Preterm Delivery by a Natural Progesterone Agent||Withdrawn||N/A|||The Baruch Padeh Medical Center, Poriya||||"Study withdrawn for financial problems. We didnwt get a grant we needed for purchesing the   medication for the study."|f||||||||||||||2017-10-11 06:16:01.640935|2017-10-11 06:16:01.640935
NCT00329732|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-24|2015-04-16|2011-05-24||March 2006||2006-03-01|April 2015|2015-04-01|April 2006|Actual|2006-04-01|April 2006|Actual|2006-04-01||Interventional|||Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks|Double-Blind, Placebo Controlled Trial Of Greater Occipital Nerve Block For The Treatment Of Migraine Status|Terminated||N/A|2|Actual|Thomas Jefferson University||2||Study terminated due to inadequate recruitment|f||||||||||||||2017-10-11 06:16:20.960259|2017-10-11 06:16:20.960259
NCT00330291|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-24|2012-09-06|||August 2005||2005-08-01|September 2012|2012-09-01|August 2006|Actual|2006-08-01|August 2006|Actual|2006-08-01||Interventional|||Xyrem for Treatment Refractory Insomnia Due to PTSD|Xyrem for Treatment Refractory Insomnia Due to PTSD|Withdrawn||Phase 2|0|Actual|State University of New York - Upstate Medical University||||terminated due to inability to recruit subjects|||||||||||||||2017-10-11 06:16:31.513797|2017-10-11 06:16:31.513797
NCT00330668|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-26|2011-05-31|2011-02-28||November 2005||2005-11-01|May 2011|2011-05-01|March 2010|Actual|2010-03-01|February 2010|Actual|2010-02-01||Interventional|||Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency|Recombinant Human Insulin-Like Growth Factor-1 (IGF-1) Treatment of Children With Growth Failure Associated With Primary IGF-1 Deficiency: An Open-Label, Multi-Center, Extension Study|Terminated||Phase 3|114|Actual|Ipsen|The study was terminated by the sponsor on identification of an unacceptable frequency of hypoglycemia which was reported at doses of ≥200 mcg/kg once daily. Only safety results are presented as efficacy data were not analyzed according to protocol.|1||Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day|f||||t||||||||||2017-10-11 06:16:37.272773|2017-10-11 06:16:37.272773
NCT00331006|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-26|2013-06-07|2013-01-07||June 2006||2006-06-01|June 2013|2013-06-01|January 2012|Actual|2012-01-01|November 2010|Actual|2010-11-01||Interventional|RICH|All subjects who began the screening phase|Rituximab to Treat Severe Hemophilia A|Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (A TMH CTN Study)|Completed||Phase 2|23|Actual|New England Research Institutes|The study was terminated before reaching its target sample size of 50 subjects due to low enrollment rates. Therefore, confidence intervals for proportions are wide.|1|||f||||t||||||||||2017-10-11 06:16:49.179035|2017-10-11 06:16:49.179035
NCT00331045|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-26|2015-09-01|||April 2006||2006-04-01|September 2009|2009-09-01|December 2006|Actual|2006-12-01|October 2006|Actual|2006-10-01||Interventional|||Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid|Clinical Evaluation of Alvimopan (SB767905) on Constipation and Related Symptoms Associated With Opioid -A Placebo-controlled Double-blind Study in Cancer Patients-|Terminated||Phase 2|21|Actual|Cubist Pharmaceuticals LLC||4||"Subject registration did not proceed as expected; difficult to complete within scheduled time   frame; prematurely terminated w/ 21 subjects randomized."|f||||||||||||||2017-10-11 06:16:49.931076|2017-10-11 06:16:49.931076
NCT00308087|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-28|2013-12-02|2010-06-11||May 2006||2006-05-01|December 2013|2013-12-01|June 2009|Actual|2009-06-01|June 2009|Actual|2009-06-01||Interventional|PREMIER||Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma|Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-cell Lymphoma|Terminated||Phase 2|75|Actual|Sanofi|One hundred ninety-six patients were planned and 75 enrolled prior to termination. The study was terminated early due to low enrollment, and the extent of changes needed to the protocol to keep pace with therapeutic changes for indolent lymphoma.|2||Terminated by sponsor due to low enrollment; see details below|f||||t||||||||||2017-10-11 06:16:53.153866|2017-10-11 06:16:53.153866
NCT00308113|ClinicalTrials.gov processed this data on October 10, 2017|2006-03-27|2013-10-16|2013-08-07||April 2007||2007-04-01|October 2013|2013-10-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||CoQ10 and Prednisone in Non-Ambulatory DMD|PITT0503: Clinical Trial of Coenzyme Q10 and Prednisone in Duchenne Muscular Dystrophy|Terminated||Phase 3|3|Actual|Cooperative International Neuromuscular Research Group|In December 2007 the CINRG Data Safety and Monitoring Board (DSMB) met and recommended to close the study as the AAN had released practice parameters recommending that all patients with DMD should be offered treatment with corticosteroids.|4||New enrollment has been suspended, currently following previously enrolled participants|f||||t||||||||||2017-10-11 06:16:54.494568|2017-10-11 06:16:54.494568
NCT00324987|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-10|2017-08-15|2017-05-10||April 2008||2008-04-01|August 2017|2017-08-01|July 2015|Actual|2015-07-01|July 2015|Actual|2015-07-01||Interventional|S0502||Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor|A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors|Terminated||Phase 3|12|Actual|National Cancer Institute (NCI)|Trial was terminated due to poor accrual. No conclusions should be drawn from the reported data due to the small sample size.|2||The trial failed to accrue|f||||t||||||||||2017-10-11 06:17:17.459342|2017-10-11 06:17:17.459342
NCT00331422|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-30|2012-11-06|2009-11-23||October 2005||2005-10-01|November 2012|2012-11-01|March 2009|Actual|2009-03-01|March 2008|Actual|2008-03-01||Interventional|||Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced|Terminated||Phase 2|7|Actual|Masonic Cancer Center, University of Minnesota|1 of the 2 evaluable patients was switched from Paclitaxel to Taxotere during the course of her treatment due to toxicity (adverse effects), but since it remains a platinum-based chemotherapy she is included in the evaluable group.|1||Study was terminated due to lack of available funding.|f||||t||||||||||2017-10-11 06:17:33.480924|2017-10-11 06:17:33.480924
NCT00332839|ClinicalTrials.gov processed this data on October 10, 2017|2006-05-31|2014-08-15|2014-03-14||November 2005||2005-11-01|August 2014|2014-08-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|||Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.|Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-coated Mycophenolate Sodium and Everolimus in Comparison to Standard Therapy With Enteric-coated Mycophenolate Sodium and Ciclosporin Microemulsion in Stable Renal Transplant Patients|Terminated||Phase 4|93|Actual|Novartis|Adverse Events data were not collected during the Follow-up period.|2||"The trial was terminated early due to slow enrollment. It was determined that the planned   sample size of 300 could not be achieved."|f||||||||||||||2017-10-11 06:17:37.903097|2017-10-11 06:17:37.903097
NCT00333983|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-02|2014-02-03|2013-08-30||June 2006||2006-06-01|February 2014|2014-02-01|February 2011|Actual|2011-02-01|April 2010|Actual|2010-04-01||Interventional|||Evaluation of Robotic Arm Rehabilitation in Stroke Patients|Evaluation of Robotic Arm Rehabilitation in Stroke Patients|Completed||N/A|62|Actual|VA Office of Research and Development|This study was terminated early with the current number of subjects analyzed. A midstudy futility analysis showed a need for 99 participants per group to determine signifcance between the robotic training over the intensive conventional exercise.|2|||f||||t||||||||||2017-10-11 06:18:12.918431|2017-10-11 06:18:12.918431
NCT00334646|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-06|2012-07-26|||August 2005||2005-08-01|July 2012|2012-07-01|September 2009|Actual|2009-09-01|September 2009|Actual|2009-09-01||Interventional|||Cyclophosphamide Drug Interaction Study In Cancer Patients|An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 and Intravenous Cyclophosphamide in Cancer Patients|Terminated||Phase 1|10|Actual|GlaxoSmithKline||2||compound terminated|f||||||||||||||2017-10-11 06:18:23.580842|2017-10-11 06:18:23.580842
NCT00334685|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-07|2008-07-15|||July 2006||2006-07-01|July 2008|2008-07-01||||||||Interventional|||[S,S]-Reboxetine Add-On Trial|[S,S]-Reboxetine Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN) Concomitantly Treated With Pregabalin.|Terminated||Phase 2|354||Pfizer||||The DMC terminated the study on the basis of futility (insufficient clinical response).|f||||t||||||||||2017-10-11 06:18:23.91383|2017-10-11 06:18:23.91383
NCT00334867|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-07|2013-06-27|||December 2005||2005-12-01|June 2013|2013-06-01||||January 2006|Actual|2006-01-01||Interventional|||Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma|A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma|Withdrawn||Phase 3|0|Actual|Children's Oncology Group||2||withdrawn|f||||||||||||||2017-10-11 06:18:28.08987|2017-10-11 06:18:28.08987
NCT00336414|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-12|2007-06-27|||June 2006||2006-06-01|June 2007|2007-06-01|June 2007|Anticipated|2007-06-01|||||Interventional|||Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis|Five-Year Single-Blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis: Oral Cyclophosphamide Versus High Dose Intravenous Cyclophosphamide Versus Intermediate Dose Intravenous Cyclophosphamide|Withdrawn||Phase 3|159||Istituto Giannina Gaslini||||the study is withdrawn due to low and unexpected enrollment rate|f||||||||||||||2017-10-11 06:19:21.319434|2017-10-11 06:19:21.319434
NCT00332696|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-01|2011-09-20|2011-01-17||September 2005||2005-09-01|September 2011|2011-09-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis|Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis|Completed||Phase 2|64|Actual|Novartis|Study was terminated prematurely due to low enrollment|2|||f||||f||||||||||2017-10-11 06:20:23.648861|2017-10-11 06:20:23.648861
NCT00338455|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-16|2014-11-20|2008-10-22||September 2006||2006-09-01|November 2014|2014-11-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Interventional|||Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC|Investigation of the Use of Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC|Terminated||Phase 2|16|Actual|Scios, Inc.|Early termination of the study due to enrollment difficulties (change in standard of care for patient population as well as changing organ allocation rules by United Network for Organ Sharing); efficacy not analyzed due to limited sample size (n=16).|2||"DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated   due to slow enrollment"|f||||t||||||||||2017-10-11 06:20:28.974447|2017-10-11 06:20:28.974447
NCT00335621|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-08|2010-07-27|||June 2006||2006-06-01|May 2006|2006-05-01|December 2007||2007-12-01|||||Interventional|||Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable Chronic Obstructive Pulmonary Disease (COPD)|Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable COPD|Withdrawn||Phase 4|45|Anticipated|NHS Greater Glasgow and Clyde||||Study terminated prior to recruitment - recruitment proved impossible|f||||||||||||||2017-10-11 06:21:43.969544|2017-10-11 06:21:43.969544
NCT00343655|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-20|2008-06-13|||January 2007||2007-01-01|June 2008|2008-06-01|August 2007|Actual|2007-08-01|||||Interventional|||Evaluation of Atorvastatin Treatment on Carotid Plaque.|A Randomized Clinical Trial Of Atorvastatin 10 Mg And 80 Mg In The Reversal Of Or Stabilization Of Carotid Atheroma Lipid Pool|Terminated||Phase 3|160||Pfizer||||"The study was terminated on June 22, 2007 for inability to enroll patients within an   appropriate timeframe. There were no efficacy/safety concerns."|f||||||||||||||2017-10-11 06:21:44.695597|2017-10-11 06:21:44.695597
NCT00345384|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-27|2016-01-12|2011-08-10||May 2008||2008-05-01|January 2016|2016-01-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional||13 were withdrawn from study prior to initiation of drug due to exclusion criteria that required an overnight stay in Recovery or ICU.|Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients|Post-Operative Infusion of Low-Dose Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients: A Randomized, Double-Blind, Controlled Pilot Study|Completed||Phase 1/Phase 2|38|Actual|Baylor Research Institute|Pilot study with small numbers of participants.|2|||f||||f||||||||||2017-10-11 06:22:05.430547|2017-10-11 06:22:05.430547
NCT00346268|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-28|2011-09-21|2011-09-21||December 2006||2006-12-01|September 2011|2011-09-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional|PROSTATECTOMY||Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy|Randomized, Double-Blind Study Of The Morphine-Sparing Efficacy And Safety Of Parecoxib Sodium 40 Mg IV Followed By 20 Mg IV Every 12 Hours In The Treatment Of Pain Following Radical Prostatectomy|Terminated||Phase 4|105|Actual|Pfizer|This study was terminated prematurely due to slow recruitment.|2||See termination reason in detailed description.|f||||t||||||||||2017-10-11 06:22:40.455309|2017-10-11 06:22:40.455309
NCT00346502|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-29|2013-12-10|||January 2006||2006-01-01|December 2013|2013-12-01|December 2015|Anticipated|2015-12-01|December 2015|Anticipated|2015-12-01||Interventional|||Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)|Phase I/II Evaluation of Topical Application of 20% Betulinic Acid Ointment in the Treatment of Dysplastic Nevi With Moderate to Severe Dysplasia|Suspended||Phase 1/Phase 2|200|Anticipated|University of Illinois at Chicago||1||The study has been temporarily suspended due to funding issues|f||||||||||||||2017-10-11 06:22:43.968686|2017-10-11 06:22:43.968686
NCT00346749|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-28|2016-10-27|||December 2006||2006-12-01|October 2016|2016-10-01|July 2007|Actual|2007-07-01|July 2007|Actual|2007-07-01||Interventional|||ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.|A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared With Salmeterol DISKUS 50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Terminated||Phase 4|180||GlaxoSmithKline||1||"The study was terminated due to difficulties with finding sites and subjects willing to   participate."|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2017-10-11 06:22:52.953195|2017-10-11 06:22:52.953195
NCT00346879|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-28|2016-02-22|||August 2006||2006-08-01|February 2016|2016-02-01|January 2009|Actual|2009-01-01|December 2008|Actual|2008-12-01||Interventional|||Study to Determine Effective Dosing of Fondaparinux in Obese Persons|Thromboprophylaxis in the Morbidly Obese With Weight Based Dosing of Fondaparinux: A Pharmacodynamic Study|Withdrawn||Phase 1|0|Actual|Indiana University||1||Funding withdrawn; study closed due to lack of accrual.|f||||t||||||||||2017-10-11 06:22:54.181584|2017-10-11 06:22:54.181584
NCT00348556|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-30|2012-09-14|2012-09-14||December 2005||2005-12-01|September 2012|2012-09-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure|Efficacy of Intra-renal Infusion of BNP in Enhancing Renal Function in Human CHF With Cardiorenal Syndrome: A Pilot Study|Terminated||Phase 1/Phase 2|4|Actual|Mayo Clinic|The study was terminated early because the company providing catheter was bought out, and funding and supplies were terminated.|1||Company providing catheter bought out, funding and supplies terminated|f||||t||||||||||2017-10-11 06:23:35.524374|2017-10-11 06:23:35.524374
NCT00348894|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-04|2011-05-31|||July 2006||2006-07-01|May 2011|2011-05-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Interventional|||[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.|A Phase 2b Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Chronic Painful Diabetic Peripheral Neuropathy (DPN).|Terminated||Phase 2|136|Actual|Pfizer||2||"- Study was terminated due to insufficient clinical efficacy observed in previous studies   conducted in postherpetic neuralgia."|f||||f||||||||||2017-10-11 06:23:41.246746|2017-10-11 06:23:41.246746
NCT00349986|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-07|2009-12-04|||September 2006||2006-09-01|December 2009|2009-12-01||||June 2007|Actual|2007-06-01||Interventional|||LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus|The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients|Terminated||Phase 4|4|Actual|Sanofi||2||prematurely terminated due to loss of interest|f||||||||||||||2017-10-11 06:24:00.474146|2017-10-11 06:24:00.474146
NCT00344019|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-22|2017-06-05|2017-04-13||May 2006|Actual|2006-05-01|June 2017|2017-06-01|January 2009|Actual|2009-01-01|October 2008|Actual|2008-10-01||Interventional||Study terminated by previous investigator due to slow enrollment. Database no longer available. Data report based on IRB termination report; only gender, race data avail. 97 screened, 23 reported as completed study. Screening data as avail reported herein.|Effects of Atorvastatin on Myonecrosis|Effects of Single-Dose Atorvastatin on Peri-Procedural Myonecrosis During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes - The NO-MI Study|Terminated||Phase 4|23|Actual|Beth Israel Deaconess Medical Center||3||slow recruitment|f||||f|t|f|||f|||No|no plans to share data|2017-10-11 06:24:20.471443|2017-10-11 06:24:20.471443
NCT00351637|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-11|2012-01-18|||December 2006||2006-12-01|January 2012|2012-01-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients|Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients: a Phase II Multicenter, Open Label, Feasibility Study|Terminated||Phase 2|60|Anticipated|AHS Cancer Control Alberta||1||Study suspended due to low accrual|f||||||||||||||2017-10-11 06:24:34.392998|2017-10-11 06:24:34.392998
NCT00352079|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-13|2012-12-17|||April 2006||2006-04-01|December 2012|2012-12-01|January 2012|Actual|2012-01-01|||||Interventional|||BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer|A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder|Terminated||Phase 3|41|Actual|Canadian Cancer Trials Group||2||terminated due to poor accrual|f||||t||||||||||2017-10-11 06:24:46.580178|2017-10-11 06:24:46.580178
NCT00352651|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-12|2011-04-12|||June 2006||2006-06-01|March 2011|2011-03-01|December 2006|Actual|2006-12-01|December 2006|Actual|2006-12-01||Interventional|||Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo|Placebo-Controlled Study of Pregabalin for the Pain of Acute Herpes Zoster|Terminated||Phase 2|34|Anticipated|University of California, San Francisco||||"This study should be terminated as the study has been closed for years and the investigator has   since retired. No records are available.    Thank you, Marlene"|f||||||||||||||2017-10-11 06:24:54.359211|2017-10-11 06:24:54.359211
NCT00352768|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-14|2010-03-03|||August 2006||2006-08-01|March 2010|2010-03-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents|SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study|Terminated||Phase 4|20|Actual|Solvay Pharmaceuticals||2||This study was prematurely terminated (26 June 2009) due to slow recruitment|f||||t||||||||||2017-10-11 06:24:57.521022|2017-10-11 06:24:57.521022
NCT00353743|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-13|2008-12-18|||May 2006||2006-05-01|March 2007|2007-03-01|December 2007|Actual|2007-12-01|November 2007|Actual|2007-11-01||Interventional|APA||The Use of Antibiotics After Hospital Discharge in Septic Abortion|A Randomized Clinical Trial on the Use or Not of Antibiotics After Hospital Discharge in Septic Abortion.|Terminated||N/A|56|Actual|Hospital de Clinicas de Porto Alegre||2||Rate of cure was higher than expected, IRB suspended for no additional benefit|f||||t||||||||||2017-10-11 06:25:13.250919|2017-10-11 06:25:13.250919
NCT00353808|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-17|2011-04-06|||July 2006||2006-07-01|April 2011|2011-04-01|October 2007|Actual|2007-10-01|||||Interventional|||A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.|An Open-Label Extension Trial Assessing The Safety And Tolerability Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN).|Terminated||Phase 2|112|Actual|Pfizer||1||"This study has been terminated early as the esreboxetine development program is being   discontinued. There are no safety or efficacy concerns."|f||||||||||||||2017-10-11 06:25:13.861887|2017-10-11 06:25:13.861887
NCT00347919|ClinicalTrials.gov processed this data on October 10, 2017|2006-06-30|2016-01-28|2009-11-19||July 2006||2006-07-01|January 2016|2016-01-01|March 2015|Actual|2015-03-01|August 2008|Actual|2008-08-01||Interventional|||Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer|A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors|Completed||Phase 2|189|Actual|GlaxoSmithKline|In 2008 at primary completion, study was terminated. In 2011, protocol amendment 4 (Am4), allowed continuation of treatment until PD for the 1 par. This par. completed the study per Am 4. Par. last visit occurred, the study is considered completed.|3|||f||||f||||||||||2017-10-11 06:25:26.083589|2017-10-11 06:25:26.083589
NCT00354159|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-19|2012-08-07|2012-01-12||April 2006||2006-04-01|August 2012|2012-08-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Interventional|REDUCEhf||Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)|Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic HF (REDUCEhf)|Completed||N/A|442|Actual|Medtronic Cardiac Rhythm and Heart Failure|The study was terminated early after 400 of an estimated 1300 subjects required were randomized. The study was terminated due to a pressure lead integrity issue based on analysis of pressure leads from other clinical trials.|2|||f||||t||||||||||2017-10-11 06:25:42.153049|2017-10-11 06:25:42.153049
NCT00354601|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-19|2017-07-31|2009-03-09||January 2006||2006-01-01|March 2017|2017-03-01|July 2008|Actual|2008-07-01|May 2008|Actual|2008-05-01||Interventional|||Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer|A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum|Terminated||Phase 2|2|Actual|Wake Forest University Health Sciences|Early closure due to discontinuation of funding|1||funding withdrawn|f|||||t|f||||||||2017-10-11 06:25:51.980025|2017-10-11 06:25:51.980025
NCT00356421|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-24|2009-08-25|2009-06-24||November 2006||2006-11-01|January 2009|2009-01-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional|||A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®|A 52-Week Multicenter, Open-Label, Randomized, Parallel, Two - Arm Study Comparing Exubera® (Inhaled Human Insulin) Vs. Humalog® (Insulin Lispro), Both In Combination With Insulin Glargine In Subjects With Type 1 Diabetes Mellitus|Terminated||Phase 4|58|Actual|Pfizer|As a result of Pfizer’s decision to stop marketing Exubera ®, this study was terminated. Due to the early termination of the study and the low number of subjects who completed, no descriptive statistics for efficacy endpoints are provided.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 06:26:30.228537|2017-10-11 06:26:30.228537
NCT00356525|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-24|2010-08-09|2009-06-08||September 2006||2006-09-01|August 2010|2010-08-01|April 2009|Actual|2009-04-01|June 2008|Actual|2008-06-01||Interventional|||Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor|Phase II, Randomized, Open-Label Trial of Biweekly Pemetrexed Plus Gemcitabine vs. Pemetrexed or Pemetrexed Plus Carboplatin in Relapsed Non Small Cell Lung Cancer After Neoadjuvant or Adjuvant Chemotherapy|Terminated||Phase 2|41|Actual|Eli Lilly and Company|The trial terminated early due to slow enrollment. Secondary outcomes were not analyzed due to insufficient data. Original results reported were interim analyses. Results have now been updated with final data.|4||Stopped early due to low enrollment|f||||f||||||||||2017-10-11 06:26:31.990299|2017-10-11 06:26:31.990299
NCT00356616|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-24|2008-01-25|||September 2005||2005-09-01|November 2007|2007-11-01|June 2007|Actual|2007-06-01|June 2007|Actual|2007-06-01||Interventional|||Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients|Open-Label, Single-Centre, Randomised Pilot Study to Evaluate Immunovirological and Clinical Evolution of a Combination With Nucleoside Analogues/Nucleotides (Trizivir +Tenofovir) in Multiresistant Patients With Virological Failure|Terminated||Phase 4|24|Actual|Germans Trias i Pujol Hospital||2||terminated|f||||f||||||||||2017-10-11 06:26:35.695312|2017-10-11 06:26:35.695312
NCT00356837|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-24|2010-12-10|||August 2006||2006-08-01|December 2010|2010-12-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Diagnosing Extremity Fractures and/or Dislocations Using Ultrasound Presenting to the Emergency Department|Diagnosing Extremity Fractures and/or Dislocations Using Ultrasound in Adult Patients Presenting to the Emergency Department|Terminated||N/A|323|Anticipated|United States Army Institute of Surgical Research||1||IRB terminated study due to non compliance with continuing review date.|f||||f||||||||||2017-10-11 06:26:37.654919|2017-10-11 06:26:37.654919
NCT00359151|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-28|2008-05-22|||November 2006||2006-11-01|May 2008|2008-05-01|July 2007|Actual|2007-07-01|||||Interventional|||Celebrex Total Knee Arthroplasty Study|Multicenter, Double Blind, Randomized, Placebo Controlled Trial Of The Efficacy And Safety Of Usual Care Plus Celecoxib Compared To Placebo For Peri-Operative And Rehabilitation Pain Control And Return To Function In Osteoarthritis Patients Undergoing Total Knee Arthroplasty|Terminated||Phase 4|22|Actual|Pfizer||2||This study was terminated early due to slow enrollment.|f||||f||||||||||2017-10-11 06:26:58.60854|2017-10-11 06:26:58.60854
NCT00359632|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-28|2015-06-03|2014-12-16||November 2008||2008-11-01|June 2015|2015-06-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|||Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater|Prospective Study Of Ophthalmologic Function In Patients Receiving Linezolid For Six Weeks Or Greater|Terminated||Phase 3|34|Actual|Pfizer|This pilot study was exploratory and not designed to be powered for safety or efficacy. Controls were not followed post-baseline whereas linezolid patients returned for multiple study visits. The study was terminated early due to slow enrollment.|2||"Study was stopped due to poor enrollment on 28 Feb 2012. Reason for termination was not due to   safety concerns."|f||||f||||||||||2017-10-11 06:27:11.187742|2017-10-11 06:27:11.187742
NCT00360971|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-03|2015-11-14|2014-04-16||July 2006||2006-07-01|November 2015|2015-11-01|February 2009|Actual|2009-02-01|May 2008|Actual|2008-05-01||Interventional||All eligible patients.|Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer|A Randomized, Phase III, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Palifermin (NSC# 740548; IND # 6370) for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Radiation Therapy With Concurrent Chemotherapy (Followed by Surgery for Selected Patients)|Terminated||Phase 3|21|Actual|Radiation Therapy Oncology Group|This study terminated early with 21 subjects accrued out of 298 planned, therefore no statistical testing was performed. The termination was decided due to positive preliminary results from other palifermin studies.|2||Due to positive preliminary results from other palifermin studies.|f||||t||||||||||2017-10-11 06:27:47.72801|2017-10-11 06:27:47.72801
NCT00361257|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-04|2016-01-07|2011-01-28||March 2007||2007-03-01|January 2016|2016-01-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|||Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults|Phase II, Randomized, Placebo-Controlled, Double-Blind Study of Minocycline in the Treatment of HIV-Associated Cognitive Impairment|Terminated||Phase 2|107|Actual|AIDS Clinical Trials Group|Originally, 100 participants were expected to enroll. As of the early termination notice, 107 participants were randomized, yet not all subjects could complete the 24 week assessment.|2||This study was terminated early due to futility.|f||||t||||||||||2017-10-11 06:27:53.108481|2017-10-11 06:27:53.108481
NCT00363779|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-10|2015-06-26|2012-03-30||June 2006||2006-06-01|June 2015|2015-06-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia|Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia|Terminated||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)|As there were only 5 patients treated, the primary endpoints of this protocol were not met and there is not enough data generated for statistical analysis. This protocol is being terminated due to low accrual and the investigator leaving the NIH.|1||Study terminated due to low accrual and the investigator left the NIH.|f||||f||||||||||2017-10-11 06:28:08.598192|2017-10-11 06:28:08.598192
NCT00363883|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-10|2015-01-28|2015-01-28||June 2006||2006-06-01|January 2014|2014-01-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium|Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium|Terminated||Phase 2|14|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.|1||Trial stopped early for futility|f||||||||||||||2017-10-11 06:28:10.126129|2017-10-11 06:28:10.126129
NCT00364429|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-11|2016-01-07|||July 2005||2005-07-01|January 2016|2016-01-01|July 2005|Actual|2005-07-01|July 2005|Actual|2005-07-01||Interventional|||SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia|Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study|Terminated||Phase 1|55|Actual|GlaxoSmithKline||||terminated|f||||f||||||||||2017-10-11 06:28:22.684599|2017-10-11 06:28:22.684599
NCT00364533|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-11|2014-04-03|2008-12-19||October 2006||2006-10-01|April 2014|2014-04-01|December 2007|Actual|2007-12-01|December 2007|Actual|2007-12-01||Interventional|||A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety|A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension|Terminated||Phase 3|367|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Sponsor terminated study, sample size not reached. The protocol section describes 4 study arms defining the treatment groups in the study design. The participant flow module describes the 5 treatment groups analyzed for the primary endpoint|4||Slow enrollment|f||||f||||||||||2017-10-11 06:28:23.385365|2017-10-11 06:28:23.385365
NCT00365820|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-17|2012-04-19|||July 2006||2006-07-01|April 2012|2012-04-01|April 2007|Actual|2007-04-01|April 2007|Actual|2007-04-01||Interventional|||Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain|A Randomized, Double-blind, Placebo-controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain|Terminated||Phase 2/Phase 3|670||Novartis||||"This study was terminated early as a result of regulatory action suspending tegaserod use in   2007"|f||||||||||||||2017-10-11 06:28:54.74847|2017-10-11 06:28:54.74847
NCT00358111|ClinicalTrials.gov processed this data on October 10, 2017|2006-07-27|2014-05-12|||July 2006||2006-07-01|May 2014|2014-05-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Study of LUMA Cervical Imaging System as Adjunct to Colposcopy|A Single Arm Multi-Center Post Approval Study of LUMA as Adjunct to Colposcopy|Terminated||Phase 4|10|Actual|SpectraScience||1||PMA withdrawn|f||||t||||||||||2017-10-11 06:29:19.022867|2017-10-11 06:29:19.022867
NCT00372528|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-05|2012-09-21|2012-09-21||March 2007||2007-03-01|September 2012|2012-09-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|||An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures|An Open-Label, Multi-Center, Add-On Study Of Pregabalin (LYRICA) In Subjects With Refractory Partial Seizures Who Have Completed Studies 1008-010, 1008-035, 1008-114 Or 1008-164|Terminated||Phase 3|21|Actual|Pfizer|This was a compassionate use study and no formal primary outcome measure was specified a priori. Descriptive safety data were collected, subsequently safety outcome was designated as primary outcome as per National Institute of Health (NIH) criteria.|1||"This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug.   No efficacy or safety concerns factored into this decision."|f||||f||||||||||2017-10-11 06:29:57.428488|2017-10-11 06:29:57.428488
NCT00373633|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-06|2014-08-13|||September 2006||2006-09-01|August 2014|2014-08-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Extrapleural Intercostal Catheter vs. Thoracic Epidural for Thoracotomy Pain|A Prospective Randomized Trial Comparing Extrapleural Intercostal Local Anesthesia Versus Thoracic Epidural for the Managment of Acute Post Thoracotomy Pain|Terminated||Phase 1|26|Actual|Virginia Commonwealth University||2||terminated due to diminishing frequency of thorocotomies and slow enrollment|f||||||||||||||2017-10-11 06:30:33.450327|2017-10-11 06:30:33.450327
NCT00362466|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-09|2009-11-18|2009-07-24||April 2007||2007-04-01|November 2009|2009-11-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional|||A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy|An Open-Label Randomized Phase III Study of Dasatinib vs. High-Dose (600 mg) Imatinib Mesylate in the Treatment of Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Are Imatinib Failures or Who Have Had a Suboptimal Response After 3-18 Months of Therapy With 400 mg Imatinib|Terminated||Phase 3|3|Actual|Bristol-Myers Squibb|Study was terminated early due to insufficient enrollment.|2||Insufficient Enrollment|f||||f||||||||||2017-10-11 06:31:14.131331|2017-10-11 06:31:14.131331
NCT00362765|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-09|2008-08-12|||October 2006||2006-10-01|August 2008|2008-08-01|July 2007|Actual|2007-07-01|||||Interventional|||Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study|Assessment of Insulin Sensitivity in Type 2 Diabetics Treated With Metformin, Fenofibrate and Their Combination.|Terminated||Phase 2/Phase 3|8|Actual|Solvay Pharmaceuticals||4||"The study was prematurely terminated, due to difficulties in the recruitment of T2DM patients   who are not under statin therapy at inclusion."|f||||f||||||||||2017-10-11 06:31:19.016109|2017-10-11 06:31:19.016109
NCT00374543|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-08|2014-03-20|2013-05-20||February 2006||2006-02-01|March 2014|2014-03-01|November 2008|Actual|2008-11-01|October 2007|Actual|2007-10-01||Interventional|||Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder|Ziprasidone for the Treatment of Generalized Anxiety Comorbidity in Patients With Bipolar Disorder|Terminated||Phase 4|3|Actual|Massachusetts General Hospital|This study was terminated due to extreme difficulties in participant recruitment. Therefore, the sample size is extremely low, leaving inconclusive data.|2||Recruitment goal could not be achieved|f||||t||||||||||2017-10-11 06:31:35.142411|2017-10-11 06:31:35.142411
NCT00375596|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-12|2015-02-19||||||February 2015|2015-02-01||||||||Interventional|||A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis|Study Withdrawn Prior to Determining Official Title|Withdrawn||Phase 2|0|Actual|Bausch & Lomb Incorporated||||"Study withdrawn without starting or enrolling subjects due to a business decision to not   proceed with the project."|f||||f||||||||||2017-10-11 06:31:45.739597|2017-10-11 06:31:45.739597
NCT00376259|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-13|2011-06-28|2010-12-20||January 2007||2007-01-01|June 2011|2011-06-01||||August 2008|Actual|2008-08-01||Interventional|||Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone|An Open-label, Multicenter, Randomized Study of Combination Therapy With Oral LDT600 (Telbivudine) Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-positive Patients With Chronic Hepatitis B Who Are Lamivudine Resistant|Terminated||Phase 3|43|Actual|Novartis|The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA).|2||"The study was not completed as planned and was terminated early with agreement from the   European Medicines Agency (EMEA)"|f||||||||||||||2017-10-11 06:31:58.525652|2017-10-11 06:31:58.525652
NCT00377325|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-15|2014-11-20|||June 2007||2007-06-01|November 2014|2014-11-01|September 2013|Actual|2013-09-01|June 2013|Actual|2013-06-01||Interventional|||The Effectiveness of Lower Cyclosporine Doses for Psoriasis|Cyclosporine in the Pharmacotherapy of Psoriasis|Withdrawn||Phase 2|0|Actual|University of Rochester||3||Study terminated by the DSMB due to low recruitment|f||||t||||||||||2017-10-11 06:32:20.315025|2017-10-11 06:32:20.315025
NCT00377455|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-14|2016-08-16|2011-03-28||September 2006||2006-09-01|August 2016|2016-08-01|March 2010|Actual|2010-03-01|September 2009|Actual|2009-09-01||Interventional|||Placebo Controlled Trial of Bosentan in Scleroderma Patients|Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension|Terminated||Phase 2|5|Actual|Georgetown University||2||Study was terminated due to inadequate enrolment|f||||f||||||||||2017-10-11 06:32:22.308182|2017-10-11 06:32:22.308182
NCT00369330|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-28|2012-08-31|||September 2006||2006-09-01|August 2006|2006-08-01||||||||Interventional|||KONVERT-AF - Relevance of Point in Time for Conversion of Acute Atrial Fibrillation|Prospective, Randomized Parallel-group Study for Evaluation of Impact of Early Versus Delayed Cardioversion of Acute Atrial Fibrillation on Further Clinical Course|Withdrawn||N/A|0|Actual|German Atrial Fibrillation Network||||withdrawn because of insufficient financial capacities|f||||||||||||||2017-10-11 06:32:27.746674|2017-10-11 06:32:27.746674
NCT00378781|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-19|2012-02-22||||||February 2012|2012-02-01||||||||Interventional|||Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection|Prospective, Randomized Trial Comparing Heparin and Minocycline-EDTA Flush for the Prevention of Catheter-Related Infections and Occlusions|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||2||Study withdrawn.|f||||f||||||||||2017-10-11 06:34:00.267222|2017-10-11 06:34:00.267222
NCT00380042|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-21|2009-12-30|||September 2006||2006-09-01|September 2008|2008-09-01|March 2009|Actual|2009-03-01|October 2007|Actual|2007-10-01||Interventional|PROSPECT||Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder|Feasibility Study of the Safety and Effectiveness of Cortical Stimulation for Subjects With Major Depressive Disorder|Terminated||Phase 1|12|Anticipated|Northstar Neuroscience||2||Study terminated as a result of the dissolution of the Sponsor.|f||||t||||||||||2017-10-11 06:34:45.824364|2017-10-11 06:34:45.824364
NCT00368693|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-24|2015-04-06|||August 2005||2005-08-01|April 2015|2015-04-01|September 2007|Actual|2007-09-01|September 2007|Actual|2007-09-01||Interventional|||Efficacy and Safety Study of Dermal-Living Skin Replacement to Treat Diabetic Foot Ulcers|Pivotal Study to Evaluate the Efficacy and Safety of Dermal - Living Skin Replacement (Dermal - LSR) in the Treatment of Chronic Diabetic Foot Ulcers|Terminated||Phase 3|20|Actual|University of California, Davis||1||Study terminated due to low enrollment.|f||||f||||||||||2017-10-11 06:35:38.731993|2017-10-11 06:35:38.731993
NCT00368719|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-24|2015-04-06|||September 2007||2007-09-01|April 2015|2015-04-01|July 2016||2016-07-01|||||Interventional|||Evaluation to Assess the Long Term Safety of Tacrolimus Ointment for Atopic Dermatitis|APPLES: A Prospective Pediatric Longitudinal Evaluation To Assess The Long Term Safety Of Tacrolimus Ointment For The Treatment Of Atopic Dermatitis|Withdrawn||Phase 4|0|Actual|University of California, Davis||1||withdrawn due to contractual issues|f||||f||||||||||2017-10-11 06:35:38.978971|2017-10-11 06:35:38.978971
NCT00369265|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-24|2012-08-23|2012-07-11||August 2006||2006-08-01|August 2012|2012-08-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|||Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux|A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis|Terminated||Phase 4|18|Actual|American Institute for Voice and Ear Research|The study was terminated due to inadequate subject recruitment.|2||Pharmaceutical company purchased by another company and funding was terminated.|f||||||||||||||2017-10-11 06:35:53.036041|2017-10-11 06:35:53.036041
NCT00374712|ClinicalTrials.gov processed this data on October 10, 2017|2005-09-12|2007-11-06|||January 2005||2005-01-01|November 2007|2007-11-01|November 2007|Actual|2007-11-01|||||Observational|||Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia|Study of Klotho Gene Polymorphisms in the Regulation of Serum Phosphate Levels in Hemodialysis Patients|Terminated||N/A|40|Actual|Assistance Publique - Hôpitaux de Paris|||1|terminated|f||||f||||||Samples With DNA|"     DNA   "|||2017-10-11 06:35:54.739982|2017-10-11 06:35:54.739982
NCT00374738|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-07|2016-05-10|||November 2006||2006-11-01|May 2016|2016-05-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||Effects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms, Neurosteroids and Brain Function|Effects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms, Neurosteroids and Brain Function|Completed||N/A|34|Actual|Samueli Institute for Information Biology||2|||f||||f||||||||No|Study terminated/inactive.|2017-10-11 06:35:55.014131|2017-10-11 06:35:55.014131
NCT00384527|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-05|2015-05-04|||December 2006||2006-12-01|October 2008|2008-10-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Interventional|||Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease|Multicenter, Double-blind Study of Nitazoxanide Compared to Vancomycin in the Treatment of Clostridium Difficile-associated Disease|Terminated||Phase 3|50|Actual|Romark Laboratories L.C.||2||Study was terminated early due to slow recruitment.|f||||f||||||||||2017-10-11 06:36:11.727476|2017-10-11 06:36:11.727476
NCT00385827|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-06|2014-08-18|2014-05-13|2013-01-31|November 2006||2006-11-01|August 2014|2014-08-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional||Analysis population included all participants who received at least one dose of study drug in Part 1 and all randomized participants in Part 2.|A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)|A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)|Terminated||Phase 2|106|Actual|Centocor, Inc.|Results of few secondary endpoints were not reported as the study was terminated early due to the premature suspension and subsequent halting of study enrollment.|3||"Prematurely stopped after Independent Data Monitoring Committee (IDMC) evaluation for lack of   efficacy."|f||||t||||||||||2017-10-11 06:36:43.6315|2017-10-11 06:36:43.6315
NCT00366795|ClinicalTrials.gov processed this data on October 10, 2017|2006-08-18|2016-04-18||2016-04-18|August 2006||2006-08-01|April 2016|2016-04-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|SPARe-2||Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver|Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo in the Absence of Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.|Terminated||Phase 3|241|Actual|Sanofi||2||Study was terminated due to safety reason.|f||||||||||||||2017-10-11 06:37:14.403075|2017-10-11 06:37:14.403075
NCT00387010|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-10|2012-09-19|2012-08-17||December 2006||2006-12-01|September 2012|2012-09-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Interventional|||Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain|A 4-week Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Pain|Terminated||Phase 3|218|Actual|Teva Pharmaceutical Industries|This study was terminated early. Additional research is recommended to develop a valid measure of anxiety, specifically related to breakthrough pain.|1||"The sponsor felt enough information was available for the exploratory assessment of the effect   of treatment with FBT on pain anxiety"|f||||f||||||||||2017-10-11 06:37:31.663238|2017-10-11 06:37:31.663238
NCT00389090|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-16|2012-02-07|||October 2006||2006-10-01|February 2012|2012-02-01|February 2009|Actual|2009-02-01|June 2008|Actual|2008-06-01||Interventional|||A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma|A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma|Terminated||Phase 2|32|Actual|Keryx / AOI Pharmaceuticals, Inc.||1||AOI Pharma terminated the license agreement. IND Transferred to NCI|f||||f||||||||||2017-10-11 06:37:40.873529|2017-10-11 06:37:40.873529
NCT00390364|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-18|2014-10-07|2014-09-15||October 2006||2006-10-01|October 2014|2014-10-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Interventional|||Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy|Phase II Study of Single Agent RAD001 in Patients With Colon Cancer and Activating Mutations in the PI3KCA Gene|Terminated||Phase 2|1|Actual|Sidney Kimmel Comprehensive Cancer Center|Out of 28 subjects pre-screened/screened, only one was enrolled and treated, and she progressed after 1 cycle. Study terminated by investigator because of low enrollment.|1||Withdrawn due to low accrual|||||||||||||||2017-10-11 06:38:06.819241|2017-10-11 06:38:06.819241
NCT00390702|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-19|2012-08-22|||October 2006||2006-10-01|August 2012|2012-08-01|August 2016|Anticipated|2016-08-01|August 2012|Actual|2012-08-01||Interventional|pfm-01/2005||Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System|International Multicentre Clinical Device Investigation on Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System for VSD Occlusion Developed by Pfm AG, Cologne|Suspended||Phase 2/Phase 3|338|Anticipated|pfm medical ag||1||"further recruitment terminated after CE mark attained; enclosed patients will be followed up to   5 years"|f||||t||||||||||2017-10-11 06:38:15.046054|2017-10-11 06:38:15.046054
NCT00390975|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-20|2012-05-03|||January 2007||2007-01-01|May 2012|2012-05-01|March 2007|Actual|2007-03-01|March 2007|Actual|2007-03-01||Interventional|||Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis|An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms|Terminated||Phase 4|40|Anticipated|Novartis||||"This study was terminated early as a result of regulatory action suspending tegaserod use in   2007"|||||||||||||||2017-10-11 06:38:25.610663|2017-10-11 06:38:25.610663
NCT00381225|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-26|2017-09-05|||November 2006||2006-11-01|September 2017|2017-09-01|March 18, 2008|Actual|2008-03-18|March 18, 2008|Actual|2008-03-18||Interventional|||Feasibility of Ultra-sound Guided Radiofrequency Ablation in the Management of Head and Neck Neoplasia.|Feasibility of Ultra-sound Guided Radiofrequency Ablation in the Management of Head and Neck Neoplasia.|Withdrawn||N/A|0|Actual|Johns Hopkins University||1||Administratively withdrawn by the IRB prior to IRB approval|f|||||f|f||||||||2017-10-11 06:38:45.667084|2017-10-11 06:38:45.667084
NCT00381810|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-26|2017-07-05|2009-11-11||June 22, 2006|Actual|2006-06-22|June 2017|2017-06-01|February 29, 2012|Actual|2012-02-29|July 31, 2008|Actual|2008-07-31||Interventional|VOYAGER||A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus|An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g|Terminated||Phase 3|31|Actual|Genentech, Inc.|Since study U2971g did not demonstrate efficacy, a decision was made not to evaluate efficacy in this study and only safety results were evaluated.|1||"During a safety review of studies U2970g and U2971g, the Data Monitoring Committee recommended   that enrollment in this extension trial be terminated."|f||||||||||||||2017-10-11 06:38:50.568322|2017-10-11 06:38:50.568322
NCT00382863|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-28|2012-06-07|2011-05-13||October 2006||2006-10-01|June 2012|2012-06-01|May 2012|Actual|2012-05-01|May 2011|Actual|2011-05-01||Interventional|PEERLESS-HF||Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial|Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial|Terminated||Phase 2/Phase 3|220|Actual|Paracor Medical, Inc|An interim analysis indicated trial futility based on a primary endpoint. Enrollment was suspended in July, 2009. Study was terminated as of April, 2011 due to insufficient resources.|2||Resources unavailable to continue study follow-up.|f||||t||||||||||2017-10-11 06:39:12.926216|2017-10-11 06:39:12.926216
NCT00383097|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-28|2012-05-22|||September 2006||2006-09-01|May 2012|2012-05-01|February 2010|Actual|2010-02-01|February 2010|Actual|2010-02-01||Interventional|ALDI||Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma|Administration of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes Following CD45 Antibody to Patients With Relapsed EBV-Positive Hodgkin's or Non-Hodgkin's Lymphoma or Chronic Active EBV Infection (ALDI)|Terminated||Phase 1|6|Actual|Baylor College of Medicine||1||The trial was terminated in 2010 due to lack of enrollment.|f||||t||||||||||2017-10-11 06:39:20.355366|2017-10-11 06:39:20.355366
NCT00383266|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-02|2015-12-04|2015-10-20||October 2006||2006-10-01|December 2015|2015-12-01|June 2010|Actual|2010-06-01|November 2009|Actual|2009-11-01||Interventional|||A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer|A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer|Terminated||Phase 2|9|Actual|Washington University School of Medicine|The study was terminated due to lack of participant accrual.|1||Low accrual|f||||t||||||||||2017-10-11 06:39:25.391665|2017-10-11 06:39:25.391665
NCT00383630|ClinicalTrials.gov processed this data on October 10, 2017|2006-09-29|2013-03-06|||August 2007||2007-08-01|March 2013|2013-03-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure|The Effect of Intramyocardial Injection of Immunoselected Bone Marrow Cells on Myocardial Function in LVAD Bridge to Transplant Patients|Terminated||Phase 2|1|Actual|Columbia University||3||Study has been terminated due to logistical barriers to cell processing and poor enrollment|f||||t||||||||||2017-10-11 06:39:32.761547|2017-10-11 06:39:32.761547
NCT00383942|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-02|2017-01-23|2016-06-01||August 31, 2006|Actual|2006-08-31|January 2017|2017-01-01|June 18, 2008|Actual|2008-06-18|June 18, 2008|Actual|2008-06-18||Interventional|RIPE|The baseline analysis population comprises all patients who were randomized|Ripening Interventions: Prostaglandins vs EASI Catheter|The RIPE Study: Ripening Interventions: Prostaglandins vs EASI Catheter|Terminated||Phase 4|80|Actual|Loyola University|This trial was terminated prematurely due to a department policy change regarding inductions of labor.|2||Change in treatment plan for this population terminated the project|f||||t|t|t|f|f|f|||No|There is no plan to share individual participant data|2017-10-11 06:39:40.174683|2017-10-11 06:39:40.174683
NCT00393094|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-25|2012-07-06|2012-03-27||September 2006||2006-09-01|July 2012|2012-07-01|March 2010|Actual|2010-03-01|January 2010|Actual|2010-01-01||Interventional|||Bevacizumab and Irinotecan to Treat Brain Tumors|A Phase II Trial of Bevacizumab and Irinotecan for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment w/Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (NCT00271609)(Bevacizumab Alone for Recurrent Gliomas)|Terminated||Phase 2|31|Actual|National Institutes of Health Clinical Center (CC)|Evaluating combination therapy, 19 GBM patients were enrolled. Accrual was terminated after it became clear that we could not reach our efficacy rule of 3 or more of 29 patients responding. The AG arm never fully accrued before the study was closed.|1||Terminated due to the limitations of accrual.|f||||f||||||||||2017-10-11 06:40:20.581923|2017-10-11 06:40:20.581923
NCT00394303|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-31|2009-03-31|||February 2007||2007-02-01|June 2007|2007-06-01|August 2009|Anticipated|2009-08-01|||||Interventional|||Tight Intra-Operative Glucose Control During Coronary Artery Bypass Surgery|Tight Intra-Operative Glucose Control Using Continuous Insulin Infusion During Coronary Artery Bypass Surgery: Randomized Controlled Trial|Terminated||Phase 4|1400|Anticipated|Rabin Medical Center||2||"Trial suspended on 26 February, following the publication of a trial with negative results (Ann   Intern Med 146(4), 2007). Pending ethics committee re-approval."|f||||t||||||||||2017-10-11 06:40:50.209412|2017-10-11 06:40:50.209412
NCT00387153|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-10|2009-10-27|2009-06-23||August 2005||2005-08-01|October 2009|2009-10-01|October 2006|Actual|2006-10-01|October 2006|Actual|2006-10-01||Interventional|||Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer|Phase 1 OL, Dose Escalating, Multiple Dose Study To Determine The Safety, Tolerability, MTD, And Pharmacokinetics Of MPC-2130 Administered As Daily IV Infusions For 5 Days, Repeated Every 21 Days, In Patients With Refractory Cancer|Terminated||Phase 1|8|Actual|Myriad Therapeutics, Inc.||1||Last subject enrolled experienced bradycardia; study was terminated by Sponsor.|f||||f||||||||||2017-10-11 06:41:19.907575|2017-10-11 06:41:19.907575
NCT00387829|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-12|2017-08-07|2013-06-07||October 2006||2006-10-01|August 2017|2017-08-01|December 2011|Actual|2011-12-01|December 2010|Actual|2010-12-01||Interventional||A total of 343 patients were randomized in the study (Intent-to-treat population). Four patients received treatment (1 Duragen Plus; 3 Surgery alone), but were not randomized correctly, and were followed-up for safety only. Hence the total patients in the Safety Population is 347.|DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery|Randomized Controlled Trial of DuraGen Plus® Adhesion Barrier Matrix to Minimize Adhesions Following Lumbar Discectomy|Terminated||N/A|347|Actual|Integra LifeSciences Corporation||2||Sponsor voluntarily terminated study|f||||f||||||||||2017-10-11 06:41:32.371537|2017-10-11 06:41:32.371537
NCT00387894|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-12|2013-05-25|2013-04-12||January 2007||2007-01-01|April 2013|2013-04-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional|||Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma|Phase-2 Study of Tarceva in Patients With Recurrent EGFR Positive and Phosphatase and Tensin Homolog (PTEN) Wild Type Glioblastoma Multiforme and Gliosarcoma|Terminated||Phase 2|6|Actual|University of California, San Francisco|The study was terminated early for 2 reasons: 1. ongoing literature at the time confirming that the selection process was not likely to enrich for a patient population expected to benefit, and 2. Rapid disease progression in the first 6 patients.|1||Insufficient accrual of population likely to benefit; progression in 6 patients|f||||t||||||||||2017-10-11 06:41:34.05627|2017-10-11 06:41:34.05627
NCT00394953|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-01|2016-11-23|2016-08-12||December 2006||2006-12-01|November 2016|2016-11-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional||The Safety Population was defined as all participants who received at least one dose of methoxy polyethylene glycol-epoetin beta or darbepoetin alfa and had a safety follow-up, whether withdrawn prematurely or not.|A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients|A Randomized, Controlled, Open Label, Multicenter, Parallel-group Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Hemodialysis|Completed||Phase 3|490|Actual|Hoffmann-La Roche||2|||f||||||||||||||2017-10-11 06:41:55.428949|2017-10-11 06:41:55.428949
NCT00395057|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-31|2015-08-25|2011-11-09||January 2007||2007-01-01|August 2015|2015-08-01|February 2009|Actual|2009-02-01|October 2008|Actual|2008-10-01||Interventional|||A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration||Terminated||Phase 2|138|Actual|Allergan|"The study was terminated early due to a company decision (non-safety related). Because the study was terminated early, data for certain outcome measures (ie, Visual Functioning Questionnaire [VFQ] at Month 3) were not analyzed."|4||The study was terminated early due to company decision (non-safety related).|f||||||||||||||2017-10-11 06:41:59.089998|2017-10-11 06:41:59.089998
NCT00395161|ClinicalTrials.gov processed this data on October 10, 2017|2006-10-31|2013-04-16|2012-11-14||April 2007||2007-04-01|April 2013|2013-04-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|CRISIS||The CRISIS Prevention Study|The Critical Illness Stress-induced Immune Suppression Prevention Trial|Terminated||Phase 3|293|Actual|University of Utah|The Data Safety Monitoring Board met on November 30, 2009. Interim analysis of the first 273 patients was presented. Per the Board's recommendations, the study was terminated based on futility.|2||Terminated for futility on 11/30/09 based on the recommendation of the DSMB|f||||t||||||||||2017-10-11 06:42:03.286069|2017-10-11 06:42:03.286069
NCT00396812|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-06|2013-02-06|2012-10-11||November 2006||2006-11-01|February 2013|2013-02-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)|An Open Label, Single Arm, Single Center, Phase I/II Trial of Rituximab (a Monoclonal Antibody to CD20) for the Treatment of Early Rheumatoid Arthritis|Terminated||Phase 1/Phase 2|4|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The trial terminated early due to rituximab’s risk-benefit ratio for individuals with early active Rheumatoid Arthritis. Mechanistic samples were not processed and corresponding endpoints were not assessed. Only descriptive statistics are presented.|1||The perceived risk-benefit ratio for individuals with early active RA|f||||||||||||||2017-10-11 06:42:23.152041|2017-10-11 06:42:23.152041
NCT00400764|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-15|2011-11-15|2011-09-01||June 2006||2006-06-01|November 2011|2011-11-01||||May 2010|Actual|2010-05-01||Interventional|||A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas|A Phase Ib/II, Open-Label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Dulanermin Administered Intravenously in Combination With Rituximab to Subjects With Follicular and Other Low-Grade, CD20+, B-Cell Non-Hodgkin's Lymphomas That Have Progressed Following Previous Rituximab Therapy|Terminated||Phase 1/Phase 2|72|Actual|Genentech, Inc.|The Sponsor terminated the study on 5 May 2010, prior to the completion of the 36-month follow-up (FU) period, based on the primary analysis results. All patients were off-study or in survival FU (the treatment period was completed).|5|||f||||||||||||||2017-10-11 06:43:29.575544|2017-10-11 06:43:29.575544
NCT00401960|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-20|2017-04-06|2016-12-29||September 2006||2006-09-01|April 2017|2017-04-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional||see study inclusion criteria|Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.|Open Label Study to Assess the Efficacy and Safety of Daptomycin in Combination With Anti-Cell Wall Active Therapy in the Treatment of Enterococcal Endocarditis|Terminated||Phase 4|6|Actual|Weill Medical College of Cornell University|study terminated due to insufficient enrollment; data therefore not analyzed|2||inadequate enrollment|f||||t||||||||No|This was a pilot single arm study, for which IPD are not pertinent|2017-10-11 06:43:57.369745|2017-10-11 06:43:57.369745
NCT00402298|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-20|2011-04-01|||January 2008||2008-01-01|March 2011|2011-03-01|February 2011|Actual|2011-02-01|November 2010|Actual|2010-11-01||Interventional|||Randomized Placebo-controlled Study of MDMA-assisted Psychotherapy in People With PTSD - Israel|MDMA-assisted Psychotherapy in Twelve People With War and Terrorism-related Posttraumatic Stress Disorder (PTSD)|Terminated||Phase 2|12|Anticipated|Multidisciplinary Association for Psychedelic Studies||2||"This study was terminated after enrolling five subjects due to staff turnover and its effects   on quality of data collection."|f||||f||||||||||2017-10-11 06:44:11.057048|2017-10-11 06:44:11.057048
NCT00402818|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-20|2014-08-28|||May 2006||2006-05-01|August 2014|2014-08-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Observational|RESTORE||RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization|RESTORE (Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-label, Multi-centre, Phase IV Study of Subcutaneously Administered Raptiva® (Efalizumab) in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Treatment With Raptiva®|Terminated||Phase 4|294|Actual|Merck KGaA|||1|"The study was terminated after the EMEA recommended to suspend the marketing authorisation of   Raptiva in the EU"|f||||||||||||||2017-10-11 06:44:28.271431|2017-10-11 06:44:28.271431
NCT00395603|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-02|2017-03-17|||September 2006||2006-09-01|March 2017|2017-03-01|June 2007|Actual|2007-06-01|June 2007|Actual|2007-06-01||Interventional|||Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)|Compare Ezetimibe 10mg and Simvastatin 40mg vs Atorvastatin 80mg Daily in Subjects With Cardiovascular Heart Disease and/or Diabetes Mellitus With Uncontrolled Lipids on Statin Therapy|Terminated||Phase 3|550|Anticipated|Merck Sharp & Dohme Corp.||||This study was terminated early due to poor recruitment.|f||||||||||||||2017-10-11 06:44:39.441495|2017-10-11 06:44:39.441495
NCT00395967|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-02|2015-04-10|2009-01-27||April 2005||2005-04-01|April 2015|2015-04-01|August 2006|Actual|2006-08-01|July 2005|Actual|2005-07-01||Interventional|||AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone|Effect of AMD3100 (240µg/kg) on the Apheresis Yield of CD34+ Cells When Given To Multiple Myeloma or Non-Hodgkin's Lymphoma Patients Predicted to be Unable to Mobilize ≥2 x 10^6 CD34+ Cells in Three Apheresis Days When Given G-CSF Alone|Terminated||Phase 2|5|Actual|Sanofi|Limited enrollment due to early termination of the study.|1||Enrollment terminated in 2005 to focus on Phase 3 study enrollment.|f||||f||||||||||2017-10-11 06:44:49.122349|2017-10-11 06:44:49.122349
NCT00403234|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-21|2012-08-27|2010-07-28||November 2006||2006-11-01|August 2012|2012-08-01|August 2007|Actual|2007-08-01|April 2007|Actual|2007-04-01||Interventional|||Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study to Evaluate the Analgesic Efficacy of BTDS on Postoperative Pain During Rehabilitation Following Total Knee Arthroplasty|Terminated||Phase 2|10|Actual|Purdue Pharma LP|This trial was terminated early due to administrative reasons not related to efficacy or safety. The efficacy data are not presented since the objective of this study was changed prior to study unblinding, identifying it as a safety study.|4||due to administrative reasons not related to efficacy or safety.|f||||||||||||||2017-10-11 06:45:02.912289|2017-10-11 06:45:02.912289
NCT00404950|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-28|2017-02-02|||July 2005|Actual|2005-07-01|February 2017|2017-02-01|July 2012|Actual|2012-07-01|October 2010|Actual|2010-10-01||Observational|||Effects of Hyperglycemia During Cardiopulmonary Bypass on Renal Function|Effects of Hyperglycemia During Cardiopulmonary Bypass on Renal Function|Completed||N/A|200|Actual|Weill Medical College of Cornell University|||1||f||||f||||||Samples Without DNA|"     At the following times when plasma glucose will be measured, an additional 6 mL of blood will     be drawn (from indwelling routine arterial line catheter) into EDTA tubes and immediately     centrifuged: baseline following induction, once during cardiopulmonary bypass, at arrival in     the intensive care unit, and the morning after surgery- totaling 24 mls of blood. The     platelet rich plasma will be withdrawn and one half of the volume immediately frozen for     subsequent HPLC measurement of BH2 and BH4. The remaining plasma will be subjected to     progressive centrifugation steps in order to concentrate the platelet fraction that will then     be suspended in buffer and frozen. VASP expression and phosphorylation will be determined by     Western blot.   "|No|Will not share|2017-10-11 06:45:40.11301|2017-10-11 06:45:40.11301
NCT00399009|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-13|2008-06-05|||January 2004||2004-01-01|June 2008|2008-06-01|November 2007|Actual|2007-11-01|November 2007|Actual|2007-11-01||Interventional|||Comparative Study of Circular Stapling Instruments|Comparative Study of Circular Stapling Instruments Concerning the Risk of Anastomotic Dehiscence After Anterior Resection for Rectal Cancer.|Terminated||N/A|880|Anticipated|Uppsala University Hospital||||"One of the instruments in the study was withdrawn from the market before the calculated number   of persons were included."|f||||||||||||||2017-10-11 06:46:13.715856|2017-10-11 06:46:13.715856
NCT00399659|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-14|2012-04-30|||November 2006||2006-11-01|April 2012|2012-04-01|April 2007|Actual|2007-04-01|April 2007|Actual|2007-04-01||Interventional|||Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.|A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain|Terminated||Phase 3|360|Actual|Novartis||||"This study was terminated early as a result of regulatory action suspending tegaserod use in   2007"|||||||||||||||2017-10-11 06:46:24.934211|2017-10-11 06:46:24.934211
NCT00409331|ClinicalTrials.gov processed this data on October 10, 2017|2006-12-07|2012-07-31|2009-12-11||December 2006||2006-12-01|July 2012|2012-07-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|||Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment|A Phase II Study To Assess The Efficacy of Amifostine for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment With Intensity- Modulated Radiation Therapy (IMRT) for Parotid Salivary Sparing|Terminated||Phase 2|3|Actual|M.D. Anderson Cancer Center||1||Study terminated by Principal Investigator; no patients completed study.|f||||f||||||||||2017-10-11 06:47:32.567735|2017-10-11 06:47:32.567735
NCT00410410|ClinicalTrials.gov processed this data on October 10, 2017|2006-12-11|2015-03-04|2010-08-12||December 2006||2006-12-01|March 2015|2015-03-01|November 2009|Actual|2009-11-01|June 2009|Actual|2009-06-01||Interventional|||A Study of Abatacept in Patients With Active Ulcerative Colitis|A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Ulcerative Colitis (UC) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy|Completed||Phase 3|591|Actual|Bristol-Myers Squibb|This study was terminated after review of the IP1C results due to lack of efficacy. Enrollment for the MP and for IP2C was not completed. Participants in MP, IP2C, and OL were early terminated at the time of study termination.|3|||f||||t||||||||||2017-10-11 06:48:13.455994|2017-10-11 06:48:13.455994
NCT00412217|ClinicalTrials.gov processed this data on October 10, 2017|2006-12-15|2016-10-11|2016-08-02||November 2006||2006-11-01|October 2016|2016-10-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Interventional||Intent-to-Treat (ITT) Population: All participants who were randomized in the study.|A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer|Phase III Randomized, Controlled Trial of Erlotinib (Tarceva) as Maintenance Therapy in Patients With Squamous Cell Carcinoma of the Head and Neck Treated With Resection and Radiotherapy With or Without Concomitant Chemotherapy With Curative Aim|Terminated||Phase 3|94|Actual|Hoffmann-La Roche|The Study was terminated early as a result of slow recruitment. Results should be interpreted with consideration of the small sample size.|2||The study was terminated because recruitment was too slow.|f||||||||||||||2017-10-11 06:48:48.975901|2017-10-11 06:48:48.975901
NCT00413218|ClinicalTrials.gov processed this data on October 10, 2017|2006-12-18|2017-08-22|2017-07-05|2015-08-17|March 8, 2007|Actual|2007-03-08|August 2017|2017-08-01|March 3, 2015|Actual|2015-03-03|March 3, 2015|Actual|2015-03-03||Interventional|||Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections|A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections|Completed||Phase 3|450|Actual|Astellas Pharma Inc|Enrollment in the clinical study was suspended in January 2009 pending further characterization of newly identified impurities. After successful completion of the studies, regulatory notifications and transfer of sponsorship from Basilea to Astellas,|2|||f||||t||||||||||2017-10-11 06:49:30.611095|2017-10-11 06:49:30.611095
NCT00416793|ClinicalTrials.gov processed this data on October 10, 2017|2006-12-27|2014-05-12|2011-06-14||December 2006||2006-12-01|October 2013|2013-10-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Interventional|||Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer|A Phase II Study of Bortezomib in Combination With Carboplatin in Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|9|Actual|National Cancer Institute (NCI)|Given the toxicity and lack of objective responses observed with this regimen, the protocol met prospective criteria for early stopping and was terminated.|1|||f||||||||||||||2017-10-11 06:51:13.306807|2017-10-11 06:51:13.306807
NCT00416884|ClinicalTrials.gov processed this data on October 10, 2017|2006-12-27|2017-09-25|2011-05-31||May 2003||2003-05-01|July 2011|2011-07-01|March 2008|Actual|2008-03-01|March 2008|Actual|2008-03-01||Interventional|||Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML|Fludarabine, Campath, TBI T-Cell Deplete NMSCT With Post-Transplant T-Cell Infusions for CML Failing Imatinib Therapy With Imatinib (STI571)|Terminated||Phase 2|1|Actual|OHSU Knight Cancer Institute|Study was terminated early due to low enrollment, hence the study did not have any treatment-related mortalities to report.|1||Low enrollment|f||||t||||||||||2017-10-11 06:51:14.026042|2017-10-11 06:51:14.026042
NCT00420407|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-09|2017-09-07|2012-09-11||February 2007||2007-02-01|April 2013|2013-04-01|February 2011|Actual|2011-02-01|April 2009|Actual|2009-04-01||Interventional||Vasopressin enrolled 40 and two withdrawn and never received drug (38) Normal saline enrolled 41 and one withdrawn and never received drug (40)|Low Dose Vasopressin in Traumatic Shock|Prospective, Randomized, Double-Blind, Multi-Center Trial of Low Dose Vasopressin Versus Placebo in Traumatic Shock Resuscitation|Terminated||N/A|81|Actual|The University of Texas Health Science Center at San Antonio||2||accrual rate|f||||t||||||||||2017-10-11 06:51:43.553691|2017-10-11 06:51:43.553691
NCT00414024|ClinicalTrials.gov processed this data on October 10, 2017|2006-12-19|2012-04-19|||February 2007||2007-02-01|April 2012|2012-04-01|May 2007|Actual|2007-05-01|May 2007|Actual|2007-05-01||Interventional|||Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.|An Open Label 52-week Study to Evaluate the Safety and Efficacy of Tegaserod Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain|Terminated||Phase 3|11|Actual|Novartis||||"This study was terminated early as a result of regulatory action suspending tegaserod use in   2007"|||||||||||||||2017-10-11 06:52:43.775496|2017-10-11 06:52:43.775496
NCT00414037|ClinicalTrials.gov processed this data on October 10, 2017|2006-12-19|2015-10-23|||December 2006||2006-12-01|October 2015|2015-10-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||How do Sleeping Pills Affect Pain in the Brain?|Subchronic Effects of Eszopiclone (Lunesta) on Pain Behavior and Circuitry in Primary Insomnia|Terminated||Phase 4|40|Actual|University of California, San Diego||2||Funding terminated by sponsor, insufficient data collection|f||||f||||||||||2017-10-11 06:52:43.849372|2017-10-11 06:52:43.849372
NCT00424294|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-18|2014-09-10|2014-09-10|2009-04-06|June 2006||2006-06-01|September 2014|2014-09-01|February 2008|Actual|2008-02-01|December 2007|Actual|2007-12-01||Interventional||Full analysis set (FAS) was an intent-to-treat analysis set including all participants randomized to treatment who had taken at least 1 dose of study drug.|A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CP-195543 And Celecoxib Dual Therapy In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate|Terminated||Phase 2|70|Actual|Pfizer|The study was terminated early because it was determined that the dual therapy with CP-195543 and celecoxib had poor tolerability and a high discontinuation rate.|3||See Detailed Description field|f||||t||||||||||2017-10-11 06:53:23.582237|2017-10-11 06:53:23.582237
NCT00424645|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-17|2012-12-04|2010-11-09||January 2007||2007-01-01|December 2012|2012-12-01|January 2008|Actual|2008-01-01|January 2008|Actual|2008-01-01||Interventional|||Voraxaze for Delayed Methotrexate Clearance|Randomized, Double-Blind, Placebo Controlled Trial of Voraxaze™ in Patients With a Delayed MTX Clearance|Terminated||Phase 1/Phase 2|3|Actual|M.D. Anderson Cancer Center||2||Sponsor terminated due to low accrual.|f||||t||||||||||2017-10-11 06:53:42.03835|2017-10-11 06:53:42.03835
NCT00424749|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-19|2011-11-03|2011-09-12||June 2007||2007-06-01|November 2011|2011-11-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Rituxan in Churg Strauss Syndrome With Renal Involvement|A Pilot Study on the Use of Rituximab in the Treatment of Churg- Strauss Syndrome With Renal Involvement|Terminated||Phase 2|4|Actual|Mayo Clinic|The limited number of individuals enrolled into the study makes it difficult to draw firm conclusions that are more than hypothesis generating. The company providing study drug terminated study due to lack of funds.|1||Company providing study drug terminated study due to lack of funds|f||||t||||||||||2017-10-11 06:53:42.918356|2017-10-11 06:53:42.918356
NCT00425113|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-19|2013-05-10|2013-02-07||December 2006||2006-12-01|May 2013|2013-05-01|February 2013|Actual|2013-02-01|October 2012|Actual|2012-10-01||Interventional||2 subjects excluded: 1 for uncontrolled diabetes mellitus and 1 for diagnosis of extrapulmonary TB. 2 additional subjects withdrew: 1 self- withdrew and the other was withdrawn for missing >14 days of study drug.|Metronidazole for Pulmonary Tuberculosis (South Korea)|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Metronidazole Combined With Antituberculous Chemotherapy vs. Antituberculous Chemotherapy With Placebo in Subjects With Multi-Drug Resistant Pulmonary Tuberculosis|Completed||Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)|Major limitation of our study was the small sample size. Planned enrollment was 80 subjects but DSMB recommended closing the study to new enrollment after 35 subjects due to increased peripheral neuropathy in the metronidazole arm.|2|||f||||t||||||||||2017-10-11 06:53:52.573725|2017-10-11 06:53:52.573725
NCT00425438|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-22|2014-09-22|2014-08-14||March 2007||2007-03-01|September 2014|2014-09-01|April 2008|Actual|2008-04-01|April 2008|Actual|2008-04-01||Interventional||Safety population: all participants who recieved at least one dose of study drug.|A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.|A Randomized, Open-label Study to Compare the Effect of CellCept Plus Corticosteroids, and Cyclophosphamide Plus Corticosteroids Followed by Azathioprine, on Remission Rate in Patients With Lupus Nephritis|Terminated||Phase 3|52|Actual|Hoffmann-La Roche|The study was terminated early due to administrative reasons.|2||Study was terminated early for administrative reasons.|f||||||||||||||2017-10-11 06:53:57.675924|2017-10-11 06:53:57.675924
NCT00425815|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-22|2016-02-05|||April 2009||2009-04-01|February 2016|2016-02-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia|A Placebo-Controlled Trial of Org 24448 (Ampakine) Added to Atypical Antipsychotics in Patients With Schizophrenia|Withdrawn||Phase 2|0|Actual|University of California, Los Angeles||3||Study terminated at Sponsor's request.|f||||f||||||||||2017-10-11 06:54:03.278123|2017-10-11 06:54:03.278123
NCT00425919|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-19|2007-12-18|||January 2007||2007-01-01|December 2007|2007-12-01|October 2007|Actual|2007-10-01|||||Interventional|||Study Evaluating PPM-204 In Subjects With Type 2 Diabetes|A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Safety And Efficacy Of PPM-204 In Subjects With Type 2 Diabetes|Terminated||Phase 2|500||Wyeth is now a wholly owned subsidiary of Pfizer||||Study terminated as a result of interim analysis not meeting predetermined criteria.|f||||||||||||||2017-10-11 06:54:04.57041|2017-10-11 06:54:04.57041
NCT00418093|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-02|2014-06-18|2012-04-27||September 2006||2006-09-01|June 2014|2014-06-01|October 2011|Actual|2011-10-01|January 2011|Actual|2011-01-01||Interventional|||Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma|A Phase II Evaluation of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma|Terminated||Phase 2|19|Actual|Dana-Farber Cancer Institute|The trial was closed after enrolling 19 of the 53 projected patient accrual.|1||THe study was terminated early due to a lack of accural|f||||||||||||||2017-10-11 06:54:19.195437|2017-10-11 06:54:19.195437
NCT00418132|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-03|2016-03-10|||August 2000||2000-08-01|March 2016|2016-03-01|October 2007|Actual|2007-10-01|||||Interventional|||Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis|T Cell Immunity in Collagen Biosynthesis of Scleroderma|Terminated||Phase 1|30|Actual|New York University School of Medicine||2||Study terminated early due to difficulties in subject recruitment|f||||t||||||||||2017-10-11 06:54:19.57227|2017-10-11 06:54:19.57227
NCT00418145|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-02|2017-04-10|2015-08-05||September 2003||2003-09-01|April 2017|2017-04-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional||16 participants were enrolled into the study. Data not available separated by arm. Data is also no longer accessible. Data was with biostatistician who no longer has data.|Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks|Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)|Terminated||Phase 3|16|Actual|Icahn School of Medicine at Mount Sinai|The trial was terminated due to difficulties obtaining drug and matching placebo and the inability to meet recruitment. There was no data analysis done for this trial due to low enrollment and data will not be meaningful.|2||low enrollment - data was not analyzed for this study|f||||f||||||||||2017-10-11 06:54:19.660571|2017-10-11 06:54:19.660571
NCT00419549|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-05|2009-01-28|||October 2003||2003-10-01|January 2009|2009-01-01|September 2005|Actual|2005-09-01|September 2005|Actual|2005-09-01||Interventional|||Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)|Effect of Transdermal Glyceryl-Trinitrate and Parecoxib (Valdecoxib) for the Prevention of Post -ERCP Pancreatitis|Terminated||Phase 2/Phase 3|371|Actual|All India Institute of Medical Sciences, New Delhi||3||Because one of the drugs Valdecoxib was withdrawn due to safety concerns.|f||||f||||||||||2017-10-11 06:54:51.705774|2017-10-11 06:54:51.705774
NCT00427401|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-25|2008-09-25|||February 2007||2007-02-01|September 2008|2008-09-01|June 2007|Actual|2007-06-01|||||Interventional|||A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks|A Double Blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-00915275 After Oral Administration To Subjects With Type 2 Diabetes Mellitus For 4-Weeks|Terminated||Phase 2|40||Pfizer||||"This study was terminated May 7, 2007. The study stopped due to tablet formulation issues. No   safety issues were involved in the termination decision."|f||||||||||||||2017-10-11 06:55:11.166307|2017-10-11 06:55:11.166307
NCT00427960|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-25|2010-11-30|2009-03-25||December 2006||2006-12-01|November 2010|2010-11-01|February 2008|Actual|2008-02-01|February 2008|Actual|2008-02-01||Interventional|||Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg|A Phase IV, 6-week, Randomised, Double-blind, Multicentre, Parallel Group, Comparative Study to Evaluate the Efficacy of Rosuvastatin 5mg and Atorvastatin 10mg in UK Asian Subjects With Primary Hypercholesterolaemia|Terminated||Phase 4|55|Actual|AstraZeneca|The study achieved only 8% of the randomised target number of patients and for this reason alone was terminated early. Planned statistical analyses could not be performed. No scientifically valid conclusions can be drawn from the limited study data.|2||Due to inadequate recruitment|f||||||||||||||2017-10-11 06:55:31.361186|2017-10-11 06:55:31.361186
NCT00429026|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-29|2013-02-26|2009-02-26||January 2004||2004-01-01|February 2013|2013-02-01|March 2008|Actual|2008-03-01|March 2008|Actual|2008-03-01||Interventional|||Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Adaptive Randomization of Fludarabine-Melphalan Versus Fludarabine-Cyclophosphamide Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor for Metastatic Renal Cell Carcinoma|Terminated||Phase 2|40|Actual|M.D. Anderson Cancer Center|Primary outcome measure was not assessed due to early study termination, e.g. patients did not receive assigned treatment.|2||Slow accrual, study terminated.|f||||t||||||||||2017-10-11 06:55:54.938108|2017-10-11 06:55:54.938108
NCT00429052|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-30|2012-03-06|||November 2006||2006-11-01|January 2007|2007-01-01|September 2008|Actual|2008-09-01|||||Observational|||Mechanism of Percutaneous Revascularization for Coronary Bifurcation Disease|Insights Into the Mechanism of Percutaneous Revascularization of Coronary Bifurcation Disease in the Drug-eluting Stent Era. An Angiographic and Intravascular Ultrasound Study. The INSIGHT Trial|Terminated||N/A|24|Actual|University of Florida|||1|"PI left institution,inability to enroll and analyze data due to software/technical limitations,   pt enrollment terminated early with no data generated"|f||||f||||||||||2017-10-11 06:55:55.274284|2017-10-11 06:55:55.274284
NCT00422877|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-15|2017-05-08|||January 2007||2007-01-01|May 2017|2017-05-01|March 2008|Actual|2008-03-01|March 2008|Actual|2008-03-01||Interventional|||Taxoprexin® Treatment for Advanced Primary Cancers of the Liver|Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Second Line Therapy for Patients With Advanced Primary Cancers of the Liver, Including Hepatocellular Carcinoma and Carcinoma of the Gallbladder or Biliary Tract|Terminated||Phase 2|13|Actual|Luitpold Pharmaceuticals||1||Sponsor suspended development of the drug on September 3, 2008.|f||||f||||||||No||2017-10-11 06:56:07.349417|2017-10-11 06:56:07.349417
NCT00422942|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-15|2014-07-14|2014-05-07||January 2006||2006-01-01|July 2014|2014-07-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)|An Open-label, Exploratory Study of the Pharmacokinetic and Pharmacodynamic Activity of MabThera in Combination With Methotrexate in Synovial Tissue and in Peripheral Blood of Patients With Active Rheumatoid Arthritis.|Terminated||Phase 2|3|Actual|Hoffmann-La Roche|Study terminated after enrollment of 3 participants due to recruitment difficulties and since the objectives and data under study had been published from other, independent sources it was not appropriate to expose further participants to study drug.|1||Study was terminated after enrollment of 3 participants due to recruitment difficulties.|f||||||||||||||2017-10-11 06:56:08.262842|2017-10-11 06:56:08.262842
NCT00423150|ClinicalTrials.gov processed this data on October 10, 2017|2006-11-30|2017-05-12|2010-05-27||January 26, 2007|Actual|2007-01-26|May 2017|2017-05-01|June 11, 2009|Actual|2009-06-11|June 11, 2009|Actual|2009-06-11||Interventional|||Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)|A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter|Terminated||Phase 2|86|Actual|Merck Sharp & Dohme Corp.|Due to low response rate for colorectal cancer in interim analyses, low enrollment in head & neck and non-small cell lung cancer groups due to low methylation rates, and low overall response rate in esophageal cancer group, the study was terminated.|1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00423176|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-17|2017-03-15|2009-07-29||December 2006||2006-12-01|March 2017|2017-03-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional|||The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)|Efficacy and Safety of 200mcg BID Mometasone Furoate Nasal Spray (MFNS) Versus Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis|Terminated||Phase 3|237|Actual|Merck Sharp & Dohme Corp.|The study was terminated early due to a very high screening failure rate (mainly caused by the necessity to demonstrate CT changes at baseline indicative of acute sinusitis), which limits any conclusions.|2||"Based on business priorities. Not related to any safety or efficacy issue & took place before   data were unblinded or analyzed"|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00423800|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-17|2017-03-09|2011-01-27||December 2006||2006-12-01|March 2017|2017-03-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional|||Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)|Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) Therapy (1.5 mcg/kg/Week + 800-1200 mg/Day) in Naïve Genotype 1 Hepatitis C Patients With High Baseline Viral Load Who Are HCV-RNA Negative at Week 4 and Week 12|Terminated||Phase 3|56|Actual|Merck Sharp & Dohme Corp.|Due to the small sample size (n=5), no conclusions should be drawn.|2||The study was terminated due to difficulty in recruiting participants.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00429858|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-30|2013-10-14|||January 2007||2007-01-01|October 2013|2013-10-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|||Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer|Individualized Management of Pancreatic Cancer With Targeted Therapeutics (IMPACTT): A Phase II Clinical Trial|Terminated||Phase 2|21|Actual|University of California, San Francisco||1||Study accrual rate is very slow, it was mandated by NCI to be terminated.|f||||t||||||||||2017-10-11 06:56:40.205928|2017-10-11 06:56:40.205928
NCT00434278|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-11|2017-05-12|2010-10-18||March 2007||2007-03-01|May 2017|2017-05-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional|||A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease|Terminated||Phase 4|27|Actual|Genentech, Inc.|Because the study was terminated (for administrative reasons and infeasibility of enrollment), no conclusions can be made about the effect of Pulmozyme on exercise tolerance in this population.|2||This study was terminated for administrative reasons. There were no safety concerns.|f||||||||||||||2017-10-11 06:56:53.243533|2017-10-11 06:56:53.243533
NCT00435487|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-13|2011-10-07|2009-12-22||June 2007||2007-06-01|October 2011|2011-10-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome|Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin In High Risk Patients Of Non-ST Elevation Acute Coronary Syndromes Intended For Early Invasive Strategy|Terminated||Phase 4|173|Actual|Pfizer|This study was terminated due to insufficient recruitment of subjects.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 06:57:17.732381|2017-10-11 06:57:17.732381
NCT00439140|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-21|2013-12-09|2013-12-09||June 2007||2007-06-01|December 2013|2013-12-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder||Terminated||Phase 3|41|Actual|Allergan||4||In agreement with FDA the study was terminated based on data available.|f||||t||||||||||2017-10-11 06:58:09.414334|2017-10-11 06:58:09.414334
NCT00432159|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-05|2016-10-13|2014-05-27||July 2006||2006-07-01|October 2016|2016-10-01|May 2016|Actual|2016-05-01|May 2013|Actual|2013-05-01||Interventional||Intent-to-treat|Comparison of DISCOVER™ Artificial Cervical Disc and ACDF for Treatment of Cervical DDD (IDE Study)|A Multi-Center, Prospective, Randomized Controlled Trial Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion for the Treatment of Cervical Degenerative Disc Disease|Completed||N/A|500|Actual|DePuy Spine|Enrollment terminated early, and beginning in March 2013, follow-up visits beyond 24 months were limited to Discover subjects only.|5|||f||||t||||||||||2017-10-11 06:58:52.539838|2017-10-11 06:58:52.539838
NCT00432341|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-05|2011-11-14|2011-11-14||June 2007||2007-06-01|November 2011|2011-11-01|June 2009|Actual|2009-06-01|March 2009|Actual|2009-03-01||Interventional|||Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia||Terminated||Phase 4|54|Actual|Allergan|The study was terminated early due to difficulties with patient recruitment.|2||Study was terminated early due to difficulties with patient recruitment|f||||||||||||||2017-10-11 06:59:03.155264|2017-10-11 06:59:03.155264
NCT00433017|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-08|2011-04-18|2011-01-12||May 2007||2007-05-01|April 2011|2011-04-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)|24-month Randomized, Double-masked, Controlled, Multicenter, Phase II Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to AMD.|Terminated||Phase 2/Phase 3|255|Actual|Novartis||2||Study was terminated based on the results of analyses performed as planned at Month 12.|f||||||||||||||2017-10-11 06:59:19.326327|2017-10-11 06:59:19.326327
NCT00440271|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-26|2014-06-17|2009-10-20||February 2007||2007-02-01|January 2014|2014-01-01||||October 2008|Actual|2008-10-01||Interventional|||SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC|SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavi/r IN Race/Gender HIV+ Patients Randomized to Therapeutic Drug Monitoring or Standard of Care|Terminated||Phase 3|33|Actual|Boehringer Ingelheim|The study was terminated early due to low patient enrollment, and, therefore, no analysis was performed on the primary and secondary endpoints|2|||f||||||||||||||2017-10-11 06:59:39.020965|2017-10-11 06:59:39.020965
NCT00441558|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-28|2014-05-14|2014-05-14||February 2007||2007-02-01|May 2014|2014-05-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional|||A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).|Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD|Terminated||Phase 3|1723|Actual|Sprout Pharmaceuticals, Inc||1||terminated for administrative reasons|f||||t||||||||||2017-10-11 06:59:51.04351|2017-10-11 06:59:51.04351
NCT00441584|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-28|2017-03-08|2009-06-18||July 2005||2005-07-01|March 2017|2017-03-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional|||The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)|Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys|Terminated||Phase 3|117|Actual|Merck Sharp & Dohme Corp.|Due to slow enrollment, an unplanned interim analysis was conducted: 75 of 93 (80.6%) subjects who had reached treatment Week 12 did not achieve early virologic response. Given the low likelihood of response, a decision was made to stop enrollment.|1||Subject accrual was prematurely terminated due slow enrollment.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00441766|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-27|2011-12-16|2011-12-16||March 2007||2007-03-01|December 2011|2011-12-01|February 2008|Actual|2008-02-01|February 2008|Actual|2008-02-01||Interventional|||Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain||Terminated||Phase 2|213|Actual|Allergan|Only Part A results are presented; Due to termination of the study, Part B was never conducted.|4||Study was terminated due to company decision after Part A. Part B was never conducted|f||||||||||||||2017-10-11 06:59:55.865017|2017-10-11 06:59:55.865017
NCT00442351|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-28|2015-09-28|2010-03-26||September 2006||2006-09-01|September 2015|2015-09-01|April 2007|Actual|2007-04-01|April 2007|Actual|2007-04-01||Interventional|||Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)|"A Comparative Study of The Efficacy and Tolerability of Maintenance Treatment of Patients With Mild/Moderate Persistent Asthma With Asmanex Twisthaler 220 mcg QD PM Versus Asmanex Placebo QD PM"|Terminated||Phase 4|26|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to a high screening failure rate and poor enrollment that resulted from stringent inclusion and exclusion criteria. Efficacy data were not evaluated.|2||Slow Enrollment|f||||f||||||||||2017-10-11 07:00:08.058775|2017-10-11 07:00:08.058775
NCT00442416|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-01|2016-07-05|2016-07-05||February 2007||2007-02-01|July 2016|2016-07-01|January 2008|Actual|2008-01-01|January 2008|Actual|2008-01-01||Interventional||Safety population included all participants who received at least one dose of the study drug and had at least one post-baseline safety assessment.|A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.|A Two-arm, Randomized, Open-label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 Versus Epoetin Alfa in Peritoneal Dialysis Patients Who Self Inject or Receive In-center Injections.|Terminated||Phase 3|80|Actual|Hoffmann-La Roche|The study was prematurely terminated during enrollment period due to legal reasons. Therefore, the planned statistical analysis of the primary endpoint was not performed.|2||Strategic decision unrelated to safety or efficacy|f||||||||||||||2017-10-11 07:00:08.928372|2017-10-11 07:00:08.928372
NCT00442923|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-02|2013-05-24||||||May 2013|2013-05-01||||||||Interventional|MARC||"The Evaluation of Stimulant Withdrawal"|Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse|Withdrawn||Phase 2|0|Actual|Oregon Health and Science University||||This study was withdrawn for lack of progress. No subjects were recruited.|f||||t||||||||||2017-10-11 07:00:24.369798|2017-10-11 07:00:24.369798
NCT00443573|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-02|2008-05-05|||December 2006||2006-12-01|May 2008|2008-05-01||||August 2007|Anticipated|2007-08-01||Interventional|||Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer|Multicenter, Two-Stage Study to Evaluate the Safety and Efficacy of Second-Line Metastatic Colorectal Carcinoma Treatment With Recombinant NAPc2|Suspended||Phase 1/Phase 2|100|Anticipated|ARCA Biopharma, Inc.||1||Company suspended development of product.|f||||t||||||||||2017-10-11 07:00:43.660468|2017-10-11 07:00:43.660468
NCT00443703|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-02|2017-02-14|2009-10-16||May 2007||2007-05-01|February 2017|2017-02-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)|A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study A|Terminated||Phase 3|352|Actual|Merck Sharp & Dohme Corp.|The reason for early termination: Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRA™.|2||"primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus   lopinavir (+) ritonavir"|f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00443729|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-02|2017-02-14|2009-10-12||May 2007||2007-05-01|February 2017|2017-02-01|April 2009|Actual|2009-04-01|October 2008|Actual|2008-10-01||Interventional|||MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)|A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study B|Terminated||Phase 3|355|Actual|Merck Sharp & Dohme Corp.|Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRA™.|2||"Primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus   lopinavir (+) ritonavir"|f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00430027|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-30|2013-10-22|2013-10-22||November 2006||2006-11-01|October 2013|2013-10-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|||Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma|Pilot Feasibility Trial of Preoperative Capecitabine, Oxaliplatin, Cetuximab and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma|Terminated||N/A|8|Actual|University of Colorado, Denver|This study was terminated due slow accrual.|1||This study was terminated due slow accrual.|f||||t||||||||||2017-10-11 07:00:51.279287|2017-10-11 07:00:51.279287
NCT00430300|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-30|2013-05-17|2013-05-17|2011-03-16|January 2007||2007-01-01|May 2013|2013-05-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Interventional|||Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.|A Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Evaluate the Efficacy And Safety of UK-432,097 Dry Powder For Inhalation In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease.|Terminated||Phase 2|87|Actual|Pfizer|Study was terminated prematurely due to futility based on results of interim analysis.|2|||f||||t||||||||||2017-10-11 07:00:58.737968|2017-10-11 07:00:58.737968
NCT00430716|ClinicalTrials.gov processed this data on October 10, 2017|2007-01-31|2011-05-25|2011-04-22||April 2008||2008-04-01|May 2011|2011-05-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.|A Multinational, Multicentre, Randomized, Parallel Group, Double-Blind Study To Assess The Efficacy and Safety Of 1 mg, 5 mg and 20 mg TID of Oral Sildenafil in the Treatment of Subjects Aged 18 Years and Over With Pulmonary Arterial Hypertension (PAH)|Terminated||Phase 4|130|Actual|Pfizer|The trial was not designed to demonstrate the equivalence of doses and due to premature study termination, the resulting sample size was not adequately powered to show superiority.|4||"This study was terminated at the recommendation of an independent Data Monitoring Committee.   The decision was not based on any safety concerns."|f||||t||||||||||2017-10-11 07:01:14.905531|2017-10-11 07:01:14.905531
NCT00437073|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-15|2015-09-24|2012-09-13||May 2007||2007-05-01|October 2012|2012-10-01|February 2010|Actual|2010-02-01|January 2009|Actual|2009-01-01||Interventional|||Brain Metastases In ErbB2-Positive Breast Cancer|Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy|Terminated||Phase 2|22|Actual|GlaxoSmithKline||2||"Lapatinib-topotecan arm enrollment closed early per protocol amendment 2. Then enrollment into   remaining arm terminated due to operational issues."|f||||||||||||||2017-10-11 07:01:38.117147|2017-10-11 07:01:38.117147
NCT00437203|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-16|2012-03-06|2012-03-06||December 2006||2006-12-01|March 2012|2012-03-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional|||PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine|Phase I Study of PF-00477736 With Gemcitabine In Patients With Advanced Solid Malignancies|Terminated||Phase 1|43|Actual|Pfizer|The study was prematurely terminated due to business reasons.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 07:01:40.794165|2017-10-11 07:01:40.794165
NCT00437398|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-20|2013-04-18|2013-03-05||July 2006||2006-07-01|March 2013|2013-03-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Islet Transplantation for Type 1 Diabetes Mellitus|Islet Transplantation for Type 1 Diabetes Mellitus|Terminated||Phase 1/Phase 2|2|Actual|Mayo Clinic|The study was terminated early due to difficulty in recruiting subjects, and ran short of funds. The sample size (n=2) was too small to perform a meaningful analysis.|1||"The study was terminated early due to difficulty in recruiting subjects, and ran short of   funds."|f||||t||||||||||2017-10-11 07:01:52.085334|2017-10-11 07:01:52.085334
NCT00437489|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-20|2009-04-13|2008-12-11||June 2007||2007-06-01|February 2009|2009-02-01|December 2007|Actual|2007-12-01|December 2007|Actual|2007-12-01||Interventional|||A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.|A 16 Week Open-Label Outpatient, Randomized, Parallel Study Assessing The Impact Of Two Different Initial Dose Prescriptions For Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents.|Terminated||Phase 4|49|Actual|Pfizer|As a result of Pfizer's decision (18Oct2007) to return the worldwide rights for Exubera (insulin human [rDNA origin]) Inhalation Powder) to Nektar, from which Pfizer licensed inhaled insulin technology, it was decided to terminate this study.|2||"This protocol was terminated not for safety reasons, but because Pfizer decided to return the   worldwide rights for Exubera to Nektar, on 18 October 2007."|f||||f||||||||||2017-10-11 07:01:52.895385|2017-10-11 07:01:52.895385
NCT00437671|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-20|2016-01-18|||March 2007||2007-03-01|January 2016|2016-01-01|September 2007|Actual|2007-09-01|September 2007|Actual|2007-09-01||Interventional|||Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels|Pharmacokinetics Of Active And Passive Tetanus Immunization Given Concurrently In Subjects With No Known Primary Immunization History Or In Subjects With Tetanus Antibody Levels Below Protective Levels|Terminated||Phase 4|6|Actual|Grifols Therapeutics Inc.||1||Study terminated for cGCP non-compliance. Analyses could not be performed.|f||||f||||||||||2017-10-11 07:01:55.17682|2017-10-11 07:01:55.17682
NCT00447096|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-12|2016-06-08|||February 2007||2007-02-01|June 2016|2016-06-01|February 2010|Actual|2010-02-01|February 2010|Actual|2010-02-01||Interventional|rTMS||rTMS for Treatment of Depressed Phase of Bipolar Disorder Type II|rTMS (Repetitive Transcranial Magnetic Stimulation) for Acute Treatment of Depressed Phase of Bipolar Disorder Type II|Withdrawn||Phase 2|0|Actual|University of Texas Southwestern Medical Center||2||No results, funding terminated and PI no longer at institution|f||||f||||||||||2017-10-11 07:02:05.120153|2017-10-11 07:02:05.120153
NCT00447226|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-13|2012-06-07|2010-01-11||May 2007||2007-05-01|June 2012|2012-06-01|September 2009|Actual|2009-09-01|May 2009|Actual|2009-05-01||Interventional|||Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists|A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects With ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer|Terminated||Phase 2|32|Actual|GlaxoSmithKline|Study terminated prematurely: preliminary assessment (prompted by low screening/enrollment rates) showed primary objective of tumor response rate not met. Also unable to test primary treatment comparison after randomization following SD at 12 wks.|2||"The study had failed to meet the primary objective of tumor response rate at 12 weeks from   first dose."|f||||f||||||||||2017-10-11 07:02:07.3627|2017-10-11 07:02:07.3627
NCT00447265|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-12|2013-02-06|2011-10-07||February 2008||2008-02-01|February 2013|2013-02-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional|||Etanercept for the Treatment of Lupus Nephritis|A Randomized, Double-Blind, Placebo-Controlled, Phase II, Multi-Center Study for Treatment of Lupus Nephritis by Inhibition of Tumor Necrosis Factor-alpha Using Etanercept|Terminated||Phase 2|1|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study terminated early with 1 subject enrolled. Based on safety info from other trials, the protocol chairs decided possible risks to patients outweighed the potential benefits. Analysis of groups is not possible. Study objectives cannot be met.|2||The perceived risk-benefit ratio for individuals with early active RA|f||||||||||||||2017-10-11 07:02:07.921804|2017-10-11 07:02:07.921804
NCT00448448|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-14|2017-07-12|2014-05-19||February 2007||2007-02-01|July 2017|2017-07-01|September 2013|Actual|2013-09-01|September 2013|Actual|2013-09-01||Interventional|BrAIST|Age, gender, race, height, Scoliosis Research Society curve classification, Cobb angle, Risser grade|Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)|Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)|Terminated||N/A|383|Actual|University of Iowa|Study was terminated early due to efficacy. 119 subjects were still on protocol.|2||Stopped for efficacy|f||||t||||||||||2017-10-11 07:02:29.576256|2017-10-11 07:02:29.576256
NCT00448539|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-15|2012-11-12|2012-04-16||March 2007||2007-03-01|November 2012|2012-11-01|December 2010|Actual|2010-12-01|May 2010|Actual|2010-05-01||Interventional|||Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|Completed||Phase 3|286|Actual|Eisai Inc.|This study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.|2|||f||||f||||||||||2017-10-11 07:02:30.575032|2017-10-11 07:02:30.575032
NCT00448682|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-15|2016-12-14|2013-02-21||June 2005||2005-06-01|December 2016|2016-12-01|March 2010|Actual|2010-03-01|December 2009|Actual|2009-12-01||Interventional|||Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery|A Phase II Study of Weekly 24-hour Infusion 5-fluoro-deoxyuridine (FUdR)/Leucovorin With Oxaliplatin and Docetaxel (Taxotere) as First-line Treatment in Patients With Metastatic Gastric Adenocarcinoma (IIT# 14065)|Terminated||Phase 2|25|Actual|University of Miami|The study was terminated prematurely by the University of Miami Institutional Review Board. The results have not been analyzed.|1|||f||||t||||||||||2017-10-11 07:02:36.299408|2017-10-11 07:02:36.299408
NCT00448708|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-15|2011-10-13|2011-06-08||March 2007||2007-03-01|October 2011|2011-10-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access|Trial to Assess the Effectiveness of Maintaining Patency and Safety of the Vascular Wrap Paclitaxel-Eluting Mesh After Surgical Implantation With the Lifespan® ePTFE Vascular Graft in the Upper Extremity for Hemodialysis Vascular Access|Terminated||N/A|222|Actual|Angiotech Pharmaceuticals|Due to an observed imbalance in the number of graft infections, enrollment in the 1-year study 012-VWAV06 was suspended at the recommendation of the DSMC. Many of the planned efficacy analyses did not occur as a result of this suspension.|2||Due to an imbalance in graft infections between groups.|f||||t||||||||||2017-10-11 07:02:36.608461|2017-10-11 07:02:36.608461
NCT00449163|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-15|2017-04-05|2013-01-23||March 1, 2006|Actual|2006-03-01|April 2017|2017-04-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer|Phase II Study of Avastin, Irinotecan, High Dose 24 Hour Continuous Intravenous Infusion of Floxuridine and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer|Terminated||Phase 2|25|Actual|University of Miami|A total of 25 subjects were enrolled however; data were analyzed for 22 subjects only. Study was terminated early by the University of Miami Institutional Review Board.|1||Study terminated by University of Miami Institutional Review Board|f||||t||||||||||2017-10-11 07:02:48.797259|2017-10-11 07:02:48.797259
NCT00441194|ClinicalTrials.gov processed this data on October 10, 2017|2007-02-27|2012-03-02|||November 2006||2006-11-01|March 2012|2012-03-01|May 2007|Actual|2007-05-01|||||Observational|||To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series|To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series With Respect to Reliability, Reproducibility, Test Duration, Patient Preference, Technician Preference.|Terminated||Phase 4|80|Anticipated|Haag Streit USA|||1|Study terminated due to resources|f||||t||||||||||2017-10-11 07:03:07.516411|2017-10-11 07:03:07.516411
NCT00453856|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-28|2007-08-08|||March 2007||2007-03-01|August 2007|2007-08-01||||||||Interventional|||Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children|Efficacy of Sulfadoxine-Pyrimethamine in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children in Lambaréné|Terminated||Phase 4|139|Anticipated|Albert Schweitzer Hospital||||"The study was terminated because of Early Treatment Failure in child.The justification for this   decision are concerns about safety of children."|f||||||||||||||2017-10-11 07:03:40.410558|2017-10-11 07:03:40.410558
NCT00453908|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-28|2007-08-17|||May 2004||2004-05-01|August 2007|2007-08-01||||||||Interventional|ALF-RIK||Alfuzosin Versus Placebo in Acute Urinary Retention|Does Alfuzosin OD vs. Placebo in Male Patients Facilitate Spontaneous Voiding During Clean Intermittent Self-Catheterization Following Acute Urinary Retention?|Terminated||Phase 3|160||Sanofi||||The study was early terminated due to slow and difficult recruitment|f||||f||||||||||2017-10-11 07:03:40.639651|2017-10-11 07:03:40.639651
NCT00445328|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-07|2009-10-05|2009-07-20||June 2007||2007-06-01|October 2009|2009-10-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Interventional|||Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients|Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients.|Terminated||Phase 4|84|Actual|Pfizer|Study terminated prematurely due to delay in overall study start-up and inability to meet predefined protocol recruitment milestones; sample size too small to permit meaningful statistical analyses. No statistical analyses for all but 2 endpoints.|2||See Detailed Description|f||||f||||||||||2017-10-11 07:05:13.842669|2017-10-11 07:05:13.842669
NCT00445705|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-07|2015-08-25|2011-12-16||March 2007||2007-03-01|August 2015|2015-08-01|January 2008|Actual|2008-01-01|January 2008|Actual|2008-01-01||Interventional|||Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome||Terminated||Phase 2|211|Actual|Allergan|This study was terminated early due to company decision. Only Part A results are presented; Part B was never conducted.|4||This study was terminated early due to company decision. Part B was never conducted.|f||||||||||||||2017-10-11 07:05:23.020888|2017-10-11 07:05:23.020888
NCT00446511|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-09|2011-06-30|2011-01-11||June 2007||2007-06-01|June 2011|2011-06-01|June 2009|Actual|2009-06-01|June 2009|Actual|2009-06-01||Interventional|||Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension|An Extension to Study Protocol CVAL489K2302 to Evaluate the Long Term Safety, Tolerability and Efficacy of Valsartan in Children 6 to 17 Years of Age With Hypertension, Versus Enalapril Treatment for 14 Weeks, or Combined With Enalapril Versus Enalapril for 66 Weeks in Chronic Kidney Disease Patients.|Completed||Phase 3|250|Actual|Novartis|Study was prolonged from 14 to 66 wks for CKD patients only. Most CKD patients completed the initial 14 wk extension period prior to amendment approval and the study was terminated prematurely with 3 CKD patients progressing to a maximum of Visit 13.|4|||f||||f||||||||||2017-10-11 07:05:44.576517|2017-10-11 07:05:44.576517
NCT00456963|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-04|2011-07-04|||September 2007||2007-09-01|July 2011|2011-07-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|PHIDIAS||Prevention of Diabetes and Hypertension|Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.|Terminated||Phase 4|3000|Anticipated|Istituto Auxologico Italiano||3||"Because of delay in approval of the protocol by a number of Ethics Commitees the trial was   terminated on March 4, 2010. No patient had received any study drug."|f||||t||||||||||2017-10-11 07:06:19.050826|2017-10-11 07:06:19.050826
NCT00457574|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-05|2013-08-27|||March 2007||2007-03-01|August 2013|2013-08-01|August 2010|Actual|2010-08-01|July 2009|Actual|2009-07-01||Interventional|||Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas|A Single-Center, Open-Label, Phase I Study of Single-Agent GMX1777 Administered as a 24-Hour Infusion Every 3 Weeks to Patients With Refractory Solid Tumors or Lymphomas|Withdrawn||Phase 1|0|Actual|Teva Pharmaceutical Industries||1||Study terminated prematurely due to financial constraints.|f||||f||||||||||2017-10-11 07:06:35.548018|2017-10-11 07:06:35.548018
NCT00457899|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-05|2007-11-26|||July 2007||2007-07-01|November 2007|2007-11-01|September 2007|Actual|2007-09-01|||||Interventional|RAPID||Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder|RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration)|Terminated||Phase 3|234|Anticipated|AstraZeneca||||Study terminated due to poor recruitment|f||||||||||||||2017-10-11 07:06:43.344071|2017-10-11 07:06:43.344071
NCT00457951|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-06|2016-10-25|2016-01-26||April 2007||2007-04-01|October 2016|2016-10-01|October 2009|Actual|2009-10-01|August 2009|Actual|2009-08-01||Interventional|COPD|Open-Label followed by multi-center, randomized, double-blind, placebo-controlled trial in hospitalized subjects with exacerbations of COPD. In the double-blind phase, 145 subjects consented and 138 met criteria and were randomized.|A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD|An Open-Label Phase Followed by a Randomized, Double-Blind, Placebo-Controlled Phase in a Study Designed to Evaluate Intravenous 2-O, 3-O Desulfated Heparin (ODSH) in Subjects With Exacerbations of Chronic Obstructive Pulmonary Disease|Terminated||Phase 2|158|Actual|Cantex Pharmaceuticals|PGX-ODSH-2006, Ph II in patients with exacerbation of COPD. There were no safety issues. An interim analysis demonstrated lack of efficacy for the primary and secondary endpoints; therefore, Cantex terminated the study on August 11, 2009.|3||Interim analysis: safety without efficacy ODSH in patients with acute COPD.|f||||t||||||||||2017-10-11 07:06:43.666529|2017-10-11 07:06:43.666529
NCT00450242|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-21|2012-06-12|2012-02-27||December 2006||2006-12-01|June 2012|2012-06-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|||5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis|Use of 5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis|Terminated||Phase 2|14|Actual|University of North Carolina, Chapel Hill|The study terminated due to lack of funding and difficulties with recruitment. More extensive data analysis to include secondary outcome measures was not performed due to inability to fund statistical programming and analysis efforts.|2||lack of funding|f||||f||||||||||2017-10-11 07:06:57.518468|2017-10-11 07:06:57.518468
NCT00450333|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-21|2014-06-06|2009-08-18||October 2006||2006-10-01|November 2009|2009-11-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Interventional|||Dynepo Infrequent Dosing Study|An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Three Dosing Schedules of Subcutaneous Dynepo in Adult Patients With Anaemia Associated With Chronic Kidney Disease Who Are Pre-Dialysis or Require Peritoneal Dialysis or Haemodialysis|Terminated||Phase 3|407|Actual|Shire|This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses.|4||"The termination of the study is not linked to a product recall or result of any safety signal.   Rather it was sponsor's commercial decision to withdraw the MA"|f||||f||||||||||2017-10-11 07:07:01.159871|2017-10-11 07:07:01.159871
NCT00451698|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-22|2013-07-25|2013-03-21||October 2007||2007-10-01|July 2013|2013-07-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|EPO||Erythropoietin and Pediatric Cardiac Surgery|Erythropoietin and Pediatric Cardiac Surgery|Terminated||N/A|9|Actual|Medical College of Wisconsin|Data for all recruited patients was included with available results. The number of participants fell far short of study goals and the study was terminated prematurely due to inadequate enrollment.|2||Inadequate patient enrollment|f||||t||||||||||2017-10-11 07:07:27.247075|2017-10-11 07:07:27.247075
NCT00451841|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-22|2017-01-19|||March 2007||2007-03-01|January 2017|2017-01-01|June 2020|Anticipated|2020-06-01|June 2013|Actual|2013-06-01||Observational|||Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux|Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux|Suspended||N/A|30|Anticipated|University of Massachusetts, Worcester|||2|insufficient enrollment; study suspended pending analysis|f||||f||||||Samples Without DNA|"     frozen sputum supernatant and exhaled breath condensate fixed sputum cell preparations   "|||2017-10-11 07:07:28.595812|2017-10-11 07:07:28.595812
NCT00452361|ClinicalTrials.gov processed this data on October 10, 2017|2007-03-23|2012-07-27|2009-09-24||April 2007||2007-04-01|July 2012|2012-07-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|||Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient|A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipient|Terminated||Phase 4|31|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|Study terminated early due to difficulties in enrolling qualified patients. No patients completed 104 weeks (primary outcome); a few completed 60 weeks. Insufficient data were available for efficacy analyses.|2|||f||||f||||||||||2017-10-11 07:07:39.045085|2017-10-11 07:07:39.045085
NCT00464191|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-20|2009-09-19|||April 2006||2006-04-01|September 2009|2009-09-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional|||Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment|Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment|Terminated||Phase 4|150|Anticipated|Nordfjord Psychiatric Centre||2||The study has been terminated because too few patients have been recruited|f||||||||||||||2017-10-11 07:08:13.756369|2017-10-11 07:08:13.756369
NCT00464347|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-19|2010-03-23|||January 2007||2007-01-01|October 2007|2007-10-01|September 2007|Actual|2007-09-01|||||Interventional|VERTACL||TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration|Multi-Center, Randomized, Phase II Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide and Avastin® in Combination With Photodynamic Therapy in Participants With Neovascular Age Related Macular Degeneration|Terminated||Phase 2|100|Anticipated|National Eye Institute (NEI)||2||Study was terminated because of poor enrollment.|f||||t||||||||||2017-10-11 07:08:22.887987|2017-10-11 07:08:22.887987
NCT00465257|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-23|2008-05-16|||May 2007||2007-05-01|May 2008|2008-05-01||||||||Interventional|||Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar|Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction as New Treatment Policy for Uncomplicated Plasmodium Falciparum Malaria in Zanzibar|Suspended||Phase 4|110|Anticipated|Karolinska University Hospital||||Due to lack of malaria patients in Zanzibar the study has been suspended.|f||||||||||||||2017-10-11 07:08:40.633706|2017-10-11 07:08:40.633706
NCT00467831|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-28|2013-06-03|2013-06-03||April 2007||2007-04-01|June 2013|2013-06-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Interventional|||Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome|Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome|Terminated||Phase 1/Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)|The study was terminated because enrollment was too low. The results shown are not statistically significant.|1||insufficient enrollment|f||||f||||||||||2017-10-11 07:09:37.483026|2017-10-11 07:09:37.483026
NCT00467896|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-27|2013-03-27|2012-09-27||September 2006||2006-09-01|March 2013|2013-03-01|June 2011|Actual|2011-06-01|November 2010|Actual|2010-11-01||Interventional|||"The Power 15 Study: Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting"|"A Comparison of Safety and Inhalation Times of Ventavis (Iloprost) Inhalation Solution Delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 Power 15 Study"|Terminated||Phase 2|62|Actual|Actelion|Study was terminated early due to the discontinuation of the I-neb Power Disc-15 development program.|1||Sponsor's decision|f||||||||||||||2017-10-11 07:09:41.066447|2017-10-11 07:09:41.066447
NCT00468299|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-01|2011-06-23|2011-04-12||April 2007||2007-04-01|June 2011|2011-06-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|MiMi||MiMi: A Randomized Trial of Mifepristone and Misoprostol for Treatment of Early Pregnancy Failure|Treatment of Early Pregnancy Failure|Terminated||N/A|16|Actual|Boston University|The study was terminated because of poor enrollment. Few eligible women were referred.|2||poor enrollment|f||||t||||||||||2017-10-11 07:09:46.852188|2017-10-11 07:09:46.852188
NCT00469079|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-03|2014-10-03|2013-10-29||January 2007||2007-01-01|October 2014|2014-10-01|February 2009|Actual|2009-02-01|February 2009|Actual|2009-02-01||Interventional|ANTS3||Health Effects of SLT, Cigarette Smoking, and New Tobacco Products|Comparing the Health Effects of Smokeless Tobacco, Cigarette Smoking, and New Tobacco Products Advertised as Safer Alternatives Part of Tobacco Exposure Reduction|Completed||Phase 2|130|Actual|University of Minnesota - Clinical and Translational Science Institute|Smokeless tobacco products commercially available have been introduced, withdrawn, or changed at a relatively rapid rate resulting in products that are no longer available and changes that occurred during the time period that the study occurred.|3|||f||||t||||||||||2017-10-11 07:10:13.278039|2017-10-11 07:10:13.278039
NCT00458744|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-09|2014-08-07|||February 2007||2007-02-01|August 2014|2014-08-01||||July 2008|Anticipated|2008-07-01||Interventional|||Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment|A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias|Withdrawn||Phase 1|0|Actual|Children's Oncology Group||||Study withdrawn because of toxicity reported on the adult phase 1 trial.|||||f||||||||||2017-10-11 07:10:20.388901|2017-10-11 07:10:20.388901
NCT00459108|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-09|2015-03-19|2014-06-19||April 2007||2007-04-01|June 2014|2014-06-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional|||Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery|A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma|Terminated||Phase 2|25|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.|1||Halted early for futility.|f||||||||||||||2017-10-11 07:10:26.756972|2017-10-11 07:10:26.756972
NCT00460967|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-16|2007-11-06|||January 2007||2007-01-01|April 2007|2007-04-01|December 2009|Anticipated|2009-12-01|||||Interventional|RHEO-AMD||Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis|Safety and Effectiveness, in a Multi-Center, Randomized, Sham Controlled Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD)Using Rheopheresis|Suspended||Phase 3|325|Anticipated|OccuLogix||2||"In light of the company's current financial position we have indefinately suspended the   Rheo-AMD trial."|f||||f||||||||||2017-10-11 07:10:51.009486|2017-10-11 07:10:51.009486
NCT00461929|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-16|2009-02-12|||February 2005||2005-02-01|April 2007|2007-04-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|GIST||Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib|Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib.|Terminated||Phase 4|68|Anticipated|University Health Network, Toronto||||study terminated 12Feb09 due to low recruitment|f||||f||||||||||2017-10-11 07:11:12.774659|2017-10-11 07:11:12.774659
NCT00462228|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-10|2016-11-22|2012-05-18||April 2007||2007-04-01|October 2016|2016-10-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury|Double-blind Cross-over Study of the Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury, Protocol NAM-MD-44|Terminated||Phase 4|11|Actual|University of Missouri-Columbia|The enrollment goal for the study was 20 subjects. The study included 11 subjects but was terminated due to a lack of additional subjects.|2||The study was stopped due to a lack of additional subjects.|f||||f||||||||No||2017-10-11 07:11:17.268977|2017-10-11 07:11:17.268977
NCT00462384|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-18|2016-03-02|2016-03-02||February 2008||2008-02-01|March 2016|2016-03-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional||Safety population: included all participants who were treated with at least one dose of the study medication.|A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.|An Open-label, Multi-center Study to Demonstrate Correction of Anemia and to Assess the Maintenance of Hemoglobin Levels Using Subcutaneous Once Monthly Injections of Mircera in Pre-dialysis Patients With Chronic Kidney Disease|Terminated||Phase 3|39|Actual|Hoffmann-La Roche|This study was terminated early due to strategic decision unrelated to safety or efficacy.|1||Strategic decision unrelated to safety or efficacy|f||||||||||||||2017-10-11 07:11:21.987778|2017-10-11 07:11:21.987778
NCT00470392|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-04|2016-10-03|2013-09-26||May 2007||2007-05-01|October 2016|2016-10-01|July 2012|Actual|2012-07-01|July 2010|Actual|2010-07-01||Interventional|||Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis|Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis|Terminated||N/A|9|Actual|VA Office of Research and Development|No synchronized T cell reactivation was observed upon immunohistochemical analysis, nor upon analysis of T cell death associated gene (TDAG) mRNA by PCR, with Clobetasol treatment, so this arm was terminated.|2||Recruiting complete and administrative termination|f||||t||||||||||2017-10-11 07:11:53.727756|2017-10-11 07:11:53.727756
NCT00470535|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-03|2017-01-09|2014-12-03||January 2007||2007-01-01|January 2017|2017-01-01|September 2010|Actual|2010-09-01|January 2009|Actual|2009-01-01||Interventional|||Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer|Phase II Study of Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Adenocarcinoma|Terminated||Phase 2|18|Actual|Roswell Park Cancer Institute|This study was terminated earlier due to a phase III study that showed this drug was not better than sorafenib|1||"This study was terminated earlier due to a phase III study that showed this drug inferior to   sorafenib"|f||||t||||||||||2017-10-11 07:11:55.36591|2017-10-11 07:11:55.36591
NCT00470743|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-07|2015-09-01|||May 2007||2007-05-01|June 2009|2009-06-01|June 2009|Anticipated|2009-06-01|June 2009|Anticipated|2009-06-01||Interventional|||Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies|A Randomised Controlled Trial Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus In Very Premature Infants|Withdrawn||Phase 4|0|Actual|KK Women's and Children's Hospital||2||Funding withdrawn|f||||f||||||||||2017-10-11 07:12:01.77617|2017-10-11 07:12:01.77617
NCT00471120|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-07|2015-08-03|||November 2006||2006-11-01|August 2015|2015-08-01|February 2008|Actual|2008-02-01|April 2007|Actual|2007-04-01||Interventional|||Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer|Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women|Terminated||N/A|20|Actual|CytoCore, Inc.||1||Study terminated due to protocol deficiencies.|f||||t||||||||||2017-10-11 07:12:07.312393|2017-10-11 07:12:07.312393
NCT00471237|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-07|2017-08-03|2017-08-02|2010-10-13|May 14, 2007|Actual|2007-05-14|August 2017|2017-08-01|December 26, 2008|Actual|2008-12-26|December 26, 2008|Actual|2008-12-26||Interventional|||A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.|Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis|Terminated||Phase 2|564|Actual|GlaxoSmithKline|The study was terminated for futility in a phased manner by the sponsor on 25-Sep-2008 once the results of a planned 6-month interim analysis were available.|4||Terminated for futility by sponsor after a pre-planned interim review of data|f||||t||||||||||2017-10-11 07:12:14.858582|2017-10-11 07:12:14.858582
NCT00471367|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-07|2009-09-23|||April 2007||2007-04-01|September 2009|2009-09-01|December 2008|Actual|2008-12-01|||||Interventional|||Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877|A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma|Terminated||Phase 1|44|Anticipated|AstraZeneca||1||Part B of the study was terminated early due to a lack of enrollment.|f||||||||||||||2017-10-11 07:12:22.318225|2017-10-11 07:12:22.318225
NCT00471809|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-08|2016-07-28|||March 2006||2006-03-01|April 2012|2012-04-01|March 2007|Actual|2007-03-01|||||Interventional|MARS||Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)|Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)|Terminated||Phase 4|210||National Heart, Lung, and Blood Institute (NHLBI)||||"The CARE Network DSMB recommended to the NHLBI that the MARS trial be terminated, based on a   futility analysis with 55 randomized children."|f||||t||||||||||2017-10-11 07:12:32.838488|2017-10-11 07:12:32.838488
NCT00472082|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-10|2013-12-19|2012-11-09||May 2007||2007-05-01|December 2013|2013-12-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients|An Open Label, Single-Center Pilot Study of Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Primary Renal Transplant Recipients|Terminated||Phase 1/Phase 2|5|Actual|Emory University||1||This study was terminated at the request of the drug manufacturer.|f||||t||||||||||2017-10-11 07:12:36.60495|2017-10-11 07:12:36.60495
NCT00472264|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-09|2009-07-01|||May 2007||2007-05-01|July 2009|2009-07-01|November 2008|Actual|2008-11-01|October 2008|Actual|2008-10-01||Observational|||A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients|An Exploratory Study To Investigate The Reproducibility Of Lung 18Fluoro-Deoxyglucose Positron Emission Tomography In Patients With Chronic Obstructive Airways Disease (COPD) In The Absence Of Anti-Inflammatory Treatments|Terminated||Early Phase 1|20|Actual|Pfizer|||1|"Study terminated on Nov 7, 2008 as a result of poor recruitment and changes in business   priorities. The decision was not based on safety concerns."|f||||f||||||||||2017-10-11 07:12:39.7239|2017-10-11 07:12:39.7239
NCT00460278|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-11|2008-06-02|||April 2007||2007-04-01|June 2008|2008-06-01||||||||Interventional|||Study of XL418 in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL418 Administered Orally Daily to Subjects With Solid Tumors|Suspended||Phase 1|63|Anticipated|Exelixis||||Enrollment suspended due to low drug exposure.|||||t||||||||||2017-10-11 07:12:51.407533|2017-10-11 07:12:51.407533
NCT00460460|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-12|2011-01-24|||March 2007||2007-03-01|January 2011|2011-01-01|August 2007|Actual|2007-08-01|||||Interventional|||Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies|A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN|Terminated||Phase 1|75|Anticipated|AstraZeneca||||Study was terminated due to low enrollment|f||||||||||||||2017-10-11 07:12:55.879192|2017-10-11 07:12:55.879192
NCT00460551|ClinicalTrials.gov processed this data on October 10, 2017|2007-04-12|2011-12-05|2011-09-12||April 2007||2007-04-01|December 2011|2011-12-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|||Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer|A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients|Terminated||Phase 2|13|Actual|Genmab|The trial was prematurely closed. The original protocol contained Part 1A, followed by Part 1B and Part 2. The trial was terminated when 13 patients were enrolled in Part 1A. Scans for efficacy were planned for Part 1B and Part 2.|1||Due to considerations regarding the appropriate therapeutic regimen for these patients.|f||||t||||||||||2017-10-11 07:12:58.427601|2017-10-11 07:12:58.427601
NCT00476580|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-21|2015-08-27|||April 2007||2007-04-01|August 2015|2015-08-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Observational|||Health Habits and Cancer Risk Comparison Among Migrant Sri Lankans and Sri Lankans|Health Habits and Cancer Risk Among a US Migrant Sri Lankan Population and a Comparison With Siblings Living in Sri Lanka|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center|||2|Study terminated.|f||||f||||||||||2017-10-11 07:15:08.395691|2017-10-11 07:15:08.395691
NCT00477230|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-21|2012-06-26|2012-06-26||March 2007||2007-03-01|June 2012|2012-06-01|May 2009|Actual|2009-05-01|May 2009|Actual|2009-05-01||Interventional|ENABLE||Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs|Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic Atrial Fibrillation (AF)|Terminated||Phase 3|64|Actual|CardioFocus|This study was terminated early due to Sponsor decision. Therefore, full patient assignement to treatments post-randomziation did not occur. Results and other measures cannot be determined because most patients exited the study before completion.|2||Study terminated based on decision of Sponsor.|f||||t||||||||||2017-10-11 07:15:22.458953|2017-10-11 07:15:22.458953
NCT00478439|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-22|2010-10-26|||December 2007||2007-12-01|October 2010|2010-10-01|October 2010|Actual|2010-10-01|September 2009|Actual|2009-09-01||Interventional|||Investigation of Macular Pigment Augmentation on Dark Adaptation|Investigation of Macular Pigment Augmentation on Dark Adaptation|Terminated||Phase 4|13|Actual|University of Alabama at Birmingham||1||Study terminated: Recruitment delay due to equipment malfunction|f||||f||||||||||2017-10-11 07:15:44.696007|2017-10-11 07:15:44.696007
NCT00478673|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-24|2012-07-02|2010-12-20||May 2007||2007-05-01|July 2012|2012-07-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|SONOMA||Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA|The NexStent® Carotid Stent System: A Post Market Approval Evaluation Study In Conjunction With the FilterWire EZ™ Embolic Protection System|Terminated||Phase 4|298|Actual|Boston Scientific Corporation|Enrollment was terminated in June 2008 due to market withdrawal of the NexStent Carotid Stent System. The early termination of enrollment led to a smaller than expected number of analyzable subjects (298 actual vs. 1500 anticipated).|1||"Enrollment was terminated in June 2008 due to market withdrawal of the NexStent Carotid Stent   System."|f||||f||||||||||2017-10-11 07:15:49.271092|2017-10-11 07:15:49.271092
NCT00479258|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-24|2008-10-31|2008-10-29||October 2007||2007-10-01|October 2008|2008-10-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Interventional|||Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents|Safety And Efficacy Of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents Ages 6-17 Years With Type 1 Diabetes Mellitus: A 12 Month, Outpatient, Randomized, Open Label, Parallel Group Comparative Trial.|Terminated||Phase 3|554|Anticipated|Pfizer|Pfizer announced Oct07 it would stop marketing Exubera; recruitment placed on hold. Nektar, from which Pfizer licensed Exubera, announced April 9, 2008 it had stopped its search for a new marketing partner. Study terminated; no further recruitment.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 07:16:01.053768|2017-10-11 07:16:01.053768
NCT00479856|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-25|2012-05-31|2010-05-03||November 2007||2007-11-01|June 2011|2011-06-01|March 2010|Actual|2010-03-01|September 2009|Actual|2009-09-01||Interventional|||Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer|An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.|Terminated||Phase 2|9|Actual|GlaxoSmithKline||1||Study was terminated due to difficulty in identifying eligible subjects|f||||||||||||||2017-10-11 07:16:15.74412|2017-10-11 07:16:15.74412
NCT00480012|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-29|2011-08-28|||May 2005||2005-05-01|August 2011|2011-08-01||||June 2007|Anticipated|2007-06-01||Interventional|||The Effects of TMS on Memory-consolidation in Human Primary Visual Cortex|The Effects of Transcranial Magnetic Stimulation of the Brain on Memory-consolidation in Human Primary Visual Cortex|Withdrawn||N/A|0|Anticipated|Sheba Medical Center||1||Due to administrative issues, the study was withdrawn.|f||||||||||||||2017-10-11 07:16:19.923666|2017-10-11 07:16:19.923666
NCT00473408|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-14|2016-12-05|||March 2007||2007-03-01|December 2016|2016-12-01|November 2011|Actual|2011-11-01|May 2007|Actual|2007-05-01||Observational|Gliomstudien||The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas|The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas|Terminated||N/A|1|Actual|Haukeland University Hospital|||1|Moved to another country, not possible to recruit from abroad.|f||||f||||||Samples With DNA|"     Tumor samples and blood samples are collected and frozen for future analysis for tumor     vascularization and tumor stem cells.   "|No|Only one patient was included before the study was terminated.|2017-10-11 07:16:37.554357|2017-10-11 07:16:37.554357
NCT00473889|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-14|2015-06-08|2009-09-03||May 2007||2007-05-01|June 2015|2015-06-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)|A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat or Placebo in Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC)|Terminated||Phase 2/Phase 3|253|Actual|Merck Sharp & Dohme Corp.|The study was stopped following a pre-planned interim analysis because the goal for this study to continue was not met, based on 100 events, a reduction in the hazard ratio for progression-free survival by > 23% with a one-sided p-value < 0.1|2||"The study was terminated based on the recommendation by the DSMB following a pre-planned   protocol interim analysis because the endpoint was not achieved."|f||||f||||||||||2017-10-11 07:16:52.731592|2017-10-11 07:16:52.731592
NCT00474188|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-14|2009-08-27|2009-06-30||May 2007||2007-05-01|August 2009|2009-08-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid ®) in Combination With Dexamethasone in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Terminated||Phase 2|26|Actual|Celgene|Study terminated prematurely as a business decision. Analyses of efficacy not conducted.|1||Business decision|f||||t||||||||||2017-10-11 07:16:59.973381|2017-10-11 07:16:59.973381
NCT00474409|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-03|2017-06-01|||May 2007||2007-05-01|May 2017|2017-05-01||||||||Interventional|||A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation|A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation|Withdrawn||Phase 4|0|Actual|Eisai Inc.||||Due to poor enrollment, this study was withdrawn/ terminated.|f||||||||||||||2017-10-11 07:17:03.30367|2017-10-11 07:17:03.30367
NCT00481403|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-31|2015-03-09|||May 2006||2006-05-01|March 2015|2015-03-01|December 2016|Anticipated|2016-12-01|December 2016|Anticipated|2016-12-01||Observational|||Study of Sperm Molecular Factors Implicated in Male Fertility|Microarray Analysis in Sperm From Fertile and Infertile Males Without Basic Sperm Analysis Abnormalities|Unknown status|Active, not recruiting|N/A|100|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||1||f||||f||||||Samples Without DNA|"     After sperm washing, sperm pellet was suspended in trizol and immediately frozen by direct     immersion in liquid nitrogen and stored in a nitrogen tank until mRNA extraction.   "|||2017-10-11 07:17:20.653291|2017-10-11 07:17:20.653291
NCT00481585|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-30|2014-02-01|||May 2007||2007-05-01|February 2014|2014-02-01||||July 2009|Actual|2009-07-01||Observational|||The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture|The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture|Terminated||N/A|13|Actual|Hackensack University Medical Center|||1|study team failed to complete timely reviews, study suspended|f||||t||||||||||2017-10-11 07:17:22.088474|2017-10-11 07:17:22.088474
NCT00482274|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-04|2017-04-26|2010-07-27||May 2007||2007-05-01|April 2017|2017-04-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Docetaxel in Treating Patients With Relapsed Prostate Cancer|Phase II Study of the Early Use of Docetaxel in Patients With Biochemical Relapse After Primary Therapy for Prostate Cancer and an Incomplete Response to Androgen Deprivation Therapy.|Terminated||Phase 2|3|Actual|OHSU Knight Cancer Institute|Due to withdrawal of sponsor support, this study was terminated after only 3 subjects were enrolled (of the planned 36 subjects). Sufficient data were not obtained to make statistically significant conclusions.|1||Drug supplier stopped funding due to loss of study drug (docetaxel) patent.|f||||||||||||||2017-10-11 07:17:42.118697|2017-10-11 07:17:42.118697
NCT00483119|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-05|2016-01-21|2015-10-05||April 2007||2007-04-01|January 2016|2016-01-01|February 2011|Actual|2011-02-01|February 2010|Actual|2010-02-01||Interventional||This number is based only on the number of patients who passed screening and then were enrolled. Please note that this study was not evaluable due to the untimely death of the study Principal Investigator as noted previously.|Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus|Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus|Terminated||Phase 2|9|Actual|New York University School of Medicine|Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.|2||Study was terminated due to the death of the PI.|f||||t||||||||||2017-10-11 07:17:53.648284|2017-10-11 07:17:53.648284
NCT00477503|ClinicalTrials.gov processed this data on October 10, 2017|2007-05-21|2012-07-31|||May 2007||2007-05-01|July 2012|2012-07-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA|Phase 1 Study Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA|Terminated||Phase 1|1|Actual|M.D. Anderson Cancer Center||3||One participant enrolled, study terminated .|f||||f||||||||||2017-10-11 07:18:04.300053|2017-10-11 07:18:04.300053
NCT00483405|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-06|2017-06-13|2017-03-28||October 2006||2006-10-01|June 2017|2017-06-01|December 2010|Actual|2010-12-01|February 2010|Actual|2010-02-01||Interventional|NRR|29 patients received any protocol directed therapy, but only 28 patients were included in any efficacy analysis because one patient was found to have a sarcoma and was withdrawn from the study.|Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer|Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma|Completed||Phase 2|33|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||No||2017-10-11 07:18:07.440926|2017-10-11 07:18:07.440926
NCT00490061|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-20|2017-01-13|2016-11-11||July 2007||2007-07-01|January 2017|2017-01-01|June 2016|Actual|2016-06-01|January 2013|Actual|2013-01-01||Interventional|||Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy|A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.|Terminated||Phase 2|17|Actual|Stanford University|Due to low accrual, this study was terminated prior to reaching 60 subjects.|1||Poor accrual.|f||||t||||||||No||2017-10-11 07:18:27.901131|2017-10-11 07:18:27.901131
NCT00491738|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-25|2009-04-09|2009-02-06||August 2007||2007-08-01|April 2009|2009-04-01||||January 2008|Actual|2008-01-01||Interventional|||A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)|A Multicenter, Phase II, Randomized, Blinded, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Sutent With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer|Terminated||Phase 2|16|Actual|Genentech, Inc.|Based on the early safety results from this study, Genentech terminated further recruitment and discontinued treatment. Insufficient efficacy information was available to perform additional outcome analyses.|2||"Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly   tolerated."|f||||||||||||||2017-10-11 07:19:09.720561|2017-10-11 07:19:09.720561
NCT00493038|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-26|2014-11-03|2009-01-20||February 2006||2006-02-01|November 2014|2014-11-01|January 2008|Actual|2008-01-01|January 2008|Actual|2008-01-01||Interventional|||Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis|Prospective, Multicenter, Randomized, Double Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg OD for 7 Days Versus a Standard Antibiotic Therapy for 10 Days in the Treatment of Acute Bacterial Rhino Sinusitis|Terminated||Phase 4|293|Actual|Bayer|The study was prematurely terminated due to slow enrollment beyond the planned study timelines.|2||The study was prematurely terminated due to slow enrollment beyond the planned study timelines.|f||||f||||||||||2017-10-11 07:19:24.558645|2017-10-11 07:19:24.558645
NCT00486980|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-14|2008-01-28||||||January 2008|2008-01-01||||||||Interventional|||Intramuscular Peramivir for the Treatment of Uncomplicated Influenza|A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAMUSCULAR PERAMIVIR IN SUBJECTS WITH UNCOMPLICATED ACUTE INFLUENZA|Withdrawn||Phase 3|||BioCryst Pharmaceuticals||||"This study was withdrawn for administrative reasons. The dose ranging plan for the program was   revised."|||||||||||||||2017-10-11 07:21:02.870908|2017-10-11 07:21:02.870908
NCT00487162|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-13|2016-10-04|2010-12-03||June 2007||2007-06-01|September 2016|2016-09-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional||males and females between the ages of 18 and 89.|The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality|The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality|Terminated||N/A|56|Actual|Rutgers, The State University of New Jersey|Study was terminated. No final conclusion drawn. A sentinel article was published in Feb 2009 issue of Anesthesiology which questioned the safety of intense insulin therapy/strict glycemic control.|2||potential harm of insulin infusion outweights the benefit.|f||||f||||||||No||2017-10-11 07:21:05.078173|2017-10-11 07:21:05.078173
NCT00487279|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-13|2012-03-25|2012-01-04||June 2007||2007-06-01|March 2012|2012-03-01|April 2011|Actual|2011-04-01|December 2010|Actual|2010-12-01||Interventional|DETERMINE||DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation|DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation|Terminated||N/A|81|Actual|St. Jude Medical||2||Study terminated early due to inability to enroll.|f||||t||||||||||2017-10-11 07:21:09.480395|2017-10-11 07:21:09.480395
NCT00487578|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-14|2013-02-04|2009-11-16||October 2006||2006-10-01|February 2013|2013-02-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional|||Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction|Evaluation of the Efficacy of Naratriptan for the Treatment and Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction|Terminated||Phase 4|12|Actual|Cady, Roger, M.D.|"Study terminated October 2009 (in 4th year) due to low enrollment and anticipated drug expiration November 2009 (study drug had previously been re-supplied at expiration of 1st batch November 2007).
NCT00488059|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-18|2011-07-18|2009-11-11||June 2007||2007-06-01|July 2011|2011-07-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|AMICI||A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients|A Multicenter, Open-label Study Evaluating the Antiviral Activity and Safety of Enfuvirtide (ENF) Once Daily (QD) or Twice Daily (BID) in Triple-class Experienced HIV-1 Infected Patients Changing Their Therapy to a Standard of Care (SOC) Regimen That Includes Initiating Raltegravir Plus an Optimized Background (OB) Antiviral Regimen|Terminated||Phase 4|29|Actual|Hoffmann-La Roche||2||This study was terminated early due to poor enrollment.|f||||||||||||||2017-10-11 07:21:30.267007|2017-10-11 07:21:30.267007
NCT00488891|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-18|2012-08-28|||April 2007||2007-04-01|August 2012|2012-08-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Observational|POST||The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia|The Paliperidone ER Outcomes Study of Schizophrenia Patients in Typical Clinical Practice|Terminated||Phase 4|43|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|||2|The study was terminated because it was not enrolling at the expected rate|f||||f||||||Samples With DNA|"     10 mL blood sample is collected from patients who consent to the pharmacogenomic component of     the study.   "|||2017-10-11 07:22:08.49136|2017-10-11 07:22:08.49136
NCT00489216|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-20|2017-04-12|2017-02-21||December 2006||2006-12-01|April 2017|2017-04-01|October 2008|Actual|2008-10-01|June 2008|Actual|2008-06-01||Interventional|NRR|Patients with evidence of an inflammatory, erythematous rash and skin biopsy consistent with cutaneous Graft-Versus-Host disease who had failed to improve after at least 4 weeks of methylprednisolone at 0.5mg/kg were eligible for enrollment. Two patients were enrolled in the study.|Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids|Weekly Subcutaneous Efalizumab for the Treatment of Steroid Refractory Graft-Versus-Host Disease of the Skin and Liver|Terminated||N/A|2|Actual|UNC Lineberger Comprehensive Cancer Center|The study was terminated early due to funding withdrawal/insufficient accrual limiting the data to be analyzed.|1||insufficient accrual/funding withdrawn|f||||t||||||||||2017-10-11 07:22:11.317604|2017-10-11 07:22:11.317604
NCT00496002|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-02|2009-04-23|||August 2007||2007-08-01|April 2009|2009-04-01||||||||Interventional|QUASH 1||Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus|A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus|Terminated||Phase 3|||Pharmasset||2||The study was terminated in the interest of patient safety.|f||||||||||||||2017-10-11 07:22:26.097906|2017-10-11 07:22:26.097906
NCT00496080|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-03|2012-09-06|2012-06-19||June 2007||2007-06-01|September 2012|2012-09-01|October 2010|Actual|2010-10-01|September 2010|Actual|2010-09-01||Interventional|DUAO||Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding|A Pivotal Study of Doppler Guided Uterine Artery Occlusion as Treatment for the Reduction of Fibroid Associated Bleeding|Terminated||N/A|87|Actual|Ethicon, Inc.|Study was terminated early because 6 mo interim analysis of parallel European study showed that device was not meeting the primary endpoint. Target enrollment was 200 subjects, but results are based on 87 subjects who were treated with the device.|1||Trial terminated early due to results from a similar study.|f||||t||||||||||2017-10-11 07:22:27.613978|2017-10-11 07:22:27.613978
NCT00496158|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-02|2009-04-23|||August 2007||2007-08-01|April 2009|2009-04-01||||||||Interventional|QUASH2||Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus|A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus|Terminated||Phase 3|||Pharmasset||||The study was terminated in the interest of patient safety.|f||||||||||||||2017-10-11 07:22:28.409138|2017-10-11 07:22:28.409138
NCT00496782|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-03|2010-11-10|2009-06-23||July 2007||2007-07-01|March 2010|2010-03-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|||Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay|Surrogate Marker For Tropism-A Multi-Center, Open Label, Pilot Study|Terminated||Phase 1|16|Actual|ViiV Healthcare|Study terminated prematurely due to slow enrollment. Premature termination of study was not due to any safety concerns. Efficacy data not summarized due to low sample size; only safety was summarized.|1||See Detailed Description|f||||f||||||||||2017-10-11 07:22:46.916541|2017-10-11 07:22:46.916541
NCT00497679|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-05|2009-05-13|||August 2006||2006-08-01|May 2009|2009-05-01|July 2007|Actual|2007-07-01|||||Interventional|||AZD1152 in Patients With Advanced Solid Malignancies-Study 3|A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies|Terminated||Phase 1|45|Anticipated|AstraZeneca||1||"Study is now terminated due to technical difficulties with administration of study drug in this   patient population with this schedule"|f||||f||||||||||2017-10-11 07:23:00.395833|2017-10-11 07:23:00.395833
NCT00485654|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-12|2012-03-14|||January 1990||1990-01-01|February 2008|2008-02-01|February 2008|Actual|2008-02-01|January 2005|Actual|2005-01-01||Observational|||Racial Distribution of Heterotaxy Syndrome|Racial Distribution of Heterotaxy Syndrome and Effects on Clinical Outcomes Protocol|Terminated||N/A|65|Actual|Children's Healthcare of Atlanta|||1|study was terminated because study conclusions varied.|f||||f||||||||||2017-10-11 07:23:15.700554|2017-10-11 07:23:15.700554
NCT00485966|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-11|2008-11-03|||June 2007||2007-06-01|November 2008|2008-11-01|June 2008|Anticipated|2008-06-01|||||Interventional|||Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|A Phase 2, Multi-Center, Open Label Study Evaluating Clinical Efficacy, Safety, and Pharmacodynamic Effects of Quarfloxacin (CX-3543) in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Withdrawn||Phase 2|25|Anticipated|Cylene Pharmaceuticals||1||This study was withdrawn prior to patient enrollment|f||||f||||||||||2017-10-11 07:23:21.767826|2017-10-11 07:23:21.767826
NCT00486265|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-13|2010-12-07|2010-07-20||July 2007||2007-07-01|July 2010|2010-07-01|July 2009|Actual|2009-07-01|||||Interventional|||Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)|A Phase I/II, Open-Label, Multi-Center, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD4877 Administered on Days 1, 2 and 3 in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML) Excluding Promyelocytic Leukemia|Terminated||Phase 1|47|Actual|AstraZeneca|On 16 June 2009, the study was terminated for a lack of efficacy. None of the 8 patients had experienced CR or CRi. The secondary efficacy outcome measures were not evaluated due to early termination and small number of participants.|1||"AML assess. of response in Part B patients find treatment failure in all 8 evaluable for marrow   response following a maximum of 2 induction courses of therapy"|f||||||||||||||2017-10-11 07:23:25.884965|2017-10-11 07:23:25.884965
NCT00486720|ClinicalTrials.gov processed this data on October 10, 2017|2007-06-14|2015-06-08|2010-04-19||June 2007||2007-06-01|June 2015|2015-06-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)|A Randomized Phase IIa Study of Vorinostat in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome|Terminated||Phase 2|22|Actual|Merck Sharp & Dohme Corp.|This trial was terminated because the pre-specified futility criterion was met.|2|||f||||||||||||||2017-10-11 07:23:35.892899|2017-10-11 07:23:35.892899
NCT00499369|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-10|2014-07-25|2013-10-22||June 2007||2007-06-01|March 2014|2014-03-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Interventional||All eligible patients are included in this analysis.|Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy|Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients With Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab With Either FOLFOX, OPTIMOX or XELOX|Terminated||Phase 3|72|Actual|National Cancer Institute (NCI)|Due to inadequate accrual, study was terminated and limited outcome data was reported.|3||Due to inadequate accrual, study was terminated and limited outcome data was reported.|f||||||||||||||2017-10-11 07:24:19.099567|2017-10-11 07:24:19.099567
NCT00499382|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-10|2012-07-31|||September 2004||2004-09-01|July 2012|2012-07-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Observational|||Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging|Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging|Terminated||N/A|5|Actual|M.D. Anderson Cancer Center|||1|Slow accrual; study terminated.|f||||f||||||||||2017-10-11 07:24:22.699295|2017-10-11 07:24:22.699295
NCT00499590|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-10|2014-09-29|2014-09-25||August 2007||2007-08-01|September 2014|2014-09-01|May 2009|Actual|2009-05-01|March 2009|Actual|2009-03-01||Interventional|COBALT||Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD|A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).|Terminated||Phase 3|338|Actual|OPKO Health, Inc.|Study was terminated early.|3|||f||||t||||||||||2017-10-11 07:24:25.882042|2017-10-11 07:24:25.882042
NCT00500240|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-10|2015-06-02|2013-06-05||April 2004||2004-04-01|June 2015|2015-06-01|April 2012|Actual|2012-04-01|April 2012|Actual|2012-04-01||Interventional|||Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)|Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia|Terminated||Phase 3|52|Actual|M.D. Anderson Cancer Center|Study terminated early due to futility at the pre-determined interim analysis point.|2||Terminated early due to futility.|f||||f||||||||||2017-10-11 07:24:39.494268|2017-10-11 07:24:39.494268
NCT00501345|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-13|2012-07-27|2009-09-24||February 2002||2002-02-01|July 2012|2012-07-01|February 2008|Actual|2008-02-01|February 2008|Actual|2008-02-01||Interventional|||Aspirin in Patients With Myocardial Infarction and Thrombocytopenia|Effects of Aspirin on Platelet Function and Clinical Outcome in Patients With Thrombocytopenia, Neoplasm, and Myocardial Infarction|Terminated||Phase 3|5|Actual|M.D. Anderson Cancer Center|A change in hospital practice where patients with thrombocytopenia now routinely receive aspirin for acute coronary syndromes makes it difficult to obtain a baseline thromboelastogram.|1||Low accrual, study terminated.|f||||f||||||||||2017-10-11 07:25:07.197726|2017-10-11 07:25:07.197726
NCT00501371|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-10|2011-12-13|||July 2007||2007-07-01|December 2011|2011-12-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional|||MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia|Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia|Terminated||Phase 3|85|Actual|Health Ever Bio-Tech Co., Ltd.||2||"Study terminated for re-design. A new IND study (US FDA, July 2009) will be conducted in US and   Taiwan. Termination not related to safety concerns."|f||||f||||||||||2017-10-11 07:25:07.907425|2017-10-11 07:25:07.907425
NCT00505258|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-19|2013-02-19||||||February 2013|2013-02-01|April 2009|Anticipated|2009-04-01|||||Interventional|||Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia|Randomized, Open-Label Study Evaluating the Safety and Rate of Bacterial Clearance of Ceftobiprole 500 Milligram Every 8 Hours Compared to Conventional Therapy in the Treatment of Hospitalized Subjects With Staphylococcus Aureus Bacteremia|Withdrawn||Phase 2|0|Actual|Basilea Pharmaceutica||||The study was withdrawn due to lack of an appropriate patient population.|||||f||||||||||2017-10-11 07:25:34.718489|2017-10-11 07:25:34.718489
NCT00506064|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-23|2012-12-03|2010-03-29||February 2004||2004-02-01|December 2012|2012-12-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||Melatonin Postoperative Sleep Study in Breast Cancer Patients|Melatonin Postoperative Sleep Study in Breast Cancer Patients|Terminated||Phase 1|4|Actual|M.D. Anderson Cancer Center|Study terminated early due to low recruitment, no analysis done.|2||Terminated due to low accrual.|f||||f||||||||||2017-10-11 07:25:50.897583|2017-10-11 07:25:50.897583
NCT00506363|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-23|2009-10-04|||January 2008||2008-01-01|October 2009|2009-10-01|January 2009|Actual|2009-01-01|December 2008|Actual|2008-12-01||Interventional|||Safety and Efficacy of Different Onset Times of Treatment With Pulsed Dye Laser on Improvement of Surgical Scars|The Effect of Different Onset Times of Treatment With 595-nm Pulsed Dye Laser on Improvement of Surgical Scars: A Double Blind Randomised Clinical Trial|Terminated||N/A|15|Anticipated|Tehran University of Medical Sciences||3||"The trial was terminated on May 2008 after inclusion of 10 patients due to low recruitment and   patient compliance."|f||||f||||||||||2017-10-11 07:26:01.490918|2017-10-11 07:26:01.490918
NCT00506662|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-24|2016-05-11|2010-10-19||July 2007||2007-07-01|May 2016|2016-05-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|3L||Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes|The Effect of Insulin Detemir on Glucose Control in Ageing Subjects With Type 2 Diabetes.|Terminated||Phase 4|86|Actual|Novo Nordisk A/S|Trial terminated prematurely due to low recruitment, and thus it was not possible to assess efficacy in this trial due to the small number of patients in each treatment group.|2||See termination reason in detailed description|f||||f||||||||||2017-10-11 07:26:10.441914|2017-10-11 07:26:10.441914
NCT00507429|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-25|2014-05-12|2013-08-16||August 2007||2007-08-01|February 2014|2014-02-01|November 2011|Actual|2011-11-01|October 2011|Actual|2011-10-01||Interventional|FACT||Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer|A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT]|Terminated||Phase 2/Phase 3|80|Actual|Mateon Therapeutics|The study was to enroll 180 subjects. Enrollment was terminated early due to low accrual rate. Eighty subjects were enrolled.|2||Low rate of subject accrual|f||||t||||||||||2017-10-11 07:26:28.168465|2017-10-11 07:26:28.168465
NCT00508027|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-26|2013-08-20|2013-02-11||June 2007||2007-06-01|August 2013|2013-08-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional||42 subjects started the study; of these,12 were withdrawn from the study and 30 completed the study: dose level 1 (n=16); dose level 2 (n=12), dose level 3 (n=2). Only those participants who completed the study were included in the final analyses (n=30).|Simvastatin (Zocor) Therapy in Sickle Cell Disease|Phase I/II Study of Simvastatin (Zocor) Therapy in Sickle Cell Disease|Completed||Phase 1/Phase 2|42|Actual|Children's Hospital & Research Center Oakland||1|||f||||t||||||||||2017-10-11 07:26:40.680713|2017-10-11 07:26:40.680713
NCT00508118|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-25|2014-07-29|2011-09-21||January 2008||2008-01-01|January 2013|2013-01-01|April 2008|Actual|2008-04-01|April 2008|Actual|2008-04-01||Interventional|NICNACS||NICardipine Neuroprotection in AortiC Surgery (NICNACS)|NICardipine Neuroprotection in AortiC Surgery (NICNACS)|Terminated||Phase 2|7|Actual|Duke University|This study was terminated early because of safety concerns in the active treatment group. In 3 patients randomized, the blind was broken in 3 because of refractory hypotension and acidosis requiring vasopressor therapy. All 3 were on active drug.|2||3/7 subjects experienced hypotension. Study was terminated.|f||||f||||||||||2017-10-11 07:26:41.806882|2017-10-11 07:26:41.806882
NCT00508872|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-27|2012-07-27|2010-10-08||November 2005||2005-11-01|July 2012|2012-07-01|June 2009|Actual|2009-06-01|June 2009|Actual|2009-06-01||Interventional|||Folfox-B Study for Patients With Colorectal Liver Metastases|Single-Institution Phase II Trial of Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab (Folfox-B) for Initially Unresectable Colorectal Liver Metastases: Downstaging Followed By Hepatic Resection|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center||1||Slow accrual, study terminated.|f||||f||||||||||2017-10-11 07:27:01.753947|2017-10-11 07:27:01.753947
NCT00509366|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-30|2014-08-15|2014-05-07||May 2007||2007-05-01|August 2014|2014-08-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|TOP0602|The number of participants in each group reflects the number of participants at the end of the study period (COMPLETED) in the Participant Flow Analysis, with the exception of 3 patients who were assigned treatment, but not treated, and were added to the number of screen failures.|Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer|Phase II Prospective Study Evaluating the Role of Personalized Chemotherapy Regimens for Chemo-Naive Select Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy|Terminated||Phase 2|101|Actual|Duke University|The microarray-based prediction model of chemotherapy sensitivity, used to allocate patients into the cisplatin treatment arms, was irreproducible and inaccurate. Quality of life measurements were incomplete and could not be analyzed.|4||Study terminated due to reproducibility issues with genomics prediction model.|f||||t||||||||||2017-10-11 07:27:12.971977|2017-10-11 07:27:12.971977
NCT00509600|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-27|2012-08-01|2009-08-31||September 2004||2004-09-01|August 2012|2012-08-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia|Phase IIA Window Study of Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center|Early termination due to low accrual. Rare disease with less than 100 cases diagnosed per year.|1||Slow enrollment; study terminated.|f||||t||||||||||2017-10-11 07:27:19.654548|2017-10-11 07:27:19.654548
NCT00502840|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-17|2017-07-11|2014-06-04||July 23, 2007|Actual|2007-07-23|July 2017|2017-07-01|September 20, 2011|Actual|2011-09-20|September 20, 2011|Actual|2011-09-20||Interventional||Safety Population: all participants who received at least 1 dose of the trial medication and had at least 1 safety follow-up, whether withdrawn prematurely or not. A safety follow-up was assumed if the participant had at least 1 documented study visit after baseline or if at least 1 adverse event had been documented with start date after baseline.|A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.|An Open Label Study to Evaluate the Safety of Re-treatment With MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent (Extension Study to ML19070).|Completed||Phase 3|193|Actual|Hoffmann-La Roche||1|||f||||||||||||||2017-10-11 07:28:01.164412|2017-10-11 07:28:01.164412
NCT00502996|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-17|2016-08-22|2016-06-29||February 2006||2006-02-01|August 2016|2016-08-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional||The safety population included all eligible participants who received one treatment dose of rituximab and have completed the follow up period (Week 48) regardless of whether withdrawn or not from the study.|A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.|Multicenter Non-Comparative Expanded Access Program of to Assess Safety of Rituximab (Mab Anti Cd-20) in Patients With Rheumatoid Arthritis (Ser)|Completed||Phase 3|246|Actual|Hoffmann-La Roche||1|||f||||||||||||||2017-10-11 07:28:06.350045|2017-10-11 07:28:06.350045
NCT00503698|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-18|2017-01-23|2009-12-15||July 2007||2007-07-01|January 2017|2017-01-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|OPPORTUNITY||The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis|Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis|Terminated||Phase 3|712|Actual|Novo Nordisk A/S|Trial terminated early due to slow recruitment, which largely reduced the power of showing differences. The end of trial visit was used to describe week 104.|2||See termination reason in detailed description|f||||t||||||||||2017-10-11 07:28:20.077403|2017-10-11 07:28:20.077403
NCT00509925|ClinicalTrials.gov processed this data on October 10, 2017|2007-07-31|2017-01-30|2010-04-19||July 2007||2007-07-01|January 2017|2017-01-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Interventional|||Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes|A 32-week National, Single-centre, Open-labelled, Randomised, Crossover Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes|Terminated||Phase 4|23|Actual|Novo Nordisk A/S|This open-label study was terminated prematurely due to 2 unplanned interim analyses having been performed. At this point, only 23 out of the planned 30 patients had been randomised into the study.|2||See detailed description|f||||f||||||||||2017-10-11 07:28:35.932093|2017-10-11 07:28:35.932093
NCT00510497|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-01|2016-05-12|2016-01-12||July 2007||2007-07-01|May 2016|2016-05-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Interventional||11 particpants were enrolled but one received no study vaccines and was withdrawn and not included in any analyses.|Autologous Dendritic Cell Vaccine in HIV1 Infection|Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells|Completed||Phase 1/Phase 2|11|Actual|University of Pittsburgh||1|||f||||t||||||||||2017-10-11 07:28:48.96768|2017-10-11 07:28:48.96768
NCT00511134|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-01|2012-03-09|2009-09-28||April 2007||2007-04-01|March 2012|2012-03-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban|A Placebo-Controlled, Randomized Trial of Eszopiclone for the Treatment of Bupropion- and Abstinence-Related Insomnia During Smoking Cessation|Terminated||Phase 4|4|Actual|Yale University||2||Study has been terminated due low recruitment of participant population.|f||||f||||||||||2017-10-11 07:29:01.610637|2017-10-11 07:29:01.610637
NCT00511160|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-02|2016-10-04|||August 2007||2007-08-01|October 2016|2016-10-01|August 2010|Actual|2010-08-01|August 2010|Actual|2010-08-01||Interventional|||Cardiotropic Viruses in Cardiac Surgery Patients Without Clinical Evidence of Myocarditis or Myocarditic Sequelae|Prevalence of Cardiotropic Viruses in Cardiac Surgery Patients Without Clinical Evidence of Myocarditis or Myocarditic Sequelae|Terminated||N/A|120|Actual|Robert Bosch Gesellschaft für Medizinische Forschung mbH||2||Study suspended due to logistical/personnel difficulties|f||||t||||||||No||2017-10-11 07:29:02.34115|2017-10-11 07:29:02.34115
NCT00511576|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-03|2015-01-06|||August 2007||2007-08-01|January 2015|2015-01-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional|||Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors|A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MGCD0103 (MG-0103) in Combination With Docetaxel (Taxotere®) in Subjects With Advanced Solid Malignancies|Terminated||Phase 1|54|Anticipated|Mirati Therapeutics Inc.||2||"Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103.   All Celgene-sponsored trials with MGCD0103 will be closed."|f||||f||||||||||2017-10-11 07:29:15.216299|2017-10-11 07:29:15.216299
NCT00511901|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-03|2013-12-27|2013-08-27||November 2005||2005-11-01|November 2011|2011-11-01|May 2008|Actual|2008-05-01|May 2008|Actual|2008-05-01||Interventional||Intention to treat|Prevalence and Treatment of Anemia in Rehabilitation Patients|Prevalence and Treatment of Anemia in Patients Admitted to Subacute Rehabilitation Hospital|Terminated||Phase 4|22|Actual|Rutgers, The State University of New Jersey|Limited number of eligible subjects, burdensome protocol requirements impeded recruitment, controversy concerning safety of epoetin alpha which led to early termination of study|2||"Study enrollment was suspended in response to an FDA alert regarding the study drug. The study   was subsequently terminated"|f||||t||||||||||2017-10-11 07:29:21.612689|2017-10-11 07:29:21.612689
NCT00512798|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-06|2012-09-19|2012-06-27||June 2003||2003-06-01|September 2012|2012-09-01|March 2008|Actual|2008-03-01|July 2006|Actual|2006-07-01||Interventional|||Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma|(Inhibition of NF-kB Signaling in Melanoma Therapy) A Phase I/II Clinical Trial of PS-341, a Proteasome Inhibitor, in Combination With an Extended Continuous Oral Schedule of Temozolomide in Patients With Advanced Refractory Solid Tumors With the Phase II Component Only in Patients With Melanoma|Terminated||Phase 1/Phase 2|47|Actual|Vanderbilt-Ingram Cancer Center||2||This study was terminated due to lack of efficacy|f||||t||||||||||2017-10-11 07:29:39.659006|2017-10-11 07:29:39.659006
NCT00514813|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-09|2014-06-06|2009-08-18||June 2007||2007-06-01|November 2009|2009-11-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Interventional|||Dynepo Long-Term Safety Study|An Open-Label, Phase IV, Multi-Centre Study to Investigate the Long-Term Safety and Efficacy of Subcutaneous Dynepo in Adult Patients With Anaemia Associated With Chronic Kidney Disease|Terminated||Phase 4|152|Actual|Shire|This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses.|1||"The termination of the study is not linked to a product recall or result of any safety signal.   Rather it was sponsor's commercial decision to withdraw the MA"|f||||f||||||||||2017-10-11 07:29:58.558999|2017-10-11 07:29:58.558999
NCT00515112|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-09|2014-05-12|2014-05-12||July 2007||2007-07-01|May 2014|2014-05-01|August 2012|Actual|2012-08-01|November 2010|Actual|2010-11-01||Interventional|||Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer|A Randomized, Double Blind, Placebo-Controlled Phase II Study of Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer|Terminated||Phase 2|6|Actual|University of Chicago||2||This study has been terminated due to poor accrual|f||||t||||||||||2017-10-11 07:30:13.344015|2017-10-11 07:30:13.344015
NCT00515788|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-13|2012-03-08|||February 2006||2006-02-01|March 2012|2012-03-01|June 2009|Actual|2009-06-01|June 2009|Actual|2009-06-01||Interventional|||DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis|Phase I Study of Temozolomide and Intrathecal DepoCyt in Patients With Neoplastic Meningitis|Terminated||Phase 1|11|Actual|M.D. Anderson Cancer Center||1||Study terminated due to slow accrual with no expansion to additional phase.|f||||f||||||||||2017-10-11 07:30:31.301327|2017-10-11 07:30:31.301327
NCT00516542|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-14|2012-07-23|||June 2007||2007-06-01|July 2012|2012-07-01|December 2010|Actual|2010-12-01|July 2009|Actual|2009-07-01||Interventional|||Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer|A Phase I Study of DHEA in Combination With Letrozole in ER- Breast Cancer|Terminated||Phase 1|6|Actual|OHSU Knight Cancer Institute||1||Study was terminated due to lack of accrual|f||||t||||||||||2017-10-11 07:30:50.444472|2017-10-11 07:30:50.444472
NCT00518284|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-16|2012-02-21|2012-02-21||January 2008||2008-01-01|February 2012|2012-02-01|September 2009|Actual|2009-09-01|August 2009|Actual|2009-08-01||Interventional|||Prevention of Restenosis Following Revascularization|A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA)|Terminated||Phase 2|6|Actual|Celgene||4||"Study was terminated due to changing sponsor priorities, and was not based on safety or   outcomes data."|f||||f||||||||||2017-10-11 07:31:04.117514|2017-10-11 07:31:04.117514
NCT00519090|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-17|2011-11-04|2010-11-11||October 2007||2007-10-01|November 2011|2011-11-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|ENEST||Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|A Phase III Randomized, Open- Label Multi-center Study of Nilotinib Versus Imatinib in Adult Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Cytogenetic Response (CyR) on Imatinib|Terminated||Phase 3|6|Actual|Novartis||2||This study was terminated due to limited enrollment.|f||||t||||||||||2017-10-11 07:31:28.617538|2017-10-11 07:31:28.617538
NCT00519831|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-21|2017-05-10|2017-03-24||August 2007||2007-08-01|May 2017|2017-05-01|November 2009|Actual|2009-11-01|February 2008|Actual|2008-02-01||Interventional|||Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC|Phase II Study of Vinflunine and Cetuximab in the Second Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer|Terminated||Phase 2|18|Actual|UNC Lineberger Comprehensive Cancer Center|Study was terminated early due to unavailable drug/funding. Preliminary analysis reported.|1||Drug unavailable|f||||t||||||||||2017-10-11 07:31:43.544971|2017-10-11 07:31:43.544971
NCT00522080|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-27|2007-08-27|||March 2005||2005-03-01|August 2007|2007-08-01|December 2005|Actual|2005-12-01|||||Observational|||Screening for Hip and Knee Osteoarthritis in the General Population: Predictive Value of a Questionnaire and Prevalence Estimates|Screening for Hip and Knee Osteoarthritis in the General Population: Predictive Value of a Questionnaire and Prevalence Estimates|Terminated||N/A|||Centre Hospitalier Universitaire de Nice||||terminated study|f||||t||||||||||2017-10-11 07:32:53.963384|2017-10-11 07:32:53.963384
NCT00522171|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-27|2009-11-30|2009-10-19||September 2007||2007-09-01|November 2009|2009-11-01|April 2009|Actual|2009-04-01|February 2009|Actual|2009-02-01||Observational|LBL||Harmonic Versus Electro Surgery in Lower Body Lift Procedures|A Randomized, Prospective, Parallel Group Study Comparing the Harmonic™ to Electro Surgery in Lower Body Lift Procedures|Terminated||Phase 4|30|Actual|Ethicon Endo-Surgery|||1|This study was terminated early due to lack of adequate enrollment.|f||||f||||||||||2017-10-11 07:32:54.57848|2017-10-11 07:32:54.57848
NCT00522418|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-27|2015-01-09|2010-04-02||February 2006||2006-02-01|October 2012|2012-10-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Interventional||All participants who completed the baseline assessment and at least one postbaseline follow-up QOLIE-89 assessment, and met local IRB consent requirements|Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients|An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy|Terminated||Phase 4|122|Actual|Cyberonics, Inc.|This study was terminated as a result of a decision by Cyberonics, Inc. The decision to terminate the study was primarily due to insufficient enrollment. The decision was not the result of a safety or efficacy signal.|2||Insufficient enrollment|f||||t||||||||||2017-10-11 07:33:00.673016|2017-10-11 07:33:00.673016
NCT00522457|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-28|2011-04-28|2011-03-01||January 2008||2008-01-01|April 2011|2011-04-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Interventional|||Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy|Phase II Study Of The Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/Neu Overexpressing (3+ Or 2+/FISH+) Metastatic Breast Cancer Progressing After Trastuzumab Treatment|Terminated||Phase 2|19|Actual|Neovii Biotech|The study was prematurely terminated. This decision was based on strategic changes in the company's research and development program and resulted in limited patient data.|1||change in development plan, not due to safety concerns.|f||||t||||||||||2017-10-11 07:33:01.955911|2017-10-11 07:33:01.955911
NCT00523367|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-30|2013-01-15|2012-03-08||August 2007||2007-08-01|January 2013|2013-01-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|GERD/COPD||COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI|COPD Patients Diagnosed With Gastro Esophageal Reflux Disease Have Decreased Rates of COPD Exacerbations After Treatment With High Dose Proton Pump Inhibitor Therapy (Esomeprazole or Lansoprazole)|Terminated||N/A|25|Actual|University of Florida||1||terminated due to enrollment|f||||t||||||||||2017-10-11 07:33:21.020827|2017-10-11 07:33:21.020827
NCT00517361|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-14|2014-03-10|2014-01-22||August 2007||2007-08-01|March 2014|2014-03-01|April 2012|Actual|2012-04-01|April 2011|Actual|2011-04-01||Interventional|||Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer|A Phase II Study of Carboplatin and Bevacizumab (Avastin) Combination Therapy for ER Negative, PR Negative, and HER2/Neu Negative Metastatic Breast Cancer|Terminated||Phase 2|11|Actual|University of Chicago||1||This study has been terminated due to poor accrual|f||||t||||||||||2017-10-11 07:33:27.831503|2017-10-11 07:33:27.831503
NCT00517699|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-16|2014-07-15|2014-06-09||September 2007||2007-09-01|July 2014|2014-07-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional||Safety population: all participants who received any amount of study drug.|A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.|An Open Label Study of the Effect of Rituxan, High Dose Methotrexate and High Dose Cytarabine on Response Rate in Patients With Primary Central Nervous System Lymphoma.|Terminated||Phase 2|5|Actual|Hoffmann-La Roche|The study was terminated early due to lack of enrollment.|1||Study was terminated early due to lack of enrollment.|f||||||||||||||2017-10-11 07:33:35.608213|2017-10-11 07:33:35.608213
NCT00517881|ClinicalTrials.gov processed this data on October 10, 2017|2007-08-16|2016-04-21|2016-04-21||June 2007||2007-06-01|April 2016|2016-04-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional||The safety population included all participants who were treated with at least 1 dose of the study drug and a safety follow-up, whether withdrawn prematurely or not.|Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia|A Single Arm Open Label Study to Assess the Efficacy, Safety and Tolerability of Once Monthly Administration of Subcutaneous C.E.R.A. for the Maintenance of Haemoglobin Levels in Pre-dialysis Patients With Chronic Renal Anaemia|Terminated||Phase 3|29|Actual|Hoffmann-La Roche|The study was terminated early due to the slow recruitment rate.|1||The study was terminated due to the slow recruitment rate.|f||||f||||||||||2017-10-11 07:33:39.45645|2017-10-11 07:33:39.45645
NCT00527943|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-07|2017-03-31|2014-05-09||December 1, 2007|Actual|2007-12-01|March 2017|2017-03-01|July 1, 2011|Actual|2011-07-01|July 1, 2011|Actual|2011-07-01||Interventional|||Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)|Terminated||Phase 3|12944|Actual|Merck Sharp & Dohme Corp.|Prior to the planned study completion, the Data Safety Monitoring Board recommended that all participants stop treatment and that the study be closed-out. The protocol-defined target number of primary efficacy endpoints had been reached by this time.|2||The trial was terminated at the request of the Data and Safety Monitoring Board.|f||||t||||||||||2017-10-11 07:35:08.447407|2017-10-11 07:35:08.447407
NCT00529464|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-12|2016-04-05|2009-09-01||November 2006||2006-11-01|December 2012|2012-12-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|||Spectroscopy Versus Standard Care in Cervical Cancer Patients|A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia|Terminated||Phase 3|2|Actual|M.D. Anderson Cancer Center|This study was terminated due to difficulty enrolling subjects.|3||Two participants enrolled, both inevaluable.|f||||t||||||||||2017-10-11 07:35:38.746821|2017-10-11 07:35:38.746821
NCT00529633|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-12|2017-05-30|2016-03-25||September 2007||2007-09-01|May 2017|2017-05-01|December 2009|Actual|2009-12-01|December 2008|Actual|2008-12-01||Interventional|ICM||The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients|Phase 3 Study: The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients|Terminated||Phase 3|16|Actual|University of California, Davis|Early termination -- Study is terminated due to low enrollment of subjects willing to enter this study|2||Low enrollment -- We could not recruit patients willing to be enrolled|f||||t||||||||No||2017-10-11 07:35:48.293758|2017-10-11 07:35:48.293758
NCT00530270|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-14|2013-03-29|2009-07-16||December 2006||2006-12-01|March 2013|2013-03-01|November 2008|Actual|2008-11-01|June 2008|Actual|2008-06-01||Interventional|||Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease|Randomized Trial of Oral Dexamethasone for Acute Chest Syndrome|Terminated||Phase 3|12|Actual|Children's Hospital Medical Center, Cincinnati|Primary limitation of this study is that is was terminated prior to enrolling all of the subjects necessary to address the primary question.|2||Study was closed June 23, 2008 due to low enrollment.|f||||t||||||||||2017-10-11 07:35:59.059071|2017-10-11 07:35:59.059071
NCT00530361|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-13|2016-09-19||||||July 2011|2011-07-01|September 2009|Anticipated|2009-09-01|||||Interventional|||An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)|A Double-Blind, Randomized, Placebo-Controlled Study of Nesiritide Administered After Induction of Anesthesia in Heart Failure Patients With Renal Insufficiency Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (NAPA-CS)|Withdrawn||Phase 3|0|Actual|Scios, Inc.||||Study was withdrawn prior to patient dosing based on a business decision.|||||f||||||||||2017-10-11 07:36:01.899296|2017-10-11 07:36:01.899296
NCT00531076|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-17|2011-04-04|||October 2007||2007-10-01|January 2011|2011-01-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|||Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer|Phase I Study of Concurrent Bevacizumab (Avastin) With Involved-field Thoracic Radiotherapy for Inoperable Non-squamous Non-small Cell Lung Cancer, Followed by Both Concurrent and Maintenance Bevacizumab|Terminated||Phase 1|6|Actual|VU University Medical Center||1||Study terminated due to toxicity|f||||f||||||||||2017-10-11 07:36:21.337578|2017-10-11 07:36:21.337578
NCT00532285|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-19|2011-06-22|||September 2005||2005-09-01|September 2007|2007-09-01|August 2009|Actual|2009-08-01|April 2006|Actual|2006-04-01||Interventional|||Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer|Phase II Study of Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer|Terminated||Phase 2|44|Actual|National Cancer Center, Korea||1||terminated|f||||f||||||||||2017-10-11 07:37:26.686814|2017-10-11 07:37:26.686814
NCT00532883|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-20|2013-01-14|2010-04-01||January 2007||2007-01-01|January 2010|2010-01-01|August 2009|Actual|2009-08-01|March 2009|Actual|2009-03-01||Interventional|||Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease|Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial|Terminated||Phase 2|44|Actual|St. Jude Children's Research Hospital|This study was stopped early due to slow enrollment. It should therefore be viewed as a pilot study.|4||Enrollment has been terminated due to a slow rate of enrollment.|f||||t||||||||||2017-10-11 07:37:37.937685|2017-10-11 07:37:37.937685
NCT00533351|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-19|2016-01-27|2011-12-15||March 2008||2008-03-01|January 2016|2016-01-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional|||Safety and Efficacy of AGN201781 in Neuropathic Pain||Terminated||Phase 2|9|Actual|Allergan|This study was terminated early due to low enrollment (only 9 of the required 40 subjects had been enrolled). Due to the low number of patients who completed the treatment period of the study, no analyses were performed.|2||This study was terminated early due to low enrollment.|f||||f||||||||||2017-10-11 07:37:44.985175|2017-10-11 07:37:44.985175
NCT00533546|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-19|2016-09-01|2015-10-16||September 2007||2007-09-01|September 2016|2016-09-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|APCAST||Activated Protein C in Acute Stroke Trial|Activated Protein C in Acute Stroke Trial|Terminated||Phase 2|12|Actual|University of Rochester|Study was terminated after completion of Tier One dosing level (n=12 subjects) due to lack of recruitment.|1||Lack of recruitment|f||||t||||||||||2017-10-11 07:37:47.479983|2017-10-11 07:37:47.479983
NCT00533572|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-20|2015-05-22|||August 2007||2007-08-01|May 2015|2015-05-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Observational|||Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer|Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer|Terminated||N/A|1|Actual|Stanford University|||1|"Study was suspended until FDA approved the IND. Study has since been terminated and a new   screening process has been implemented."|f||||||||||||||2017-10-11 07:37:47.872335|2017-10-11 07:37:47.872335
NCT00534339|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-21|2014-10-03|||December 2010||2010-12-01|November 2010|2010-11-01|February 2016|Anticipated|2016-02-01|April 2012|Anticipated|2012-04-01||Interventional|||EasyBand GOAL Trial||Withdrawn||N/A|0|Actual|Allergan||1||"This study was withdrawn to further optimize the device. No patients were enrolled in the   trial."|f||||||||||||||2017-10-11 07:38:11.049416|2017-10-11 07:38:11.049416
NCT00534456|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-20|2011-04-07|||January 2007||2007-01-01|April 2011|2011-04-01|October 2007|Actual|2007-10-01|October 2007|Actual|2007-10-01||Interventional|||An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial|Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Darbepoetin Alfa Treatment on Cardiac Function and Disease Specific Biomarkers in Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia: An Exploratory Sub-study for the RED-HF™ Trial|Terminated||Phase 3|12|Actual|Amgen||2||Study terminated|f||||||||||||||2017-10-11 07:38:15.223699|2017-10-11 07:38:15.223699
NCT00528827|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-10|2012-03-15|||September 2007||2007-09-01|March 2012|2012-03-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension|A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension|Withdrawn||Phase 2|0|Actual|Facet Biotech||4||"Due to the sale of Cardene IV, the sponsor has stopped enrollment and withdrawn the study. No   safety issues were identified."|f||||t||||||||||2017-10-11 07:38:34.729379|2017-10-11 07:38:34.729379
NCT00536497|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-25|2015-02-12|||September 2007||2007-09-01|February 2015|2015-02-01||||||||Interventional|||Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.|A 2 Part Open-label, Randomised, Crossover Study to Compare the Effects of Formulation, Food and Particle Size on the Pharmacokinetic Profiles of a Single 175mg Dose of GW842166X in Healthy Male and Female Volunteers|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||||Compound terminated|||||f||||||||||2017-10-11 07:38:57.464808|2017-10-11 07:38:57.464808
NCT00536809|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-27|2012-03-15|2010-01-19||September 2007||2007-09-01|February 2011|2011-02-01|November 2008|Actual|2008-11-01|October 2008|Actual|2008-10-01||Interventional|||Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer|A Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced or Metastatic Colorectal Cancer|Completed||Phase 1|12|Actual|GlaxoSmithKline|Phase II of the study was terminated due to lake of interest. Two participants were enrolled prior to termination. Due to the small sample size in Phase II, the data were not analyzed. The two participants' data were analyzed with Phase I data.|2|||f||||f||||||||||2017-10-11 07:39:01.661009|2017-10-11 07:39:01.661009
NCT00536822|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-27|2013-06-15|||June 2013||2013-06-01|June 2013|2013-06-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Observational|||Antioxidant Status During Burn Rehabilitation|Prospective Assessment of Antioxidant Status of Pediatric Patients During Burn Rehabilitation|Withdrawn||N/A|0|Actual|Shriners Hospitals for Children|||1|Study withdrawn due to hospital emphasis on funded studies.|f||||t||||||None Retained|"     No specimens.   "|||2017-10-11 07:39:02.532284|2017-10-11 07:39:02.532284
NCT00537134|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-26|2017-08-02|||September 2006||2006-09-01|August 2017|2017-08-01|August 2018|Anticipated|2018-08-01|August 2017|Anticipated|2017-08-01||Interventional|TEAM||Trial on Endovascular Aneurysm Management|Safety and Efficacy of Endovascular Treatment of Unruptured Intracranial Aneurysms in the Prevention of Aneurysmal Haemorrhages: A Randomized Comparison With Indefinite Deferral of Treatment in 2002 Patients Followed for 10 Years|Suspended||N/A|2002|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2||The CIHR Financial support was withdrawn because of insufficient recruitment|f||||t||||||||||2017-10-11 07:39:07.860314|2017-10-11 07:39:07.860314
NCT00537199|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-26|2016-04-05|2009-12-11||November 2006||2006-11-01|December 2009|2009-12-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||OraTest in Combination With Visual Examination and Visual Examination Alone|Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401)|Terminated||Phase 3|1|Actual|M.D. Anderson Cancer Center|Early termination by sponsor resulted in only 1 patient enrolled and no analysis.|1||Study terminated early as per request by sponsor, Zila Biotechnology, Inc.|f||||f||||||||||2017-10-11 07:39:08.369358|2017-10-11 07:39:08.369358
NCT00537511|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-27|2013-05-07|2013-03-06||February 2008||2008-02-01|May 2013|2013-05-01|December 2010|Actual|2010-12-01|November 2010|Actual|2010-11-01||Interventional||Safety Population|A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide|A Multicenter, Phase I/IIA, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose and To Evaluate the Safety Profile of CC-4047 Administered in Combination With Cisplatin and Etoposide in Patients With Extensive Disease Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|22|Actual|Celgene||1||This study was terminated for administrative reasons.|f||||f||||||||||2017-10-11 07:39:23.967455|2017-10-11 07:39:23.967455
NCT00538291|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-01|2014-08-19|2014-06-12||August 2005||2005-08-01|August 2014|2014-08-01||||February 2009|Actual|2009-02-01||Interventional|||Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment|CA225103: A Phase II Study of a Combination of Cetuximab and Capecitabine in Patients With Metastatic Colorectal Cancer After Progression on Previous Fluoropyrimidine Containing Therapy|Terminated||Phase 2|13|Actual|City of Hope Medical Center|Study was terminated due to a lack of efficacy (less than 2 of 13 patients responded to treatment in the first stage of a Simon's two stage design).|1||Study was terminated early due to lack of efficacy.|f||||||||||||||2017-10-11 07:39:37.358873|2017-10-11 07:39:37.358873
NCT00538824|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-02|2017-05-03|2017-02-22||December 2007|Actual|2007-12-01|May 2017|2017-05-01|September 22, 2010|Actual|2010-09-22|September 22, 2010|Actual|2010-09-22||Interventional|DexTR||Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma|A Phase II Study of Dexamethasone (DECADRON®), Thalidomide (THALOMID®), and Lenalidomide (REVLIMID®) for Subjects With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 2|5|Actual|Weill Medical College of Cornell University|The study was terminated early due to lack of sufficient accrual|1||low enrollment|f||||f||||||||||2017-10-11 07:40:00.829074|2017-10-11 07:40:00.829074
NCT00538980|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-02|2017-05-23|2017-05-23||April 30, 2007|Actual|2007-04-30|May 2017|2017-05-01|August 27, 2010|Actual|2010-08-27|August 25, 2010|Actual|2010-08-25||Interventional|||Dasatinib in Polycythemia Vera|A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104|Terminated||Phase 2|10|Actual|Weill Medical College of Cornell University||1||This study was terminated due to lack of efficacy.|f||||||||||||||2017-10-11 07:40:06.043015|2017-10-11 07:40:06.043015
NCT00539838|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-03|2017-05-11||2013-01-17|December 2007||2007-12-01|May 2017|2017-05-01|September 2011|Actual|2011-09-01|July 2011|Actual|2011-07-01||Interventional|BEGIN||A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)|A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus|Terminated||Phase 3|33|Actual|Genentech, Inc.||2||"The study was terminated prematurely when the decision was made that ocrelizumab was not likely   to benefit this patient population."|f||||||||||||||2017-10-11 07:40:08.530806|2017-10-11 07:40:08.530806
NCT00539942|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-03|2017-02-22|2012-02-07||April 2007||2007-04-01|February 2017|2017-02-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy|Extended Deep Venous Thrombosis Prophylaxis in Gynecologic Oncology Surgery With Intermittent Compression Devices (ICD) With or Without Postoperative Arixtra (Fondaparinux Sodium): A Randomized Controlled Trial|Terminated||Phase 3|7|Actual|University of Alabama at Birmingham|This trial was terminated early due to poor enrollment and recruitment and the very small number of subjects analyzed. As such, the data is uninterpretable.|2||Problems with accrual|f||||t||||||||||2017-10-11 07:40:09.745854|2017-10-11 07:40:09.745854
NCT00540033|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-03|2007-10-04|||February 2005||2005-02-01|October 2007|2007-10-01|June 2007|Actual|2007-06-01|||||Interventional|||Probiotics Reduce Incidence of Necrotizing Enterocolitis for Very Low Birth Weight Infants|Phase 2 Study of Oral Probiotics Reduce the Incidence and Severity of Necrotizing Enterocolitis for Very Low Birth Weight Infants -Multi-Center Randomized Control Trial|Terminated||Phase 2|217|Actual|China Medical University Hospital||1||terminated because of enough case number|f||||t||||||||||2017-10-11 07:40:11.678466|2017-10-11 07:40:11.678466
NCT00540332|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-04|2009-02-27|||October 2007||2007-10-01|January 2009|2009-01-01|September 2008|Anticipated|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy|A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy|Withdrawn||Phase 1/Phase 2|0|Actual|Swedish Orphan Biovitrum||2||The 20070201 study was terminated based on evaluation of Palifermin solid tumor data.|f||||||||||||||2017-10-11 07:40:19.694552|2017-10-11 07:40:19.694552
NCT00541229|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-05|2017-04-07|2009-06-05||August 24, 2007|Actual|2007-08-24|April 2017|2017-04-01|July 1, 2008|Actual|2008-07-01|June 17, 2008|Actual|2008-06-17||Interventional|||Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)|A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Clinical Trial of Sitagliptin 100 mg and Sitagliptin 200 mg in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet and Exercise|Completed||Phase 1|103|Actual|Merck Sharp & Dohme Corp.|The pre-specified rule for non-superiority of sitagliptin 200 mg compared with 100 mg was met at the planned interim analysis. As such, the trial was terminated as pre-specified.|3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00541918|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-09|2015-10-27|||June 2007||2007-06-01|October 2015|2015-10-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional|||COGNITIVE - Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations|COGNITIVE - Comparison of Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations|Withdrawn||Phase 4|0|Actual|Medical University of Gdansk||2||study suspended due to staff indisposition|f||||f||||||||||2017-10-11 07:40:57.347104|2017-10-11 07:40:57.347104
NCT00534898|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-24|2010-06-28||||||September 2007|2007-09-01||||||||Interventional|||Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients|Comparison Efficacy of Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients: Double-blind Placebo Controlled Study|Withdrawn||Phase 3|||Beersheva Mental Health Center||||The study withdrawn due to lack financial support|f||||t||||||||||2017-10-11 07:41:06.028403|2017-10-11 07:41:06.028403
NCT00534937|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-24|2013-01-28|2012-11-29||September 2007||2007-09-01|January 2013|2013-01-01|December 2010|Actual|2010-12-01|July 2010|Actual|2010-07-01||Interventional|||Flexitouch Compression System for Venous Stasis Ulcer|A Randomized Trial of the Flexitouch Compression System as an Adjunctive Treatment for Venous Stasis Ulcer|Terminated||Phase 4|89|Actual|West Penn Allegheny Health System|The study was terminated early due to lack of enrollment which ultimately lead to a limited number of subjects to include in an analysis.|2||Ineffective Recruitment (Business Decision)|f||||t||||||||||2017-10-11 07:41:06.393473|2017-10-11 07:41:06.393473
NCT00536107|ClinicalTrials.gov processed this data on October 10, 2017|2007-09-26|2013-08-01|2013-08-01||October 2007||2007-10-01|August 2013|2013-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional|||Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy|Terminated||Phase 4|14|Actual|AstraZeneca|This study was terminated early because the purpose of this study had been fulfilled by other supporting data, and due to small number of patients enrolled (14 patients).|2|||f||||f||||||||||2017-10-11 07:41:32.647284|2017-10-11 07:41:32.647284
NCT00543582|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-11|2015-06-04||2015-06-04|October 2007||2007-10-01|June 2015|2015-06-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional|||MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma|A Phase 2, Open-label Trial to Evaluate the Efficacy and Safety of MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma, and to Evaluate the Pharmacokinetics of Different Formulations of MGCD0103|Terminated||Phase 2|23|Actual|Mirati Therapeutics Inc.||1||"Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103.   All Celgene-sponsored trials with MGCD0103 will be closed."|f||||f||||||||||2017-10-11 07:42:02.169227|2017-10-11 07:42:02.169227
NCT00543608|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-11|2009-02-12|||November 2007||2007-11-01|February 2009|2009-02-01|May 2009|Anticipated|2009-05-01|April 2009|Anticipated|2009-04-01||Interventional|||Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia|Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens|Terminated||Phase 2|135|Anticipated|Arpida AG||3||Trial terminated due to financial resource limitations|f||||t||||||||||2017-10-11 07:42:02.316833|2017-10-11 07:42:02.316833
NCT00544180|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-15|2009-09-24|||May 2005||2005-05-01|September 2009|2009-09-01||||September 2006|Actual|2006-09-01||Interventional|||ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week|Record on Satisfaction of Patients With Actonel 35 mg Once a Week|Terminated||Phase 4|7|Actual|Sanofi||1||The trial was terminated due to lack of compliance with GCP regulations.|f||||f||||||||||2017-10-11 07:42:09.676348|2017-10-11 07:42:09.676348
NCT00544648|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-13|2014-05-21|2014-03-19||November 2007||2007-11-01|May 2014|2014-05-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional||Consented patients|Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC|A Phase I/II Study of Nab-Paclitaxel and Carboplatin With Concurrent Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer (NSCLC)|Terminated||Phase 1/Phase 2|13|Actual|Vanderbilt-Ingram Cancer Center|This Phase I/II study progressed into Phase II, but terminated shortly thereafter due to lack of funding.|1||"Ph I completed. Funding became unavailable causing Ph II to cease after two patients were   enrolled."|f||||t||||||||||2017-10-11 07:42:16.877968|2017-10-11 07:42:16.877968
NCT00544778|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-13|2014-08-19|2014-06-12||August 2001||2001-08-01|August 2014|2014-08-01||||November 2011|Actual|2011-11-01||Interventional|||Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma|Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas|Terminated||Phase 2|7|Actual|City of Hope Medical Center|The study was terminated…protocol objectives not met. It was closed prematurely due to withdrawal of support by the sponsor. Subjects have been followed, but there is not enough data generated to continue following the subjects.”|1||The study was terminated prematurely due to withdrawal of support by the sponsor.|f||||||||||||||2017-10-11 07:42:19.41035|2017-10-11 07:42:19.41035
NCT00544908|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-13|2015-09-18|2015-08-19||September 2007||2007-09-01|September 2015|2015-09-01||||October 2012|Actual|2012-10-01||Interventional|||Dasatinib in Treating Patients With Stage IV Pancreatic Cancer|A Phase II Clinical Trial of Dasatinib in Patients With Metastatic Pancreatic Cancer|Terminated||Phase 2|7|Actual|City of Hope Medical Center|Study was terminated early due to toxicity.|1||Toxicity|f||||||||||||||2017-10-11 07:42:22.594156|2017-10-11 07:42:22.594156
NCT00539188|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-02|2013-03-25|2012-12-21||September 2007||2007-09-01|March 2013|2013-03-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD|A Double-Blind, Placebo-controlled Pilot Study of NAC Addition to Dialectical Behavioral Therapy for the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder|Terminated||Phase 2|6|Actual|Yale University||2||Study terminated due to poor subject compliance.|f||||f||||||||||2017-10-11 07:42:37.595096|2017-10-11 07:42:37.595096
NCT00539513|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-02|2013-03-25|2012-12-21||June 2006||2006-06-01|March 2013|2013-03-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional|||N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder|A Double-Blind Study of N-Acetylcysteine Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder and Depression|Terminated||Phase 2|10|Actual|Yale University||2||Researchers terminated study due to limited enrollment.|f||||f||||||||||2017-10-11 07:42:51.607237|2017-10-11 07:42:51.607237
NCT00545571|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-16|2016-05-19|2016-04-12||October 2007||2007-10-01|May 2016|2016-05-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional||Intent-to-Treat (ITT) Population: All participants who received at least one dose of study drug and for whom data were available from at least one follow-up variable.|MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia|A Single Arm, Open Label, Interventional Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Hemoglobin Levels in Hemodialysis Patients With Chronic Renal Anemia|Completed||Phase 3|120|Actual|Hoffmann-La Roche|The Study was prematurely terminated in Austria as a consequence of Mircera reimbursement denial. However, the Study completed regularly in Switzerland and the overall status of the Study is considered completed.|1|||f||||||||||||||2017-10-11 07:43:00.921997|2017-10-11 07:43:00.921997
NCT00547118|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-19|2015-02-24|2014-05-05||November 2007||2007-11-01|February 2015|2015-02-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional||Eighteen participants signed consent and 17 were randomized to study medication (rimonabant n=8, placebo n=9). One participant from each groupwaswithdrawn prior to the receipt of studymedication. One placebo participant refused the neurocognitive assessments. The remaining 14 participants (rimonabant n=7, placebo n=7) completed.|The Effects of Rimonabant, on Weight and Metabolic Risk Factors|The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia|Terminated||Phase 2|17|Actual|University of Maryland||2||Withdrawn due to medication withdrawal from the EMEA|f||||t||||||||||2017-10-11 07:43:36.911643|2017-10-11 07:43:36.911643
NCT00547911|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-19|2014-06-17|2014-06-17||October 2007||2007-10-01|June 2014|2014-06-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|||Augmenting Effects of L-DOPS With Carbidopa and Entacapone|L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone|Terminated||Phase 1/Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)|Study was prematurely terminated due to a small amount of DOPAL contamination in the droxidopa. Because of the early termination only a small number of subjects were enrolled in each condition. Recently, the FDA has approved droxidopa.|6||Study terminated due to contamination droxidopa|f||||f||||||||||2017-10-11 07:43:48.195763|2017-10-11 07:43:48.195763
NCT00548106|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-22|2012-06-13||||||July 2010|2010-07-01||||||||Interventional|||Safety Study of Infant Formula With Partially Hydrolized Whey|Evaluation of a New Cow's Milk Infant Formula Containing Partially Hydrolized Whey|Withdrawn||N/A|0|Actual|Soroka University Medical Center||2||Study withdrawn due to the company decision|f||||t||||||||||2017-10-11 07:43:50.496647|2017-10-11 07:43:50.496647
NCT00542828|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-10|2015-03-17|2010-04-07||October 2007||2007-10-01|March 2015|2015-03-01|July 2009|Actual|2009-07-01|May 2009|Actual|2009-05-01||Interventional|RISE||Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome|A Phase II Study of the Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in Patients With Low and Intermediate-1 Risk Myelodysplastic Syndrome|Terminated||Phase 2|16|Actual|Sanofi|The study was terminated early due to a slow enrollment rate; therefore, only safety data were collected from participants for 45 days following the last day of infusion (Day 5).|1||Study terminated due to slow enrollment.|f||||f||||||||||2017-10-11 07:44:23.514849|2017-10-11 07:44:23.514849
NCT00549575|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-24|2007-10-25|||July 2000||2000-07-01|October 2007|2007-10-01|June 2006|Actual|2006-06-01|||||Interventional|||L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)|L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial|Terminated||Phase 3|44|Actual|Nantes University Hospital||2||terminated|f||||||||||||||2017-10-11 07:44:32.464544|2017-10-11 07:44:32.464544
NCT00551759|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-30|2014-04-02|2014-01-17||June 2008||2008-06-01|April 2014|2014-04-01|April 2016|Anticipated|2016-04-01|October 2011|Actual|2011-10-01||Interventional||Eligible and treated patients|Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer|A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy With Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Patients With Operable Adenocarcinoma of the Esophagus|Terminated||Phase 2|22|Actual|Eastern Cooperative Oncology Group||1||"The study used a two-stage design. After stage one, the study was terminated due to excess   toxicity."|f||||f||||||||||2017-10-11 07:44:54.766899|2017-10-11 07:44:54.766899
NCT00551785|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-30|2015-03-24|||September 2007||2007-09-01|March 2015|2015-03-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Observational|EMPOWER||Surveillance Study of Women Taking Intrinsa®|The Multinational Postmarketing Observational Study of Women Prescribed Intrinsa|Terminated||Phase 4|328|Actual|Center for Epidemiology and Health Research, Germany|||2|The marketing authorization for Intrinsa was withdrawn.|f||||t||||||||||2017-10-11 07:44:55.757311|2017-10-11 07:44:55.757311
NCT00545948|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-16|2014-06-25|2014-05-07||December 2007||2007-12-01|June 2014|2014-06-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|TOP0703|One patient in each of the vinorelbine and pemetrexed arms did not undergo protocol-based treatment, resulting in 22 total patients who were treated with either vinorelbine or pemetrexed. These two enrolled patients who were not administered treatment were added to the 7 original screen failures.|Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer|Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemo With Either Vinorelbine or Pemetrexed for the Adj Tx of Early Stage NSCLC in Patients Using Genomic Expression Profiles of Chemo Sensitivity to Guide Therapy|Terminated||Phase 2|31|Actual|Duke University||2||Study terminated due to reproducibility issues with genomics prediction model.|f||||t||||||||||2017-10-11 07:45:38.037487|2017-10-11 07:45:38.037487
NCT00553514|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-01|2014-01-20|2013-05-29||December 2007||2007-12-01|January 2014|2014-01-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional|||AS900672-Enriched in Ovulation Induction|A Phase II, Multicentre, Randomised, Assessor-blinded, Active-comparator, Parallel-group Dose Finding Trial to Evaluate AS900672-enriched Versus Follitropin Alfa (GONAL-f®) in Oligo-anovulatory Infertile Women Undergoing Ovulation Induction (OI)|Terminated||Phase 2|71|Actual|Merck KGaA|The study was terminated after Merck Serono had taken the decision not to pursue the development of AS900672-enriched in ovulation induction|5||"The study was terminated after Merck Serono had taken the decision not to pursue the   development of AS900672-enriched in ovulation induction"|f||||||||||||||2017-10-11 07:46:10.70571|2017-10-11 07:46:10.70571
NCT00554073|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-05|2009-08-18|||May 2008||2008-05-01|August 2009|2009-08-01|August 2009|Anticipated|2009-08-01|||||Observational|||Whole Body Magnetic Resonance Angiography in Ischemic Patients at 1.5 and 3T|Whole Body Magnetic Resonance Angiography in Patients With Symptomatic Peripheral Ischemia: A Comparison Between 1.5 and 3T MRI-systems|Suspended||N/A|12|Anticipated|Copenhagen University Hospital at Herlev|||1|"It was not possible to perform 2 MRI studies in each patient due to practical problems. The   study was not suspended due to safety issues."|f||||t||||||||||2017-10-11 07:46:20.040041|2017-10-11 07:46:20.040041
NCT00554736|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-05|2015-04-20|||May 2006||2006-05-01|April 2015|2015-04-01|August 2008|Anticipated|2008-08-01|December 2007|Anticipated|2007-12-01||Interventional|||Lactobacillus Acidophilus L92 on Markers of Allergic Inflammation by Nasal Provocation With Grass Pollen|A Randomized, Double-blind, Placebo-controlled Trial of Lactobacillus Acidophilus L92 on Markers of Allergic Inflammation by Nasal Provocation With Grass Pollen|Withdrawn||Phase 3|0|Actual|University of California, Davis||1||Sponsor suspended study do to funding|f||||t||||||||||2017-10-11 07:46:31.302499|2017-10-11 07:46:31.302499
NCT00554762|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-05|2015-02-12|||November 2007||2007-11-01|February 2015|2015-02-01|March 2008|Anticipated|2008-03-01|March 2008|Anticipated|2008-03-01||Interventional|||Dose Response and Efficacy of GW842166 in Pain|A Phase I, Placebo Controlled, Randomised, Double Blind Two-way Crossover Study to Investigate the Dose Response and Efficacy of Single and Repeat Doses of GW842166 in Healthy Volunteers Using Pharmacodynamic Pain Assessments.|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||||Compound terminated|f||||f||||||||||2017-10-11 07:46:31.652861|2017-10-11 07:46:31.652861
NCT00554840|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-06|2017-05-15|2016-05-11||November 2007||2007-11-01|May 2017|2017-05-01|April 2011|Actual|2011-04-01|December 2010|Actual|2010-12-01||Interventional||One participant was withdrawn by the P.I. after assignment to the placebo group, but prior to receiving treatment.|Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia|Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia|Completed||Phase 2|16|Actual|University of Maryland|Larger studies are needed to confirm these encouraging results.|2|||f||||t||||||||||2017-10-11 07:46:32.582527|2017-10-11 07:46:32.582527
NCT00555984|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-07|2017-04-19|||September 2007|Actual|2007-09-01|April 2017|2017-04-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|TIVA||Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors|Effect of Total Intravenous Anesthesia Versus Anesthesia With Volatile Agents on Inflammatory Markers Following Elective Craniotomy for Primary Brain Tumor|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2||PI decision to terminate. No usable data collected|f||||t||||||||No|Study terminated early|2017-10-11 07:47:12.871041|2017-10-11 07:47:12.871041
NCT00556075|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-07|2014-08-08|2014-06-24||November 2007||2007-11-01|August 2014|2014-08-01|July 2009|Actual|2009-07-01|May 2009|Actual|2009-05-01||Interventional||Safety population|Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis|A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis|Terminated||Phase 2|67|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with complete study data.|3||Clinical hold for safety|f||||t||||||||||2017-10-11 07:47:14.082087|2017-10-11 07:47:14.082087
NCT00550199|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-26|2013-08-15|||November 2007||2007-11-01|August 2013|2013-08-01|February 2010|Actual|2010-02-01|February 2010|Actual|2010-02-01||Interventional|||LBH589 and Gemcitabine in the Treatment of Solid Tumors|A Phase I Study of LBH589 in Combination With Gemcitabine in the Treatment of Solid Tumors|Terminated||Phase 1|17|Actual|SCRI Development Innovations, LLC||1||Study terminated due to LBH589 toxicity.|f||||f||||||||||2017-10-11 07:47:58.619037|2017-10-11 07:47:58.619037
NCT00550654|ClinicalTrials.gov processed this data on October 10, 2017|2007-10-25|2016-11-16|2012-08-20||October 2007||2007-10-01|November 2016|2016-11-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain|A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligo|Terminated||Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)||1||Study was terminated due to poor accrual.|f||||f||||||||No||2017-10-11 07:48:21.316426|2017-10-11 07:48:21.316426
NCT00558376|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-13|2009-05-04|||January 2008||2008-01-01|May 2009|2009-05-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional|||Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy|Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy - An Investigator Blinded Prospective Controlled Trial|Terminated||N/A|23|Actual|Sheba Medical Center||2||Study terminated due to FDA alert regarding Fleet phosphosoda|f||||f||||||||||2017-10-11 07:48:42.240946|2017-10-11 07:48:42.240946
NCT00558558|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-13|2016-04-06|2011-09-02||October 2007||2007-10-01|September 2011|2011-09-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional|||Haelan and Nutrition in Cancer Patients|A Phase II Study Examining the Role of Fermented Soy Beverage for Improving Cancer-Associated Anorexia and Cachexia|Terminated||Phase 2|6|Actual|M.D. Anderson Cancer Center||1||Study terminated due to low recruitment.|f||||f||||||||||2017-10-11 07:48:45.625579|2017-10-11 07:48:45.625579
NCT00560352|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-16|2017-02-01|2012-04-02||February 2008||2008-02-01|July 2012|2012-07-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma|A Phase I Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 1|16|Actual|Bristol-Myers Squibb|The study was terminated due to an unexpectedly low recruitment rate, and no participants were enrolled in a planned dose-expansion phase.|1|||f||||f|t|f||||||||2017-10-11 07:49:24.891837|2017-10-11 07:49:24.891837
NCT00553735|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-02|2017-02-07|2012-10-02||August 2007||2007-08-01|April 2013|2013-04-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye|The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye|Terminated||Phase 4|8|Actual|Massachusetts Eye and Ear Infirmary|The study was terminated early due to a high number of patients who withdrew themselves, failed to show for their appointments, or were lost to follow-up.|2||High number of withdrawals, appt. no-shows, or those lost to follow-up.|f||||f||||||||No||2017-10-11 07:49:44.420197|2017-10-11 07:49:44.420197
NCT00562055|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-19|2008-06-19|||November 2007||2007-11-01|June 2008|2008-06-01||||||||Interventional|||Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.|Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.|Withdrawn||Phase 2|96|Anticipated|Pfizer||2||This study was withdrawn due to business reasons.|f||||||||||||||2017-10-11 07:50:05.488887|2017-10-11 07:50:05.488887
NCT00563459|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-21|2013-01-25||2013-01-15|November 2007||2007-11-01|January 2013|2013-01-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|||Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.|A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects With Partial Onset Seizures|Terminated||Phase 3|89|Actual|SK Life Science||3||"Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this   indication were terminated."|f||||t||||||||||2017-10-11 07:50:39.098506|2017-10-11 07:50:39.098506
NCT00563706|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-21|2014-02-03|2014-02-03|2009-04-23|December 2007||2007-12-01|February 2014|2014-02-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional||Safety population included all randomized participants who received at least 1 dose of double-blind test article.|Study Evaluating Vabicaserin in Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Risperidone-Referenced, Parallel-Group, Adaptive-Design Study of the Efficacy, Safety, and Tolerability of Vabicaserin (SCA-136) in Subjects With Acute Exacerbations of Schizophrenia|Completed||Phase 2|199|Actual|Pfizer|Because of the failure of all vabicaserin doses to meet the primary efficacy objective, the study was terminated prematurely and planned analyses of secondary efficacy endpoints were not performed.|3|||f||||t||||||||||2017-10-11 07:50:41.444095|2017-10-11 07:50:41.444095
NCT00557206|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-09|2013-11-04|||April 2005||2005-04-01|November 2013|2013-11-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|||Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer|Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck|Terminated||Phase 2|35|Actual|Minneapolis Veterans Affairs Medical Center||1||Funding was terminated|f||||f||||||||||2017-10-11 07:50:58.922402|2017-10-11 07:50:58.922402
NCT00557505|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-12|2012-02-21|2012-01-10||December 2007||2007-12-01|February 2012|2012-02-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||A Study Of PF-03732010 In Patients With Advanced Solid Tumors|A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of PF-03732010 In Patients With Advanced Solid Tumors|Completed||Phase 1|43|Actual|Pfizer|Results are not provided because development of the study drug was terminated, as neither anti-tumor activity nor pharmacodynamic modulation was observed.|1|||f||||f||||||||||2017-10-11 07:51:07.839236|2017-10-11 07:51:07.839236
NCT00557518|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-12|2009-01-29|||November 2007||2007-11-01|January 2009|2009-01-01|November 2009|Anticipated|2009-11-01|September 2009|Anticipated|2009-09-01||Interventional|||Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria|A Randomized, Placebo-Controlled Trial of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria|Terminated||Phase 2|80|Anticipated|Synvista Therapeutics, Inc||2||Study has been terminated early due to financial constraints.|f||||f||||||||||2017-10-11 07:51:10.620444|2017-10-11 07:51:10.620444
NCT00567866|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-03|2010-07-12|||January 2008||2008-01-01|July 2010|2010-07-01|September 2009|Actual|2009-09-01|September 2009|Actual|2009-09-01||Interventional|||Methamphetamine-Quetiapine Interactions in Humans|Methamphetamine-Quetiapine Interaction in Humans: A Pilot Study|Terminated||Early Phase 1|10|Actual|University of Arkansas||3||Study was terminated due to insufficient funds|f||||t||||||||||2017-10-11 07:51:40.751781|2017-10-11 07:51:40.751781
NCT00567879|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-04|2016-04-04|2016-04-04||April 2008||2008-04-01|March 2016|2016-03-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Interventional|||A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab|A Phase Ib/IIa Trial of Panobinostat in Combination With Trastuzumab in Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed During or Following Therapy With Trastuzumab|Terminated||Phase 1/Phase 2|56|Actual|Novartis||1||The study was terminated early due to insufficient evidence of clinical benefit.|f||||||||||||||2017-10-11 07:51:40.876076|2017-10-11 07:51:40.876076
NCT00570375|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-06|2009-04-16|||November 2007||2007-11-01|April 2009|2009-04-01|November 2012|Anticipated|2012-11-01|November 2009|Anticipated|2009-11-01||Interventional|||The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome|Phase II of Erlotinib an Epidermal Growth Factor Receptor Inhibitor in the Treatment of Myelodysplastic Syndrome|Withdrawn||Phase 2|35|Anticipated|University of Cincinnati||1||"Rami Komrokji, MD author of this protocol no longer is at the University of Cincinnati and this   study has been withdrawn."|f||||f||||||||||2017-10-11 07:52:51.341943|2017-10-11 07:52:51.341943
NCT00572156|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-10|2015-11-10|2015-08-06|2011-04-18|December 2007||2007-12-01|November 2015|2015-11-01|March 2012|Actual|2012-03-01|April 2010|Actual|2010-04-01||Interventional||All Subjects|rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency|Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 rhIGF-1) Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency: A Six-year, Randomized, Multi-center, Open-label, Parallel-group, Active Treatment Controlled, Dose Selection Trial|Terminated||Phase 2|106|Actual|Ipsen|The study was prematurely terminated once the last subject had completed three years of treatment (compared to the six years planned in protocol Amendment) for strategic reasons.|4||The study was prematurely terminated due to strategic reasons.|f||||t||||||||||2017-10-11 07:53:15.58812|2017-10-11 07:53:15.58812
NCT00573131|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-11|2016-01-12|2014-04-17||January 2008||2008-01-01|January 2016|2016-01-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer|A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer|Terminated||Phase 2|154|Actual|BTG International Inc.|Study prematurely terminated due to lack of efficacy in primary endpoint.|2||OncoGel did not show any impact on overall tumor response|f||||t||||||||||2017-10-11 07:53:33.146125|2017-10-11 07:53:33.146125
NCT00573157|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-11|2016-02-22|2016-02-22||December 2007||2007-12-01|February 2016|2016-02-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional||Baseline analysis population included all the participants randomized in the trial.|The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis|A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects With Lupus Nephritis in Combination With Mycophenolate Mofetil Therapy.|Terminated||Phase 2/Phase 3|6|Actual|EMD Serono|The study was terminated due to unanticipated safety issues.|2||The study was terminated due to unanticipated safety issues|f||||t||||||||||2017-10-11 07:53:34.241761|2017-10-11 07:53:34.241761
NCT00566462|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-29|2017-07-27|2012-11-20||October 2007||2007-10-01|July 2017|2017-07-01|April 2008|Actual|2008-04-01|April 2008|Actual|2008-04-01||Interventional|||Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT|Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT|Terminated||Phase 2|1|Actual|Eisai Inc.|This study was terminated at the sponsor request after only 1 subject was enrolled and completed the study and therefore the data is limited. Similiar research in this area have required a minimum of 5-6 completers to develop a valid analysis.|2||Study stopped due to lack of efficacy.|f||||||||||||||2017-10-11 07:54:24.47072|2017-10-11 07:54:24.47072
NCT00566956|ClinicalTrials.gov processed this data on October 10, 2017|2007-11-30|2015-07-20|||October 1999||1999-10-01|November 2007|2007-11-01|June 2004|Actual|2004-06-01|||||Interventional|||Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection|Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection Improves Pregnancy Outcome in In-vitro Fertilization: a Randomised Controlled Trial|Terminated||Phase 2|66|Actual|Birmingham Women's NHS Foundation Trust||2||The study was terminated because it is very difficult to recruit more patients.|f||||t||||||||||2017-10-11 07:54:37.435813|2017-10-11 07:54:37.435813
NCT00567541|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-03|2016-03-02|2016-02-04||June 2007||2007-06-01|March 2016|2016-03-01|December 2012|Actual|2012-12-01|December 2011|Actual|2011-12-01||Interventional|BBPM|fifteen of 16 subjects were randomized and their devices activated. One subject experienced and AE prior to device activation and was exited from the study|An Implantable Microneuromodulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects|Feasibility Study of the Bioness Battery-Powered Microneuromodulator (BBPM) to Treat Chronic Shoulder Pain in Chronic Post-Stroke Subjects|Completed||Phase 2|16|Actual|Bioness Inc|Further study plans terminated due to high migration/adverse event rates Small sample size Didn't include socio-environmental factors which could affect subject’s overall functionality Three different sites/subtle stimulator implantation variances|2|||f||||f||||||||No||2017-10-11 07:54:53.347102|2017-10-11 07:54:53.347102
NCT00573937|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-12|2016-01-21|2010-10-04||August 2007||2007-08-01|January 2016|2016-01-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||Methadone Versus Morphine for Cancer-Related Pain|Methadone Versus Morphine for Moderate to Severe Cancer-Related Pain: A Double-Blind Randomized Parallel Group Study|Terminated||Phase 2|1|Actual|Mayo Clinic|Due to slow accrual of subjects, the study was terminated after one subject started in the standard control group (morphine). No subject received investigational study drug (methadone). Therefore no data were analyzed.|2||Slow accrual.|f||||f||||||||||2017-10-11 07:55:04.171695|2017-10-11 07:55:04.171695
NCT00576160|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-14|2015-05-13|||August 2007||2007-08-01|May 2015|2015-05-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|||Improving Medication Adherence in Post-ACS Patients|Improving Med Adherence in Post-ACS Patients: Phase 1B Dose-Finding RCT|Terminated||Phase 1|22|Actual|Columbia University||2||"This was a dosing study to determine acceptability. Participants found protocol burdensome and   so we terminated."|f||||t||||||||||2017-10-11 07:55:14.673331|2017-10-11 07:55:14.673331
NCT00577395|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-19|2013-04-15|2009-11-18||July 2008||2008-07-01|April 2013|2013-04-01|February 2009|Actual|2009-02-01|February 2009|Actual|2009-02-01||Interventional|||Bone Microarchitecture in Osteopenic Postmenopausal Women|A 12-month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing 150 mg Once-a-month Risedronate and Placebo Using 3-dimensional Micro MRI (Magnetic Resonance Imaging).|Terminated||Phase 4|13|Actual|Warner Chilcott|NOTE: The study was terminated early (after 5 months), prior to acquiring any efficacy endpoints; consequently, NO subject efficacy analyses were performed|2|||f||||f||||||||||2017-10-11 07:55:43.706386|2017-10-11 07:55:43.706386
NCT00577772|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-17|2012-10-01|2012-08-30||November 2007||2007-11-01|October 2012|2012-10-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|||Transit Time and Bacterial Overgrowth Using SmartPill Capsule|An Exploratory Assessment of Small Bowel Transit Time and Small Bowel Bacterial Overgrowth Using the SmartPill Capsule|Terminated||N/A|17|Actual|Mayo Clinic|The study was terminated early because enrollment goals were not met.|2||Enrollment Goal Not Met|f||||f||||||||||2017-10-11 07:55:53.24701|2017-10-11 07:55:53.24701
NCT00570960|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-10|2014-12-01|2013-01-14||June 2007||2007-06-01|December 2014|2014-12-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|||Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis|Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis|Terminated||Phase 4|8|Actual|University of Virginia|The study was terminated early because the manufacturer of Dextran 70 ceased all production of the study drug approximately 10 months into the study. It was felt by the principle investigator that continuation of the study was impossible.|2||drug product became unavilable|f||||t||||||||||2017-10-11 07:56:18.334767|2017-10-11 07:56:18.334767
NCT00578097|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-18|2015-11-30|||February 2008||2008-02-01|November 2015|2015-11-01|December 2009|Actual|2009-12-01|June 2009|Actual|2009-06-01||Interventional|||Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder|A Phase II, International, Multi-centre, Prospective, Randomised, Parallel-group, Double-blind, Dose-ranging, Placebo-controlled, 12-week, Study to Assess the Efficacy and Safety of a One Injection Cycle With Either Botulinum Toxin Type-A (Dysport® 125, 250 or 500 Units) or Placebo Followed by an Optional 6-month Extension Phase in the Symptomatic Treatment of Micturition Urgency and Frequency in Continent Female Subjects Suffering From Idiopathic Overactive Bladder.|Terminated||Phase 2|81|Actual|Ipsen||4||The study was terminated early due to poor recruitment.|f||||f||||||||||2017-10-11 07:56:23.411196|2017-10-11 07:56:23.411196
NCT00579059|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-17|2017-06-19|2009-05-20||May 2004||2004-05-01|June 2017|2017-06-01|November 2007|Actual|2007-11-01|November 2007|Actual|2007-11-01||Interventional|||Maxim® Knee Pop-Top® Tibia vs. Regular Maxim® Knee Tibia|A Randomized Data Collection of the Maxim® Knee System With Removable Molded Polyethylene Tibia and the Regular Maxim® Knee System|Terminated||N/A|31|Actual|Zimmer Biomet|Study was terminated after enrollment failed to produce sufficient data to be analyzed.|2||The study sponsor canceled the study.|f||||f||||||||||2017-10-11 07:56:34.249873|2017-10-11 07:56:34.249873
NCT00579254|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-20|2009-06-18|2009-05-01||December 2007||2007-12-01|May 2009|2009-05-01|May 2008|Actual|2008-05-01|May 2008|Actual|2008-05-01||Observational|EXCEL||Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors|Real Life Experience With Caduet Evaluating Effectiveness, Safety and Tolerability in the Management of Cardiovascular Risk Factors (EXCEL Study)|Terminated||Phase 4|112|Actual|Pfizer|The objectives for this terminated study could not be assessed due to limited data available. (Efficacy parameters were to include BP, heart rate, lipid profile, urine albumin.)||1|See the termination reason in detailed description.|f||||f||||||||||2017-10-11 07:56:37.381442|2017-10-11 07:56:37.381442
NCT00580164|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-20|2015-12-29|||January 2006||2006-01-01|December 2015|2015-12-01|December 2010|Actual|2010-12-01|May 2010|Actual|2010-05-01||Observational|||The Role of Splinting in Fingertip Injuries|The Role of Splinting in Fingertip Injuries|Withdrawn||N/A|0|Actual|Massachusetts General Hospital|||2|Very few subjects were enrolled. Therefore, the study was terminated.|f||||f||||||||||2017-10-11 07:56:52.668877|2017-10-11 07:56:52.668877
NCT00574275|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-14|2016-05-04|2012-08-17|2011-07-21|December 2007||2007-12-01|May 2016|2016-05-01|November 2010|Actual|2010-11-01|October 2009|Actual|2009-10-01||Interventional|VANILLA||Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer|A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer|Terminated||Phase 3|546|Actual|Sanofi|"As the study was terminated due to futility, some changes were made to the planned analyses, and the analyses for the following outcome measures were not performed:
NCT00575016|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-13|2015-09-17|2011-09-09|2011-03-31|December 2007||2007-12-01|September 2015|2015-09-01|July 2010|Actual|2010-07-01|February 2010|Actual|2010-02-01||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder||Terminated||Phase 2|74|Actual|Allergan|Due to recruitment difficulties, study enrollment was stopped early.|4||The study was terminated early due to enrollment challenges.|f||||||||||||||2017-10-11 07:57:48.434778|2017-10-11 07:57:48.434778
NCT00581529|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-20|2014-10-14|2014-08-14||November 2004||2004-11-01|October 2014|2014-10-01|August 2014|Actual|2014-08-01|October 2010|Actual|2010-10-01||Interventional||34 for patients were enrolled and treated. 2 patients were excluded from all analysis due to fair baseline cosmesis. 2 additional patients underweant mastectomies and were therefore excluded from analysis (comsesis could not be assessed at 5 years). 30 patients were analyzed.|Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy|Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy in Early Stage Breast Cancer After Breast-Conserving Surgery|Terminated||Phase 2|34|Actual|University of Michigan Cancer Center|The trial was terminated early because fair/poor cosmesis developed in 7 of 32 women.|1||The trial was terminated early because fair/poor cosmesis developed in 7 of 32 women.|f||||t||||||||||2017-10-11 07:57:59.136223|2017-10-11 07:57:59.136223
NCT00584025|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2008-06-02|||December 2007||2007-12-01|June 2008|2008-06-01||||August 2008|Anticipated|2008-08-01||Interventional|||Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease||Withdrawn||Phase 4|20|Anticipated|University of South Florida||2||Study withdrawn due to personnel limitations.|f||||f||||||||||2017-10-11 07:58:36.668051|2017-10-11 07:58:36.668051
NCT00584090|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2012-11-30|||November 2007||2007-11-01|October 2010|2010-10-01||||April 2011|Anticipated|2011-04-01||Interventional|||Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease||Withdrawn||Phase 4|0|Actual|University of South Florida||2||Study withdrawn with intent of persuing larger, multi-site study.|f||||f||||||||||2017-10-11 07:58:37.389643|2017-10-11 07:58:37.389643
NCT00584246|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2008-06-02|||November 2007||2007-11-01|June 2008|2008-06-01||||August 2008|Anticipated|2008-08-01||Interventional|||Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome|Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome|Withdrawn||Phase 4|22|Anticipated|University of South Florida||2||Study withdrawn due to budget (personnel) limitations.|f||||f||||||||||2017-10-11 07:58:39.642182|2017-10-11 07:58:39.642182
NCT00584740|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2015-03-24|2015-01-28||August 2008||2008-08-01|March 2015|2015-03-01|August 2010|Actual|2010-08-01|August 2010|Actual|2010-08-01||Interventional|||Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single iv Infusions of AIN457 10 mg/kg (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Active Crohn's Disease|Terminated||Phase 2|59|Actual|Novartis||2||"The study was terminated prematurely after futility criterion was met at planned interim   analysis of 41 patients."|f||||f||||||||||2017-10-11 07:58:46.216433|2017-10-11 07:58:46.216433
NCT00584909|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2017-01-25|2011-09-21||March 2006||2006-03-01|January 2017|2017-01-01|September 2011|Actual|2011-09-01|September 2010|Actual|2010-09-01||Interventional|||A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus|A Phase II Study of Paclitaxel and Carboplatin in Patients With Intermediate-Risk Adenocarcinoma of the Endometrium|Terminated||Phase 2|13|Actual|University of Alabama at Birmingham|This study was terminated early due to slow accrual. 4 patients withdrew from the study due to side-effects from the treatment. All 9 patients were evaluable for toxicity and PFS.|1||low accrual|f||||t||||||||||2017-10-11 07:58:50.648705|2017-10-11 07:58:50.648705
NCT00585026|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2011-06-14|||October 2006||2006-10-01|December 2009|2009-12-01|June 2007|Actual|2007-06-01|||||Interventional|||Randomized Clinical Trial of Bifocal Lenses Versus Computer-specific Progressive Addition Lenses|Randomized Clinical Trial of Bifocal Lenses Versus Computer-specific Progressive Addition Lenses on Symptoms and Performance on a Computer|Terminated||Phase 3|40|Anticipated|University of Alabama at Birmingham||||PI left UAB; protocol administratively terminated by UAB IRB.|f||||||||||||||2017-10-11 07:58:53.027907|2017-10-11 07:58:53.027907
NCT00578591|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-19|2012-07-06|||June 2007||2007-06-01|July 2012|2012-07-01||||||||Interventional|Rituximab GVHD||Rituximab for GVHD|CHIMERIC MONOCLONAL CD-20 ANTIBODY (RITUXIMAB) FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-AGVHD): A PILOT STUDY|Withdrawn||Phase 2|0|Actual|Baylor College of Medicine||1||No eligible patients were identified so the study was terminated.|f||||t||||||||||2017-10-11 07:59:02.372041|2017-10-11 07:59:02.372041
NCT00585221|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2016-12-20|2012-06-15||July 2007||2007-07-01|December 2016|2016-12-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients|A Phase II Study Combining Targeted Therapy With Immunotherapy Using Imatinib Plus Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients|Terminated||Phase 2|8|Actual|University of Utah||1||PI terminated at the recommendation of DSMC & IRB|f||||t||||||||||2017-10-11 07:59:13.238702|2017-10-11 07:59:13.238702
NCT00585234|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2014-12-08|||December 2005||2005-12-01|December 2014|2014-12-01|March 2012|Actual|2012-03-01|March 2012|Actual|2012-03-01||Observational|||Tools for the Objective Clinical Assessment of Pediatric Spinal Deformity|Tools for Objective Clinical Assessment of Pediatric Spinal Deformity and the Results of Surgical Intervention--Simultaneous Measurement of Sagittal and Coronal Balance and Symmetry With Digital Photography.|Withdrawn||N/A|0|Actual|University of Utah|||1|Study has been withdrawn.|f||||f||||||||||2017-10-11 07:59:13.452557|2017-10-11 07:59:13.452557
NCT00585312|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-01|2014-10-28|2014-10-28||September 2006||2006-09-01|October 2014|2014-10-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional|CHIP|The intent-to-treat (ITT) population (N: 106) consisted of all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether the participants received any study drug or received a different drug from that to which they were randomized.|Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)|A Phase III Placebo-Controlled Trial Of Celecoxib In Genotype Positive Subjects With Familial Adenomatous Polyposis|Terminated||Phase 3|106|Actual|Pfizer|The study was early terminated and, due to the low number of participants, no efficacy analysis was performed. Only descriptive statistics was performed.|2||See termination reason in detailed description.|f||||t||||||||||2017-10-11 07:59:14.199276|2017-10-11 07:59:14.199276
NCT00587015|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2011-11-21|||August 2007||2007-08-01|November 2011|2011-11-01|October 2009|Actual|2009-10-01|March 2008|Actual|2008-03-01||Interventional|||A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)|A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)|Terminated||Phase 1|50|Anticipated|MedImmune LLC||1||"Due to a lack of IP supply and then terminated because they were combined into one new study   with the new IP formulation."|f||||f||||||||||2017-10-11 07:59:45.705728|2017-10-11 07:59:45.705728
NCT00587132|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2013-06-19|2013-04-29||November 2006||2006-11-01|June 2013|2013-06-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Interventional|||Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma|Pilot Study Using Secretin and Iodinated Intravenous Contrast and 64-Channel CT in Patients at High Risk for Pancreatic Adenocarcinoma|Terminated||Phase 1/Phase 2|4|Actual|Mayo Clinic|The study was terminated early due to lack of funding.|4||Lack of funding|f||||f||||||||||2017-10-11 07:59:47.331609|2017-10-11 07:59:47.331609
NCT00587223|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2010-06-25|2010-03-29||December 2007||2007-12-01|June 2010|2010-06-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)|A Prospective, Multicenter, Within Subject Controlled Study to Evaluate the Effect of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa|Terminated||Phase 3|1|Actual|Organogenesis|Study terminated early, the 1 enrolled subject subsequently discontinued study at Day 7.|2||Insufficient patient enrollment|f||||t||||||||||2017-10-11 07:59:50.469537|2017-10-11 07:59:50.469537
NCT00587457|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2017-06-12|2017-02-27||March 7, 2007|Actual|2007-03-07|June 2017|2017-06-01|April 7, 2008|Actual|2008-04-07|April 7, 2008|Actual|2008-04-07||Interventional||Safety population included all participants who received any treatment of moxetumomab pasudotox.|A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia|A Phase I, Multicenter, Dose-Escalation Study of CAT-8015 in Patients With Relapsed or Refactory Chronic Lymphocytic Leukemia (CLL) Prolymphocytic Leukemia (PLL), or Small Lymphocytic Leukemia (SLL)|Terminated||Phase 1|11|Actual|MedImmune LLC|The study was terminated early due to unavailability of investigational product.|3||The study is terminated early due to unavailability of investigational product.|f||||f||||||||||2017-10-11 07:59:54.667229|2017-10-11 07:59:54.667229
NCT00587847|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2015-09-16|2013-05-29||August 2005||2005-08-01|September 2015|2015-09-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional||This was a pilot study with enrollment goal of 20 based on our patient population with potential to meet inclusion criteria. This goal was not met due to patient preferance for no further treatment which is standard of care.|Campath Maintenance in Chronic Lymphocytic Leukemia|Maintenance Alemtuzumab in Refractory Chronic Lymphocytic Leukemia|Terminated||N/A|12|Actual|Northwell Health|Trial was terminated early due to poor accrual.|1||Insufficient recruitment.|f||||f||||||||||2017-10-11 08:00:02.331569|2017-10-11 08:00:02.331569
NCT00588146|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-26|2013-02-19|2012-12-20||January 2007||2007-01-01|February 2013|2013-02-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional|||Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia|Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia|Terminated||Phase 2|10|Actual|Mayo Clinic|The study was terminated early because Schering-Plough discontinued supplying study drug.|2||Schering-Plough discontinued supplying study drug.|f||||t||||||||||2017-10-11 08:00:07.292129|2017-10-11 08:00:07.292129
NCT00582036|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-19|2011-03-23|2011-01-06||February 2007||2007-02-01|March 2011|2011-03-01|May 2009|Actual|2009-05-01|May 2009|Actual|2009-05-01||Interventional|||Glucose Control In Hematopoetic Stem Cell Transplant|Glucose Control In Hematopoetic Stem Cell Transplant|Terminated||N/A|11|Actual|University of Oklahoma|This study was terminated early due to lack of enrollment.|2||study terminated due to lack of enrollment|f||||f||||||||||2017-10-11 08:00:15.248003|2017-10-11 08:00:15.248003
NCT00588471|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-22|2012-10-09|2012-10-09||November 2002||2002-11-01|October 2012|2012-10-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional|||Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention|The Effect of Acute Statin Treatment on Inflammation and Peripheral Arterial Tone in Patients Undergoing Percutaneous Coronary Intervention.|Terminated||N/A|57|Actual|Mayo Clinic|The study was terminated early because not enough subjects could be recruited.|2||The study was terminated because not enough subjects could be recruited.|f||||f||||||||||2017-10-11 08:00:28.165129|2017-10-11 08:00:28.165129
NCT00592007|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-26|2017-05-03|2016-11-26||September 2007||2007-09-01|May 2017|2017-05-01|April 2012|Actual|2012-04-01|January 2012|Actual|2012-01-01||Interventional|||Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer|Phase II Trial Evaluating Addition of Fulvestrant to Erlotinib in Patients With Stage IIIB/IV NSCLC Who Are Stable on Erlotinib and Exhibit Positivity for Estrogen or Progesterone Receptor|Terminated||Phase 2|7|Actual|University of California, San Diego||1||Study was terminated due to slow subject accrual|f||||t||||||||||2017-10-11 08:00:32.186039|2017-10-11 08:00:32.186039
NCT00592085|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-27|2016-07-18|||December 2007||2007-12-01|September 2009|2009-09-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional|||Combined Treatment for Tobacco and Alcohol Use|Combined Treatment for Tobacco and Alcohol Use|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||2||No patients registered; study terminated.|f||||t||||||||||2017-10-11 08:00:33.344751|2017-10-11 08:00:33.344751
NCT00593957|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-04|2014-03-26|2013-03-08||August 2004||2004-08-01|July 2013|2013-07-01|June 2010|Actual|2010-06-01|April 2010|Actual|2010-04-01||Interventional|||Trial of Dextromethorphan in Rett Syndrome|Trial of Dextromethorphan in Rett Syndrome|Terminated||Phase 2|38|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|The trial was terminated due to the FDA requiring a placebo controlled trial instead of the ongoing open label trial. As recruitment was delayed,the total number of participants was also less than anticipated.|3||Study changed to a placebo controlled trial of dextromethorphan|f||||t||||||||||2017-10-11 08:01:13.149629|2017-10-11 08:01:13.149629
NCT00597909|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-09|2016-03-01|2016-02-03||December 2007||2007-12-01|March 2016|2016-03-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy|Terminated||Phase 2|1|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland|One participant was enrolled but did not receive drug or was randomized.|3||Study was terminated due to lack of enrollment and business decisions.|f||||t||||||||||2017-10-11 08:01:59.234032|2017-10-11 08:01:59.234032
NCT00598104|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-09|2016-03-02|||January 2008||2008-01-01|March 2016|2016-03-01||||December 2008|Actual|2008-12-01||Interventional|||Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma|A Randomized, Double-blinded, Placebo Controlled, Parallel Group, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Doses of QAX576 in Moderate Persistent Allergic Asthmatics Following Inhaled Corticosteroid Withdrawal|Withdrawn||Phase 1/Phase 2|0|Actual|Novartis||2||"Due to the lack of enrolment and complexity of design, this study in asthma was terminated. No   subjects have been dosed for this study."|||||f||||||||||2017-10-11 08:02:02.040904|2017-10-11 08:02:02.040904
NCT00599053|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-10|2017-04-17|2012-05-30||May 2007||2007-05-01|April 2017|2017-04-01|August 2009|Actual|2009-08-01|July 2009|Actual|2009-07-01||Interventional|||Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates|Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates|Terminated||Phase 1/Phase 2|7|Actual|University of Alabama at Birmingham|Early termination due to small number enrolled.|2||"Enrollment was terminated early due to a change in practice on the obstetrical side that   included administering azithromycin to women with preterm labor."|f||||t||||||||||2017-10-11 08:02:23.358391|2017-10-11 08:02:23.358391
NCT00588861|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-19|2017-01-26|2010-06-14||September 2002||2002-09-01|January 2012|2012-01-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Shell Using Simplex® or Palacos® Bone Cement|Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Acetabular Shell Using Simplex® or Palacos® Bone Cement|Terminated||N/A|400|Actual|Zimmer Biomet|Study was terminated prematurely after sponsor no longer distributed the products involved and follow-up failed to produce sufficient data to be analyzed.|2||Study was terminated due to insufficient data and lack of patient follow-up|f||||f||||||||||2017-10-11 08:02:48.630901|2017-10-11 08:02:48.630901
NCT00589550|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-05|2015-06-04|2015-05-06||February 2008||2008-02-01|June 2015|2015-06-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|||PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase I Study Of Peginterferon Alfa-2b (PEG-INTRON) With Sorafenib (Nexavar) In Patients With Unresectable Or Metastatic Clear Cell Renal Carcinoma (RCC).|Terminated||Phase 1|1|Actual|Ohio State University Comprehensive Cancer Center|Trial was terminated due to low patient accrual|1||low accrual|f||||t||||||||||2017-10-11 08:02:52.843181|2017-10-11 08:02:52.843181
NCT00590538|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-27|2011-06-29|2010-11-15||February 2003||2003-02-01|June 2011|2011-06-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)|A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygous Cystic Fibrosis Patients|Terminated||Phase 1/Phase 2|9|Actual|Children's Hospital of Philadelphia|No analysis was completed on data collected; More clinically efficacious compounds have been identified which suggested that completion of this study might not be as critical as when initially proposed; therefore, the study was terminated by PI.|2||12/15/2008 Voluntarily placed on inactive status-requested by the PI|f||||t||||||||||2017-10-11 08:03:10.814186|2017-10-11 08:03:10.814186
NCT00590603|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-26|2014-01-07|||July 2008||2008-07-01|December 2012|2012-12-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|AAV||Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Arsenic Trioxide (Trisenox), Ascorbic Acid and Bortezomib Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 1|25|Actual|Duke University||1||Poor accrual - terminated during Phase I; Phase II never started.|f||||t||||||||||2017-10-11 08:03:13.771283|2017-10-11 08:03:13.771283
NCT00590889|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-26|2015-11-18|2015-06-22||July 1998||1998-07-01|November 2015|2015-11-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional|AVERT|1 subject age is missing|Artificial Valve Endocarditis Reduction Trial|Artificial Valve Endocarditis Reduction Trial|Terminated||N/A|807|Actual|St. Jude Medical|This study was terminated early. No final report was created.|2||"A post-PMA begun in 1998; enrollment halted in 2000 due to an anomaly in one study arm. The   protocol required annual study visits after 2000."|f||||t||||||||||2017-10-11 08:03:17.459082|2017-10-11 08:03:17.459082
NCT00591019|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-27|2015-09-23|2011-02-28||August 2006||2006-08-01|September 2015|2015-09-01|June 2008|Actual|2008-06-01|March 2008|Actual|2008-03-01||Interventional|||Use of Modafinil in the Treatment of Tinnitus|Use of Modafinil in the Treatment of Tinnitus|Terminated||Phase 1|7|Actual|University of Arkansas|Study was terminated early due to lack of change in primary and secondary outcome measures.|2||Terminated early due to lack of change in primary and secondary outcome measures.|f||||f||||||||||2017-10-11 08:03:21.512868|2017-10-11 08:03:21.512868
NCT00601198|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-14|2010-03-22|||October 2006||2006-10-01|March 2010|2010-03-01|February 2010|Actual|2010-02-01|February 2010|Actual|2010-02-01||Interventional|||A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer|Phase II Study of the Efficacy of Amifostine (Ethyol) in Reducing the Incidence and Severity of Oxaliplatin-Induced Neuropathy in Patients With Colorectal Cancer|Terminated||Phase 2|97|Anticipated|University of Cincinnati||1||Funding support withdrawn|f||||f||||||||||2017-10-11 08:04:00.654867|2017-10-11 08:04:00.654867
NCT00595023|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-04|2016-01-11|||December 2007||2007-12-01|January 2010|2010-01-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Observational|||GeneSearch Breast Lymph Node (BLN) Assay Timing Study|GeneSearch Breast Lymph Node (BLN) Assay Timing Study|Terminated||Phase 4|233|Actual|Janssen Diagnostics, LLC|||1|GeneSearch™ BLN Assay has been voluntarily withdrawn from the US market.|f||||f||||||||||2017-10-11 08:04:55.475988|2017-10-11 08:04:55.475988
NCT00595296|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-04|2016-01-11|||December 2007||2007-12-01|January 2016|2016-01-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Observational|||GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study|GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study|Terminated||N/A|461|Actual|Janssen Diagnostics, LLC|||1|GeneSearch™ BLN Assay has been voluntarily withdrawn from the US market.|f||||f||||||Samples With DNA|"     Samples of the lymph node tissue homogenate and RNA extract are collected if the subject     gives permission via the informed consent form.   "|||2017-10-11 08:04:59.583475|2017-10-11 08:04:59.583475
NCT00596778|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-08|2008-01-16|||February 2004||2004-02-01|January 2008|2008-01-01|December 2004|Actual|2004-12-01|December 2004|Actual|2004-12-01||Interventional|||Chest Physiotherapy on Immediate Postoperative in Patients Submitted to High Abdominal Surgery|Chest Physiotherapy on Immediate Postoperative in Patients Submitted to High Abdominal Surgery|Terminated||N/A|31|Actual|University of Sao Paulo||1||terminated|f||||f||||||||||2017-10-11 08:05:23.923454|2017-10-11 08:05:23.923454
NCT00596830|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-03|2013-12-11|2013-09-25|2011-04-22|April 2008||2008-04-01|December 2013|2013-12-01|September 2012|Actual|2012-09-01|March 2011|Actual|2011-03-01||Interventional|||Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology|Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer|Terminated||Phase 3|681|Actual|Pfizer|The study was terminated early due to futility. CP-751,871 will not undergo further development in the indication of advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).|2||See termination reason in detailed description.|f||||t||||||||||2017-10-11 08:05:25.176967|2017-10-11 08:05:25.176967
NCT00596947|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-08|2017-03-29|2011-02-18||October 2005||2005-10-01|March 2017|2017-03-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional|||Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant|Randomized, Prospective Single-center Study Comparing a Rapid Discontinuation of Corticosteroids (Steroid Withdrawal) With Corticosteroid Therapy in Kidney Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy|Terminated||Phase 4|18|Actual|University of Pennsylvania|The trial was terminated early due to low enrollment. Therefore no results beyond basic results section are reported due to uninterpretable data.|2||due to low study enrollment|f||||f||||||||||2017-10-11 08:05:28.195238|2017-10-11 08:05:28.195238
NCT00603525|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-16|2014-05-22|2011-10-20||January 2008||2008-01-01|April 2014|2014-04-01|July 2013|Actual|2013-07-01|March 2011|Actual|2011-03-01||Interventional|||Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy|A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Patients With Active Rheumatoid Arthritis Who Have Previously Had an Inadequate Response to One or More TNF Antagonist Therapies|Terminated||Phase 3|169|Actual|GlaxoSmithKline||2||"Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical   development of autoimmune indications on the subcutaneous delivery."|f||||f||||||||||2017-10-11 08:05:48.431876|2017-10-11 08:05:48.431876
NCT00604565|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-17|2015-08-05|2015-03-11||January 2008||2008-01-01|August 2015|2015-08-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients|A Prospective, Randomized, Open-label, Multi-center, Controlled Clinical Trial of the Safety and Efficacy of Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate|Terminated||N/A|11|Actual|Charles Drew University of Medicine and Science|Study suspended after 1st 11 subjects enrolled. Study design changed significantly upon re-initiation, so 1st 11 subjects analyzed for safety only; no efficacy. Efficacy analysis from study after re-initiation is found under protocol NIH-FP-01 PRIME.|2||major planned changes to study design|f||||f||||||||||2017-10-11 08:06:11.094551|2017-10-11 08:06:11.094551
NCT00589303|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-21|2013-02-25|2013-02-25||December 2007||2007-12-01|February 2013|2013-02-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional|PACIFIC||AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study|Pacing and AV Node Ablation Compared to Drug Therapy in Symptomatic Elderly Patients With Atrial Fibrillation Clinical Trial (PACIFIC) - Pilot Study|Terminated||Phase 3|27|Actual|Mayo Clinic|The study was terminated when about half of the subjects were enrolled due to lack of funding.|2||Lack of funding|f||||t||||||||||2017-10-11 08:06:54.425368|2017-10-11 08:06:54.425368
NCT00594906|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-07|2014-12-03|2012-10-24||January 2008||2008-01-01|March 2013|2013-03-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional|||Use of Teriparatide to Accelerate Fracture Healing|Use of Teriparatide to Accelerate Fracture Healing|Terminated||N/A|10|Actual|University of Rochester|Early termination leading to small numbers of subjects analyzed.|2||The study was terminated due to poor enrollment.|f||||f||||||||||2017-10-11 08:06:56.830736|2017-10-11 08:06:56.830736
NCT00606541|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-22|2014-07-31|||January 2008||2008-01-01|December 2012|2012-12-01|November 2012|Actual|2012-11-01|December 2011|Actual|2011-12-01||Interventional|||An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)|An Open Label, Double-blind Discontinuation Study of Quetiapine (Extended Release) XR in Social Anxiety Disorder|Terminated||Early Phase 1|55|Actual|Duke University||2||The study was terminated by the sponsor due to budgetary issues|f||||t||||||||||2017-10-11 08:07:05.744442|2017-10-11 08:07:05.744442
NCT00606554|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-03|2013-07-24|2011-02-07||January 2008||2008-01-01|June 2011|2011-06-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Clinical Trial of a Computer-driven Weaning System for Patients Requiring Mechanical Ventilation|A Randomized Controlled Trial of Computer-Driven Weaning Compared With Standard of Care Weaning in Medical Patients Requiring Mechanical Ventilation|Terminated||N/A|33|Actual|Boston Medical Center|This trial was terminated early due to slow recruitment. It did not reach the target N of 220.|2||Slow recruitment of subjects|f||||f||||||||||2017-10-11 08:07:05.84609|2017-10-11 08:07:05.84609
NCT00607477|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-22|2014-06-03|2010-11-22||January 2008||2008-01-01|June 2014|2014-06-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|||Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension|A Pilot Study of the Treatment of VEGF-Signaling Pathway Inhibitor-Induced Hypertension With Direct Vasodilators, Minoxidil and Hydralazine|Terminated||N/A|2|Actual|University of Chicago|This study enrolled only 2 subjects and due to poor accrual, enrollment was stopped early. Due to the limited number of subjects available results cannot be assessed.|2||Study has been terminated due to poor accrual.|f||||f||||||||||2017-10-11 08:07:43.156068|2017-10-11 08:07:43.156068
NCT00607711|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-24|2008-04-30|||March 2008||2008-03-01|January 2008|2008-01-01|November 2009|Anticipated|2009-11-01|November 2009|Anticipated|2009-11-01||Interventional|||Study of Oral Palifosfamide Tris in Solid Tumors|A Phase I Study of Oral Palifosfamide Tris in Advanced, Refractory, Solid Tumors|Suspended||Phase 1|20|Anticipated|Ziopharm||1||IND was withdrawn|f||||f||||||||||2017-10-11 08:07:45.931162|2017-10-11 08:07:45.931162
NCT00608777|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-23|2012-08-07|2012-03-05||January 2008||2008-01-01|August 2012|2012-08-01|February 2009|Actual|2009-02-01|February 2009|Actual|2009-02-01||Interventional|||Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)|Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Mild Breakthrough in Moderate to Severe Plaque Psoriasis Patients Receiving Efalizumab ( Raptiva).|Terminated||Phase 4|6|Actual|Derm Research, PLLC|Study terminated due to withdrawal of Raptiva from the market. Study specifically designed to address a side effect associated with the administration of Raptiva. Therefore no data analysis completed for this study and no measuremnet of outcomes.|1||Withdrawal of marketing autorization of efalizumab by the EMEA.|f||||f||||||||||2017-10-11 08:08:15.931137|2017-10-11 08:08:15.931137
NCT00609440|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-25|2008-10-17|||January 2006||2006-01-01|January 2008|2008-01-01|May 2007|Actual|2007-05-01|August 2006|Actual|2006-08-01||Interventional|||Morquio's Syndrome: a Case Study|Morquio's Syndrome: a Case Study|Terminated||Phase 4|1|Actual|Clínica de Hidroterapia e Recuperacao Funcional||1||terminated|f||||f||||||||||2017-10-11 08:08:27.952837|2017-10-11 08:08:27.952837
NCT00609739|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-06|2012-01-31|2011-11-22||June 1999||1999-06-01|January 2012|2012-01-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation|Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation|Terminated||Phase 1/Phase 2|1|Actual|Masonic Cancer Center, University of Minnesota|Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.|1||Low accrual|f||||t||||||||||2017-10-11 08:08:37.553595|2017-10-11 08:08:37.553595
NCT00611455|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-16|2017-05-31|2011-09-21||January 1, 2008||2008-01-01|April 2017|2017-04-01|July 15, 2013|Actual|2013-07-15|June 8, 2009|Actual|2009-06-08||Interventional|||Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy|A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy|Terminated||Phase 3|265|Actual|GlaxoSmithKline||2||"Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical   development of autoimmune indications on the subcutaneous delivery."|f||||f||||||||||2017-10-11 08:09:00.005249|2017-10-11 08:09:00.005249
NCT00612222|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-08|2015-10-06|2012-03-13||January 2008||2008-01-01|October 2015|2015-10-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization|Terminated||Phase 2|4|Actual|National Institutes of Health Clinical Center (CC)|Early termination leading to small numbers of subjects analyzed.|1||The study was terminated due to low accrual.|f||||t||||||||||2017-10-11 08:09:19.949995|2017-10-11 08:09:19.949995
NCT00612833|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-29|2013-09-09|||January 2009||2009-01-01|September 2013|2013-09-01||||||||Interventional|||A Randomized Controlled Trial of Three Vasectomy Techniques|A Randomized Controlled Trial of Three Vasectomy Techniques|Terminated||N/A|||FHI 360||3||FHI 360 participation in the study was terminated due to lack of funding|f||||t||||||||||2017-10-11 08:09:35.066577|2017-10-11 08:09:35.066577
NCT00613509|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-16|2016-04-12|2010-09-14||June 2008||2008-06-01|April 2016|2016-04-01|June 2010|Actual|2010-06-01|April 2010|Actual|2010-04-01||Interventional|||Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma|Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma|Terminated||Phase 2|23|Actual|Sanofi||2||"No safety concerns, the study was terminated due to slow enrollment. All enrolled patients were   followed per protocol."|f||||t||||||||||2017-10-11 08:09:44.952424|2017-10-11 08:09:44.952424
NCT00613886|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-03|2013-06-26|||March 2006||2006-03-01|June 2013|2013-06-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|NPH||Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus|Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus|Terminated||N/A|16|Actual|University of California, Irvine||1||"Funding was withdrawn by Codman as expected number of patient subjects enrolled did not meet   expected numbers."|f||||f||||||||||2017-10-11 08:09:59.91778|2017-10-11 08:09:59.91778
NCT00616109|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-04|2014-03-13|2013-02-07||September 2007||2007-09-01|March 2014|2014-03-01|January 2011|Actual|2011-01-01|December 2009|Actual|2009-12-01||Interventional||Lung cancer patients who are greater than or equal to 18 years old, who have had a response or maintained stable disease after undergoing no more that 4 cycles with platinum with etoposide chemotherapy|Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC|Phase II Trial of Sunitinib (Sutent, SU11248) Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer|Completed||Phase 2|16|Actual|University of Michigan Cancer Center|The trial was to be terminated at stage 1 if less than, or equal to, 8 patients were progression free at 4 months. The PFS rate did not reach the threshold required for study continuation and, therefore, the study was discontinued early.|1|||f||||t||||||||||2017-10-11 08:10:12.125043|2017-10-11 08:10:12.125043
NCT00616902|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-05|2012-01-18|2010-05-21||January 2009||2009-01-01|January 2012|2012-01-01|May 2009|Actual|2009-05-01|May 2009|Actual|2009-05-01||Interventional|PRIMO II||The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5|Clinical Study Protocol M10-221 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5|Terminated||Phase 3|12|Actual|Abbott|This study was prematurely terminated due to low enrollment. Only 12 subjects were randomized at 10 investigative sites with none of the subjects completing the study.|2||This study was prematurely terminated due to low enrollment|f||||t||||||||||2017-10-11 08:10:25.425538|2017-10-11 08:10:25.425538
NCT00617058|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-05|2012-11-28|2012-10-29||March 2007||2007-03-01|November 2012|2012-11-01|September 2010|Actual|2010-09-01|June 2010|Actual|2010-06-01||Interventional|ZAC||Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine|Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine|Terminated||Phase 2|1|Actual|University of North Carolina, Chapel Hill|In terms of study limitations, this research study was only able to enroll a single study participant before the trial was terminated prematurely due to study start-up for a larger, multisite effort examining similar outcome measures.|3||Terminated in lieu of similar,competing large, multi-site study.|f||||t||||||||||2017-10-11 08:10:31.666455|2017-10-11 08:10:31.666455
NCT00617279|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-18|2011-12-08|2011-02-07||December 2007||2007-12-01|December 2011|2011-12-01|February 2010|Actual|2010-02-01|February 2010|Actual|2010-02-01||Interventional|PRODIGY||GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft|Comparison of Primary Patency Between GORE PROPATEN Vascular Graft and Disadvantaged Autologous Vein Graft For Below-Knee Arterial Bypass (PRODIGY Study)|Terminated||Phase 4|31|Actual|W.L.Gore & Associates|The study was terminated prior to completion of enrollment. The primary patency and secondary endpoints were not calculated due to the paucity of data.|2||Study terminated due to low enrollment|f||||f||||||||||2017-10-11 08:10:37.669163|2017-10-11 08:10:37.669163
NCT00617864|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-05|2012-02-20|||September 2007||2007-09-01|February 2012|2012-02-01||||||||Interventional|||The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome|The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome.|Withdrawn||N/A|0|Actual|Yale University||2||"The syndrome of hyperstimulation is so rare that after one year no patients were eligible.The   study was withdrawn and never started."|f||||t||||||||||2017-10-11 08:10:56.522471|2017-10-11 08:10:56.522471
NCT00617890|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-17|2017-05-15|2015-11-09||February 1, 2008|Actual|2008-02-01|May 2017|2017-05-01|August 31, 2013|Actual|2013-08-31|August 31, 2011|Actual|2011-08-31||Interventional||Three participants did not receive study treatment but are included in the baseline population.|A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)|A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy|Terminated||Phase 2|219|Actual|Merck Sharp & Dohme Corp.|The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed.|4||The study was prematurely terminated for strategic reasons, not for a safety concern.|f||||f||||||||||2017-10-11 08:10:56.799908|2017-10-11 08:10:56.799908
NCT00610311|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-06|2015-10-06|2012-03-14||January 2008||2008-01-01|September 2015|2015-09-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)|Early termination leading to a small number of subjects analyzed.|1||The study was terminated due to low accrual.|f||||t||||||||||2017-10-11 08:11:04.924242|2017-10-11 08:11:04.924242
NCT00610935|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-25|2014-12-15||2011-12-21|January 2007||2007-01-01|December 2014|2014-12-01|September 2008|Actual|2008-09-01|June 2008|Actual|2008-06-01||Interventional|||Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza.|Terminated||Phase 3|82|Actual|BioCryst Pharmaceuticals||2||This study was terminated for administrative reasons.|f||||t||||||||||2017-10-11 08:11:16.765127|2017-10-11 08:11:16.765127
NCT00618358|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-08|2015-03-26|||March 2007||2007-03-01|January 2010|2010-01-01||||||||Interventional|VSS||Vascular Sealant Study|A Prospective, Randomized, Multi-Center, Two Arm Study to Evaluate the Safety and Effectiveness of the Vascular Sealant System Compared With Gelfoam/Thrombin for Control of Anastomosis Suture Line Bleeding in Patients Undergoing Vascular Reconstructive Surgery With PTFE Grafts|Terminated||Phase 1|||Georgetown University||2||Sponsor - Confluent Surgical terminated study re: surgical techniques Letter dated 4/31/2008|f||||t||||||||||2017-10-11 08:11:23.585871|2017-10-11 08:11:23.585871
NCT00620048|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-07|2015-03-30|||March 2008||2008-03-01|November 2011|2011-11-01||||January 2011|Actual|2011-01-01||Interventional|||Stem Cell Study for Subjects With Congestive Heart Failure|Injection of Autologous CD34+ Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia and LVEF < 40%|Terminated||Phase 1|4|Actual|Losordo, Douglas, M.D.||2||Study terminated due to lack of funding.|f||||f||||||||||2017-10-11 08:12:03.523151|2017-10-11 08:12:03.523151
NCT00620100|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-11|2009-05-29|||September 2004||2004-09-01|May 2009|2009-05-01|April 2005|Actual|2005-04-01|April 2005|Actual|2005-04-01||Interventional|||To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent|A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel (Taxotere®) + Anthracycline (Epirubicin or Doxorubicin) x 4 Cycles Followed by Docetaxel (T) Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed > or = 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere®-Based Chemotherapy|Terminated||Phase 2|2|Actual|Sanofi||1||the study was early terminated due to lack of recruitment.|f||||||||||||||2017-10-11 08:12:04.173159|2017-10-11 08:12:04.173159
NCT00615160|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-31|2011-01-11|||December 2006||2006-12-01|December 2007|2007-12-01||||September 2008|Actual|2008-09-01||Interventional|||PTK/ZK in Disseminated Malignant Melanoma|Phase II Randomized, Parallel-Group Trial on PTK-ZK With or Without DTIC in Patients With Non-resectable Metastatic Malignant Melanoma|Suspended||Phase 1/Phase 2|30|Anticipated|University of Schleswig-Holstein||2||Substance was withdrawn from further development.|f||||t||||||||||2017-10-11 08:12:57.836075|2017-10-11 08:12:57.836075
NCT00615329|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-01|2014-11-24|||April 2003||2003-04-01|November 2014|2014-11-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Observational|||Huntsman Biopsy Study|The Huntsman Cancer Institute - The Use of Microarray Analysis in Characterizing Mesenchymal Tissue Tumors: Differentiation of Normal, Benign, and Malignant Conditions|Terminated||N/A|142|Actual|State University of New York - Upstate Medical University|||1|Huntmans Cancer Institute terminated study|f||||f||||||Samples With DNA|"     cDNA microarrays facilitate the systematic and comprehensive analysis of transcriptional     alterations occurring in diseased tissues.   "|||2017-10-11 08:13:01.328946|2017-10-11 08:13:01.328946
NCT00615381|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-21|2015-04-21|||January 2009||2009-01-01|April 2015|2015-04-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|||Supraphysiologic Insulin to Improve Outcomes After Surgical Treatment of Unruptured Cerebral Aneurysms|Clinical Trial of Euglycemia Maintenance With Supraphysiologic Insulin vs Conventional Intensive Insulin Therapy to Improve Outcomes (Neurologic, Neuropsychiatric, and Biomarkers) After Surgical Treatment of Unruptured Cerebral Aneurysms|Withdrawn||N/A|0|Actual|Northwestern University||2||Study was not initiated and has been withdrawn due to lack of appropriate cases|f||||f||||||||||2017-10-11 08:13:01.842241|2017-10-11 08:13:01.842241
NCT00622531|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-14|2015-11-16|||January 2007||2007-01-01|November 2015|2015-11-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Observational|USE-BNP||Serial BNP Testing for Heart Failure Management|Utilizing, Studying, Evaluating BNP for Monitoring in Patients With Heart Failure (USE-BNP)|Terminated||N/A|108|Actual|Siemens Healthcare Diagnostics Inc|||2|Study terminated due to insufficient enrollment|f||||f||||||Samples Without DNA|"     plasma   "|||2017-10-11 08:13:42.946534|2017-10-11 08:13:42.946534
NCT00623727|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-09|2013-07-08|2011-06-10||June 2008||2008-06-01|July 2013|2013-07-01|October 2010|Actual|2010-10-01|April 2010|Actual|2010-04-01||Interventional|||BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A|Randomized, Active-controlled, Double-blind, Parallel Design Study to Evaluate the Efficacy and Safety of a Once-a-week Prophylaxis Treatment With BAY79-4980 Compared to Three Times-per-week Prophylaxis With rFVIII-FS in Previously Treated Patients With Severe Hemophilia A|Terminated||Phase 2|143|Actual|Bayer|The recruitment and double-blind study phase were prematurely terminated after a scheduled interim analysis confirmed overt failure regarding the primary endpoint as judged by the independent Data and Safety Monitoring Board.|2|||f||||t||||||||||2017-10-11 08:14:13.171063|2017-10-11 08:14:13.171063
NCT00623909|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-14|2017-02-03|||January 2008||2008-01-01|February 2017|2017-02-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||Laser Therapy in the Treatment of Post Thoracotomy Pain; A Pilot Study|Laser Therapy in the Treatment of Post Thoracotomy Pain; A Pilot Study.|Withdrawn||N/A|0|Actual|Weill Medical College of Cornell University||1||Principal Investigator left the institution|f||||f||||||||No|Not Applicable, study terminated prior to enrollment and closed|2017-10-11 08:14:18.229229|2017-10-11 08:14:18.229229
NCT00624468|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-15|2016-01-19|2016-01-19||June 2008||2008-06-01|January 2016|2016-01-01|January 2011|Actual|2011-01-01|September 2009|Actual|2009-09-01||Interventional||Intent-to-treat (ITT) population included all randomized participants.|Atacicept in Subjects With Optic Neuritis|A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course|Terminated||Phase 2|34|Actual|EMD Serono|The Sponsor voluntarily terminated this trial after observing increased Multiple Sclerosis (MS) disease activity in trial 28063 (ATAMS).|2||"EMD Serono voluntarily decided to terminate this trial after observing increased MS disease   activity in trial 28063 ATAMS [Please refer to ATAMS]"|f||||t||||||||||2017-10-11 08:14:32.046285|2017-10-11 08:14:32.046285
NCT00627497|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-21|2012-04-24|2011-11-29||February 2008||2008-02-01|April 2012|2012-04-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion|A Prospective, Randomized, Controlled Pivotal Clinical Investigation of DIAM™ Spinal Stabilization System in Patients With Degenerative Lumbar Spinal Stenosis.|Terminated||Phase 3|32|Actual|Medtronic Spinal and Biologics|Studies terminated before full cohort of participants were enrolled. Data and adverse events presented are through 24 months of follow-up.|4||slow patient recruitment|f||||t||||||||||2017-10-11 08:14:48.231082|2017-10-11 08:14:48.231082
NCT00627913|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-25|2010-04-22|||February 2008||2008-02-01|January 2008|2008-01-01|May 2010|Anticipated|2010-05-01|May 2010|Anticipated|2010-05-01||Interventional|||Retrobulbar Injection of Anesthesia Versus Healon 5 in the Management of Intraoperative Floppy Iris Syndrome|Retrobulbar Injection of Anesthesia Versus Injection of Healon 5 Viscoelastic Into the Anterior Chamber in the Management of Intraoperative Floppy Iris Syndrome|Terminated||N/A|6|Actual|Penn State University||2||Study terminated due to insufficient subject participation|f||||t||||||||||2017-10-11 08:14:55.272052|2017-10-11 08:14:55.272052
NCT00628264|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-25|2009-05-29|||March 2008||2008-03-01|May 2009|2009-05-01|June 2009|Anticipated|2009-06-01|June 2009|Anticipated|2009-06-01||Interventional|||Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery|Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery|Terminated||Phase 2|75|Anticipated|Action Pharma A/S||2||The study was terminated due to a considerably lower recruitment rate than anticipated|f||||t||||||||||2017-10-11 08:15:05.345789|2017-10-11 08:15:05.345789
NCT00629707|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-04|2012-09-12|2012-06-18||June 2008||2008-06-01|September 2012|2012-09-01|June 2011|Actual|2011-06-01|March 2011|Actual|2011-03-01||Interventional|||Cerebral Edema in Pediatric Diabetic Ketoacidosis|Cerebral Edema in Pediatric Diabetic Ketoacidosis|Completed||N/A|20|Actual|University of California, Davis|Study terminated after enrollment of 20 subjects. Review of data from these subjects showed minimal difference between groups and substantial variability suggesting that a larger sample would be very unlikely to show significant differences.|2|||f||||t||||||||||2017-10-11 08:15:21.681684|2017-10-11 08:15:21.681684
NCT00621530|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-11|2017-08-31|2015-06-01||March 2008||2008-03-01|August 2017|2017-08-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement|Effect of Intrathecal Ketorolac on Mechanical Hypersensitivity After Total Hip Arthroplasty|Terminated||Phase 2|62|Actual|Wake Forest University Health Sciences|The trial was terminated because the study drug became unavailable.|2||Terminated due to discontinuation of Acular PF (investigational medication)|f||||t||||||||||2017-10-11 08:15:26.843232|2017-10-11 08:15:26.843232
NCT00622089|ClinicalTrials.gov processed this data on October 10, 2017|2008-01-03|2008-05-22|||January 2008||2008-01-01|May 2008|2008-05-01|December 2008|Anticipated|2008-12-01|December 2008|Anticipated|2008-12-01||Interventional|||Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients|An Open Label Follow-On Study of Safety and Pharmacodynamic Effects of 24 Weeks of Treatment With DIO-902 in Combination With Metformin and Atorvastatin in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-503)|Terminated||Phase 2/Phase 3|150|Anticipated|DiObex||3||Program terminated|f||||f||||||||||2017-10-11 08:15:38.379659|2017-10-11 08:15:38.379659
NCT00622167|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-12|2012-01-03|2011-07-28||January 2008||2008-01-01|January 2012|2012-01-01|June 2009|Actual|2009-06-01|April 2008|Actual|2008-04-01||Interventional|||Comparison of DSCT With IB-IVUS and Angiography in the Assessment of Coronary Artery Disease|Comparison of Dual Source Computed Tomography (DSCT) With Integrated Backscatter Intravascular Ultrasound (IB-IVUS) and Contrast Angiography in the Assessment of Coronary Artery Disease|Terminated||N/A|24|Actual|Massachusetts General Hospital|Study terminated after imaging 4 subjects due to slow enrollment. Results will not be analyzed.|1||Subject recruitment was slow, so enrollment has been closed.|f||||f||||||||||2017-10-11 08:15:38.812055|2017-10-11 08:15:38.812055
NCT00632463|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-03|2013-03-12|2013-02-22||February 2008||2008-02-01|March 2013|2013-03-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness|RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness|Completed||Phase 2|21|Actual|ADMA Biologics, Inc.|Unfortunately enrollment in this study was suspended early due to slow accrual rates.|3|||f||||t||||||||||2017-10-11 08:15:44.505815|2017-10-11 08:15:44.505815
NCT00632541|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-28|2015-12-02|2015-12-02||October 2007||2007-10-01|December 2015|2015-12-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional||From October 2008 to March 2009, 18 patients were enrolled. Nearly half of the patients have triple negative (ER-, PR-, HER2-) disease, and most had received 1 or 2 prior chemotherapy regimens.|A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer|A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109|Terminated||Phase 2|18|Actual|Hoosier Cancer Research Network|The study was terminated early due to a poor safety profile as well as the lack of significant efficacy of this combination over bevacizumab alone in the short followup period where it was evaluated. Therefore, secondary objectives were not analyzed.|1||Significant Toxicities Experienced|f||||t||||||||||2017-10-11 08:15:46.364929|2017-10-11 08:15:46.364929
NCT00634049|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-05|2016-06-09|2015-12-02||April 2008||2008-04-01|June 2016|2016-06-01|May 2016|Actual|2016-05-01|January 2014|Actual|2014-01-01||Interventional|VITAL|Intent to Treat Population (ITT)|Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi|Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi|Completed||Phase 3|149|Actual|Astellas Pharma Inc|Enrollment in the clinical study was suspended in January 2009 pending further characterization of newly identified impurities. After successful study completion resumption of enrollment started in April 2011 for the 9766-CL-0103/WSA-CS-003 study.|1|||f||||t||||||||||2017-10-11 08:16:32.553188|2017-10-11 08:16:32.553188
NCT00634166|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-11|2016-03-15|2014-09-22||September 2007||2007-09-01|April 2013|2013-04-01|April 2014|Actual|2014-04-01|December 2013|Actual|2013-12-01||Interventional||The full analysis set (FAS) consisted of all subjects in the safety analysis set who had at least 1 graft assessment after Day 1. Subjects who had no graft assessments after Day 1 were excluded from the FAS population.|Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group|Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group|Terminated||Phase 4|220|Actual|Mylan Bertek Pharmaceuticals|The study was terminated on 17 June 2013 due to the recommendation and request by the FDA to design a superiority clinical study to satisfy the sponsor’s post marketing study commitment for SS5%.|2||"FDA request as study could not serve as the confirmatory trial as required under Subpart H   approval."|f||||f||||||||||2017-10-11 08:16:36.942074|2017-10-11 08:16:36.942074
NCT00634517|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-07|2013-07-11||2013-07-10|March 2008||2008-03-01|July 2013|2013-07-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma|A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, 4-Week Study to Evaluate the Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Patients With Asthma in Pediatric Patients With Asthma|Terminated||Phase 3|48|Actual|Amphastar Pharmaceuticals, Inc.||2||IND voluntarily withdrawn, without prejudice|f||||f||||||||||2017-10-11 08:16:42.945241|2017-10-11 08:16:42.945241
NCT00634829|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-07|2013-07-11||2013-07-10|February 2008||2008-02-01|July 2013|2013-07-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|||Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction|Randomized, Double-Blind, Controlled, Single-Dose, Three-Treatment, Cross-Over Study of The Protective Effects Of Albuterol-HFA In Preventing Exercise-Induced Bronchoconstriction In Adolescent And Adult Asthmatic Patients|Terminated||Phase 3|24|Actual|Amphastar Pharmaceuticals, Inc.||3||IND voluntarily withdrawn, without prejudice|f||||f||||||||||2017-10-11 08:16:48.123744|2017-10-11 08:16:48.123744
NCT00625729|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-26|2012-11-06|2010-07-02||January 2008||2008-01-01|November 2012|2012-11-01|April 2010|Actual|2010-04-01|December 2009|Actual|2009-12-01||Interventional|||Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia|MT2007-12 Allogeneic Natural Killer Cells With Rituximab in Patients With CD20 Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. Strategies to Increase Sensitivity of CLL Tumor Cells to Natural Killer Cell-Immune-Mediated Cytolysis|Terminated||Phase 1/Phase 2|6|Actual|Masonic Cancer Center, University of Minnesota|Study was terminated early due to lack of NK expansion and failure to meet primary outcome.|1||No patients exhibited natural killer cell expansion (primary endpoint).|f||||t||||||||||2017-10-11 08:16:58.384199|2017-10-11 08:16:58.384199
NCT00625833|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-14|2009-02-16|||December 2007||2007-12-01|February 2009|2009-02-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional|||A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.|A Randomized, Double-Blind Placebo Controlled Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.|Terminated||Phase 2|330|Anticipated|Pfizer||2||Study was terminated for futility following the planned interim analysis.|f||||f||||||||||2017-10-11 08:16:59.696146|2017-10-11 08:16:59.696146
NCT00625872|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-19|2012-01-27|2012-01-27||July 2008||2008-07-01|January 2012|2012-01-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|SGA-POWER||Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy|Neuromuscular Changes In Small For Gestational Age (SGA) Children During Somatropin Therapy - A Prospective Randomized, Controlled, Open-Label Multicenter Trial|Terminated||Phase 3|23|Actual|Pfizer|The study was prematurely discontinued, therefore not all data was powered.|2||"The study terminated on 19-Jan-2011 due to insufficient recruitment of patients. No safety   reasons contributed to the termination of the study."|f||||f||||||||||2017-10-11 08:17:00.262802|2017-10-11 08:17:00.262802
NCT00626444|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-21|2016-10-19|2014-11-24||February 2008||2008-02-01|October 2016|2016-10-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)|Phase II Trial of High Dose Intravenous Vitamin C in Patients With Refractory Non-Hodgkin Lymphoma|Terminated||Phase 2|2|Actual|Thomas Jefferson University|Study was terminated due to poor accrual. No reportable data has been collected for any of the specified outcome measures.|1||Slow accrual|f||||t||||||||||2017-10-11 08:17:14.038681|2017-10-11 08:17:14.038681
NCT00626574|ClinicalTrials.gov processed this data on October 10, 2017|2008-02-07|2012-09-25|2011-09-08||July 2007||2007-07-01|September 2012|2012-09-01|February 2009|Actual|2009-02-01|February 2009|Actual|2009-02-01||Interventional|EPO||Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa|A Double Blinded, Placebo Controlled, Pilot Study to Evaluate the Safety of Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa|Terminated||Phase 4|3|Actual|University of South Florida|In late October 2008, we received a letter from the sponsor requesting that we terminate any further work on this study.|2||"This study is terminated as a result of data from a study that showed increased mortality in   stroke patients."|f||||t||||||||||2017-10-11 08:17:19.011846|2017-10-11 08:17:19.011846
NCT00634933|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-05|2013-02-06|2012-12-27|2012-07-17|March 2008||2008-03-01|February 2013|2013-02-01|October 2012|Actual|2012-10-01|February 2010|Actual|2010-02-01||Interventional|||Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis|A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate|Terminated||Phase 2|222|Actual|Pfizer|As the results of the primary analysis did not meet the predefined efficacy criteria, the development of TRU-015 was discontinued.|3||"The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No   safety reasons contributed to the termination of the study."|f||||f||||||||||2017-10-11 08:17:33.192966|2017-10-11 08:17:33.192966
NCT00636441|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-09|2015-11-16|2014-05-07||April 2008||2008-04-01|October 2014|2014-10-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional||All patients who signed a consent form are included in the baseline analysis.|Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer|A Randomized Phase II Trial Evaluating the Performance of Genomic Expression Profiles to Direct the Use of Preoperative Chemotherapy for Early Stage Breast Cancer|Terminated||Phase 2|56|Actual|Duke University||2||Study terminated due to reproducibility issues with genomics prediction model|f||||f||||||||||2017-10-11 08:17:58.990429|2017-10-11 08:17:58.990429
NCT00637312|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-10|2014-02-12|2014-02-12||March 2008||2008-03-01|February 2014|2014-02-01|February 2013|Actual|2013-02-01|July 2011|Actual|2011-07-01||Interventional|||Advent™ Cervical Disc Versus ACDF for Treatment of One Level Degenerative Disc Disease (IDE Study)|Clinical Trial Comparing the Blackstone Advent™ Cervical Disc to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of One Level Degenerative Disc Disease|Terminated||N/A|108|Actual|Orthofix Inc.|The study was suspended for a high rate of adverse events in the treatment group. Enrollment was stopped and patients were followed for 36 months in the Advent group. Approval is not being pursued and thus no analysis has been completed.|2||Greater-than-anticipated rate of revisions|f||||t||||||||||2017-10-11 08:18:21.911885|2017-10-11 08:18:21.911885
NCT00637780|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-11|2017-01-03|2016-09-20||June 2010||2010-06-01|January 2017|2017-01-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional||The only 2 participants who were enrolled and completed the study at study termination were included in all analyses.|Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis|An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis|Terminated||Phase 4|2|Actual|Pfizer|The study was terminated prematurely and only 2 participants were enrolled and completed the study.|1||"Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns   contributed to the termination of the study"|f||||f||||||||||2017-10-11 08:18:32.776526|2017-10-11 08:18:32.776526
NCT00638157|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-12|2016-01-05|2013-03-04||March 2008||2008-03-01|January 2016|2016-01-01|November 2011|Actual|2011-11-01|November 2011|Actual|2011-11-01||Interventional||Intent-to-Treat (ITT) Population used. Includes all randomized subjects.|Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)|A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin® (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis|Terminated||Phase 4|24|Actual|Cubist Pharmaceuticals LLC|As the study was terminated prematurely, conclusions that can be drawn from the efficacy results are limited.|2||commitment completed|f||||f||||||||||2017-10-11 08:18:37.904774|2017-10-11 08:18:37.904774
NCT00630994|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-06|2015-11-25|2012-01-09||March 2008||2008-03-01|November 2012|2012-11-01|April 2012|Actual|2012-04-01|August 2009|Actual|2009-08-01||Interventional|||Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis|Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis|Terminated||Phase 2|4|Actual|Mayo Clinic|Study terminated early. Most analyses were not performed.|1||Stopped due to slow accrual|f||||t||||||||||2017-10-11 08:18:58.292337|2017-10-11 08:18:58.292337
NCT00638378|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-12|2012-01-20|2011-12-15|2010-06-17|February 2008||2008-02-01|January 2012|2012-01-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|||Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer|A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer|Terminated||Phase 2|22|Actual|Incyte Corporation||1||"According to the protocol, the sponsor terminated the study after it was determined that less   than 2 of the first 22 patients showed a PSA50 response."|f||||f||||||||||2017-10-11 08:19:31.483477|2017-10-11 08:19:31.483477
NCT00638482|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-12|2008-03-17|||July 2003||2003-07-01|July 2003|2003-07-01|December 2005|Actual|2005-12-01|December 2005|Actual|2005-12-01||Interventional|DESY||Dose-Dependent Effect of Thiazide in Dent's Disease Hypercalciuria|Pharmacodynamic Evaluation of the ANTICALCIURIC Effect of Hydrochlorothiazide in Dent's Disease|Terminated||Phase 2/Phase 3|10|Actual|Assistance Publique - Hôpitaux de Paris||1||terminated|f||||f||||||||||2017-10-11 08:19:32.943964|2017-10-11 08:19:32.943964
NCT00640016|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-13|2016-12-07|2016-06-03||January 2008||2008-01-01|December 2016|2016-12-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Interventional||Analysis population included all participants who were enrolled.|A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma|A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354|Terminated||Phase 2|14|Actual|MedImmune LLC|Study was prematurely terminated due to low recruitment rate, delay due to temporary halt and potential for expiry date of study drug. It was not considered possible to draw meaningful conclusions from the small dataset.|4||The study was terminated prematurely by the sponsor due to slow recruitment.|f||||f||||||||||2017-10-11 08:19:52.46402|2017-10-11 08:19:52.46402
NCT00635427|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-06|2015-05-15|2013-12-11||May 2008||2008-05-01|March 2014|2014-03-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional||Two participants who did not have type 1 Gaucher disease were withdrawn from the ITT study as per SAP definition and removed from the long-term efficacy analyses in this study, needed to support the interpretation of the long-term efficacy results. Therefore, 93 of 95 (97.9%) participants were included in the HGT-GCB-044 ITT population.|An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease|An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease|Completed||Phase 3|95|Actual|Shire||3|||f||||f||||||||||2017-10-11 08:20:27.328237|2017-10-11 08:20:27.328237
NCT00635505|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-07|2013-07-11||2013-07-10|September 2007||2007-09-01|July 2012|2012-07-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|||Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients|Randomized, Placebo-Controlled, Parallel, Multi-Center, 12-Week Study to Evaluate the Efficacy and Safety of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Adult and Adolescent Asthmatic Patients|Terminated||Phase 3|300|Actual|Amphastar Pharmaceuticals, Inc.||3||IND voluntarily withdrawn, without prejudice|f||||f||||||||||2017-10-11 08:20:30.830326|2017-10-11 08:20:30.830326
NCT00642603|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-19|2011-05-31|2010-06-10||May 2008||2008-05-01|May 2011|2011-05-01|September 2012|Anticipated|2012-09-01|March 2009|Actual|2009-03-01||Interventional|||A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer|A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|41|Actual|Hoffmann-La Roche|This study was terminated early because interim data from a predecessor study invalidated the scientific rationale that provided justification for the conduct of this study. Efficacy analyses were not performed.|2|||f||||||||||||||2017-10-11 08:20:48.143872|2017-10-11 08:20:48.143872
NCT00642746|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-24|2014-09-24|2014-02-12||March 2008||2008-03-01|September 2014|2014-09-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional||11 patients included for all baseline measures except for age, categorical because the age is missing for the 1 patient who eventually was ineligible.|Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)|Phase II Study of Erlotinib (Tarceva) Alternating With Chemotherapy for Second-line Treatment of Metastatic Colorectal Cancer With Molecular Correlates for p53 Pathway|Terminated||Phase 2|16|Actual|OHSU Knight Cancer Institute|Study terminated before target enrollment was reached due to excessive toxicities and limited enrollment.|2||Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.|f||||t||||||||||2017-10-11 08:20:52.436282|2017-10-11 08:20:52.436282
NCT00643175|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-24|2009-12-29|||June 2007||2007-06-01|December 2009|2009-12-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Observational|||Effectiveness of Automated Inpatient Endocrinology Consultation for Osteoporotic Hip Fracture||Terminated||N/A|20|Anticipated|State University of New York - Upstate Medical University|||1|Dr. Grose has left this practice, this study is terminated|f||||||||||||||2017-10-11 08:21:01.726704|2017-10-11 08:21:01.726704
NCT00644332|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-24|2012-05-29|2012-05-29||November 2007||2007-11-01|May 2012|2012-05-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Interventional|||An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)|An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Women's Ischemia Symptom Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)|Completed||Phase 4|172|Actual|Gilead Sciences|The study was terminated early at 86% of targeted enrollment (172 of approximately 200 subjects).|1|||f||||f||||||||||2017-10-11 08:21:34.115891|2017-10-11 08:21:34.115891
NCT00638625|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-12|2015-05-12|||January 2010||2010-01-01|May 2015|2015-05-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Observational|||Correlation of X-ray and Pathology With Needle Biopsy of Lung Tumors|Pilot Study of Radiologic-Pathologic Correlation in Lung Tumors Based on Core Needle Biopsy|Withdrawn||N/A|0|Actual|State University of New York - Upstate Medical University|||1|Due to specimen collection difficulties; this study has been terminated|f||||f||||||||||2017-10-11 08:21:45.387697|2017-10-11 08:21:45.387697
NCT00646282|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-25|2015-01-14|2015-01-14||April 2008||2008-04-01|January 2015|2015-01-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|PAD||Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients|Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney|Terminated||Phase 4|12|Actual|Emory University|Due to slow enrollment and primary investigator leaving institution, the study was terminated. Subjects were notified and those on active drug returned to their physicians to be treated according to standard of care.|2||slow enrollment and discontinued once original principal investigator left Emory|f||||f||||||||||2017-10-11 08:22:07.454501|2017-10-11 08:22:07.454501
NCT00646659|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-27|2013-01-07|||February 2008||2008-02-01|January 2013|2013-01-01|April 2011|Actual|2011-04-01|May 2010|Actual|2010-05-01||Interventional|||Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery|Randomized Phase II Feasibility Study of Cetuximab Combined With 4 Cycles of TPF Followed by Platinum Based Chemo-radiation Strategies|Terminated||Phase 2|47|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||Recruitment was suspended prematurely for safety concerns and closed after IDMC review|f||||||||||||||2017-10-11 08:22:11.601552|2017-10-11 08:22:11.601552
NCT00642304|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-19|2016-09-16|2016-09-16||July 2008||2008-07-01|September 2016|2016-09-01|January 2010|Actual|2010-01-01|December 2009|Actual|2009-12-01||Interventional||Safety population included all participants who received at least one dose trial medication and underwent a safety follow-up, whether withdrawn prematurely or not.|A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.|A Single Arm Open Label Study to Assess Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneously C.E.R.A. for the Maintenance of Hemoglobin Levels in Patients With Chronic Renal Anemia Not on Dialysis|Completed||Phase 3|20|Actual|Hoffmann-La Roche||1|||f||||||||||||||2017-10-11 08:22:38.71135|2017-10-11 08:22:38.71135
NCT00651131|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-31|2017-08-28|||June 1, 2004|Actual|2004-06-01|August 2017|2017-08-01|March 1, 2005|Actual|2005-03-01|March 1, 2005|Actual|2005-03-01||Interventional|PSW||Cubicin(R) for Complicated Post-surgical Wound Infections|Cubicin(R) for Complicated Post-surgical Wound Infections|Terminated||Phase 4|69|Actual|Cubist Pharmaceuticals LLC||1||terminated due to slow enrollment|f||||f||||||||||2017-10-11 08:23:17.107723|2017-10-11 08:23:17.107723
NCT00645515|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-20|2008-04-25|||June 2003||2003-06-01|April 2008|2008-04-01|December 2003|Actual|2003-12-01|||||Interventional|||A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia|Ziprasidone Versus Risperidone In The Treatment Of Chronic Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study|Terminated||Phase 3|240|Anticipated|Pfizer||2||"This study was terminated on November 20, 2003 because of poor recruitment. This study was not   terminated due to safety/efficacy."|f||||f||||||||||2017-10-11 08:23:32.819262|2017-10-11 08:23:32.819262
NCT00652093|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-11|2016-02-24|2012-07-10||March 2008||2008-03-01|February 2016|2016-02-01|August 2011|Actual|2011-08-01|November 2010|Actual|2010-11-01||Interventional|LUSTORII||Lumbar Stenosis Outcomes Research II|Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial|Terminated||Phase 4|24|Actual|University of Rochester|This study terminated early (leading to small number of subjects analyzed) due to US Food and Drug Administration (FDA) removing active control (Darvocet) from the U.S. market.|6||Removal of Darvocet from US market|f||||t||||||||||2017-10-11 08:23:38.924981|2017-10-11 08:23:38.924981
NCT00652366|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-01|2015-01-27|2014-12-08||May 2008||2008-05-01|January 2015|2015-01-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Interventional||Safety analysis population (SAP): all participants who received at least 1 dose of the trial medication and had at least 1 safety follow-up, whether withdrawn prematurely or not.|A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer|A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer.|Completed||Phase 2|467|Actual|Hoffmann-La Roche||2|||f||||||||||||||2017-10-11 08:23:41.985843|2017-10-11 08:23:41.985843
NCT00648895|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-28|2010-08-30|2010-07-21||November 2007||2007-11-01|August 2010|2010-08-01||||July 2009|Actual|2009-07-01||Interventional|||A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients|Effect of Nebivolol on Forearm Vasodilation, Nitric Oxide Bioavailability, and Oxidative Stress in Patients With Stage 1/2 Hypertension|Completed||Phase 3|12|Actual|Forest Laboratories|The study was terminated early because of difficulties with enrollment. Only 12 of 30 planned patients were enrolled.|2|||f||||f||||||||||2017-10-11 08:24:30.902737|2017-10-11 08:24:30.902737
NCT00649220|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-27|2011-09-22|2011-08-09||July 2008||2008-07-01|September 2011|2011-09-01|June 2009|Actual|2009-06-01|May 2009|Actual|2009-05-01||Interventional|MemAP||Memantine and Antipsychotics Use|Prospective, Single-arm, Multi-centre, Open-label Study to Investigate the Potential to Reduce Concomitant Antipsychotics Use in Patients With Moderate to Severe Dementia of Alzheimer's Type (DAT) Treated With Memantine|Terminated||Phase 4|19|Actual|Merz Pharmaceuticals GmbH|Early termination due to too slow enrollment lead to a small sample size, limiting the ability for confirmatory analysis. All analysis of the primary efficacy endpoint were treated as exploratory.|1||Study terminated due to too slow enrollment|f||||f||||||||||2017-10-11 08:24:35.153762|2017-10-11 08:24:35.153762
NCT00652236|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-27|2008-03-31|||January 2006||2006-01-01|March 2008|2008-03-01|February 2008|Actual|2008-02-01|December 2007|Actual|2007-12-01||Observational|||Cost of Long Term Disability in Patients With Chronic Non-Specific Low Back Pain|Cost of Long Term Disability in Patients With Chronic Non-Specific Low Back Pain. Three-Year Follow up of a Randomized Trial|Terminated||N/A|174|Actual|Klinik Valens|||2|Study was terminated according the study protocol end of 2007|f||||f||||||||||2017-10-11 08:25:46.611909|2017-10-11 08:25:46.611909
NCT00667095|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-23|2014-07-10|2014-05-09||April 2008||2008-04-01|July 2014|2014-07-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Over Active Bladder Instillation Study - Botox|Evaluation of the Efficacy of Botulinum-A Toxin/DMSO Instillation in the Treatment of Women With Over Active Bladder (OAB) Syndrome and/or Urinary Urge Incontinence|Terminated||Phase 3|25|Actual|Mayo Clinic||2||Study terminated early due to PI's extended medical leave.|f||||t||||||||||2017-10-11 08:26:09.347121|2017-10-11 08:26:09.347121
NCT00667277|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-24|2014-08-08|2014-04-11||March 2008||2008-03-01|August 2014|2014-08-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis|Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis|Terminated||Phase 2|13|Actual|Icahn School of Medicine at Mount Sinai|The study was terminated due to lack of response activity in the setting of an unacceptable toxicity profile at the completion of the first stage.|1||lack of response activity in the setting of an unacceptable toxicity profile|f||||t||||||||||2017-10-11 08:26:14.503639|2017-10-11 08:26:14.503639
NCT00667810|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-24|2015-12-04|2013-10-22||June 2008||2008-06-01|December 2015|2015-12-01|August 2013|Actual|2013-08-01|October 2012|Actual|2012-10-01||Interventional||Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.|Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers|Terminated||Phase 3|901|Actual|Pfizer|The impact of study termination, the shorter observational periods and the resulting small sample size coupled with not having enough participants with post baseline assessments for various reasons were limiting factors for data interpretation.|3||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2017-10-11 08:26:31.969756|2017-10-11 08:26:31.969756
NCT00667849|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-21|2015-11-04|2015-09-24||September 2008||2008-09-01|November 2015|2015-11-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|TRUST||Trial to Evaluate UltraSound in the Treatment of Tibial Fractures|Trial to Evaluate UltraSound in the Treatment of Tibial Fractures|Terminated||N/A|501|Actual|Bioventus LLC|Poor Compliance: Protocol defined compliance as ≥18 minutes use per day. Devices have a treatment monitor that showed average compliance of 42.3% (sham) and 44.6% (active) in 80% of treatment days. Poor treatment adherence confounds results.|2||Study was terminated due to futility|f||||t||||||||||2017-10-11 08:26:36.860531|2017-10-11 08:26:36.860531
NCT00668785|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-25|2015-04-07|2013-09-06||March 2007||2007-03-01|April 2015|2015-04-01|March 2012|Actual|2012-03-01|June 2010|Actual|2010-06-01||Interventional|||Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)|Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)|Terminated||Phase 2|6|Actual|Jumper, J. Michael, M.D.|Study was terminated by Sponsor and Investigator due to low enrollment. Data not analyzed. Technical problems with measurement leading to unreliable or uninterpretable data.|1||Study was terminated due to low enrollment|f||||f||||||||||2017-10-11 08:26:50.367536|2017-10-11 08:26:50.367536
NCT00669214|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-28|2017-05-12|2010-08-24||February 2008|Actual|2008-02-01|May 2017|2017-05-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|SCALP||A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp|A Phase IV Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp|Completed||Phase 4|89|Actual|Genentech, Inc.|Since the completion of this study, efalizumab has been voluntarily withdrawn from the U.S. market because of a safety issue.|2|||f||||||||||||||2017-10-11 08:26:57.964227|2017-10-11 08:26:57.964227
NCT00655824|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-04|2013-09-19|2012-03-26||January 2008||2008-01-01|September 2013|2013-09-01|March 2013|Actual|2013-03-01|May 2011|Actual|2011-05-01||Interventional|||Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403|An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo|Terminated||Phase 2|124|Actual|GlaxoSmithKline|Development of the IV route of ofatumumab (OFA) administration in RA will no longer be pursued. This study was prematurely terminated; OFA treatment was discontinued. Participants could complete only <=7 treatment courses and a follow-up evaluation.|1||"The clinical development of intravenously administered ofatumumab in RA will no longer be   pursued, so this study was prematurely terminated by the Sponsor."|f||||f||||||||||2017-10-11 08:27:11.225584|2017-10-11 08:27:11.225584
NCT00655915|ClinicalTrials.gov processed this data on October 10, 2017|2008-03-28|2011-03-08|||December 2007||2007-12-01|March 2011|2011-03-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Observational|||Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release|Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release|Terminated||N/A|200|Anticipated|Vanderbilt University|||1|Study was terminated by principal investigator|f||||f||||||||||2017-10-11 08:27:18.094436|2017-10-11 08:27:18.094436
NCT00656318|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-07|2009-08-24|||August 2008||2008-08-01|August 2009|2009-08-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Observational|||Impact of Oral Contraceptives on GABA and Neurosteroids|Impact of Oral Contraceptives on GABA and Neurosteroids|Terminated||N/A|6|Actual|Yale University|||2|Funding withdrawn from study sponsor.|f||||f||||||||||2017-10-11 08:27:24.300358|2017-10-11 08:27:24.300358
NCT00670956|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-30|2015-03-18|2015-03-18||April 2008||2008-04-01|March 2015|2015-03-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional|CCAM Steroids|Only one participant was enrolled to the study before it was terminated; no participants were enrolled to the control arm|Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)|Investigation of Prenatal Steroids for Treatment of Prenatally Diagnosed CCAMs|Terminated||Phase 1/Phase 2|1|Actual|University of California, San Francisco||2||"Recruitment has been poor. Study drug is being offered as part of standard care of women   carrying a pregnancy diagnosed with CCAM"|f||||t||||||||||2017-10-11 08:27:57.425685|2017-10-11 08:27:57.425685
NCT00671528|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-01|2014-12-29|2011-05-19||July 2009||2009-07-01|December 2014|2014-12-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)|Double-blind Evaluation of the Safety and Efficacy of Quadriderme® (Betamethasone Diproprionate, Clotrimazole and Gentamicin) Compared With Betamethasone Diproprionate Combined With Gentamicin Sulfate and With Betamethasone Diproprionate in the Treatment of Impetiginous Eczema|Terminated||Phase 4|3|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to lack of recruitment (only 3 of 201 participants were enrolled). Statistical analyses were not performed.|3||terminated early due to lack of recruitment [only 3 of 207 subjects were enrolled]|f||||f||||||||||2017-10-11 08:28:05.329522|2017-10-11 08:28:05.329522
NCT00671541|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-01|2012-02-16|||March 2006||2006-03-01|February 2012|2012-02-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Interventional|||Nasospore Stent For Use in Enodscopic Sinus Surgery|Nasospore Stent For The Use in Endoscopic Sinus Surgery|Withdrawn||Phase 4|0|Actual|Lahey Clinic||2||Principal Investigator left the institution requested study terminated.|f||||f||||||||||2017-10-11 08:28:05.663681|2017-10-11 08:28:05.663681
NCT00671593|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-02|2013-07-15|||October 2006||2006-10-01|July 2013|2013-07-01|April 2009|Actual|2009-04-01|April 2008|Actual|2008-04-01||Interventional|||Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge|Genetics of Environmental Asthma: Differential Gene Expression in the Lung and Peripheral Blood After Inhaled Allergen Challenge|Terminated||Phase 1|40|Actual|Duke University||1||funding terminated|f||||t||||||||||2017-10-11 08:28:06.305006|2017-10-11 08:28:06.305006
NCT00672009|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-01|2014-09-03|||April 2008||2008-04-01|September 2014|2014-09-01|August 2012|Actual|2012-08-01|April 2011|Actual|2011-04-01||Interventional|||A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer|A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer|Terminated||Phase 2|11|Actual|Cedars-Sinai Medical Center||1||The sponsor terminated funding for the study.|f||||f||||||||||2017-10-11 08:28:14.679451|2017-10-11 08:28:14.679451
NCT00672204|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-02|2017-01-26|2013-02-20||November 2007||2007-11-01|January 2017|2017-01-01|August 2012|Actual|2012-08-01|December 2010|Actual|2010-12-01||Interventional|RAPTIVA||Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes|Efalizumab (Raptiva) Combined With Sirolimus in Type 1 Diabetic Islet Allograft Recipients|Terminated||Phase 1/Phase 2|23|Actual|University of Minnesota - Clinical and Translational Science Institute|Early termination due to Raptiva being withdrawn from market|1||Raptiva was withdrawn from the market|f||||t||||||||||2017-10-11 08:28:16.66618|2017-10-11 08:28:16.66618
NCT00661336|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-17|2015-03-12|||April 2008||2008-04-01|April 2010|2010-04-01||||December 2009|Actual|2009-12-01||Interventional|||A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma|An Open-Label, Multicenter, Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic Buthionine Sulfoximine (BSO) in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma|Withdrawn||Phase 1|0|Actual|Duke University||||The study was withdrawn due to lack of patients.|||||||||||||||2017-10-11 08:28:48.922075|2017-10-11 08:28:48.922075
NCT00661388|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-16|2016-07-28|2016-06-09||August 2008||2008-08-01|July 2016|2016-07-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional||Safety population included all participants who received at least one dose of the trial medication and underwent a safety follow-up, whether withdrawn prematurely or not.|A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anaemia in Pre-dialysis Patients Not Currently Treated With ESA.|Completed||Phase 3|75|Actual|Hoffmann-La Roche||1|||f||||||||||||||2017-10-11 08:28:51.201168|2017-10-11 08:28:51.201168
NCT00661505|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-16|2017-06-13|2016-06-08||May 31, 2008|Actual|2008-05-31|May 2017|2017-05-01|June 30, 2010|Actual|2010-06-30|June 30, 2010|Actual|2010-06-30||Interventional||Baseline characteristics are presented for the safety population which included all participants who received at least one dose C.E.R.A. and underwent a safety follow-up, whether withdrawn prematurely or not.|A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia|A Single Arm Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Haemodialysis Patients With Chronic Renal Anaemia.|Completed||Phase 3|132|Actual|Hoffmann-La Roche|Low number of participants completed the study as per the protocol. Administration of iron (oral/IV) was as per discretion of individual centers; therefore, C.E.R.A. responses have been limited by iron levels too low for efficient erythropoiesis.|1|||f|||||f|f||||||||2017-10-11 08:28:56.477147|2017-10-11 08:28:56.477147
NCT00661973|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-16|2015-06-03|||April 2008||2008-04-01|June 2011|2011-06-01|March 2011|Anticipated|2011-03-01|December 2010|Anticipated|2010-12-01||Interventional|||Inhaled Corticosteroids on Airway Smooth Muscle in Asthma|The Effect of Inhaled Corticosteroids (ICS) on Airway Smooth Muscle in Asthma|Withdrawn||Phase 4|0|Actual|Imperial College London||1||The study was withdrawn for administrative reasons|f||||f||||||||||2017-10-11 08:29:12.474778|2017-10-11 08:29:12.474778
NCT00662116|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-17|2009-01-29|||March 2008||2008-03-01|January 2009|2009-01-01|December 2009|Anticipated|2009-12-01|October 2009|Anticipated|2009-10-01||Interventional|BREAK-DHF-I||Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure|Terminated||Phase 2|160|Anticipated|Synvista Therapeutics, Inc||2||Study has been terminated early due to financial constraints.|f||||t||||||||||2017-10-11 08:29:19.420529|2017-10-11 08:29:19.420529
NCT00662220|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-17|2014-07-11|||April 2008||2008-04-01|July 2014|2014-07-01|November 2013|Actual|2013-11-01|June 2013|Actual|2013-06-01||Interventional|VIRID||High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4|High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4|Terminated||Phase 3|110|Actual|Foundation for Liver Research||2||"Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study   had to be terminated."|f||||t||||||||||2017-10-11 08:29:21.404038|2017-10-11 08:29:21.404038
NCT00662831|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-16|2011-12-01|2011-08-11||April 2008||2008-04-01|December 2011|2011-12-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|FEENICS||Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients|A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients|Completed||Phase 2/Phase 3|276|Actual|Pfizer|Study enrollment was terminated before planned number of participants was obtained. Although randomized participants were allowed to complete entire course of therapy according to protocol and study status was therefore designated as completed.|2|||f||||t||||||||||2017-10-11 08:29:36.093855|2017-10-11 08:29:36.093855
NCT00665444|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-21|2017-09-28|2016-01-14||April 2008||2008-04-01|September 2017|2017-09-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional|||Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder|Reducing Medical Risks in Individuals With Bipolar Disorder: Enhancing Outcomes With Aripiprazole|Terminated||N/A|3|Actual|University of Pittsburgh||1||The study was terminated by the sponser due to low study enrollment.|f||||f||||||||||2017-10-11 08:30:23.369091|2017-10-11 08:30:23.369091
NCT00665522|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-22|2015-04-09|||December 2007||2007-12-01|April 2015|2015-04-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Observational|||A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg)|A Prospective Safety Surveillance Study of IONSYS (Fentanyl HCl)|Terminated||Phase 4|218|Actual|Alza Corporation, DE, USA|||2|"Study was terminated at the request of the company due to the recall of marketed product in   Europe."|f||||f||||||||||2017-10-11 08:30:26.008819|2017-10-11 08:30:26.008819
NCT00665652|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-22|2011-06-22|||April 2008||2008-04-01|June 2011|2011-06-01|April 2014|Anticipated|2014-04-01|April 2014|Anticipated|2014-04-01||Interventional|MGUS||Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance|A Phase II Trial of Lenalidomide as a Treatment for Neuropathy Associated With Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)|Suspended||Phase 2|30|Anticipated|Dartmouth-Hitchcock Medical Center||1||The study has been suspended for slower than anticipated enrollment to date.|f||||t||||||||||2017-10-11 08:30:29.260945|2017-10-11 08:30:29.260945
NCT00665665|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-23|2016-12-22|||November 2007||2007-11-01|December 2016|2016-12-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|||Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers|Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Healthy Male and Female Volunteers|Terminated||Phase 1|101|Actual|Novo Nordisk A/S||4||The trial is terminated due to re-evaluation of the compound|f||||f||||||||||2017-10-11 08:30:29.349603|2017-10-11 08:30:29.349603
NCT00665730|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-23|2015-05-07|||July 2007||2007-07-01|May 2015|2015-05-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional|||Evaluation of the Safety and Effectiveness of Sepraspray™ in Reducing Post-surgical Adhesions|Evaluation of the Safety and Effectiveness of Sepraspray™ in Limiting the Formation of Postoperative Adhesions to Serosal Tissue (Abdominal Surgery)|Terminated||N/A|5|Actual|Sanofi||2||Study terminated due to low enrollment.|f||||t||||||||||2017-10-11 08:30:30.093871|2017-10-11 08:30:30.093871
NCT00666497|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-23|2015-04-22||2015-04-06|June 2008||2008-06-01|April 2015|2015-04-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)|A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML or Intermediate-2 or High-Risk MDS|Terminated||Phase 2|6|Actual|Mirati Therapeutics Inc.||3||"Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103.   All Celgene-sponsored trials with MGCD0103 with be closed."|f||||t||||||||||2017-10-11 08:30:49.64918|2017-10-11 08:30:49.64918
NCT00661011|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-15|2015-02-11|||January 2007||2007-01-01|February 2015|2015-02-01|June 2014|Actual|2014-06-01|December 2013|Actual|2013-12-01||Interventional|||Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy|A Phase II Study Assessing the Curative Effect of the Combination of Lobectomy Followed by Mediastinal Concomitant Radiochemotherapy in Patients With Locally Advanced Unresectable Stage III Non-small Cell Lung Cancer Responding to Induction Chemotherapy|Terminated||Phase 2|75|Actual|European Lung Cancer Working Party||1||The study was terminated due to too slow recruitment|f||||t||||||||||2017-10-11 08:31:06.758777|2017-10-11 08:31:06.758777
NCT00673075|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-29|2010-09-02|2010-09-02||May 2008||2008-05-01|September 2010|2010-09-01||||September 2009|Actual|2009-09-01||Interventional|||The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease|Efficacy and Tolerability of Nebivolol Compared With Carvedilol in Patients With Coronary Artery Disease and Stage I or II Hypertension|Completed||Phase 4|39|Actual|Forest Laboratories|The study was terminated early because of difficulties with enrollment. Only 39 out of 160 planned patients were randomized.|2|||f||||f||||||||||2017-10-11 08:31:17.594681|2017-10-11 08:31:17.594681
NCT00673179|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-06|2014-09-03|2013-06-12||May 2008||2008-05-01|September 2014|2014-09-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy|Outpatient Chemotherapy in Pediatric Osteosarcoma: Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy|Terminated||N/A|7|Actual|M.D. Anderson Cancer Center|Study could not meet accrual goal due to logistical considerations, terminated early.|2||Low accrual.|f||||f||||||||||2017-10-11 08:31:19.809851|2017-10-11 08:31:19.809851
NCT00674557|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-07|2013-07-09|||June 2008||2008-06-01|March 2009|2009-03-01|March 2009|Actual|2009-03-01|||||Interventional|||Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer|A Cancer Research UK Randomised Phase II Trial of ATN-224 (Copper Binding Agent) in Combination With Exemestane Versus Exemestane Alone in Post-menopausal Women With Recurrent or Advanced, Oestrogen and/or Progesterone Receptor Positive Breast Cancer|Terminated||Phase 2|111|Anticipated|National Cancer Institute (NCI)||||"Withdrawn as the clinical development of ATN-224 was terminated by the drug company who was   providing ATN-224 for the study"|f||||||||||||||2017-10-11 08:31:40.228241|2017-10-11 08:31:40.228241
NCT00674999|ClinicalTrials.gov processed this data on October 10, 2017|2007-12-26|2012-11-13|||June 2005||2005-06-01|November 2012|2012-11-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|Amnion||Use of Amnion on Partial Thickness Burns|Project Title The Treatment of Partial Thickness Burns: Treated Amnion Versus Currently in Use Topical Medications|Withdrawn||Phase 2/Phase 3|0|Actual|The University of Texas Medical Branch, Galveston||3||Hurricane- terminated study due to skin bank being destroyed|f||||f||||||||||2017-10-11 08:31:52.103592|2017-10-11 08:31:52.103592
NCT00676143|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-02|2016-05-03|2013-10-14||January 2008||2008-01-01|May 2016|2016-05-01|November 2012|Actual|2012-11-01|October 2012|Actual|2012-10-01||Interventional||Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.|Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients|A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers|Terminated||Phase 3|1100|Actual|Pfizer||2||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2017-10-11 08:32:12.489072|2017-10-11 08:32:12.489072
NCT00664066|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-21|2009-09-28|2009-08-18||April 2008||2008-04-01|September 2009|2009-09-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Observational|DELFT||DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)|A Non-Interventional, Post-Authorisation Study to Assess Adverse Events and Drug Utilisation Among Chronic Kidney Disease Patients Treated With DYNEPO|Terminated||N/A|3|Actual|Shire|This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses.||1|"The termination of the study is not linked to a product recall or result of any safety signal.   Rather it was sponsor's commercial decision to withdraw the MA"|f||||||||||||||2017-10-11 08:32:16.895825|2017-10-11 08:32:16.895825
NCT00670202|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-29|2017-02-10|2017-02-10||March 13, 2008|Actual|2008-03-13|February 2017|2017-02-01|January 20, 2011|Actual|2011-01-20|January 20, 2011|Actual|2011-01-20||Interventional|||Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis|The Effect of Fasudil on Rho Kinase Activity in Patients Scheduled for Elective Carotid Endarterectomy|Terminated||Phase 2|2|Actual|Brigham and Women's Hospital|Study was terminated early due to poor enrollment. The patients and physicians remained blinded to study drug assignment for the 2 patients who completed the protocol and no analyses were performed.|2||Slow enrollment|f||||f||||||||||2017-10-11 08:32:30.071534|2017-10-11 08:32:30.071534
NCT00677924|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-13|2011-11-21|2011-09-12||April 2008||2008-04-01|November 2011|2011-11-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|GEN206||Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer|A Dose-Escalation, Randomized Phase I/II Trial of Zalutumumab - a Human Monoclonal Anti-EGF Receptor Antibody - With or Without Irinotecan Chemotherapy in Cetuximab Refractory Colorectal Cancer Patients Who Have Failed Standard Chemotherapy and Progressed During or Within 3 Months of Stopping Cetuximab-Based Therapy|Terminated||Phase 1/Phase 2|9|Actual|Genmab|The trial was prematurely closed when 9 out of 97 patients were enrolled. The trial design was originally divided in two parts. Patient allocation was terminated before Part 2 was started.|2||Due to changes in portfolio review|f||||t||||||||||2017-10-11 08:33:08.412706|2017-10-11 08:33:08.412706
NCT00678041|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-10|2016-08-03|2016-05-10||May 2008||2008-05-01|August 2016|2016-08-01|May 2009|Actual|2009-05-01|May 2009|Actual|2009-05-01||Interventional|APPIC|This is a randomized, double-blind, placebo-controlled clinical trial|Nitrofurantoin and Urinary Tract Infections (UTIs)|A Randomized, Double-blind, Placebo-controlled Trial Examining the Effect of Nitrofurantoin Prophylaxis in Women Performing Clean Intermittent Self-catheterization (CISC) After Surgery for Urinary Incontinence and/or Pelvic Organ Prolapse|Terminated||N/A|10|Actual|University of Pittsburgh|Study terminated prior to accumulation of any data. Participating subjects were withdrawn prior to measuring any outcome data|2||Inadequate patient recruitment|f||||f||||||||No||2017-10-11 08:33:09.773644|2017-10-11 08:33:09.773644
NCT00678288|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-14|2014-11-24|2010-09-10||April 2008||2008-04-01|November 2014|2014-11-01|June 2009|Actual|2009-06-01|June 2009|Actual|2009-06-01||Interventional|||A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.|A Phase II, Randomized, Open-label, Multicenter, Study Evaluating the Efficacy of Sorafenib Alone and Sorafenib in Combination With Low Dose Interferon Alpha-2a as Second-line Treatment of Sunitinib Failure in Patients With Metastatic Renal Cell Carcinoma|Terminated||Phase 2|16|Actual|Bayer|The study was terminated early by the Sponsor due to low accrual. No efficacy analyses were performed.|2|||f||||f||||||||||2017-10-11 08:33:14.995854|2017-10-11 08:33:14.995854
NCT00679055|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-14|2017-03-30|2015-01-30||March 31, 2007|Actual|2007-03-31|March 2017|2017-03-01|August 26, 2008|Actual|2008-08-26|August 26, 2008|Actual|2008-08-26||Interventional|||A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)|An Exploratory Double-Blind, Placebo Controlled, Randomized, 12-Week Oral Dose Study to Evaluate the Effects of MK0736 on Atherosclerotic Disease Biomarkers in Lower Extremity Plaque Excised From Patients With Peripheral Arterial Disease|Terminated||Phase 1|14|Actual|Merck Sharp & Dohme Corp.|Study terminated due to lack of recruitment.|2||Lack of recruitment|f||||f||||||||||2017-10-11 08:33:36.45228|2017-10-11 08:33:36.45228
NCT00679081|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-14|2012-01-09|2011-10-10||May 2008||2008-05-01|January 2012|2012-01-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional|||A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage|A Prospective, Randomized, Controlled Pilot Study of CelTx(TM) (Apligraf®) as an Alternative to Tissue From the Palate in the Treatment of Gingival Recession Requiring Root Coverage|Terminated||Phase 1/Phase 2|15|Actual|Organogenesis|This study was terminated early due to suboptimal clinical outcomes. Due to two study design changes, the data could not be combined and analyzed for effectiveness (ie, no secondary effectiveness endpoints were tested).|2|||f||||f||||||||||2017-10-11 08:33:36.886038|2017-10-11 08:33:36.886038
NCT00673439|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-05|2013-05-03|2013-05-03||November 2007||2007-11-01|May 2013|2013-05-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional|||Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)|A Phase II Trial Using Fondaparinux in Patients With Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)|Terminated||Phase 2|3|Actual|James Graham Brown Cancer Center|Study terminated, results data not available|1||study terminated due to low accrual|f||||t||||||||||2017-10-11 08:33:46.614054|2017-10-11 08:33:46.614054
NCT00673582|ClinicalTrials.gov processed this data on October 10, 2017|2008-04-30|2009-08-24|||April 2008||2008-04-01|August 2009|2009-08-01|March 2013|Anticipated|2013-03-01|December 2012|Anticipated|2012-12-01||Interventional|||Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients|Randomized, Multicentre, Double- Blind, Placebo Controlled Trial of Rosuvastatin 10 mg for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Ultrasound in HIV-positive Patients Treated With Antiretrovirals|Terminated||Phase 4|250|Anticipated|University of British Columbia||2||Sponsor has withdrawn the funding|f||||t||||||||||2017-10-11 08:33:51.621733|2017-10-11 08:33:51.621733
NCT00673595|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-05|2012-02-21|2012-02-21||March 2007||2007-03-01|February 2012|2012-02-01|February 2010|Actual|2010-02-01|February 2009|Actual|2009-02-01||Interventional|||Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo|Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo|Terminated||N/A|19|Actual|Mayo Clinic|This study was terminated early due to difficulty with recruiting subjects and with subjects complying with the protocol.|2||Difficulty with recruiting sujects and subjects complying with the protocol|f||||t||||||||||2017-10-11 08:33:51.729458|2017-10-11 08:33:51.729458
NCT00682591|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-20|2009-02-03|||July 2008||2008-07-01|February 2009|2009-02-01|December 2011|Anticipated|2011-12-01|December 2011|Anticipated|2011-12-01||Observational|||Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy|Evaluation of Neurocognitive Performance, Quality of Life, and Emotional State in Drug Substituted Patients (Methadone, Buprenorphine, Suboxone) Under Hepatitis C Therapy (Peginterferon Alfa and Ribavirin)|Withdrawn||N/A|190|Anticipated|University of Wuerzburg|||1|Study had to be withdrawn because financial support was cancelled.|f||||t||||||||||2017-10-11 08:34:21.459868|2017-10-11 08:34:21.459868
NCT00682721|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-16|2012-02-29|||February 2009||2009-02-01|February 2012|2012-02-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional|||Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women|Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||Sponsor has withdrawn support for this study and it will not be performed|f||||f||||||||||2017-10-11 08:34:24.143671|2017-10-11 08:34:24.143671
NCT00683917|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-22|2014-08-05|2014-06-25||May 2008||2008-05-01|August 2014|2014-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional||Study prematurely terminated|Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids|A Multi-center, Active Controlled, Pharmacokinetic, Safety and Efficacy Study of Proellex in Pre-Menopausal Women With Symptomatic Uterine Fibroids to Assess Persistence of Response|Terminated||Phase 2|10|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2017-10-11 08:35:06.733916|2017-10-11 08:35:06.733916
NCT00686036|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-27|2016-10-27|2011-04-27||May 2008||2008-05-01|October 2016|2016-10-01|October 2010|Actual|2010-10-01|April 2010|Actual|2010-04-01||Interventional|ZENITH||Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy|A Randomized, Double-blind, Multicentre, Phase II Controlled Trial Assessing ZACTIMATM (Vandetanib) Against Placebo in Prolonging the Off-treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy|Terminated||Phase 2|17|Actual|Sanofi|It was planned that approx 100 patients would be recruited over a period of approx 2 years, due to slow recruitment the study was terminated early. No statistical analyses was done and no conclusion can be drawn about the outcomes in this study.|2||Slow recruitment|f||||f||||||||||2017-10-11 08:35:35.585071|2017-10-11 08:35:35.585071
NCT00686270|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-27|2011-06-22|||May 2008||2008-05-01|June 2011|2011-06-01|May 2012|Anticipated|2012-05-01|May 2012|Anticipated|2012-05-01||Interventional|||A Long Term Safety Study of Apricitabine in HIV-infected Patients|A Phase 3, Open Label 96-week Extension Study of the Safety of Apricitabine in Treatment-experienced HIV-1 Infected Patients Who Have Completed Protocol AVX-301 or AVX-302 or Who Have Met the Criteria for Open-label Access to ATC Because of Virological Failure/Lack of Response|Withdrawn||Phase 3|0|Actual|Avexa||1||Study was withdrawn owing to Sponsor decision|f||||f||||||||||2017-10-11 08:35:46.55416|2017-10-11 08:35:46.55416
NCT00686699|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-27|2017-06-02|2016-03-10|2009-04-13|July 10, 2006|Actual|2006-07-10|June 2017|2017-06-01|March 6, 2008|Actual|2008-03-06|March 6, 2008|Actual|2008-03-06||Interventional|||Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)|A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders|Terminated||Phase 2|11|Actual|Merck Sharp & Dohme Corp.|This study was terminated due to low enrollment.|2||The study was terminated after 9 participants completed due to lack of enrollment for 6 months.|f||||f||||||||||2017-10-11 08:35:53.340675|2017-10-11 08:35:53.340675
NCT00686881|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-27|2017-03-08|2012-02-03||December 2006||2006-12-01|March 2017|2017-03-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)|A Clinical Study of SCH 54031 as Monotherapy in IFN-treated Patients With Chronic Hepatitis C|Terminated||Phase 3|261|Actual|Merck Sharp & Dohme Corp.|This study was prematurely discontinued because of low enrollment.|2||This study was terminated due to low enrollment|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00687544|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-27|2017-03-08|2011-09-22||December 2005||2005-12-01|March 2017|2017-03-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)|Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon|Terminated||Phase 4|11|Actual|Merck Sharp & Dohme Corp.|The study was terminated early due to low enrollment. The primary and secondary outcomes were not evaluated. A formal safety analysis was not performed for the 11 participants enrolled in the study.|1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00688545|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-29|2013-07-22|2013-05-07||April 2009||2009-04-01|July 2013|2013-07-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Observational|SINCERE||Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis|SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs|Terminated||N/A|275|Actual|Pfizer|Study terminated prematurely: Sponsor released by FDA from post-marketing commitment. As a result, only a small number of participants/analyses could be performed, data must be interpreted with caution. Endpoints arbitrarily assigned as primary.||2|See termination reason in detailed description.|f||||f||||||||||2017-10-11 08:37:06.084821|2017-10-11 08:37:06.084821
NCT00689390|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-27|2017-03-10|2015-09-01||February 2007||2007-02-01|March 2017|2017-03-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional||All Enrolled Participants|Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)|Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C|Terminated||Phase 2/Phase 3|1954|Actual|Merck Sharp & Dohme Corp.||2||The study was terminated due to satisfaction of post-marketing commitments|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00689884|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-30|2012-07-31|2012-01-16||January 2007||2007-01-01|October 2011|2011-10-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|||Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies|A Prospective Feasibility and Cost Analysis of Peripheral Blood Stem Cell Mobilization Using Pegfilgrastim in Patients With Hematologic Malignancies|Terminated||N/A|7|Actual|Dartmouth-Hitchcock Medical Center|Outcome was not reported. The study was terminated for lack of enrollment. Data collection was terminated. No data analysis was performed.|1||Lack of enrollment.|f||||t||||||||||2017-10-11 08:37:48.551411|2017-10-11 08:37:48.551411
NCT00691795|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-03|2012-02-13||||||February 2012|2012-02-01|December 2011|Actual|2011-12-01|||||Interventional|||Epidural Fentanyl-bupivacaine Versus Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor|Comparison of Fentanyl-bupivacaine and Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor in Patients With Continuous Epidural Analgesia|Withdrawn||Phase 4|0|Actual|Columbia University||2||Study was recently terminated due to poor enrollment - never enrolled.|f||||f||||||||||2017-10-11 08:38:41.311092|2017-10-11 08:38:41.311092
NCT00691821|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-27|2011-07-25|||April 2009||2009-04-01|July 2011|2011-07-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|NPWT||Negative Pressure Wound Therapy for the Treatment of Chronic Pressure Wounds|A 12-week, Prospective, Open-label, Randomized, Controlled Clinical Trial Comparing Negative Pressure Wound Therapy (NPWT) to Standard Wound Care for the Treatment of Chronic Pressure Wounds of the Pelvic Region|Terminated||Phase 4|184|Anticipated|St. Joseph's Healthcare Hamilton||2||"Patients not meeting inclusion criteria, therefore recruitment rate low, terminated due to the   lack of feasibility to complete the study in a timely manner."|f||||f||||||||||2017-10-11 08:38:42.13519|2017-10-11 08:38:42.13519
NCT00692003|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-03|2017-02-01|2012-08-13||August 1, 2008|Actual|2008-08-01|February 2017|2017-02-01|January 9, 2009|Actual|2009-01-09|November 2008|Actual|2008-11-01||Interventional|||Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures|A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures|Terminated||Phase 3|21|Actual|Eisai Inc.|This study was terminated early at the Sponsor’s discretion. When this study was discontinued, only 6 subjects had been treated. Data from the 5 subjects treated with zonisamide were insufficient to draw firm conclusions regarding efficacy.|2||Sponsor's decision|f||||||||||||||2017-10-11 08:38:46.110735|2017-10-11 08:38:46.110735
NCT00692692|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-04|2013-08-03|2013-08-03||June 2007||2007-06-01|July 2013|2013-07-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional||36 total with 20 in the experimental group and 16 in the control group|Use of Dermal Matrix in Breast Reconstruction|The Use of An Acellular Dermal Matrix Sling in a Two-stage Breast REconstruciton After Mastectomy: A Double-blinded Randomized Trial|Terminated||N/A|36|Actual|Vanderbilt University|Study was terminated early due to more infections recorded in the dermal matrix group; I currently do not have the exact number|2||higher rate of post-operative infectin in the Dermal Matrix arm of the study|f||||f||||||||||2017-10-11 08:38:53.899266|2017-10-11 08:38:53.899266
NCT00693472|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-27|2017-04-21|2017-02-08|2009-04-17|August 15, 2007||2007-08-15|April 2017|2017-04-01|January 9, 2009|Actual|2009-01-09|December 12, 2008|Actual|2008-12-12||Interventional|||Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)|Efficacy of SCH 420814 to Reduce the Frequency or Severity of Neuroleptic Induced Akathisia|Terminated||Phase 2|46|Actual|Merck Sharp & Dohme Corp.|The study was terminated early by the sponsor due to lack of enrollment.|4|||f||||f||||||||||2017-10-11 08:39:06.931701|2017-10-11 08:39:06.931701
NCT00695903|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-10|2017-02-22|2011-08-23||September 2008||2008-09-01|February 2017|2017-02-01|October 2010|Actual|2010-10-01|August 2010|Actual|2010-08-01||Interventional|HDSAB||Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia|A Phase 2 Multicenter, Randomized, Double-blinded, Study to Describe the Safety, Efficacy, and Pharmacokinetics of Daptomycin 10 mg/kg/Day and Vancomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia|Terminated||Phase 2|38|Actual|Cubist Pharmaceuticals LLC|Because the study was terminated early due to lack of enrollment, there were not sufficient patients to provide meaningful analysis for the following secondary outcomes: persistent/recurrent bacteremia and time to defervescence/clearance.|2||terminated due to lack of enrollment|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00696319|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-09|2011-06-30|||January 2007||2007-01-01|June 2011|2011-06-01|June 2013|Anticipated|2013-06-01|June 2012|Anticipated|2012-06-01||Interventional|||Dynamic Stability of the Anterior Cruciate Ligament (ACL) Deficient Knee|Dynamic Stability of the ACL Deficient Knee - a Prospective Cohort Study|Suspended||N/A|150|Anticipated|Oslo University Hospital||2||Study was suspended due to lack of resources.|f||||f||||||||||2017-10-11 08:39:48.839671|2017-10-11 08:39:48.839671
NCT00696462|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-02|2012-09-11|||March 2007||2007-03-01|September 2012|2012-09-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||The Effect of Forced Air Warming During Cesarean Section on Postoperative Infectious Morbidity|The Effect of Forced Air Warming During Cesarean Section on Postoperative Infectious Morbidity|Withdrawn||N/A|0|Actual|Vanderbilt University||2||Study terminated for lack of funds to initiate study|f||||t||||||||||2017-10-11 08:39:53.308208|2017-10-11 08:39:53.308208
NCT00697593|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-11|2014-01-20|2010-06-29||January 2008||2008-01-01|January 2014|2014-01-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|EASY||ChangE From Any Systemic psoriasiS therapY to Raptiva|A Phase IV Open Label Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Transitioning From Previous Systemic Antipsoriasis Therapies (Methotrexate, Cyclosporine, Retinoids or Psoralen-Ultraviolet Light A (PUVA), Narrow-Band Ultraviolet Light B (NBUVB) to Raptiva 1mg/kg/ Week Therapy.|Terminated||Phase 4|70|Actual|Merck KGaA||1||"The study was terminated after the European Medicines Agency recommended to suspend the   marketing authorisation of Raptiva in the European Union"|f||||||||||||||2017-10-11 08:40:13.90519|2017-10-11 08:40:13.90519
NCT00697697|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-12|2013-12-09|2013-08-19||April 2008||2008-04-01|December 2013|2013-12-01|December 2009|Actual|2009-12-01|August 2009|Actual|2009-08-01||Interventional||Subjects were randomly assigned to treatment.|A Study of 2 Doses of MAP0010 in Asthmatic Children|A Randomized, Double-blind, Active-controlled, Phase 3 Extension Study Investigating the Safety and Efficacy Over 40 Weeks of 2 Doses of MAP0010 in Asthmatic Children (12 Months to 8 Years Old at the Time of Enrollment Into the MAP0010-CL-P301 Study)|Terminated||Phase 3|192|Actual|Allergan|The study was terminated due to a corporate decision before all subjects had completed the study.|2||Corporate decision|f||||f||||||||||2017-10-11 08:40:15.835396|2017-10-11 08:40:15.835396
NCT00697827|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-11|2012-06-05|2012-05-03||June 2008||2008-06-01|June 2012|2012-06-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|In-Space||A Study of the In-Space Device for Treatment of Moderate Spinal Stenosis|A Multi-Center Randomized Controlled Trial of the In-Space Compared to X STOP® for Treatment of Moderate Degenerative Lumbar Spinal Stenosis|Terminated||Phase 3|44|Actual|Synthes USA HQ, Inc.|Study terminated early secondary to low enrollment leading to small number of subjects available for analyses.|2||Study terminated due to low enrollment.|f||||f||||||||||2017-10-11 08:40:17.970036|2017-10-11 08:40:17.970036
NCT00699842|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-13|2016-10-19|2014-02-27||July 2008||2008-07-01|October 2016|2016-10-01|May 2012|Actual|2012-05-01|January 2011|Actual|2011-01-01||Interventional|||A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients|A Phase I/II Optimal Dose Study of Lenalidomide in the Non-5q- LOW and INT-1 Risk MDS Patients|Terminated||Phase 1/Phase 2|8|Actual|Thomas Jefferson University|Study was terminated as the objectives of this study have already been addressed in a larger study, and therefore the study is unlikely to yield any new information. The study closed before any data for the outcome measures was able to be collected.|1||Administratively terminated per FDA recommendation|f||||t||||||||||2017-10-11 08:40:41.070885|2017-10-11 08:40:41.070885
NCT00700739|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-18|2015-09-02|2015-07-13||May 2008||2008-05-01|September 2015|2015-09-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Study to Investigate the Performance of Cervical Arthroplasty for the Treatment of Cervical Degenerative Disc Disease|A Multi-Centre, Prospective, Randomized, Post Marketing Surveillance Study Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of Cervical Degenerative Disc Disease|Terminated||Phase 4|60|Actual|DePuy International|Study was terminated early therefore the latest clinical data available is at the 12 month post-operative timepoint and the latest radiographic data available is at the 6 month post-operative timepoint.|2||study progress and recruitment rate too low|f||||t||||||||||2017-10-11 08:41:12.989167|2017-10-11 08:41:12.989167
NCT00701870|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-18|2013-11-25|||October 2008||2008-10-01|November 2013|2013-11-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional|||Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non‑Small Cell Lung Cancer|Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Chemotherapy Induced Neutropenia in Patients With Locally Advanced or Metastatic Non‑Small Cell Lung Cancer Receiving First-Line Chemotherapy|Terminated||Phase 2|1|Actual|Telik||2||Study TLK199.2102 was terminated for lack of enrollment.|f||||f||||||||||2017-10-11 08:41:46.067533|2017-10-11 08:41:46.067533
NCT00702221|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-19|2016-06-20|2014-09-10||June 2008||2008-06-01|April 2016|2016-04-01|September 2010|Actual|2010-09-01|June 2009|Actual|2009-06-01||Interventional||All analyzed subjects|Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension|A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension|Terminated||Phase 2|20|Actual|BTG International Inc.|Study prematurely terminated|2||Dose limiting adverse effects|f||||t||||||||Yes|Investigators provide information to participants|2017-10-11 08:41:50.136072|2017-10-11 08:41:50.136072
NCT00694408|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-06|2017-01-19|||June 2008||2008-06-01|January 2017|2017-01-01|August 2011|Actual|2011-08-01|August 2011|Actual|2011-08-01||Interventional|||A Pilot Trial of Pediatric Liver Transplantation Without Steroids|A Randomized Pilot Trial of a Steroid-free Immunosuppressant Regimen in Pediatric Liver Transplantation|Terminated||Phase 3|15|Actual|Birmingham Women's and Children's NHS Foundation Trust||2||Study terminated due to withdrawal from market of Daclizumab|f||||t||||||||||2017-10-11 08:41:53.10653|2017-10-11 08:41:53.10653
NCT00695396|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-05|2012-10-02|2011-02-08||June 2008||2008-06-01|October 2012|2012-10-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|||A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion|A Randomized, Double Blind, Placebo Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes at Risk For Transfusion|Terminated||Phase 3|25|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Because this study was terminated prematurely due to slow enrollment, only limited data were collected. No formal statistical testing was performed. Only descriptive statistics were provided.|4||"The study was stopped due to low subject enrollment. No safety issue or other concern factored   into this decision."|f||||t||||||||||2017-10-11 08:42:08.218522|2017-10-11 08:42:08.218522
NCT00695448|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-09|2017-07-23|||June 24, 2008|Actual|2008-06-24|July 2017|2017-07-01|March 31, 2009|Actual|2009-03-31|March 31, 2009|Actual|2009-03-31||Interventional|||Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma|A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients With Solid Tumors or Lymphoma|Terminated||Phase 1|11|Actual|GlaxoSmithKline||1||"This study was terminated prematurely due to lack of sufficient exposure following single- and   repeat-dosing."|f||||f||||||||||2017-10-11 08:42:09.401195|2017-10-11 08:42:09.401195
NCT00704301|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-20|2010-08-12|||November 2008||2008-11-01|October 2009|2009-10-01|May 2010|Actual|2010-05-01|April 2010|Actual|2010-04-01||Interventional|||Rivastigmine for Intensive Care Unit (ICU) Delirium|Rivastigmine for Delirium in Intensive Care Patients, a Double-blind, Randomized Placebo-controlled add-on Trial|Terminated||Phase 4|104|Actual|UMC Utrecht||2||The study is prematurely terminated due to a safety issue|f||||t||||||||||2017-10-11 08:43:02.25066|2017-10-11 08:43:02.25066
NCT00704210|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-20|2016-10-14|||August 2006||2006-08-01|October 2016|2016-10-01|July 2009|Anticipated|2009-07-01|December 2008|Anticipated|2008-12-01||Interventional|SpiDERS||Effectiveness of Mechanical Decompression for Low Back Pain Relief|Effectiveness of Mechanical Decompression for Low Back Pain Relief|Withdrawn||N/A|0|Actual|State University of New York - Upstate Medical University||2||Study withdrawn by sponsor|f||||f||||||||||2017-10-11 08:43:01.362059|2017-10-11 08:43:01.362059
NCT00704834|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-23|2017-07-13|||March 2006||2006-03-01|July 2017|2017-07-01|August 2027|Anticipated|2027-08-01|August 2027|Anticipated|2027-08-01||Observational|||Gene Expression Profiles in Multiple Sclerosis (MS)|Gene Expression Profiles in Patients With Multiple Sclerosis|Suspended||N/A|120|Anticipated|University of California, Davis|||4|Temporarily suspended due to funding issues|f||||f||||||Samples With DNA|"     35cc of peripheral blood will be obtained from each subject via venipuncture.   "|||2017-10-11 08:43:12.630774|2017-10-11 08:43:12.630774
NCT00704847|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-24|2012-10-22|2012-08-13||June 2008||2008-06-01|September 2012|2012-09-01|June 2011|Actual|2011-06-01|May 2011|Actual|2011-05-01||Interventional|||Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis|Terminated||Phase 3|1030|Actual|Nordic Bioscience A/S|The study showed an underexposure to calcitonin compared to what was expected from phase I trials.|2||Male subjects were terminated due to an imbalance in prostate cancer events|f||||t||||||||||2017-10-11 08:43:12.755343|2017-10-11 08:43:12.755343
NCT00704938|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-24|2015-10-06|2012-07-10||June 2008||2008-06-01|September 2015|2015-09-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional|||Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer|Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)|This study was terminated prior to completing accrual due to the withdrawal of support from our collaborator.|2||Terminated due to withdrawal of support from our collaborator.|f||||t||||||||||2017-10-11 08:43:15.485407|2017-10-11 08:43:15.485407
NCT00698750|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-13|2017-06-19|||April 2004||2004-04-01|June 2017|2017-06-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Observational|||A Clinical Investigation of the Copeland™ Humeral Resurfacing Head|A Prospective, Non-controlled, Clinical Investigation of the Copeland™ Humeral Resurfacing Head|Terminated||N/A|34|Actual|Zimmer Biomet|||1|Sponsor terminated study early due to limited enrollment and follow-up.|f||||f||||||||||2017-10-11 08:43:29.757204|2017-10-11 08:43:29.757204
NCT00699348|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-17|2016-03-08|2016-03-08||July 2008||2008-07-01|March 2016|2016-03-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|CARISMA|The safety population included all participants who were treated with at least 1 dose of C.E.R.A. and had a safety follow-up, whether withdrawn prematurely or not.|A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Hemodialysis Patients With Chronic Renal Anaemia|Completed||Phase 3|351|Actual|Hoffmann-La Roche||1|||f||||||||||||||2017-10-11 08:43:45.283564|2017-10-11 08:43:45.283564
NCT00699361|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-13|2014-02-10|||August 2008||2008-08-01|June 2008|2008-06-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure|Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure|Withdrawn||Phase 3|0|Actual|Johann Wolfgang Goethe University Hospital||2||Study withdrawn for financial issues|f||||t||||||||||2017-10-11 08:43:45.993735|2017-10-11 08:43:45.993735
NCT00699374|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-16|2012-12-07|2012-12-07||July 2008||2008-07-01|December 2012|2012-12-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer|A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma|Terminated||Phase 3|1075|Actual|Pfizer|Study terminated early due to futility. Subsequently, EQ-5D data were not collected or analyzed.|2||See termination reason in detailed description.|f||||t||||||||||2017-10-11 08:43:46.130473|2017-10-11 08:43:46.130473
NCT00709618|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-02|2014-06-30|2012-12-13||June 2008||2008-06-01|June 2014|2014-06-01|May 2012|Actual|2012-05-01|May 2012|Actual|2012-05-01||Interventional|||Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects|A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women With ErbB2 Overexpressing Metastatic Breast Cancer|Terminated||Phase 2|44|Actual|GlaxoSmithKline|The study was terminated due to low screening and a low enrollment rate after 3 years.|||"Evolving standard of care practices in this disease setting was limiting enrolment and leading   to a delay in delivering this study information to the public."|f||||f||||||||||2017-10-11 08:44:56.865711|2017-10-11 08:44:56.865711
NCT00709891|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-30|2015-02-05|2015-01-20||May 2008||2008-05-01|February 2015|2015-02-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional||Eligible population: All participants who met the study inclusion/exclusion criteria, had not been enrolled in the study previously, and had not withdrawn consent before undergoing any study procedures. Of the enrolled population, 321 participants did not meet these criteria.|Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease|Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease in Women Undergoing Routine Cervical Cancer Screening|Completed||N/A|47208|Actual|Hoffmann-La Roche||1|||f||||||||||||||2017-10-11 08:45:08.028455|2017-10-11 08:45:08.028455
NCT00702702|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-18|2014-08-05|2014-06-23||June 2008||2008-06-01|August 2014|2014-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional||Study prematurely terminated for safety reasons|Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids|A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy|Terminated||Phase 3|56|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped study for safety and FDA put study on hold because of safety.|f||||t||||||||||2017-10-11 08:45:19.892651|2017-10-11 08:45:19.892651
NCT00713596|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-09|2016-03-18|2012-04-19||July 2008||2008-07-01|March 2016|2016-03-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|||Study Evaluating Benefit of Using Fibrin Glue in Septorhinoplasty|The Use of Fibrin Sealant During Septorhinoplasty: Short and Long Term Benefits|Terminated||N/A|25|Actual|Mayo Clinic|Study was terminated due to principal investigator leaving the institution.|3||Lead investigator moved to a new medical center; study was stopped when he left.|f||||t||||||||||2017-10-11 08:45:47.720425|2017-10-11 08:45:47.720425
NCT00714376|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-10|2012-10-30|||May 2008||2008-05-01|October 2012|2012-10-01|July 2008|Actual|2008-07-01|July 2008|Actual|2008-07-01||Interventional|TAX1||Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients|Phase II Single Center Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients With an Early Rising PSA Following Radical Prostatectomy|Terminated||Phase 2|6|Actual|CHU de Quebec-Universite Laval||1||Prematurely terminated due to financial considerations|f||||t||||||||||2017-10-11 08:46:01.866841|2017-10-11 08:46:01.866841
NCT00714519|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-10|2013-08-29|||July 2008||2008-07-01|August 2013|2013-08-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|||Feasibility Study of the Execution of an Efficacy Trial in the Nursing Home Setting|A Phase II Feasibility Study of Xenaderm® Ointment Exploring Design Issues for Phase III Efficacy in Partial-Thickness Wounds|Withdrawn||Phase 2|0|Actual|Healthpoint||2||"The study was terminated due to the inability to enroll subjects. No subjects were or ever will   be enrolled into this study."|f||||f||||||||||2017-10-11 08:46:04.897431|2017-10-11 08:46:04.897431
NCT00706329|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-25|2013-06-05|2013-06-05||April 2008||2008-04-01|June 2013|2013-06-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Interventional|MIC|The study was terminated prematurely by the IRB due to data integrity and compliance concerns.|Minimally Invasive Closure of Umbilical Hernias|Study of Minimally Invasive Closure of Umbilical Hernias|Terminated||N/A|25|Actual|South Shore Hospital|The study was terminated prematurely by the IRB due to data integrity and compliance concerns. Results are not shared due to data integrity concerns. These concerns are outlined in an FDA warning letter.|1||"The study was terminated prematurely by the IRB due to data integrity and protocol compliance   issues"|f||||f||||||||||2017-10-11 08:46:28.043863|2017-10-11 08:46:28.043863
NCT00706459|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-24|2012-11-13|||March 2005||2005-03-01|November 2012|2012-11-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Observational|||Advanced MR Imaging in Patients With Painful, Degenerative Disc Disease: A Pilot Study|Advanced MR Imaging in Patients With Painful, Degenerative Disc Disease: A Pilot Study|Terminated||N/A|53|Actual|University of California, San Francisco|||5|Due to funding issue, study has been terminated.|f||||f||||||Samples Without DNA|"     Disc specimens are taken out during back surgery and will be studied using techniques for     tissue analysis to explain the properties and characteristics of disc tissue from patients     with back pain.   "|||2017-10-11 08:46:39.975939|2017-10-11 08:46:39.975939
NCT00715884|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-11|2013-12-17|2011-02-25||July 2008||2008-07-01|December 2013|2013-12-01|September 2014|Anticipated|2014-09-01|March 2010|Actual|2010-03-01||Interventional|ELITE||Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems|A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems (ELITE).|Unknown status|Active, not recruiting|N/A|678|Actual|Cordis Corporation|The study was terminated early by the Sponsor for business reasons. Hence the data was under powered for hypothesis testing. No definitive conclusions can be made from this data.|2|||f||||t||||||||||2017-10-11 08:47:33.970265|2017-10-11 08:47:33.970265
NCT00716469|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-14|2015-04-14|||July 2008||2008-07-01|April 2015|2015-04-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional|PDT||Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas|Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using Intratumoral Delivery of Non-coherent Light for Photoactivation of LS11 in Children With Plexiform Neurofibromas|Terminated||Phase 1|7|Actual|Children's Hospital of Philadelphia||1||The study is terminated due to expiration of study materials.|f||||t||||||||||2017-10-11 08:47:48.583928|2017-10-11 08:47:48.583928
NCT00716560|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-14|2016-10-19|||May 2005||2005-05-01|October 2016|2016-10-01|March 2009|Actual|2009-03-01|March 2009|Actual|2009-03-01||Observational|||Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin|Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin|Terminated||N/A|8|Actual|Thomas Jefferson University|||1|Administratively terminated.|f||||f||||||||||2017-10-11 08:47:51.189026|2017-10-11 08:47:51.189026
NCT00717275|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-15|2012-09-14|2012-07-10||September 2008||2008-09-01|July 2012|2012-07-01|June 2011|Actual|2011-06-01|January 2011|Actual|2011-01-01||Interventional|||Study of Temozolomide to Treat Newly Diagnosed Brain Metastases|A Phase II Study of Temozolomide (TMZ) Following Stereotactic Radiosurgery (SRS) for Patients With Newly Diagnosed Brain Metastases|Terminated||Phase 2|3|Actual|University of Florida|This single center study was terminated early due to slow accrual; therefore, statistical analysis of the 3 participants was not done.|1||Slow accrual.|f||||t||||||||||2017-10-11 08:48:08.222584|2017-10-11 08:48:08.222584
NCT00717522|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-16|2013-03-06|2013-03-06|2012-10-08|August 2008||2008-08-01|March 2013|2013-03-01|January 2009|Actual|2009-01-01|January 2009|Actual|2009-01-01||Interventional|||Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma|A Phase 2, Multicenter, Open-label, Single Arm, Two-stage Study to Evaluate the Efficacy and Safety of CC-4047 (Pomalidomide) in Patients With Advanced Soft Tissue Sarcomas Who Have Relapsed or Are Refractory to Systemic Anticancer Therapy|Terminated||Phase 2|7|Actual|Celgene||1||"Study enrollment was terminated due to a corporate strategic decision unrelated to patient   safety."|f||||t||||||||||2017-10-11 08:48:13.398867|2017-10-11 08:48:13.398867
NCT00717639|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-30|2011-08-05|||May 2008||2008-05-01|July 2010|2010-07-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|||Vasovist Magnetic Resonance Angiography (MRA) in Peripheral Arterial Occlusive Disease|Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients With Peripheral Artery Disease|Terminated||Phase 4|150|Anticipated|Heidelberg University||1||Required contrast media (Vasovist) withdrawn from market|f||||f||||||||||2017-10-11 08:48:14.740793|2017-10-11 08:48:14.740793
NCT00710905|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-03|2011-11-21|2011-10-04||October 2009||2009-10-01|November 2011|2011-11-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional|||Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3|Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3|Terminated||Phase 4|50|Actual|Alcon Research||1||Postmarket study terminated as the SN6AD3 is no longer promoted.|f||||f||||||||||2017-10-11 08:48:23.318432|2017-10-11 08:48:23.318432
NCT00712270|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-07|2016-02-25|||April 2005||2005-04-01|February 2016|2016-02-01|November 2010|Actual|2010-11-01|December 2008|Actual|2008-12-01||Interventional|BEST||Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia|A Randomized Double-blind Trial of Aripiprazole and Risperidone in Schizophrenia: An Evaluation of Neuroimaging, Neuropsychological, and Pharmacogenomic Markers of Differential Treatment Response|Terminated||Phase 4|21|Actual|Kettering Health Network||3||Study terminated due to failure to meet sufficient enrollment for valid analysis|f||||f||||||||No||2017-10-11 08:48:54.758461|2017-10-11 08:48:54.758461
NCT00712621|ClinicalTrials.gov processed this data on October 10, 2017|2008-06-18|2009-11-20|||February 2010||2010-02-01|November 2009|2009-11-01|February 2014|Anticipated|2014-02-01|February 2014|Anticipated|2014-02-01||Interventional|||Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination|Phase II Two Arm Randomized Controlled Clinical Trial to Study Quality of Life and Survival of Breast Cancer Patients After Completion of Chemotherapy or Radiation Therapy or Surgery or Any Combination Therapy in Stage I to IV Carcinoma|Withdrawn||Phase 2|460|Anticipated|American Scitech International||2||"Study is withdrawn due to unavailability of eligible subject population. We will request the   sponsors to extend the time for enrollment."|f||||f||||||||||2017-10-11 08:49:00.845944|2017-10-11 08:49:00.845944
NCT00719901|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-19|2015-01-09|2013-08-08||July 2008||2008-07-01|October 2013|2013-10-01|June 2012|Actual|2012-06-01|April 2011|Actual|2011-04-01||Interventional||One patient withdrew prior to beginning treatment and was replaced, thus, will be excluded in all analysis.|Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Trial of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma|Terminated||Phase 1/Phase 2|11|Actual|National Cancer Institute (NCI)|This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open. No results from the phase II portion are available.|1||"This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase   I; therefore, the phase II portion will never open."|f||||||||||||||2017-10-11 08:49:42.084971|2017-10-11 08:49:42.084971
NCT00720083|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-19|2015-11-14|2013-03-22||November 2008||2008-11-01|November 2015|2015-11-01|August 2011|Actual|2011-08-01|August 2011|Actual|2011-08-01||Interventional||All eligible patients.|Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer|A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|34|Actual|Radiation Therapy Oncology Group|This study terminated early with 34 subjects accrued out of 170 planned, therefore no analyses were performed.|2||Withdrawal of drug supply.|f||||t||||||||||2017-10-11 08:49:44.798899|2017-10-11 08:49:44.798899
NCT00722436|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-23|2017-02-10|2016-09-16||July 2008||2008-07-01|February 2017|2017-02-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Tranexamic Acid for Craniofacial Surgery|Tranexamic Acid for the Reduction of Allogeneic Blood Exposure in Infants and Children Having Craniofacial Surgery|Terminated||Phase 4|20|Actual|University of Pittsburgh|Study terminated because two studies published during the trial demonstrated efficacy of tranexamic acid at a lower dose.|2||Study dose changed based on recent publications|f||||f||||||||No|We stopped the study early because emerging data came out that demonstrated benefit with significantly lower doses than our study. We were compelled to stop enrolling.|2017-10-11 08:50:56.366804|2017-10-11 08:50:56.366804
NCT00723203|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-25|2014-09-03|2014-06-12||April 2008||2008-04-01|September 2014|2014-09-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional|||Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia|A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60|Terminated||Phase 2|16|Actual|City of Hope Medical Center|There were no responses observed in the first 12 evaluable patients accrued to the first stage of the two-stage Optimum design of Simon. As a result the study was terminated due to a lack of efficacy.|1||Terminated early due to a lack of efficacy|f||||t||||||||||2017-10-11 08:51:09.016587|2017-10-11 08:51:09.016587
NCT00724061|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-26|2013-11-25|2013-11-25||September 2008||2008-09-01|November 2013|2013-11-01|December 2011|Actual|2011-12-01|June 2011|Actual|2011-06-01||Interventional|||Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL|Pilot Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy in Cutaneous T-Cell Lymphoma|Terminated||N/A|7|Actual|Northwestern University|Only 7 patients were enrolled before the study was terminated by the Data Monitoring Committee due to poor accrual. Accrual was limited by a worldwide psoralen shortage and well as the exclusion of patients with prior UV light exposure.|1||Closed early due to poor accrual.|f||||t||||||||||2017-10-11 08:51:30.168654|2017-10-11 08:51:30.168654
NCT00728000|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-31|2009-04-24|||August 2008||2008-08-01|April 2009|2009-04-01|August 2010|Anticipated|2010-08-01|August 2009|Anticipated|2009-08-01||Interventional|||Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma|Phase II Study Of Neoadjuvant Chemotherapy With Gemcitabine, Oxaliplatin And Erlotinib (Gemoxt) In Borderline Resectable Pancreatic Adenocarcinoma|Withdrawn||Phase 2|20|Anticipated|University of Cincinnati||1||study withdrawn due to lack of enrollment|f||||f||||||||||2017-10-11 08:51:59.105921|2017-10-11 08:51:59.105921
NCT00728507|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-30|2017-03-08|2016-08-03||November 2009||2009-11-01|March 2017|2017-03-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|||Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis|A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis|Terminated||Phase 2|121|Actual|Johns Hopkins University||2||Funding withdrawn|f||||t||||||||||2017-10-11 08:52:08.697852|2017-10-11 08:52:08.697852
NCT00729365|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-04|2015-02-24|2014-12-30||July 2008||2008-07-01|February 2015|2015-02-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|PREVENTKD||PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)|Nocturnal Hypertension and Prevention of Microalbuminuria in Type 1 Diabetes|Terminated||Phase 3|65|Actual|Northwestern University|"The study was terminated prematurely because of new information from the literature from other studies showing that this study could not be successful.
This study was terminated prematurely due to slow recruitment rate leading to a small (23) number of subjects analyzed."||1||f||||f||||||||||2017-10-11 08:52:29.359734|2017-10-11 08:52:29.359734
NCT00729833|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-30|2014-05-21|2014-04-11||September 2008||2008-09-01|May 2014|2014-05-01|April 2013|Actual|2013-04-01|August 2011|Actual|2011-08-01||Interventional||Full Analysis Set: All enrolled participants who received at least 1 dose of figitumumab plus sunitinib.|Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors|Phase 1, Open Label, Sequential Cohort, Dose Escalation Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors|Terminated||Phase 1|45|Actual|Pfizer|This study was terminated prematurely. Subsequently, ADA samples were not assayed and the pharmacokinetics of sunitinib plus its metabolite were not analyzed.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 08:52:31.744559|2017-10-11 08:52:31.744559
NCT00731692|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-07|2017-05-09|2015-12-16||July 28, 2008|Actual|2008-07-28|May 2017|2017-05-01|June 22, 2015|Actual|2015-06-22|June 22, 2015|Actual|2015-06-22||Interventional|INFORMS||This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.|A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis|Terminated||Phase 3|970|Actual|Novartis||3||"The extension study was terminated early after the results of the core study showed the study   did not meet primary endpoint; confirmed disability progression"|f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
NCT00732303|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-07|2016-03-23|2016-02-24||January 2009||2009-01-01|March 2016|2016-03-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer|A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129|Terminated||Phase 2|8|Actual|Hoosier Cancer Research Network||1||Study terminated due to withdrawal of pharmaceutical funding|f||||t||||||||||2017-10-11 08:53:19.18861|2017-10-11 08:53:19.18861
NCT00732940|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-08|2013-08-01|2011-04-07||October 2008||2008-10-01|March 2013|2013-03-01|March 2012|Actual|2012-03-01|October 2009|Actual|2009-10-01||Interventional|||Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 2, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)|Terminated||Phase 2|56|Actual|Human Genome Sciences Inc.||2||Sponsor terminated study for business reasons.|f||||t||||||||||2017-10-11 08:53:29.705738|2017-10-11 08:53:29.705738
NCT00724841|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-28|2016-07-20||2013-08-28|June 2008||2008-06-01|July 2016|2016-07-01|August 2010|Actual|2010-08-01|July 2008|Actual|2008-07-01||Interventional|||A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma|A Multi-Center, Open-Label, Phase I/II Study of GEM1777 in Combination With Temozolomide Administered Every 4 Weeks to Patients With Metastatic Melanoma|Terminated||Phase 1/Phase 2|1|Actual|Teva Pharmaceutical Industries||6||Study terminated prematurely due to financial contraints.|f||||f||||||||||2017-10-11 08:53:36.956007|2017-10-11 08:53:36.956007
NCT00725400|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-28|2011-07-19|||February 2010||2010-02-01|July 2011|2011-07-01|February 2014|Anticipated|2014-02-01|February 2014|Anticipated|2014-02-01||Interventional|||Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma|Phase II Open Label Comparative Study of Cetuximab and Radiation Therapy Vs Surgery Before or After Radiation Therapy in Patients With Stage II to IV Colorectal Carcinoma|Withdrawn||Phase 2|450|Anticipated|American Scitech International||2||"Study is withdrawn due to unavailability of eligible subject population. We will request the   sponsors to extend the time for enrollment."|f||||f||||||||||2017-10-11 08:53:56.314932|2017-10-11 08:53:56.314932
NCT00726037|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-29|2016-08-23|2013-04-26||October 2008||2008-10-01|August 2016|2016-08-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer|A Pilot Study Evaluating the Efficacy of Regulatory T-cell (T-reg) Suppression by Denileukin Diftitox (Ontak) in Metastatic Pancreatic Cancer|Terminated||Phase 2|7|Actual|Loyola University|This study was prematurely terminated, because the study drug Ontak is no longer supplied by the manufacturer for this study. Data is not analyzed for any outcome measures.|1||Collaborator withdrew support due to a drug supply interruption.|f||||t||||||||No||2017-10-11 08:54:08.825733|2017-10-11 08:54:08.825733
NCT00726375|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-28|2015-12-04|2014-07-08||May 2008||2008-05-01|December 2015|2015-12-01|September 2014|Actual|2014-09-01|July 2013|Actual|2013-07-01||Interventional|||The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease|The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease|Completed||Phase 3|34|Actual|University of Michigan Cancer Center|Due to difficulties obtaining approval for insurance coverage of the study drug, only 34 of 50 patients were enrolled. The study was terminated prematurely and findings were reported for 34 patients.|1|||f||||t||||||||||2017-10-11 08:54:13.64892|2017-10-11 08:54:13.64892
NCT00726986|ClinicalTrials.gov processed this data on October 10, 2017|2008-07-31|2014-11-05|2014-07-08||July 2008||2008-07-01|November 2014|2014-11-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional|||Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Sorafenib in Conjunction With Chemotherapy and as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer|Terminated||Phase 2|18|Actual|Case Comprehensive Cancer Center|This study was terminated after enrolling 18 patients on the basis of excessive toxicity observed and preliminary efficacy data showing that study was unlikely to meet primary end point.|1||Extreme toxicity|f||||t||||||||||2017-10-11 08:54:26.701189|2017-10-11 08:54:26.701189
Study terminated early; 13 patients received eculizumab or placebo in TP2."|2|||f||||t||||||||||2017-10-11 08:54:30.063846|2017-10-11 08:54:30.063846
NCT00733486|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-11|2015-06-08|||August 2005||2005-08-01|June 2015|2015-06-01|February 2011|Actual|2011-02-01|December 2010|Actual|2010-12-01||Interventional|||A Study to Evaluate the Performance of the DePuy Low Contact Stress (LCS®) Complete Anterior-Posterior Glide (APG) Mobile Bearing Knee|A Prospective, Non-Comparative Study to Evaluate the Performance of the DePuy Low Contact Stress (LCS®) Complete Anterior-Posterior Glide (AP Glide) Mobile Bearing Knee System in Primary Knee Arthroplasty|Terminated||Phase 4|233|Actual|DePuy International||1||"The study was terminated at 2 years as investigators were unable to continue participation in   the study."|f||||f||||||||||2017-10-11 08:54:40.06999|2017-10-11 08:54:40.06999
NCT00734812|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-12|2013-01-23|||May 2008||2008-05-01|January 2013|2013-01-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Laparoscopic Supracervical Hysterectomy Versus Total Laparoscopic Hysterectomy|LSH vs. TLH, A Randomized Single Blind Trial|Withdrawn||Phase 3|0|Actual|Brigham and Women's Hospital||2||Study was withdrawn prior to any enrollment.|f||||f||||||||||2017-10-11 08:55:18.80742|2017-10-11 08:55:18.80742
NCT00734864|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-04|2012-11-20|||June 2009||2009-06-01|November 2012|2012-11-01|June 2012|Anticipated|2012-06-01|June 2010|Anticipated|2010-06-01||Interventional|||Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma|Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma|Withdrawn||Phase 1|0|Actual|Duke University||2||Study drug supplier withdrew support for the study. Study was withdrawn from the Duke IRB.|f||||f||||||||||2017-10-11 08:55:19.525957|2017-10-11 08:55:19.525957
NCT00735345|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-13|2015-03-06|||August 2008||2008-08-01|March 2015|2015-03-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|||Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma|Chemotherapy Induction and Chemoradiotherapy Combined With Cetuximab Respectively in Patients With Non-Metastatic Esophageal Carcinoma: A Multicentric Phase II Study|Terminated||Phase 2|50|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1||because of safety concerns the study was terminated prematurely|f||||f||||||||||2017-10-11 08:55:27.195304|2017-10-11 08:55:27.195304
NCT00735553|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-13|2014-08-05|2014-06-25||August 2008||2008-08-01|August 2014|2014-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional||Study prematurely terminated|Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids|A Phase III, Three-arm, Parallel Design, Placebo-controlled, Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids|Terminated||Phase 3|77|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2017-10-11 08:55:32.502692|2017-10-11 08:55:32.502692
NCT00736385|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-13|2016-12-05|2015-03-17||April 2009||2009-04-01|December 2016|2016-12-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|NAFLD||Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)|Hyperinsulinemia and Insulin Resistance in Nonalcoholic Fatty Liver Disease. Metformin for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial|Terminated||Phase 4|11|Actual|Duke University|Study was terminated early due to difficulties with enrollment.|2|||f||||f||||||||||2017-10-11 08:56:13.605015|2017-10-11 08:56:13.605015
NCT00738699|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-18|2017-02-10|2016-12-13|2013-11-18|September 2008||2008-09-01|February 2017|2017-02-01|January 2012|Actual|2012-01-01|December 2011|Actual|2011-12-01||Interventional|FAR-122|Intent-to-Treat population included, the primary population for the evaluation of efficacy, was defined as all participant who were randomly assigned to test article, analyzed by the treatment assigned.|An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer|A Randomized, Double Blind, Placebo-Controlled Study of the Efficacy and Safety oF MORAb-003(Farletuzumab) in Combination With Paclitaxel Therapy in Subjects With Platinum-Resistant or Refractory Relapsed Ovarian Cancer|Terminated||Phase 2|415|Actual|Morphotek|This study was prematurely terminated by the sponsor following results of the preplanned futility analysis showing the study was unlikely to meet its statistically-defined coprimary endpoints.|2||study did not meet pre-specified criteria for continuation following interim futility analysis|f||||t||||||||||2017-10-11 08:56:33.202509|2017-10-11 08:56:33.202509
NCT00739050|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-19|2017-03-31|2010-08-26||September 19, 2007|Actual|2007-09-19|March 2017|2017-03-01|February 1, 2008|Actual|2008-02-01|February 1, 2008|Actual|2008-02-01||Interventional|||Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)|Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus|Terminated||Phase 4|4|Actual|Merck Sharp & Dohme Corp.|The Investigator was not able to recruit the required patients and was not able to get the necessary equipment. The protocol was terminated for Administrative Reasons.|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00739219|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-19|2009-01-19|||December 2006||2006-12-01|October 2008|2008-10-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|Outcomes||Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)|Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO) Using the Apieron NO Analyzer|Terminated||Phase 4|260|Actual|Apieron||2||Study terminated due to lack of care guidelines in the protocol.|f||||f||||||||||2017-10-11 08:56:41.105519|2017-10-11 08:56:41.105519
NCT00739882|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-20|2014-01-26|2010-06-28||April 2008||2008-04-01|January 2014|2014-01-01|June 2009|Actual|2009-06-01|June 2009|Actual|2009-06-01||Interventional|TRUST||TRUST Study: Raptiva ® in Hand & Foot Psoriasis|A Phase IV Multicentre, Randomised, Double-blind, Placebo Controlled, Trial to Evaluate the Safety and Efficacy of Raptiva ® in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Involving Hands and/or Feet, With or Without Pustules.|Terminated||Phase 4|76|Actual|Merck KGaA|Following the recommendation of the European Medicines Agency (EMEA) to suspend the marketing authorization of Raptiva® and the subsequent premature termination of this trial analysis of efficacy-related endpoints was not performed|2||"The study was terminated after the European Medicines Agency recommended to suspend the   marketing authorisation of Raptiva in the European Union"|f||||||||||||||2017-10-11 08:56:52.278126|2017-10-11 08:56:52.278126
NCT00740597|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-22|2014-06-12|2014-06-12||July 2008||2008-07-01|June 2014|2014-06-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|||Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma|Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas|Terminated||Phase 2|1|Actual|City of Hope Medical Center|Study closed 05/12/2010 (opened 7/25/2008): No patients were accrued and treated per protocol in nearly two years (2 patients were screened). The study was terminated by the IRB when the PI decided not to continue. Protocol objectives were not met.|1||No patients were enrolled on the study|f||||t||||||||||2017-10-11 08:57:28.868686|2017-10-11 08:57:28.868686
NCT00742053|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-25|2017-07-12|2012-04-25||June 2008||2008-06-01|July 2017|2017-07-01|March 2009|Actual|2009-03-01|December 2008|Actual|2008-12-01||Interventional|||Electrocardiogram (ECG) Guided Peripherally Inserted Central Catheter (PICC) Placement|A Study of Electrocardiogram (ECG) Guidance for Placement of Peripherally Inserted Central Catheters (PICC)|Terminated||N/A|7|Actual|C. R. Bard|The study was terminated early due to poor enrollment.|1||Enrollment rate was too slow.|f||||f||||||||||2017-10-11 08:57:54.656345|2017-10-11 08:57:54.656345
NCT00742313|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-25|2014-02-17|2013-11-08||June 2009||2009-06-01|November 2013|2013-11-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Interventional|||Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)|Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)|Terminated||Phase 4|50|Actual|Duke University|This study was terminated early|2||No statistical differences on study endpoints between groups.|f||||f||||||||||2017-10-11 08:58:01.316077|2017-10-11 08:58:01.316077
NCT00743197|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-26|2011-11-30|2011-09-13||May 2008||2008-05-01|November 2011|2011-11-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Women With Chest Pain and Normal Coronary Arteries Study|Women With Chest Pain and Normal Coronary Arteries Study: A Randomized Study of Medical Treatment and Therapeutic Lifestyle Changes|Terminated||N/A|3|Actual|Northwestern University|Study terminated due to departure of PI; all work including analyses ceased upon departure.In addition,study end points were based on changes b/w groups treatment vs. usual care) at 12 mo follow up- none of the subjects completed the Mo 12 visit.|2||Terminated due to departure of PI from institution.|f||||f||||||||||2017-10-11 08:58:17.833099|2017-10-11 08:58:17.833099
NCT00737061|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-14|2017-08-08|2009-08-26||November 2002||2002-11-01|August 2017|2017-08-01|February 4, 2013|Actual|2013-02-04|December 2005|Actual|2005-12-01||Interventional|EASE||Safety & Efficacy Study of the Adiana System for Women Who Desire Permanent Birth Control (Sterilization)|A Multi-Center, Prospective Evaluation of the Adiana System for Transcervical Sterilization Using Electrothermal Energy in Women Aged 18-45 - The EASE Trial|Terminated||N/A|770|Actual|Hologic, Inc.|At the time of analysis, 481 completed 3 years. Due to the cumulative nature of the analysis, subjects may be lost to follow-up at one time and return to follow-up at a subsequent point. All subjects who have not withdrawn consent will be followed.|1||Product Pre-Market Approval withdrawn|f||||t||||||||||2017-10-11 08:58:31.993706|2017-10-11 08:58:31.993706
NCT00737113|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-15|2014-03-18|||September 2008||2008-09-01|March 2014|2014-03-01|December 2013|Actual|2013-12-01|May 2012|Actual|2012-05-01||Interventional|||Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant|Recombinant Human Growth Hormone(RH-GH) For Accelerating Immune Reconstitution In Pediatric and Adult Patients Undergoing Allogeneic Stem Cell Transplantation|Terminated||Phase 1|14|Actual|Duke University||1||Study was terminated early due to low accrual.|f||||f||||||||||2017-10-11 08:58:34.554546|2017-10-11 08:58:34.554546
NCT00737282|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-14|2014-08-05|2014-06-25||October 2008||2008-10-01|August 2014|2014-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional||Study prematurely terminated|Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids|A Phase III, Open-Label, Parallel, Randomized, Multicenter Study Evaluating the Safety of 25 And 50 mg Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids|Terminated||Phase 3|175|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|2||Repros stopped study for safety and FDA put study on hold.|f||||t||||||||||2017-10-11 08:58:37.514395|2017-10-11 08:58:37.514395
NCT00737594|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-15|2016-02-16|2016-02-16||July 2008||2008-07-01|February 2016|2016-02-01|March 2009|Actual|2009-03-01|February 2009|Actual|2009-02-01||Interventional||Study was terminated early, data was not analyzed.|Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension|A Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension|Terminated||Phase 2|9|Actual|Sucampo Pharma Americas, LLC||3||Failure to enroll a suitable number of qualified subjects.|f||||t||||||||||2017-10-11 08:58:46.266158|2017-10-11 08:58:46.266158
NCT00737763|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-19|2014-05-09|||October 2008||2008-10-01|May 2014|2014-05-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|BRiTE||Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab|Beta Cell Rescue in New Onset Type 1 Diabetes Mellitus With the LFA-1 Antibody Efalizumab|Withdrawn||Phase 2|0|Actual|Emory University||2||drug withdrawn from market|f||||t||||||||||2017-10-11 08:58:51.024368|2017-10-11 08:58:51.024368
NCT00745303|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-01|2008-09-01|||May 2002||2002-05-01|September 2008|2008-09-01|March 2004|Actual|2004-03-01|May 2003|Actual|2003-05-01||Observational|||Effect of Tai Chi Chuan on Autonomic Nervous Modulation in Aged Subjects|Effect of Tai Chi Chuan on Autonomic Nervous Modulation, Blood Lipid and Cytokines Production in Aged Subjects|Completed||N/A|50|Actual|Taipei Veterans General Hospital, Taiwan|||2||f||||f||||||Samples Without DNA|"     Blood sample obtained from each subject was withdrawn for the quantitative measurements of     total cholesterol (TC), high-density lipoprotein--cholesterol (HDL-C), high-density     lipoprotein--cholesterol (LDL-C), triglyceride (TG), fasting blood sugar (FBS), and uric acid     (UA). The immunoenzymometric assays for the quantitative measurement of tumor necrosis     factor-α (TNF-α) and interferon-γ (IFN-γ) in the serum were also performed on the blood     sample from each subject.   "|||2017-10-11 08:59:07.953921|2017-10-11 08:59:07.953921
NCT00746382|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-03|2016-11-30|||November 2008||2008-11-01|October 2016|2016-10-01|September 2009|Anticipated|2009-09-01|June 2009|Anticipated|2009-06-01||Interventional|||A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)|A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis|Withdrawn||Phase 2|0|Actual|AstraZeneca||2||Study withdrawn due to business decisions. No subjects were treated.|f||||f||||||||||2017-10-11 08:59:20.67048|2017-10-11 08:59:20.67048
NCT00746434|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-03|2016-12-02|||November 2008||2008-11-01|October 2016|2016-10-01|September 2009|Anticipated|2009-09-01|June 2009|Anticipated|2009-06-01||Interventional|||A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis|A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis|Withdrawn||Phase 2|0|Actual|AstraZeneca||2||Study withdrawn due to business decisions. No subjects were treated.|f||||t||||||||||2017-10-11 08:59:21.608364|2017-10-11 08:59:21.608364
NCT00746590|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-03|2016-05-03|2016-05-03||September 2008||2008-09-01|May 2016|2016-05-01|August 2009|Actual|2009-08-01|June 2009|Actual|2009-06-01||Interventional|||Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma|A Phase 2 Study of the Anti-tumour Activity and Safety of Prolarix™ in Hepatocellular Carcinoma (HCC)|Terminated||Phase 2|1|Actual|BTG International Inc.||1||Study terminated prematurely by sponsor for business reason. One patient was enrolled.|f||||f||||||||Yes||2017-10-11 08:59:23.514442|2017-10-11 08:59:23.514442
NCT00746824|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-27|2012-08-31|||August 2008||2008-08-01|August 2012|2012-08-01|March 2009|Actual|2009-03-01|January 2009|Actual|2009-01-01||Interventional|||A Study to Determine the Effects of TM30339 on Weight Loss in Obese Individuals.|TM30339: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Repeated Subcutaneous Dose-range Study Designed to Determine the Weight Loss in Obese Subjects.|Terminated||Phase 2|192|Actual|7TM Pharma A/S||6||The IND was withdrawn.|f||||f||||||||||2017-10-11 08:59:29.698066|2017-10-11 08:59:29.698066
NCT00746941|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-03|2014-07-02|2013-01-03||January 2009||2009-01-01|July 2014|2014-07-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)|A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)|Terminated||Phase 1/Phase 2|37|Actual|Biogen|From ongoing analysis, it became clear, based on conditional power calculations, that the study would not reach its primary endpoint, a decrease of JC viral load in CSF with mefloquine treatment; therefore, the study was terminated early.|2||Primary endpoint not achieved|f||||f||||||||||2017-10-11 08:59:31.195328|2017-10-11 08:59:31.195328
NCT00747032|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-01|2012-05-04|||September 2010||2010-09-01|May 2012|2012-05-01|April 2011|Anticipated|2011-04-01|February 2011|Anticipated|2011-02-01||Interventional|||To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis|Multi-Center, Double-Blind, Randomized, Vehicle-controlled, Parallel-Group Study Comparing NYC-0462 Ointment To a Vehicle Control|Withdrawn||Phase 3|0|Actual|Nycomed||2||Study withdrawn due to business decisions. No subjects were treated.|f||||f||||||||||2017-10-11 08:59:35.652747|2017-10-11 08:59:35.652747
NCT00747136|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-02|2016-04-12|||August 2008||2008-08-01|April 2011|2011-04-01|March 2013|Actual|2013-03-01|October 2012|Actual|2012-10-01||Observational|||WavSTAT® Optical Biopsy System to Target Esophageal Biopsies|A Prospective Evaluation of the WavSTAT® Optical Biopsy System to Target Esophageal Biopsies: An Adjunctive Tool to Assist the Endoscopist to Identify Dysplasia or Cancer|Terminated||N/A|47|Actual|SpectraScience|||1|Study has been terminated for inadequate results|f||||t||||||Samples Without DNA|"     esophageal biopsies will be collected.   "|||2017-10-11 08:59:37.377842|2017-10-11 08:59:37.377842
NCT00747305|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-04|2015-10-21|||October 2008||2008-10-01|April 2015|2015-04-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery|Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma|Terminated||Phase 1|17|Actual|Medical University of South Carolina||1||Study terminated early due to low accrual.|f||||t||||||||||2017-10-11 08:59:39.918487|2017-10-11 08:59:39.918487
NCT00748527|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-05|2013-07-09|||July 2007||2007-07-01|September 2008|2008-09-01|November 2010|Actual|2010-11-01|December 2009|Actual|2009-12-01||Interventional|||Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Cancer Research UK Randomised, Multicentre, Phase II Trial of the DNAhypomethylating Agent, 5-Aza-2'-Deoxycytidine (Decitabine) Given Intravenously in Combination With Carboplatin, Versus Carboplatin Alone Given 4 Weekly in Patients With Progressive, Advanced Ovarian Cancer|Terminated||Phase 2|134|Anticipated|National Cancer Institute (NCI)||2||"The study was withdrawn due to certain adverse events [hypersensitivity]."|f||||||||||||||2017-10-11 08:59:58.001337|2017-10-11 08:59:58.001337
NCT00748566|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-05|2013-04-29|2013-04-29||December 2008||2008-12-01|April 2013|2013-04-01|May 2012|Actual|2012-05-01|May 2012|Actual|2012-05-01||Interventional|||One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome|A One-Year, Phase IV, Open-Label, Non-Comparative Trial Of The Effect Of Ziprasidone HCL On Metabolic Syndrome Risk Factors In Patients With Psychotic Disorders|Terminated||Phase 4|172|Actual|Pfizer|The study was prematurely terminated by sponsor due to changes in organizational strategy and resources, not due to safety concerns.|1||See Detailed Description|f||||f||||||||||2017-10-11 08:59:58.772918|2017-10-11 08:59:58.772918
NCT00744614|ClinicalTrials.gov processed this data on October 10, 2017|2008-08-29|2010-10-19|||November 2007||2007-11-01|October 2010|2010-10-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Observational|||Use Of Capnography As Surrogate Measure Of PC02 In Medical Intensive Care Unit (ICU) Patients|Use Of Capnography As Surrogate Measure Of PC02 In Medical ICU Patients|Terminated||N/A|70|Anticipated|Lahey Clinic|||1|"Principal Investigator (central contact) has left the organization and requests the study be   terminated"|f||||f||||||||||2017-10-11 09:00:53.568882|2017-10-11 09:00:53.568882
NCT00752999|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-15|2012-04-26|||November 2008||2008-11-01|April 2012|2012-04-01|March 2010|Anticipated|2010-03-01|November 2009|Anticipated|2009-11-01||Interventional|SOLEIL||Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Systemic Lupus Erythematosus Patients With Active Disease|Withdrawn||Phase 2|0|Actual|Rigel Pharmaceuticals||2||Study was withdrawn for business reasons before study start.|f||||t||||||||||2017-10-11 09:01:39.854428|2017-10-11 09:01:39.854428
NCT00754221|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-16|2011-05-31|||May 2008||2008-05-01|May 2011|2011-05-01|May 2009|Actual|2009-05-01|May 2009|Actual|2009-05-01||Interventional|||Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia|A Multi-center, Long-term, Open-label Extension Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia|Terminated||Phase 3|390|Actual|Pfizer||1||"This study has been terminated early as the esreboxetine development program is being   discontinued. There are no safety or efficacy concerns."|f||||t||||||||||2017-10-11 09:02:03.833516|2017-10-11 09:02:03.833516
NCT00754637|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-17|2017-06-19|||December 2009||2009-12-01|June 2017|2017-06-01|June 2023|Anticipated|2023-06-01|December 2022|Anticipated|2022-12-01||Observational|MTT||Microplasty Tibial Tray Data Collection|Microplasty Tibial Tray Multi-Center Data Collection|Withdrawn||N/A|0|Actual|Zimmer Biomet|||1|The study was withdrawn because it no longer fit the business need.|f||||f||||||||||2017-10-11 09:02:12.872685|2017-10-11 09:02:12.872685
NCT00755261|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-17|2015-05-07|2015-04-15||September 2008||2008-09-01|May 2015|2015-05-01|November 2010|Actual|2010-11-01|September 2010|Actual|2010-09-01||Interventional|||Phase II Study of Doxorubicin and Avastin® in Sarcoma.|Phase II Study of Doxorubicin and Avastin® for Patients With Advanced Soft-tissue Sarcomas.|Terminated||Phase 2|4|Actual|Sidney Kimmel Comprehensive Cancer Center||1||The study has been terminated due to low accrual.|f||||t||||||||||2017-10-11 09:02:22.785991|2017-10-11 09:02:22.785991
NCT00750919|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-10|2015-07-02|2014-05-22||October 2008||2008-10-01|July 2015|2015-07-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)|A Twenty-six Weeks, Open-label Extension Trial to Evaluate Safety and Efficacy of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 21106|Terminated||Phase 3|184|Actual|Merck Sharp & Dohme Corp.|This study was terminated due to the Sponsor's decision not to continue development of esmertazapine for this indication.|1||"This trial was stopped prematurely due to the Sponsor's decision not to continue the   development of esmertazapine for this indication."|f||||f||||||||||2017-10-11 09:03:00.359197|2017-10-11 09:03:00.359197
NCT00756912|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-18|2014-07-10|||September 2008||2008-09-01|July 2014|2014-07-01||||November 2008|Actual|2008-11-01||Interventional|||A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors|A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors|Terminated||Phase 1|30|Actual|Eisai Inc.||1||"This study was terminated in November 2008 due to a business decision (resources)."|f||||f||||||||||2017-10-11 09:03:05.165274|2017-10-11 09:03:05.165274
NCT00758693|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-19|2012-01-10|||October 2008||2008-10-01|September 2011|2011-09-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|||Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)|Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia: A Phase II Study|Withdrawn||Phase 2|0|Actual|University of Kentucky||1||Funding was withdrawn due to insufficient accrual|f||||f||||||||||2017-10-11 09:03:36.962812|2017-10-11 09:03:36.962812
NCT00761410|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-26|2016-06-17|||October 2004||2004-10-01|June 2016|2016-06-01|May 2015|Actual|2015-05-01|February 2010|Actual|2010-02-01||Interventional|||A Study to Determine the Performance of the Press Fit Condylar (P.F.C.) Sigma RP-F Knee System|A Prospective, Non-Comparative Multi Centre Study to Evaluate the Clinical Performance of the DePuy Press Fit Condylar (P.F.C.) Sigma Rotating Platform High Flexion Knee.|Terminated||Phase 4|170|Actual|DePuy International||1||Study was terminated early due to prolonged recruitment period.|f||||f||||||||||2017-10-11 09:04:19.424541|2017-10-11 09:04:19.424541
NCT00761514|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-25|2009-10-23|2009-08-26||November 2006||2006-11-01|October 2009|2009-10-01|August 2008|Actual|2008-08-01|August 2008|Actual|2008-08-01||Interventional|VIVIR||Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira|Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira as Their First Anti-TNF Monoclonal Antibody (VIVIR)|Terminated||Phase 4|14|Actual|Abbott|This study was terminated early due to lack of enrollment. Only 7 subjects completed 24 weeks of treatment. That number is too small to provide reliable data on the effectiveness of the treatment.|1||The study was terminated due to low enrollment.|f||||f||||||||||2017-10-11 09:04:21.487682|2017-10-11 09:04:21.487682
NCT00761839|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-29|2015-05-05|||July 2008||2008-07-01|May 2015|2015-05-01|December 2009|Actual|2009-12-01|June 2009|Actual|2009-06-01||Interventional|||Does Use of a Wound After-care Summary Improve Patient Satisfaction and Time to Wound Healing?|Does Use of a Wound After-care Summary Improve Patient Satisfaction and Time to Wound Healing?|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||"Study was withdrawn because of a problem with the software used for generating the aftercare   summary."|f||||f||||||||||2017-10-11 09:04:31.484211|2017-10-11 09:04:31.484211
NCT00763009|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-24|2017-04-24|2016-05-10||September 2002|Actual|2002-09-01|April 2017|2017-04-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Persantine: Variation in Response Trial|Persantine: Variation in Response Trial|Terminated||Phase 4|8|Actual|UConn Health|Trial terminated early due to poor patient enrollment. All patients responded hemodynamically. Therefore, analysis of responders vs non-responders could not be performed. Adenosine transporter was not analyzed since there was no comparator group.|1||Limited numbers of patients qualified for trial|f||||t|t|f||||||||2017-10-11 09:05:03.80825|2017-10-11 09:05:03.80825
NCT00763347|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-26|2012-05-18|||November 2006||2006-11-01|May 2012|2012-05-01|February 2007|Actual|2007-02-01|February 2007|Actual|2007-02-01||Interventional|||Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate Treatment With SYR-619 in Subjects With Type 2 Diabetes|Terminated||Phase 2|82|Actual|Takeda||6||Voluntarily terminated based on preliminary non-clinical findings.|f||||f||||||||||2017-10-11 09:05:11.793907|2017-10-11 09:05:11.793907
NCT00766597|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-03|2015-12-28|2015-11-12||August 2009||2009-08-01|December 2015|2015-12-01|August 2010|Actual|2010-08-01|July 2010|Actual|2010-07-01||Interventional||The HIV-1 infected antiretroviral therapy experienced participants With CCR5-tropic virus who started treatment in Step II|Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents|Phase I/II Open-Label Study to Evaluate the PK, Safety, Tolerability and Antiviral Activity of Vicriviroc, a Novel CCR5 Antagonist in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents|Completed||Phase 1/Phase 2|9|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Study was terminated early with Merck's announcement on July 15, 2010 on the discontinuation of the development of Vicriviroc, with 4 participants given study drug and only 1 participant reached Week 24.|1|||f||||||||||||||2017-10-11 09:05:29.260702|2017-10-11 09:05:29.260702
NCT00766870|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-03|2010-09-28|||September 2008||2008-09-01|September 2010|2010-09-01|February 2009|Actual|2009-02-01|January 2009|Actual|2009-01-01||Interventional|||Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder|A Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active-referenced Study Evaluating the Efficacy and Safety of Three Fixed Dose Regimens of Lu AA34893 in the Treatment of Major Depressive Disorder|Terminated||Phase 2|35|Actual|H. Lundbeck A/S||5||Study was previously paused and is now terminated|f||||f||||||||||2017-10-11 09:05:34.149883|2017-10-11 09:05:34.149883
NCT00768040|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-06|2012-02-02|2012-02-02||September 2008||2008-09-01|February 2012|2012-02-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema|A Randomized, Double-masked, Placebo-controlled, add-on Study to Assess the Efficacy of Oral Aliskiren 300 mg Once Daily for Diabetic Macular Edema|Terminated||Phase 2|39|Actual|Novartis|This study was terminated early due to low recruitment of patients. The study lacked power against the original objective of statistically significance for changes in central retinal thickness due to the much reduced sample size.|2||Inadequate enrollment|f||||f||||||||||2017-10-11 09:05:54.433533|2017-10-11 09:05:54.433533
NCT00768482|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-07|2017-06-12||2011-01-05|September 2008||2008-09-01|June 2017|2017-06-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|PRO-810||A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence|A Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence|Terminated||Phase 3|9|Actual|Braeburn Pharmaceuticals||1||This study was terminated for reasons not related to efficacy or safety|f||||t||||||||||2017-10-11 09:06:04.829043|2017-10-11 09:06:04.829043
NCT00769834|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-08|2009-04-28|||January 2010||2010-01-01|April 2009|2009-04-01|April 2011|Anticipated|2011-04-01|December 2010|Anticipated|2010-12-01||Observational|||Disc Edema in Patients With Chronic Kidney Disease|Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease|Withdrawn||N/A|323|Anticipated|University of Mississippi Medical Center|||1|Study withdrawn due to logistic reasons and will be re-organized at a later date|f||||f||||||||||2017-10-11 09:06:41.744851|2017-10-11 09:06:41.744851
NCT00769847|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-07|2015-05-29|||September 2008||2008-09-01|May 2015|2015-05-01|September 2013|Anticipated|2013-09-01|July 2009|Actual|2009-07-01||Observational|||Endoscopic Treatment for Isolated, Single Suture Craniosynostosis|Endoscopic Treatment for Isolated, Single Suture Craniosynostosis|Withdrawn||N/A|0|Actual|University of Utah|||1|Study was withdrawn due to lack of resources.|f||||f||||||||||2017-10-11 09:06:41.830397|2017-10-11 09:06:41.830397
NCT00771056|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-08|2016-08-18|2015-12-17||July 2008||2008-07-01|August 2016|2016-08-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Hydroxychloroquine in Untreated B-CLL Patients|Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients With Hydroxychloroquine.|Terminated||Phase 2|23|Actual|Northwell Health||1||study suspended while data is reviewed for safety and efficacy.|f||||f||||||||No|There is no plan to contact each individual patient (participant in the trial) and inform hem/her of results of this trial as it affects each one of them.|2017-10-11 09:07:11.879782|2017-10-11 09:07:11.879782
NCT00771134|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-10|2014-05-14||2014-05-14|December 2008||2008-12-01|May 2014|2014-05-01|August 2009|Actual|2009-08-01|June 2009|Actual|2009-06-01||Interventional|||Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression|Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of Lu AA39959 in the Treatment of Depression in Patients With Bipolar I or II Disorder|Terminated||Phase 2|105|Actual|H. Lundbeck A/S||3||Study was previously suspended and is now terminated|f||||f||||||||||2017-10-11 09:07:12.889552|2017-10-11 09:07:12.889552
NCT00771316|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-09|2017-02-14|2010-04-22||December 2008||2008-12-01|February 2017|2017-02-01|June 2009|Actual|2009-06-01|June 2009|Actual|2009-06-01||Interventional|||Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)|A Phase 3, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK0826 and Meropenem in Patients With Complicated Urinary Tract Infection|Terminated||Phase 3|6|Actual|Merck Sharp & Dohme Corp.|The reason for early termination: Study was terminated early due to feasibility issues including slow enrollment.|2||feasibility and low enrollment|f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00764348|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-30|2011-09-06||||||September 2011|2011-09-01||||||||Observational|||Evaluation of Wound Biofilm in Acute and Chronic Wounds|Evaluation of Wound Biofilm in Acute and Chronic Wounds|Withdrawn||N/A|0|Actual|Southwest Regional Wound Care Center|||1|withdrawn as MSU approval obained|f||||f||||||Samples With DNA|"     traumatic, diabetic foot ulcer, decubitus ulcer, venous leg ulcer   "|||2017-10-11 09:07:48.764944|2017-10-11 09:07:48.764944
NCT00764582|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-26|2009-08-24|||September 2008||2008-09-01|August 2009|2009-08-01||||March 2009|Anticipated|2009-03-01||Interventional|||Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery|A Randomized, Observer-masked, Parallel-group, Multicenter Trial Evaluating the Ocular Penetration of 1.5% Levofloxacin Ophthalmic Solution and 0.5% Moxifloxacin Ophthalmic Solution in Subjects Undergoing Corneal Transplant Surgery|Terminated||Phase 4|60|Anticipated|Santen Inc.||2||Study terminated due to lack of enrollment.|f||||f||||||||||2017-10-11 09:07:55.045832|2017-10-11 09:07:55.045832
NCT00765063|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-30|2011-12-01|2011-08-11||October 2008||2008-10-01|December 2011|2011-12-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|||The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)|A 6 Month, Prospective, Open-Label Multiple Center Extension Trial To Evaluate The Long Term Safety And Sustained Efficacy Of Fragmin In The Treatment Of Chronic Foot Ulcers In Diabetic Patients With Peripheral Arterial Occlusive Disease|Completed||Phase 2/Phase 3|62|Actual|Pfizer|Study enrollment was terminated before planned number of participants was obtained. Although randomized participants were allowed to complete entire course of therapy according to protocol and study status was therefore designated as completed.|1|||f||||f||||||||||2017-10-11 09:08:05.047181|2017-10-11 09:08:05.047181
NCT00765375|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-30|2015-04-28|2012-08-29||September 2008||2008-09-01|April 2015|2015-04-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||Safety and Efficacy of the Use of Botox on Acne|Double-Blind, Randomized, Placebo-Controlled Study to Determine the Safety and the Efficacy of Using Botulinum Neurotoxin Type A Injections for Subjects With Mild to Moderate Acne Vulgaris|Terminated||Phase 2|5|Actual|DeNova Research|Study terminated after 5 subjects|1||Investigator decision|f||||t||||||||||2017-10-11 09:08:14.578904|2017-10-11 09:08:14.578904
NCT00766181|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-01|2010-05-24|||October 2008||2008-10-01|November 2008|2008-11-01|April 2009|Anticipated|2009-04-01|February 2009|Anticipated|2009-02-01||Observational|||Satisfaction With Pediatric Intravenous Catheter Placement in the Emergency Department|An Evaluation of Parent and Nurse Satisfaction Associated With Pediatric Peripheral Intravenous Catheter Placement Using Standard of Care vs. ZingoTM in the Emergency Department|Terminated||N/A|200|Anticipated|Anesiva, Inc.|||2|Product withdrawn from distribution|f||||f||||||||||2017-10-11 09:08:27.88157|2017-10-11 09:08:27.88157
NCT00766220|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-01|2012-12-28|||October 2009||2009-10-01|December 2012|2012-12-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver|Phase II Randomized Study of SIR-Spheres, Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Metastases to the Liver|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2||Slow Accrual and withdrawn/exclusion of 2 participants.|f||||t||||||||||2017-10-11 09:08:28.102331|2017-10-11 09:08:28.102331
NCT00772629|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-13|2014-01-21|2009-03-16||January 2004||2004-01-01|January 2014|2014-01-01|April 2004|Actual|2004-04-01|April 2004|Actual|2004-04-01||Interventional|||Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults|Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults Who Were Either Previously Vaccinated With Unconjugated Meningococcal Polysaccharide (Serogroups A, C or Serogroups A, C, Y, and W-135) Vaccine or Not Vaccinated With Meningococcal Vaccine|Terminated||Phase 2|18|Actual|Sanofi|Enrollment was terminated before the planned sample size was achieved because the principal investigator and the Sponsor decided that sufficient sera had been obtained to meet the secondary objective of the study.|2||See detailed description for termination reason|f||||f||||||||||2017-10-11 09:08:50.703685|2017-10-11 09:08:50.703685
NCT00772668|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-12|2016-12-14|2013-01-18||September 2008||2008-09-01|December 2016|2016-12-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Treating Patients With Stage III or Stage IV Follicular Lymphoma or Marginal Zone Lymphoma|Pilot Study of RCVELP as First Line Therapy for Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL)|Terminated||N/A|3|Actual|University of Miami|This study was terminated early due to lack of funding. All patients were removed from the study. No results were analyzed.|1||Funding|f||||t||||||||||2017-10-11 09:08:51.094928|2017-10-11 09:08:51.094928
NCT00772785|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-09|2017-06-12||2011-01-05|September 2008||2008-09-01|June 2017|2017-06-01|February 2009|Actual|2009-02-01|February 2009|Actual|2009-02-01||Interventional|PRO-809||Study of Probuphine in Patients With Opioid Dependence|An Open-label, Multi-center Extension Study of Probuphine in Patients With Opioid Dependence|Terminated||Phase 3|16|Actual|Braeburn Pharmaceuticals||1||This study was terminated for reasons not related to efficacy or safety|f||||t||||||||||2017-10-11 09:08:52.143536|2017-10-11 09:08:52.143536
NCT00772954|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-10|2012-04-19|2012-03-13||March 2006||2006-03-01|April 2012|2012-04-01|June 2006|Actual|2006-06-01|June 2006|Actual|2006-06-01||Interventional|||Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity|A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of Two Doses of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Adult Volunteers (18 - 55 Years)|Terminated||Phase 1|36|Actual|Sanofi|This study was terminated early in light of issues with CTM stability. All other study procedures and visits were performed per protocol.|3||Issues with CTM stability.|f||||f||||||||||2017-10-11 09:08:56.540236|2017-10-11 09:08:56.540236
NCT00773474|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-14|2016-01-21|2015-12-15||October 2008||2008-10-01|January 2016|2016-01-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Lonafarnib in Metastatic Breast Cancer|A Phase II Study of Lonafarnib in Patients With Metastatic Breast Cancer|Terminated||Phase 2|29|Actual|Hoosier Cancer Research Network||1||funding terminated|f||||t||||||||||2017-10-11 09:09:06.784986|2017-10-11 09:09:06.784986
NCT00774306|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-16|2014-11-19|2014-11-19||April 2009||2009-04-01|November 2014|2014-11-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Antiepileptic Drugs and Vascular Risk Markers|The Effects of Antiepileptic Drugs on Serum Lipids and Inflammation in Patients With Subarachnoid Hemorrhage|Terminated||N/A|52|Actual|Thomas Jefferson University|"Study terminated due to 1) change in clinical practice; 2) inadequate recruitment and follow-up.
NCT00776100|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-17|2017-01-13|2016-11-16||October 2008||2008-10-01|January 2017|2017-01-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional||All participants who met the eligibility criteria and started the study.|Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer|A Randomized Phase II Study of Oligometastatic Stage IV Non-Small Cell Lung Cancer (NSCLC) Treated With Systemic Therapy Plus Either Radiotherapy to All Sites of Gross Residual Disease or No Radiotherapy|Terminated||Phase 2|3|Actual|Alliance for Clinical Trials in Oncology||2||Study was terminated prematurely due to slow accrual.|f||||f||||||||||2017-10-11 09:09:50.856279|2017-10-11 09:09:50.856279
NCT00776659|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-20|2013-09-12|2013-09-12||December 2008||2008-12-01|September 2013|2013-09-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Observational|||An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin|An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin|Terminated||N/A|39|Actual|Pfizer|Study was terminated due to slow enrollment and observational nature of the study. Low number of participants enrolled was not sufficient to conduct the planned analysis. Study was not terminated due to safety concerns.||1|See termination reason in detailed description.|f||||f||||||||||2017-10-11 09:09:56.921785|2017-10-11 09:09:56.921785
NCT00780676|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-24|2015-07-16|2015-06-10||June 2009||2009-06-01|July 2015|2015-07-01|May 2014|Actual|2014-05-01|May 2014|Actual|2014-05-01||Interventional||Individuals who were positive for more than one predictor were assigned to the marker arm for which they had the highest percentile positivity.|Personalized Treatment Selection for Metastatic Breast Cancer|Personalized Treatment Selection for Metastatic Breast Cancer|Terminated||Phase 2|97|Actual|M.D. Anderson Cancer Center|Study terminated according to early stopping rules.|4||Closed early for futility.|f||||f||||||||||2017-10-11 09:10:40.288052|2017-10-11 09:10:40.288052
NCT00781326|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-27|2016-08-05|2016-03-22||August 2008||2008-08-01|August 2016|2016-08-01|February 2009|Actual|2009-02-01|February 2009|Actual|2009-02-01||Interventional|||Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression|Treatment of Depression Occurring in the Setting of Cerebrovascular Risk -- A Pilot Study|Terminated||Phase 4|9|Actual|University of Pittsburgh|Study was terminated for administrative reasons at the end of Phase I (open label antidepressant treatment). No subjects entered Phase II (Nimodipine vs Placebo).|1||Final cost of study medication was significantly greater than initial estimate,|f||||f||||||||||2017-10-11 09:10:47.972511|2017-10-11 09:10:47.972511
NCT00781833|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-27|2012-01-19|||October 2008||2008-10-01|January 2012|2012-01-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||Use of Implanted Microstimulators for Decreasing Spasticity and Improving Motion Following Spinal Cord Injury|Case Study Testing the Use of Implanted Microstimulators for Decreasing Spasticity and Improving Motion Following Spinal Cord Injury|Terminated||N/A|1|Actual|The Alfred E. Mann Foundation for Scientific Research||1||Participation of single subject enrolled was terminated.|f||||f||||||||||2017-10-11 09:11:12.082791|2017-10-11 09:11:12.082791
NCT00782483|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-29|2014-06-19|2014-01-06||October 2008||2008-10-01|June 2014|2014-06-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Personalized Interactive Laser Therapy of Port Wine Stain|Personalized Interactive Laser Therapy of Port Wine Stain - Study 2|Terminated||N/A|6|Actual|University of Arkansas|PI relocated and protocol was terminated, and no subject returned for treatment under protocol.|1||PI moved out of state.|f||||t||||||||||2017-10-11 09:11:29.08923|2017-10-11 09:11:29.08923
NCT00782639|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-28|2012-01-24|2011-06-29||March 2009||2009-03-01|January 2012|2012-01-01|September 2009|Actual|2009-09-01|September 2009|Actual|2009-09-01||Interventional|RECARE||Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients|RECARE (REnal Safety Following the Intra-Arterial Administration of Iopamidol vs. Iodixanol During Coronary AngiogRaphy in DiabEtic Patients)|Terminated||Phase 4|23|Actual|Bracco Diagnostics, Inc|This study was terminated early due to low enrollment. Only 1 patient in the Iopamiro-370 group had CIN (per all 3 definitions [first 3 secondary outcome measures] of CIN); therefore, no formal analyses were performed.|2||This study was terminated early due to slow enrollment.|f||||f||||||||||2017-10-11 09:11:34.270108|2017-10-11 09:11:34.270108
Started: 14 patients Completed: 13 patients Comments: 1 patient on extensive pathology review was found to have a solitary fibrous tumor, not GIST."|Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)|Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib|Terminated||Phase 2|13|Actual|Fox Chase Cancer Center|The study failed to meet its accrual goals. Study terminated prior to accruing 17 subjects due to futility of meeting endpoint.|1||Stopped early for futility, unable to meet accrual goals|f||||f||||||||||2017-10-11 09:11:36.812345|2017-10-11 09:11:36.812345
NCT00775606|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-17|2014-05-30|2013-06-28||October 2008||2008-10-01|May 2014|2014-05-01|January 2011|Actual|2011-01-01|December 2010|Actual|2010-12-01||Interventional|||Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease|A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-based HAART (Highly Active Antiretroviral Therapy) Regimen in Antiretroviral-Naïve Subjects With Advanced HIV Disease|Terminated||Phase 4|15|Actual|Rush University Medical Center|Study was terminated due to the slow recruitment and the small number of subjects.|2||Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.|f||||f||||||||||2017-10-11 09:11:48.001661|2017-10-11 09:11:48.001661
NCT00785356|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-03|2014-08-05|2014-06-25||October 2008||2008-10-01|August 2014|2014-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional||Study prematurely terminated|Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids|A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy|Terminated||Phase 3|8|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2017-10-11 09:12:06.179842|2017-10-11 09:12:06.179842
NCT00786318|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-05|2017-09-22|||September 2008||2008-09-01|September 2017|2017-09-01|July 2011|Anticipated|2011-07-01|July 2011|Anticipated|2011-07-01||Interventional|||Ziprasidone vs Standard Therapy for Agitated Patients in the ED|Prospective Double Blind Randomized Trial of Intramuscular Ziprasidone Compared With Standard Antipsychotic Therapy For The Treatment Of The Acutely Agitated Patient In The Emergency Department|Withdrawn||Phase 4|0|Actual|George Washington University||2||Sponsor terminated|f||||f||||||||||2017-10-11 09:12:24.393908|2017-10-11 09:12:24.393908
NCT00787618|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-06|2014-08-08|2014-06-25||October 2008||2008-10-01|August 2014|2014-08-01|July 2009|Actual|2009-07-01|June 2009|Actual|2009-06-01||Interventional||Study prematurely terminated, no data available|Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females|A Single-Dose, Open-Label, Parallel Group Study To Evaluate The Pharmacokinetics And Safety Profile Of PROELLEX® (CDB-4124) In Female Subjects With Various Stages Of Impaired Renal Function And In Healthy Female Volunteers|Terminated||Phase 1/Phase 2|6|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Increased LFTs|f||||f||||||||||2017-10-11 09:12:47.796092|2017-10-11 09:12:47.796092
NCT00779038|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-23|2014-04-22|2013-01-10||August 2008||2008-08-01|April 2014|2014-04-01|September 2008|Actual|2008-09-01|September 2008|Actual|2008-09-01||Interventional|||Safety and Efficacy Study of Fentanyl Iontophoretic Transdermal System (ITS) for Management of Moderate to Severe Acute Pain in Participants Who Have Undergone Elective Spine or Orthopedic Surgery|Clinical Outcome Study in Postoperative Pain Management to Demonstrate the Efficacy and Safety of IONSYS (Fentanyl ITS Iontophoretic Transdermal System) in Daily Clinical Practice and to Assess Its Convenience (IPAC)|Terminated||Phase 4|13|Actual|Janssen Cilag N.V./S.A.|No efficacy results were reported because the study was prematurely terminated, following the worldwide voluntary withdrawal of Fentanyl Iontophoretic Transdermal System (IONSYS) by Janssen-Cilag.|1||Stopped prematurely in 2008 due to IONSYS withdrawal off the market globally|f||||f||||||||||2017-10-11 09:12:55.901339|2017-10-11 09:12:55.901339
NCT00780455|ClinicalTrials.gov processed this data on October 10, 2017|2008-05-28|2015-05-08|2013-01-22||October 2008||2008-10-01|May 2015|2015-05-01|September 2009|Actual|2009-09-01|September 2009|Actual|2009-09-01||Interventional|||Rehabilitation Study in MS Patients|Multicenter, Open Label, Randomized and Parallel Group Phase IV Pilot Study Evaluating the Effectiveness of Functional Rehabilitation Protocol in RRMS Patients Treated With Betaferon®|Terminated||Phase 4|4|Actual|Bayer|Due to the very low number of patients enrolled in the study, no statistical report was done. Study was early terminated.|2|||f||||f||||||||||2017-10-11 09:13:22.575277|2017-10-11 09:13:22.575277
NCT00793546|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-29|2012-10-04|2012-10-04|2011-11-15|February 2009||2009-02-01|October 2012|2012-10-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer|A Phase 2, Randomized, Open-Label Study Of Bosutinib Administered In Combination With Exemestane Versus Exemestane Alone As Second Line Therapy In Postmenopausal Women With Locally Advanced Or Metastatic ER+/PgR+/ErbB2- Breast Cancer|Terminated||Phase 2|42|Actual|Pfizer|Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 09:14:13.755964|2017-10-11 09:14:13.755964
NCT00801801|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-02|2017-04-07|2012-06-08||January 2008||2008-01-01|April 2017|2017-04-01|March 2011|Actual|2011-03-01|October 2009|Actual|2009-10-01||Interventional||Subjects with advanced non-squamous cell non-small cell lung cancer with poor performance status will receive treatment in this non-randomized, open-label Phase II Study of Metronomic Chemotherapy (docetaxel) plus sorafenib as first-line therapy.|Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC|Pilot Phase IIa Study of Metronomic Chemotherapy With Taxotere (Docetaxel) Plus Nexavar (Sorafenib) as First-Line Therapy in Performance Status-2 Patients With Advanced Non-Squamous Cell Non-Small Cell Lung Cancer|Terminated||Phase 2|5|Actual|University of Alabama at Birmingham|The study initially sought to accrue a maximum sample size of 43 subjects. However, due to subjects' measured response and levels of clinical benefit in addition to a cut in funding, the study was stopped early and terminated.|1||Sponsors withdrew funding; preliminary efficacy data was not encouraging.|f||||t||||||||||2017-10-11 09:15:26.057292|2017-10-11 09:15:26.057292
NCT00802633|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-03|2013-12-21|2013-12-21||November 2008||2008-11-01|December 2013|2013-12-01|June 2012|Actual|2012-06-01|December 2011|Actual|2011-12-01||Interventional|||Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?|Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?|Terminated||N/A|80|Actual|Vanderbilt University|Study terminated after 80 subjects|2||Enrollment was stopped after eighty patients were enrolled.|f||||f||||||||||2017-10-11 09:15:37.780288|2017-10-11 09:15:37.780288
NCT00803283|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-04|2013-08-08|2013-05-07||November 2008||2008-11-01|August 2013|2013-08-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Interventional|||A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain|A Randomized, Open-Labeled, Multi-Center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Comparing With Morphine SR in Cancer Pain Patients|Terminated||Phase 3|2|Actual|Johnson & Johnson Taiwan Ltd|This study had inadequate number of participants. 'The study was terminated early and the data for efficacy assessments were missing.|2|||f||||||||||||||2017-10-11 09:15:57.906254|2017-10-11 09:15:57.906254
NCT00790452|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-07|2011-11-04|2011-11-04||November 2008||2008-11-01|November 2011|2011-11-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional|||Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma|A Randomized Phase II Trial of Aspirin for Primary Prophylaxis of Venous Thromboembolism in Glioblastoma|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center|Study terminated early due due to a drug supply issue.|2||Low accrual.|f||||t||||||||||2017-10-11 09:16:58.748394|2017-10-11 09:16:58.748394
NCT00791076|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-13|2017-06-29|2017-05-01||October 2007|Actual|2007-10-01|June 2017|2017-06-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional||This study was terminated prematurely when the PI left the institution. Although 8 participants were enrolled in this study, their assignment to Arm/Group is unknown, since no data are available.|The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients|The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 (Auto-immune) and Post-pancreatectomy Diabetic Patients|Terminated||Phase 2|8|Actual|Johns Hopkins University||2||PI left JHU|f||||f||||||||||2017-10-11 09:17:11.134095|2017-10-11 09:17:11.134095
NCT00791089|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-13|2017-08-10|2017-03-24||November 2008||2008-11-01|August 2017|2017-08-01|October 2011|Actual|2011-10-01|December 2009|Actual|2009-12-01||Interventional||Baseline analysis is provided for all persons who actually began their assignment.|Effects of Fish Oil on Post Ablation Arrhythmias|Effect of Omega-3 Fatty Acids on Short and Long-Term Maintenance of Sinus Rhythm After Radiofrequency Catheter Ablation for Atrial Fibrillation|Terminated||Phase 4|12|Actual|University of Michigan|The Study was terminated before subject enrollment completion, due to financial concerns and loss of major support from the 21-day cardiac monitoring device. So small sample size means data should be interpreted with great caution.|2||unable to secure funding and long term follow up|f||||t||||||||||2017-10-11 09:17:11.336778|2017-10-11 09:17:11.336778
NCT00808613|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-15|2013-02-25|||December 2008||2008-12-01|February 2013|2013-02-01|January 2012|Anticipated|2012-01-01|January 2012|Anticipated|2012-01-01||Interventional|||Optetrak Posterior Stabilized Versus Optetrak Hi-Flex|A Prospective, Single-center, Non-randomized, Consecutive Series Clinical Study Comparing the Functional Differences Between a Standard Posterior Stabilized Total Knee Replacement and a High-flexion Posterior Stabilized Total Knee Replacement|Withdrawn||Phase 4|0|Actual|Exactech||2||Study withdrawn prior to initiation|f||||f||||||||||2017-10-11 09:17:41.701004|2017-10-11 09:17:41.701004
NCT00808899|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-11|2017-04-24|2010-04-19||December 2008||2008-12-01|May 2010|2010-05-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma|Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma|Terminated||Phase 2|4|Actual|St. Jude Children's Research Hospital|NB2008 was closed because of the publication of a new standard of care for treating high-risk neuroblastoma.At the time of closure, NB2008 had enrolled only 4 patients, which was an insufficient number of patients to answer the primary objective.|1||Voluntarily closed and terminated by the PI due to lack of feasibility|f||||f||||||||||2017-10-11 09:17:44.544276|2017-10-11 09:17:44.544276
NCT00808990|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-15|2016-04-07|||February 2013||2013-02-01|April 2016|2016-04-01|September 2015|Actual|2015-09-01|August 2015|Actual|2015-08-01||Interventional|||The Effect of Probiotics on Non Alcoholic Fatty Liver Disease|Probiotics and Non Alcoholic Steatohepatitis (NASH)|Terminated||Phase 1|38|Actual|Rabin Medical Center||2||"Time table was unfulfilled due to incompetent research coordinator. Inaccurate results and No   conclusions can be withdrawn"|f||||f||||||||||2017-10-11 09:17:45.517646|2017-10-11 09:17:45.517646
NCT00809380|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-15|2013-03-18|||June 2009||2009-06-01|March 2013|2013-03-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|PP||Parental Presence During Fracture Reduction in Children at the Emergency Department; A Randomized Controlled Trial|Parental Presence During Fracture Reduction in Children at the Emergency Department; A Randomized Controlled Trial|Terminated||N/A|12|Actual|St. Justine's Hospital||2||Study ws terminated because of a too low recruitment rate.|f||||f||||||||||2017-10-11 09:18:06.524146|2017-10-11 09:18:06.524146
NCT00795353|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-11|2013-02-27|||July 2008||2008-07-01|March 2011|2011-03-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Observational|AWARE-2||Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Amevive Wisdom Acquired Through Real-world Evidence - 2 (A.W.A.R.E.-2) Program: Long-Term Study|Terminated||N/A|64|Actual|Astellas Pharma Inc|||1|"The study was terminated early due to insufficient subject enrolment in order to meet the   primary and secondary endpoints"|f||||f||||||Samples With DNA|"     10mL blood sample - Biomarker Substudy only   "|||2017-10-11 09:19:11.003401|2017-10-11 09:19:11.003401
NCT00795639|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-20|2015-03-04|2012-01-30||December 2008||2008-12-01|March 2015|2015-03-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension|Terminated||Phase 3|183|Actual|Pfizer|Study terminated early.|2||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,   specifically new emerging evidence of hepatic injury."|f||||t||||||||||2017-10-11 09:19:15.11701|2017-10-11 09:19:15.11701
NCT00796510|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-20|2012-01-20|2011-12-09||July 2010||2010-07-01|April 2011|2011-04-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Interventional|||Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety|A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension|Terminated||Phase 3|3|Actual|Pfizer|Due to the premature termination only 3 participants were recruited into this study. No summarization or analysis was done.|2||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,   specifically new emerging evidence of hepatic injury"|f||||f||||||||||2017-10-11 09:19:31.427987|2017-10-11 09:19:31.427987
NCT00796666|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-20|2015-03-04|2012-01-26||May 2009||2009-05-01|March 2015|2015-03-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil|A Phase 3, Multi-Center, Randomized, Double-Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001 (NCT00795639)|Terminated||Phase 3|131|Actual|Pfizer|Study terminated early by sponsor, no Week 48 information collected.|2||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,   specifically new emerging evidence of hepatic injury."|f||||t||||||||||2017-10-11 09:19:40.853714|2017-10-11 09:19:40.853714
NCT00796705|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-20|2012-09-28|2012-07-05||November 2008||2008-11-01|August 2012|2012-08-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|||Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)|Switching Anti-TNF-alpha Agents in Patients With RA With An Inadequate Response to TNF-alpha Inhibition|Terminated||Phase 4|13|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study terminated early due to recruitment feasibility issues. Thirteen subjects were enrolled and received treatment. No mechanistic analyses were performed.|2||Lack of Enrollment|f||||t||||||||||2017-10-11 09:19:42.882882|2017-10-11 09:19:42.882882
NCT00797550|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-24|2017-03-07|||April 2006||2006-04-01|March 2017|2017-03-01|October 2008|Actual|2008-10-01|August 2006|Actual|2006-08-01||Interventional|||Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion|Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion|Terminated||Phase 1/Phase 2|2|Actual|Vericel Corporation||2||Study was terminated early for business reasons (not safety reasons).|f||||f||||||||||2017-10-11 09:19:59.05373|2017-10-11 09:19:59.05373
NCT00799201|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-24|2015-07-27|||August 2007||2007-08-01|July 2015|2015-07-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients|A Prospective, Randomized Trial of Enteral Naloxone Versus a Traditional Bowel Regimen in Prevention of Constipation and Decreased Gastric Motility in Critically Ill Trauma Patients|Terminated||Phase 4|3|Actual|CAMC Health System||1||"Naloxone became unavailable due to manufacturing shortatges requiring the study to be   terminated."|f||||t||||||||||2017-10-11 09:20:00.086429|2017-10-11 09:20:00.086429
NCT00800436|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-01|2016-10-24|2016-10-24||November 2008||2008-11-01|October 2016|2016-10-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional||"Safety Population: All participants who received at least one dose of study medication, whether prematurely withdrawn from the study or not. The Total column (n=70) includes 4 female participants who were counted twice as they were treated in both Cohort 2 and Cohort A."|A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females|An Open-Label, Two-Part, Multi-Centre, Trastuzumab Dose-Finding Study in Healthy Male Volunteers and HER2 Positive Female Patients|Completed||Phase 1|66|Actual|Hoffmann-La Roche||7|||f||||||||||||||2017-10-11 09:20:35.687875|2017-10-11 09:20:35.687875
NCT00800566|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-01|2012-07-31|||November 2008||2008-11-01|July 2012|2012-07-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Interventional|||Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)|Phase I Study of Oral Clofarabine for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Sponsor terminated.|f||||t||||||||||2017-10-11 09:20:38.671075|2017-10-11 09:20:38.671075
NCT00800670|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-01|2017-09-05|||June 2009||2009-06-01|September 2017|2017-09-01|July 2013|Actual|2013-07-01|December 2012|Actual|2012-12-01||Interventional|||Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine|Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine|Terminated||Phase 1|24|Actual|McMaster University||2||Study was terminated after the low dose cohort had been enrolled|f||||f||||||||||2017-10-11 09:20:41.39386|2017-10-11 09:20:41.39386
NCT00805740|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-26|2013-05-30|2013-05-30||April 2009||2009-04-01|May 2013|2013-05-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida|Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection|Terminated||Phase 3|41|Actual|Pfizer|The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns.|2||"The study was terminated prematurely on May 18, 2012 due to slow enrollment. The study was not   terminated due to any safety issues or concerns."|f||||t||||||||||2017-10-11 09:22:02.294988|2017-10-11 09:22:02.294988
NCT00805844|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-09|2011-07-13|||September 2008||2008-09-01|July 2011|2011-07-01|September 2009|Actual|2009-09-01|July 2009|Actual|2009-07-01||Observational|||Motor Evoked Potentials and SedLine|Monitoring Depth of Anesthesia With the SedLine Facilitates Motor Evoked Potential (MEP) Monitoring During Corrective Spinal Surgery|Terminated||N/A|70|Anticipated|University of California, San Francisco|||2|Sponsor terminated the study|f||||f||||||||||2017-10-11 09:22:04.659457|2017-10-11 09:22:04.659457
NCT00806910|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-10|2011-06-22|||October 2008||2008-10-01|June 2011|2011-06-01|February 2010|Actual|2010-02-01|February 2010|Actual|2010-02-01||Interventional|||Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion|Evaluation of the Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion|Withdrawn||Phase 4|0|Actual|Albert Einstein Healthcare Network||2||Sponsor support withdrawn|f||||f||||||||||2017-10-11 09:22:28.681709|2017-10-11 09:22:28.681709
NCT00807209|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-09|2012-04-15|2011-11-29|2010-08-25|December 2008||2008-12-01|November 2011|2011-11-01|February 2009|Actual|2009-02-01|February 2009|Actual|2009-02-01||Interventional|||Dose Finding Posterolateral Thoracotomy Study|A Phase 2 Open-Label, Parallel Group, Randomized, Dose-Finding Study to Assess the Efficacy and Safety of Intercostal SKY0402 in Subjects Undergoing Posterolateral Thoracotomy|Terminated||Phase 2|3|Actual|Pacira Pharmaceuticals, Inc|The study was terminated early due to Sponsor's decision, unrelated to safety. As there was only one patient in each group, no efficacy analyses were performed.|3||Sponsor decision unrelated to safety|f||||f||||||||||2017-10-11 09:22:36.155315|2017-10-11 09:22:36.155315
NCT00814892|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-24|2013-10-08|2013-05-16||January 2009||2009-01-01|October 2013|2013-10-01|March 2010|Actual|2010-03-01|December 2009|Actual|2009-12-01||Interventional||Since only two participants were accrued, patient confidentiality prevents the reporting of these two participants.|Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer|A Phase II Trial to Determine the Safety, Tolerability and Efficacy of an Allogeneic Whole Cell Vaccine Administered With Autologous Myeloid Dendritic Cells to Patients With Non-Metastatic Androgen Independent Prostate Carcinoma|Terminated||Phase 2|2|Actual|Mayo Clinic||1||Study was terminated due to funding issues.|f||||t||||||||||2017-10-11 09:23:16.885847|2017-10-11 09:23:16.885847
NCT00815932|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-30|2017-10-03|||September 2016||2016-09-01|October 2017|2017-10-01|October 2017|Actual|2017-10-01|October 2017|Actual|2017-10-01||Interventional|||The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To CRPS or Diabetic Neuropathy|The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To Complex Regional Pain Syndrome (CRPS) or Diabetic Neuropathy-A PILOT, DOUBLE-BLIND, SHAM-CONTROLLED, CROSS-OVER STUDY|Withdrawn||N/A|0|Actual|Soroka University Medical Center||4||Due to unfixable problem in the research machine we had to withdrawn from the study|f||||||||||||||2017-10-11 09:23:33.529519|2017-10-11 09:23:33.529519
NCT00816192|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-30|2012-07-26|||December 2008||2008-12-01|July 2012|2012-07-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|CATAFABL||Comparison of Externally Versus Internally Cooled Tip Catheter Ablation in Paroxysmal Atrial Fibrillation|Comparison of Externally Versus Internally Cooled Tip Catheter in Achieving Long-term Electrical Isolation of Pulmonary Veins in Paroxysmal Atrial Fibrillation|Terminated||N/A|86|Actual|University Hospital, Bordeaux||2||The production of the device used in this study has been suspended.|f||||f||||||||||2017-10-11 09:23:38.273886|2017-10-11 09:23:38.273886
NCT00816686|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-01|2013-02-26|||October 2008||2008-10-01|May 2010|2010-05-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|||A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer|A Phase 1, Open-Label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M18 Given as Monotherapy in Subjects With Advanced Renal Cell Carcinoma|Terminated||Phase 1|7|Actual|Astellas Pharma Inc||5||Trial was terminated due to the need to re-formulate the study drug.|f||||f||||||||||2017-10-11 09:23:45.783228|2017-10-11 09:23:45.783228
NCT00816829|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-02|2009-07-17|2009-01-08||September 2005||2005-09-01|July 2009|2009-07-01|January 2008|Actual|2008-01-01|January 2008|Actual|2008-01-01||Interventional|||Effect of Fenofibrate on Sleep Apnea Syndrome|A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome|Terminated||Phase 2|34|Actual|Solvay Pharmaceuticals|Only treatment emergent events have been presented. They are defined as events started at or after the 1st administration of study medication and includes events started prior to the 1st administration but which worsened after the 1st intake.|2||The study was prematurely terminated because of slow recruitment|f||||f||||||||||2017-10-11 09:23:47.420261|2017-10-11 09:23:47.420261
NCT00798031|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-24|2017-05-25|||October 2008||2008-10-01|May 2017|2017-05-01|August 2014|Actual|2014-08-01|August 2014|Actual|2014-08-01||Interventional|Short implant||Case Series Evaluation of a Short Dental Implant|Case Series Evaluation of a Short Dental Implant Placed in the Posterior Maxilla in an Early Loading Protocol|Withdrawn||N/A|0|Actual|University of Iowa||1||As of 2017 study was terminated since investigators retired. No subjects recruited.|f||||t||||||||||2017-10-11 09:23:51.130244|2017-10-11 09:23:51.130244
NCT00798304|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-25|2014-11-21|2014-11-21||January 2009||2009-01-01|November 2014|2014-11-01|September 2009|Actual|2009-09-01|June 2009|Actual|2009-06-01||Interventional|||Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants|An Open Label, Randomized, Phase 1/2 Trial Of The Safety, Tolerability, And Immunogenicity Of Meningococcal Group B Rlp2086 Vaccine In Healthy Infants|Terminated||Phase 2|46|Actual|Pfizer|Immunogenicity results were not reported because the study was terminated due to the reactogenicity profile of the vaccine in infants prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.|3||"Following program review within Pfizer, decision was made not to go ahead with this study. This   study is cancelled"|f||||t||||||||||2017-10-11 09:23:57.88602|2017-10-11 09:23:57.88602
NCT00798525|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-25|2012-06-20|||January 2009||2009-01-01|June 2012|2012-06-01|March 2012|Actual|2012-03-01|March 2012|Actual|2012-03-01||Interventional|ALiCia||Argatroban Versus Lepirudin in Critically Ill Patients|Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial|Terminated||Phase 4|70|Actual|Heinrich-Heine University, Duesseldorf||2||Supply of Lepirudin ended on 01. April 2012, thus trial terminated on 31. March 2012|f||||t||||||||||2017-10-11 09:24:04.652899|2017-10-11 09:24:04.652899
NCT00804479|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-04|2016-01-20|||January 2002||2002-01-01|January 2016|2016-01-01|March 2004|Actual|2004-03-01|March 2004|Actual|2004-03-01||Observational|CALM-PD Cohort||The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)|Unblinded, Multicenter, Prospective Follow-up of Long-term Consequences of Initiating Patients With Parkinson's Disease on Either Pramipexole or Levodopa.|Terminated||N/A|222|Actual|University of Rochester|||1|Funding for the CALM-PD Cohort Study was terminated by sponsor.|f||||f||||||||||2017-10-11 09:24:16.24589|2017-10-11 09:24:16.24589
NCT00805285|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-08|2013-03-30|2013-01-24||October 2008||2008-10-01|March 2013|2013-03-01|March 2010|Actual|2010-03-01|October 2009|Actual|2009-10-01||Interventional||The only enrolled patient was withdrawn secondary to disease worsening.|The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis|Oral Budesonide and Rectal Hydrocortisone for the Treatment of Extensive Ulcerative Colitis: A Pilot Study|Terminated||Phase 2|2|Actual|University of Maryland|The study was terminated early by the University of Maryland HRPO secondary to limited recruitment of participants. This resulted in an inability to analyze the results.|1||Study terminated due to insufficient enrollment|f||||t||||||||||2017-10-11 09:24:36.138007|2017-10-11 09:24:36.138007
NCT00811018|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-09|2012-03-29|2012-03-29||March 2003||2003-03-01|November 2011|2011-11-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional|STRIDE-3||A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension|A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension|Terminated||Phase 3|1192|Actual|Pfizer|Mean and dispersion for clinical abnormalities were intended to be reported but due to early termination of study (09-Dec-2010) only number and percent of participants are available.|1||"This trial was prematurely terminated on Dec 9 2010 due to safety concerns, specifically   emerging evidence of hepatic injury."|f||||f||||||||||2017-10-11 09:24:52.648552|2017-10-11 09:24:52.648552
NCT00811174|ClinicalTrials.gov processed this data on October 10, 2017|2008-12-17|2017-06-16|2013-07-25||January 2009||2009-01-01|June 2017|2017-06-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional||The study was terminated prematurely. Owing to the limited data available (only 5 patients enrolled, of whom 2 completed the study and 3 ended treatment prematurely), efficacy and PK analyses were not performed. The safety analysis did not yield any unexpected results suggestive of a change in the risk–benefit evaluation of Octagam 10%.|Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases|Clinical Study to Evaluate the Efficacy, Safety and Kinetics of Octagam 10% for Replacement Therapy in Primary Immunodeficiency Diseases|Terminated||Phase 3|5|Actual|Octapharma||1||Due to limited data available, efficacy, and PK analyses were not performed.|f||||f||||||||||2017-10-11 09:24:59.391658|2017-10-11 09:24:59.391658
NCT00818961|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-07|2013-10-28|2013-03-22||May 2005||2005-05-01|October 2013|2013-10-01|March 2012|Actual|2012-03-01|March 2011|Actual|2011-03-01||Interventional|||Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer|Reduced Intensity Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies|Terminated||Phase 2|36|Actual|Northside Hospital, Inc.||1||terminated early due to meeting end point with fewer patients than anticipated|f||||f||||||||||2017-10-11 09:25:24.225796|2017-10-11 09:25:24.225796
NCT00819637|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-08|2015-03-17|2010-02-17||January 2009||2009-01-01|March 2015|2015-03-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|||A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients|A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients Presenting to the Emergency Department and to Evaluate Its Side Effect and Safety Profile When Used in This Clinical Situation.|Terminated||Phase 4|2|Actual|Henry Ford Health System||3||Unable to enroll r/t study design & staffing issues. The trial terminated.|f||||f||||||||||2017-10-11 09:25:50.639203|2017-10-11 09:25:50.639203
NCT00819910|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-08|2014-04-08|2013-02-06||September 2008||2008-09-01|April 2014|2014-04-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|RAFAEL||Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)|Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)|Terminated||Phase 4|41|Actual|Brooke Army Medical Center|First, the study was terminated early per FDA recommendations restricting rosiglitazone use. Second, recruitment of patients was slow due to deployment restraints.|4||Slow recruitment and increase in deployment overseas limiting follow up|f||||t||||||||||2017-10-11 09:25:55.629848|2017-10-11 09:25:55.629848
NCT00797667|ClinicalTrials.gov processed this data on October 10, 2017|2008-11-24|2017-05-26|2014-08-13||November 12, 2008|Actual|2008-11-12|May 2017|2017-05-01|May 20, 2009|Actual|2009-05-20|May 20, 2009|Actual|2009-05-20||Interventional||All enrolled participants who recieved at least one dose of study drug.|MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)|A Phase IIa, Multicenter, Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine|Terminated||Phase 2|660|Actual|Merck Sharp & Dohme Corp.|Based on a recommendation from the external Data Safety Monitoring Board (DSMB), a decision to terminate the trial was made on 26-Mar-2009.|3||"The study was terminated based on a recommendation of the DSMB following the identification of   two patients with significant elevations in serum transaminases"|f||||t||||||||||2017-10-11 09:26:11.355944|2017-10-11 09:26:11.355944
NCT00823979|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-15|2014-03-24|2014-01-28|2013-11-19|March 2009||2009-03-01|March 2014|2014-03-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional||Intent-to-Treat (ITT) population included all randomized participants who received at least 1 dose of study drug.|A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1|A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1|Terminated||Phase 2|105|Actual|Pfizer|The trial was terminated on 12 April, 2012 due to lack of efficacy at the Week 24 analysis. The decision to terminate the trial was not based on any safety concerns.|3||See termination reason in detailed description.|f||||t||||||||||2017-10-11 09:27:32.688123|2017-10-11 09:27:32.688123
NCT00817531|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-05|2012-08-27|2012-05-07||December 2008||2008-12-01|August 2012|2012-08-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients|A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple-Negative Breast Cancer Patients Developing Effective Therapies for Er-Negative Breast Cancer Using Genomics and Proteomics: Project 3|Terminated||Phase 2|22|Actual|Baylor Breast Care Center|The study was terminated after internal analysis due to treatment futility. It does not meet the required number of responses to continue the study.|1||terminated due to futility after interim analysis|f||||t||||||||||2017-10-11 09:27:57.271274|2017-10-11 09:27:57.271274
NCT00818259|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-06|2017-05-02|2014-10-02||February 5, 2009|Actual|2009-02-05|May 2017|2017-05-01|January 20, 2014|Actual|2014-01-20|January 20, 2014|Actual|2014-01-20||Interventional||For analysis purposes, baseline (BL) data are presented by study part groups. The BL analysis population includes all unique enrolled participants in Parts I, II, III, IV and V. Part III participants who entered Parts IV and V are only counted in Part III; Part IV participants who entered Part V are only counted in Part IV.|A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)|A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy|Terminated||Phase 1|92|Actual|Merck Sharp & Dohme Corp.||7||"Study terminated early prior to completing targeted enrollment of participants <6 months of age   due to recruitment challenges."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00818389|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-06|2011-03-18|2010-05-10||January 2009||2009-01-01|March 2011|2011-03-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional|||Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|Terminated||Phase 2/Phase 3|84|Actual|Massachusetts General Hospital||2||"NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of   84 subjects."|f||||t||||||||||2017-10-11 09:28:11.540446|2017-10-11 09:28:11.540446
NCT00827099|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-21|2012-03-19|2011-07-28||June 2006||2006-06-01|March 2012|2012-03-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|||Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer|Transplantation of Two Partially Matched Umbilical Cord Blood Units Following Reduced Intensity Conditioning to Enhance Engraftment and Limit Transplant-Related Mortality in Adults With Hematologic Malignancies|Terminated||Phase 2|5|Actual|Northside Hospital, Inc.|This study was terminated early, therefore no additional data measures or outcomes are available.|1||Unacceptable morbidity & mortality|f||||f||||||||||2017-10-11 09:28:32.237125|2017-10-11 09:28:32.237125
NCT00828100|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-20|2009-03-05|||February 2009||2009-02-01|March 2009|2009-03-01||||May 2009|Anticipated|2009-05-01||Interventional|||Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B|Comparison of fluID Rapid Influenza and BinaxNOW® Influenza A & B|Suspended||Phase 3|650|Anticipated|Nanogen, Inc.||||Study currently suspended due to a lack of available funding.|f||||f||||||||||2017-10-11 09:28:53.059551|2017-10-11 09:28:53.059551
NCT00833768|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-29|2015-03-19|||January 2009||2009-01-01|March 2015|2015-03-01|September 2009|Actual|2009-09-01|September 2009|Actual|2009-09-01||Interventional|ASPIRE||A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis|A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease (CKD) Patients Not on Dialysis|Terminated||Phase 3|5|Actual|Sanofi||2||"After an extensive review,the ASPIRE in CKD study was terminated because it was not possible to   complete the study in an appropriate time frame."|f||||f||||||||||2017-10-11 09:29:23.032158|2017-10-11 09:29:23.032158
NCT00834899|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-31|2013-05-22|2013-02-24||January 2009||2009-01-01|February 2013|2013-02-01|March 2012|Actual|2012-03-01|March 2012|Actual|2012-03-01||Interventional|||A Safety Study of Eptifibatide in Patients With Sickle Cell Disease|A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell Disease|Terminated||Phase 1/Phase 2|13|Actual|University of North Carolina, Chapel Hill|The study was terminated early resulting in small numbers of subjects analyzed.|2||Slow accrual and no cost extension not approved by NHLBI|f||||t||||||||||2017-10-11 09:29:54.225891|2017-10-11 09:29:54.225891
NCT00836043|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-02|2013-12-02|||October 2008||2008-10-01|December 2013|2013-12-01|April 2009|Actual|2009-04-01|April 2009|Actual|2009-04-01||Observational|||Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia|Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia (CLL)|Terminated||N/A|6|Actual|Sanofi|||1|Study terminated due to low enrollment.|f||||f||||||||||2017-10-11 09:30:24.062979|2017-10-11 09:30:24.062979
NCT00836069|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-03|2009-05-29|||October 2008||2008-10-01|May 2009|2009-05-01|April 2010|Anticipated|2010-04-01|April 2010|Anticipated|2010-04-01||Interventional|||Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder|A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder|Terminated||Phase 3|15|Anticipated|Cedars-Sinai Medical Center||4||Pfizer has terminated the execution of this protocol|f||||f||||||||||2017-10-11 09:30:24.42414|2017-10-11 09:30:24.42414
NCT00825266|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-16|2017-02-13|2016-11-21||September 2008||2008-09-01|February 2017|2017-02-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Insulin Resistance in Pulmonary Arterial Hypertension|The Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial Hypertension|Terminated||Phase 2|2|Actual|Stanford University|Study terminated due to poor enrollment|2||difficulty in finding eligible subjects|f||||||||||||||2017-10-11 09:30:33.833725|2017-10-11 09:30:33.833725
NCT00836355|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-03|2016-03-29|2016-02-29||April 2009||2009-04-01|March 2016|2016-03-01|January 2010|Actual|2010-01-01|December 2009|Actual|2009-12-01||Interventional|||Enoxaparin and/or Minocycline in Acute Stroke|Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke|Terminated||N/A|6|Actual|New York University School of Medicine|This trial was terminated early because of logistical challenges in data collection. No outcome measures data was able to be collected.|4||Too few acute stroke patients available to meet enrollment requirements.|f||||f||||||||||2017-10-11 09:30:50.272502|2017-10-11 09:30:50.272502
NCT00836875|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-03|2017-05-23|2014-05-09||May 2009|Actual|2009-05-01|May 2017|2017-05-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional||Safety population: included all participants who received at least 1 dose of study medication.|A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children|A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients.|Terminated||Phase 3|31|Actual|Pfizer|The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns. Interpretation of the data are limited due to the small sample size and descriptive design.|1||"This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any   safety issues or concerns."|f||||t||||||||||2017-10-11 09:30:58.271987|2017-10-11 09:30:58.271987
NCT00837421|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-04|2017-01-30|||December 2006||2006-12-01|January 2017|2017-01-01|November 2011|Actual|2011-11-01|November 2011|Actual|2011-11-01||Observational|||The Ohio State University Sepsis Registry|The Ohio State University Sepsis Registry|Terminated||N/A|230|Actual|Ohio State University|||1|Lack of resources has prevented the study from continuation.|f||||f||||||Samples With DNA|"     Blood   "|No|The study was terminated and after analysis data integrity issues prohibited accurate IPD sharing. The data records have been destroyed.|2017-10-11 09:31:06.87684|2017-10-11 09:31:06.87684
NCT00837824|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-23|2015-03-19|2008-12-05||December 2002||2002-12-01|March 2015|2015-03-01|August 2003|Actual|2003-08-01|August 2003|Actual|2003-08-01||Interventional|||Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme|A Phase 2, Randomized, Open Label, Dose-Ranging, Multiple Dose Study of Fabrazyme® In Patients With Fabry Disease and With Severe Renal Disease|Terminated||Phase 2|20|Actual|Sanofi|The trial was terminated early due to inadequate study design, leading to small numbers of subjects analyzed.|2||The trial was terminated early due to inadequate study design.|f||||t||||||||||2017-10-11 09:31:12.394043|2017-10-11 09:31:12.394043
NCT00838227|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-05|2014-09-16|||February 2008||2008-02-01|September 2014|2014-09-01|June 2012|Anticipated|2012-06-01|January 2012|Anticipated|2012-01-01||Interventional|||Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder|Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder: A Pilot Study|Withdrawn||Phase 2|0|Actual|Manhattan Psychiatric Center||1||This study was withdrawn because there was no source of funding to implement the study.|f||||t||||||||||2017-10-11 09:31:22.642862|2017-10-11 09:31:22.642862
NCT00838578|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-04|2015-11-05|2014-03-19||March 2009||2009-03-01|November 2015|2015-11-01|October 2012|Actual|2012-10-01|July 2012|Actual|2012-07-01||Interventional|||Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer|Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer|Terminated||Phase 1/Phase 2|65|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1||Per protocol, the study was terminated based on interim analysis results|f||||f||||||||||2017-10-11 09:31:27.099966|2017-10-11 09:31:27.099966
NCT00829049|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-22|2012-08-20|2011-09-22||October 2007||2007-10-01|August 2012|2012-08-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|||Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris||Terminated||Phase 4|165|Actual|Allergan|Study enrollment was terminated due to company decision before the target enrollment of 220 patients was reached.|2||"Study enrollment was terminated due to company decision before the target enrollment of 220   patients was reached."|f||||f||||||||||2017-10-11 09:31:48.304703|2017-10-11 09:31:48.304703
NCT00832299|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-27|2013-03-07|2013-02-25||January 2009||2009-01-01|March 2013|2013-03-01|August 2011|Actual|2011-08-01|August 2011|Actual|2011-08-01||Interventional|||Neo-Adjuvant FOLFOX for Rectal Carcinoma|A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6|Terminated||Phase 2|2|Actual|Beth Israel Medical Center||1||terminated for lack of enrollment|f||||f||||||||||2017-10-11 09:32:54.874573|2017-10-11 09:32:54.874573
NCT00832338|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-29|2017-08-01|2016-12-07||April 2009||2009-04-01|August 2017|2017-08-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional|||Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores|Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25|Terminated||Phase 2|23|Actual|Emory University||1||Funding withdrawn|f||||t||||||||||2017-10-11 09:32:55.262427|2017-10-11 09:32:55.262427
NCT00832520|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-29|2015-06-16|2012-07-20||November 2008||2008-11-01|June 2015|2015-06-01|June 2011|Actual|2011-06-01|July 2010|Actual|2010-07-01||Interventional|||Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight|INST 0816: Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight|Terminated||Phase 2|13|Actual|New Mexico Cancer Care Alliance|Early termination leading to no subjects analyzed.There will be no publication, as this study was terminated after the original PI left employment with the institution.|1||Low accrual rate.|f||||t||||||||||2017-10-11 09:32:58.627835|2017-10-11 09:32:58.627835
NCT00832624|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-28|2017-04-27|2010-07-06||November 26, 2008|Actual|2008-11-26|April 2017|2017-04-01|September 2, 2009|Actual|2009-09-02|September 2, 2009|Actual|2009-09-02||Interventional|||The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)|Open-label, Non Placebo-Controlled Study To Verify the Effect of Sitagliptin In Adult Patients With Type 2 Diabetes and Inadequate Glycemic Control|Terminated||Phase 4|10|Actual|Merck Sharp & Dohme Corp.|The planned 18-week study was terminated early due to reconsideration of the study design. None of the 10 patients progressed beyond the second study visit, no laboratory tests were performed, and adverse experience data were not collected.|1||Business Reasons|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00832650|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-28|2010-12-02|2010-12-02||April 2009||2009-04-01|December 2010|2010-12-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Interventional|||Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose Study To Investigate The Effects Of 8 Mg Fesoterodine SR Tablets And 10 Mg Solifenacin Tablet On Gastrointestinal Transit In Healthy Female Subjects.|Terminated||Phase 1|60|Actual|Pfizer|Study was terminated due to futility based on interim analysis with 60 subjects. Although the results of statistical test for the primary endpoint was interpreted, the other endpoint results were interpreted based on statistical inference.|3||"Protocol A0221057 was terminated on December 25, 2009 for futility. There were no safety   concerns related to this decision."|f||||f||||||||||2017-10-11 09:33:00.762711|2017-10-11 09:33:00.762711
NCT00841633|ClinicalTrials.gov processed this data on October 10, 2017|2008-10-10|2011-10-11|||February 2009||2009-02-01|October 2011|2011-10-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional|||Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study|Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study|Terminated||Phase 3|15|Actual|UMC Utrecht||2||"Our RCT recently started. The RCT is similar to the feasibility trial, so it was terminated to   avoid 2 trials running simultaniously."|f||||f||||||||||2017-10-11 09:33:36.219178|2017-10-11 09:33:36.219178
NCT00843050|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-12|2012-06-20|2012-02-29||November 2009||2009-11-01|June 2012|2012-06-01|August 2012|Anticipated|2012-08-01|February 2011|Actual|2011-02-01||Interventional|||A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma|Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma|Terminated||Phase 2|13|Actual|Piramal Enterprises Limited|The Sponsor has terminated the study based on interim results. All subjects were off study at the time of termination. There are no major safety or tolerability concerns from this study. The study results published here are preliminary results.|1||"The study was terminated based on interim results and all subjects were off study at that time.   No major safety or tolerability concerns"|f||||f||||||||||2017-10-11 09:34:04.519055|2017-10-11 09:34:04.519055
NCT00843986|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-11|2014-04-30|2010-09-09||April 2009||2009-04-01|April 2014|2014-04-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional|CONVERT-H||Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)|A Phase-3b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety and Efficacy of Conivaptan in Symptomatic Acute Decompensated Heart Failure (ADHF) Subjects With Hyponatremia|Terminated||Phase 3|9|Actual|Cumberland Pharmaceuticals|"The study was terminated because of difficulties in enrolling eligible patients per the protocol inclusion and exclusion criteria.
Outcome Measures were not analyzed due to the abbreviated enrollment at early study termination."|2||"The clinical study has been terminated based on difficulties to enroll eligible subjects per   protocol inclusion and exclusion criteria."|f||||f||||||||||2017-10-11 09:34:29.907433|2017-10-11 09:34:29.907433
NCT00846391|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-17|2016-02-04|2010-08-26||December 2008||2008-12-01|February 2016|2016-02-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional|||A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)|A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK8245 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control|Terminated||Phase 2|14|Actual|Merck Sharp & Dohme Corp.|This study was terminated due to the continuing inability to recruit patients. No efficacy analysis was performed because of insufficient sample size for meaningful analysis due to early study termination and insufficient sample size.|3||Study was terminated due to inability to recruit patients.|f||||||||||||||2017-10-11 09:34:41.440878|2017-10-11 09:34:41.440878
NCT00847951|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-17|2017-09-18|||October 2008|Actual|2008-10-01|September 2017|2017-09-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Ultrasound for Perfusion in Neonates|3D Ultrasound for Perfusion in Neonates|Withdrawn||N/A|0|Actual|University of Michigan||1||Study terminated at this time by investigator. Will create new protocol.|f||||f||||||||||2017-10-11 09:35:24.736341|2017-10-11 09:35:24.736341
NCT00839917|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-06|2017-03-15|2012-09-07||February 2008||2008-02-01|March 2017|2017-03-01|May 2008|Actual|2008-05-01|May 2008|Actual|2008-05-01||Interventional|||A Study of ProQuad™ in Healthy Children in Korea (V221-023)|A Multicenter, Randomized, Open-Label Study to Compare the Immunogenicity, Safety, and Tolerability of Measles, Mumps, Rubella, and Varicella of Combination Vaccine ProQuad With Concomitant Administration of M-M-R II and VARIVAX in Healthy Korean Children|Terminated||Phase 3|30|Actual|Merck Sharp & Dohme Corp.|Formal testing of the study hypotheses was not possible because of low enrollment|2||"Study terminated early because of insufficient enrollment before expiration date of the   investigational vaccine lot"|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00850421|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-23|2017-09-07|2013-07-10||April 2004||2004-04-01|July 2013|2013-07-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|||Pilot Study of BOTOX for Migraine Headaches|A Single-Center Pharmacoeconomic Pilot Study of BOTOX® (Botulinum Toxin Type A) for the Prophylactic Treatment of Migraine Headaches|Terminated||N/A|35|Actual|HealthPartners Institute|This study was terminated and PI left organization. No results available to report|1||Recently published BOTOX efficacy data and study design deficits.|f||||f||||||||||2017-10-11 09:36:50.210339|2017-10-11 09:36:50.210339
NCT00844155|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-13|2010-04-01|||March 2009||2009-03-01|February 2010|2010-02-01|July 2009|Anticipated|2009-07-01|July 2009|Anticipated|2009-07-01||Interventional|||Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit|A Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir (Tamiflu®) in Patients in the Intensive Care Unit|Withdrawn||N/A|0|Actual|University of Manitoba||2||Study has been withdrawn as the H1N1 epidemic made this study redundant|f||||f||||||||||2017-10-11 09:37:04.564856|2017-10-11 09:37:04.564856
NCT00845832|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-17|2014-12-15|2014-06-23||March 2009||2009-03-01|December 2014|2014-12-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional||Safety population: All participants who were randomized and received any part of an infusion of study medication; participants who received the incorrect therapy from that intended were summarized in the group according to the therapy actually received for the majority of the time through Week 48.|A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate|A Randomized, Active Controlled, Double-blind, Study to Compare the Safety and Reduction in Disease Activity With the Combination of Rituximab (MabThera®)and Tocilizumab (RoActemra®) Versus Tocilizumab in Patients With Active Rheumatoid Arthritis With an Incomplete Response to Methotrexate|Terminated||Phase 2|24|Actual|Hoffmann-La Roche||2||"The study was terminated early because of a related decision to stop the development of   ocrelizumab in rheumatoid arthritis."|f||||||||||||||2017-10-11 09:37:41.505511|2017-10-11 09:37:41.505511
NCT00845845|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-17|2013-06-18|2013-02-06||March 2006||2006-03-01|June 2013|2013-06-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|||Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)|Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)|Terminated||Phase 2|12|Actual|University of Illinois at Chicago|The study was terminated on October 12, 2010 due to low enrollment. Consequently, no analyses were completed.|2||Terminated due to low enrollment.|f||||f||||||||||2017-10-11 09:37:42.513394|2017-10-11 09:37:42.513394
NCT00855842|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-02|2011-06-10|2011-04-04||March 2009||2009-03-01|June 2011|2011-06-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|DAIS||Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion|Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion|Terminated||N/A|4|Actual|Boston University|The study was terminated early because the clinical facility changed and eligible patients were not seen at the facility.|1||inadequate enrollment|f||||f||||||||||2017-10-11 09:38:24.829462|2017-10-11 09:38:24.829462
NCT00856089|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-04|2013-05-28|||May 2009||2009-05-01|April 2011|2011-04-01|October 2009|Anticipated|2009-10-01|October 2009|Anticipated|2009-10-01||Interventional|||Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization|Prevalence of Methicillin-resistant Staphylococcus Aureus (MRSA) in a Medical Center and Efficacy of Altabax in Clearing MRSA Nasal Colonization|Withdrawn||Phase 4|0|Actual|Ochsner Health System||1||Study is withdrawn and no one enrolled due to changes in personnel|f||||t||||||||||2017-10-11 09:38:28.803675|2017-10-11 09:38:28.803675
NCT00856674|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-04|2010-06-01|||March 2009||2009-03-01|June 2010|2010-06-01|June 2010|Anticipated|2010-06-01|June 2010|Anticipated|2010-06-01||Interventional|||Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy|A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous OPL-CCL2-LPM in Patients With IgA Nephropathy|Terminated||Phase 1|30|Anticipated|Osprey Pharmaceuticals USA, Inc.||1||Study terminated due to resources and slow enrollment; not due to safety|f||||f||||||||||2017-10-11 09:38:57.437726|2017-10-11 09:38:57.437726
NCT00857818|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-06|2013-11-07|2011-05-17||April 2009||2009-04-01|July 2011|2011-07-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome|A 16-Week, Randomized, Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Non-HDL Cholesterol Among Patients With Schizophrenia and Bipolar I Disorder Who Have Pre-existing Metabolic Syndrome|Terminated||Phase 3|64|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|The study terminated early due to low enrollment. Mean changes from baseline in: the Clinical Global Impression-Severity Scale and the Impact of Weight on Quality of Life scores were not analyzed due to insufficient data for meaningful conclusions.|2||Slow Accrual|f||||f||||||||||2017-10-11 09:39:24.660756|2017-10-11 09:39:24.660756
NCT00858598|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-09|2017-06-19|||December 2009||2009-12-01|June 2017|2017-06-01|January 2014|Anticipated|2014-01-01|July 2013|Anticipated|2013-07-01||Observational|PO||Pro Osteon Bone Void Filler Study|Pro Osteon Bone Void Filler Data Collection|Withdrawn||N/A|0|Actual|Zimmer Biomet|||1|Study never started. Study suspended indefinitely.|f||||f||||||||||2017-10-11 09:39:41.801838|2017-10-11 09:39:41.801838
NCT00858754|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-09|2011-07-22|||March 2009||2009-03-01|July 2011|2011-07-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional|||Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects|A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain|Withdrawn||Phase 4|340|Anticipated|Valeant Pharmaceuticals International, Inc.||2||"Withdrawn [This study was terminated early by Wyeth, prior to dosing any subjects, for business   reasons not related to safety."|f||||f||||||||||2017-10-11 09:39:44.320398|2017-10-11 09:39:44.320398
NCT00858845|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-06|2013-09-04|2013-06-19||May 2008||2008-05-01|September 2013|2013-09-01|December 2012|Actual|2012-12-01|March 2011|Actual|2011-03-01||Interventional|||Using Clonidine to Improve Leg Weakness in People With Heart Failure|Clonidine and the Skeletal Myopathy of Heart Failure|Completed||Phase 4|11|Actual|University of California, Los Angeles|This is a small trial, but it was not terminated early, and there were no technical issues.|1|||f||||t||||||||||2017-10-11 09:39:48.13234|2017-10-11 09:39:48.13234
NCT00859339|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-09|2016-03-15|2016-03-15||March 2009||2009-03-01|March 2016|2016-03-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional|||Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC|A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123|Terminated||Phase 2|9|Actual|Hoosier Cancer Research Network|Study was terminated due to pre-defined stopping rules (patient toxicities)|1||Patient Toxicities|f||||t||||||||No||2017-10-11 09:39:55.863092|2017-10-11 09:39:55.863092
NCT00852631|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-26|2012-06-12|2011-05-18||February 2009||2009-02-01|May 2012|2012-05-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Seroquel XR in Adults With Schizophrenia|Open-label Multicentre Study on Efficacy and Safety of Oral Quetiapine (Seroquel XR) in Adults With Schizophrenia|Terminated||Phase 3|28|Actual|AstraZeneca||1||The study was prematurely terminated due to insufficient recruitment.|f||||f||||||||||2017-10-11 09:40:13.762949|2017-10-11 09:40:13.762949
NCT00852774|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-25|2014-07-25|||May 2009||2009-05-01|July 2014|2014-07-01|August 2011|Actual|2011-08-01|August 2011|Actual|2011-08-01||Observational|||Steep Trendelenburg Positioning on Intra-Ocular Pressure During Surgery for Endometrial Robotics Versus Laparotomy|Effects of Steep Trendelenburg Positioning on Intra-Ocular Pressure During Surgery For Endometrial Cancer: Robotics Versus Laparotomy|Withdrawn||N/A|0|Actual|Ohio State University Comprehensive Cancer Center|||2|terminated due to low staffing|f||||f||||||||||2017-10-11 09:40:16.458703|2017-10-11 09:40:16.458703
NCT00853567|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-27|2014-08-05|2014-06-25||February 2009||2009-02-01|August 2014|2014-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional||Study prematurely terminated|Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids|A Phase III, Three-Arm, Parallel Design, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids|Terminated||Phase 3|71|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2017-10-11 09:40:41.621137|2017-10-11 09:40:41.621137
NCT00859859|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-10|2011-07-19|||October 2006||2006-10-01|July 2011|2011-07-01|February 2009|Actual|2009-02-01|February 2009|Actual|2009-02-01||Interventional|||Vagus Nerve Stimulation in Rheumatoid Arthritis|Vagus Nerve Stimulation in Rheumatoid Arthritis|Terminated||Phase 1|23|Actual|Northwell Health||1||"The protocol was terminated early (prior to complete enrollment) after interim analysis proved   data to be statistically insignificant"|f||||f||||||||||2017-10-11 09:41:12.204424|2017-10-11 09:41:12.204424
NCT00860535|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-05|2015-09-28|2011-06-28||June 2009||2009-06-01|September 2015|2015-09-01|June 2010|Actual|2010-06-01|April 2010|Actual|2010-04-01||Interventional|||Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)|A Multicenter Phase Ib Trial to Determine Whether a Gene Expression Signature Changes in Response to Treatment With Bcr-Abl Inhibitors in Patients With Blast Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphocytic Leukemia|Terminated||Phase 1|9|Actual|Merck Sharp & Dohme Corp.|Part I aimed to have 10 evaluable patients. Due to slow enrollment, 9 patients who met the inclusion/exclusion criteria were enrolled over a period of 9 months. Part I was terminated early and Part II was cancelled due to slow enrollment.|1|||f||||f||||||||||2017-10-11 09:41:21.12747|2017-10-11 09:41:21.12747
NCT00861159|ClinicalTrials.gov processed this data on October 10, 2017|2008-09-29|2011-01-11|||September 2011||2011-09-01|January 2011|2011-01-01|September 2011|Anticipated|2011-09-01|September 2011|Anticipated|2011-09-01||Observational|||RLIP76 in Human Serum in Adults With Rheumatologic Diseases|Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.|Withdrawn||N/A|100|Anticipated|University of North Texas Health Science Center|||1|Study withdrawn due to lack of staffing resources and subject interest|f||||t||||||||||2017-10-11 09:41:27.775518|2017-10-11 09:41:27.775518
NCT00861471|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-12|2016-05-31|2011-04-29||May 2005||2005-05-01|May 2016|2016-05-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer|Phase I/II, Open Label Study of Sequential Taxotere® (Docetaxel) and Gleevec® (Imatinib Mesylate) in Hormone Refractory Prostate Cancer|Terminated||Phase 1/Phase 2|24|Actual|New York University School of Medicine|This study was terminated before it reached the target accrual number due to slow accrual, leading to small number of subjects analyzed (12 out of the target number of 37).|1||due to slow accrual|f||||t||||||||||2017-10-11 09:41:30.465815|2017-10-11 09:41:30.465815
NCT00861965|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-12|2015-04-01|||January 2010||2010-01-01|April 2015|2015-04-01||||November 2012|Actual|2012-11-01||Interventional|||Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match Alternative to Allogeneic Transplant for Blood Cancers|A Phase I/II Study of Polyclonally Activated, Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStimTM) in Patients With Relapsed or Refractory Hematological Malignancy Without Prior Conditioning|Withdrawn||Phase 1/Phase 2|0|Actual|Immunovative Therapies, Ltd.||1||withdrawn due to poor recruitment|f||||f||||||||||2017-10-11 09:41:50.017663|2017-10-11 09:41:50.017663
NCT00863083|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-16|2010-06-17|||February 2009||2009-02-01|June 2010|2010-06-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|||Reducing Barriers to Behavior Change Among Youth With Pediatric Overweight and Obesity|Reducing Barriers to Behavior Change Among Youth With Pediatric Overweight and Obesity|Terminated||N/A|12|Actual|Medical College of Wisconsin||2||Study was terminated due to poor enrollment.|f||||f||||||||||2017-10-11 09:42:16.675438|2017-10-11 09:42:16.675438
NCT00864630|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-17|2011-05-23|||September 2010||2010-09-01|May 2011|2011-05-01|December 2011|Anticipated|2011-12-01|October 2011|Anticipated|2011-10-01||Interventional|||Neuroimaging for Depression|Objective Detection, Evaluation and Countermeasures for In-flight Depression|Terminated||N/A|68|Anticipated|Massachusetts General Hospital||2||"The study upon which this project depended for subjects and the intervention was terminated   prematurely due to lack of funds."|f||||f||||||||||2017-10-11 09:42:19.30533|2017-10-11 09:42:19.30533
NCT00865579|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-10|2017-09-15|||April 2009|Actual|2009-04-01|September 2017|2017-09-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients|Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients|Terminated||Phase 3|964|Actual|Newron||1||study terminated early due to change in Sponsorship|f||||||||||||||2017-10-11 09:42:36.164314|2017-10-11 09:42:36.164314
NCT00866034|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-19|2014-02-04|2013-10-17||February 2009||2009-02-01|February 2014|2014-02-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Cetrotide Treatment Optimization|Prospective, Multicenter,Randomized Controlled Trial Towards Identifying the Optimal GnRH Antagonist Treatment Protocol|Terminated||Phase 4|617|Actual|UMC Utrecht|The study was terminated prematurely because no significant difference was observed in clinical outcome after 617 inclusions. A much larger population would be needed to detect a small significant difference in favour of either study arm.|2||Due to limited rate of patient inclusion|f||||t||||||||||2017-10-11 09:42:43.530857|2017-10-11 09:42:43.530857
NCT00866281|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-19|2015-11-18|2015-09-08||September 2009||2009-09-01|November 2015|2015-11-01|September 2014|Actual|2014-09-01|September 2014|Actual|2014-09-01||Interventional||The analysis was performed in full analysis set (FAS) population, defined as all participants to whom study treatment was assigned.|A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia|A Phase I/II, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Twice Daily Oral Midostaurin and to Evaluate the Preliminary Clinical and Pharmacodynamic Response in Pediatric Patients With Relapsed or Refractory Leukemia|Terminated||Phase 1/Phase 2|22|Actual|Novartis|The study was terminated early since despite considerable efforts to boost recruitment, no new participants were enrolled in the final year of this study.|2||"Despite considerable efforts to boost recruitment during the final year of the study, no new   patients were enrolled."|f||||||||||||||2017-10-11 09:42:47.625869|2017-10-11 09:42:47.625869
NCT00866723|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-19|2017-04-26|2014-11-19||March 2009||2009-03-01|April 2017|2017-04-01|June 2012|Actual|2012-06-01|December 2011|Actual|2011-12-01||Interventional||The analysis dataset is comprised of all treated patients.|Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer|Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin|Terminated||Phase 2|5|Actual|Dana-Farber Cancer Institute|Early termination leading to small numbers of subjects analyzed.|1||Recruitment has been terminated prematurely because of poor enrollment.|f||||t||||||||||2017-10-11 09:43:00.858288|2017-10-11 09:43:00.858288
NCT00860158|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-11|2016-02-04|2016-01-07||March 2009||2009-03-01|February 2016|2016-02-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer|A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer|Terminated||Phase 2|1|Actual|Hoosier Cancer Research Network|This study was terminated due to slow accrual and no results were analyzed.|1||Slow accrual; closed by funder|f||||t||||||||No||2017-10-11 09:43:10.879787|2017-10-11 09:43:10.879787
NCT00860353|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-11|2010-12-02|||February 2009||2009-02-01|December 2010|2010-12-01|May 2009|Actual|2009-05-01|||||Interventional|||Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551|A Double Blind, Randomised, Placebo-controlled, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single, Ascending, Oral Doses of AZD2551 in Healthy Male Subjects|Terminated||Phase 1|90|Anticipated|AstraZeneca||2||"Due to portfolio and logistical issues, this study will not be re-started at the present time.   The study is not being terminated for safety reasons."|f||||f||||||||||2017-10-11 09:43:17.210686|2017-10-11 09:43:17.210686
NCT00867139|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-20|2013-08-08|2012-12-21||March 2009||2009-03-01|August 2013|2013-08-01|January 2010|Actual|2010-01-01|August 2009|Actual|2009-08-01||Interventional|||TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients|A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients|Completed||Phase 1/Phase 2|7|Actual|Fred Hutchinson Cancer Research Center|Study was terminated. Limitations of this study include: small sample size pilot study; inability to enroll the projected number of patients for full analysis before the study was terminated.|3|||f||||t||||||||||2017-10-11 09:43:19.160325|2017-10-11 09:43:19.160325
NCT00868374|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-24|2016-11-09|2013-11-01||June 2008||2008-06-01|November 2016|2016-11-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|MDD/GAD||Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder|Quetiapine XR Monotherapy or Adjunctive Therapy to Antidepressants in the Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder|Terminated||Phase 3|23|Actual|University Hospitals Cleveland Medical Center||2||Study terminated due to low enrollment|f||||t||||||||||2017-10-11 09:43:37.144989|2017-10-11 09:43:37.144989
NCT00868439|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-23|2016-01-25|2015-11-11|2014-11-03|April 2009||2009-04-01|January 2016|2016-01-01|December 2009|Actual|2009-12-01|November 2009|Actual|2009-11-01||Interventional|PEARL-HF|One participant received one dose of patiromer and did not return to the clinic in a timely manner; the participant was terminated from the study for protocol noncompliance, and because the participant did not have post-treatment efficacy data, the participant was excluded from the Full Analysis Set but retained in the Safety Analysis Set.|Evaluation of Patiromer in Heart Failure Patients|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients|Completed||Phase 2|120|Actual|Relypsa, Inc.||2|||f||||f||||||||||2017-10-11 09:43:37.801429|2017-10-11 09:43:37.801429
NCT00869310|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-24|2014-01-03|||September 2009||2009-09-01|January 2014|2014-01-01|May 2012|Actual|2012-05-01|May 2012|Actual|2012-05-01||Interventional|||Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis|Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial|Terminated||Phase 3|303|Actual|S. Maria Hospital, Terni||2||we terminated the study before enrolling 303/560 due to a slow accrual|f||||f||||||||||2017-10-11 09:43:51.895645|2017-10-11 09:43:51.895645
NCT00869414|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-25|2017-05-30|2017-04-13||July 2009|Actual|2009-07-01|May 2017|2017-05-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional||This study was prematurely terminated because the PI is deceased. The Baseline data for the specific arms is unknown since no data are available. Only the baseline data for the overall population is available and reported.|Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes|Comparison of Glycemic Response to Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes Using Continuous Glucose Monitoring|Terminated||N/A|16|Actual|Johns Hopkins University||3||PI deceased|f||||t||||||||||2017-10-11 09:43:55.84124|2017-10-11 09:43:55.84124
NCT00869674|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-25|2013-05-29|||February 2009||2009-02-01|June 2009|2009-06-01|November 2009|Actual|2009-11-01|October 2009|Actual|2009-10-01||Interventional|||GeneSearch™ Breast Lymph Node (BLN) Assay China Registration Study|一项比较GeneSearch 乳腺淋巴结（BLN）检测试剂盒和永久病理切片检测乳腺癌患者腋窝前哨淋巴结转移的前瞻性、多中心临床试验 A Prospective and Multi-center Clinical Trial By Comparing GeneSearch™ Breast Lymph Node (BLN) Test Kit To Permanent Pathological Section On Detecting Axillary Sentinel Lymph Node Metastases In Breast Cancer Patients|Terminated||Phase 3|540|Actual|Johnson & Johnson Medical, China||2||Investigational products has been suspended from the US market|f||||f||||||||||2017-10-11 09:44:01.08093|2017-10-11 09:44:01.08093
NCT00869973|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-25|2013-01-22|||September 2009||2009-09-01|October 2009|2009-10-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional|||Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients|Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study|Terminated||Phase 3|580|Actual|S. Maria Hospital, Terni||2||We terminated the study after enrolling 580/900 patients due to a slow accrual|f||||f||||||||||2017-10-11 09:44:05.575062|2017-10-11 09:44:05.575062
NCT00864175|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-26|2012-01-20||2010-06-18|July 2007||2007-07-01|January 2012|2012-01-01|October 2011|Actual|2011-10-01|June 2011|Actual|2011-06-01||Interventional|||Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer|A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|68|Actual|Incyte Corporation||4||Incyte suspended development of the compound.|f||||f||||||||||2017-10-11 09:44:23.077175|2017-10-11 09:44:23.077175
NCT00871208|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-27|2015-05-11|||May 2009||2009-05-01|May 2015|2015-05-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy|Randomized, Placebo-Controlled Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids vs. Low-Potency Corticosteroid Mono-therapy|Withdrawn||Phase 4|0|Actual|St. Luke's-Roosevelt Hospital Center||2||Funding withdrawn|f||||t||||||||||2017-10-11 09:45:08.375868|2017-10-11 09:45:08.375868
NCT00872222|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-30|2016-10-06|||January 2007||2007-01-01|September 2016|2016-09-01|September 2009|Actual|2009-09-01|September 2009|Actual|2009-09-01||Interventional|||A Single Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement|Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle™ Acetabular Cup Prosthesis With a Ceramic-on-ceramic Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement|Terminated||Phase 4|98|Actual|DePuy International||1||Study terminated early due to business reasons|f||||f||||||||||2017-10-11 09:45:26.139376|2017-10-11 09:45:26.139376
NCT00875875|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-03|2015-06-08|||June 2009||2009-06-01|June 2015|2015-06-01|June 2009|Anticipated|2009-06-01|June 2009|Actual|2009-06-01||Interventional|Rifaximin 600||Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea|Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center, Houston||2||No study population in Mexico (H1N1). Study withdrawn from IRB consideration.|f||||f||||||||||2017-10-11 09:45:50.810729|2017-10-11 09:45:50.810729
NCT00870441|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-25|2013-02-27|||March 2009||2009-03-01|June 2010|2010-06-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|||Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Multiple Dose, Multi-Center Study to Compare the Safety of ASP2151 to Valacylcovir and Placebo in Healthy Male and Female Subjects|Terminated||Phase 1|442|Actual|Astellas Pharma Inc||3||Study terminated due to treatment-emergent serious adverse events|f||||f||||||||||2017-10-11 09:46:38.103742|2017-10-11 09:46:38.103742
NCT00882713|ClinicalTrials.gov processed this data on October 10, 2017|2009-02-17|2016-08-12|2016-07-02||February 2009||2009-02-01|August 2016|2016-08-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional||Safety population included all participants who have been treated with at least one dose of the study drug and a safety follow-up, whether withdrawn prematurely or not.|A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once- Monthly Administration of Subcutaneous CERA for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anemia|Completed||Phase 3|202|Actual|Hoffmann-La Roche||1|||f||||||||||||||2017-10-11 09:46:55.503117|2017-10-11 09:46:55.503117
NCT00883116|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-16|2017-01-27|2013-12-06||August 2009||2009-08-01|January 2017|2017-01-01|February 2014|Actual|2014-02-01|June 2012|Actual|2012-06-01||Interventional|IXAMPLE2|Baseline analyses are for randomized participants.|A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer|A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy|Terminated||Phase 3|551|Actual|R-Pharm|This study was terminated per Data Monitoring Committee. Results from an interim analysis showed that there was no favorable benefit/risk ratio with ixabepilone and that ixabepilone did not improve survival compared with control chemotherapies.|2||"Interim analysis results showed that ixabepilone did not improve survival compared with control   chemotherapies."|f||||t||||||||||2017-10-11 09:47:03.964661|2017-10-11 09:47:03.964661
NCT00884390|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-16|2014-08-20|2014-03-20||May 2009||2009-05-01|August 2014|2014-08-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|||Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings|A Postauthorization Safety Surveillance Study Of Patients Switching To ReFacto AF From ReFacto Or Other Factor VIII Products In Usual Care Settings|Terminated||Phase 4|208|Actual|Pfizer|The study was terminated early by agreement with the EMA before full recruitment was attained, but this is not considered to affect the overall results and the ability of the study to address its objectives.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 09:47:32.980594|2017-10-11 09:47:32.980594
NCT00873444|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-19|2016-05-09|||July 2006||2006-07-01|March 2016|2016-03-01|November 2006|Actual|2006-11-01|November 2006|Actual|2006-11-01||Interventional|||A Randomised Study to Compare Metal Ion Release and Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-Metal or a Metal-on-Metal Bearing|Randomised, Controlled, Prospective, Multi-Centre, Post Market Surveillance Study Comparing a Ceramic-on-Metal Bearing and a Metal-on-Metal Bearing in Subjects Requiring Primary Total Hip Arthroplasty for Non-Inflammatory Degenerative Joint Disease|Terminated||Phase 4|5|Actual|DePuy International||2||"Study progress very slow therefore terminated as other projects underway to investigate the   same research question which will deliver results earlier"|f||||f||||||||||2017-10-11 09:47:35.155347|2017-10-11 09:47:35.155347
NCT00874302|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-31|2014-06-26||||||June 2014|2014-06-01||||||||Interventional|||Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms|A Phase III, Open Label, Randomized, Multicenter Study Evaluating the Safety and Efficacy of 25 mg and 50 mg Doses of Proellex to Assess Recurrence of Symptoms in the Treatment of Symptomatic Uterine Fibroids|Withdrawn||Phase 3|0|Actual|Repros Therapeutics Inc.||2||Study terminated for safety and the FDA put the study on hold for safety.|f||||t||||||||||2017-10-11 09:47:51.044417|2017-10-11 09:47:51.044417
NCT00874497|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-31|2017-03-03|2016-08-23|2016-06-24|March 2009||2009-03-01|March 2017|2017-03-01|August 2015|Actual|2015-08-01|July 2015|Actual|2015-07-01||Interventional|EMPHASIS|The safety population included all randomized participants who had received study medication. Participants in this population were used for all demographic and safety summaries. Participants were analyzed based on the treatment which they had received.|Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema|A Multi-center, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Pharmacodynamics, Efficacy and Safety of 50 mg Tetomilast Administered as Oral Tablets in Patients With Chronic Obstructive Pulmonary Disease Associated With Emphysema THIS STUDY IS CLOSED TO ENROLLMENT AND NEW SITES|Terminated||Phase 2|84|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|This trial was terminated early, not due to a safety concern, but due to a business decision to cease development of the tetolimast clinical program.|2||Sponsor Terminated|f||||||||||||||2017-10-11 09:47:52.786455|2017-10-11 09:47:52.786455
NCT00875095|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-02|2016-09-07|||October 2007||2007-10-01|September 2016|2016-09-01|December 2008|Actual|2008-12-01|December 2008|Actual|2008-12-01||Observational|||Impact of Sperm DNA Integrity on Artificial Reproductive Treatment (ART)|Impact of Sperm DNA Integrity on ART Treatment|Terminated||N/A|8|Actual|Northwell Health|||2|"Study funding was withdrawn by the sponsor following agreement that slow patient recruitment   warranted a new approach."|f||||f||||||Samples Without DNA|"     Smears of semen samples will be stained and stored.   "|||2017-10-11 09:48:04.368993|2017-10-11 09:48:04.368993
NCT00884533|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-16|2015-04-15|||June 2009||2009-06-01|April 2015|2015-04-01|August 2009|Anticipated|2009-08-01|August 2009|Anticipated|2009-08-01||Interventional|Rosi XR||QTc Study of Rosi XR in Healthy Volunteers|A Study to Evaluate the Effect of Extended Release Rosiglitazone (RSG XR) on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||3||The whole project was terminated|f||||||||||||||2017-10-11 09:48:12.791945|2017-10-11 09:48:12.791945
NCT00884715|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-20|2013-09-17||2013-09-09|July 2009||2009-07-01|September 2013|2013-09-01|December 2011|Actual|2011-12-01|November 2011|Actual|2011-11-01||Interventional|||Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome|Open Label Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome|Terminated||Phase 1/Phase 2|10|Actual|Endo Pharmaceuticals||2||Program was terminated for business reasons|f||||f||||||||||2017-10-11 09:48:14.330385|2017-10-11 09:48:14.330385
NCT00885755|ClinicalTrials.gov processed this data on October 10, 2017|2009-03-16|2016-07-01|2015-09-01||August 2009||2009-08-01|July 2016|2016-07-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional||Intent-to-treat (ITT) population: All registered participants were included in the ITT population.|A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer|A Prospective Study to Evaluate Alterations in Molecular Biomarkers in HER2 Neu Positive Metastatic Breast Cancer Together With Assessment of Trastuzumab Use Beyond Progression After Initial Response to Trastuzumab-taxane Based Treatment|Completed||Phase 2|33|Actual|Hoffmann-La Roche|The study was prematurely terminated on December 31, 2012. The end of study follow-up was February 18, 2013.|1|||f||||||||||||||2017-10-11 09:48:35.708288|2017-10-11 09:48:35.708288
NCT00886470|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-22|2016-12-05||2016-12-05|June 2009||2009-06-01|December 2016|2016-12-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns|Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns|Terminated||Phase 1/Phase 2|16|Actual|Noveome Biotherapeutics, formerly Stemnion||3||This study was terminated early due to slow accrual of patients.|f||||t||||||||||2017-10-11 09:48:45.915295|2017-10-11 09:48:45.915295
NCT00886496|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-21|2012-06-19|||November 2006||2006-11-01|August 2007|2007-08-01|April 2011|Actual|2011-04-01|||||Interventional|||Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia|A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia|Withdrawn||Phase 1|0|Actual|Enzon Pharmaceuticals, Inc.||||No participants enrolled. IND withdrawn.|||||||||||||||2017-10-11 09:48:46.439544|2017-10-11 09:48:46.439544
NCT00887315|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-22|2013-11-13|2013-06-24||April 2009||2009-04-01|November 2013|2013-11-01|June 2011|Actual|2011-06-01|March 2011|Actual|2011-03-01||Interventional|SMART||The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Trial of Docetaxel, Cisplatin, and Hypofractionated Radiotherapy Versus Docetaxel and Cisplatin for Limited Volume Stage IV Non-small Cell Lung Cancer: The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial|Terminated||Phase 2|11|Actual|University of Chicago|Funding was withdrawn before conclusions were reached so the study was terminated and no data was collected and analyzed.|2||Slow accrual and loss of sponsor|f||||t||||||||||2017-10-11 09:49:11.376303|2017-10-11 09:49:11.376303
NCT00878501|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-08|2012-05-28|2011-01-27||March 2009||2009-03-01|May 2012|2012-05-01|July 2009|Actual|2009-07-01|July 2009|Actual|2009-07-01||Interventional|OA19||Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee|A Phase II Randomised, Double-blind, Parallel Group, 4-week Treatment, Adaptive Dose Finding, Multi-centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the Knee|Terminated||Phase 2|241|Actual|AstraZeneca||3||The study was terminated after the planned interim analysis.|f||||f||||||||||2017-10-11 09:49:12.536038|2017-10-11 09:49:12.536038
NCT00878605|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-07|2015-01-26|2014-12-17||April 2010||2010-04-01|January 2015|2015-01-01|September 2013|Actual|2013-09-01|June 2013|Actual|2013-06-01||Interventional|||Development of A Novel Anti-Hyperglycemic Agent|Development of A Novel Anti-Hyperglycemic Agent|Terminated||Phase 2|38|Actual|VA Office of Research and Development|This subject was terminated early and data was not analyzed due to inability to recruit and therefore small numbers of subjects to analyze leading to uninterpretable data.|4||Unable to reach accrual target.|f||||t||||||||||2017-10-11 09:49:14.653757|2017-10-11 09:49:14.653757
NCT00879619|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-08|2016-12-06|2013-04-19||July 2009||2009-07-01|April 2013|2013-04-01|November 2011|Actual|2011-11-01|October 2011|Actual|2011-10-01||Interventional|||Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients|A Pilot Phase I/II Study to Evaluate the Effects of Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients With Biochemical Relapse|Terminated||Phase 1/Phase 2|4|Actual|University of California, Irvine|The study was terminated due to slow accrual. Zero subjects were analyzed.|1||Terminated due to slow accrual.|f||||t||||||||||2017-10-11 09:49:31.950813|2017-10-11 09:49:31.950813
NCT00880009|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-08|2012-10-04|2012-10-04|2012-03-29|July 2009||2009-07-01|October 2012|2012-10-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer|A Phase 2, Randomized, Open-Label Study Of Bosutinib Administered In Combination With Letrozole Versus Letrozole Alone As First Line Therapy In Post-Menopausal Women With Locally Advanced Or Metastatic ER+/PgR+/ErbB2- Breast Cancer|Terminated||Phase 2|16|Actual|Pfizer|Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 09:49:42.999411|2017-10-11 09:49:42.999411
NCT00880399|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-09|2017-08-09|2017-04-20|2012-02-23|March 1, 2009||2009-03-01|April 2017|2017-04-01|June 16, 2010|Actual|2010-06-16|June 1, 2010|Actual|2010-06-01||Interventional|orvepitant MDD||A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|Terminated||Phase 2|328|Actual|GlaxoSmithKline|The study was terminated early upon recommendation of IDMC that was reviewing data from this trial and two other ongoing trials with same drug. When the trial was terminated 331 participants were randomized, compared to a target of 348 participants.|3||To allow assessment of isolated events of seizure during program|f||||t||||||||||2017-10-11 09:49:53.719805|2017-10-11 09:49:53.719805
NCT00881023|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-10|2016-08-01||2016-02-25|July 2010||2010-07-01|August 2016|2016-08-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional|CAIS||Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration|A Multicenter, Randomized, Pivotal Study to Evaluate the Safety and Efficacy of the Cartilage Autograft Implantation System (CAIS) for the Surgical Treatment of Articular Cartilage Lesions of the Knee|Terminated||N/A|75|Actual|DePuy Mitek||3||Study was terminated because of very low enrollment rate.|f||||f||||||||No|These data will not be used in support of an FDA submission, and the product will not be commercialized. As such, there is no plan to share the IPD.|2017-10-11 09:50:07.193518|2017-10-11 09:50:07.193518
NCT00881205|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-14|2012-03-08|2012-01-20||April 2009||2009-04-01|March 2012|2012-03-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Interventional|EXCITING||Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment|A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase|Terminated||Phase 4|86|Actual|Novartis|This study was terminated early due to low recruitment numbers. This study did not have the anticipated 80% power.|2||Termination of study due to low enrollment|f||||||||||||||2017-10-11 09:50:08.452802|2017-10-11 09:50:08.452802
NCT00881608|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-14|2014-08-08|2014-06-26||February 2009||2009-02-01|August 2014|2014-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional||Study prematurely terminated, no data available|Study to Evaluate Menses Induction in Women Administered Proellex|An Open-Label, Escalating Dose, Single Center, Cross-over Design, Phase I Study to Evaluate Menses Induction in Women Administered Proellex|Terminated||Phase 1|11|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|5||Repros stopped study for safety and the FDA put the study on hold for safety.|f||||f||||||||||2017-10-11 09:50:17.160561|2017-10-11 09:50:17.160561
NCT00887445|ClinicalTrials.gov processed this data on October 10, 2017|2009-01-30|2010-04-27|||July 2008||2008-07-01|April 2010|2010-04-01|May 2009|Actual|2009-05-01|May 2009|Actual|2009-05-01||Interventional|||First in Man Study With SLV341|A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV341 in Young Healthy Male Subjects|Terminated||Phase 1|87|Actual|Solvay Pharmaceuticals||2||The study was terminated on June 25th, 2009 due to strategic decision|f||||f||||||||||2017-10-11 09:50:26.088446|2017-10-11 09:50:26.088446
NCT00887497|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-22|2011-09-26|||April 2009||2009-04-01|September 2011|2011-09-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|||Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery|Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery|Terminated||Phase 4|10|Anticipated|University of California, Irvine||1||terminated due to failure to enroll patients after two years of approval|f||||t||||||||||2017-10-11 09:50:27.867005|2017-10-11 09:50:27.867005
NCT00889421|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-24|2014-06-06|2014-06-06||November 2009||2009-11-01|June 2014|2014-06-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional||patients with refractory uveitis|Apremilast in the Treatment of Uveitis|An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.|Terminated||Phase 1/Phase 2|3|Actual|Oregon Health and Science University|Study was terminated prematurely due to inefficacy in the three initial patients enrolled. Endpoints were not analyzed as participants did not make it to the 6 month time frame before discontinuing the study.|1||Investigator discretion due to lack of efficacy in three subjects enrolled|f||||||||||||||2017-10-11 09:50:46.112534|2017-10-11 09:50:46.112534
NCT00889720|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-28|2011-10-12|2011-07-27||November 2009||2009-11-01|July 2011|2011-07-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|||A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery|A Multicenter, Open Label Study To Investigate The Feasibility And Efficacy Of A Smoking Cessation Program With Varenicline In Patients Undergoing Elective Surgery|Completed||Phase 4|16|Actual|Pfizer|This study was terminated after 16 of 100 planned subjects were enrolled due to slow recruitment and non-compliance with the protocol; only selected efficacy listings of the surgical population and key safety data were reported.|1|||f||||f||||||||||2017-10-11 09:50:50.580787|2017-10-11 09:50:50.580787
NCT00879112|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-08|2011-08-10|||April 2009||2009-04-01|August 2011|2011-08-01|December 2009|Anticipated|2009-12-01|December 2009|Anticipated|2009-12-01||Interventional|||Study of MB07811 in Subjects With Hypercholesterolemia|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of MB07811 for 12 Weeks Followed by a 6-Week Off Drug Phase in Subjects With Primary Hypercholesterolemia|Withdrawn||Phase 2|80|Anticipated|Ligand Pharmaceuticals||4||Study terminated prior to initiation|f||||f||||||||||2017-10-11 09:51:14.576607|2017-10-11 09:51:14.576607
NCT00879229|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-08|2014-05-05|2013-08-09||July 2009||2009-07-01|May 2014|2014-05-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|ARTEMIS-PH|Full Analysis Set: participants who were randomized and received at least one dose of study drug|ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension|Terminated||Phase 3|40|Actual|Gilead Sciences|Study GS-US-300-0128 was terminated early with enrollment of 40 of 225 planned subjects.|2|||f||||t||||||||||2017-10-11 09:51:15.641019|2017-10-11 09:51:15.641019
NCT00891033|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-28|2015-02-20|||April 2009||2009-04-01|February 2015|2015-02-01|August 2013|Actual|2013-08-01|August 2013|Actual|2013-08-01||Interventional|||Panobinostat/Velcade in Multiple Myeloma|Phase I Exploratory Study of Panobinostat IV in Combination With Bortezomib in Relapsed/Refractory Multiple Myeloma Patients|Terminated||Phase 1|12|Actual|University of Arkansas||4||This study was terminated because the drug company stopped making the study drug|f||||t||||||||||2017-10-11 09:51:20.793273|2017-10-11 09:51:20.793273
NCT00891293|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-30|2011-01-22|2009-05-06||March 2006||2006-03-01|November 2010|2010-11-01|May 2008|Actual|2008-05-01|May 2008|Actual|2008-05-01||Interventional|||A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™|A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™|Completed||Phase 4|93|Actual|GlaxoSmithKline|LOV111821/OM5XX was terminated due to the lack of substantial incremental change in the primary endpoint lipid values above that reached in either the original study (LOV111859/OM5) or the first extension study (LOV111860/OM5X).|1|||f||||f||||||||||2017-10-11 09:51:27.000154|2017-10-11 09:51:27.000154
NCT00891774|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-30|2011-10-04|2011-04-15||December 2008||2008-12-01|October 2011|2011-10-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|||Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI|An Open-label, Multi-Center, Prospective, Post Market Study to Assess the Safety and Effectiveness of EVOLENCE® in Facial Augmentation of Subjects With Fitzpatrick Skin Color Types IV, V, and VI|Completed||Phase 4|172|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|This was not a controlled trial and the company made a business decision to discontinue marketing the product in the US, so the program has been terminated. No analysis will be performed on Secondary Outcome Measures.|1|||f||||f||||||||||2017-10-11 09:51:33.848712|2017-10-11 09:51:33.848712
NCT00891904|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-30|2016-03-14|2014-01-29||April 2009||2009-04-01|March 2016|2016-03-01||||July 2011|Actual|2011-07-01||Interventional||All treated and eligible patients|Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer|A Feasibility Study of Re-irradiation Using Stereotactic Body Radiation Therapy (SBRT) and Cetuximab for Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Terminated||N/A|2|Actual|Roswell Park Cancer Institute|Trial terminated early. Too few patients to analyze.|1||Low accrual|f||||t||||||||||2017-10-11 09:51:36.402179|2017-10-11 09:51:36.402179
NCT00893048|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-01|2017-07-21|||January 15, 2010|Actual|2010-01-15|July 2017|2017-07-01|August 31, 2010|Actual|2010-08-31|August 31, 2010|Actual|2010-08-31||Interventional|||The Use of Oral Steroids in the Treatment of Cellulitis|Utility of Prednisone in the Treatment of Cellulitis|Withdrawn||Phase 2|0|Actual|Milton S. Hershey Medical Center||2||Study never enrolled any subjects before auto-terminated by the internal IRB.|f||||f||||||||||2017-10-11 09:52:00.91823|2017-10-11 09:52:00.91823
NCT00900666|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-12|2013-05-02|2013-05-02||January 2009||2009-01-01|May 2013|2013-05-01|December 2011|Actual|2011-12-01|June 2011|Actual|2011-06-01||Interventional|||Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury|Randomized Controlled Trial on the Effects of Botulinum Toxin Injections in the Rectus Femoris on Gait Function in Stiff Knee Gait Following Acquired Brain Injury|Terminated||N/A|19|Actual|Mary Free Bed Rehabilitation Hospital|Early termination due to difficulty identifying and recruiting participants.|2||Original subject recruitment goal was unrealistic. Study was terminated at N=19.|f||||f||||||||||2017-10-11 09:53:46.239863|2017-10-11 09:53:46.239863
NCT00901290|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-12|2010-12-08|||May 2009||2009-05-01|October 2009|2009-10-01|September 2009|Anticipated|2009-09-01|September 2009|Anticipated|2009-09-01||Interventional|||Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects|A Randomized, Open-Label, Two-way Crossover Study to Determine the Effects of Co-administration of AZD7325 and a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects|Suspended||Phase 1|56|Anticipated|AstraZeneca||2||suspended pending data analysis|f||||f||||||||||2017-10-11 09:53:54.137189|2017-10-11 09:53:54.137189
NCT00901537|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-12|2014-06-02|||February 2009||2009-02-01|June 2014|2014-06-01|October 2011|Actual|2011-10-01|September 2011|Actual|2011-09-01||Interventional|||Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer|Phase I Study of Azacitidine in Combination With Cisplatin in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1|24|Anticipated|Loma Linda University||1||Sponsor terminated due to no enrollments within last 4 months.|f||||f||||||||||2017-10-11 09:53:56.605785|2017-10-11 09:53:56.605785
NCT00895245|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-07|2017-04-13|2017-01-09||February 2009||2009-02-01|April 2017|2017-04-01|February 2011|Actual|2011-02-01|September 2010|Actual|2010-09-01||Interventional|||Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy|A Phase II Clinical Trial Investigating the Efficacy of Single-Dose Fosaprepitant for the Prevention of Cisplatin-Induced Nausea and Vomiting (CINV) in Patients With Head & Neck Cancer Undergoing Concurrent Chemotherapy and Radiation|Terminated||Phase 2|6|Actual|University of Washington|This study was terminated early due to lack of efficacy.|1||Study stopped due to lack of efficacy in first 6 patients|f||||f||||||||No||2017-10-11 09:54:16.313883|2017-10-11 09:54:16.313883
NCT00895284|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-06|2013-05-09|2013-05-09||March 2007||2007-03-01|May 2013|2013-05-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||A Trial on Laparoscopic Hysterectomy Versus Robotic Hysterectomy|Laparoscopic Hysterectomy With and Without Robotic Assistance: a Randomized Prospective Trial|Terminated||Phase 4|3|Actual|Mayo Clinic|The study was terminated due to lack of funding.|2||Lack of funding|f||||f||||||||||2017-10-11 09:54:16.795055|2017-10-11 09:54:16.795055
NCT00895895|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-07|2012-12-21|2012-12-21||May 2009||2009-05-01|December 2012|2012-12-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Interventional|||Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease|A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease|Terminated||Phase 2|526|Actual|Pfizer|Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.|5||See termination reason in detailed description.|f||||t||||||||||2017-10-11 09:54:27.569161|2017-10-11 09:54:27.569161
NCT00903006|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-13|2015-01-21|2014-06-27||November 2009||2009-11-01|June 2014|2014-06-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional|||Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer|A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer|Terminated||Phase 1/Phase 2|11|Actual|M.D. Anderson Cancer Center|Study terminated early due to small sample size.|4||Low Accrual|f||||t||||||||||2017-10-11 09:54:48.447921|2017-10-11 09:54:48.447921
NCT00903838|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-14|2011-08-25|||September 2009||2009-09-01|August 2011|2011-08-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Interventional|||A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.|A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.|Terminated||Phase 2|37|Actual|Abbott||2||The study was terminated on 31 May, 2011, due to strategic considerations.|f||||f||||||||||2017-10-11 09:55:06.879697|2017-10-11 09:55:06.879697
NCT00903942|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-15|2015-04-24|||March 2008||2008-03-01|April 2015|2015-04-01||||March 2012|Anticipated|2012-03-01||Interventional|||Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)|A Modified Two Stage Phase II Study of Combination Abraxane and Radiation for Stage III Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|University of Rochester||1||funding was withdrawn from Drug company|f||||f||||||||||2017-10-11 09:55:07.848104|2017-10-11 09:55:07.848104
NCT00904397|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-15|2010-02-12|||July 2004||2004-07-01|February 2010|2010-02-01||||November 2004|Actual|2004-11-01||Interventional|||Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain|A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% With Celecoxib 200 mg in Patients With Chronic Axial Low Back Pain|Terminated||Phase 4|98|Actual|Endo Pharmaceuticals||2||Rofecoxib was withdrawn from the market due to safety concerns.|f||||||||||||||2017-10-11 09:55:16.314343|2017-10-11 09:55:16.314343
NCT00905294|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-19|2013-06-17|||August 2009||2009-08-01|June 2013|2013-06-01|August 2010|Actual|2010-08-01|August 2010|Actual|2010-08-01||Observational|ADVANCE-PCI||Study of ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Coronary Artery Disease|ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Patients Undergoing Percutaneous Coronary Intervention|Terminated||N/A|11|Actual|University College Cork|||1|Funding withdrawn|f||||f||||||Samples Without DNA|"     serum, plasma   "|||2017-10-11 09:55:31.625331|2017-10-11 09:55:31.625331
NCT00905398|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-15|2015-07-07|||May 2009||2009-05-01|July 2015|2015-07-01|July 2015|Anticipated|2015-07-01|June 2012|Actual|2012-06-01||Interventional|ALLPhi||Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|Estudo da eficácia do Nilotinibe Concomitante à Quimioterapia no Tratamento de Pacientes Com Leucemia linfoblástica Aguda Filadélfia Positiva recém-diagnosticada|Terminated||Phase 1/Phase 2|8|Actual|Universidade Federal do Rio de Janeiro||1||The study was terminated due to excessive toxicity and low compliance to the protocol scheme.|f||||t||||||||||2017-10-11 09:55:35.332174|2017-10-11 09:55:35.332174
NCT00905437|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-19|2013-04-25|2013-04-25||November 2009||2009-11-01|April 2013|2013-04-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional|||Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients Undergoing Total Hip Replacement|Randomized Double-Blind, Multi-Center Study Of Efficacy And Tolerability Of Pregabalin Versus Placebo As An Adjunct To Standard Of Care For Perioperative Management Of Patients Undergoing Total Hip Arthroplasty|Terminated||Phase 3|72|Actual|Pfizer|As the enrollment rate was very low, the study was prematurely terminated. The number of enrolled participants was too low for meaningful formal statistical conclusions.|2||"The Study was terminated on May 24th 2012 due to a slow recruitment rate. The study was not   terminated for reasons of safety or efficacy."|f||||f||||||||||2017-10-11 09:55:36.443327|2017-10-11 09:55:36.443327
NCT00908310|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-13|2014-07-16|2014-06-17||May 2009||2009-05-01|July 2014|2014-07-01|September 2013|Actual|2013-09-01|June 2013|Actual|2013-06-01||Interventional||The 202 subjects that received contrast media were evaluated for safety.|Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)|A Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive OMNISCAN (Gadodiamide Injection) for Contrast-enhanced Magnetic Resonance Imaging.|Completed||Phase 4|213|Actual|GE Healthcare|As a result of the FDA reference ID: #2954949, subject enrolment was terminated at 213 subjects. All subjects (202 subjects) who received any dose of Omniscan were followed as per protocol until study completion, withdrawal, or lost-to-follow-up.|1|||f||||t||||||||||2017-10-11 09:56:03.617845|2017-10-11 09:56:03.617845
NCT00909584|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-26|2013-11-20|||April 2009||2009-04-01|November 2013|2013-11-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional|||Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia|Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Severe Chronic Neutropenia|Terminated||Phase 2|9|Actual|Telik||2||Study TLK199.2103 was terminated for business reasons.|f||||f||||||||||2017-10-11 09:56:26.162251|2017-10-11 09:56:26.162251
NCT00910000|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-26|2017-06-19|2016-03-29||June 2009||2009-06-01|June 2017|2017-06-01|October 2015|Actual|2015-10-01|January 2013|Actual|2013-01-01||Interventional|||Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer|Phase Ib/II Study of Combination of Vorinostat, Carboplatin and Gemcitabine + Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer|Terminated||Phase 1/Phase 2|15|Actual|Dana-Farber Cancer Institute|The study was terminated early for toxicities and the emergence of better tolerated and more promising biologic agents added to platinum-based chemotherapy and/or use as maintenance.|6||Terminated due to unacceptable toxicity|f||||t||||||||No||2017-10-11 09:56:43.717727|2017-10-11 09:56:43.717727
NCT00910299|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-28|2012-05-08|2012-04-10||July 2009||2009-07-01|April 2012|2012-04-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional|TRIGGER-PCI||Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)|Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent|Terminated||Phase 2|423|Actual|Eli Lilly and Company|The study was terminated early, and no formal statistical time-to-event analysis was performed.|2||Due to the low rate of primary endpoint events experienced in the study to date|f||||t||||||||||2017-10-11 09:56:50.441351|2017-10-11 09:56:50.441351
NCT00910416|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-27|2016-09-22|||May 2009||2009-05-01|September 2016|2016-09-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Observational|||The Comparability of Bispectral Index and Neurosense During Anesthesia|The Comparability of Bispectral Index and Neurosense During Total Intravenous Anesthesia and Balanced Anesthesia|Terminated||N/A|40|Actual|Hopital Foch|||2|Differences between BIS and Neurosense are important. This study can be terminated.|f||||f||||||||||2017-10-11 09:56:52.444976|2017-10-11 09:56:52.444976
NCT00911326|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-28|2014-08-06|2014-07-08||May 2009||2009-05-01|August 2014|2014-08-01|August 2013|Actual|2013-08-01|August 2013|Actual|2013-08-01||Interventional||Of the 101 participants who enrolled in the trial, 85 were administered the study agent, Lymphoseek, and therefore this participant number is used for the baseline analysis.|Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma|A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma|Terminated||Phase 3|101|Actual|Navidea Biopharmaceuticals|The study was prospectively structured to include an interim analysis at 33.3% enrollment. The trial was terminated early based on an interim review by the Data and Safety Monitoring Committee for positive efficacy outcome and lack of safety concern.|1||"The trial was terminated early based on an interim review by the Data and Safety Monitoring   Committee for positive efficacy outcome and no safety concerns."|f||||t||||||||||2017-10-11 09:57:15.269853|2017-10-11 09:57:15.269853
NCT00912444|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-01|2016-11-19|||July 2009||2009-07-01|November 2016|2016-11-01|October 2015|Actual|2015-10-01|May 2012|Actual|2012-05-01||Interventional|NATT||Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer|A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer|Terminated||Phase 3|102|Actual|Shanghai Jiao Tong University School of Medicine||2||"TAC treatment was associated with better survial outcome compared with TC treatment, we   terminated recruiting and waiting for longer follow up period."|f||||t||||||||||2017-10-11 09:57:35.393134|2017-10-11 09:57:35.393134
NCT00906204|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-19|2015-11-02|2015-09-11||March 2010||2010-03-01|November 2015|2015-11-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|STAT|Patients who received a kidney transplant along with the study intervention, either single-dose or divided-dose rabbit anti-thymocyte globulin.|Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation|Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Trial to Assess Safety of Single Dose vs. Traditional Administration of Thymoglobulin Induction for Renal Transplantation|Completed||Phase 2|99|Actual|Wright State University|After an interim analysis at the trial mid-point, the trial was terminated because a futility trend analysis showed a >1.72% chance of the primary endpoint rates between the two groups achieving a significant difference with further enrollment.|2|||f||||t||||||||||2017-10-11 09:57:51.118236|2017-10-11 09:57:51.118236
NCT00906243|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-14|2012-03-29|2012-02-29||May 2009||2009-05-01|February 2012|2012-02-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||RNActive®-Derived Therapeutic Vaccine|Phase I/IIa Study of RNActive®-Derived Therapeutic Vaccine in Advanced or Metastatic Hormone Refractory Prostate Cancer|Terminated||Phase 1/Phase 2|6|Actual|University of Florida|This study was terminated early by decision of the Sponsor after 6 subjects had been enrolled in the Phase I part of the study. No efficacy evaluations were planned during the Phase I part of the study.|1||Study Closed after completion of Phase I|f||||f||||||||||2017-10-11 09:57:51.936305|2017-10-11 09:57:51.936305
NCT00907179|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-20|2015-07-20|||July 2009||2009-07-01|July 2015|2015-07-01|July 2015|Actual|2015-07-01|July 2015|Actual|2015-07-01||Interventional|||Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer|Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1|12|Actual|University of Pittsburgh||1||Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..|f||||t||||||||||2017-10-11 09:58:11.958598|2017-10-11 09:58:11.958598
NCT00907218|ClinicalTrials.gov processed this data on October 10, 2017|2009-05-20|2013-07-31|2013-05-09||April 2009||2009-04-01|July 2013|2013-07-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)|An Open Pilot Study of Varenicline (Chantix) in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD): Effects on ADHD and Cigarette Smoking|Terminated||Phase 4|2|Actual|Massachusetts General Hospital|Extremely slow enrollment so the study was terminated early.|1||extremely slow enrollment|f||||f||||||||||2017-10-11 09:58:12.22337|2017-10-11 09:58:12.22337
NCT00913003|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-02|2015-02-02|2015-01-21||May 2009||2009-05-01|February 2015|2015-02-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|||Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery|Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery|Terminated||Phase 4|22|Actual|Northwestern University|This study was terminated early because the PI left the institution.|2||PI terminated employment with the University|f||||f||||||||||2017-10-11 09:58:21.172482|2017-10-11 09:58:21.172482
NCT00915278|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-03|2014-02-25|2014-02-25||September 2009||2009-09-01|February 2014|2014-02-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional||The analyzed population is the total number of enrolled subjects who started treatment.|A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors|A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors|Terminated||Phase 1|33|Actual|Pfizer|This study was terminated prematurely because PK data did not enable sufficient confidence in producing desired clinical benefit. Potential re-occurrence of cytokine mediated infusion reaction at higher doses did not support further development.|1||"The study was terminated on 26 February 2013. Risk-benefit assessment is no longer positive and   does not support further development"|f||||f||||||||||2017-10-11 09:58:22.82161|2017-10-11 09:58:22.82161
NCT00916617|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-04|2017-04-27|2013-09-25||June 2009||2009-06-01|April 2017|2017-04-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Interventional||All participants who received at least 1 dose of study medication in study NCT00916617 were included in the safety population.|Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab|A Multicenter, Open Label, Multiple Dose, Parallel Group Investigation Of The Long-term Safety, Tolerability, Reactogenicity, Pharmacokinetics And Pharmacodynamics Of Aab-001 Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer's Disease|Terminated||Phase 2|62|Actual|Pfizer||1||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2017-10-11 09:59:04.770732|2017-10-11 09:59:04.770732
NCT00913692|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-03|2012-05-03|2012-02-29||June 2009||2009-06-01|May 2012|2012-05-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis|A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis|Terminated||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)|The protocol was terminated early due to slow recruitment.|1||Terminated due to slow recruitment.|f||||t||||||||||2017-10-11 10:00:16.022561|2017-10-11 10:00:16.022561
NCT00914433|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-02|2012-11-30|||April 2009||2009-04-01|November 2012|2012-11-01|April 2010|Actual|2010-04-01|December 2009|Actual|2009-12-01||Interventional|||Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers|A Phase 1,Randomized, Double--blind, Placebo-controlled Study Assessing the Safety and Tolerability, the Pharmacodynamics and Pharmacokinetics of Single-ascending and Repeated Doses of Inhaled TPI 1100 in Healthy Subjects|Withdrawn||Phase 1|0|Actual|Pharmaxis||1||Drug development suspended|f||||t||||||||||2017-10-11 10:00:24.792694|2017-10-11 10:00:24.792694
NCT00923117|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-17|2015-09-29|2013-05-03||June 2008||2008-06-01|July 2014|2014-07-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Sunitinib to Treat Recurrent Brain Cancer|A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas|Terminated||Phase 2|87|Actual|National Institutes of Health Clinical Center (CC)|The study was terminated based on results of an interim analysis for futility.|2||The study was terminated based on results of an interim analysis for futility.|f||||t||||||||||2017-10-11 10:00:42.942527|2017-10-11 10:00:42.942527
NCT00923806|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-17|2015-10-18|||December 2008||2008-12-01|October 2015|2015-10-01|November 2011|Actual|2011-11-01|November 2011|Actual|2011-11-01||Interventional|||Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer|Phase I/II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes|Terminated||Phase 1|3|Actual|National Institutes of Health Clinical Center (CC)||1||Study was terminated due to poor accrual.|f||||t||||||||||2017-10-11 10:00:50.381702|2017-10-11 10:00:50.381702
NCT00923949|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-17|2015-09-29|2012-01-11||August 2008||2008-08-01|February 2012|2012-02-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer|Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer|Terminated||Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)|Study never published; terminated early due to low accrual.|1||Study never published; terminated early due to low accrual.|f||||f||||||||||2017-10-11 10:00:54.197418|2017-10-11 10:00:54.197418
NCT00924209|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-17|2012-08-21|2012-07-19||March 2009||2009-03-01|August 2012|2012-08-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional|||A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer|Phase II Study of Neoadjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2), Non-Squamous Cell Non-Small Cell Lung Cancer|Terminated||Phase 2|7|Actual|National Institutes of Health Clinical Center (CC)|No primary or secondary goals were met because of low accrual for which the study was closed.|1||Study was terminated due to poor accrual.|f||||f||||||||||2017-10-11 10:01:01.822007|2017-10-11 10:01:01.822007
NCT00924287|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-17|2015-10-06|2012-01-05||November 2008||2008-11-01|October 2015|2015-10-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer|Phase I/II Study of Metastatic Cancer That Expresses Her-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-Her-2 Gene Engineered Lymphocytes|Terminated||Phase 1/Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)|This study was terminated after the first patient on study died as a result of the treatment.|1||"This study was terminated after the first patient treated on study died as a result of the   treatment."|f||||t||||||||||2017-10-11 10:01:02.537516|2017-10-11 10:01:02.537516
NCT00924508|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-17|2013-12-30|2013-09-18||July 2008||2008-07-01|December 2013|2013-12-01|July 2012|Actual|2012-07-01|September 2011|Actual|2011-09-01||Interventional|||Hydrogel Patch for the Treatment of Eczema|A Study to Compare the Efficacy of Triamcinolone 0.1% Cream Occluded With Hydrogel Patch to Triamcinolone 0.1% Cream Without Occlusion in the Treatment of Eczema|Terminated||N/A|23|Actual|University of California, San Francisco|Due to loss of funding, enrollment was terminated prior to intended accrual of 30 participants.|1||Loss of Funding|f||||f||||||||||2017-10-11 10:01:07.240798|2017-10-11 10:01:07.240798
terminated by the sponsor. All randomized participants received at least one dose of study medication. Data presented are for Cohort 1 and Cohort 2, where applicable."|6|||f||||f||||||||||2017-10-11 10:01:12.638827|2017-10-11 10:01:12.638827
NCT00925548|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-17|2014-07-23|2014-06-24||September 2009||2009-09-01|July 2014|2014-07-01|August 2010|Actual|2010-08-01|August 2010|Actual|2010-08-01||Interventional|STRIDE|Safety population included all participants who received at least one dose of any study treatment (L-BLP25, placebo, cyclophosphamide, saline, or any of the three hormonal therapies).|STRIDE - STimulating Immune Response In aDvanced brEast Cancer|A Randomized, Double-blind, Controlled Phase III Study of Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Post-menopausal Women With Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer|Terminated||Phase 3|16|Actual|EMD Serono|Efficacy data were not analyzed as the trial was prematurely terminated following the clinical hold on the investigational new drug application for tecemotide (L-BLP25)|2||See termination reason in the below Purpose statement|f||||t||||||||||2017-10-11 10:01:24.034027|2017-10-11 10:01:24.034027
NCT00925769|ClinicalTrials.gov processed this data on October 10, 2017|2009-04-15|2015-07-13|2015-07-13||January 2009||2009-01-01|July 2015|2015-07-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional||Per-protocol population: All participants who received at least 1 evaluation period of 3 cycles of the complete study regimen (of all 3 drugs) at the recommended dose unless withdrawn from therapy earlier because of toxicity.|ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer|An Open Label Study to Evaluate the Safety and Effect on Disease Progression of Triple Combination Treatment With Erlotinib (Tarceva), Bevacizumab (Avastin), and Capecitabine (Xeloda) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer (REBECA-Trial).|Completed||Phase 1|32|Actual|Hoffmann-La Roche|Planned Part 2 of the study was not implemented and outcome measures related to Part 2 were not analyzed.|1|||f||||||||||||||2017-10-11 10:01:30.427264|2017-10-11 10:01:30.427264
NCT00926263|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-21|2013-03-27|2013-01-18||July 2009||2009-07-01|March 2013|2013-03-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|||A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects|A Phase 1, Open Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, And Effect On QT/QTc Interval For CP-751,871 Following Single Intravenous Administration To Healthy Adult Subjects|Terminated||Phase 1|28|Actual|Pfizer|This study was terminated prior to enrollment of participants into Cohort 3 (2 doses of 20 mg/kg on consecutive days). Therefore, endpoints relating to that cohort were not assessed.|3||See termination reason in detailed description.|f||||f||||||||||2017-10-11 10:01:38.391842|2017-10-11 10:01:38.391842
NCT00918125|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-10|2015-10-15|2013-01-22||November 2010||2010-11-01|April 2013|2013-04-01|April 2012|Actual|2012-04-01|April 2012|Actual|2012-04-01||Observational|VIVID-01||Educational Videos to Improve Patient Decision Making and Race Disparities in Implantable Cardioverter Defibrillator Use|The Use of Educational Videos to Improve Patient Decision Making and Racial Disparities in the Implantation of Implantable Cardioverter Defibrillators (ICDs)|Completed||N/A|59|Actual|Duke University|Study terminated early and thus only 59 out of the proposed 90 patients were enrolled.||3||f||||f||||||||||2017-10-11 10:01:41.510224|2017-10-11 10:01:41.510224
NCT00919126|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-11|2014-09-15|2014-06-04||June 2009||2009-06-01|September 2014|2014-09-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional||The analysis was done in the Intention To Treat (ITT) Data Set (Randomised Patients).|General Anesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia.|An International Phase III Randomised Trial Comparing the Propofol Consumption During General Anaesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia Alone in ASA III Patients With Increased Risk of Perioperative Cardiac Complications.|Terminated||Phase 3|102|Actual|Air Liquide SA|The study has been terminated earlier due to difficulties to find patients meeting the inclusion criteria.|3||Enrollment rate|f||||f||||||||||2017-10-11 10:02:02.184498|2017-10-11 10:02:02.184498
NCT00926575|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-19|2013-10-10|2013-07-12||October 2009||2009-10-01|August 2013|2013-08-01|May 2012|Actual|2012-05-01|December 2011|Actual|2011-12-01||Interventional|SUPPORTS|DSMB terminated study for futility; no safety concerns during analysis of patient population. Overall, 1 SAE considered possibly related to study drug, all others were not related to study drug.|Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD|Terminated||Phase 3|140|Actual|Soligenix|DSMB terminated study for futility; no safety concerns during analysis of patient population. Overall, 1 SAE considered possibly related to study drug, all others were not related to study drug.|2||An independent Data Safety Monitoring Board recommended the study be stopped due to futility|f||||t||||||||||2017-10-11 10:02:30.14332|2017-10-11 10:02:30.14332
NCT00928200|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-24|2010-08-18|||May 2009||2009-05-01|August 2010|2010-08-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)|Intravenous Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia and Allergy to E. Coli Asparaginase (IND 104224)|Terminated||Phase 1|30|Anticipated|Therapeutic Advances in Childhood Leukemia Consortium||1||Study was terminated due to lack of accrual.|f||||t||||||||||2017-10-11 10:03:05.500087|2017-10-11 10:03:05.500087
NCT00928642|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-25|2014-10-20|2013-04-05||June 2009||2009-06-01|October 2014|2014-10-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer|A Phase II Trial of Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer Who Have Failed at Least Two Prior Therapies|Completed||Phase 2|8|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine|This study was terminated due to a combination of poor accrual and lack of evidence of benefit.|1|||f||||f||||||||||2017-10-11 10:03:17.034001|2017-10-11 10:03:17.034001
NCT00929370|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-25|2009-06-25|||July 2008||2008-07-01|June 2009|2009-06-01|March 2009|Actual|2009-03-01|October 2008|Actual|2008-10-01||Interventional|GT1110791||A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.|A 4-Part Parallel Group, Randomized, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Repeat Doses of GSK1018921 in Healthy Volunteers and Stable Patients With Schizophrenia and to Evaluate Its Effects on Pharmacokinetics of Midazolam.|Terminated||Phase 1|34|Actual|GlaxoSmithKline||1||"Study has now been terminated due to changes in project strategy. Current available data will   be analysed and reported in a synoptic study report."|f||||||||||||||2017-10-11 10:03:34.979599|2017-10-11 10:03:34.979599
NCT00932152|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-01|2016-07-19|2016-01-14||September 2010||2010-09-01|July 2016|2016-07-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional|||Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer|A Phase II Randomized Trial of Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer Who Have Received First-line Platinum-based Chemotherapy With or Without Bevacizumab|Terminated||Phase 2|3|Actual|University of Pittsburgh||4||Poor enrollment/suspended to accrual; will close per AstraZeneca request|f||||t||||||||||2017-10-11 10:03:52.009936|2017-10-11 10:03:52.009936
NCT00932464|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-01|2012-05-10|||August 2012||2012-08-01|May 2012|2012-05-01|August 2012|Anticipated|2012-08-01|August 2012|Anticipated|2012-08-01||Interventional|||Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib|An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study To Determine The Effect Of A High-Fat Meal On The Relative Bioavailability And Pharmacokinetics Of A Single Dose Of The 240 mg Formulation Of Neratinib In Healthy Subjects|Withdrawn||Phase 1|0|Actual|Puma Biotechnology, Inc.||2||Study withdrawn as it no longer is deemed necessary per project status.|f||||f||||||||||2017-10-11 10:04:04.461229|2017-10-11 10:04:04.461229
NCT00932841|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-02|2012-03-16|||January 2008||2008-01-01|March 2012|2012-03-01|August 2011|Actual|2011-08-01|August 2011|Actual|2011-08-01||Interventional|VSL#3||The Use of VSL#3 in Irritable Bowel Syndrome in Children|The Use of VSL#3 in Irritable Bowel Syndrome in Children|Terminated||Phase 1|15|Actual|Dayton Children's Hospital||3||PI has re-located. PI terminated FDA IND # and closed study.|f||||t||||||||||2017-10-11 10:04:08.514491|2017-10-11 10:04:08.514491
NCT00934297|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-06|2011-07-27|||July 2009||2009-07-01|July 2011|2011-07-01|July 2011|Actual|2011-07-01|July 2010|Actual|2010-07-01||Observational|||Visualization Tool for Investigation of Breast Lesions|Evaluation of a New Multi-modality Visualization Tool for Investigation of Breast Lesions|Terminated||N/A|10|Anticipated|Sunnybrook Health Sciences Centre|||1|The study was terminated as the PI left the institution.|f||||f||||||||||2017-10-11 10:04:37.939786|2017-10-11 10:04:37.939786
NCT00934635|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-06|2014-01-14|2010-12-13||September 2009||2009-09-01|January 2014|2014-01-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Interventional|||A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls|"The Therapeutic Window of the Atypical Antipsychotic Paliperidone Extended Release (ER)-A Positron Emission Tomography Study With [18F]Fallypride as the Radiotracer"|Terminated||Phase 4|2|Actual|Janssen-Cilag G.m.b.H|Two subjects enrolled, both completed study per protocol. Study was prematurely terminated, data obtained were not submitted to further statistical analysis and will not be applicable for scientific analysis due to the low number of subjects.|9|||f||||f||||||||||2017-10-11 10:04:42.936827|2017-10-11 10:04:42.936827
NCT00934791|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-06|2013-02-04|2013-02-04||February 2009||2009-02-01|February 2013|2013-02-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|||Polycystic Liver Disease in Kidney Transplant|Single Center, Open-label Randomized Prospective Trial: Effect of Sirolimus on Polycystic Liver Disease|Terminated||N/A|2|Actual|Mayo Clinic|This study was terminated due to inadequate enrollment, no data was collected on the participant.|2||Terminated due to inadequate enrollment|f||||f||||||||||2017-10-11 10:04:50.036718|2017-10-11 10:04:50.036718
NCT00935857|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-07|2014-09-23|2012-12-03||April 2009||2009-04-01|September 2014|2014-09-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional||An interim analysis was performed at 30 patients as described in initial protocol. The study was terminated at the interim analysis.|Balloon Colonoscopy for Incomplete Colonoscopy|Balloon Colonoscopy Versus Repeat Standard Colonoscopy for Prior Incomplete Colonoscopy: A Randomized Controlled Trial|Terminated||N/A|30|Actual|Northwestern University|Early termination due to interim analysis showing statistical difference; single operator.|2||Significant difference at interim analysis|f||||f||||||||||2017-10-11 10:05:04.674236|2017-10-11 10:05:04.674236
NCT00936585|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-09|2015-12-07|2013-04-24||July 2009||2009-07-01|December 2015|2015-12-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease|NIH SUBSTUDY:Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single Infusions of AIN457 in Patients With Moderate to Severe Active Crohn's Disease|Terminated||N/A|2|Actual|National Institutes of Health Clinical Center (CC)|The NIH sub study ended earlier than anticipated as the Novartis main study was terminated for futility. As a result, not enough patients were enrolled to perform any analysis of data.|1||Study halted by the sponsor|f||||t||||||||||2017-10-11 10:05:19.167796|2017-10-11 10:05:19.167796
NCT00936923|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-09|2015-05-19|||June 2008||2008-06-01|May 2015|2015-05-01|December 2012|Anticipated|2012-12-01|December 2011|Anticipated|2011-12-01||Interventional|||Effect of Diuretics on Fluid Status Control and Residual Renal Function in Peritoneal Dialysis Patients|Effect of Diuretics on Fluid Status Control and Residual Renal Function in Peritoneal Dialysis Patients|Withdrawn||Phase 3|0|Actual|Sun Yat-sen University||3||The study was withdrawn prior to enrollment of first participant.|f||||t||||||||||2017-10-11 10:05:24.531934|2017-10-11 10:05:24.531934
NCT00929825|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-04|2016-08-08|||February 2008||2008-02-01|August 2016|2016-08-01|August 2011|Anticipated|2011-08-01|June 2011|Actual|2011-06-01||Interventional|||Therapies for Salivary Flux Stimulation in Patients Transplanted With Hematopoietic Stem Cells|Effects of Mechanical and Electrical Sialogogues in Stimulation of the Flow and Biochemical Composition of Saliva in Patients Transplanted With Hematopoietic Stem Cells|Withdrawn||Phase 1|0|Actual|Federal University of Minas Gerais||4||The Hospital had the Unit of Stem cells Tranplantion suspended|f||||t||||||||Yes|"Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 May;113(5):628-37. doi: 10.1016/j.oooo.2011.10.012. Epub 2012 Apr 12.
NCT00931996|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-25|2013-01-23|2011-11-08||June 2009||2009-06-01|January 2013|2013-01-01|November 2011|Actual|2011-11-01|November 2011|Actual|2011-11-01||Interventional|||Oculomotor and Spatial Cognition Deficits in Schizophrenia|Clinical and Computational Studies of Dopamine Function in Schizophrenia|Terminated||N/A|12|Actual|University of Illinois at Chicago|Early termination leading to small numbers of subjects analyzed|1||Study was terminated due to low accrual.|f||||f||||||||||2017-10-11 10:06:25.108148|2017-10-11 10:06:25.108148
NCT00932035|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-29|2017-05-05|2016-12-09||June 2009||2009-06-01|May 2017|2017-05-01|May 2014|Actual|2014-05-01|May 2014|Actual|2014-05-01||Interventional|||Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer|Reducing Extremity Lymphedema Through Axillary Lymphatic Preservation Surgery|Terminated||Phase 1/Phase 2|39|Actual|City of Hope Medical Center|Study was terminated early due to loss of principal investigator. As a result accrual of subjects and data collection are incomplete.|2||Loss of principal investigator|f||||t||||||||||2017-10-11 10:06:25.661331|2017-10-11 10:06:25.661331
NCT00944125|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-17|2016-03-02|2015-02-25||June 2009||2009-06-01|March 2016|2016-03-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|DIVA|Includes both randomized groups, Group A: Randomized to Dual LV pacing for three months then crossed over to Standard BiV pacing for three months, then programmed at the physician discretion. Group B: Randomized to Standard BiV pacing for three months then crossed over to Dual LV pacing for three months, then programmed to physician discretion.|Dual Site Left Ventricular (LV) Pacing|Dual Site LV Pacing Study: Prospective Randomized Blinded Crossover Study of Patients Meeting Current CRT-D Indication to be Implanted With Dual LV Pacing Leads and Paced Chronically for at Least 6 Months Post-implant.|Terminated||N/A|50|Actual|Aurora Health Care|Study terminated early form administrative reasons (no safety concerns), no analysis was completed.|2||for administrative reasons (no safety concerns), no analysis completed|f||||f||||||||||2017-10-11 10:07:58.509368|2017-10-11 10:07:58.509368
NCT00945178|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-17|2010-12-08|||August 2009||2009-08-01|December 2009|2009-12-01|September 2009|Actual|2009-09-01|September 2009|Actual|2009-09-01||Interventional|||Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers|A Single-centre, Randomised, Double-blind, Placebo-controlled, Two-part Study to Assess Safety, Tolerability, Pharmacokinetics of Orally Administered AZD1386|Terminated||Phase 1|11|Actual|AstraZeneca||4||The study was terminated due to results in another study (NCT00878501).|f||||t||||||||||2017-10-11 10:08:15.159298|2017-10-11 10:08:15.159298
NCT00945243|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-22|2017-08-22|2016-11-17||July 1, 2009|Actual|2009-07-01|August 2017|2017-08-01|December 1, 2011|Actual|2011-12-01|December 1, 2011|Actual|2011-12-01||Interventional||Number of subjects enrolled and treated per protocol|Clinical Outcomes Study Evaluating the Zero-P PEEK|Prospective, Multi-Center Clinical Outcomes Study Evaluating the Zero-P PEEK for Anterior Cervical Interbody Fusion in the Treatment of Cervical Degenerative Disc Disease|Terminated||N/A|14|Actual|Synthes USA HQ, Inc.||1||This study was terminated early due to lower than expected enrollment rates.|f||||f||||||||||2017-10-11 10:08:15.564835|2017-10-11 10:08:15.564835
NCT00945477|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-22|2013-10-25|2012-10-24||July 2009||2009-07-01|October 2013|2013-10-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade|A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.|Terminated||Phase 2|11|Actual|Illinois CancerCare, P.C.|Because of slow enrollment, the study was terminated. The study planned enrollment of 34 subjects, 11 were enrolled.|1||Slow enrollment|f||||f||||||||||2017-10-11 10:08:18.672055|2017-10-11 10:08:18.672055
NCT00946088|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-22|2017-02-07|2016-10-24||October 2009||2009-10-01|February 2017|2017-02-01|March 2015|Actual|2015-03-01|February 2013|Actual|2013-02-01||Interventional|||Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial|Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial|Terminated||Phase 2/Phase 3|7|Actual|Stanford University|Very limited enrollment, study terminated early.|2||lower than expected enrollment|f||||f||||||||No||2017-10-11 10:08:28.075304|2017-10-11 10:08:28.075304
NCT00939887|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-13|2010-02-04|||September 2009||2009-09-01|February 2010|2010-02-01|December 2009|Actual|2009-12-01|December 2009|Actual|2009-12-01||Interventional|||A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)|A Phase 1, Healthy Volunteer Qualification Of Ligand [11C] PF-04767135 And Randomized Determination Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET|Terminated||Phase 1|12|Actual|Pfizer||1||"This study was terminated on January 6, 2010, due to toxicology findings in animals exposed to   PF-04455242 for three months."|f||||f||||||||||2017-10-11 10:09:05.102208|2017-10-11 10:09:05.102208
NCT00940641|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-15|2011-01-21|||August 2009||2009-08-01|January 2011|2011-01-01|October 2009|Anticipated|2009-10-01|October 2009|Anticipated|2009-10-01||Interventional|||Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration|A Phase 1, Open, Two Period, Single-Centre, Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After Intravenous and 14C-labelled Oral Administration of AZD7325 to Healthy Male Volunteers|Suspended||Phase 1|8|Anticipated|AstraZeneca||2||Study withdrawn prior to enrollment due to AZ business decision unrelated to safety.|f||||f||||||||||2017-10-11 10:09:15.497507|2017-10-11 10:09:15.497507
NCT00946309|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-23|2016-09-24|2015-08-20||July 2010||2010-07-01|June 2016|2016-06-01|May 2015|Actual|2015-05-01|May 2014|Actual|2014-05-01||Interventional|PHASE|One participant enrolled to the placebo arm was determined to be ineligible, and was withdrawn from the study Two additional participants enrolled to the placebo arm became ineligible after enrollment, and were withdrawn from the study|Effects of Sulforaphane on Normal Prostate Tissue|In Vivo Effects of Sulforaphane Supplementation on Normal Human Prostate|Completed||Phase 1/Phase 2|45|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2017-10-11 10:09:18.071749|2017-10-11 10:09:18.071749
NCT00948688|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-27|2017-03-30|2017-01-27||August 2009||2009-08-01|March 2017|2017-03-01|November 2013|Actual|2013-11-01|June 2012|Actual|2012-06-01||Interventional|||Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas|Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas|Terminated||Phase 1/Phase 2|10|Actual|Massachusetts General Hospital|Only 10 participants were enrolled on this trial that planned for 50. Phase II portion of the study was not reached and therefore endpoint analysis is severely limited by sample size.|1||Funding was withdrawn after only 10 participants were enrolled|f||||t||||||||No||2017-10-11 10:09:29.598269|2017-10-11 10:09:29.598269
NCT00949897|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-29|2013-03-11|||March 2009||2009-03-01|March 2013|2013-03-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|||Comparison Study of Biofoam Porous Metal Versus Allograft to Treat Adult Acquired Flatfoot|A Randomized, Prospective, Controlled Trial for Lateral Column Lengthening in Adult Acquired Flatfoot Using Biofoam Porous Metal Compared With Allograft|Withdrawn||Phase 4|0|Actual|OrthoCarolina Research Institute, Inc.||2||Funding terminated|f||||t||||||||||2017-10-11 10:09:50.135072|2017-10-11 10:09:50.135072
NCT00938314|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-09|2011-11-24|2011-09-01||August 2009||2009-08-01|November 2011|2011-11-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|REGENESIS-LED||Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients|A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled, Multicenter, Dose Escalation Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED)|Terminated||Phase 2|96|Actual|Stem Cell Therapeutics Corp.|The trial was terminated after 96 of a planned 128 patients were enrolled, thus limiting opportunities to demonstrate a clear statistical benefit of active therapy compared to placebo.|4||Slow Enrollment|f||||t||||||||||2017-10-11 10:10:19.612537|2017-10-11 10:10:19.612537
NCT00951808|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-31|2013-04-16|2012-04-25||July 2009||2009-07-01|April 2013|2013-04-01|July 2010|Actual|2010-07-01|June 2010|Actual|2010-06-01||Interventional|PROACTIVE|The randomization trial has been terminated due to the lack of enrollment. Therefore, the results were not reported by Arm and the total number of subjects (237) enrolled in the feasibility study was used.|Preventing Acute Chest Syndrome by Transfusion Feasibility Study|Preventing Acute Chest Syndrome by Transfusion Feasibility Study( PROACTIVE Feasibility Study)|Completed||N/A|237|Actual|New England Research Institutes|The feasibility study has been completed, but the randomization trial has been terminated early due to the lack of enrollment. Therefore, the results were reported with the subjects who completed the feasibility study and were not reported by Arm.|3|||f||||t||||||||||2017-10-11 10:10:48.176068|2017-10-11 10:10:48.176068
NCT00953290|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-04|2011-05-06|2011-02-17||January 2009||2009-01-01|May 2011|2011-05-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|||Thigh Circumference Reduction Study|Cutera Radio Frequency Device for Thigh Circumference Reduction|Terminated||N/A|4|Actual|Cutera Inc.|Early termination of the study resulting in analysis of small numbers of subjects, and technical issues with repeatability and reproducibility of circumference measurements leading to termination.|2||The study was terminated because the preliminary data did not indicate efficacy.|f||||f||||||||||2017-10-11 10:11:18.804747|2017-10-11 10:11:18.804747
NCT00953615|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-04|2012-01-24|2011-08-08||April 2006||2006-04-01|January 2012|2012-01-01|May 2009|Actual|2009-05-01|May 2009|Actual|2009-05-01||Interventional|||Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)|Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis|Terminated||Phase 2|1|Actual|Mayo Clinic|Only one subject was enrolled, so study was terminated.|1||Lack of enrollment|f||||t||||||||||2017-10-11 10:11:24.832653|2017-10-11 10:11:24.832653
NCT00953706|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-04|2015-08-27|2012-02-27|2011-09-21|September 2009||2009-09-01|August 2015|2015-08-01|May 2013|Actual|2013-05-01|July 2010|Actual|2010-07-01||Interventional|DISCOVER||Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation|Terminated||Phase 2|140|Actual|Vertex Pharmaceuticals Incorporated|In Part B, the treatment duration was 96 weeks; however, due to early study termination all analysis were performed up to Week 64, as planned.|2||"Following review of results obtained from a pre-specified 6-month analysis of Part B data the   study was terminated on the basis of futility."|f||||t||||||||||2017-10-11 10:11:26.519519|2017-10-11 10:11:26.519519
NCT00946907|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-24|2011-12-20|||July 2009||2009-07-01|December 2011|2011-12-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional|pericardite||Benign Acute Pericarditis: Brief Versus Longer Treatment Using Aspirin|Benign Acute Pericarditis: Brief Versus Longer Treatment. Randomized, Multicentric, Double Blind, Non Inferiority Trial|Terminated||Phase 4|34|Actual|University Hospital, Brest||2||"This study was suspended by principal investigator's decision. All the sites were not opened,   and the recruitment was so slow."|f||||t||||||||||2017-10-11 10:11:34.459348|2017-10-11 10:11:34.459348
NCT00947284|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-01|2016-05-19|2013-08-14||January 2010||2010-01-01|October 2013|2013-10-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity|Effect of Kappa Opioid Agonist-Antagonists in the Heat/Capsaicin Sensitization Model|Terminated||N/A|3|Actual|University of California, San Francisco|The lead investigator passed away and co-investigators could not find complete data on his computer. The experimental model for skin sensitivity did not work in the first 3 participants, and the study was terminated without collecting outcomes data.|2||Experimental pain model didn't work as anticipated.|f||||t||||||||||2017-10-11 10:11:41.152791|2017-10-11 10:11:41.152791
NCT00957255|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-11|2017-04-04|||March 2009||2009-03-01|April 2017|2017-04-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|||Rotator Cuff Repair (RCR) With and Without OrthoADAPT Augmentation|Rotator Cuff Repair (RCR) With and Without OrthoADAPT Augmentation|Withdrawn||N/A|0|Actual|Baxter Healthcare Corporation||2||Funding withdrawn|f||||f||||||||||2017-10-11 10:12:14.20574|2017-10-11 10:12:14.20574
NCT00957580|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-11|2017-07-19|2016-07-04||September 30, 2009|Actual|2009-09-30|July 2017|2017-07-01|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Interventional||Baseline analysis population included all the subjects who were treated with at least one administration of pimasertib.|Trial of Pimasertib in Hematological Malignancies|Phase II Trial With Safety-Run-In of MEK Inhibitor MSC1936369B in Subjects With Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies|Terminated||Phase 2|81|Actual|EMD Serono|The trial has been terminated due to an estimated low probability of clinical benefit based on limited anti-leukemic effects observed in safety run-in (Part 1).|5||"The trial has been terminated due to an estimated low probability of clinical benefit based on   limited anti-leukemic effects observed in safety run-in (Part 1)"|f||||t||||||||||2017-10-11 10:12:20.300654|2017-10-11 10:12:20.300654
NCT00957749|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-10|2011-01-29|||August 2009||2009-08-01|January 2011|2011-01-01||||April 2010|Anticipated|2010-04-01||Interventional|||Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A|A Multicenter, Open-Label Study of the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered cPMP (Precursor Z) in Patients With Molybdenum Cofactor Deficiency Type A|Withdrawn||Phase 1/Phase 2|10|Anticipated|Orphatech Pharmaceuticals, GmbH||1||IND application was withdrawn, and therefore study listing is being withdrawn.|f||||f||||||||||2017-10-11 10:12:26.129693|2017-10-11 10:12:26.129693
NCT00958776|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-12|2015-01-28|2015-01-16|2014-07-17|November 2009||2009-11-01|January 2015|2015-01-01|October 2013|Actual|2013-10-01|November 2012|Actual|2012-11-01||Interventional||All enrolled subjects|A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza|A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza|Terminated||Phase 3|405|Actual|BioCryst Pharmaceuticals|Interim analysis of the primary efficacy endpoint (time to clinical resolution) performed after the end of the 2012 Southern Hemisphere influenza season lead to study termination for futility. Final enrollment was ~70% of the planned enrollment.|2||This study was terminated for futility|f||||t||||||||||2017-10-11 10:12:52.165785|2017-10-11 10:12:52.165785
NCT00958893|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-11|2014-08-08|2014-06-25||June 2008||2008-06-01|August 2014|2014-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional||Study prematurely terminated|An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext|An Open-Label Extension Study Evaluating Safety and Efficacy of Proellex® In Women With Leiomyomata Who Have Previously Completed ZPU 003 Ext|Terminated||Phase 2|4|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|1||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2017-10-11 10:12:57.754355|2017-10-11 10:12:57.754355
NCT00962143|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-17|2017-04-04|||June 2008||2008-06-01|April 2017|2017-04-01|January 2011|Anticipated|2011-01-01|December 2010|Anticipated|2010-12-01||Interventional|||Acute Achilles Repair With or Without OrthADAPT Augmentation|Prospective, Randomized, Multi-center: Acute Achilles Repair With or Without OrthADAPT Augmentation|Withdrawn||N/A|0|Actual|Baxter Healthcare Corporation||2||Funding withdrawn|f||||f||||||||||2017-10-11 10:13:33.463812|2017-10-11 10:13:33.463812
NCT00954512|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-23|2017-05-16|2015-11-18||September 25, 2009|Actual|2009-09-25|May 2017|2017-05-01|June 7, 2011|Actual|2011-06-07|June 7, 2011|Actual|2011-06-07||Interventional|||Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)|A Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (Phase 1B/2; Protocol No. P04722)|Terminated||Phase 1/Phase 2|15|Actual|Merck Sharp & Dohme Corp.||6||This study was terminated for business reasons.|f||||f||||||||||2017-10-11 10:14:11.240356|2017-10-11 10:14:11.240356
NCT00954785|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-06|2013-06-19|||November 2009||2009-11-01|August 2009|2009-08-01|July 2011|Anticipated|2011-07-01|December 2010|Anticipated|2010-12-01||Interventional|||Etoricoxib in Acute Ankle Ligament Sprains|The Efficacy and Safety of Administration of the COX-2 Selective NSAID, Etoricoxib (120mg od. for 7 Days) Compared to Diclofenac (50 mg Tds. for 7 Days) and Placebo as Adjunct Treatment in the First 7 Days of Treatment of Acute Grade II Lateral Ankle Ligaments Sprains: A Clinical Trial|Withdrawn||Phase 4|0|Actual|University of Cape Town||3||The study was terminated by Merck USA. The company did not supply drugs for the study.|f||||t||||||||||2017-10-11 10:14:15.772455|2017-10-11 10:14:15.772455
NCT00954876|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-17|2012-01-27|||August 2009||2009-08-01|January 2012|2012-01-01|January 2010|Actual|2010-01-01|January 2010|Actual|2010-01-01||Interventional|||Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer|Phase II, Multi-Center, Open-Label, Prospective Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type KRAS Colorectal Cancer Who Are Considered Nonoptimal Candidates or Are Intolerant to a First-Line Oxaliplatin/Irinotecan Regimen|Withdrawn||Phase 2|0|Actual|Translational Drug Development||1||Study has been terminated due to lack of accrual.|f||||f||||||||||2017-10-11 10:14:16.640188|2017-10-11 10:14:16.640188
NCT00954915|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-04|2012-08-20|2012-03-27||December 2009||2009-12-01|August 2012|2012-08-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|||Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis|A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis|Terminated||Phase 1/Phase 2|1|Actual|MacroGenics|This study was terminated, with only 1 subject enrolled, due to meeting the study criteria for discontinuation regarding local or regional injection site reactions.|1||Injection site reaction met protocol-defined stopping criteria.|f||||f||||||||||2017-10-11 10:14:16.948671|2017-10-11 10:14:16.948671
NCT00955136|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-05|2014-06-26|||July 2012||2012-07-01|June 2014|2014-06-01|April 2015|Anticipated|2015-04-01|April 2013|Anticipated|2013-04-01||Interventional|||Utilization of Diagnostic Ultrasound in the Detection and Therapy of Acute Coronary Syndromes|Utilization of Diagnostic Ultrasound in the Detection and Therapy of Acute Coronary Syndromes|Withdrawn||N/A|0|Actual|University of Nebraska||1||The study was withdrawn due to many implementation difficulties.|f||||f||||||||||2017-10-11 10:14:19.633308|2017-10-11 10:14:19.633308
NCT00956293|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-07|2014-05-23|2014-03-26||July 2009||2009-07-01|May 2014|2014-05-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|Senator||Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program|6-month, Open-label, Randomized, Multicenter, Prospective, Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program|Terminated||Phase 4|207|Actual|Novartis||2||"The study was terminated because the required sample size of 240-260 de novo senior renal   transplant patients was not achieved within a reasonable time."|f||||||||||||||2017-10-11 10:14:38.741157|2017-10-11 10:14:38.741157
NCT00965055|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-24|2013-01-25|||September 2009||2009-09-01|January 2013|2013-01-01|September 2012|Actual|2012-09-01|September 2011|Actual|2011-09-01||Interventional|||Ezetimibe in Patients Hypo-responsive to Statins|Atorvastatin vs. Atorvastatin/Ezetimibe in Patients With Hypo-response to Initial Dose Statin Therapy|Terminated||Phase 3|2|Actual|University of California, San Diego||2||"The study was terminated due to inability to recruit subjects. A total of 2/100 anticipated   were radomized."|f||||t||||||||||2017-10-11 10:15:05.469019|2017-10-11 10:15:05.469019
NCT00965146|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-11|2017-05-05|2012-11-09||June 2001||2001-06-01|April 2013|2013-04-01||||July 23, 2009|Actual|2009-07-23||Interventional|||Scorpio® Cruciate Retaining (CR) Outcomes Study|An Open Label, Post-market, Non-randomized, Multi-center Study of the Outcomes of the Scorpio® Cruciate Retaining (CR) Total Knee System|Terminated||N/A|215|Actual|Stryker Orthopaedics|This study was terminated early due to lagging follow up prior to the 15 year endpoint.|1||Terminated due to lagging follow-up.|f||||f||||||||||2017-10-11 10:15:07.559322|2017-10-11 10:15:07.559322
NCT00965731|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-24|2015-10-06|2012-12-07||January 2010||2010-01-01|October 2015|2015-10-01|January 2014|Actual|2014-01-01|December 2011|Actual|2011-12-01||Interventional|||Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer|Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.|Completed||Phase 1|27|Actual|Pfizer|The sponsor terminated phase 2 of this study; no data was collected during phase 2, leading to phase 2 outcomes not analyzed. The decision was based on strategic considerations regarding the clinical program only; there were no safety concerns.|2|||f||||f||||||||||2017-10-11 10:15:18.24332|2017-10-11 10:15:18.24332
NCT00960726|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-17|2012-07-27||||||July 2012|2012-07-01||||||||Interventional|||NOV-002 in Myelodysplastic Syndrome (MDS)|Phase 2 Study of NOV-002 in Low and Intermediate-1 Risk Myelodysplastic Syndrome|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Study withdrawn at sponsor request.|f||||f||||||||||2017-10-11 10:16:13.849712|2017-10-11 10:16:13.849712
NCT00959946|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-14|2013-01-18|2012-10-04|2012-04-17|September 2009||2009-09-01|January 2013|2013-01-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer|A Phase 1/2, Open-Label Study Of Bosutinib Administered In Combination With Capecitabine In Subjects With Solid Tumor And ErbB2 Negative Locally Advanced Or Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|32|Actual|Pfizer|Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment.|1|||f||||f||||||||||2017-10-11 10:15:51.676232|2017-10-11 10:15:51.676232
NCT00959985|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-14|2017-04-26|2017-01-04||August 2009||2009-08-01|April 2017|2017-04-01|August 2014|Actual|2014-08-01|August 2014|Actual|2014-08-01||Interventional|||Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer|Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer: A Randomized Trial|Terminated||N/A|23|Actual|Massachusetts General Hospital|This trial was terminated due to slow accrual and small number of subjects for whom data was collected (23 out of expected 334). Study did not reach statistical power to conduct detailed analysis, results should be interpreted with this in mind|4||low accrual|f||||t||||||||Undecided||2017-10-11 10:15:53.860071|2017-10-11 10:15:53.860071
NCT00960063|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-14|2017-05-19|2015-11-19||November 11, 2009|Actual|2009-11-11|May 2017|2017-05-01|December 22, 2010|Actual|2010-12-22|December 22, 2010|Actual|2010-12-22||Interventional|||A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)|A Phase 1/1B Dose-Escalation Study to Determine the Safety and Tolerability of SCH 717454 Administered in Combination With Chemotherapy in Pediatric Subjects With Advanced Solid Tumors (Protocol No. 05883)|Terminated||Phase 1|4|Actual|Merck Sharp & Dohme Corp.||3||Study was terminated for business reasons.|f||||f||||||||||2017-10-11 10:15:54.822335|2017-10-11 10:15:54.822335
NCT00960297|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-13|2013-11-08|2013-08-27||August 2009||2009-08-01|November 2013|2013-11-01|May 2013|Actual|2013-05-01|November 2012|Actual|2012-11-01||Interventional|||Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC|Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer|Terminated||Phase 2|4|Actual|SCRI Development Innovations, LLC||1||Study was terminated due to slow accrual|f||||f||||||||||2017-10-11 10:15:59.377181|2017-10-11 10:15:59.377181
NCT00968331|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-28|2012-08-24|||March 2009||2009-03-01|August 2012|2012-08-01|December 2011|Actual|2011-12-01|December 2009|Actual|2009-12-01||Interventional|||Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)||Terminated||Phase 2|25|Actual|University of Bologna||1||"The EC withdrawn the approval becuase of possible conflicts of interests between our Institute   and Supporter (Celgene)"|f||||||||||||||2017-10-11 10:16:34.071302|2017-10-11 10:16:34.071302
NCT00968383|ClinicalTrials.gov processed this data on October 10, 2017|2009-06-30|2015-05-13|||September 2009||2009-09-01|May 2015|2015-05-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|COAT||Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment|Late Percutaneous Coronary Intervention of the Occluded Infarct-Related Artery in Patients With Preserved Infarct Zone Viability Determined With Magnetic Resonance Imaging|Terminated||N/A|11|Actual|Institute of Cardiology, Warsaw, Poland||2||The study was prematurely terminated due to low enrollment.|f||||f||||||||||2017-10-11 10:16:34.40177|2017-10-11 10:16:34.40177
NCT00968617|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-27|2015-10-30|2011-10-07||November 2009||2009-11-01|October 2015|2015-10-01|May 2010|Actual|2010-05-01|April 2010|Actual|2010-04-01||Interventional|||A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)|A Phase IIb Randomized, Active Comparator-Controlled, Open-Label Clinical Trial to Study the Efficacy and Safety of MK2578 for the Treatment of Anemia in ESA (Erythropoiesis-Stimulating Agent)-Naive Patients With Chronic Kidney Disease Who Are Not on Dialysis.|Terminated||Phase 2|7|Actual|Merck Sharp & Dohme Corp.|Cohort 1 (MK2578 1.0 mcg/kg) was the only cohort initiated because the study was prematurely terminated by the sponsor. 7 participants received at least 1 dose of MK2578 & 2 participants received all 3 doses. Data presented are for Cohort 1.|4|||f||||f||||||||||2017-10-11 10:16:37.32486|2017-10-11 10:16:37.32486
NCT00969124|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-27|2017-06-26|2016-07-18||January 2009||2009-01-01|June 2017|2017-06-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional||Per-protocol population of patients for whom the colonoscopy procedure was completed using the Third Eye Retroscope, not including the 30 who were withdrawn due to reasons stated above.|Impact of Experience on Results With the Third Eye Retroscope|Impact of Experience With the Third Eye Retroscope on Detection Rates and Withdrawal Times During Colonoscopy|Completed||N/A|328|Actual|Avantis Medical Systems|No randomization or blinding and no separate control group. Determinations regarding adequacy of bowel cleansing and whether each polyp could have been detected with the colonoscope alone involved a judgement by the endoscopist.|1|||f||||f||||||||No||2017-10-11 10:16:56.472052|2017-10-11 10:16:56.472052
NCT00971126|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-01|2016-05-03|||July 2009||2009-07-01|September 2009|2009-09-01|March 2010|Actual|2010-03-01|January 2010|Actual|2010-01-01||Interventional|||Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)|A Phase I/II Study of Sorafenib With Combination of Thalidomide in Advanced or Metastatic Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|3|Actual|National Health Research Institutes, Taiwan||1||"Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated   early this trial."|f||||t||||||||||2017-10-11 10:17:35.833164|2017-10-11 10:17:35.833164
NCT00972335|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-02|2015-05-18|2015-01-05||January 2010||2010-01-01|May 2015|2015-05-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional||All treated patients (one enrolled patient was not treated)|Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma|A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma|Terminated||Phase 2|18|Actual|SCRI Development Innovations, LLC|Enrollment closed early due to slow accrual, leading to small number of subjects analyzed - biomarker analysis outcome measure not analyzed or reported|1||Study terminated early due to slow accrual|f||||f||||||||||2017-10-11 10:17:55.228783|2017-10-11 10:17:55.228783
NCT00972543|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-04|2014-01-20|2010-06-28||September 2008||2008-09-01|January 2014|2014-01-01||||May 2009|Actual|2009-05-01||Interventional|||Raptiva in Palm and Sole Psoriasis|A Phase IV Multicentre, Randomized Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Raptiva in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis Involving Palms and/or Soles, With or Without Pustules.|Terminated||Phase 4|6|Actual|Merck KGaA||2||"The study was terminated after the European Medicines Evaluation Agency recommended to suspend   the marketing authorisation of Raptiva in the European Union"|f||||f||||||||||2017-10-11 10:18:02.501424|2017-10-11 10:18:02.501424
NCT00976027|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-11|2012-07-24|2012-06-19||September 2009||2009-09-01|July 2012|2012-07-01|April 2012|Actual|2012-04-01|May 2011|Actual|2011-05-01||Interventional|||Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older|Multi-Year Efficacy Study of Fluzone High-Dose Trivalent Vaccine Compared With Fluzone® Vaccine In Adults ≥ 65 Years of Age|Terminated||Phase 3|9172|Actual|Sanofi|The study was terminated due to lack of primary endpoint cases in 2009-2010 influenza season (coincided with the H1N1 Pandemic). There were no safety concerns; enrolled subjects were followed per-protocol.|2||"No safety concerns, study terminated due to lack of primary endpoint cases in 2009-2010 Flu   season (coincided with H1N1 Pandemic) Subjects followed per-protocol"|f||||t||||||||||2017-10-11 10:18:40.359793|2017-10-11 10:18:40.359793
NCT00976456|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-11|2016-02-11|2016-01-12||September 2009||2009-09-01|February 2016|2016-02-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional|65plus|271 patients were enrolled and randomized, due to Screening failure and subject withdrawn consent the intent-to-treat (ITT) population comprised 253 evaluable patients (BP n=119; BPC n=134).|Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer|Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer|Completed||Phase 3|271|Actual|Martha-Maria Krankenhaus Halle-Dölau gGmbH||2|||f||||t||||||||||2017-10-11 10:18:48.68891|2017-10-11 10:18:48.68891
NCT00976508|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-10|2013-10-23|2013-10-23||November 2009||2009-11-01|October 2013|2013-10-01|October 2012|Actual|2012-10-01|September 2011|Actual|2011-09-01||Interventional|||Figitumumab Combined With Pegvisomant For Advanced Solid Tumors|Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors|Terminated||Phase 1|24|Actual|Pfizer|The study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 10:18:50.21415|2017-10-11 10:18:50.21415
NCT00976534|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-09|2009-12-21|||September 2009||2009-09-01|December 2009|2009-12-01|February 2010|Anticipated|2010-02-01|||||Interventional|AVANT||Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain|A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)|Terminated||Phase 2|90|Anticipated|AstraZeneca||2||The study was terminated due to results in another study (NCT00878501).|f||||f||||||||||2017-10-11 10:18:53.130244|2017-10-11 10:18:53.130244
NCT00977067|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-12|2017-06-20|||June 2007|Actual|2007-06-01|June 2017|2017-06-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|||A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies|A Phase Ia, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0152, an IAP Protein Antagonist, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies|Terminated||Phase 1|40|Actual|Genentech, Inc.||1||"The study was terminated early by the Sponsor for reasons unrelated to patient safety or   anti-tumor activity."|f||||||||||||||2017-10-11 10:19:08.639685|2017-10-11 10:19:08.639685
NCT00977379|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-14|2016-09-26|2016-09-26||August 2009||2009-08-01|September 2016|2016-09-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|XERAD|Intent to treat (ITT) population included all randomized participants except one participant from “WBRT+Capecitabine Followed by Capecitabine Maintenance” arm who was randomized by error.|A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis|XERAD: Open-Label, Phase II, Randomized, Comparative, Multicentre Trial of Concurrent Whole Brain Radiation Therapy (WBRT) and Capecitabine (Xeloda®) Followed by Maintenance Capecitabine Compared With Standard WBRT in Breast Cancer Patients With Newly Diagnosed Brain Metastasis|Terminated||Phase 2|24|Actual|Hoffmann-La Roche|Study was prematurely terminated due to an insufficient number of participants enrolled and therefore results are only based on a small sample of breast cancer participants with newly diagnosed brain metastasis and should be considered with caution.|2||Due to an insufficient number of participants enrolled.|f||||||||||||||2017-10-11 10:19:18.405547|2017-10-11 10:19:18.405547
NCT00977561|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-10|2013-01-18|2013-01-18|2012-05-08|April 2010||2010-04-01|January 2013|2013-01-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|||A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer|A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer|Terminated||Phase 2|9|Actual|Pfizer|The study was terminated prematurely due to low participants enrollment and the halting of the figitumumab development program. The only endpoint analyzed was safety and tolerability of figitumumab ± cisplatin (or carboplatin) and etoposide.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 10:19:21.787751|2017-10-11 10:19:21.787751
NCT00978146|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-15|2017-04-19|||October 2009||2009-10-01|April 2017|2017-04-01|January 2015|Anticipated|2015-01-01|January 2015|Anticipated|2015-01-01||Interventional|||Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors|Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors in Adults and Children (CHP-914)|Withdrawn||Phase 2|0|Actual|Children's Hospital of Philadelphia||1||Study was administratively withdrawn by the IRB; no subjects were enrolled|f||||t||||||||||2017-10-11 10:19:39.61263|2017-10-11 10:19:39.61263
NCT00978341|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-15|2010-01-06|2009-09-28||February 2007||2007-02-01|January 2010|2010-01-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|||Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design|A Methodology Study to Assess the Ability of a Randomised, Double Blind, Placebo Controlled, Crossover Trial Design in Spinal Cord Injury Patients With Pain of Neuropathic Origin to Detect Improvement in Pain Endpoints Using Pregabalin as a Benchmark Compound|Terminated||N/A|15|Actual|Pfizer|This study was terminated prematurely.|2||See Detailed Description|f||||t||||||||||2017-10-11 10:19:41.179757|2017-10-11 10:19:41.179757
NCT00979004|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-16|2012-09-27||2011-07-07|September 2009||2009-09-01|September 2012|2012-09-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional|||A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients|A Phase 2, Multi-Center, Single-Blind, Placebo-Controlled Pharmacodynamic Evaluation of ICA-105665 in Epilepsy Patients With a Photo-Induced Paroxysmal EEG Response|Terminated||Phase 2|13|Actual|Pfizer||1||"The study was terminated on September 12, 2010 per protocol following a serious adverse event   that occurred with the first subject dosed at 600 mg."|f||||f||||||||||2017-10-11 10:19:51.544344|2017-10-11 10:19:51.544344
NCT00979693|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-16|2014-09-16|||January 2012||2012-01-01|September 2014|2014-09-01|June 2013|Anticipated|2013-06-01|April 2013|Anticipated|2013-04-01||Interventional|||Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma|Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.|Withdrawn||Phase 2|0|Actual|Multidisciplinary Association for Psychedelic Studies||2||"The study was suspended because the PI was unable to get permission from his department to   submit the protocol to the local IRB?"|f||||f||||||||||2017-10-11 10:20:07.661173|2017-10-11 10:20:07.661173
NCT00979836|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-17|2011-02-16|||April 2008||2008-04-01|February 2011|2011-02-01||||July 2010|Actual|2010-07-01||Interventional|||Calcium Dobesilate for Chronic Venous Wounds|Randomized, Double-blind Multicenter Clinical Trial Comparing the Efficacy of Calcium Dobesilate With Placebo in the Treatment of Ulcer Secondaries to Chronic Venous Disease|Suspended||Phase 3|230|Anticipated|Fundacion Iberoamericana Itaca||2||The financial support was withdrawn.|f||||f||||||||||2017-10-11 10:20:08.692977|2017-10-11 10:20:08.692977
NCT00973622|ClinicalTrials.gov processed this data on October 10, 2017|2009-08-26|2013-07-31|2013-01-23||October 2009||2009-10-01|July 2013|2013-07-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|rTMS||Changing Thought and Action in Tobacco Dependence With Transcranial Magnetic Stimulation|Changing Thought and Action in Tobacco Dependence With Transcranial Magnetic Stimulation|Completed||N/A|66|Actual|University of Arkansas|We experienced significant subject attrition among smokers. We did not experience such attrition among nonsmokers. Also, six smokers were withdrawn because the MRI screen revealed brain abnormalities. No nonsmokers were withdrawn for this reason.|2|||f||||f||||||||||2017-10-11 10:20:53.975593|2017-10-11 10:20:53.975593
NCT00974675|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-08|2017-03-22|2017-03-22||September 29, 2006|Actual|2006-09-29|March 2017|2017-03-01|August 3, 2007|Actual|2007-08-03|August 3, 2007|Actual|2007-08-03||Interventional||Safety population included all participants who received at least 1 dose of investigational medicinal product (IMP: CAT-354 or placebo) including those who did not complete the study.|A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma|A Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Intravenous Doses of 3 Dose Levels of CAT-354 in Subjects With Moderate Asthma|Terminated||Phase 1|23|Actual|MedImmune LLC|Recruitment to the study was terminated before the planned number of participants was enrolled in CAT-354 10 mg/kg group due to the slow recruitment rate.|4||"Study recruitment was terminated before the planned number of subjects was enrolled in CAT-354   10 mg/kg group due to the slow recruitment rate."|f||||f||||||||||2017-10-11 10:21:11.211658|2017-10-11 10:21:11.211658
NCT00975767|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-10|2015-01-06|||August 2009||2009-08-01|January 2015|2015-01-01|August 2014|Actual|2014-08-01|July 2013|Actual|2013-07-01||Interventional|||A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer|A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|126|Actual|Mirati Therapeutics Inc.||2||"The study was terminated due to a need for a reformulation of the study drug. Phase 1   completed, no patients enrolled in Phase 2."|f||||f||||||||||2017-10-11 10:21:42.611709|2017-10-11 10:21:42.611709
NCT00982995|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-21|2015-11-05|2014-09-05||November 2010||2010-11-01|November 2015|2015-11-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional|HUM21469||Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients|UMCC 2008.048 Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients|Terminated||Phase 2|3|Actual|University of Michigan Cancer Center|Accrual for the study was low. Due to issues with funding, we were unable to add a second site in order to accrue additional patients and the study was closed.|1||site terminated due to lack of enrollment|f||||t||||||||||2017-10-11 10:21:51.191932|2017-10-11 10:21:51.191932
NCT00983736|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-22|2012-08-24|||October 2009||2009-10-01|November 2010|2010-11-01|September 2010|Actual|2010-09-01|September 2010|Actual|2010-09-01||Interventional|||Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation|Terminated||Phase 3|1050|Anticipated|Valeant Pharmaceuticals International, Inc.||2||This study was terminated because of recruitment difficulties.|f||||f||||||||||2017-10-11 10:22:04.49106|2017-10-11 10:22:04.49106
NCT00990366|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-05|2011-10-10|||October 2009||2009-10-01|October 2011|2011-10-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve|Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve|Terminated||N/A|15|Actual|Turku University Hospital||2||Interim analysis results, study terminated 5/2010|f||||f||||||||||2017-10-11 10:23:09.891816|2017-10-11 10:23:09.891816
NCT00991016|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-05|2010-11-23|||October 2009||2009-10-01|November 2010|2010-11-01|August 2010|Actual|2010-08-01|August 2010|Actual|2010-08-01||Interventional|||Single and Multiple Dose Safety, Tolerability, and Pharmacokinetics Study of PF-04805712 in Healthy Volunteers|A Phase 1 Randomized, Double Blind (3rd Party Open), Placebo Controlled Combined Single And Multiple Dose Safety, Tolerability And Pharmacokinetics Study Of Orally Administered PF-04805712 In Healthy Volunteers|Terminated||Phase 1|61|Actual|Pfizer||1||"B1411001 was terminated after completion of 4 cohorts of the multiple ascending dose phase, as   additional data were deemed unnecessary. No safety concerns."|f||||f||||||||||2017-10-11 10:23:37.505318|2017-10-11 10:23:37.505318
NCT00992394|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-08|2015-12-04|2014-04-03||January 2010||2010-01-01|December 2015|2015-12-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|ReSPONSE|A total of 174 subjects were randomized.Three subjects were randomized but did not take at least 1 dose of investigational product, and were therefore excluded from the safety population. One subject was excluded from the mITT population. The reason for exclusion was lack of at least one post-baseline PGA.|Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept|Randomized Open-label Study Comparing 2 Different Strategies For Management Of Subjects With Plaque Psoriasis Who Have Responded To Etanercept Treatment|Completed||Phase 4|174|Actual|Pfizer|Enrollment in this study was slower than expected. Thus, recruitment was terminated early and only 58 percent of planned participants were randomized. As a result, no hypothesis testing was conducted and only descriptive statistics are reported.|2|||f||||f||||||||||2017-10-11 10:23:47.749905|2017-10-11 10:23:47.749905
NCT00993421|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-09|2011-06-02|2011-05-11|2011-02-25|October 2009||2009-10-01|June 2011|2011-06-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||A Weight Loss Study in Overweight Men and Women|LY377604 + Sibutramine Hydrochloride Monohydrate: A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women|Terminated||Phase 2|343|Actual|Eli Lilly and Company||7||Clinical trial terminated due to results from recent nonclinical studies|f||||t||||||||||2017-10-11 10:24:06.306155|2017-10-11 10:24:06.306155
NCT00994214|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-13|2016-01-07|2015-10-14||October 2009||2009-10-01|November 2015|2015-11-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|TULIPIA||Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly|Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM 23A760 in Acromegalic Patients|Terminated||Phase 2|109|Actual|Ipsen|The study was terminated prematurely due to lack of efficacy.|4||Preliminary data from this study does not support expected inhibition of GH and IGF-1|f||||f||||||||||2017-10-11 10:24:28.808732|2017-10-11 10:24:28.808732
NCT00985738|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-11|2016-04-15|2016-03-16||September 2009||2009-09-01|March 2016|2016-03-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional||A one sided test of proportions with an alpha level of 0.025 was performed for a conservative Fisher’s exact method. It was estimated that an 80% power in a test of proportions with 100 men in each arm would detect a 17% difference in proportion of men with increased tumor volume (upstaging) between the treatment arm and the control arm.|Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer|A Randomized Placebo-Controlled Double-Blind Clinical Trial to Assess the Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer|Terminated||Phase 2|16|Actual|University of Colorado, Denver|This study was terminated due to low accrual.|2||Low recruitment|f||||t||||||||No||2017-10-11 10:24:45.548627|2017-10-11 10:24:45.548627
NCT00985946|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-25|2017-06-19|2017-03-17||May 2010||2010-05-01|June 2017|2017-06-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional|||Study of Panobinostat in Patients With Neuroendocrine Tumors|A Phase II Trial of Panobinostat in Patients With Neuroendocrine Tumors|Terminated||Phase 2|15|Actual|University of Wisconsin, Madison|This study was terminated early because of the use of objective response rate as the primary outcome measure, which is a shortcoming of this study.|1||Study did not meet statistical requirements to continue.|f||||t||||||||||2017-10-11 10:24:49.613946|2017-10-11 10:24:49.613946
NCT00986258|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-28|2014-05-09|2012-05-31||October 2009||2009-10-01|May 2014|2014-05-01|January 2011|Actual|2011-01-01|December 2010|Actual|2010-12-01||Interventional|||Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability|An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability|Terminated||Phase 3|136|Actual|Grünenthal GmbH|The results of this trial have to be interpreted under the consideration that it was an open-label trial which was prematurely terminated.|1||This clinical trial was terminated early, due to slow recruitment and study drug shortages.|f||||f||||||||||2017-10-11 10:25:07.736503|2017-10-11 10:25:07.736503
NCT00988052|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-28|2017-09-13|||November 30, 2009|Actual|2009-11-30|September 2017|2017-09-01|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course|A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis|Terminated||Phase 3|472|Actual|Teva Pharmaceutical Industries||1||"Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the   study drug in the relevant dose."|f||||t|t|f||||||||2017-10-11 10:25:34.516448|2017-10-11 10:25:34.516448
NCT00994331|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-09|2011-03-08|||October 2009||2009-10-01|March 2011|2011-03-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Stereotaxis Computed Tomography (CT) Co-Registration Study|Randomized Feasibility Study Comparing the Clinical Utility of the Stereotaxis Navigant™ Computed Tomography Angiography Importation and Co- Registration Feature, the NaviView™ Assisted Navigation Feature, and Standard Angiography|Terminated||N/A|4|Actual|Stereotaxis||3||Study terminated due to lack of enrollment.|f||||f||||||||||2017-10-11 10:25:51.545008|2017-10-11 10:25:51.545008
NCT00996892|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-12|2016-11-04|2016-03-03||November 2009||2009-11-01|November 2016|2016-11-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional||All enrolled participants.|Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors|Terminated||Phase 1|178|Actual|Genentech, Inc.|The study was terminated prior to the initiation of Stage 2B and as per changes in planned analysis the data for duration of objective response and PFS were not analyzed.|6||"A recommended Phase 2 dose and schedule was not identified and the study was terminated before   initiation of Stage 2B."|f||||||||||||||2017-10-11 10:25:56.250973|2017-10-11 10:25:56.250973
NCT00996918|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-14|2013-11-12|2013-11-12||December 2009||2009-12-01|November 2013|2013-11-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Interventional|||A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients|A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000|Terminated||Phase 3|198|Actual|Pfizer|Bapineuzumab program was discontinued prematurely. Efficacy results obtained after Week 78 are not presented due to the very small number of participants after this time point.|2||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2017-10-11 10:26:08.584063|2017-10-11 10:26:08.584063
NCT00997243|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-16|2017-04-03|2013-05-07||November 2009|Actual|2009-11-01|April 2017|2017-04-01|May 2011|Actual|2011-05-01|September 2010|Actual|2010-09-01||Interventional|||Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes|Phase II Study of 5-azacytidine and Lintuzumab in Myelodysplastic Syndromes (MDS)|Terminated||Phase 2|7|Actual|Ohio State University Comprehensive Cancer Center|The study was terminated early by the sponsor due to the removal of lintuzumab from the market.|1||Drug no longer being supplied by sponsor|f||||t||||||||||2017-10-11 10:26:17.20143|2017-10-11 10:26:17.20143
NCT00998101|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-17|2012-03-05|||July 2009||2009-07-01|March 2012|2012-03-01|November 2009|Actual|2009-11-01|November 2009|Actual|2009-11-01||Interventional|||Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy|A Phase II Trial of Carboplatin, Ixabepilone and Cetuximab in Chemotherapy Naive Advanced Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|UNC Lineberger Comprehensive Cancer Center||1||Study was withdrawn due issuses related to the science|f||||t||||||||||2017-10-11 10:26:31.65931|2017-10-11 10:26:31.65931
NCT00998608|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-08|2009-10-18|||August 2007||2007-08-01|October 2009|2009-10-01|October 2009|Actual|2009-10-01|July 2009|Actual|2009-07-01||Interventional|||Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia|A Randomized, Double-Blind, Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Combined With Low Dose of Haloperidol in the Treatment of Schizophrenic Disorder|Terminated||Phase 4|88|Actual|Kaohsiung Kai-Suan Psychiatric Hospital||1||terminated|f||||t||||||||||2017-10-11 10:26:42.391325|2017-10-11 10:26:42.391325
NCT00998764|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-16|2015-11-30|2013-10-15||December 2009||2009-12-01|November 2015|2015-11-01|November 2012|Actual|2012-11-01|October 2012|Actual|2012-10-01||Interventional||The safety population included all participants who consented to participate in the extension and received at least one dose of the investigational product (in the extension study).|A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients|A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.|Terminated||Phase 3|494|Actual|Pfizer||1||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2017-10-11 10:26:44.085686|2017-10-11 10:26:44.085686
NCT01001390|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-22|2014-02-27|2014-01-15||October 2009||2009-10-01|January 2014|2014-01-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional||Two participants were enrolled, however, neither participant continued to wear their ankle foot orthoses after the initial visit.|The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop|The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop|Terminated||N/A|2|Actual|St. Jude Children's Research Hospital|The study was terminated due to poor accrual and poor participant compliance.|2||The study closed due to poor accrual and difficulty with participant compliance.|f||||f||||||||||2017-10-11 10:27:47.137656|2017-10-11 10:27:47.137656
NCT01001598|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-22|2014-09-12|||November 2009||2009-11-01|September 2014|2014-09-01|May 2014|Actual|2014-05-01|May 2014|Actual|2014-05-01||Interventional|||Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita|Phase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita|Terminated||Phase 1/Phase 2|5|Actual|Boston Children’s Hospital||1||Study was terminated due to under enrollment|f||||t||||||||||2017-10-11 10:27:50.91554|2017-10-11 10:27:50.91554
NCT01002287|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-26|2014-11-07|2012-06-21||October 2009||2009-10-01|November 2014|2014-11-01|May 2011|Actual|2011-05-01|October 2010|Actual|2010-10-01||Interventional|||An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery|An Evaluation of the SprayShield Adhesion Barrier System in Reducing Post-Operative Adhesion in Abdominal Surgery|Terminated||N/A|11|Actual|Integra LifeSciences Corporation|Early termination leading to small numbers of subjects analyzed|2||Study was terminated for business purposes, not for safety or efficacy reasons.|f||||f||||||||||2017-10-11 10:27:59.211496|2017-10-11 10:27:59.211496
NCT00995449|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-05|2014-06-04|2012-05-07||January 2010||2010-01-01|June 2014|2014-06-01|February 2012|Actual|2012-02-01|March 2011|Actual|2011-03-01||Interventional|||Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis|A Phase 2, Randomized, Placebo‑Controlled, Dose‑Ranging Study to Evaluate the Safety and Efficacy of the Anti-GM-CSF Monoclonal Antibody KB003 in Subjects With Active Rheumatoid Arthritis and Inadequate Prior Treatment Outcome From Biologic Therapy|Terminated||Phase 2|9|Actual|KaloBios Pharmaceuticals|The study was terminated upon completion of safety run-in due to program refocus.|4||Program refocus|f||||t||||||||||2017-10-11 10:28:23.88287|2017-10-11 10:28:23.88287
NCT00995566|ClinicalTrials.gov processed this data on October 10, 2017|2009-09-17|2012-02-06|2011-12-27||April 2010||2010-04-01|May 2011|2011-05-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Observational|PROSE||A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin|Thelin (Sitaxentan Sodium) Patient Safety Registry A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin|Terminated||N/A|54|Actual|Pfizer|The protocol did not identify the priority of endpoints. Therefore, all endpoints arbitrarily assigned as primary.||1|"The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new   emerging evidence of hepatic injury."|f||||f||||||||||2017-10-11 10:28:26.28998|2017-10-11 10:28:26.28998
NCT01004419|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-28|2015-09-30|||November 2009||2009-11-01|September 2015|2015-09-01|May 2011|Anticipated|2011-05-01|November 2010|Anticipated|2010-11-01||Interventional|||Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer|Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|University of Wisconsin, Madison||1||Support for investigational products has been withdrawn.|f||||t||||||||||2017-10-11 10:29:34.202753|2017-10-11 10:29:34.202753
NCT01004822|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-28|2015-10-16|2015-05-11||March 2010||2010-03-01|October 2015|2015-10-01|May 2014|Actual|2014-05-01|May 2014|Actual|2014-05-01||Interventional||Safety analysis population included all randomized subjects who received at least one dose of study medication.|A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors|A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Cvx-241, A Selective Angiopoietin-2 And Vascular Endothelial Growth Factor Binding, Anti-angiogenic Covx-body, In Patients With Advanced Solid Tumors|Terminated||Phase 1|31|Actual|Pfizer|The study was terminated early by the sponsor due to lack of significant pharmacological effects (safety/Pharmacodynamics/efficacy) through 25 mg/kg cohort. Hence, no participant could reach out to Stage 2.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 10:29:39.848093|2017-10-11 10:29:39.848093
NCT01000155|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-20|2017-06-21|2015-09-09||October 2009||2009-10-01|June 2017|2017-06-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional||The analysis dataset is comprised of all treated patients.|Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease|A Phase II Pharmacodynamic Investigation of the Efficacy of Vorinostat to Induce Fetal Hemoglobin in Adults With Severe Sickle Cell Disease Who Have Not Benefitted From Prior Therapy|Terminated||Phase 2|5|Actual|Dana-Farber Cancer Institute|The trial did not meet it's accrual goal due to slow accrual.|1||The study terminated early due to slow accrual.|f||||t||||||||||2017-10-11 10:30:17.15273|2017-10-11 10:30:17.15273
NCT01000493|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-15|2017-08-31|2017-03-31|2012-02-23|November 2, 2009|Actual|2009-11-02|July 2017|2017-07-01|June 28, 2010|Actual|2010-06-28|June 28, 2010|Actual|2010-06-28||Interventional|||Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study Evaluating the Efficacy and Safety of the Neurokinin-1 Receptor Antagonist Orvepitant (GW823296) in Post Traumatic Stress Disorder (PTSD)|Completed||Phase 2|132|Actual|GlaxoSmithKline|The study was prematurely terminated on 11 May 2010 upon the recommendation of the Data Safety Monitoring Board.|2|||f||||t|t|f||||||||2017-10-11 10:30:22.890057|2017-10-11 10:30:22.890057
NCT01006785|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-01|2012-10-17|||August 2009||2009-08-01|October 2012|2012-10-01|March 2012|Actual|2012-03-01|March 2012|Actual|2012-03-01||Interventional|||Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer|Phase II Clinical Study: A Randomized, Open, and Dose Ranging Study to Evaluate the Efficacy and Safety of DLBS1425 in Subjects With Metastatic / Advanced Breast Cancer|Terminated||Phase 2|15|Actual|Dexa Medica Group||2||The study was terminated due to difficulty of find eligible subjects|f||||||||||||||2017-10-11 10:30:32.63095|2017-10-11 10:30:32.63095
Withdrawn prior to exposure to study drug (N=2) Oxytocin N=1 withdrawn due to abnormal EKG Placebo N=1 Participant withdrew consent
NCT01014442|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-16|2016-12-19|2016-12-19||January 2010||2010-01-01|July 2015|2015-07-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional||The safety population included all participants who received at least one dose of study drug and a safety follow-up, whether withdrawn prematurely or not.|A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients|Pharmacokinetics of Mycophenolate Mofetil in de Novo Lung Allograft Recipients|Completed||Phase 3|68|Actual|Hoffmann-La Roche||2|||f||||||||||||||2017-10-11 10:32:19.672362|2017-10-11 10:32:19.672362
NCT01016847|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-19|2014-11-07|2014-11-07||January 2010||2010-01-01|December 2012|2012-12-01|November 2013|Actual|2013-11-01|November 2013|Actual|2013-11-01||Interventional|||Moderate to Persistent Asthma in the Obese Subject|A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study to Evaluate the Effect of the Leukotriene Antagonist (Singulair©) Plus Moderate Dose Beclomethasone Compared to High Dose Beclomethasone in Obese Subjects With Moderate Persistent Asthma|Terminated||Phase 4|38|Actual|Duke University|Early terminiation due to poor enrollment.|2||Unable to enroll enough study subjects. Study has been terminated|f||||t||||||||||2017-10-11 10:32:57.173294|2017-10-11 10:32:57.173294
NCT01017263|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-19|2014-02-18|2013-09-13||December 2009||2009-12-01|September 2013|2013-09-01|August 2012|Actual|2012-08-01|August 2012|Actual|2012-08-01||Interventional|||Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity|Vyvanse and Glucose Intolerance in Children With ADHD and Obesity|Terminated||Phase 4|14|Actual|Duke University|Study was terminated due to the high number of failures of lab criteria for glucose intolerance which is one of the entry criterion. No data were analyzed.|1||Due very high screen fail rate, pre study feasibility not consistent with screened population.|f||||f||||||||||2017-10-11 10:33:09.961915|2017-10-11 10:33:09.961915
NCT01017822|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-20|2013-06-21||||||June 2013|2013-06-01||||||||Interventional|||Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase I/II Study of Induction Conatumumab and Gemcitabine, Followed by Conatumumab, Capecitabine and 3-D Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Radiation Therapy Oncology Group||1||This study was withdrawn due to study agent availability.|f||||t||||||||||2017-10-11 10:33:19.097062|2017-10-11 10:33:19.097062
NCT01017991|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-20|2015-03-25|||December 2009||2009-12-01|December 2012|2012-12-01|March 2013|Actual|2013-03-01|August 2012|Actual|2012-08-01||Interventional|||Feeding Intervention for Infants With Crying|"Effects of an Infant Formula With Probiotics on Signs and Symptoms of Colic."|Terminated||N/A|65|Actual|Nestlé||2||The study has been terminated as a result of low enrollment.|f||||f||||||||||2017-10-11 10:33:23.447907|2017-10-11 10:33:23.447907
NCT01009931|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-06|2015-11-02|2015-06-16||March 2011||2011-03-01|November 2015|2015-11-01|September 2014|Actual|2014-09-01|October 2011|Actual|2011-10-01||Interventional|||Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies|A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia|Terminated||Phase 2|1|Actual|Rutgers, The State University of New Jersey||1||Study was terminated early due to lack of experimental medication (supply issues)|f||||f||||||||||2017-10-11 10:33:47.061236|2017-10-11 10:33:47.061236
NCT01010594|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-09|2013-03-20|||November 2009||2009-11-01|March 2013|2013-03-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|||Two Pieces of Fruit to Type 2 Diabetics?|Two Pieces of Fruit to Type 2 Diabetics?|Terminated||N/A|64|Actual|Hospitalsenheden Vest||2||PI changed job and project was not economically viable and therefor terminated|f||||t||||||||||2017-10-11 10:33:59.930896|2017-10-11 10:33:59.930896
NCT01010685|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-07|2014-02-04|||December 2009||2009-12-01|February 2014|2014-02-01|March 2014|Anticipated|2014-03-01|March 2014|Anticipated|2014-03-01||Interventional|||Safety Study of Keyhole Gallbladder Surgery With Removal of Gallbladder Via the Stomach Rather Than Through the Skin|Safety and Feasibility Trial of Laparoscopic Small Port Cholecystectomy With Transgastric Gallbladder Recovery|Withdrawn||N/A|0|Actual|Colchester Hospital University NHS Foundation Trust||1||Specialised equipment required withdrawn from market|f||||t||||||||||2017-10-11 10:34:00.963749|2017-10-11 10:34:00.963749
NCT01011634|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-09|2013-05-14|2013-02-24||May 2007||2007-05-01|May 2013|2013-05-01|November 2008|Actual|2008-11-01|November 2008|Actual|2008-11-01||Interventional|||Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions|A Double Blinded, Placebo-controlled Randomized Control Trial Comparing Intravenous Moderate Sedation and Oral/Sublingual Analgesia/Anxiolysis for First Trimester Surgical Abortions|Terminated||Phase 4|18|Actual|University of California, San Francisco||2||7% enrollment. Study terminated after a small number of recruited patients|f||||t||||||||||2017-10-11 10:34:21.852204|2017-10-11 10:34:21.852204
NCT01018810|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-24|2011-07-27|2011-06-01|2011-02-25|December 2009||2009-12-01|July 2011|2011-07-01|August 2010|Actual|2010-08-01|May 2010|Actual|2010-05-01||Interventional|||A Study for Adults With Plaque Psoriasis|LY2525623 (IL-23 Antibody) Multiple-Dose Study in Adults With Plaque Psoriasis|Terminated||Phase 2|8|Actual|Eli Lilly and Company|Study BDAD was terminated early due to non-safety related complexities in LY2525623 development. Numerical summaries and statistical comparisons for the 8 patients enrolled are not appropriate and may be scientifically/clinically misleading.|7||"The trial was terminated for several reasons, including complexities in development of   LY2525623, but not because of safety concerns"|f||||t||||||||||2017-10-11 10:34:34.529183|2017-10-11 10:34:34.529183
NCT01024244|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-01|2011-11-29|2011-09-15|2011-02-25|December 2009||2009-12-01|November 2011|2011-11-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|||A Study of LY2599506 in Patients With Type 2 Diabetes|A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients With Type 2 Diabetes Mellitus Treated With Diet and Exercise, With or Without Metformin|Terminated||Phase 2|78|Actual|Eli Lilly and Company|Since Study GMAH was terminated after enrolling only 78 participants with just 10 participants completing 12 weeks of treatment with LY2599506, only disposition, demographics, and safety data are reported.|5||Terminated due to nonclinical safety findings|f||||f||||||||||2017-10-11 10:35:15.489834|2017-10-11 10:35:15.489834
NCT01015300|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-16|2012-05-09|||December 2009||2009-12-01|May 2012|2012-05-01|April 2012|Actual|2012-04-01|October 2011|Actual|2011-10-01||Interventional|||Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease|D0904 - A Pilot Study of Bevacizumab (Avastin) in Patients With Unresectable or Recurrent Hemangioblastoma From Von Hippel-Lindau Disease.|Terminated||Early Phase 1|1|Actual|Dartmouth-Hitchcock Medical Center||1||Study terminated due to low accrual.|f||||t||||||||||2017-10-11 10:35:44.997401|2017-10-11 10:35:44.997401
NCT01015443|ClinicalTrials.gov processed this data on October 10, 2017|2009-10-01|2016-09-16|2016-06-17||December 2009||2009-12-01|September 2016|2016-09-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|INSPIRE|Intention to treat (ITT) subjects included all the subjects randomized into the study.|Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population|A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects With Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy|Terminated||Phase 3|285|Actual|Merck KGaA|The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.|2||"The study is terminated prematurely as the sponsor decided to discontinue program with   Tecemotide in NSCLC."|f||||t||||||||||2017-10-11 10:35:46.778658|2017-10-11 10:35:46.778658
NCT01015677|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-17|2017-06-05|2016-02-26||December 17, 2009|Actual|2009-12-17|June 2017|2017-06-01|July 30, 2010|Actual|2010-07-30|July 30, 2010|Actual|2010-07-30||Interventional|||A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)|A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Examine MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Women|Terminated||Phase 2|99|Actual|Merck Sharp & Dohme Corp.|The study was terminated at the end of Stage 1 so no participants entered Stage 2 and no participants received MK-6913 25 mg.|4|||f||||f||||||||||2017-10-11 10:35:51.204768|2017-10-11 10:35:51.204768
NCT01016054|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-16|2013-02-26|||October 2009||2009-10-01|February 2013|2013-02-01|April 2010|Actual|2010-04-01|April 2010|Actual|2010-04-01||Interventional|||A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer|A Phase 1b, Parallel Arm, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Two Different Chemotherapy Regimens in Women With Platinum Resistant or Platinum Sensitive Ovarian Cancer|Terminated||Phase 1|4|Actual|Astellas Pharma Inc||2||Trial was terminated to allow sponsors to evaluate the future development of the drug program|f||||f||||||||||2017-10-11 10:36:00.470897|2017-10-11 10:36:00.470897
NCT01016067|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-17|2015-01-07|2014-10-29||November 2010||2010-11-01|January 2015|2015-01-01|December 2013|Actual|2013-12-01|October 2013|Actual|2013-10-01||Interventional|||Tibial Delayed Healing Pivotal Clinical Trial|A Prospective, Randomized, Multicenter Pivotal Clinical Trial of the INFUSE/MASTERGRAFT™ Delayed Healing Device With Rigid Internal Fixation in the Treatment of Tibial Delayed Healing|Terminated||Phase 3|23|Actual|Medtronic Spinal and Biologics|This trial was terminated due to difficulty in patient recruitment. Early termination led to a small number of subjects analyzed. Results should be interpreted with caution.|2||Difficulty in patient recruitment|f||||t||||||||||2017-10-11 10:36:00.586462|2017-10-11 10:36:00.586462
NCT01025323|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-02|2013-03-12|||December 2007||2007-12-01|March 2013|2013-03-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|SHARPP||Study of Hispanics to Assess Risk Prevention in Prehypertension|Lifestyle Intervention in Multinational Hispanics With Prehypertension|Terminated||N/A|58|Actual|Florida Heart Research Institute||2||"The study was terminated due to difficult recruitment and retention of subjects, these were   attributed by subjects to conflict with their job schedule."|f||||f||||||||||2017-10-11 10:36:06.697479|2017-10-11 10:36:06.697479
NCT01026103|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-03|2014-01-29|2014-01-29||January 2010||2010-01-01|January 2014|2014-01-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional||30 patients consented; 1 patient was withdrawn by physician for elevated liver function test. Twenty-nine (29) patients had baseline characteristics but 1 did not receive study device in error leaving 28 patients enrolled.|Tri Staple Technology Stapler Used in Gastric Bypass|A Prospective, Single-center Investigation of the Safety and Performance of the Endo GIA™ Stapler With Endo GIA™ Sulu With Tri-Staple™ Technology in a Gastric Bypass Procedure|Completed||N/A|28|Actual|Medtronic - MITG||1|||f||||f||||||||||2017-10-11 10:36:16.569833|2017-10-11 10:36:16.569833
NCT01028300|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-08|2016-02-02|2015-12-22||April 2010||2010-04-01|February 2016|2016-02-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Clinical Outcomes of Lumbar Degenerative Disc Disease in Active-Duty U.S. Service Personnel|Clinical Outcomes of Lumbar Degenerative Disc Disease Treated Operatively in Active-Duty U.S. Service Personnel With Lumbar Total Disc Replacement|Terminated||N/A|4|Actual|Synthes USA HQ, Inc.|Study was terminated early due to slow enrollment. Only Two subjects were seen for follow-up visits, and only at 3 months post surgery.|1||Terminated due to enrollment failure|f||||t||||||||||2017-10-11 10:37:14.778032|2017-10-11 10:37:14.778032
NCT01020812|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-24|2016-06-27|2014-12-05||September 2009||2009-09-01|June 2016|2016-06-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma|Phase II Study of Combination Stereotactic Body Radiotherapy (SBRT) With Transarterial Chemo-Embolization (TACE) for Unresectable Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|11|Actual|Stanford University|The low enrollment of patients led to the study being terminated before the full sample size could be reached. This resulted in a smaller than anticipated pool of patients to be analyzed and conclusions that are more difficult to generalize.|1||enrollment was too low|f||||t||||||||||2017-10-11 10:37:47.242161|2017-10-11 10:37:47.242161
NCT01021423|ClinicalTrials.gov processed this data on October 10, 2017|2009-11-25|2012-02-10|2011-10-31||April 2010||2010-04-01|February 2012|2012-02-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|RENEW||A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma|Terminated||Phase 3|9|Actual|Celgene|Study terminated early. Most analyses were not performed.|2||"Terminated by sponsor due to new unpublished data that rendered the current design of the study   no longer clinically relevant. There were no safety concerns."|f||||t||||||||||2017-10-11 10:37:56.369508|2017-10-11 10:37:56.369508
NCT01028586|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-07|2013-03-27|||October 2009||2009-10-01|August 2012|2012-08-01||||May 2012|Actual|2012-05-01||Interventional|MOTION||MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)|A Phase III, Double-blind, Placebo-controlled Extension Trial to Investigate the Long-term Efficacy and Safety of Low (50 mg/Day) and High (100 mg/Day) Dose Safinamide, as add-on Therapy in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist|Terminated||Phase 3|507|Actual|Newron||3||"Trial is terminated due to a company decision to return all rights for Safinamide back to   Newron Pharmaceuticals"|f||||t||||||||||2017-10-11 10:38:18.069109|2017-10-11 10:38:18.069109
NCT01033734|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-15|2016-07-13|2016-01-15||December 2010||2010-12-01|July 2016|2016-07-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional||All-participants population included all participants who were enrolled in the study.|A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza|An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection|Completed||Phase 1|8|Actual|Hoffmann-La Roche|Low number of participants enrolled in the study at the time that the study was terminated limits conclusions that can be derived from the study data.|1|||f||||||||||||||2017-10-11 10:38:25.417169|2017-10-11 10:38:25.417169
NCT01034657|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-16|2017-08-08|2016-08-25||November 2009||2009-11-01|August 2017|2017-08-01|August 2012|Actual|2012-08-01|August 2012|Actual|2012-08-01||Interventional|GEPARD|Core Phase (all participants)|LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)|A One Year, Open Label, Multicenter Trial of LBH589 Alone or in Combination With ESA in Red Blood Cell Transfusion-dependent LOW and INT-1 MDS Patients Being Either Refractory to ESA or With a Low Probability of Response - the GErman PAnobinostat Low Risk MDS Trial - GEPARD Study|Terminated||Phase 2|34|Actual|Novartis||2||"The study was terminated due to lack of efficacy of single agent LBH589 in the 4 month open   label core phase and due to enrollment difficulties."|f||||||||||||||2017-10-11 10:38:54.559386|2017-10-11 10:38:54.559386
NCT01035216|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-17|2014-12-22|||September 2009||2009-09-01|September 2011|2011-09-01|November 2013|Actual|2013-11-01|November 2013|Actual|2013-11-01||Interventional|||A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Terminated||Phase 1|18|Actual|SBI Biotech Co., Ltd.||1||This study has been terminated.|f||||f||||||||||2017-10-11 10:39:03.419737|2017-10-11 10:39:03.419737
NCT01025492|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-01|2016-07-19|2016-07-19||November 2009||2009-11-01|July 2016|2016-07-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional||The clinical trial collaborator/corporate sponsor prematurely terminated the study and did not provide unblinding information to the investigator or study team. It is not known to which arm/group each of the participants enrolled, therefore all enrolled subjects were included in a single arm/group.|Study of Trilipix Effects on Lipids and Arteries|Mechanisms of Atheroprotection by Fenofibric Acid (ABT 335) Added to a Statin in Subjects With Insulin Resistance (Hypertriglyceridemia and Low HDL-C)|Terminated||Phase 4|24|Actual|University of Utah||2||Collaborator/corporate sponsor withdrew funding and permission to continue.|f||||f||||||||No||2017-10-11 10:39:26.221123|2017-10-11 10:39:26.221123
NCT01025713|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-01|2015-07-07|||December 2009||2009-12-01|July 2015|2015-07-01|April 2010|Anticipated|2010-04-01|March 2010|Actual|2010-03-01||Interventional|||A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)|Withdrawn||Phase 1|0|Actual|Gilead Sciences||3||Development program terminated.|f||||f||||||||||2017-10-11 10:39:29.403371|2017-10-11 10:39:29.403371
NCT01036399|ClinicalTrials.gov processed this data on October 10, 2017|2009-07-07|2012-08-24|||November 2008||2008-11-01|August 2012|2012-08-01|August 2011|Actual|2011-08-01|August 2009|Actual|2009-08-01||Interventional|||Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients||Terminated||Phase 2|9|Actual|University of Bologna||1||"The EC withdrawn the approval becuase of possible conflicts of interests between our Institute   and Supporter (Celgene)"|f||||t||||||||||2017-10-11 10:39:42.63247|2017-10-11 10:39:42.63247
NCT01036529|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-17|2013-09-30|2013-06-04||February 2010||2010-02-01|September 2013|2013-09-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional|Evidence|This represents the number of subjects with demographic information provided at enrollment (collected before baseline visit).|Spinal Cord Stimulation With Precision® System Versus Reoperation for Failed Back Surgery Syndrome|Spinal Cord Stimulation With Precision® Spinal Cord Stimulation System Versus Reoperation for Failed Back Surgery Syndrome|Terminated||Phase 4|28|Actual|Boston Scientific Corporation|This study was terminated early due to slow enrollment. Only 28 of the 200 planned subjects were enrolled. Based on the small numbers and early termination, the primary outcome measures were not analyzed.|2||Closed due to continued slow enrollment.|f||||f||||||||||2017-10-11 10:39:43.806398|2017-10-11 10:39:43.806398
NCT01038752|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-22|2015-05-04|2014-10-15||August 2010||2010-08-01|May 2015|2015-05-01|May 2013|Actual|2013-05-01|November 2012|Actual|2012-11-01||Interventional|||Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer|Combination of Non-Cytotoxic Suramin With Docetaxel and Carboplatin in Chemo-Naive Non-small Cell Lung Cancer (NSCLC): A Randomized Single-Blind Placebo-Controlled Phase II Study|Terminated||Phase 2|14|Actual|Optimum Therapeutics, LLC|The study was terminated prematurely due to the loss of follow-up of 6 of 14 participants before progression and slow accrual. Due to the resulting small numbers, no analysis was attempted.|2|||f||||t||||||||||2017-10-11 10:39:56.969169|2017-10-11 10:39:56.969169
NCT01040208|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-28|2016-07-14|2013-06-06||January 2010||2010-01-01|July 2016|2016-07-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Interventional|||12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress|Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire|Terminated||Phase 3|111|Actual|Sprout Pharmaceuticals, Inc||3||Study terminated by Sponsor for administrative reasons prior to completion|f||||t||||||||||2017-10-11 10:40:21.046132|2017-10-11 10:40:21.046132
NCT01028911|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-07|2014-05-16|2014-04-09||December 2009||2009-12-01|May 2014|2014-05-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional||Safety population included all participants who took at least 1 dose of study drug.|A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease|A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy|Terminated||Phase 1|9|Actual|Pfizer|The study was terminated early due to slow recruitment and the need to use the existing information to determine dosing for another study.|2||"This study terminated 27Apr2010 due to slow recruitment and the need to use the existing   information to determine dosing for another study."|f||||f||||||||||2017-10-11 10:40:23.453074|2017-10-11 10:40:23.453074
NCT01029795|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-09|2011-11-29|2011-09-15|2011-02-25|February 2010||2010-02-01|November 2011|2011-11-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus|A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus|Terminated||Phase 2|38|Actual|Eli Lilly and Company|Since Study GMAJ was terminated after enrolling only 38 participants with just 1 participant completing 12 weeks of treatment, only disposition, demographics, and safety data are reported.|2||Terminated due to nonclinical safety findings|f||||f||||||||||2017-10-11 10:40:40.725254|2017-10-11 10:40:40.725254
NCT01030666|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-10|2016-09-28|2012-09-22||April 2007||2007-04-01|September 2016|2016-09-01|February 2011|Actual|2011-02-01|January 2011|Actual|2011-01-01||Interventional|GTRDOXY||Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy|Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy. A Randomized Placebo-controlled Clinical Trial|Terminated||Phase 4|61|Actual|Goethe University|The study had to be terminated due to shelf life of test drug running out prior to including 90 patients resulting in the low test power of 50%.|2||shelf life of investigational drug ran out before 90 patients could be included|f||||f||||||||No||2017-10-11 10:40:50.345492|2017-10-11 10:40:50.345492
NCT01032044|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-11|2016-03-22|2015-11-03||February 2010||2010-02-01|March 2016|2016-03-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional|CLEAN-MARGIN|Exploratory analysis of the data according to the intent-to-treat principle resulted in no suggestion of systematic bias in the two groups regarding withdrawals. Only 1 patient was withdrawn because of intolerance to fluorescein.|CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia|Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia|Completed||N/A|164|Actual|Mauna Kea Technologies||2|||f||||f||||||||||2017-10-11 10:41:11.321942|2017-10-11 10:41:11.321942
NCT01032694|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-14|2011-11-21|2011-11-21||April 2010||2010-04-01|November 2011|2011-11-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Observational|PROSTO||Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia|Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia|Terminated||N/A|30|Actual|Pfizer|||2|"This study was terminated January 11, 2011 due to low enrollment. This study is not being   terminated because of safety or efficacy concerns."|f||||f||||||||||2017-10-11 10:41:23.828033|2017-10-11 10:41:23.828033
NCT01042678|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-01|2014-04-14|2014-04-14||February 2010||2010-02-01|April 2014|2014-04-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema|A Phase I/II, Open-label, Single Ascending Dose Study Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of Intravitreal MP0112 in Patients With Diabetic Macular Edema (DME)|Terminated||Phase 1|18|Actual|Allergan||6||The study was terminated due to a company decision.|f||||t||||||||||2017-10-11 10:42:00.123161|2017-10-11 10:42:00.123161
NCT01036724|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-17|2017-08-30|2014-06-18||November 1, 2009|Actual|2009-11-01|August 2017|2017-08-01|August 25, 2010|Actual|2010-08-25|August 1, 2010|Actual|2010-08-01||Observational|CO1||Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation|Comparative Study of Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation|Terminated||N/A|107|Actual|Biosense Webster, Inc.|The study was terminated early, with 107 enrolled and 93 evaluable subjects, due to difficulty enrolling despite prolonged extension of the enrollment period. The original design called for 176 enrolled and 122 evaluable patients.||2|Enrollment challenges|f||||f||||||||||2017-10-11 10:42:25.081565|2017-10-11 10:42:25.081565
NCT01036802|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-18|2016-04-05|2013-07-03||December 2009||2009-12-01|January 2014|2014-01-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Interventional|||Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease|An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease|Terminated||Phase 2|3|Actual|University of North Carolina, Chapel Hill|This study was terminated early due to difficulty in accruing subjects.|2||Difficulty in accruing subjects|f||||t||||||||||2017-10-11 10:42:26.7985|2017-10-11 10:42:26.7985
NCT01045694|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-07|2017-09-07|2017-05-18||March 2011||2011-03-01|September 2017|2017-09-01|October 2015|Actual|2015-10-01|August 2012|Actual|2012-08-01||Interventional||8 participants were randomized; 2 withdrew voluntarily. Study was terminated due to lack of funds, and unblinding did not occur - it is not known how many participants were placed in each group.|Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint|Botulinum Toxin Versus Steroid Injection for Basal Joint Arthritis of the Thumb: a Randomized, Double Blind, Placebo-controlled Clinical Trial|Terminated||Phase 4|8|Actual|University of Missouri-Columbia|The study was terminated early due to lack of funds and no data was analyzed.|3||Unable to acquire additional funding needed to continue this study.|f||||t||||||||||2017-10-11 10:42:50.380521|2017-10-11 10:42:50.380521
NCT01045798|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-07|2017-02-21|2013-03-26||December 2010||2010-12-01|February 2017|2017-02-01|April 2012|Actual|2012-04-01|April 2012|Actual|2012-04-01||Interventional|||Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)|MSG-04 (Also Known as Merck Caspofungin Protocol 067): A Pilot, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Empirical Therapy for Invasive Candidiasis in High-Risk Patients in the Critical Care Setting|Terminated||Phase 2|15|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to low participant enrollment.|2||Low participant enrollment: 15 enrolled of 114 planned|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT01047319|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-08|2017-09-13|||April 30, 2010|Actual|2010-04-30|September 2017|2017-09-01|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis|A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis|Terminated||Phase 3|634|Actual|Teva Pharmaceutical Industries||1||"Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the   study drug in the relevant dose"|f||||t|t|f||||||||2017-10-11 10:43:16.220563|2017-10-11 10:43:16.220563
NCT01048723|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-13|2013-11-21|2012-07-13||January 2010||2010-01-01|July 2012|2012-07-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|||Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas|A Single-arm, Open Label Phase II Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas|Terminated||Phase 2|2|Actual|H. Lee Moffitt Cancer Center and Research Institute|This study was terminated early due to sponsor budget cuts. We could not meet our accrual goal to perform planned analysis of 40 participants.|1||Novartis terminated funding|f||||t||||||||||2017-10-11 10:43:58.801512|2017-10-11 10:43:58.801512
NCT01049217|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-13|2013-08-27|2013-05-06||April 2010||2010-04-01|August 2013|2013-08-01|May 2012|Actual|2012-05-01|May 2012|Actual|2012-05-01||Interventional|||Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial Of Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081244)|Terminated||Phase 3|377|Actual|Pfizer|Based on Data Monitoring Committee (DMC) interim efficacy analysis results indicating a low probability for success, the study was terminated on April 2, 2012; the termination was unrelated to any safety findings that could impact participant health.|2||See termination reason in detailed description.|f||||t||||||||||2017-10-11 10:44:06.058084|2017-10-11 10:44:06.058084
NCT01049776|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-12|2014-09-16|2014-08-11||January 2010||2010-01-01|September 2014|2014-09-01||||March 2014|Actual|2014-03-01||Interventional||Stratification was performed based on histology of disease. Enrollment was targeted to 21 patients with squamous histology and 21 patients with non- squamous histology. Due to the lack of patients with squamous histology, the study was closed prior to meeting the enrollment goal of 44 subjects.|GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line|A Phase II Study of GW786034 in Patients With Non Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens. An Institutional Pilot Study|Terminated||Phase 2|32|Actual|Illinois CancerCare, P.C.|Due to the lack of patients with squamous histology, the study was closed prior to meeting the enrollment goal of 44 subjects.|1||"Study was terminated due to positive results seen in statistical analysis. Adequate patient   enrollment was achieved."|f||||f||||||||||2017-10-11 10:44:18.79906|2017-10-11 10:44:18.79906
NCT01050946|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-14|2015-10-21|2015-08-26||July 2009||2009-07-01|October 2015|2015-10-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|Haplo/Cord||Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit|Phase II Study: HSCT Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit|Terminated||Phase 2|1|Actual|Medical College of Wisconsin||1||Only one patient was enrolled. Due to low accrual study was terminated|f||||t||||||||||2017-10-11 10:44:39.428519|2017-10-11 10:44:39.428519
NCT01044966|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-06|2015-10-01|||September 2009||2009-09-01|September 2013|2013-09-01|September 2014|Actual|2014-09-01|August 2013|Actual|2013-08-01||Interventional|||A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma|Phase I/II Intraventricular DepoCyt (OD # 06-2348) in Glioblastoma (76,730, 11/06)|Terminated||Phase 1/Phase 2|29|Actual|Medical University of South Carolina||1||The study was terminated due to lack of adequate patient enrollment into trial.|f||||t||||||||||2017-10-11 10:44:54.218047|2017-10-11 10:44:54.218047
NCT01051440|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-14|2012-12-19|2012-07-30||February 2010||2010-02-01|December 2012|2012-12-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|||Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression|A Magnetic Resonance Spectroscopy and fMRI Study of the Effects of Lisdexamfetamine on Bipolar Depression|Terminated||Phase 4|2|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.|The study was terminated before completion due to low enrollment. One subject was randomized to lisdexamfetamine and one was randomized to placebo. Therefore, it was not possible to obtain complete data.|2||Slow enrollment|f||||||||||||||2017-10-11 10:45:12.268669|2017-10-11 10:45:12.268669
NCT01053663|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-20|2016-06-16|2016-01-15||January 2011||2011-01-01|June 2016|2016-06-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional||All-participants population included all participants who were enrolled in the study.|A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza|An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection|Terminated||Phase 1|9|Actual|Hoffmann-La Roche|Low number of participants enrolled in the study at the time that the study was terminated limits conclusions that can be derived from the study data.|1||The study was terminated prematurely after three influenza seasons.|f||||||||||||||2017-10-11 10:45:34.192937|2017-10-11 10:45:34.192937
NCT01048593|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-11|2012-08-16|2012-05-24||January 2010||2010-01-01|August 2012|2012-08-01|June 2010|Actual|2010-06-01|May 2010|Actual|2010-05-01||Interventional|||Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery|A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Cataract Surgery Patients|Terminated||Phase 2|6|Actual|ICON Bioscience Inc|Early termination leading to small numbers of subjects analyzed.|3||Study was terminated in order to examine study data.|f||||f||||||||||2017-10-11 10:45:50.252765|2017-10-11 10:45:50.252765
NCT01054911|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-20|2016-08-02|2016-01-26||October 2009||2009-10-01|August 2016|2016-08-01|September 2015|Actual|2015-09-01|September 2014|Actual|2014-09-01||Interventional||Gastrointestinal stromal tumor comprise 1% of gastrointestinal tumors. There are 6000 new cases per year in the United States without apparent geographic, ethnic, or gender prevalence.|Evaluation of Patients With Bulky GIST Using Sunitinib|Pilot Trial of Neoadjuvant Sunitinib in Patients With Bulky GIST|Terminated||N/A|5|Actual|University of Alabama at Birmingham|This Pilot trial was terminated early due sluggish accrual; thereby, resulting in much smaller numbers.|1||poor accrual|f||||t||||||||No||2017-10-11 10:46:01.017021|2017-10-11 10:46:01.017021
NCT01056315|ClinicalTrials.gov processed this data on October 10, 2017|2009-12-21|2013-04-19|2012-04-05||November 2009||2009-11-01|April 2013|2013-04-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Interventional|||A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Analgesic Efficacy and Safety of a New Analgesic Compared to Placebo in Subjects With Painful Diabetic Peripheral Neuropathy|Terminated||Phase 2|553|Actual|Grünenthal GmbH|No participants were analyzed as the study was terminated|2||Trial was stopped due to difficult enrolment|f||||f||||||||||2017-10-11 10:46:09.94732|2017-10-11 10:46:09.94732
NCT01056601|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-25|2012-11-06|2011-07-28||September 2010||2010-09-01|November 2012|2012-11-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy|Phase II Study of Panobinostat (LBH589) Given in Combination With Bortezomib (Velcade) in Patients With Pancreatic Cancer Progressing on Gemcitabine Therapy Alone or Gemcitabine in Combination|Terminated||Phase 2|7|Actual|Masonic Cancer Center, University of Minnesota|Study was terminated early leading to small numbers of subjects analyzed; no solid conclusion can be derived.|1||Funding not available|f||||t||||||||||2017-10-11 10:46:17.183522|2017-10-11 10:46:17.183522
NCT01057901|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-25|2014-06-16|2014-04-14||January 2010||2010-01-01|June 2014|2014-06-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Interventional|||Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America|24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America|Terminated||Phase 3|748|Actual|Sprout Pharmaceuticals, Inc||2||Study terminated for administrative reasons.|f||||t||||||||||2017-10-11 10:46:39.231721|2017-10-11 10:46:39.231721
NCT01055600|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-07|2015-05-11|||March 2013||2013-03-01|May 2015|2015-05-01|July 2014|Anticipated|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||Milk-only Lactation Study for Patients on Eltrombopag|A Phase IV Study Evaluating Eltrombopag Concentrations in Breast Milk of Nursing Mothers Taking Eltrombopag|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||1||"Protocol opened to recruitment in Nov 2009. No potential subjects identified in 5 years;   therefore, study was terminated in Jul 2014 due to lack of feasibility"|f||||f||||||||||2017-10-11 10:47:44.312793|2017-10-11 10:47:44.312793
NCT01065441|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-07|2012-11-29|||December 2009||2009-12-01|May 2011|2011-05-01|July 2012|Anticipated|2012-07-01|December 2011|Anticipated|2011-12-01||Interventional|||Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer|A Phase I/II Study of an Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancers|Withdrawn||Phase 1/Phase 2|0|Actual|Immunovative Therapies, Ltd.||1||Protocol withdrawn for lack of financial support|f||||f||||||||||2017-10-11 10:47:54.772788|2017-10-11 10:47:54.772788
NCT01065623|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-08|2014-09-30|||April 2010||2010-04-01|September 2014|2014-09-01|August 2010|Actual|2010-08-01|August 2010|Actual|2010-08-01||Interventional|||Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors|An Open Label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY79-4620 Administered as an Intravenous Infusion Once Every 2 Weeks in Patients With Advanced Solid Tumors|Terminated||Phase 1|2|Actual|Bayer||1||The study was terminated due to safety reasons|f||||f||||||||||2017-10-11 10:48:01.10948|2017-10-11 10:48:01.10948
The study was prematurely terminated due to high screening failures and low recruitment rate. Therefore, the data only showed a trend."|1|||f||||||||||||||2017-10-11 10:48:04.820013|2017-10-11 10:48:04.820013
NCT01067118|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-09|2017-02-09|||April 2010||2010-04-01|February 2017|2017-02-01|June 2011|Anticipated|2011-06-01|January 2011|Anticipated|2011-01-01||Interventional|||A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.|Ultra-Short Acting Insulin Versus Short Acting Insulin Effect on Postprandial Hyperglycemia AKA RCT Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Glycemia|Withdrawn||Phase 2|0|Actual|Stanford University||2||The study was suspended due to lack of study drug|f||||t||||||||||2017-10-11 10:48:27.160968|2017-10-11 10:48:27.160968
NCT01067326|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-08|2013-01-09|2013-01-09||February 2010||2010-02-01|January 2013|2013-01-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis|The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis|Terminated||Phase 3|22|Actual|Mayo Clinic|The study was terminated early due to safety concerns from the ALTITUDE trial; there was an unexpected increase in adverse events (non-fatal stroke, renal complications, hyperkalemia and hypotension). Novartis ended all studies regarding Aliskiren.|2||Novartis ended all studies regarding Aliskiren.|f||||f||||||||||2017-10-11 10:48:28.582714|2017-10-11 10:48:28.582714
NCT01069120|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-10|2014-08-05|2014-06-25||April 2009||2009-04-01|August 2014|2014-08-01|August 2009|Actual|2009-08-01|August 2009|Actual|2009-08-01||Interventional||Study prematurely terminated|Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids|A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex® in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304|Terminated||Phase 3|27|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|2||Repros stopped study due to safety and FDA placed study on hold|f||||t||||||||||2017-10-11 10:49:46.577001|2017-10-11 10:49:46.577001
NCT01069965|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-16|2014-09-26|||October 2010||2010-10-01|September 2014|2014-09-01|October 2011|Actual|2011-10-01|August 2011|Actual|2011-08-01||Interventional|||Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus|Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety & Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin & Sulfonylurea or Metformin in T2 Diabetic Patients|Terminated||Phase 2|196|Actual|N-Gene Research Laboratories, Inc.||6||Funding support withdrawn.|f||||f||||||||||2017-10-11 10:50:00.138937|2017-10-11 10:50:00.138937
NCT01065051|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-08|2013-12-31|2013-11-04||November 2010||2010-11-01|December 2013|2013-12-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Interventional|HEARTWORK||Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)|Terminated||Phase 2|1|Actual|Bayer|The study was terminated prematurely due to low recruitment (one subject enrolled only). No statistical analyses of efficacy parameters were performed. Therefore, no clinically meaningful conclusions can be drawn from the data generated.|2|||f||||f||||||||||2017-10-11 10:51:01.629542|2017-10-11 10:51:01.629542
NCT01071993|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-18|2017-08-14|2017-04-07||March 2010||2010-03-01|August 2017|2017-08-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|SCIN|Participants signed consent; however, study was terminated prior to randomization.|Efficacy of Statins In Prevention of CIN|Efficacy Of Statins In The Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Insufficiency (SCIN Trial): A Double-Blind, Placebo-Controlled Trial|Terminated||N/A|21|Actual|University of Oklahoma|Study Sponsor no longer supplied study drug/placebo.|2||Sponsor can not supply drugs anymore.|f||||t||||||||||2017-10-11 10:51:10.748866|2017-10-11 10:51:10.748866
NCT01072227|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-18|2017-05-25|||July 2010||2010-07-01|May 2017|2017-05-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Observational|||Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Taiwan|Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Taiwan|Terminated||N/A|10|Actual|GlaxoSmithKline|||1|The study was terminated for logistic reasons|f||||||||||Samples With DNA|"     Tissue   "|||2017-10-11 10:51:30.167708|2017-10-11 10:51:30.167708
NCT01073852|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-22|2013-01-21|||June 2011||2011-06-01|January 2013|2013-01-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Hydroxychloroquine Efficacy in Chronic Urticaria|Hydroxychloroquine Efficacy in Chronic Urticaria|Withdrawn||N/A|0|Actual|Vanderbilt University||2||withdrawn, not funded|f||||t||||||||||2017-10-11 10:52:00.16184|2017-10-11 10:52:00.16184
NCT01074099|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-01|2015-12-14|2014-08-18||February 2011||2011-02-01|August 2014|2014-08-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|||Feasibility Study of BMAC Enhanced CABG|Feasibility Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting(CABG) Surgery|Terminated||Phase 1/Phase 2|5|Actual|Harvest Technologies|The study was terminated early. Only 5 subjects were enrolled and they were followed for a year for safety data only. One efficacy data was collected.|2||Pilot results in change to protocol, new study needed.|f||||f||||||||||2017-10-11 10:52:14.715676|2017-10-11 10:52:14.715676
NCT01074333|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-22|2014-06-16|||September 2008||2008-09-01|June 2014|2014-06-01|January 2012|Actual|2012-01-01|December 2011|Actual|2011-12-01||Observational|||An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment|Prospective, Multicenter, Observational Study on Erbitux® (Cetuximab) in Patients With EGFR-expressing, KRAS Wild-type Metastatic Colorectal Cancer|Terminated||N/A|146|Actual|Merck KGaA|||1|This study was terminated due to low recruitment|f||||f||||||||||2017-10-11 10:52:20.225186|2017-10-11 10:52:20.225186
NCT01074606|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-23|2012-09-18|||January 2010||2010-01-01|August 2011|2011-08-01||||March 2011|Actual|2011-03-01||Interventional|||Visual Function After Implantation of AcrySof® Toric Lens||Terminated||Phase 4|56|Actual|Alcon Research||1||The study was terminated based on a business decision.|f||||f||||||||||2017-10-11 10:52:25.115281|2017-10-11 10:52:25.115281
NCT01075841|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-24|2014-07-01|||March 2009||2009-03-01|December 2010|2010-12-01||||March 2009|Actual|2009-03-01||Observational|||A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck|A Korean Post-Marketing Surveillance Study On Erbitux (Cetuximab) In Patients With Recurrent And/Or Metastatic Squamous Cell Carcinoma Of The Head And Neck|Withdrawn||N/A|0|Actual|Merck KGaA|||1|"After loss of orphan drug status in Korea, study was withdrawn due to Regulatory Authority   request. Patients will be enrolled into NCT01075828 instead."|f||||f||||||||||2017-10-11 10:52:46.441833|2017-10-11 10:52:46.441833
NCT01077193|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-25|2014-01-08|2013-07-09||November 2009||2009-11-01|January 2014|2014-01-01|May 2012|Actual|2012-05-01|May 2012|Actual|2012-05-01||Interventional||Intent-to-Treat Population: All subjects who underwent the gastric plication surgery.|Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication|Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication|Terminated||N/A|44|Actual|Ethicon Endo-Surgery||1||"Study was terminated due to commercial considerations and potential patient attrition at 3   years. There were no patient safety or procedure efficacy reasons."|f||||f||||||||||2017-10-11 10:53:22.614444|2017-10-11 10:53:22.614444
NCT01078922|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-23|2014-07-02|2014-04-01||February 2010||2010-02-01|July 2014|2014-07-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional|||Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas|A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas|Terminated||Phase 2|11|Actual|Oncology Specialists, S.C.||1||Study terminated due to slow acrual|f||||f||||||||||2017-10-11 10:54:23.674462|2017-10-11 10:54:23.674462
NCT01079949|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-02|2014-01-26|2012-11-12||November 2007||2007-11-01|January 2014|2014-01-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|||A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age|Lutropin Alfa (Luveris®) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age: Phase II Clinical Trial|Terminated||Phase 2|93|Actual|Merck KGaA||2||Trial was terminated due to low recruitment rate|f||||f||||||||||2017-10-11 10:54:44.551073|2017-10-11 10:54:44.551073
NCT01080105|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-02|2012-06-29|||June 2012||2012-06-01|June 2012|2012-06-01|December 2013|Anticipated|2013-12-01|December 2013|Anticipated|2013-12-01||Interventional|AIM||Internet Intervention for the Prevention of Depression - Approaches to Improving Mood|Technology Assisted Behavioral Intervention for the Prevention of Depression|Withdrawn||Phase 1|0|Actual|Northwestern University||3||This is withdrawn because we started working on studies that are funded.|f||||f||||||||||2017-10-11 10:54:48.806727|2017-10-11 10:54:48.806727
NCT01082965|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-26|2013-07-03|2013-07-03||July 2010||2010-07-01|July 2013|2013-07-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional|||Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease|A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease|Terminated||N/A|18|Actual|Pfizer|The study was terminated because of the prohibitively low recruitment rate and the reassessment of the Neuroscience Research Unit portfolio. The decision to terminate the study was not based on any safety or efficacy concerns.|2||"The study was terminated because of slow enrollment. The decision to terminate the trial was   not based on any safety or efficacy concerns."|f||||f||||||||||2017-10-11 10:55:42.75539|2017-10-11 10:55:42.75539
NCT01083160|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-19|2012-01-17|2011-11-23||April 2008||2008-04-01|January 2012|2012-01-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Observational|FALLA||Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use|Clinical Outcomes,Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab. A Multicenter Post-Marketing Observational Study in Routine Clinical Use|Terminated||N/A|82|Actual|Abbott|||1|The study was terminated due to low enrollment because inclusion criteria are obsolete.|f||||||||||||||2017-10-11 10:55:45.949049|2017-10-11 10:55:45.949049
NCT01086761|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-09|2014-04-14|2014-04-14||March 2010||2010-03-01|April 2014|2014-04-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration|A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)|Terminated||Phase 1|32|Actual|Allergan||6||The study was terminated due to a company decision following completion of Part A.|f||||t||||||||||2017-10-11 10:56:46.49828|2017-10-11 10:56:46.49828
NCT01088997|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-12|2016-06-02|2015-05-20||June 2010||2010-06-01|June 2016|2016-06-01|May 2015|Actual|2015-05-01|February 2013|Actual|2013-02-01||Interventional|||Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn|Milrinone Pharmacokinetics and Pharmacodynamics in Newborns With Persistent Pulmonary Hypertension of the Newborn - a Pilot Study to Enable a Randomized Trial of Intervention|Terminated||N/A|12|Actual|Children's Hospital of Philadelphia|Study enrollment was terminated early resulting in a small number of evaluable subjects for analysis.|2||Inadequate enrollment|f||||t||||||||||2017-10-11 10:57:44.146585|2017-10-11 10:57:44.146585
NCT01090830|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-22|2013-03-19|||April 2010||2010-04-01|March 2013|2013-03-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Interventional|HCH003||Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer|Phase Ib/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat When Used in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Untreated Non-small Cell Lung Cancer.|Terminated||Phase 1/Phase 2|7|Actual|Holy Cross Hospital, Florida||1||Principal Investigator has left institution. IND withdrawn.|f||||f||||||||||2017-10-11 10:58:08.7853|2017-10-11 10:58:08.7853
NCT01085513|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-11|2014-05-21|2014-02-25||February 2009||2009-02-01|May 2014|2014-05-01|June 2013|Actual|2013-06-01|December 2012|Actual|2012-12-01||Interventional||no analysis has been performd since study was premature terminated|Diagnosis of Intestinal Motility by Image Analysis Using Capsule Endoscopy|Intestinal Motility Evaluation by Endoluminal Image Analysis Using Capsule Endoscopy (CE-EIA): a Multi-center Clinical Trial|Terminated||Phase 2|143|Actual|Given Imaging Ltd.||2|||f||||f||||||||||2017-10-11 10:58:44.070163|2017-10-11 10:58:44.070163
NCT01092546|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-23|2013-11-20|2013-09-05||March 2010||2010-03-01|November 2013|2013-11-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional||4 of the 16 Subjects were withdrawn prior to study dosing.|Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus|A Principal, Prospective, Open-label Biopsy Study to Validate Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Normal Pressure Hydrocephalus (NPH) Subjects.|Terminated||Phase 3|12|Actual|GE Healthcare||1||Changed focus of the program|f||||t||||||||||2017-10-11 10:59:00.540473|2017-10-11 10:59:00.540473
NCT01095250|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-25|2015-10-05|2015-02-12|2012-05-02|April 2010||2010-04-01|October 2015|2015-10-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|INSURE||Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis|A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)|Terminated||Phase 3|30|Actual|Novartis|Study CAIN457C2302 was terminated to avoid continuing patients on a study with a low probability of success. Since patients did not reach the endpoint of analysis there can be no meaningful interpretation of data and data will be not provided.|4||"Terminated: Study in Behcet's disease with mostly active uveitis did not meet its primary   endpoint."|f||||||||||||||2017-10-11 10:59:05.860173|2017-10-11 10:59:05.860173
NCT01095887|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-26|2015-06-26|2015-06-03||May 2010||2010-05-01|June 2015|2015-06-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|ABOi||Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation|A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi LDKTx)|Terminated||Phase 1/Phase 2|6|Actual|Mayo Clinic|The study was terminated early due to poor enrollment.|1||Poor enrollment|f||||f||||||||||2017-10-11 10:59:16.546184|2017-10-11 10:59:16.546184
NCT01096381|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-30|2012-02-23|||March 2010||2010-03-01|February 2012|2012-02-01|August 2011|Actual|2011-08-01|July 2011|Actual|2011-07-01||Observational|||Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor|A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension|Terminated||N/A|8|Actual|Vanderbilt-Ingram Cancer Center|||2|funding withdrawn due to fellow's departure from VICC|f||||t||||||||||2017-10-11 10:59:25.009882|2017-10-11 10:59:25.009882
NCT01096446|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-30|2014-11-19|2013-11-25||April 2008||2008-04-01|November 2014|2014-11-01|July 2010|Actual|2010-07-01|May 2010|Actual|2010-05-01||Interventional||Twelve infants were randomized into the experimental arm and 10 infants were randomized into the control arm.|Intravenous Fat Emulsions and Premature Infants|Tolerance of Higher Infusion Rates of Intravenous Fat Emulsions in Extremely Low Birthweight Infants During the First Week of Life|Terminated||N/A|19|Actual|OSF Healthcare System|This study was terminated early because 100% of the infants in the experimental grouped developed hypertriglyceridemia (>200 gm/dl), which did not support our primary hypothesis.|2||To many infants in the experimental group developed hypertriglyceridemia|f||||t||||||||||2017-10-11 10:59:25.502325|2017-10-11 10:59:25.502325
NCT01098643|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-02|2017-03-30|||October 2009|Actual|2009-10-01|March 2010|2010-03-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional|||Satisfaction With Placement of Implantable Venous Access Devices in Patients With Solid Tumors|Patient Satisfaction With Placement of Implantable Venous Access Devices|Terminated||N/A|88|Actual|Vanderbilt University Medical Center||1||not enough pts for available to reach goal|f||||f||||||||No|never published, terminated|2017-10-11 11:00:23.678948|2017-10-11 11:00:23.678948
NCT01098864|ClinicalTrials.gov processed this data on October 10, 2017|2010-01-19|2015-03-03|||May 2011||2011-05-01|March 2015|2015-03-01|January 2014|Anticipated|2014-01-01|January 2014|Anticipated|2014-01-01||Interventional|||Transcranial Magnetic Stimulation of the Prefrontal Cortex: Effects on Risky Decision Making and Temporal Discounting.|Transcranial Magnetic Stimulation of the Prefrontal Cortex: Effects on Risky Decision Making and Temporal Discounting.|Withdrawn||N/A|0|Actual|University of Arkansas||1||"Study was withdrawn prior to the first subject being enrolled due to the Co-Investigator   leaving the university"|f||||t||||||||||2017-10-11 11:00:28.063227|2017-10-11 11:00:28.063227
NCT01099020|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-02|2015-05-29|||April 2010||2010-04-01|May 2015|2015-05-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Observational|||Temporal Pattern of Circulating DNA for Patients Receiving Irradiation|Temporal Pattern of Circulating DNA for Patients Receiving Total Body Irradiation|Terminated||N/A|13|Actual|University of Rochester|||1|Funding for project was withdrawn|f||||f||||||||||2017-10-11 11:00:29.183659|2017-10-11 11:00:29.183659
NCT01099397|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-01|2012-08-29|2012-05-10||May 2009||2009-05-01|August 2012|2012-08-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Observational|||Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study|Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study|Completed||N/A|26|Actual|University of Florida|This was a pilot study to evaluate two glucose phenotypes in a small sample from a larger trial. As such, our sample size was small. Further, if participants were withdrawn from the parent trial, they were also withdrawn from the sub-study.||1||f||||f||||||Samples With DNA|"     Serum and plasma   "|||2017-10-11 11:00:34.713053|2017-10-11 11:00:34.713053
NCT01099761|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-02|2017-03-08|2016-05-10|2013-01-24|April 2010||2010-04-01|March 2017|2017-03-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|||Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy|Terminated||Phase 2|24|Actual|Acceleron Pharma, Inc.||3||Based on preliminary safety data.|f||||t||||||||No|Abstract summarizing trial data has been published online in Muscle & Nerve 23-Dec-2016 https://www.ncbi.nlm.nih.gov/pubmed/27462804 The Sponor currently has no plans to make IPD available for a number of reasons; (i) the study was terminated by the Sponsor prematurely based upon concerns for potential adverse drug reactions following long-term use, which were identified in chronic toxicity studies in animals, (ii) the study population was one with a rare disease, in a groups of subjects with a relatively narrow age range, across a small number of study sites. The Sponsor believes that these factors, taken together, make patient anonymity a significant challenge.|2017-10-11 11:00:42.033195|2017-10-11 11:00:42.033195
NCT01100437|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-07|2012-07-05|2012-02-27||April 2010||2010-04-01|November 2011|2011-11-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients|A Single-Center, Randomized, Double-Blind, Two-Way Crossover Study to Evaluate Whether a Single-Dose Administration of Crushed and Whole EMBEDA Induces Clinical Opiate Withdrawal Signs and Symptoms in Opioid-Dependent Patients With Chronic, Non-Cancer Pain Who Are Stabilized on EMBEDA¿|Terminated||Phase 4|14|Actual|Pfizer|Sponsor terminated study early on 10-Mar-2011.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-11 11:00:52.982533|2017-10-11 11:00:52.982533
NCT01092832|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-10|2016-05-17|2014-06-02||October 2010||2010-10-01|May 2016|2016-05-01|June 2013|Actual|2013-06-01|May 2013|Actual|2013-05-01||Interventional||Safety population: all participants who received at least 1 dose of study medication.|A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients|A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric Subjects|Terminated||Phase 3|23|Actual|Pfizer|The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns. Interpretation of the data are limited due to the small sample size and descriptive design.|1||"This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any   safety issues or concerns."|f||||t||||||||||2017-10-11 11:00:56.190976|2017-10-11 11:00:56.190976
NCT01100515|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-05|2010-04-08|||October 1989||1989-10-01|April 2010|2010-04-01|February 2000|Actual|2000-02-01|January 2000|Actual|2000-01-01||Interventional|||Hyperbaric Oxygen Therapy for Acute Domestic Carbon Monoxide (CO) Poisoning|Phase 3 Study of Hyperbaric Oxygen Therapy in Non-Comatose Patients With Acute Domestic Carbon Monoxide Poisoning|Terminated||Phase 3|179|Actual|University of Versailles||2||this study was suspended for futility|f||||f||||||||||2017-10-11 11:01:29.580337|2017-10-11 11:01:29.580337
NCT01103024|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-09|2012-05-02||2012-05-02|December 2010||2010-12-01|May 2012|2012-05-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|INSURE||Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis|A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study)|Terminated||Phase 3|27|Actual|Novartis||4||"Core study in non-infectious active uveitis was terminated. Patients came only for the planned   safety follow-up visit in this extension study."|f||||||||||||||2017-10-11 11:02:02.557206|2017-10-11 11:02:02.557206
NCT01103063|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-07|2015-05-14|2014-08-25||October 2010||2010-10-01|May 2015|2015-05-01|November 2013|Actual|2013-11-01|October 2013|Actual|2013-10-01||Interventional|||Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa|A Phase 3, Open Label, Randomized, Comparative Study To Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa|Terminated||Phase 3|2891|Actual|Pfizer|This program was terminated by Pfizer based on the results of the pre-planned interim analysis for this pivotal study. The interim analysis showed no benefit of the study drug (AZCQ) compared to standard of care (SP).|2||See termination reason in detailed description.|f||||t||||||||||2017-10-11 11:02:03.397089|2017-10-11 11:02:03.397089
NCT01104844|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-14|2013-07-11||||||July 2013|2013-07-01||||||||Interventional|||Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain|Multicentre, Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Analgesic Effects of Different Maxigesic Doses Versus Acetaminophen, Ibuprofen and Placebo for the Teeth Extraction Pain|Withdrawn||Phase 2|0|Actual|AFT Pharmaceuticals, Ltd.||7||The study was withdrawn due to administrative reason|f||||f||||||||||2017-10-11 11:02:23.269721|2017-10-11 11:02:23.269721
NCT01105390|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-15|2013-08-01|||April 2010||2010-04-01|January 2013|2013-01-01||||May 2011|Actual|2011-05-01||Interventional|||AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma|A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||1||withdrawn|f||||||||||||||2017-10-11 11:02:33.778631|2017-10-11 11:02:33.778631
NCT01106846|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-16|2015-07-20|2015-06-18||March 2010||2010-03-01|July 2015|2015-07-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|||Analgesic Effect of Ketamine in Patients Undergoing Hysteroscopic Endometrial Thermal Ablation Surgery|Analgesic Effect of Ketamine in Patients Undergoing Hysteroscopic Endometrial Thermal Ablation Surgery|Terminated||N/A|22|Actual|Northwestern University|Study was terminated early.|2||Resources not available to complete.|f||||f||||||||||2017-10-11 11:03:12.225479|2017-10-11 11:03:12.225479
NCT01107899|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-19|2012-03-07|2011-12-01||October 2009||2009-10-01|March 2012|2012-03-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes|Recovery of Platelet Function After a Loading Dose of Prasugrel or Clopidogrel in Aspirin-Treated Subjects Presenting With Symptoms of Acute Coronary Syndromes|Terminated||Phase 1|29|Actual|Eli Lilly and Company|Trial was terminated early due to enrollment futility which resulted in limited data and the inability to analyze some outcome measures.|3||Terminated due to Enrollment futility|f||||f||||||||||2017-10-11 11:03:45.582967|2017-10-11 11:03:45.582967
NCT01108276|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-20|2012-03-08|||May 2010||2010-05-01|March 2012|2012-03-01|November 2011|Anticipated|2011-11-01|May 2011|Anticipated|2011-05-01||Interventional|||Comparing the Efficacy of the ConvaTec Engenex® Negative Pressure Wound Therapy Device to Moist Wound Therapy|A Prospective, Randomized, Controlled Study Comparing the Efficacy of the ConvaTec Engenex® Negative Pressure Wound Therapy (NPWT) Device to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Wounds|Withdrawn||Phase 4|0|Actual|Georgetown University||1||Study never started and therefore terminated.|f||||f||||||||||2017-10-11 11:03:53.855726|2017-10-11 11:03:53.855726
NCT01110070|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-22|2017-07-06|||July 2010||2010-07-01|July 2017|2017-07-01|December 2012|Actual|2012-12-01|December 2010|Actual|2010-12-01||Interventional|||ChonDux for Filling Full Thickness Cartilage Defects in the Femoral Condyle of the Knee|Pivotal Study in Europe for CE Mark|Terminated||N/A|21|Actual|Zimmer Biomet||2||Enrollment suspended; follow up continue|f||||f||||||||||2017-10-11 11:04:21.580194|2017-10-11 11:04:21.580194
NCT01110330|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-22|2014-04-10|2013-02-26||July 2007||2007-07-01|April 2014|2014-04-01|October 2008|Actual|2008-10-01|October 2008|Actual|2008-10-01||Interventional|||An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot|A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis|Terminated||Phase 3|583|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|The study was terminated prematurely by the sponsor due to significant discrepancies between potassium hydroxide and mycological culture results.|3||"Unexpected discordant results between the KOH microscopy and mycological culture tests at three   study sites in the UK."|f||||f||||||||||2017-10-11 11:04:40.881112|2017-10-11 11:04:40.881112
NCT01110382|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-15|2014-07-02|2014-05-30||December 2010||2010-12-01|July 2014|2014-07-01|September 2013|Actual|2013-09-01|September 2013|Actual|2013-09-01||Interventional|||A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections|A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infections|Terminated||Phase 3|41|Actual|Janssen Research & Development, LLC|This study was terminated early due to business reasons and not related to safety concerns or issues. As such, the limited enrollment precludes a meaningful conclusion about the efficacy and safety of doripenem compared with meropenem.|2||Trial terminated early per business decision|f||||t||||||||||2017-10-11 11:04:42.211647|2017-10-11 11:04:42.211647
NCT01110408|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-15|2014-07-02|2014-05-30||December 2010||2010-12-01|July 2014|2014-07-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections|A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections|Terminated||Phase 3|41|Actual|Janssen Research & Development, LLC|This study was terminated early due to business reasons and not related to safety concerns or issues. As such, the limited enrollment precludes a meaningful conclusion about the efficacy and safety of doripenem compared with cefepime.|2||Trial terminated early per business decision|f||||t||||||||||2017-10-11 11:04:43.041807|2017-10-11 11:04:43.041807
NCT01115036|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-30|2013-06-17|||April 2010||2010-04-01|December 2011|2011-12-01|April 2012|Anticipated|2012-04-01|April 2011|Anticipated|2011-04-01||Interventional|CLBH589C||A Panobinostat Presurgery|Phase II Study of Panobinostat (LBH589) for Recurrent Glioblastoma (GBM) Undergoing Planned Surgical Resection|Withdrawn||Phase 2|0|Actual|Duke University||1||No subjects were enrolled on this study, so study was closed and IND withdrawn.|f||||f||||||||||2017-10-11 11:04:45.326607|2017-10-11 11:04:45.326607
NCT01116232|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-03|2017-05-26|2013-10-22||August 2010||2010-08-01|May 2017|2017-05-01|June 2013|Actual|2013-06-01|May 2013|Actual|2013-05-01||Interventional|||Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation|A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation|Terminated||Phase 2|4|Actual|Barbara Ann Karmanos Cancer Institute|Study terminated due to lack of funding. No analysis, patient data on this protocol due to the fact that only four patients was able to be accrued.|1||Lack of funding.|f||||t||||||||||2017-10-11 11:05:08.263811|2017-10-11 11:05:08.263811
NCT01117129|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-04|2014-03-27|||April 2010||2010-04-01|March 2014|2014-03-01|June 2010|Actual|2010-06-01|June 2010|Actual|2010-06-01||Interventional|||A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)|Efficacy of MabThera in Patients With Rheumatoid Arthritis, by Measurement of Disease Parameters Through Magnetic Resonance of the Hand (RESONAR Study)|Terminated||Phase 4|2|Actual|Hoffmann-La Roche||2||"This study was prematurely terminated as 2 patients were recruited and both of them withdrawn   from the study before reaching the primary end point."|f||||||||||||||2017-10-11 11:05:24.024586|2017-10-11 11:05:24.024586
NCT01117376|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-30|2011-03-30|||May 2010||2010-05-01|May 2010|2010-05-01|August 2011|Anticipated|2011-08-01|June 2011|Anticipated|2011-06-01||Interventional|||Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients|Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients Intolerant to Enteral Feeding|Terminated||Phase 2|42|Anticipated|Shiraz University of Medical Sciences||2||"The study was prematurely terminated because of unavailibility of Methylnaltrexone in the   region"|f||||f||||||||||2017-10-11 11:05:27.494206|2017-10-11 11:05:27.494206
NCT01119040|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-06|2014-12-12|2010-10-14||November 2007||2007-11-01|December 2014|2014-12-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|PEGRescue||"Prospective Evaluation of NOTES (Natural Orifice Translumenal Endoscopic Surgery) PEG Rescue"|"Prospective Evaluation of NOTES PEG Rescue"|Terminated||N/A|1|Actual|University Hospitals Cleveland Medical Center|Study terminated early due to difficulty with patient accrual due to lack of patient population.|1||Low accrual|f||||t||||||||||2017-10-11 11:05:39.219931|2017-10-11 11:05:39.219931
NCT01121185|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-06|2016-05-05|2016-03-14|2013-10-23|June 2010||2010-06-01|March 2016|2016-03-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|MBL-HCV1|The eleven subjects who were randomized, initiated study infusions, and underwent liver transplantation were included in the analysis population.|Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C|A Phase II Randomized, Double-Blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) in Hepatitis C Infected Patients Undergoing Liver Transplantation|Terminated||Phase 2|13|Actual|MassBiologics||2||The study was terminated due to slower than anticipated subject accrual.|f||||t||||||||||2017-10-11 11:06:28.745349|2017-10-11 11:06:28.745349
NCT01110421|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-15|2014-07-02|2014-05-30|2013-12-02|December 2010||2010-12-01|July 2014|2014-07-01|March 2012|Actual|2012-03-01|March 2012|Actual|2012-03-01||Interventional|||A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia|A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia|Terminated||Phase 3|7|Actual|Janssen Research & Development, LLC|This study was terminated early due to business reasons and not related to safety concerns or issues. As such, the limited enrollment precludes a meaningful conclusion about the efficacy and safety of doripenem compared with cefepime.|2||Trial terminated early per business decision|f||||t||||||||||2017-10-11 11:06:38.175822|2017-10-11 11:06:38.175822
NCT01110642|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-22|2015-05-15|||July 2011||2011-07-01|May 2015|2015-05-01||||||||Interventional|||Novel Treatment for Syndromic Ichthyoses|Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Ichthyoses|Withdrawn||Phase 2|0|Actual|Northwestern University||1||Study was withdrawn due to lack of eligible population for study|f||||f||||||||||2017-10-11 11:06:41.803658|2017-10-11 11:06:41.803658
NCT01113463|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-27|2016-09-12|2016-06-08||April 2010||2010-04-01|September 2016|2016-09-01|December 2012|Actual|2012-12-01|June 2011|Actual|2011-06-01||Interventional||Insufficient enrollment to perform any meaningful statistical analysis, therefore study terminated early.|TPI 287 in Patients With Recurrent Glioblastoma Multiforme|A Phase 2 Open-Label Study of the Efficacy of TPI 287 in Patients With Glioblastoma Multiforme That Has Recurred or Progressed Following Prior Therapy With Radiation Plus Temozolomide|Terminated||Phase 2|17|Actual|M.D. Anderson Cancer Center|Not enough subjects were enrolled to perform any meaningful statistical analysis.|1||Low Accrual|f||||f||||||||||2017-10-11 11:07:17.518991|2017-10-11 11:07:17.518991
NCT01113541|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-28|2012-06-05|2011-10-12||July 2010||2010-07-01|June 2012|2012-06-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome|A One-year, Phase III, Open-label, Non-comparative Trial of the Effect of Ziprasidone HCl on Metabolic Syndrome Risk Factors in Patients With Bipolar Disorder|Terminated||Phase 3|13|Actual|Pfizer|This study was terminated due to slow enrollment and changes in organizational strategy and resources; most of the planned analyses in the statistical analysis plan were not performed.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 11:07:18.375388|2017-10-11 11:07:18.375388
NCT01114503|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-29|2017-04-21|2017-03-02||July 7, 2010||2010-07-07|March 2017|2017-03-01|August 29, 2012|Actual|2012-08-29|August 1, 2011|Actual|2011-08-01||Interventional|||A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease|A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy|Terminated||Phase 2|2|Actual|GlaxoSmithKline|The study was terminated due to the need of better understanding of an efficacious dose with otelixizumab from other clinical studies.|3||"Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an   efficacious dose with Otelixizumab from other clinical studies."|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2017-10-11 11:07:32.408847|2017-10-11 11:07:32.408847
NCT01114698|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-22|2013-02-11||2012-11-05|March 2011||2011-03-01|February 2013|2013-02-01|February 2012|Actual|2012-02-01|January 2012|Actual|2012-01-01||Interventional|||A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder|A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder|Terminated||Phase 2|12|Actual|Janssen Research & Development, LLC||3||Study was terminated due to sponsor portfolio decision.|f||||t||||||||||2017-10-11 11:07:39.127503|2017-10-11 11:07:39.127503
NCT01121549|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-30|2013-12-04|2013-12-04||February 2010||2010-02-01|December 2013|2013-12-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Observational|||A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer|A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer In Postmenopausal Hormone Receptors Positive Patients Following Of 2-3 Years of Initial Adjuvant Tamoxifen Therapy|Terminated||N/A|378|Actual|Pfizer|The study was prematurely terminated on 31 August 2012 due to unexpected high rate of participant withdrawal caused by Aromasin reimbursement policy change in Romania. There were no safety issues related to study termination.||1|See termination reason in detailed description.|f||||f||||||||||2017-10-11 11:07:46.073381|2017-10-11 11:07:46.073381
NCT01124825|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-12|2012-11-12|||July 2011||2011-07-01|November 2012|2012-11-01|October 2012|Actual|2012-10-01|May 2012|Anticipated|2012-05-01||Interventional|||Use of New Supraglottic Airway Devices in Severely Obese Patients: A Feasibility Study|Use of New Supraglottic Airway Devices in Severely Obese Patients: A Feasibility Study|Withdrawn||Phase 4|0|Actual|University of Louisville||2||No subjects enrolled. Funding withdrawn by sponsor.|f||||f||||||||||2017-10-11 11:08:27.960779|2017-10-11 11:08:27.960779
NCT01125735|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-17|2013-07-01|||April 2011||2011-04-01|July 2013|2013-07-01|April 2014|Anticipated|2014-04-01|June 2012|Anticipated|2012-06-01||Interventional|Celleration||MIST Therapy's Effectiveness in Wound Bed Preparation and Role of Bacterial Biofilm in Chronic, Non-healing Wounds|A Prospective, Randomized, Controlled Study of MIST Therapy's Effectiveness in Wound Bed Preparation and the Role of Bacterial Biofilm in Subjects Presenting With Chronic, Non-healing Wounds|Withdrawn||Phase 4|0|Actual|Georgetown University||2||Contract negotiations were terminated and study never started.|f||||f||||||||||2017-10-11 11:08:46.34578|2017-10-11 11:08:46.34578
NCT01118455|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-05|2014-06-25|2011-03-01||October 2004||2004-10-01|June 2014|2014-06-01|January 2010|Actual|2010-01-01|December 2009|Actual|2009-12-01||Interventional|||Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures|An Open Randomized Trial to Assess the Efficacy and Safety of Vagus Nerve Stimulation (VNS) Versus New Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures|Terminated||Phase 4|134|Actual|Cyberonics, Inc.|Study was terminated due to low enrollment.|2||Insufficient enrollment|f||||f||||||||||2017-10-11 11:09:09.176453|2017-10-11 11:09:09.176453
NCT01118819|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-13|2016-01-19|||April 2011||2011-04-01|January 2016|2016-01-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies|Phase I Safety Study of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies|Terminated||Phase 1|5|Actual|BioMed Valley Discoveries, Inc||1||"This study was terminated. An IT injection study of C. novyi-NT in patients with treatment   refractory solid tumor malignancies may be viewed at NCT01924689."|f||||t||||||||||2017-10-11 11:09:15.430319|2017-10-11 11:09:15.430319
NCT01118975|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-05|2017-04-19|2014-03-20||March 2010||2010-03-01|April 2017|2017-04-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers|GCC 0845: Pilot and Phase II- Vorinostat and Lapatinib in Patients With Advanced Solid Tumor Malignancies and Women With Recurrent Local-Regional or Metastatic Breast Cancer to Evaluate Response and Biomarkers of EMT and Breast Cancer Stem Cells|Terminated||Phase 1/Phase 2|12|Actual|University of Maryland|The most important limitation of this study is that the Phase II efficacy portion was terminated early by the sponsor.|2||Lost sponsorship for study drug|f||||t||||||||||2017-10-11 11:09:17.878255|2017-10-11 11:09:17.878255
NCT01125917|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-17|2012-08-27|2010-07-28||June 2004||2004-06-01|August 2012|2012-08-01|January 2008|Actual|2008-01-01|September 2005|Actual|2005-09-01||Interventional|||Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015|A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release Vs Buprenorphine Transdermal System (BTDS) 5 in Subjects With Moderate to Severe Low Back Pain: A 52-Week Open-label Extension Phase of BUP3015|Terminated||Phase 3|354|Actual|Purdue Pharma LP|BUP3015S was terminated early due to administrative reasons unrelated to efficacy or safety. There was full evaluation of safety but no evaluation of efficacy.|1||Terminated early due to administrative reasons.|f||||f||||||||||2017-10-11 11:09:22.509923|2017-10-11 11:09:22.509923
NCT01126632|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-15|2016-01-27|||June 2010||2010-06-01|January 2016|2016-01-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Observational|CAC||Will Cap-Assisted Colonoscopy Improve Performance of Colonoscopy: A Randomized Clinical Trial|Will Cap-Assisted Colonoscopy Improve Performance of Colonoscopy: A Randomized Clinical Trial|Withdrawn||N/A|0|Actual|Nova Scotia Health Authority|||2|Caps became unavailable by manufacturer|f||||f||||||||No|Study was terminated|2017-10-11 11:09:50.222348|2017-10-11 11:09:50.222348
NCT01126957|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-11|2017-04-19|2016-09-23||May 2007||2007-05-01|March 2017|2017-03-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional||107 participants signed the consent but 4 were found ineligible. 103 participants started and completed the study. Data were collected but not analyzed as the investigator left the institution prior to analysis and did not make data available for others to analyze.|Combined Ketamine/Propofol for Emergency Department Procedural Sedation|Combined Ketamine/Propofol for Emergency Department Procedural Sedation|Terminated||N/A|107|Actual|University of Missouri-Columbia|"107 participants were consented for the study. 4 were terminated by the investigator as they received surgery and were no longer eligible.
NCT01170728|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-26|2015-08-20|||July 2010||2010-07-01|August 2015|2015-08-01|June 2014|Actual|2014-06-01|June 2014|Actual|2014-06-01||Observational|||Virtue® Male Sling Fixation Study|Virtue® Male Sling Fixation Study|Terminated||N/A|44|Actual|Coloplast A/S|||1|The study has been terminated due to lack of subject enrollment.|f||||f||||||||||2017-10-11 11:23:54.120158|2017-10-11 11:23:54.120158
NCT01127321|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-14|2014-08-11|2014-08-11||May 2010||2010-05-01|August 2014|2014-08-01|July 2012|Actual|2012-07-01|July 2012|Actual|2012-07-01||Interventional||Safety population included all participants who were randomized into the study and received at least 1 dose of investigational product.|A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus|A Phase 1, Double-blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI-570 in SLE|Terminated||Phase 1|44|Actual|MedImmune LLC|The study was terminated early by the sponsor due to business reasons.|5||Business reasons|f||||f||||||||||2017-10-11 11:09:58.008185|2017-10-11 11:09:58.008185
NCT01127334|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-19|2012-04-02|||May 2010||2010-05-01|May 2010|2010-05-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Observational|||Pilot Study Using Echocardiography to Evaluate Patients With Heart Failure and Dyssynchrony Who Have a CRT-D Device|Validation of a Robust Method for Kinematic Analysis of Ventricular Mechanical Dyssynchrony by Two Dimensional Echocardiography in Patients With Cardiac Resynchronization Devices for Chronic Systolic Heart Failure and Conduction System Disease|Withdrawn||N/A|0|Actual|University of Mississippi Medical Center|||1|Principal Investigator terminated study|f||||f||||||||||2017-10-11 11:09:58.894844|2017-10-11 11:09:58.894844
NCT01127646|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-19|2012-11-26|2012-04-30||June 2010||2010-06-01|April 2012|2012-04-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Interventional|EMD||A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents|Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study)|Terminated||Phase 4|23|Actual|Eli Lilly and Company|This study (Study LYEN) was terminated after enrolling 23 participants due to lack of availability of study participants to accommodate the study design.|2||Due to lack of availability of study participants to accommodate the study design|f||||f||||||||||2017-10-11 11:10:06.874353|2017-10-11 11:10:06.874353
NCT01128413|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-06|2016-03-04|2016-02-06||July 2010||2010-07-01|March 2016|2016-03-01|November 2013|Actual|2013-11-01|November 2013|Actual|2013-11-01||Interventional|EFFORT||Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)|Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)|Terminated||N/A|22|Actual|Washington University School of Medicine|Trial terminated early due to lack of resources leading to small numbers of subjects analyzed.|2||lack of resources|f||||f||||||||No||2017-10-11 11:10:18.731748|2017-10-11 11:10:18.731748
NCT01128712|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-20|2017-09-12|||April 2010||2010-04-01|September 2017|2017-09-01|July 2014|Actual|2014-07-01|July 2014|Actual|2014-07-01||Interventional|||Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin|An Open Label, Randomized Study Prospectively Examining the Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin|Terminated||Phase 4|4|Actual|Northeast Regional Epilepsy Group||2||lack of enrollment. terminated in 2014. no data analysis.|f||||f||||||||||2017-10-11 11:10:30.632283|2017-10-11 11:10:30.632283
NCT01122511|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-11|2012-08-01|2012-08-01|2012-05-25|August 2010||2010-08-01|August 2012|2012-08-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Interventional|||Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration||Terminated||Phase 2|4|Actual|Allergan|The study was terminated early due to difficulties with patient recruitment. No participants reached the 12 month time-point. Efficacy analyses were not performed.|2||The study was terminated early due to difficulties with patient recruitment.|f||||f||||||||||2017-10-11 11:10:51.32011|2017-10-11 11:10:51.32011
NCT01122901|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-11|2017-03-22|2016-11-30||December 2010||2010-12-01|March 2017|2017-03-01|August 2015|Actual|2015-08-01|August 2015|Actual|2015-08-01||Interventional|||Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma|A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma|Terminated||Phase 2|47|Actual|National Cancer Institute (NCI)|Study terminated prematurely by Company due to their decision to terminate drug supply for further development of this drug. All CTEP-sponsored trials using RO4929097 were closed to accrual and all patients had to be off treatment by 7/31/12.|2||"Stopped prematurely by Company due to decision to terminate all CTEP supplied drug for further   development of RO4929097."|f||||t||||||||No||2017-10-11 11:10:57.528771|2017-10-11 11:10:57.528771
NCT01122927|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-06|2016-01-08|2015-08-05||July 2010||2010-07-01|January 2016|2016-01-01|September 2014|Actual|2014-09-01|August 2014|Actual|2014-08-01||Interventional|ATTAIN 267||Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.|A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia or Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features|Terminated||Phase 3|524|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|The study was terminated by the Sponsor as the European Medicines Agency P/99/2011Aripiprazole PIP which directed the sponsor to provide 2 years of safety data for at least 100 participants. The objective was met in April 2014.|1||"The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational   Plan was met and provided 2 years of safety data."|f||||f||||||||||2017-10-11 11:10:58.05922|2017-10-11 11:10:58.05922
NCT01123304|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-12|2014-07-16|||May 2010||2010-05-01|July 2014|2014-07-01|March 2012|Actual|2012-03-01|March 2012|Actual|2012-03-01||Interventional|||Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma|A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma|Terminated||Phase 1|18|Actual|Morphotek||1||This study has been terminated due to lack of availability of investigational product.|f||||f||||||||||2017-10-11 11:11:04.114148|2017-10-11 11:11:04.114148
NCT01132547|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-26|2015-06-04|2015-01-12||June 2010||2010-06-01|June 2015|2015-06-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer|Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk|Terminated||Phase 3|22|Actual|University of South Florida||2||The study was terminated due to slow accrual.|f||||t||||||||||2017-10-11 11:11:26.176932|2017-10-11 11:11:26.176932
NCT01133275|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-25|2017-08-16|2015-12-14||April 28, 2010|Actual|2010-04-28|August 2017|2017-08-01|June 2018|Anticipated|2018-06-01|January 31, 2015|Actual|2015-01-31||Interventional||All participants|Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS|A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients|Active, not recruiting||Phase 2|28|Actual|H. Lee Moffitt Cancer Center and Research Institute|The study was terminated at the end of step one, as no signal of higher response of the combination was observed compared to what was reported on the MDS-002 study.|1|||f||||t|t|f|||f|||||2017-10-11 11:11:39.081307|2017-10-11 11:11:39.081307
NCT01133288|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-26|2011-11-21|2011-07-11||July 2009||2009-07-01|November 2011|2011-11-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional|||Yulex Glove Prospective Study in Spina Bifida|Yulex Glove Prospective Study|Terminated||N/A|7|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|The study was not completed because funding was never received. The two (2/7)enrolled participants who met screening eligibility criteria were terminated early without receiving the yulex glove intervention.|1||The funder never paid for the study.|f||||f||||||||||2017-10-11 11:11:39.395429|2017-10-11 11:11:39.395429
NCT01133756|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-21|2016-10-11|2016-02-16|2013-05-21|March 2010||2010-03-01|October 2016|2016-10-01|September 2012|Actual|2012-09-01|February 2012|Actual|2012-02-01||Interventional|||E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125.|Terminated||Phase 1/Phase 2|7|Actual|Eisai Inc.|Due to the limited enrollment despite significant diligence to boost enrollment and the complex study design required to manage hematologic toxicity, the study was terminated before the initiation of Phase 2.|2||poor accrual|f||||f||||||||||2017-10-11 11:11:47.93235|2017-10-11 11:11:47.93235
NCT01134445|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-05|2017-06-23|||February 1, 2010|Actual|2010-02-01|June 2017|2017-06-01|June 1, 2016|Actual|2016-06-01|January 1, 2016|Actual|2016-01-01||Interventional|||An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement|Prospective, International Multi-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of the DePuy PROXIMA™ Hip in Subjects With Indications Suitable for a Primary Total Hip Arthroplasty|Terminated||Phase 4|42|Actual|DePuy International||1||Study terminated early for business reasons|f||||f||||||||||2017-10-11 11:12:07.231234|2017-10-11 11:12:07.231234
NCT01136746|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-02|2012-11-07|2012-09-12||March 2011||2011-03-01|November 2012|2012-11-01|November 2011|Actual|2011-11-01|November 2011|Actual|2011-11-01||Interventional|HMH||Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin|Randomized Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patients Without Known History of Diabetes: The HMH Trial|Terminated||Phase 3|16|Actual|Eli Lilly and Company|Due to low enrollment, this trial was terminated early, leading to small numbers of participants analyzed or some outcome measures not being able to be analyzed at all.|2||Low enrollment|f||||t||||||||||2017-10-11 11:12:19.22029|2017-10-11 11:12:19.22029
NCT01136811|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-28|2014-11-17|||June 2009||2009-06-01|November 2014|2014-11-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Safety and Efficacy of Computer Assisted Surgery for Use in Vascular Surgery Procedures|Safety and Efficacy of Computer Assisted Surgery for Use in Vascular Surgery Procedures|Terminated||N/A|8|Actual|University of Chicago||1||Study was terminated. P.I. left the institution before completing study|f||||t||||||||||2017-10-11 11:12:21.077819|2017-10-11 11:12:21.077819
NCT01131455|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-26|2014-11-12|2014-07-29||October 2009||2009-10-01|November 2014|2014-11-01|July 2010|Actual|2010-07-01|July 2010|Actual|2010-07-01||Interventional|||ACP for Local Application in Ankle Arthrodesis|Autologous Concentrated Platelet-rich Plasma (Arthrex ACP®) for Local Application in Ankle Arthrodesis: A Prospective Outcome Analysis.|Terminated||N/A|10|Actual|Columbia Orthopaedic Group, LLP||3||Study was terminated due to the untimely death of the investigator|f||||f||||||||||2017-10-11 11:13:36.407784|2017-10-11 11:13:36.407784
NCT01139359|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-04|2012-07-18|||June 2010||2010-06-01|July 2012|2012-07-01|June 2011|Anticipated|2011-06-01|June 2011|Anticipated|2011-06-01||Interventional|||Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma|A Phase I Dose Escalation Study of Darinaparsin in Combination With CHOP in Previously Untreated Patients With Lymphomas Who Are Scheduled to Receive CHOP Alone|Withdrawn||Phase 1|0|Actual|Ziopharm||1||"Study enrollment was withdrawn as it is no longer the sponsor's intention to study this   indication under this protocol."|f||||f||||||||||2017-10-11 11:14:04.228395|2017-10-11 11:14:04.228395
NCT01140412|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-07|2011-02-03|||July 2010||2010-07-01|February 2011|2011-02-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|||Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects|Open-Label, Fixed-Sequence, Crossover Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects|Terminated||Phase 1|14|Actual|ViiV Healthcare||2||"The trial prematurely terminated on November 1, 2010, due to healthy volunteer participants   experiencing non-serious fosamprenavir-related skin rash."|f||||f||||||||||2017-10-11 11:14:25.637961|2017-10-11 11:14:25.637961
NCT01140503|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-06|2015-03-03|2015-01-28||February 2010||2010-02-01|March 2015|2015-03-01|September 2011|Actual|2011-09-01|August 2011|Actual|2011-08-01||Interventional|||A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis|An Open Label Study Evaluating the Safety and Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Dermatomyositis|Terminated||N/A|5|Actual|Stanford University|Study was terminated early due to low enrollment. Therefore we only have data on 5 participants.|1||Slow recruitment of participants|f||||t||||||||||2017-10-11 11:14:26.590172|2017-10-11 11:14:26.590172
NCT01140880|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-08|2015-03-18|2014-05-27||May 2010||2010-05-01|March 2015|2015-03-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional||170 participants enrolled. 30 participants in the Yoked Contingency Management arm were involved in a protocol violation that rendered their data unusable. An additional 14 participants from each arm were either withdrawn, died (n = 1, not study related), or were lost to follow-up. Thus, baseline N = 140 (70/70), and follow-up N = 112 (56/56).|Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men|Optimizing Access to Non-occupational Post Exposure Prophylaxis for HIV Using Contingency Management in Stimulant-Using Men Who Have Sex With Men|Completed||Phase 2|170|Actual|Friends Research Institute, Inc.||2|||f||||t||||||||||2017-10-11 11:14:31.440715|2017-10-11 11:14:31.440715
NCT01134731|ClinicalTrials.gov processed this data on October 10, 2017|2010-05-20|2016-02-03|2015-05-26||May 2010||2010-05-01|February 2016|2016-02-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|AFSP||Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation|Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation|Completed||Phase 4|54|Actual|University of Alabama at Birmingham|The inherent risk of the condition and concerns about the safety of the study, the high risk of impulsive and aggressive behavior, and high levels of distress making placebo-controlled studies difficult. Placebo arm terminated early due to dropout.|3|||f||||f||||||||No||2017-10-11 11:14:43.820329|2017-10-11 11:14:43.820329
NCT01135524|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-01|2012-09-05|2010-07-15||April 2004||2004-04-01|September 2012|2012-09-01|August 2005|Actual|2005-08-01|August 2005|Actual|2005-08-01||Interventional|||Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase|A Randomized, Double-blind, Multicenter, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or OxyIR® Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain: A 52-Week Extension Phase|Terminated||Phase 3|196|Actual|Purdue Pharma LP|This study was terminated early for administrative reasons.|1||This study was terminated early for administrative reasons.|f||||f||||||||||2017-10-11 11:15:02.207546|2017-10-11 11:15:02.207546
NCT01141530|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-09|2013-12-03|||September 2009||2009-09-01|December 2013|2013-12-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Observational|||Deep Sequencing of the Breast Cancer Transcriptome|Deep Sequencing of the Breast Cancer Transcriptome|Withdrawn||N/A|0|Actual|University of Arkansas|||1|Study withdrawn due to inability to enroll subjects.|f||||t||||||Samples With DNA|"     The informed consent process for biospecimen collection we expect to use in this research has     already been obtained by the UAMS Tissue Bank personnel as a part of the UARK 2005-06     protocol. Tissue is collected during biopsies or mastectomies after pathologist approval. We     will sequence small non-coding molecules (microRNA), messenger RNA, chromatin     immunoprecipated and bisulfite treated DNA.   "|||2017-10-11 11:15:12.19919|2017-10-11 11:15:12.19919
NCT01143766|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-11|2012-11-06|2012-09-20||April 2010||2010-04-01|November 2012|2012-11-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)|Premedication With Single Dose Gabapentin to Improve Patient Tolerance in ERCP: A Double-Blind Randomized Controlled Trial|Completed||N/A|56|Actual|Indiana University|Limited sample size due to challenges with recruitment and transition to propofol-based anesthesia for sedation in ERCP. Study terminated at 50% enrollment for this reason.|2|||f||||f||||||||||2017-10-11 11:15:41.758193|2017-10-11 11:15:41.758193
NCT01144403|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-14|2016-08-31|2016-06-20||June 2010||2010-06-01|July 2016|2016-07-01|August 2014|Actual|2014-08-01|August 2014|Actual|2014-08-01||Interventional|||A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.|A Phase II Multicenter Open-label Study of MabThera(Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma|Terminated||Phase 2|8|Actual|Hoffmann-La Roche|The study was prematurely terminated with 8 participants enrolled, all of them are included into the statistical analyses.|1|||f||||||||||||||2017-10-11 11:15:55.050058|2017-10-11 11:15:55.050058
NCT01144910|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-01|2017-03-02|||May 2011||2011-05-01|March 2017|2017-03-01|September 2017|Anticipated|2017-09-01|September 2016|Anticipated|2016-09-01||Observational|BHR||The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children|A Prospective, Open Label, Single-center Study of the Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children.|Withdrawn||N/A|0|Actual|Johann Wolfgang Goethe University Hospital|||2|Due to few capacities 2011 to 2016 the study was withdrawn.|f||||f||||||Samples With DNA|"     whole blood, serum, sputum   "|||2017-10-11 11:16:02.695726|2017-10-11 11:16:02.695726
NCT01145417|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-07|2013-05-07|2013-05-07||July 2010||2010-07-01|May 2013|2013-05-01|May 2012|Actual|2012-05-01|May 2012|Actual|2012-05-01||Interventional|||Pregabalin Trial In HIV Neuropathic Pain|An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)|Terminated||Phase 3|217|Actual|Pfizer|The parent double blind trial A0081244 (NCT01049217) was stopped at interim analysis due to lack of efficacy and therefore this open label extension study was also terminated.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-11 11:16:06.764402|2017-10-11 11:16:06.764402
NCT01145703|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-16|2014-09-04|||May 2010||2010-05-01|September 2014|2014-09-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional|VitD||Vitamin D Supplementation and Metabolism in Vitamin D Deficient Elderly|Effects of Vitamin D Supplementation With and With Out Exercise on Metabolic and Physical Consequences of Vitamin D Deficiency in the Elderly|Terminated||N/A|39|Actual|Baltimore VA Medical Center||4||Investigator terminated study due to low enrollment of eligible subjects|f||||t||||||||||2017-10-11 11:16:13.71659|2017-10-11 11:16:13.71659
NCT01146353|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-16|2017-08-28|||February 2010||2010-02-01|August 2017|2017-08-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Observational|||Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy|Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy|Withdrawn||N/A|0|Actual|Midwestern University|||1|Peramivir EUA terminated by FDA.|f||||f||||||||||2017-10-11 11:16:20.104195|2017-10-11 11:16:20.104195
NCT01147458|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-16|2013-05-30|2012-12-21||July 2010||2010-07-01|May 2013|2013-05-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee|A Phase 2 Randomized, Double-Blinded, Double-Dummy, Placebo And Active Controlled Two Cohort Two-Way Cross-Over, Multi-Centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A 5-Lipoxygenase (5-Lox) Inhibitor PF-04191834 Alone And In Combination With Naproxen In Patients With Flare-Enriched Osteoarthritis Of The Knee|Terminated||Phase 2|190|Actual|Pfizer|The study was terminated early due to increases in hepatic enzymes for which a relationship to study drug could not be excluded and that could alter the potential benefit-risk for participants continuing in the study.|4||See termination reason in detailed description.|f||||f||||||||||2017-10-11 11:16:44.675354|2017-10-11 11:16:44.675354
NCT01149993|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-21|2014-06-06|||June 2010||2010-06-01|June 2014|2014-06-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional|||Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation|Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation|Withdrawn||Phase 4|0|Actual|Georgetown University||3||FDA clinical hold, IND withdrawn.|f||||f||||||||||2017-10-11 11:17:29.345877|2017-10-11 11:17:29.345877
NCT01151462|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-25|2015-10-21|||August 2010||2010-08-01|May 2013|2013-05-01|May 2013|Actual|2013-05-01|January 2013|Actual|2013-01-01||Observational|||Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.|"Postnatal HCMV Infection in Very Preterm Infants. Implications on Acute and Chronic Morbidity, Growth and Neurodevelopmental Outcomes Part of the Study on Nutrition, Growth and Development Among Very Preterm Infants."|Withdrawn||N/A|0|Actual|Oslo University Hospital|||1|The study was terminated prior to enrollment|f||||t||||||Samples With DNA|"     Serum. Mothersmilk. Urine.   "|||2017-10-11 11:18:03.736163|2017-10-11 11:18:03.736163
NCT01153061|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-08|2013-03-18|||June 2010||2010-06-01|March 2013|2013-03-01|December 2012|Actual|2012-12-01|July 2012|Actual|2012-07-01||Interventional|TEFGoreHelex||Endoscopic Closure of Tracheoesophageal Fistulas With Occluder Device|Endoscopic Closure of Tracheoesophageal Fistulas With a Cardiac Septal Defect Occluder|Terminated||Phase 4|4|Actual|University of Sao Paulo||1||The study was terminated because the rate of prothesis dislocation was too high.|f||||t||||||||||2017-10-11 11:18:18.258667|2017-10-11 11:18:18.258667
NCT01153113|ClinicalTrials.gov processed this data on October 10, 2017|2010-03-31|2011-11-30|||January 2008||2008-01-01|February 2011|2011-02-01|December 2010|Anticipated|2010-12-01|December 2009|Anticipated|2009-12-01||Interventional|||Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines|Phase II Study of Active Immunotherapy With Mature, Human Telomerase Reverse Transcriptase Messenger RNA -Transfected, Autologous Dendritic Cells (DC) Administered In A Prime-Boost Format to Subjects With Metastatic Prostate Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|University of Florida||2||IND has been withdrawn and the study is closed.|f||||f||||||||||2017-10-11 11:18:18.568111|2017-10-11 11:18:18.568111
NCT01156272|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-28|2015-08-04|||June 2010||2010-06-01|August 2015|2015-08-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Observational|||Post Market ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm|3f 19mm IDE Study Rev D|Withdrawn||N/A|0|Actual|Medtronic Cardiovascular|||1|Study terminated prematurely.|f||||f||||||||||2017-10-11 11:19:39.814451|2017-10-11 11:19:39.814451
NCT01156480|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-01|2014-04-15|2014-01-08||September 2009||2009-09-01|April 2014|2014-04-01|November 2012|Actual|2012-11-01|November 2012|Actual|2012-11-01||Interventional|steroids/NEC|premature neonates|Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants|Anti-inflammatory Treatment at the Onset of NEC in Preterm Infants- a Pilot Study|Terminated||N/A|2|Actual|NorthShore University HealthSystem Research Institute|This study was terminated due to low enrollment. We had a drop in our incidence of NEC, so there were very few eligible infants. One subject that was enrolled was soon thereafter thought NOT to have NEC, so that subject never received study drug.|2||low enrollment|f||||t||||||||||2017-10-11 11:19:48.095411|2017-10-11 11:19:48.095411
NCT01156532|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-01|2014-08-08|2014-08-08||November 2010||2010-11-01|August 2014|2014-08-01|August 2013|Actual|2013-08-01|August 2013|Actual|2013-08-01||Observational|||Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy|Observational Study; Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy|Terminated||N/A|30|Actual|AbbVie|Although a sample of 75 participants was originally planned, only 30 participants were enrolled in this study. The limited sample size can result in a potential sampling bias that cannot be tested.||1|This study was prematurely terminated due to low enrollment and not for safety reasons.|f||||||||||||||2017-10-11 11:19:48.60551|2017-10-11 11:19:48.60551
NCT01160445|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-09|2015-10-06|2012-11-07||June 2010||2010-06-01|September 2015|2015-09-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer|Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer|Terminated||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)||2||The study was terminated because we were not able to obtain the study drug.|f||||f||||||||||2017-10-11 11:20:34.238425|2017-10-11 11:20:34.238425
NCT01165450|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-15|2015-04-20|2015-04-07||November 2011||2011-11-01|April 2015|2015-04-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|NTX-PED-001|2 participants were randomized and participated in the study before its premature closure for lack of study drug.|Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects|Phase 2, Randomized, Double-masked, Vehicle-controlled, Dose-escalation Study Evaluating Efficacy/Safety of Nexagon in Subjects With Persistent Corneal Epithelial Defects (PED) Resulting From Corneal Epithelial Debridement During Diabetic Vitrectomy Surgery, Herpes Simples Virus (HSV) Keratitis, Herpes Zoster Virus (HZV) Keratitis, Corneal Burns, Post-photorefractive Keratectomy (Post-PRK), or Post-corneal Transplant Surgery.|Terminated||Phase 2|2|Actual|University of California, San Francisco|The study was terminated prematurely due to discontinued supply of study drug, and data were never analyzed; PI has left the institution and data are no longer available.|2||Drug manufacturer could not supply study drug.|f||||t||||||||||2017-10-11 11:22:25.009574|2017-10-11 11:22:25.009574
NCT01158885|ClinicalTrials.gov processed this data on October 10, 2017|2010-06-30|2012-10-24|||August 2010||2010-08-01|October 2012|2012-10-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia|Clofarabine With Cytarabine for MRD Positive Leukemia|Terminated||Phase 2|2|Actual|Therapeutic Advances in Childhood Leukemia Consortium||1||Study terminated for lack of accrual.|f||||t||||||||||2017-10-11 11:22:33.067965|2017-10-11 11:22:33.067965
NCT01160237|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-08|2016-09-09|2012-02-21||August 2010||2010-08-01|September 2016|2016-09-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM|Immunogenicity and Safety of Fluarix™/ Influsplit SSW® 2010/2011 or Pandemrix™|Terminated||Phase 3|7|Actual|GlaxoSmithKline|Only 7 subjects were enrolled in either the Pandemrix Group or the Fluarix Group and none in the Control Group since the study was terminated prematurely. Therefore most outcome measures (except unsolicited AEs and SAEs) were not analysed.|3||The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2017-10-11 11:22:53.464148|2017-10-11 11:22:53.464148
NCT01166828|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-19|2015-06-25|||January 2011||2011-01-01|June 2015|2015-06-01|May 2014|Anticipated|2014-05-01|January 2014|Anticipated|2014-01-01||Interventional|TELEPUPPS||Pressure Ulcer Prevention for SCI Using a Tele Home Program|Pressure Ulcer Prevention for SCI Using a Tele Home Program|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||Project not funded - withdrawn by VA|f||||t||||||||||2017-10-11 11:23:09.201485|2017-10-11 11:23:09.201485
NCT01167088|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-19|2011-05-28|||November 2010||2010-11-01|May 2011|2011-05-01|July 2011|Anticipated|2011-07-01|June 2011|Anticipated|2011-06-01||Interventional|MARVEL||A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)|A Double-blind Randomised Placebo-controlled Multicentre Study of 40mg MitoQ and Placebo for the Treatment of Participants With Raised Liver Enzymes Due to Non-Alcoholic Fatty Liver Disease (NAFLD)|Terminated||Phase 2|110|Anticipated|Antipodean Pharmaceuticals, Inc.||2||This study has been terminated due to poor participant recruitment|f||||f||||||||||2017-10-11 11:23:12.439725|2017-10-11 11:23:12.439725
NCT01167816|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-21|2014-05-19|||July 2010||2010-07-01|May 2014|2014-05-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer|Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer|Terminated||Phase 1|9|Actual|University of Oklahoma||1||"The study was terminated as the Prinicipal Investigator left the site- all previous subjects   enrolled are deceased"|f||||t||||||||||2017-10-11 11:23:21.622977|2017-10-11 11:23:21.622977
NCT01168856|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-15|2016-02-12|2015-12-30||September 2010||2010-09-01|February 2016|2016-02-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Observational||Eligible population included all enrolled participants excluding participants with protocol violations.|An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens|A Long-term Monitoring Study to Evaluate the Persistence of Direct Antiviral (DAA) Treatment Resistant Mutations or the Durability of Sustained Virological Response (SVR) in Patients Treated With DAA Containing Regimens for Chronic Hepatitis C Infections (CHC)|Terminated||N/A|734|Actual|Hoffmann-La Roche|Investigators were notified of the early termination of study in Jan2015 due to the completion of assessment for resistance monitoring arm and were encouraged to complete scheduled visits until Apr2015 for participants enrolled in SVR durability arm.||1|This study was terminated due to the decrease in percentage of participants.|f||||||||||None Retained|"     Serum specimens collected from patients with partial viral response or viral load rebound of     viral response to monitor for resistance mutations in viral RNA   "|||2017-10-11 11:23:45.770721|2017-10-11 11:23:45.770721
NCT01170364|ClinicalTrials.gov processed this data on October 10, 2017|2010-04-26|2017-08-01|2012-12-13||February 2009||2009-02-01|June 2017|2017-06-01|October 2010|Actual|2010-10-01|October 2010|Actual|2010-10-01||Interventional|||Studying the Effects of Sibutramine on Eating Behavior|Studying the Effects of Sibutramine on Eating Behavior|Terminated||Phase 4|14|Actual|New York State Psychiatric Institute|Early termination of the study given the withdrawal of sibutramine from the US market.|2||Terminated due to sibutramine being withdrawn from the market.|f||||f||||||||||2017-10-11 11:23:48.023233|2017-10-11 11:23:48.023233
NCT01166126|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-12|2014-04-29|2013-03-29||October 2010||2010-10-01|December 2012|2012-12-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional||All baseline participants|Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV|Phase II Trial of mTOR Inhibitor Temsirolimus Combined With MEK Inhibitor AZD 6244 in Patients With BRAF Mutant Stage IV Melanoma|Terminated||Phase 2|4|Actual|National Cancer Institute (NCI)|The study was terminated due to overall low accrual and a high rate of screening failures. Accrual goal was 38 participants and only 4 participants were actually treated.|1|||f||||||||||||||2017-10-11 11:24:30.648303|2017-10-11 11:24:30.648303
NCT01173146|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-27|2016-05-23|||December 2011||2011-12-01|May 2016|2016-05-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Observational|||Imaging of Residual Tumor During Prostatectomy|Imaging of Residual Prostate Cancer During Prostatectomy Using ProstaFluor®, a Prostate-Specific Membrane Antigen (PSMA)-Targeted Fluorescent Agent FDA Trial|Withdrawn||N/A|0|Actual|Spectros Corporation|||1|Costs for antibody production rose; supplemental funding request not approved.|f||||t||||||||No|Study withdrawn, no data collected.|2017-10-11 11:24:38.7718|2017-10-11 11:24:38.7718
NCT01175616|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-03|2016-08-11|||September 2012||2012-09-01|August 2016|2016-08-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||Creatine Augmentation in Veterans With SSRI-Resistant Major Depression|Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder|Withdrawn||Phase 4|0|Actual|University of Utah||1||Study withdrawn from ClinicalTrials.gov.|f||||t||||||||No|The study was closed prior to human subjects receiving investigational treatment.|2017-10-11 11:24:56.074215|2017-10-11 11:24:56.074215
NCT01175707|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-20|2016-01-05|2013-04-05||July 2010||2010-07-01|January 2016|2016-01-01|November 2011|Actual|2011-11-01|November 2011|Actual|2011-11-01||Interventional||All study participants|Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting|A Phase 4, Prospective, Randomized, Open-label Study to Compare Use of Cubicin With Vancomycin Administered Intravenously in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Confirmed Gram-positive Bacteria in a Home Infusion Setting|Terminated||Phase 4|80|Actual|Cubist Pharmaceuticals LLC|The study was terminated prematurely.|2||Business decision|f||||f||||||||||2017-10-11 11:24:56.897495|2017-10-11 11:24:56.897495
NCT01176318|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-04|2012-01-09||||||July 2010|2010-07-01||||||||Interventional|||Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|A Double Blind, Placebo Controlled Multicentre Study of the Effects of Standard Care Plus Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|Withdrawn||Phase 4|0|Actual|Hull and East Yorkshire Hospitals NHS Trust||2||pharmaceutical grant was withdrawn, thus no financial support to conduct the study.|f||||f||||||||||2017-10-11 11:25:10.320252|2017-10-11 11:25:10.320252
NCT01169870|ClinicalTrials.gov processed this data on October 10, 2017|2010-02-08|2012-01-01|||July 2007||2007-07-01|January 2012|2012-01-01|October 2008|Actual|2008-10-01|August 2008|Actual|2008-08-01||Interventional|||Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients|A Randomized Phase II Trial of Genexol-PM vs Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients|Withdrawn||Phase 2|0|Actual|National Cancer Center, Korea||2||withdrawn studies|f||||f||||||||||2017-10-11 11:25:47.883413|2017-10-11 11:25:47.883413
NCT01177670|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-05|2012-10-19|2012-09-18||August 2010||2010-08-01|October 2012|2012-10-01|April 2012|Actual|2012-04-01|||||Observational|APACS||Adiana Post-Approval Clinical Study (APACS)|Adiana Post-Approval Clinical Study|Terminated||N/A|169|Actual|Hologic, Inc.|After determining Adiana was not financially viable and would not become so, Hologic decided to discontinue manufacturing & sales. Hologic decided to terminate the study. All subjects were notified of termination and withdrawn by April 30, 2012.||1|Hologic made business decision to no longer sell or manufacture Adiana device.|f||||f||||||||||2017-10-11 11:25:58.108835|2017-10-11 11:25:58.108835
NCT01179737|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-03|2014-04-14|2014-01-14||July 2010||2010-07-01|April 2014|2014-04-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional||an end of study evaluation was only available for 14 of these patients|Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)|A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)|Terminated||Phase 2|23|Actual|Novartis||2||Study was terminated due to serious adverse event (SAE)|f||||t||||||||||2017-10-11 11:26:28.09418|2017-10-11 11:26:28.09418
NCT01180062|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-10|2014-12-04|||January 2011||2011-01-01|December 2014|2014-12-01|June 2014|Actual|2014-06-01|June 2014|Actual|2014-06-01||Interventional|Latanoprost SR||Safety Study of Latanoprost Slow Release Insert|A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|Terminated||Phase 1|12|Actual|University of Kentucky||3||"Study terminated early due to manufacturer not replenishing study site supply of inserts,   despite repeated requests for more inserts."|f||||t||||||||||2017-10-11 11:26:33.404911|2017-10-11 11:26:33.404911
NCT01173939|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-27|2011-05-30|||July 2010||2010-07-01|November 2010|2010-11-01||||June 2014|Anticipated|2014-06-01||Interventional|POSITIVE||Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments|Primary Prevention of MACE With Standard and Intensive Statin Treatment in Hypercholesterolemia Patients With Concomitant Diabetes and Hypertension|Terminated||N/A|10000|Anticipated|Positive Trial Group||2||"With recommendation from IDMC, Steering Committee terminated this trial due to ethical concerns   raised by J-ART study."|f||||||||||||||2017-10-11 11:27:10.423929|2017-10-11 11:27:10.423929
NCT01174979|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-02|2015-08-04|||January 2011||2011-01-01|August 2015|2015-08-01||||August 2015|Anticipated|2015-08-01||Interventional|||Caroverin and Inner Ear Diseases|Double Blind, Placebo-controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Transtympanic Treatment of Tinnitus With Caroverine|Suspended||Phase 3|170|Anticipated|Phafag AG||2||due to less patient the study was suspended|f||||t||||||||||2017-10-11 11:27:28.202317|2017-10-11 11:27:28.202317
NCT01183377|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-13|2010-08-16|||October 2006||2006-10-01|August 2010|2010-08-01|March 2009|Anticipated|2009-03-01|February 2009|Actual|2009-02-01||Observational|||Frequency of Female Athlete Triad Among Elite Female Athlete of Iran in Different Sport in 2007|Screening of Menstrual Disorder in Elite Feamle Athlete in Iran|Terminated||N/A|250|Anticipated|Tehran University of Medical Sciences|||1|the study terminated last week|f||||t||||||||||2017-10-11 11:27:57.599218|2017-10-11 11:27:57.599218
NCT01183468|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-16|2015-01-14|2015-01-06||October 2010||2010-10-01|January 2015|2015-01-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|RETAIN|Enrolled Sample|A Research Trial of Aralast in New Onset Diabetes (RETAIN)|Effect of Intravenous Alpha-1 Antitrypsin on Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus (ITN041AI)|Terminated||Phase 1|17|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|This (Part 1) was the drug dosing portion of the study; however, due to lack of a mechanistic signal and competing industry studies, the study was terminated and the trial portion (Part II, NCT01183455) was withdrawn.|4||Due to lack of mechanistic signal and competing industry studies|f||||t||||||||||2017-10-11 11:27:58.629933|2017-10-11 11:27:58.629933
NCT01186458|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-19|2016-08-30|2016-08-30||October 2010||2010-10-01|August 2016|2016-08-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional|||Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma|A Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma: Hoosier Oncology Group LYM08-134|Terminated||Phase 2|4|Actual|Hoosier Cancer Research Network|This trial was terminated after accruing four subjects to do slow accrual. Sufficient data was not collected to complete the primary objective.|1||Slow accrual|f||||t||||||||||2017-10-11 11:28:53.866005|2017-10-11 11:28:53.866005
NCT01181843|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-12|2017-02-07|||July 2010||2010-07-01|February 2017|2017-02-01|June 2014|Actual|2014-06-01|June 2014|Actual|2014-06-01||Observational|||Incidence of Respiratory Depression in Cesarean Section|A Prospective, Observational, Double-blind (Black-Box) Study Evaluating Incidence, Severity and Predictive Factors of Respiratory Depression During Postoperative Neuraxial Opioid Analgesia in Obstetric Patients After Cesarean Delivery Using Current Standard Intermittent Postoperative Monitoring Compared to Continuous Pulse Oximetry / Capnography|Terminated||N/A|100|Actual|Wake Forest University Health Sciences|||1|departmental financial support withdrawn|f||||t||||||||||2017-10-11 11:29:39.130393|2017-10-11 11:29:39.130393
NCT01190306|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-25|2016-12-05|2012-12-13||August 2010||2010-08-01|December 2016|2016-12-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||Safety Study of the VEGA UV-A System to Treat Keratoconus|Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes With Keratoconus|Terminated||Phase 3|118|Actual|Topcon Medical Systems, Inc.||2||The sponsor terminated the study prior to data analysis for financial reasons.|f||||f||||||||||2017-10-11 11:29:56.143297|2017-10-11 11:29:56.143297
NCT01190839|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-12|2016-01-05|2014-10-16||November 2010||2010-11-01|December 2015|2015-12-01|December 2014|Actual|2014-12-01|December 2014|Actual|2014-12-01||Interventional||Analysis population included all the participants who were randomly assigned to receive 1 of the study treatments.|A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence|Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence|Terminated||Phase 3|297|Actual|Janssen Biotech, Inc.||2||Study is terminated as per Sponsor's Decision.|f||||t||||||||||2017-10-11 11:30:06.272672|2017-10-11 11:30:06.272672
NCT01185509|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-18|2017-07-29|2017-04-17||November 2010|Actual|2010-11-01|July 2017|2017-07-01|September 2017|Anticipated|2017-09-01|January 2017|Actual|2017-01-01||Interventional||The analysis dataset is comprised of all treated patients.|Trastuzumab and Vinorelbine in Advanced Breast Cancer|A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumors and HER2 Positive Circulating Tumor Cells|Terminated||Phase 2|31|Actual|Dana-Farber Cancer Institute|The study terminated early due to insufficient response per statistical design.|2||Not enough confirmed responses to continue treatment.|f||||t|t|f||||||||2017-10-11 11:31:07.01358|2017-10-11 11:31:07.01358
NCT01194674|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-02|2012-08-14|2012-07-10||January 2011||2011-01-01|August 2012|2012-08-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|MIME||Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema|Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema|Terminated||Phase 1/Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)|The study was terminated early due to lack of enrollment.|1||Lack of enrollment.|f||||f||||||||||2017-10-11 11:31:34.139639|2017-10-11 11:31:34.139639
NCT01195103|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-01|2012-06-25|2012-02-27||February 2011||2011-02-01|June 2012|2012-06-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery|A Prospective Randomized Study to Assess the Efficacy and Safety of Bolus-dose Lusedra (Fospropofol Disodium) 6.5 mg/kg or 10 mg/kg Versus a Placebo (With Midazolam Rescue) for Minimal-to-moderate Sedation in Patients Undergoing Procedural Sedation for Regional Anesthesia Blocks Prior to Orthopedic Surgery|Terminated||Phase 4|13|Actual|Mayo Clinic|The study was terminated early because funding was terminated by the funding source.|3||Funding terminated by funding source.|f||||f||||||||||2017-10-11 11:31:40.828638|2017-10-11 11:31:40.828638
NCT01195779|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-03|2016-09-09|2012-03-22||September 2010||2010-09-01|September 2016|2016-09-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children|Observer-blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Adjuvanted Quadrivalent Influenza Candidate Vaccines (GSK2584786A) in Children Aged 6 to 35 Months|Terminated||Phase 2|4|Actual|GlaxoSmithKline||14||The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2017-10-11 11:31:52.325871|2017-10-11 11:31:52.325871
NCT01195974|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-03|2014-12-22|||September 2010||2010-09-01|December 2014|2014-12-01|February 2011|Actual|2011-02-01|February 2011|Actual|2011-02-01||Interventional|||A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.|A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Drospirenone and Ethinyl Estradiol When Co-administered With GSK2248761 in Healthy Adult Female Subjects|Terminated||Phase 1|13|Actual|ViiV Healthcare||3||"In a Phase II study in HIV-infected patients there were a number of seizures, although exact   causality could not be assessed phase 1 activity was terminated."|f||||f||||||||||2017-10-11 11:31:56.385787|2017-10-11 11:31:56.385787
NCT01188798|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-24|2013-03-14|2013-02-12||September 2010||2010-09-01|February 2012|2012-02-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Interventional|||Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies|Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies|Completed||Phase 3|6|Actual|St. Jude Children's Research Hospital|This study was terminated prematurely. The Data Safety and Monitoring Board (DSMB) requested major scientific study changes. This was deemed infeasible by institutional leadership and study was terminated. Therefore, no final results exist to report.|2|||f||||t||||||||||2017-10-11 11:32:17.927891|2017-10-11 11:32:17.927891
NCT01189071|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-19|2016-11-18|2016-09-23||August 2009||2009-08-01|September 2016|2016-09-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional||Three participants were recruited to the study, but no data were collected or analyzed as the author of the study left the institution and the study was terminated.|Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain|Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain|Terminated||N/A|3|Actual|University of Missouri-Columbia|Three participants were recruited to the study, but no data were collected or analyzed as the author of the study left the institution and the study was terminated.|2||Co-Investigator left institution. No data analysis occurred.|f||||f||||||||Undecided||2017-10-11 11:32:21.68405|2017-10-11 11:32:21.68405
NCT01189227|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-25|2013-05-08|2013-02-05||August 2010||2010-08-01|May 2013|2013-05-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery|A Phase III Study Evaluating the Role of Perioperative Chemotherapy in Patients With Potentially Resectable Hepatic Colorectal Metastases|Terminated||Phase 3|9|Actual|NSABP Foundation Inc||2||The study was terminated due to low accrual.|f||||t||||||||||2017-10-11 11:32:24.347909|2017-10-11 11:32:24.347909
NCT01190163|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-26|2012-08-22|||June 2010||2010-06-01|August 2012|2012-08-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|SOFTNES||Open Label Comparative Trial of Dinoprostone Plus or Minus Oxytocin Versus Oxytocin Alone in Cervical Ripening for Labor Induction|Phase IV, Multicenter, Open Label, Randomized Trial to Compare the Effectiveness and Safety of the Dinoprostone Vaginal Pessary vs. Oxytocin for Women Requiring Cervical Ripening Prior to Induction of Labor|Terminated||Phase 4|170|Actual|Ferring Pharmaceuticals||2||Study was early terminated due to problems enrolling adequate number of patients|f||||f||||||||||2017-10-11 11:32:42.913009|2017-10-11 11:32:42.913009
NCT01200264|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-10|2014-07-14|||September 2010||2010-09-01|September 2010|2010-09-01|September 2012|Anticipated|2012-09-01|December 2011|Anticipated|2011-12-01||Interventional|||Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy|Open-Label Study to Assess the Safety and Efficacy of Apremilast in Patients With Chronic Plaque Psoriasis Who Have Failed One Course of Biologic Therapy.|Withdrawn||Phase 2|0|Actual|Duke University||1||Contract never executed; withdrawn by sponsor|f||||f||||||||||2017-10-11 11:33:34.743925|2017-10-11 11:33:34.743925
NCT01201928|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-27|2012-12-05|||October 2010||2010-10-01|December 2012|2012-12-01|March 2012|Actual|2012-03-01|March 2011|Actual|2011-03-01||Observational|||Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166|A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes|Terminated||Phase 3|3|Actual|Mannkind Corporation|||2|Parent trials were either not initiated or terminated|f||||f||||||||||2017-10-11 11:34:40.051474|2017-10-11 11:34:40.051474
NCT01202266|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-13|2011-03-09|||August 2010||2010-08-01|March 2011|2011-03-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||A Multiple Dose Study Of PF-05161704 In Healthy Volunteers|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of Pf-05161704 After Administration Of Multiple Escalating Oral Doses In Healthy Volunteers|Terminated||Phase 1|32|Actual|Pfizer||8||The study was terminated on October 29, 2010 due to gastrointestinal adverse events.|f||||f||||||||||2017-10-11 11:34:48.356274|2017-10-11 11:34:48.356274
NCT01202591|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-14|2016-01-13|2015-09-07||December 2010||2010-12-01|January 2016|2016-01-01|October 2014|Actual|2014-10-01|September 2014|Actual|2014-09-01||Interventional|GLOW||Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients|A Randomised Double-blind Phase IIa Study (With Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW)|Completed||Phase 1/Phase 2|127|Actual|AstraZeneca|Enrolment to the Part B was terminated on 27 March 2014. Slow recruitment led to concerns that enrolment would not be completed in a realistic timeframe. This led to a business decision to terminate the enrolment.|3|||f||||f||||||||||2017-10-11 11:34:52.042606|2017-10-11 11:34:52.042606
NCT01203397|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-15|2013-03-01|||September 2014||2014-09-01|March 2013|2013-03-01|February 2015|Anticipated|2015-02-01|December 2014|Anticipated|2014-12-01||Interventional|||Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate In The Superficial Varicose Veins Treatment|PHASE III OF SAFETY AND EFFICACY STUDY OF TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G IN THE SUPERFICIAL VARICOSE VEINS TREATMENT|Suspended||Phase 3|70|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2017-10-11 11:35:10.065452|2017-10-11 11:35:10.065452
NCT01203618|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-28|2013-11-01|||February 2011||2011-02-01|November 2013|2013-11-01|August 2013|Anticipated|2013-08-01|June 2013|Anticipated|2013-06-01||Interventional|||Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas|Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma|Withdrawn||Phase 2|0|Actual|Morphotek||1||Trial terminated due to focus of primary therapeutic areas.|f||||t||||||||||2017-10-11 11:35:12.395405|2017-10-11 11:35:12.395405
NCT01197664|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-02|2017-05-25|||August 2010||2010-08-01|July 2014|2014-07-01|April 2014|Actual|2014-04-01|July 2012|Actual|2012-07-01||Interventional|||Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery|A Pilot Study of Paricalcitol Synergism in Conjunction With Standard-of-Care Chemo-Radiation for Resectable Rectal Cancers|Terminated||Phase 1|2|Actual|Wake Forest University Health Sciences||2||Study terminated due to funding issues|f||||f|t|f||||||||2017-10-11 11:35:35.71678|2017-10-11 11:35:35.71678
NCT01206296|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-20|2015-12-07|||August 2010||2010-08-01|December 2015|2015-12-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|||Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma|A Phase 2 Study of Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma|Terminated||Phase 2|9|Actual|Washington Hospital Center||1||Study suspended|f||||t||||||||||2017-10-11 11:35:51.210995|2017-10-11 11:35:51.210995
NCT01208233|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-22|2016-01-22|2015-02-19||December 2010||2010-12-01|January 2016|2016-01-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional||The Full Analysis Set (FAS) consisted of all randomized participants who took any study medication (active or placebo).|Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke|A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke|Terminated||Phase 2|181|Actual|Pfizer|The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results.|4||See termination reason in detailed description.|f||||t||||||||||2017-10-11 11:36:21.95655|2017-10-11 11:36:21.95655
NCT01201213|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-13|2017-05-29|||September 2009||2009-09-01|May 2017|2017-05-01|August 2012|Actual|2012-08-01|August 2012|Actual|2012-08-01||Interventional|||Bupivacaine, Levobupivacaine and Ropivacaine After Intrathecal and Extradural Injection in Labour|Median Effective Concentration of Bupivacaine, Levobupivacaine and Ropivacaine After Intrathecal and Extradural Injection for Pain Relief in the First Stage of Labour|Terminated||Phase 4|14|Actual|NHS Tayside||6||Audit pre regulatory inspection|f||||f||||||||No|study terminated|2017-10-11 11:36:33.582774|2017-10-11 11:36:33.582774
NCT01201291|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-13|2017-03-02|||November 2010||2010-11-01|March 2017|2017-03-01|September 2018|Anticipated|2018-09-01|September 2018|Anticipated|2018-09-01||Interventional|BRAINOXY||Impact of Inspired Oxygen Fraction on Outcome in Patients With Traumatic Brain Injury|Impact of Inspired Oxygen Fraction on Outcome in Patients With Traumatic Brain Injury|Terminated||N/A|67|Actual|Kuopio University Hospital||2||Due to slow recruitment the study was terminated|f||||t||||||||Undecided||2017-10-11 11:36:34.799331|2017-10-11 11:36:34.799331
NCT01208402|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-10|2014-11-25|2014-11-13||September 2010||2010-09-01|November 2014|2014-11-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|||Esmolol for Treatment of Perioperative Tachycardia|Safety and Efficacy of Esmolol for the Treatment of Peri-operative Tachycardia in Patients at Risk for Post Operative Adverse Ischemic Outcomes|Terminated||Phase 3|76|Actual|Duke University||2||Baxter has terminated the study for inadequate enrollment rate accrual.|f||||f||||||||||2017-10-11 11:36:40.700268|2017-10-11 11:36:40.700268
NCT01209689|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-24|2012-12-11|2012-12-11||October 2010||2010-10-01|December 2012|2012-12-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy|A Randomized, Double-blind, Parallel Group Placebo-controlled Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab (TCZ) Versus Placebo in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous TNF Antagonist Therapy|Terminated||Phase 3|113|Actual|Hoffmann-La Roche||3||Clinical development program terminated due to failure to achieve efficacy|f||||||||||||||2017-10-11 11:36:58.158079|2017-10-11 11:36:58.158079
NCT01210144|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-11|2013-12-02|2012-08-30||August 2008||2008-08-01|December 2013|2013-12-01|August 2010|Actual|2010-08-01|August 2010|Actual|2010-08-01||Interventional|EXPRESS||EXpression PRofile Endometrium Samples Study|Open Label Pilot Study on Gene Expression Profiling of the Endometrial Tissue in Patients Undergoing Assisted Reproductive Technology [ART: In Vitro Fertilization (IVF)/ Intracytoplasmic Sperm Injection (ICSI)] With GONAL-f®|Terminated||Phase 4|27|Actual|Merck KGaA|Gene expression of the endometrium could not be analyzed due to poor quality of biopsy samples (poor mRNA quality) and poor recruitment in the study.|2||Study terminated due to recruitment failure|f||||f||||||||||2017-10-11 11:37:04.989184|2017-10-11 11:37:04.989184
NCT01210365|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-09|2017-09-15|||January 2011|Actual|2011-01-01|September 2017|2017-09-01|September 2017|Anticipated|2017-09-01|February 2013|Actual|2013-02-01||Interventional|||Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema|Safety and Efficacy of the Combination of Furosemide 40 mg + Amiloride Hydrochloride 10 mg in the Reduction of Edema of Cardiac Origin in Patients With Congestive Heart Failure Functional Class II (NYHA)|Suspended||Phase 3|60|Anticipated|Eurofarma Laboratorios S.A.||2||The company decided to suspended the study because the investigational product will change.|f||||t||||||||||2017-10-11 11:37:07.10649|2017-10-11 11:37:07.10649
NCT01210443|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-11|2011-11-10|2011-11-10||November 2010||2010-11-01|June 2011|2011-06-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients|A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension|Terminated||Phase 3|2|Actual|Pfizer||1||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,   specifically new emerging evidence of hepatic injury."|f||||t||||||||||2017-10-11 11:37:07.66771|2017-10-11 11:37:07.66771
NCT01210521|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-27|2016-08-09|||September 2010||2010-09-01|August 2016|2016-08-01|February 2016|Actual|2016-02-01|February 2016|Actual|2016-02-01||Interventional|||Use of Vitamin D3 for the Treatment of Steroid Resistant Asthmatic Patients|Use of Vitamin D3 for the Treatment of Steroid Resistant Asthmatic Patients|Withdrawn||Phase 2|0|Actual|Florida Atlantic University||2||Sponsor terminated study due to inability to enroll subjects.|f||||t||||||||No|Study withdrwan|2017-10-11 11:37:15.304044|2017-10-11 11:37:15.304044
NCT01204853|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-06|2011-10-26|2011-10-26||August 2010||2010-08-01|October 2011|2011-10-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients|A Phase 3, Multi-Center, Open Label Study To Evaluate The Safety And Efficacy Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension|Terminated||Phase 3|2|Actual|Pfizer||1||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,   specifically new emerging evidence of hepatic injury."|f||||t||||||||||2017-10-11 11:37:35.984513|2017-10-11 11:37:35.984513
NCT01213823|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-30|2016-03-02|2012-04-09||September 2008||2008-09-01|March 2016|2016-03-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Observational|||Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins|Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins|Terminated||Phase 4|536|Actual|Pfizer|Study results were invalidated due to lack of temporality, a critical methodological element of the study that was never established for the majority of the cases of severe hepatic injury.||2|"The study was terminated on May 5, 2011, due to methodological issues. The decision to   terminate the study was not based on any safety or efficacy concerns."|f||||f||||||||||2017-10-11 11:37:59.946575|2017-10-11 11:37:59.946575
NCT01214057|ClinicalTrials.gov processed this data on October 10, 2017|2010-08-04|2013-05-17|||May 2010||2010-05-01|May 2013|2013-05-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Total Intravenous Anesthesia (TIVA) vs. Inhaled Anesthesia for Endoscopic Sinus Surgery.|Preliminary Study to Assess the Effects of Total Intravenous Anesthesia With Propofol/Remifentanyl Compared to Sevoflurane/Remifentanyl for Endoscopic Sinus Surgery: Novel Approach.|Terminated||N/A|23|Actual|The University of Texas Health Science Center, Houston||2||the study was terminated for patient recruitment difficulty and interim power analysis|f||||t||||||||||2017-10-11 11:38:03.008347|2017-10-11 11:38:03.008347
NCT01215227|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-04|2016-10-18|2016-10-18||November 2010||2010-11-01|October 2016|2016-10-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional||All Participants as Treated: All participants who received at least one dose of study drug in Extension Study P06153. Data were not reported for 3 participants who were randomized but not treated.|An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)|A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)|Terminated||Phase 3|839|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to the lack of efficacy of preladenant in the parent studies NCT1155466 and NCT01227265.|6|||f||||t||||||||||2017-10-11 11:38:28.005293|2017-10-11 11:38:28.005293
NCT01217099|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-06|2010-10-07|||May 2007||2007-05-01|May 2007|2007-05-01|May 2010|Actual|2010-05-01|May 2010|Actual|2010-05-01||Interventional|MPP||Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children|A Prospective, Open-label Trial of Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children|Terminated||N/A|47|Actual|Chongqing Medical University||2||terminated|f||||t||||||||||2017-10-11 11:38:54.992897|2017-10-11 11:38:54.992897
NCT01217632|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-30|2016-08-12|||August 2010||2010-08-01|August 2016|2016-08-01|June 2015|Actual|2015-06-01|June 2015|Actual|2015-06-01||Interventional|||A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection|A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection|Terminated||Phase 2|114|Actual|FibroGen||2||"Study terminated due to an unexpected prominent effect of entecavir alone in this patient   population."|f||||f||||||||||2017-10-11 11:39:06.710801|2017-10-11 11:39:06.710801
NCT01217814|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-07|2017-07-31|2017-05-23|2012-10-31|November 2010||2010-11-01|July 2017|2017-07-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional|||Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers|A Randomized, Double-blind, Parallel-group, Placebo- and Active Calibrator-controlled Study Assessing the Clinical Benefit of SAR153191 Subcutaneous (SC) on Top of MTX in Patients With Active RA Who Have Failed Previous TNF-α Antagonists|Terminated||Phase 2|16|Actual|Sanofi|The study was prematurely terminated due to small number of participants entering randomization.|3||"Due to delay in the study and the impact on the development timelines, not due to any   identified safety concerns"|f||||t||||||||||2017-10-11 11:39:10.51308|2017-10-11 11:39:10.51308
NCT01218815|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-01|2015-03-05|||October 2010||2010-10-01|March 2015|2015-03-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|CORAMI||Complete Infarct Related Artery Revascularization|Complete Infarct Related Artery Revascularization in Acute Myocardial Infarction Patients - CORAMI Trial|Terminated||N/A|1|Actual|Fundacja Ośrodek Badań Medycznych||2||Due to very low enrollment rate the study was terminated.|f||||f||||||||||2017-10-11 11:39:33.697924|2017-10-11 11:39:33.697924
NCT01212276|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-29|2014-07-15|||December 2010||2010-12-01|July 2014|2014-07-01|September 2012|Actual|2012-09-01|June 2012|Actual|2012-06-01||Interventional|||A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma|A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma|Terminated||Phase 1|18|Actual|Morphotek||4||Sponsor terminated protocol|f||||f||||||||||2017-10-11 11:40:00.696301|2017-10-11 11:40:00.696301
NCT01221753|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-21|2016-10-13|2016-08-15||July 2011||2011-07-01|October 2016|2016-10-01|July 2017|Anticipated|2017-07-01|July 2012|Actual|2012-07-01||Interventional|||Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study|A Phase II Study of Docetaxel/Cisplatin/5-Fluorouracil (TPF) Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Using a Modified Radiation Dose in Patients With Newly Diagnosed HPV Positive, Locally Advanced Squamous Cell Carcinoma of the Oropharynx|Terminated||Phase 2|7|Actual|Dana-Farber Cancer Institute|The study was terminated early due to weak accrual. Because of the designation of study completed at the institution conducting the study, data collected systematically on the case report forms were not accessible for results reporting.|1||Due to slow accrual|f||||t||||||||No|There is no data available.|2017-10-11 11:40:38.15697|2017-10-11 11:40:38.15697
NCT01222013|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-15|2013-03-25||||||March 2013|2013-03-01||||||||Interventional|||Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)|Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)|Suspended||Phase 2|20|Anticipated|Hospital Santa Marcelina||1||Study was suspended before recruitment, due to logistic issues.|f||||f||||||||||2017-10-11 11:40:40.59032|2017-10-11 11:40:40.59032
NCT01223430|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-18|2012-05-21|||September 2010||2010-09-01|May 2012|2012-05-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Interventional|||Simultaneously Using Traditional Chinese Medicine (Si-Ni-Tang) to Treat Septic Shock Patients|Simultaneously Using Traditional Chinese Medicine (Si-Ni-Tang) to Treat Septic Shock Patients - a Double Blind, Prospective, Randomized Controlled Study|Terminated||Phase 2|8|Actual|Changhua Christian Hospital||2||"The IRB considered our trial risky. Although there were debates between investigators and IRB,   we terminated our trial in accordance with the suggestion of IRB."|f||||t||||||||||2017-10-11 11:41:08.235986|2017-10-11 11:41:08.235986
NCT01224795|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-19|2014-12-15||2011-12-14|October 2010||2010-10-01|December 2014|2014-12-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.|A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.|Terminated||Phase 3|1|Actual|BioCryst Pharmaceuticals||2||This study was terminated for administrative reasons|f||||t||||||||||2017-10-11 11:41:31.878871|2017-10-11 11:41:31.878871
NCT01225016|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-14|2012-01-27|||October 2010||2010-10-01|January 2012|2012-01-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound|Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound|Withdrawn||N/A|0|Actual|University of Alabama at Birmingham||1||"Due to lack of funding and issues with ability to complete all procedures, it was decided that   this study could not be carried out and therefore withdrawn."|f||||t||||||||||2017-10-11 11:41:34.329096|2017-10-11 11:41:34.329096
NCT01226121|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-20|2014-05-16|2014-04-21||December 2010||2010-12-01|May 2014|2014-05-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|||Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture|A Post Market, Open-Label Study of the Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture|Terminated||Phase 4|37|Actual|Indiana Hand to Shoulder Center|Study was terminated early due to slow enrollment|3||difficulty enrolling additional patients|f||||f||||||||||2017-10-11 11:42:15.936604|2017-10-11 11:42:15.936604
NCT01220739|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-13|2016-10-07|2014-12-03||June 2011||2011-06-01|October 2016|2016-10-01|April 2013|Actual|2013-04-01|December 2012|Actual|2012-12-01||Interventional|StELLAR||Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery|Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery|Terminated||Phase 2|12|Actual|University of California, San Diego|Study was terminated early due to device sponsor filing bankruptcy.|2||Device sponsor no longer in business.|f||||t||||||||Yes|Data will be uploaded to the NINDS data sharing website.|2017-10-11 11:42:54.603432|2017-10-11 11:42:54.603432
NCT01228929|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-25|2015-09-17|2015-07-31||July 2010||2010-07-01|September 2015|2015-09-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|||Non-invasive Ocular Surface Measurements Before and After Interventions|Non-invasive Ocular Surface Measurements Before and After Interventions|Terminated||N/A|18|Actual|University of Rochester||3||The study was terminated.|f||||f||||||||||2017-10-11 11:43:13.591986|2017-10-11 11:43:13.591986
NCT01228994|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-25|2013-09-11|||October 2010||2010-10-01|September 2013|2013-09-01|August 2012|Actual|2012-08-01|August 2012|Actual|2012-08-01||Interventional|Baclofen||Baclofen for Smoking Cessation in a Non-Psychiatric Population|Testing the GABAergic Hypothesis of Nicotine Dependence: a Randomized Clinical Trial of Baclofen|Terminated||Phase 2|6|Actual|Centre for Addiction and Mental Health||3||The study was terminated because of difficulties recruiting subjects.|f||||f||||||||||2017-10-11 11:43:14.333519|2017-10-11 11:43:14.333519
NCT01235741|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-02|2015-03-26|2013-08-12||January 2011||2011-01-01|March 2015|2015-03-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional||Baseline for all participants (213) was baseline at enrollment (Day 1 of Lead-in period); baseline for participants who were randomized to treatment before study was terminated was Day 1 of randomization (last measurement before first dose of assigned drug).|A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects|A Randomized, Double-Blind, Placebo-Controled, Multicenter Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects Following A Low‑Calorie Diet Lead-In|Terminated||Phase 2|213|Actual|AstraZeneca||2||"Results from previous study DFA102 demonstrated neutralizing activity to metreleptin in invitro   assay in 2 participants."|f||||f||||||||||2017-10-11 11:45:13.985531|2017-10-11 11:45:13.985531
NCT01236664|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-08|2011-10-11|||January 2012||2012-01-01|October 2011|2011-10-01|January 2013|Anticipated|2013-01-01|January 2013|Anticipated|2013-01-01||Interventional|||An Evaluation of the Memory at Work Program|An Evaluation of the Memory at Work Program|Withdrawn||N/A|0|Actual|Baycrest||2||The sponsor is no longer developing this program and therefore has withdrawn the funding.|f||||f||||||||||2017-10-11 11:45:30.456543|2017-10-11 11:45:30.456543
NCT01237340|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-05|2013-08-04|2012-09-11||October 2010||2010-10-01|August 2013|2013-08-01|December 2011|Actual|2011-12-01|December 2011|Actual|2011-12-01||Interventional|||Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study|A Phase IIIb, Open-label, Single-arm, Multicenter Study to Assess the Immunogenicity of the Recombinant-Human Growth Hormone (r-hGH) Liquid Multidose Formulation (Saizen® Solution for Injection) When Administered to Male and Female Adults With Documented Growth Hormone Deficiency (GHD)|Terminated||Phase 3|59|Actual|EMD Serono||1||"The Sponsor voluntarily terminated this trial because compliance to strict Good Clinical   Practice (GCP) requirements was not ensured - No safety concerns"|f||||f||||||||||2017-10-11 11:45:38.372054|2017-10-11 11:45:38.372054
NCT01237613|ClinicalTrials.gov processed this data on October 10, 2017|2010-09-16|2015-06-29|2015-05-08||November 2010||2010-11-01|June 2015|2015-06-01|February 2014|Actual|2014-02-01|February 2014|Actual|2014-02-01||Interventional|||Prospective Study on Artelon® Tissue Reinforcement in Repair of Chronic Ruptures and Re-ruptures of the Achilles Tendon|Prospective Study on Artelon® Tissue Reinforcement in Repair of Chronic Ruptures and Re-ruptures of the Achilles Tendon|Terminated||N/A|4|Actual|Orthopedic Foot and Ankle Center, Ohio|The sample size is small due to the study being terminated early because of sponsor bankrupty,|1||Sponsoring company declared bankrupty|f||||f||||||||||2017-10-11 11:45:40.630888|2017-10-11 11:45:40.630888
NCT01238588|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-09|2017-07-03|2017-05-26||June 10, 2011|Actual|2011-06-10|July 2017|2017-07-01|April 8, 2016|Actual|2016-04-08|April 8, 2016|Actual|2016-04-08||Interventional|||The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan|The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan|Terminated||N/A|24|Actual|Brigham and Women's Hospital|Enrollment was much slower than anticipated due to logistical reasons, study at the direction of funding source terminated early and therefore none of the collected samples were analyzed.|1||The study stopped due to lack of funding.|f||||f||||||||||2017-10-11 11:45:52.375004|2017-10-11 11:45:52.375004
NCT01232400|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-01|2015-01-07|||July 2014||2014-07-01|January 2015|2015-01-01|August 2016|Anticipated|2016-08-01|July 2015|Anticipated|2015-07-01||Interventional|ABASH||Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage|Adrenergic Blockade After Subarachnoid Hemorrhage|Withdrawn||N/A|0|Actual|University of Michigan||2||Funding withdrawn. Design not feasible.|f||||t||||||||||2017-10-11 11:46:22.675014|2017-10-11 11:46:22.675014
NCT01232881|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-01|2011-04-27|||August 2009||2009-08-01|April 2011|2011-04-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Observational|||Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer|Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study|Terminated||N/A|27|Actual|Hoosier Cancer Research Network|||1|funding terminated|f||||t||||||Samples Without DNA|"     Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed     paraffin embedded tissue block.      Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after     the last dose of lonafarnib.   "|||2017-10-11 11:46:32.018911|2017-10-11 11:46:32.018911
NCT01238991|ClinicalTrials.gov processed this data on October 10, 2017|2010-10-21|2014-12-12|2014-12-12||December 2010||2010-12-01|December 2014|2014-12-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|||Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease|A Phase Iia, Multicenter, Treatment Assigned, Open-label, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease|Terminated||Phase 2|53|Actual|Pfizer|Since the study was early terminated and the data could not be obtained as planned, only part of the immunogenicity and safety results were summarized.|3|||f||||t||||||||||2017-10-11 11:46:41.23924|2017-10-11 11:46:41.23924
NCT01239758|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-01|2013-01-30||2013-01-24|October 2010||2010-10-01|January 2013|2013-01-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Interventional|||Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy|An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy|Terminated||Phase 2|11|Actual|Acceleron Pharma, Inc.||3||This study was terminated based on preliminary safety data.|f||||t||||||||||2017-10-11 11:46:48.432553|2017-10-11 11:46:48.432553
NCT01241279|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-12|2014-11-25|2013-05-17||October 2010||2010-10-01|November 2014|2014-11-01|December 2011|Actual|2011-12-01|November 2011|Actual|2011-11-01||Interventional|||Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses|A Two Arm Prospective, Randomized, Double-Masked Clinical Evaluation of Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses|Terminated||Phase 4|6|Actual|Bausch & Lomb Incorporated|Study terminated early due to lack of enrollment|2||Terminated due to low enrollment|f||||f||||||||||2017-10-11 11:47:23.592126|2017-10-11 11:47:23.592126
NCT01241513|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-12|2016-05-17|2012-10-22||November 2010||2010-11-01|May 2016|2016-05-01|May 2011|Actual|2011-05-01|May 2011|Actual|2011-05-01||Interventional|||Induced Changes in Ventilatory Responsiveness and Altitude Exposure|Modulation of Oxygen Sensor Reactivity to Mimic Altitude Acclimatization|Terminated||Phase 4|21|Actual|United States Army Research Institute of Environmental Medicine|Study terminated due to results of preliminary analyses.|2||Results of preliminary analyses showed no reason to continue the study|f||||t||||||||||2017-10-11 11:47:29.243096|2017-10-11 11:47:29.243096
NCT01243892|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-17|2016-10-07|2016-10-07||November 2010||2010-11-01|October 2016|2016-10-01|August 2011|Actual|2011-08-01|August 2011|Actual|2011-08-01||Observational||Study population included all enrolled somatropin-naive pre-pubertal participants with growth hormone deficiency or ISS.|A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device|A Phase IV, Open Label, Multicenter, Case-controlled Study of Growth in Patients Using the Nutropin AQ® Nuspin®|Terminated||N/A|18|Actual|Genentech, Inc.|The study was terminated prematurely due to slow enrollment.||2|The study was closed due to the slow enrollment rate.|f||||||||||||||2017-10-11 11:48:02.624394|2017-10-11 11:48:02.624394
NCT01244412|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-17|2015-05-15|2013-06-05||December 2010||2010-12-01|May 2015|2015-05-01|December 2011|Actual|2011-12-01|November 2011|Actual|2011-11-01||Observational|||Assessment of Prototype Hand-held Fundus Camera|Assessment of Prototype Hand-held Fundus Camera|Terminated||N/A|1|Actual|University of Rochester|It was determined that the project should stop in order for more technical changes to be made on the prototype||1|"The PI wanted to make additional changes to the hand held camera therefore he terminated the   study rather than continue with an outdated camera design."|f||||f||||||||||2017-10-11 11:48:09.991526|2017-10-11 11:48:09.991526
NCT01244620|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-15|2012-01-18|2012-01-18||November 2010||2010-11-01|January 2011|2011-01-01|December 2010|Actual|2010-12-01|December 2010|Actual|2010-12-01||Interventional|||A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses|A Phase 1, Open Label, Randomized, Four Period, Crossover, Multiple Dose Study To Assess The Pharmacokinetic Interaction Between Sitaxsentan and Tadalafil and The Effect Of Sildenafil On Sitaxsentan PK In Healthy Subjects|Terminated||Phase 1|16|Actual|Pfizer|Study endpoints were not analyzed due to early termination.|4||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,   specifically new emerging evidence of hepatic injury."|f||||f||||||||||2017-10-11 11:48:15.451775|2017-10-11 11:48:15.451775
NCT01244659|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-18|2013-03-01|||May 2014||2014-05-01|March 2013|2013-03-01|December 2014|Anticipated|2014-12-01|August 2014|Anticipated|2014-08-01||Interventional|||A Randomized Study Assess the Safety and Efficacy of Tacrolimus vs Prograf® in Renal Transplantation Treatment|An Open Randomized Non-inferiority Study to Compare Safety and Efficacy of Immunosuppressive Regiments Using Tacrolimus From EMS and Prograf® in Post Renal Transplanted Patients|Suspended||Phase 3|60|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2017-10-11 11:48:16.255449|2017-10-11 11:48:16.255449
NCT01245101|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-19|2016-10-28|2016-03-24||November 2010||2010-11-01|October 2016|2016-10-01|May 2013|Actual|2013-05-01|October 2012|Actual|2012-10-01||Interventional|||Addition of Raltegravir to Established Antiretroviral Suppressive Therapy|A Prospective, Open-Label, Double-Arm, Crossover, Single-Center Pilot Study to Evaluate the Addition of Raltegravir to Established Suppressive Antiretroviral Therapy While Monitoring Changes in Markers of Immune Activation Among HIV-1 Infected Individuals Without Adequate Immune Restoration|Terminated||Phase 4|15|Actual|University of Miami|Only 11 of 12 patients completed week 40 and were analyzed as per protocol. In view of poor enrollment and a simple analysis of the limited amount of data that failed to support our hypothesis, the study was terminated early.|2||Poor enrollment.|f||||f||||||||||2017-10-11 11:48:28.645862|2017-10-11 11:48:28.645862
NCT01239355|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-10|2015-09-03|2015-06-10||December 2010||2010-12-01|March 2013|2013-03-01|February 2013|Actual|2013-02-01|February 2013|Actual|2013-02-01||Interventional|||MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy|A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy|Terminated||Phase 2|15|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results|1||Early termination for discouraging results|f||||||||||||||2017-10-11 11:48:53.205172|2017-10-11 11:48:53.205172
NCT01247688|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-17|2013-12-11|||November 2010||2010-11-01|December 2013|2013-12-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Interventional|UCALL||Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies|Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies (UCALL)|Withdrawn||N/A|0|Actual|Baylor College of Medicine||1||This study was withdrawn due to low accrual.|f||||t||||||||||2017-10-11 11:49:08.620323|2017-10-11 11:49:08.620323
NCT01248130|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-19|2014-09-15|2014-09-15||November 2009||2009-11-01|September 2014|2014-09-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|||Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders|Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders|Terminated||Phase 2|7|Actual|Massachusetts General Hospital|This study was terminated early due to a change in the research priorities of the Principal Investigator in combination with low subject interest. Therefore, no data was analyzed.|2||"Due to a change in the research priorities of the principal investigator in combination with   low subject interest."|f||||f||||||||||2017-10-11 11:49:12.844637|2017-10-11 11:49:12.844637
NCT01248182|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-23|2012-04-05|||September 2010||2010-09-01|April 2012|2012-04-01|December 2011|Actual|2011-12-01|September 2011|Actual|2011-09-01||Observational|||Bone to Skin Thickness Study: Obese Versus Normal Population|Bone to Skin Thickness Study: Obese Versus Normal Population|Terminated||N/A|21|Actual|University of Mississippi Medical Center|||1|Study was terminated by investigator|f||||f||||||||||2017-10-11 11:49:13.426661|2017-10-11 11:49:13.426661
NCT01242995|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-16|2015-05-06|||May 2015||2015-05-01|May 2015|2015-05-01|May 2015|Actual|2015-05-01|May 2015|Actual|2015-05-01||Observational|||Endoscopic Retrograde Cholangiopancreatography (ERCP) With Cholangiopancreatoscopy Using a Thin Scope|Prospective Evaluation of the Clinical Utility of the Thin Scope/Anchoring Balloon Cholangiopancreatoscopy System for Disorders fo the Pancreatobiliary System|Withdrawn||N/A|0|Actual|University of Florida|||1|The device was withdrawn from clinical use|f||||f||||||||||2017-10-11 11:49:50.508834|2017-10-11 11:49:50.508834
NCT01251120|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-30|2014-11-06|2014-11-03||November 2011||2011-11-01|November 2014|2014-11-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional||Due to limited number of participants (n=2) the study was prematurely terminated.|A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis|A Pragmatic, Randomized, Parallel Group Study of the Effect on Disease Remission, Work Productivity and Tolerability of Tocilizumab in Combination With DMARDs and Individually Designed Best Practice DMARD Therapy in Patients With Early, Moderate to Severe Rheumatoid Arthritis|Terminated||Phase 4|2|Actual|Hoffmann-La Roche||2||The study was stopped prematurely due to lack of enrollment.|f||||||||||||||2017-10-11 11:50:10.44825|2017-10-11 11:50:10.44825
NCT01251354|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-23|2015-09-23|2015-08-06||November 2010||2010-11-01|September 2015|2015-09-01|July 2011|Actual|2011-07-01|June 2011|Actual|2011-06-01||Interventional|||Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy|A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.|Terminated||Phase 2|6|Actual|Ipsen|Study terminated due to poor enrollment|1||"The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the   primary endpoint will not be reached."|f||||||||||||||2017-10-11 11:50:13.209594|2017-10-11 11:50:13.209594
NCT01252238|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-01|2013-06-24|2013-06-24||June 2010||2010-06-01|June 2013|2013-06-01|December 2012|Actual|2012-12-01|December 2012|Actual|2012-12-01||Interventional|||Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance|Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance|Terminated||N/A|24|Actual|Brigham and Women's Hospital|No conclusions can be drawn from study due to very low sample size. The sponsor terminated the study after a separate study reported adverse events in a diabetic population who had taken both valsartan and aliskiren.|3||Study sponsor terminated study due to AE's reported with valsartan and aliskiren|f||||||||||||||2017-10-11 11:50:36.691243|2017-10-11 11:50:36.691243
NCT01254656|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-03|2014-05-27|2014-01-21||February 2011||2011-02-01|January 2014|2014-01-01|April 2013|Actual|2013-04-01|April 2013|Actual|2013-04-01||Interventional|||A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022|A Long Term Open-Label Extension Study Of Lersivirine For The Treatment Of HIV-1 Infection|Terminated||Phase 2|108|Actual|Pfizer|The study was terminated on 29 Jan 13 due to termination of lersivirine development program. All participants were enrolled from study A5271015 except one from A5271022. Above summarized outcome measures included participants enrolled from A5271015.|6||See termination reason in detailed description.|f||||f||||||||||2017-10-11 11:51:22.690322|2017-10-11 11:51:22.690322
NCT01256281|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-07|2015-04-06|2013-12-02||September 2010||2010-09-01|April 2015|2015-04-01|August 2013|Actual|2013-08-01|August 2013|Actual|2013-08-01||Interventional|RESCUED||Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I|RESCUED: Phase I: Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency|Terminated||Phase 1|2|Actual|Icahn School of Medicine at Mount Sinai|study was terminated due to lack of resources. no data analysis for this study.|1||lack of resources|f||||t||||||||||2017-10-11 11:51:49.209278|2017-10-11 11:51:49.209278
NCT01260870|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-13|2015-06-05||2015-06-05|August 2011||2011-08-01|June 2015|2015-06-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|||European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)|European Study of POBA Versus Cotavance Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia|Terminated||Phase 2|44|Actual|Bayer||2||Bayer terminated the program and sold the IP to Medronic|f||||t||||||||||2017-10-11 11:53:18.223629|2017-10-11 11:53:18.223629
NCT01254136|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-01|2012-01-20||2010-12-13|October 2010||2010-10-01|January 2012|2012-01-01|October 2011|Actual|2011-10-01|September 2011|Actual|2011-09-01||Interventional|||Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer|A Phase I/II Study to Assess the Safety and Therapeutic Effect of INCB007839 in Combination With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer.|Terminated||Phase 1/Phase 2|20|Anticipated|Incyte Corporation||1||Incyte has suspended development of the compound.|f||||f||||||||||2017-10-11 11:53:25.578744|2017-10-11 11:53:25.578744
NCT01261403|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-15|2014-07-16||2013-08-13|December 2010||2010-12-01|July 2014|2014-07-01|September 2013|Actual|2013-09-01|February 2012|Actual|2012-02-01||Interventional|||Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis|A Phase 2, Randomized, Double- Blind, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Active Rheumatoid Arthritis|Terminated||Phase 2|26|Actual|Celgene||3||Enrollment terminated pending additional Phase 1 data|f||||t||||||||||2017-10-11 11:53:33.369818|2017-10-11 11:53:33.369818
NCT01264835|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-17|2012-02-01|2011-11-28||December 2010||2010-12-01|February 2012|2012-02-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|||Assessment of a Slotted Anoscope That Facilitates Hemorrhoidectomy||Terminated||N/A|2|Actual|Ethicon Endo-Surgery|No analyses are being reported for the primary outcome measure as this trial was terminated early. The procedure was only performed with the slotted anoscope in 1 subject. No assessment or analysis of primary or secondary objectives was performed.|1||Slow Enrollment|f||||f||||||||||2017-10-11 11:53:42.882264|2017-10-11 11:53:42.882264
NCT01264861|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-20|2017-09-15|||March 2011|Actual|2011-03-01|September 2017|2017-09-01|January 24, 2012|Actual|2012-01-24|January 2012|Actual|2012-01-01||Interventional|||A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging|"Open-Label Escalating Dose Study Using [123|]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease Patients"|Terminated||Phase 2|5|Actual|Newron||1||"The Dopamine transporter brain imaging trial is terminated due to a company decision to return   all rights for Safinamide back to Newron Pharmaceuticals"|f||||f||||||||||2017-10-11 11:53:43.092551|2017-10-11 11:53:43.092551
NCT01264991|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-21|2016-11-07|||December 2010||2010-12-01|November 2016|2016-11-01|November 2015|Actual|2015-11-01|November 2015|Actual|2015-11-01||Interventional|SLAMSHAM||The Benefit of Arthroscopic Partial Meniscectomy in Middle-Aged Patients|The Benefit of Arthroscopic Partial Meniscectomy in Middle-Aged Patients - A Double-Blinded Randomized Placebo (Sham) Controlled Multi-Centre Trial|Terminated||N/A|41|Actual|Slagelse Hospital||2||"Recruitment stalled. Study terminated before inclusion of sufficient number of participants   included"|f||||f||||||||||2017-10-11 11:53:46.752786|2017-10-11 11:53:46.752786
NCT01265199|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-20|2013-01-21|||February 2011||2011-02-01|January 2013|2013-01-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)|Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)|Terminated||Phase 1|29|Actual|Ascenta Therapeutics||1||Study was terminated before a MTD was determined for administrative reasons|f||||f||||||||||2017-10-11 11:53:48.547606|2017-10-11 11:53:48.547606
NCT01266018|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-22|2017-05-10|2016-11-30||January 2011||2011-01-01|May 2017|2017-05-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional||All enrolled subjects|Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer|Phase II Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer|Terminated||Phase 2|22|Actual|Ludwig Institute for Cancer Research|The study was terminated early due to lack of efficacy and slow enrollment; therefore, only 22 of the planned 45 subjects were enrolled, treated, and evaluated for study endpoints.|2||Lack of efficacy in Cohort 2; slow enrollment in Cohort 1|f||||f||||||||Yes||2017-10-11 11:54:05.717474|2017-10-11 11:54:05.717474
NCT01266291|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-22|2017-06-12|2017-04-19||August 2010||2010-08-01|June 2017|2017-06-01|December 2013|Actual|2013-12-01|February 2013|Actual|2013-02-01||Interventional|STARS||Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients|Sabril for Treatment of Adult Refractory Partial Seizures Symptomatic of Tuberous Sclerosis: An Open Label, Phase IV Prospective Safety and Tolerability Study|Terminated||Phase 4|1|Actual|University of Pennsylvania|The study was terminated due to insufficient enrollment; 98 potentially eligible patients were pre-screened and only one enrolled. The study was not terminated due to concerns regarding safety or efficacy.|1||"Was not possible to enroll sufficient number of subjects to draw any worthwhile conclusions   from the study."|f||||t||||||||||2017-10-11 11:54:13.113458|2017-10-11 11:54:13.113458
NCT01257867|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-08|2012-11-07|||March 2011||2011-03-01|November 2012|2012-11-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional|||Lithia Water Study: Effects of Lithia Water on BDNF and Oxidative Stress Markers in Healthy Male Participants|Lithia Water Study: Effects of Lithia Water on BDNF and Oxidative Stress Markers in Healthy Male Participants|Terminated||N/A|5|Actual|University of British Columbia||2||This study was terminated by the Principal Investigator|f||||f||||||||||2017-10-11 11:54:33.800944|2017-10-11 11:54:33.800944
NCT01266824|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-21|2013-02-15|2012-12-10||December 2010||2010-12-01|February 2013|2013-02-01|August 2011|Actual|2011-08-01|August 2011|Actual|2011-08-01||Interventional|||Proparacaine and Mydriatic Eye Drops|Randomized Control Trial of the Effects of Proparacaine on the Pain Response to Mydriatic Eye Drops|Terminated||N/A|5|Actual|Children's Hospital of Philadelphia|Enrollment for the randomized controlled study above was poor and the study was terminated without patient analysis. An observational study of the pain response to mydriatic eye drops without use of Proparacaine was completed in place of this trial.|2||Recruitment for the study has been terminated due to poor enrollment|f||||t||||||||||2017-10-11 11:54:56.620839|2017-10-11 11:54:56.620839
NCT01267266|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-24|2015-03-18|2015-01-30||December 2010||2010-12-01|January 2013|2013-01-01|November 2013|Actual|2013-11-01|September 2012|Actual|2012-09-01||Interventional||Patients entering lead-in phase.|Saracatinib in Treating Patients With Prostate Cancer|A Randomized Discontinuation Phase 2 Study of AZD0530 as a Metastasis Inhibitor in Castrate Resistant Prostate Cancer|Terminated||Phase 2|31|Actual|National Cancer Institute (NCI)||2||Per protocol, study was terminated due to low rate of randomized patients.|f||||||||||||||2017-10-11 11:55:05.298341|2017-10-11 11:55:05.298341
NCT01267747|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-27|2014-03-26|||March 2011||2011-03-01|March 2014|2014-03-01|July 2016|Anticipated|2016-07-01|March 2016|Anticipated|2016-03-01||Observational|PAPPHY||Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation|Prospective Assessment of The Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation|Unknown status|Recruiting|N/A|1000|Anticipated|University Hospital Padova|||1||f||||t||||||Samples With DNA|"     Venous blood will be withdrawn to measure        -  levels of ions (sodium, potassium, magnesium), creatinine, proBNP, and TSH in the serum,          and        -  percent HbA1c levels, plasma aldosterone concentration (PAC), renin concentrations (DRA)          and renin activity (PRA) in the plasma.      A venous blood specimen will be used to separate buffy coat for downstream identification of     SNP associated with primary aldosteronism and development of atrial flutter or fibrillation.      Urine specimens will be collected to measure microalbuminuria.   "|||2017-10-11 11:55:11.125523|2017-10-11 11:55:11.125523
NCT01268670|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-29|2013-07-30|||July 2012||2012-07-01|July 2013|2013-07-01||||July 2013|Anticipated|2013-07-01||Interventional|||The Addition of Oral Analgesics to LET During Laceration Repair|Adjunctive Oral Analgesia for Laceration Repair: Assessing Pain in a Pediatric Emergency Department|Suspended||N/A|150|Anticipated|Children's Hospitals and Clinics of Minnesota||3||This study is currently suspended due to transition of the investigator.|f||||||||||||||2017-10-11 11:55:27.342279|2017-10-11 11:55:27.342279
NCT01262690|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-23|2011-10-11|||November 2010||2010-11-01|October 2011|2011-10-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional|||A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin|A Phase 1 Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05230901 Administered Subcutaneously To Healthy Subjects|Terminated||Phase 1|44|Actual|Pfizer||1||"The study was terminated on 21-Sept-2011 due to the emergent safety concern of sensory   symptoms."|f||||f||||||||||2017-10-11 11:55:52.403167|2017-10-11 11:55:52.403167
NCT01263028|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-16|2015-03-10|2012-08-21||August 2010||2010-08-01|March 2015|2015-03-01|September 2011|Actual|2011-09-01|September 2011|Actual|2011-09-01||Interventional|EASY||Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose|Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose|Terminated||N/A|6|Actual|Kaiser Permanente|Study terminated due to insufficient enrollment numbers.|1||"Strong enrollment efforts resulted in few eligible subjects and high screen failures due to CKD   patients with higher vitamin D levels than anticipated."|f||||f||||||||||2017-10-11 11:56:04.955739|2017-10-11 11:56:04.955739
NCT01263418|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-16|2015-10-08|||June 2011||2011-06-01|October 2015|2015-10-01|January 2018|Anticipated|2018-01-01|January 2016|Anticipated|2016-01-01||Interventional|||Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas|A Phase II Trial Of Ofatumumab In Older (≥70 Years) Patients With Previously Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas|Withdrawn||Phase 2|0|Actual|UNC Lineberger Comprehensive Cancer Center||1||No patients enrolled and funding has been withdrawn.|f||||t||||||||||2017-10-11 11:56:08.990373|2017-10-11 11:56:08.990373
NCT01274585|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-07|2014-08-11|2013-12-30||January 2011||2011-01-01|August 2014|2014-08-01|October 2013|Actual|2013-10-01|October 2013|Actual|2013-10-01||Interventional|||Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence|Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence|Terminated||N/A|5|Actual|Massachusetts General Hospital||2||Study was terminated due to low recruitment rates|f||||t||||||||||2017-10-11 11:56:44.667599|2017-10-11 11:56:44.667599
NCT01276054|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-11|2014-07-01|2014-07-01||December 2010||2010-12-01|February 2014|2014-02-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|||Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.|Reducing the Incidence and Severity of Arm Lymphedema With Axillary Reverse Mapping and Implementation of a Lymphedema Screening and Intervention Program|Terminated||Phase 2|4|Actual|University of Southern California|Study terminated early due to P.I. moving to another institution.|2||P.I. left|f||||t||||||||||2017-10-11 11:57:06.911951|2017-10-11 11:57:06.911951
NCT01278680|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-18|2015-08-17|||February 2011||2011-02-01|August 2015|2015-08-01|April 2013|Anticipated|2013-04-01|April 2013|Anticipated|2013-04-01||Interventional|||Incentives for Moving||Withdrawn||N/A|0|Actual|Harvard University||3||"Enrollment has not begun; study suspended indefinitely due to change in management at company   where we were going to conduct the study."|f||||t||||||||||2017-10-11 11:57:51.772262|2017-10-11 11:57:51.772262
NCT01278745|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-16|2017-02-28|2016-12-01||September 2011||2011-09-01|February 2017|2017-02-01|October 2015|Actual|2015-10-01|October 2015|Actual|2015-10-01||Interventional||Randomized participants|Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation|Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation (CTOT-11)|Terminated||Phase 2|362|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study was terminated with 163 participants randomized, well short of the study's goal of 300 randomized participants.|2||Due to inability to meet accrual goals within the funding period|f||||t||||||||||2017-10-11 11:57:52.325453|2017-10-11 11:57:52.325453
NCT01279733|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-19|2012-08-21|||October 2008||2008-10-01|August 2012|2012-08-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Observational|Microarray||Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis|Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis|Completed||N/A|4450|Actual|Columbia University|||1||f||||f||||||Samples With DNA|"     -  Additional 15 ml of amniotic fluid (minimum 10 ml) for amniocentesis        -  Blood sample (10 ml) from each parent will be obtained in case of a need to test for          suspected familial copy number variants (CNVs) or discrepant results, and also to          evaluate for maternal cell contamination (patient's blood sample).        -  10 ml of amniotic fluid with suspended cells, (minimum 7 ml)        -  5 mg of villi (minimum of 2mg)   "|||2017-10-11 11:58:06.260388|2017-10-11 11:58:06.260388
NCT01271907|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-06|2017-07-03|2012-11-07||April 15, 2011|Actual|2011-04-15|July 2017|2017-07-01|December 8, 2011|Actual|2011-12-08|December 8, 2011|Actual|2011-12-08||Interventional|||Drosophila-generated CTL|Phase II Study of Metastatic Melanoma Using a Nonmyeloablative Lymphodepleting Regimen Followed by Melanoma-Reactive T-Cells Sensitized in Vitro With Peptide-Pulsed Drosophila Cells|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||3||Study was terminated due to withdrawal of CRADA partner.|f||||f|t|f||||||||2017-10-11 11:58:34.726048|2017-10-11 11:58:34.726048
NCT01273064|ClinicalTrials.gov processed this data on October 10, 2017|2010-12-21|2012-06-04|2012-03-29||January 2011||2011-01-01|June 2012|2012-06-01|October 2011|Actual|2011-10-01|September 2011|Actual|2011-09-01||Interventional|||Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders|A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders|Terminated||Phase 2|114|Actual|Conatus Pharmaceuticals Inc.|This study was terminated early after 3 reports of hyperbilirubinemia occurred(2 on 60mg bid and 1 on 30mg bid of CTS 1027). Two incidents were reported as part of an SAE. The risk/benefit ratio did not warrant further continuation of the study.|4||Risk-benefit ratio|f||||t||||||||||2017-10-11 11:59:08.575848|2017-10-11 11:59:08.575848
NCT01283100|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-06|2014-12-22|||March 2011||2011-03-01|December 2014|2014-12-01|June 2011|Anticipated|2011-06-01|March 2011|Actual|2011-03-01||Interventional|||A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.|A Phase 1, Open Label, Single Sequence, Two-Way Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1379572 Pharmacokinetics in Healthy Adult Subjects|Withdrawn||Phase 1|0|Actual|ViiV Healthcare||3||"In a Phase II study in HIV-infected patients there were a number of seizures, although exact   causality could not be assessed phase 1 activity was terminated."|f||||f||||||||||2017-10-11 12:00:03.496246|2017-10-11 12:00:03.496246
NCT01283178|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-24|2016-10-27|||July 2011||2011-07-01|October 2016|2016-10-01|September 2016|Actual|2016-09-01|March 2016|Actual|2016-03-01||Interventional|||Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC|A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC)|Terminated||Phase 1|3|Actual|Virginia Commonwealth University||1||"The study was terminated. The data analysis was futile with only 3 accruals. PI opted to   terminate with IRB and withdraw FDA IND."|f||||t||||||||No|The data analysis was futile with only 3 accruals. PI opted to terminate with the IRB and withdraw the FDA IND.|2017-10-11 12:00:06.936846|2017-10-11 12:00:06.936846
NCT01271049|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-03|2012-12-11|||January 2011||2011-01-01|December 2012|2012-12-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Interventional|||An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths|A Double-blind, Randomized, Controlled Evaluation of the Tolerability of a Proprietary Oil Blend in Adults Residing in Areas Endemic for Helminth Infections.|Terminated||N/A|45|Actual|Mondelēz International, Inc.||2||Due to a business decision to stop the project, the study was terminated early.|f||||f||||||||||2017-10-11 12:00:22.318484|2017-10-11 12:00:22.318484
NCT01277120|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-13|2016-09-14|||April 2010||2010-04-01|September 2016|2016-09-01|April 2016|Actual|2016-04-01|April 2016|Actual|2016-04-01||Observational|||An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)|The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With cOlorectal Cancer Treated With AvaStin Based First Line Regimens (CRONOS 1)|Terminated||N/A|174|Actual|Hoffmann-La Roche|||1|Contract terminated with Site Management Organization|f||||||||||||||2017-10-11 12:00:30.260888|2017-10-11 12:00:30.260888
NCT01277328|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-13|2016-09-14|||May 2010||2010-05-01|September 2016|2016-09-01|August 2014|Actual|2014-08-01|August 2014|Actual|2014-08-01||Observational|||An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|Tocilizumab (RoActemra) poST Marketing Observational Study in DMARD-IR Patients to Assess Efficacy and Safety in routiNE Clinical Practice - STONE|Terminated||N/A|95|Actual|Hoffmann-La Roche|||1|Contract terminated with Site Management Organization|f||||||||||||||2017-10-11 12:00:34.105308|2017-10-11 12:00:34.105308
NCT01277510|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-13|2015-06-12|2015-04-29||June 2011||2011-06-01|May 2015|2015-05-01|April 2014|Actual|2014-04-01|April 2014|Actual|2014-04-01||Interventional|||Pediatric Chronic Kidney Disease Safety and Efficacy|A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis|Terminated||Phase 3|43|Actual|Amgen|The study was terminated early with a smaller sample size. However, the study was still sufficiently powered for the double-blind phase. The data collected in the open-label phase is very sparse.|2||"Study was suspended in agreement between sponsor and FDA due to concerns about the study design   after a fatality had occurred in the presence of hypocalcemia."|f||||t||||||||||2017-10-11 12:00:35.698337|2017-10-11 12:00:35.698337
NCT01286870|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-27|2015-10-26|||June 2009||2009-06-01|October 2015|2015-10-01|November 2020|Anticipated|2020-11-01|November 2020|Anticipated|2020-11-01||Interventional|||Becker Continued Access Study|Continued Access Study of the Mentor Becker Expander/Breast Implant|Terminated||Phase 3|11|Actual|Mentor Worldwide, LLC||1||Sponsor terminated|f||||f||||||||||2017-10-11 12:00:58.4519|2017-10-11 12:00:58.4519
NCT01287221|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-28|2014-02-11|2013-07-02||March 2011||2011-03-01|February 2014|2014-02-01|January 2013|Actual|2013-01-01|November 2012|Actual|2012-11-01||Interventional|MSA||Study of Rifampicin in Multiple System Atrophy|Double-Blind, Placebo-Controlled Study of Rifampicin in Multiple System Atrophy|Terminated||Phase 3|100|Actual|Mayo Clinic|The study was terminated early; the Data Safety and Monitoring Board recommended stopping the study after an interim analysis of the primary endpoint revealed that futility criteria were met.|2||"DSMB recommended stopping the study after an interim analysis of the primary endpoint revealed   that futility criteria were met."|f||||t||||||||||2017-10-11 12:01:05.022891|2017-10-11 12:01:05.022891
NCT01288079|ClinicalTrials.gov processed this data on October 10, 2017|2011-01-26|2012-11-14|2012-08-07||February 2011||2011-02-01|November 2012|2012-11-01|August 2012|Actual|2012-08-01|August 2012|Actual|2012-08-01||Interventional|||A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy|Terminated||Phase 2|145|Actual|AstraZeneca|The study was terminated early and thus only a fraction of the planned number of patients were randomized and many did not complete the study. As a consequence the possibility of interpreting efficacy over an 8 week period is considerably reduced.|4|||f||||f||||||||||2017-10-11 12:01:22.456264|2017-10-11 12:01:22.456264
NCT01292603|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-08|2017-07-11|2015-09-23||April 18, 2011|Actual|2011-04-18|July 2017|2017-07-01|November 14, 2017|Anticipated|2017-11-14|May 7, 2014|Actual|2014-05-07||Interventional||Safety Analysis Population (SAP): all participants who received at least one dose of study medication whether prematurely withdrawn or not. In Part 2 two participants randomized to the rituximab SC 1600 mg arm were included in Rituximab IV 500 mg/m^2 arm as they received only the first cycle of rituximab IV 375 mg/m^2.|A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia|An Adaptive, Comparative, Randomized, Parallel-group, Multi Center, Phase Ib Study of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With Chemotherapy (Fludarabine and Cyclophosphamide), in Patients With Previously Untreated CLL|Active, not recruiting||Phase 1|240|Actual|Hoffmann-La Roche||3|||f||||||||||||||2017-10-11 12:02:31.145668|2017-10-11 12:02:31.145668
NCT01285310|ClinicalTrials.gov processed this data on October 10, 2017|2010-11-19|2014-08-13|2014-04-22|2013-05-28|December 2010||2010-12-01|August 2014|2014-08-01|September 2012|Actual|2012-09-01|February 2012|Actual|2012-02-01||Interventional||Full Analysis Set (FAS) The FAS consisted of all participants who were randomized as specified per protocol during the placebo controlled period.|Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|Terminated||Phase 2|237|Actual|Celgene|The study was terminated before the 2–year time point was reached due to lack of clinical efficacy.|3||Study is terminated due to lack of efficacy|f||||t||||||||||2017-10-11 12:02:56.623356|2017-10-11 12:02:56.623356
NCT01295060|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-10|2013-09-17||2013-09-09|February 2011||2011-02-01|September 2013|2013-09-01|June 2012|Actual|2012-06-01|April 2012|Actual|2012-04-01||Interventional|||Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly|PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY|Terminated||Phase 3|12|Actual|Endo Pharmaceuticals||1||Program was terminated for business reasons|f||||f||||||||||2017-10-11 12:04:04.716502|2017-10-11 12:04:04.716502
NCT01296035|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-09|2015-07-28|2014-08-19||February 2011||2011-02-01|July 2015|2015-07-01|November 2013|Actual|2013-11-01|October 2013|Actual|2013-10-01||Interventional|PanGem||Panitumumab and Gemcitabine in Relapsed Ovarian Cancer|A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.|Terminated||Phase 2|8|Actual|Women and Infants Hospital of Rhode Island|This study was terminated prematurely due to poor accrual. The outcome measures could not be analyzed due to the small number or participants.|1||Newer technologies available; poor accrual to study.|f||||t||||||||||2017-10-11 12:04:15.402247|2017-10-11 12:04:15.402247
NCT01293227|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-04|2012-01-23|||February 2011||2011-02-01|January 2012|2012-01-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||WRx Distal Radius Wrist Fracture Study|The Effect of Intramedullary Locked Nail Versus Volar Locked Plating in the Treatment of Extra-articular and Minimally Displaced Intra-articular Distal Radius Fractures: A Prospective Randomized Trial.|Terminated||N/A|6|Actual|Mayo Clinic||1||Funding was withdrawn due to inadequete enrollment.|f||||f||||||||||2017-10-11 12:05:28.675225|2017-10-11 12:05:28.675225
NCT01302938|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-22|2013-07-22|2013-07-22||March 2011||2011-03-01|July 2013|2013-07-01|August 2012|Actual|2012-08-01|August 2012|Actual|2012-08-01||Interventional|REMOTE||Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder|Exploratory, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Center, Web-Based Phase IV Pilot Methodology Trial To Evaluate The Efficacy And Safety Of Tolterodine ER In Subjects With Overactive Bladder|Terminated||Phase 4|18|Actual|Pfizer|The study was terminated prematurely due to low participant enrollment and due to relatively small sample size; results should be interpreted with caution. Early termination of the study was not related to any safety concern.|2||"Stop date for randomization: 31/5/2012. Recruitment terminated due to lack of recruitment. No   new safety issues were identified."|f||||f||||||||||2017-10-11 12:05:46.276006|2017-10-11 12:05:46.276006
NCT01304628|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-22|2014-12-15||||||December 2014|2014-12-01||||||||Interventional|||Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma|A Phase 2a, Double-Blinded, Multi-Center, Escalating Dose Group, Placebo Controlled, Cross-Over Study to Evaluate the Safety, Efficacy and Tolerability of Subcutaneously Administered PL-3994 for the Treatment of Patients With Mild to Moderate Asthma|Withdrawn||Phase 2|0|Actual|Palatin Technologies||2||Sponsor terminated study prior to initiation.|f||||f||||||||||2017-10-11 12:06:12.29178|2017-10-11 12:06:12.29178
NCT01296698|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-14|2012-03-29|2012-03-29||March 2011||2011-03-01|March 2012|2012-03-01|June 2011|Actual|2011-06-01|April 2011|Actual|2011-04-01||Interventional|||Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week Trial to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers in a Naturalistic Environment|Terminated||Phase 3|257|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|Summary tabulations are not available for the primary and some secondary outcome measures because the study was terminated early due to a technical issue (randomization error).|2||Study terminated due to a technical issue (randomization error).|f||||f||||||||||2017-10-11 12:06:20.501034|2017-10-11 12:06:20.501034
NCT01297712|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-14|2015-06-01|||September 2009||2009-09-01|June 2015|2015-06-01|April 2011|Actual|2011-04-01|November 2010|Actual|2010-11-01||Interventional|||Endoscopic Assessment of Polyp Histology|On-Site Endoscopic Prediction of Polyp Histology During Screening Colonoscopy|Terminated||N/A|1069|Actual|Universitätsklinikum Hamburg-Eppendorf||2||enrollment terminated, analysis ongoing|f||||f||||||||||2017-10-11 12:06:34.545264|2017-10-11 12:06:34.545264
NCT01298323|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-16|2017-06-07|2014-04-25|2011-03-28|February 2011|Actual|2011-02-01|June 2017|2017-06-01|March 14, 2018|Anticipated|2018-03-14|April 2013|Actual|2013-04-01||Interventional|88|Of 103 patients randomized to vandetanib 300 mg+outreach arm, all except 1 patient took part in outreach program . This patient was withdrawn due to eligibility criteria failure and could not be contacted successfully. Hence the results have been summarized under vandetanib 300 mg for safety summaries.|Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment|A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib|Active, not recruiting||Phase 3|205|Actual|Sanofi||2|||f||||||||||||||2017-10-11 12:06:41.688952|2017-10-11 12:06:41.688952
NCT01307228|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-28|2017-03-21|||December 2010|Actual|2010-12-01|March 2017|2017-03-01|February 2013|Actual|2013-02-01|April 2011|Actual|2011-04-01||Interventional|||Effects of an Evidence Service on Health System Policymakers' Use of Research Evidence|Effects of an Evidence Service on Health System Policymakers' Use of Research Evidence|Withdrawn||N/A|0|Actual|McMaster University||2||Insufficient participants recruited for the trial|f||||f||||||||No|Not applicable - trial was terminated due to insufficient enrollment and no data was collected.|2017-10-11 12:07:33.586283|2017-10-11 12:07:33.586283
NCT01308463|ClinicalTrials.gov processed this data on October 10, 2017|2010-07-23|2017-03-20|2016-10-13||January 2011||2011-01-01|March 2017|2017-03-01|September 2016|Actual|2016-09-01|September 2016|Actual|2016-09-01||Observational|||Discovery Elbow Long-Term Survivorship|Discovery Elbow Long-Term Survivorship Study|Terminated||N/A|29|Actual|Zimmer Biomet|The early termination of this study lead to only a small number of consenting subjects available for analysis.||1|Study terminated due to change in sponsorship|f||||f||||||||||2017-10-11 12:07:51.042242|2017-10-11 12:07:51.042242
NCT01308827|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-25|2014-03-24|||March 2011||2011-03-01|March 2014|2014-03-01|March 2014|Anticipated|2014-03-01|March 2014|Anticipated|2014-03-01||Observational|||Costa Rica Epidemiological Study on S. Pneumoniae|Continuation of the Costa Rican Epidemiologic Surveillance for Invasive Pneumococcal Disease After Introduction of the Seven Valent Vaccine Into the Universal Vaccination Program|Suspended||N/A|4000|Anticipated|Instituto de Atención Pediátrica|||1|Study recruitment was suspended due to lack of funding|f||||f|||||||"     Bacterial isolates   "|||2017-10-11 12:08:11.057104|2017-10-11 12:08:11.057104
NCT01310114|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-25|2016-03-30||2013-08-12|March 2011||2011-03-01|March 2016|2016-03-01|March 2013|Actual|2013-03-01|March 2013|Actual|2013-03-01||Interventional|||Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke|A Phase 2A, Prospective, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults Following Ischemic Stroke|Terminated||Phase 2|44|Actual|Celgene Corporation||3||Study terminated by sponsor|f||||t||||||||||2017-10-11 12:08:33.625912|2017-10-11 12:08:33.625912
NCT01310803|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-04|2017-09-07|2014-10-16||May 2011||2011-05-01|September 2017|2017-09-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder|A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER|Terminated||Phase 3|1|Actual|Endo Pharmaceuticals|This study was terminated early. Only one subject was enrolled. No study results were generated.|2|||f||||||||||||||2017-10-11 12:08:43.713693|2017-10-11 12:08:43.713693
NCT01311414|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-07|2014-05-21||||||May 2014|2014-05-01||||||||Interventional|NIRSMED||Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation|Effect of Cafedrine/Theodrenaline and Urapidil During Carotid Endarterectomy on Cerebral Oxygenation Measured by Near Infrared Spectroscopy|Withdrawn||N/A|0|Actual|University of Schleswig-Holstein||1||The study was suspended due to organizational problems|f||||f||||||||||2017-10-11 12:08:49.815168|2017-10-11 12:08:49.815168
NCT01311518|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-07|2015-03-19|||March 2016||2016-03-01|November 2012|2012-11-01|August 2019|Anticipated|2019-08-01|March 2019|Anticipated|2019-03-01||Interventional|||A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction|A Randomized, Double-blind, Placebo-Controlled, Study of the Safety and Efficacy of RGN-352 in Subjects With an Acute ST Elevation Myocardial Infarction (STEMI) After Occlusion of the Proximal Left Anterior Descending Coronary Artery|Suspended||Phase 2|75|Anticipated|RegeneRx Biopharmaceuticals, Inc.||2||Trial suspended due to drug product manufacturer not GMP compliant|f||||f||||||||||2017-10-11 12:08:50.804579|2017-10-11 12:08:50.804579
NCT01305772|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-14|2014-08-19|2013-09-10||January 2011||2011-01-01|August 2014|2014-08-01|May 2012|Actual|2012-05-01|March 2012|Actual|2012-03-01||Interventional|TOP0901||Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN|Identification of a Gene Expression Signature Profile for Panitumumab Sensitivity in Untreated Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)|Terminated||Phase 2|6|Actual|Duke University|Early termination leading to small numbers of subjects analyzed.|2||This study was terminated for low accrual.|f||||t||||||||||2017-10-11 12:09:04.804049|2017-10-11 12:09:04.804049
NCT01313923|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-10|2017-05-08|2014-12-17||February 2011||2011-02-01|May 2017|2017-05-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional|||Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus|Evaluation of Sirolimus for the Treatment of the Autoimmune Blistering Dermatosis Pemphigus|Terminated||Early Phase 1|3|Actual|University of California, Irvine|No results as study has been terminated early by the investigator.|1||Lack of funding|f||||f||||||||||2017-10-11 12:09:44.602565|2017-10-11 12:09:44.602565
NCT01314417|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-11|2013-10-17|2013-07-18||February 2011||2011-02-01|October 2013|2013-10-01|January 2013|Actual|2013-01-01|January 2013|Actual|2013-01-01||Interventional|MEXX||Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate|Treatment of Non-infectious Panuveitis, Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate|Terminated||Phase 1/Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)||1||This study was terminated due to lack of recruitment.|f||||f||||||||||2017-10-11 12:09:54.014451|2017-10-11 12:09:54.014451
NCT01309126|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-08|2017-07-11|||April 2011||2011-04-01|July 2017|2017-07-01|February 2017|Actual|2017-02-01|February 2017|Actual|2017-02-01||Interventional|PRIMUS||Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer|A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer|Terminated||Phase 3|217|Actual|Biothera||2||"Due to enrollment challenges resulting from changing treatment patterns in the use of   cetuximab, the study has been terminated. No patients remain on study."|f||||t||||||||||2017-10-11 12:10:17.442591|2017-10-11 12:10:17.442591
NCT01309282|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-03|2016-08-10|2016-02-12||July 2010||2010-07-01|August 2016|2016-08-01|August 2013|Actual|2013-08-01|August 2013|Actual|2013-08-01||Observational||Safety population included all participants who received at least one dose of study drug, whether prematurely withdrawn from the study or not and who complied with the criteria for inclusion.|An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)|Portuguese Observational Re-Treatment Study of MabThera (PORTSMAB) - A Two-centre Observational Study in Sero-positive Rheumatoid Arthritis (RA) Patients Who Are Non-responders or Intolerant to a Single Tumor Necrosis Factor (TNF) Inhibitor|Completed||N/A|9|Actual|Hoffmann-La Roche|||1||f||||||||||||||2017-10-11 12:10:22.738121|2017-10-11 12:10:22.738121
NCT01316133|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-14|2016-09-06|||February 2011||2011-02-01|September 2016|2016-09-01|April 2016|Actual|2016-04-01|April 2016|Actual|2016-04-01||Interventional|APPLE||A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients|A Multicenter, Non-comparative, Open-labeled, Prospective Study to Evaluate the Efficacy and Safety of Tacrolimus (Prograf®) With Steroid in Korean Lupus Nephritis Patients Who Are Non-responders to Steroid Monotherapy|Terminated||Phase 4|37|Actual|Astellas Pharma Inc||1||Study terminated due to poor patient recruitment.|f||||f||||||||||2017-10-11 12:10:27.388713|2017-10-11 12:10:27.388713
NCT01316263|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-14|2017-01-27|2016-11-18|2013-02-25|August 2011||2011-08-01|January 2017|2017-01-01|November 2012|Actual|2012-11-01|May 2012|Actual|2012-05-01||Interventional||All participants who received any study drug.|A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors|A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)|Terminated||Phase 2|21|Actual|Eli Lilly and Company|The development of olaratumab (IMC-3G3) was put on hold in this indication due to reasons not related to efficacy and/or safety, Stage 2 of this study was not completed and trial terminated due to poor accrual.|2||Trial terminated strategically due to poor accrual.|f||||f||||||||||2017-10-11 12:10:28.990947|2017-10-11 12:10:28.990947
NCT01318993|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-03|2017-08-16|2017-07-05|2014-03-13|April 1, 2011||2011-04-01|July 2017|2017-07-01|October 29, 2013|Actual|2013-10-29|September 1, 2013|Actual|2013-09-01||Interventional|SHIELD-3|The safety population included all the participants who received at least one dose of the study drug.|Open-Label Extension Study of GSK1605786A|An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease|Terminated||Phase 3|399|Actual|GlaxoSmithKline||1||"This study was terminated due to the lack of efficacy of GSK1605786A in Crohn's disease based   on the results of Study CCX114151."|f||||t||||||||||2017-10-11 12:10:45.969868|2017-10-11 12:10:45.969868
NCT01319188|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-18|2015-05-17|||June 2010||2010-06-01|May 2015|2015-05-01|April 2015|Actual|2015-04-01|October 2012|Actual|2012-10-01||Interventional|RATE||Ranibizumab and the Risk of Arterial Thromboembolic Events|Ranibizumab for Age-Related Macular Degeneration and the Risk of Arterial Thromboembolic Events (RATE)|Terminated||Phase 4|380|Actual|Ural Medical University||3||"The study was terminated under the political pressure of the Federal Security Service of the   Russian Federation (FSB) and the Russian Society of Cardiology"|f||||t||||||||||2017-10-11 12:10:49.507538|2017-10-11 12:10:49.507538
NCT01319539|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-18|2017-08-01|2016-10-14||April 2011||2011-04-01|August 2017|2017-08-01|July 2013|Actual|2013-07-01|July 2013|Actual|2013-07-01||Interventional|||MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer|Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer|Terminated||Phase 2|12|Actual|National Cancer Institute (NCI)||1||terminated early, due to toxicity|f||||||||||||||2017-10-11 12:10:53.799504|2017-10-11 12:10:53.799504
NCT01312493|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-08|2015-08-26|||December 2011||2011-12-01|August 2015|2015-08-01|December 2018|Anticipated|2018-12-01|December 2017|Anticipated|2017-12-01||Interventional|||Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab|Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab|Withdrawn||Phase 2|0|Actual|UNC Lineberger Comprehensive Cancer Center||1||Funding source was terminated before enrollment of first subject|f||||t||||||||||2017-10-11 12:11:16.676401|2017-10-11 12:11:16.676401
NCT01313273|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-10|2015-08-28|2015-04-28||June 2011||2011-06-01|August 2015|2015-08-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|POSEIDON||Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients|Randomised, Phase III Multicenter, Open Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients Presenting Elevated Chromogranin A Levels|Terminated||Phase 3|3|Actual|Ipsen|Study terminated due to poor enrollment|2||Poor enrolment|f||||f||||||||||2017-10-11 12:11:30.320052|2017-10-11 12:11:30.320052
NCT01324622|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-23|2017-04-14|2015-04-10||January 2006||2006-01-01|April 2017|2017-04-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||Comparison of Cervical Laminectomy to Laminoplasty|Comparison of Cervical Laminectomy to Cervical Laminoplasty* in Patients With Cervical Myelopathy or Myeloradiculopathy Due to Multiple Level Cervical Spinal Canal Stenosis * ARCH™ Fixation System by SYNTHES|Terminated||N/A|24|Actual|Synthes USA HQ, Inc.|Slow enrollment and a low follow-up rate resulted in the early termination of the study and lead to a small numbers of subjects completing the study and limiting the data analysis.|2||terminated due to failure to meet enrolment goals|f||||f||||||||||2017-10-11 12:12:18.29343|2017-10-11 12:12:18.29343
NCT01316939|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-03|2017-08-07|2017-06-28|2014-03-13|May 9, 2011|Actual|2011-05-09|August 2017|2017-08-01|October 23, 2013|Actual|2013-10-23|October 23, 2013|Actual|2013-10-23||Interventional|SHIELD-2||GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease|A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease|Terminated||Phase 3|229|Actual|GlaxoSmithKline|The limited data resulting from early termination of Study CCX114157 did not allow any conclusions to be drawn about the efficacy of GSK1605786A in the maintenance of clinical remission in participants with Crohn’s disease.|3||"This study was terminated due to the lack of efficacy of GSK1605786A in Crohn's disease based   on the results of Study CCX114151."|f||||t||||||||||2017-10-11 12:12:32.698917|2017-10-11 12:12:32.698917
NCT01326065|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-27|2017-05-04|||February 2011|Actual|2011-02-01|May 2017|2017-05-01|February 2017|Actual|2017-02-01|March 2012|Actual|2012-03-01||Observational|||Implementation of Laparoscopy-assisted Surgery for Colon Cancer|Implementation of Laparoscopy-assisted Surgery for Colon Cancer. A Prospective Population-based Study|Terminated||N/A|60|Actual|Helse Stavanger HF|||1|Study had to be terminated due to lack of funding|f||||f||||||||No||2017-10-11 12:13:10.386228|2017-10-11 12:13:10.386228
NCT01326845|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-30|2017-03-01|2013-09-11||December 2011||2011-12-01|March 2017|2017-03-01|September 2012|Actual|2012-09-01|September 2012|Actual|2012-09-01||Interventional|MACS1574||Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study|A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.|Terminated||Phase 4|12|Actual|Novartis||2||The trial was terminated due to insufficient enrollment.|f||||||||||||||2017-10-11 12:13:15.990847|2017-10-11 12:13:15.990847
NCT01329549|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-01|2014-11-26|2014-11-14||April 2011||2011-04-01|November 2014|2014-11-01|October 2012|Actual|2012-10-01|October 2012|Actual|2012-10-01||Interventional||Treated set: includes all patients who were dispensed study medication and were documented to have received at least 1 dose of study medication.|Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)|An Open-label, Dose Escalation Phase I Study of the Safety and Tolerability of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Japanese Patients With a First, Second or Third Platinum-sensitive Relapse of Advanced Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer.|Terminated||Phase 1|2|Actual|Boehringer Ingelheim|The trial was prematurely terminated because of worldwide disruption of pegylated liposomal doxorubicin (PLD) supplies.|3|||f||||||||||||||2017-10-11 12:14:26.018958|2017-10-11 12:14:26.018958
NCT01331109|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-31|2013-07-31|2013-07-31||April 2011||2011-04-01|July 2013|2013-07-01|August 2012|Actual|2012-08-01|August 2012|Actual|2012-08-01||Interventional|MyFi|All demographic data was based on the safety population, which consists of 57 patients who took at least 1 dose of open-label milnacipran.|Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia|A Multicenter, Open-label, 52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia|Terminated||Phase 2|57|Actual|Forest Laboratories|This study was terminated early, resulting in a small number of patients analyzed. Only descriptive statistics were presented.|1|||f||||t||||||||||2017-10-11 12:14:49.383445|2017-10-11 12:14:49.383445
NCT01325701|ClinicalTrials.gov processed this data on October 10, 2017|2011-02-02|2017-03-02|2016-06-30||May 2011||2011-05-01|March 2017|2017-03-01|October 2014|Actual|2014-10-01|October 2014|Actual|2014-10-01||Interventional||A total of 78 subjects were enrolled: 70 in PCI-32765: 560 mg , and 8 in PCI-32765: 840 mg . All subjects received at least 1 dose of study drug.|Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)|Completed||Phase 2|78|Actual|Pharmacyclics LLC.|PCI-32765:840 mg:8 subjects were enrolled and followed through their 1st response assessment. Due to a lack of positive responses observed, enrollment was terminated for futility. Response rate should not be generalized due to small sample size.|2|||f||||f||||||||No||2017-10-11 12:15:04.185994|2017-10-11 12:15:04.185994
NCT01331824|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-06|2015-11-21|2015-10-15||February 2011||2011-02-01|November 2015|2015-11-01|July 2015|Actual|2015-07-01|July 2014|Actual|2014-07-01||Interventional|||Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma|Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma|Terminated||Phase 2|22|Actual|Icahn School of Medicine at Mount Sinai|The trial was terminated prematurely due to the results of a phase 3 study seeking registration for amrubicin in small cell lung cancer in the United States, leading the industry funder to discontinue further clinical development of amrubicin.|1||due to a development decision by the funder|f||||t||||||||||2017-10-11 12:15:06.301285|2017-10-11 12:15:06.301285
NCT01334047|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-30|2014-08-22|||April 2011||2011-04-01|August 2014|2014-08-01|April 2022|Anticipated|2022-04-01|August 2013|Actual|2013-08-01||Interventional|||Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients|Phase I/II Trial of Vaccine Therapy in Recurrent Platinum Sensitive Epithelial Ovarian Cancer Patients Using Autologous Dendritic Cells Loaded With Amplified Ovarian Cancer Stem Cell mRNA, hTERT and Survivin.|Terminated||Phase 1/Phase 2|5|Actual|Oslo University Hospital||1||"The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol   with an expected more efficient vaccine is currently being written."|f||||f||||||||||2017-10-11 12:15:33.575377|2017-10-11 12:15:33.575377
NCT01334606|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-08|2013-09-11|2013-04-26||March 2011||2011-03-01|September 2013|2013-09-01|June 2011|Actual|2011-06-01|June 2011|Actual|2011-06-01||Interventional|||Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units|Evaluation of Glycemic Control and User Acceptability of the BD Ultra-Fine Nano 4 mm x 32G Pen Needle for Injection of Long-acting or Basal Insulin Doses Above 40 Units|Terminated||N/A|21|Actual|Becton, Dickinson and Company||2||This study was terminated due to unanticipated recruitment difficulties.|f||||f||||||||||2017-10-11 12:15:39.589695|2017-10-11 12:15:39.589695
NCT01328951|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-04|2016-09-06|2016-01-29||September 2011||2011-09-01|June 2016|2016-06-01|January 2016|Actual|2016-01-01|December 2015|Actual|2015-12-01||Interventional||Intent-to-Treat (ITT) Population: All participants who were randomized to treatment.|A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy|A Randomized, Double-Blind, Placebo-Controlled Phase III Study of First-Line Maintenance Tarceva Versus Tarceva at the Time of Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following 4 Cycles of Platinum-Based Chemotherapy|Completed||Phase 3|643|Actual|Hoffmann-La Roche|Following the final analysis, the study was closed and all remaining participants were withdrawn from the study and considered “Not Completed” (as presented in the Participant Flow). However, the overall status of study was confirmed as completed.|2|||f||||||||||||||2017-10-11 12:15:59.015118|2017-10-11 12:15:59.015118
NCT01335997|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-13|2017-03-06|2016-01-13||May 2011||2011-05-01|March 2017|2017-03-01|January 2012|Actual|2012-01-01|January 2012|Actual|2012-01-01||Interventional|||Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)|A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|Terminated||Phase 3|1139|Actual|Merck Sharp & Dohme Corp.|Study was terminated for business reasons.|2||Business Reasons|f||||f||||||||||2017-10-11 12:16:14.772819|2017-10-11 12:16:14.772819
NCT01336673|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-14|2014-06-18|||June 2011||2011-06-01|June 2014|2014-06-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Observational|||Glucophage XR® Observational Study|An Observational Study on the Use of Glucophage XR® Therapy in the Management of Patients With Type 2 Diabetes|Terminated||N/A|518|Actual|Merck KGaA|||1|"The study was scheduled for completion February 2013. Because of difficulties encountered in   completing the trial the study was terminated by sponsor June 2013."|f||||f||||||||||2017-10-11 12:16:25.900306|2017-10-11 12:16:25.900306
NCT01337609|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-15|2013-08-07|2013-05-29||June 2011||2011-06-01|August 2013|2013-08-01|February 2012|Actual|2012-02-01|February 2012|Actual|2012-02-01||Interventional|||Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder|A Double-Blind, Placebo-Controlled Study of the Probiotic Ganeden BC30 (Bacillus Coagulans GBI-30, 6068) in Irritable Bowel Syndrome Comorbid With Major Depressive Disorder (MDD)|Terminated||Phase 4|5|Actual|Massachusetts General Hospital|Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and data were not analyzed.|3||"Because the study sponsor chose to discontinue funding for this protocol following a change in   leadership, the study was terminated early."|f||||f||||||||||2017-10-11 12:16:42.821672|2017-10-11 12:16:42.821672
NCT01338012|ClinicalTrials.gov processed this data on October 10, 2017|2011-03-02|2017-06-01|2017-04-26||December 2011||2011-12-01|June 2017|2017-06-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional|mCRPC|Men who previously participated in Dendreon's P-11 clinical study, received Sipuleucel-T as part of P-11, and who developed metastatic castrate resistant prostate cancer (mCRPC), Safety population includes all subjects who received at least one infusion in the current study (P10-1).|Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer|An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)|Terminated||Phase 2|8|Actual|Dendreon|This study was terminated early due to administrative reasons. Only 8 subjects were enrolled and treated. Given the small number of patients enrolled, analyses do not provide reliable results.|1||Administrative reasons.|f||||f||||||||Undecided||2017-10-11 12:16:47.172473|2017-10-11 12:16:47.172473
NCT01339910|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-20|2017-09-27|||May 2011|Actual|2011-05-01|February 2017|2017-02-01|January 2018|Anticipated|2018-01-01|January 16, 2017|Actual|2017-01-16||Interventional|||Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)|A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)|Terminated||Phase 3|272|Actual|Medical College of Wisconsin||2||Accrual terminated as recommended by the data and safety monitoring board.|f||||t||||||||||2017-10-11 12:17:36.681427|2017-10-11 12:17:36.681427
NCT01342172|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-21|2014-11-26|2014-11-20||March 2011||2011-03-01|November 2014|2014-11-01|June 2013|Actual|2013-06-01|June 2013|Actual|2013-06-01||Interventional|||Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma|Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma|Terminated||Phase 1/Phase 2|9|Actual|Icahn School of Medicine at Mount Sinai|"The trial was terminated because the regimen was deemed poorly tolerated for chronic administration because of the need for repeated dose delays and reductions coupled with slow accrual.
NCT01343823|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-27|2016-06-28|2013-09-04||June 2011||2011-06-01|June 2016|2016-06-01|June 2012|Actual|2012-06-01|June 2012|Actual|2012-06-01||Interventional||2 patients did not complete because the study terminated early and one patient did not complete because they withdrew from the study.|Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema|Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema|Terminated||Phase 2|76|Actual|Shire|The study was determined to be inadequately powered to detect a statistically significant difference between ecallantide and placebo for the primary efficacy endpoint, and therefore terminated early.|4||"Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was   substantially higher than described in medical literature."|f||||t||||||||||2017-10-11 12:18:49.546496|2017-10-11 12:18:49.546496
NCT01344538|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-27|2016-06-30|2014-06-16||April 2007||2007-04-01|June 2016|2016-06-01|December 2012|Actual|2012-12-01|May 2011|Actual|2011-05-01||Interventional||33 people enrolled with 3 withdrawn|Ginger for Colorectal Cancer Prevention|Phase II Study of the Effects of Ginger Root Extract on Eicosanoids in Colon Mucosa in People at Normal Risk for Colorectal Cancer|Completed||Phase 2|30|Actual|University of Michigan||2|||f||||t||||||||||2017-10-11 12:19:01.058137|2017-10-11 12:19:01.058137
NCT01345630|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-27|2015-12-11|2014-08-14||September 2011||2011-09-01|December 2015|2015-12-01|January 2014|Actual|2014-01-01|August 2013|Actual|2013-08-01||Interventional|MODERN||Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1|A Multicenter, Randomized, Double‑Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir For The Treatment Of Antiretroviral‑Naive Hiv‑Infected Patients With Ccr5‑Tropic Hiv‑1|Terminated||Phase 3|813|Actual|ViiV Healthcare|The study was terminated following a preliminary review of the 48- week primary clinical efficacy data by the study’s external independent Data Monitoring Committee’s recommendation based on inferior efficacy of the investigational MVC+DRV/r arm.|2||See termination reason in detailed description.|f||||t||||||||||2017-10-11 12:19:19.659905|2017-10-11 12:19:19.659905
NCT01345214|ClinicalTrials.gov processed this data on October 10, 2017|2011-04-21|2014-03-31|||May 2011||2011-05-01|March 2014|2014-03-01||||February 2014|Actual|2014-02-01||Interventional|||A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia|An Open-label, Multiple-Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia|Terminated||Phase 1|17|Actual|Ono Pharmaceutical Co. Ltd||1||The study was terminated due to slow accrual of subjects.|f||||f||||||||||2017-10-11 12:20:06.876362|2017-10-11 12:20:06.876362
NCT00720096|ClinicalTrials.gov processed this data on October 11, 2017|2008-07-21|2017-09-08|2010-10-15||July 2008||2008-07-01|December 2013|2013-12-01|October 2009|Actual|2009-10-01|October 2009|Actual|2009-10-01||Interventional|||Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan|A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy|Terminated||N/A|4|Actual|H. Lee Moffitt Cancer Center and Research Institute|Due to limited sample size, we were unable to make definitive conclusions in this trial.|2||Funds for this project have been spent, and it is thereby terminated.|f||||t||||||||||2017-10-12 04:26:55.401896|2017-10-12 04:26:55.401896
NCT00718328|ClinicalTrials.gov processed this data on October 11, 2017|2008-07-15|2017-09-08|2017-05-07||October 2008||2008-10-01|September 2017|2017-09-01|June 2009|Actual|2009-06-01|June 2009|Actual|2009-06-01||Interventional|||Simvastatin For Intracerebral Hemorrhage Study|Simvastatin For Intracerebral Hemorrhage Study|Terminated||Phase 2|1|Actual|Johns Hopkins University||2||Poor recruitment, trial terminated|f||||t||||||||||2017-10-12 04:26:55.777031|2017-10-12 04:26:55.777031
NCT00703092|ClinicalTrials.gov processed this data on October 11, 2017|2008-06-20|2017-09-08|2014-05-27||February 2008||2008-02-01|September 2017|2017-09-01|March 2010|Actual|2010-03-01|March 2010|Actual|2010-03-01||Interventional|||Pilot Study:Role of Dietary Fiber in PCOS Anovulation|Pilot Study: Role of Dietary Fiber in PCOS Anovulation|Terminated||Phase 4|2|Actual|Virginia Commonwealth University||1||P.I. left University. Study terminated|f||||t||||||||||2017-10-12 04:26:56.111842|2017-10-12 04:26:56.111842
NCT00619983|ClinicalTrials.gov processed this data on October 11, 2017|2008-02-08|2017-09-08|2017-07-11||February 2008||2008-02-01|September 2017|2017-09-01|May 2013|Actual|2013-05-01|May 2013|Actual|2013-05-01||Interventional|||Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy|Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy|Terminated||Phase 4|22|Actual|Wake Forest University Health Sciences|We recruited only a small proportion of the planned enrollment in the period of grant funding, leading to early termination of the study. Also, the failure of the electronic diaries and loss of primary outcome data prevented the planned analysis.|4||Study terminated due to low enrollment|f||||t|t|f||||||||2017-10-12 04:27:00.477866|2017-10-12 04:27:00.477866
NCT01980888|ClinicalTrials.gov processed this data on October 12, 2017|2013-11-05|2017-09-11|2017-03-30||February 5, 2014|Actual|2014-02-05|September 2017|2017-09-01|June 16, 2016|Actual|2016-06-16|May 30, 2016|Actual|2016-05-30||Interventional||Intent-to-Treat (ITT) Analysis Set: who were randomized regardless of whether subjects received any study drug(s), or received a different regimen from the regimen to which they were randomized.|Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia|Terminated||Phase 3|311|Actual|Gilead Sciences|The study was terminated in agreement with the FDA due to urgent safety measures. Due to early study termination, the prespecified efficacy analyses were not conducted. The PFS data presented are investigator assessments rather than IRC assessments.|2|||f||||t|t|f||||||||2017-10-13 05:23:22.911595|2017-10-13 05:23:22.911595
NCT01597791|ClinicalTrials.gov processed this data on October 12, 2017|2012-05-10|2017-09-12|2017-09-12||March 22, 2012|Actual|2012-03-22|September 2017|2017-09-01|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Combined Spinal Epidural Urinary Retention|Do Women Receiving Low Dose Combined Spinal Epidural for Labor Analgesia Exhibit Less Bacteriuria Using a Urinary Retention Protocol Versus Routine Urinary Catheter Placement?|Terminated||N/A|56|Actual|Northwestern University|The study was terminated early because of difficulty using the ultrasound device to estimate urinary bladder capacity and residual levels.|2||Change in procedure.US technically challenging.|f||||f||||||||||2017-10-13 05:29:50.774411|2017-10-13 05:29:50.774411
NCT01061671|ClinicalTrials.gov processed this data on October 12, 2017|2010-02-02|2017-10-09|2015-01-29||March 2010||2010-03-01|October 2017|2017-10-01|January 2014|Actual|2014-01-01|January 2014|Actual|2014-01-01||Interventional|STATCOPE||Simvastatin Therapy for Moderate and Severe COPD|Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)|Terminated||Phase 3|885|Actual|University of Minnesota - Clinical and Translational Science Institute|Early termination by the Data and Safety Monitoring Board due to futility in respect to a treatment effect. The original study population goal was 1200 and the study was terminated at 885 participants.|2||Futility|f||||t||||||||||2017-10-13 05:39:14.570246|2017-10-13 05:39:14.570246
NCT00745615|ClinicalTrials.gov processed this data on October 12, 2017|2008-09-02|2017-10-09|||December 31, 2006|Actual|2006-12-31|October 2017|2017-10-01|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease|An Active Extension of LAQ/5062 Study. a Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group Study, to Evaluate the Safety, Tolerability and Efficacy of Two Doses (0.3 mg and 0.6 mg) of Laquinimod, Orally Administered in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects (Study LAQ/5063 Active Double-Blind Phase) Followed by an Open Label Phase of Laquinimod 0.6 mg Daily (LAQ/5063 OL)|Terminated||Phase 2|209|Actual|Teva Pharmaceutical Industries||2||"Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the   study drug in the relevant dose."|f||||t|t|f||||||||2017-10-13 05:44:54.122575|2017-10-13 05:44:54.122575
NCT03190798|ClinicalTrials.gov processed this data on October 13, 2017|2017-06-15|2017-10-10|||September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-01|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effects of Canagliflozin on Intravascular Volume and Hemodynamics|A Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study to Evaluate the Effects of Canagliflozin on Intravascular Volume and Hemodynamics in Subjects With Type 2 Diabetes Mellitus and Heart Failure|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center at San Antonio||2||Study has been withdrawn from IRB review pending IND revision|f||||t|t|f||||||||2017-10-15 05:31:25.850262|2017-10-15 05:31:25.850262
NCT02929407|ClinicalTrials.gov processed this data on October 13, 2017|2016-09-13|2017-10-11|||November 2016|Actual|2016-11-01|October 2017|2017-10-01|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||A Study to Investigate the Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension|A Placebo Controlled, Double-blind, Randomised Trial Investigating Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics After Intravenous Administration of FE 204205 in Patients With Cirrhotic Portal Hypertension|Terminated||Phase 1|5|Actual|Ferring Pharmaceuticals||2||Trial terminated due to difficult recruitment|f||||||||||||||2017-10-15 05:33:04.357127|2017-10-15 05:33:04.357127
NCT02663752|ClinicalTrials.gov processed this data on October 13, 2017|2016-01-21|2017-07-20|||May 30, 2016|Actual|2016-05-30|July 2017|2017-07-01|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|EXPHAR||A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.|A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy in Hematological Centers in Belgium Using Gene Expressing Profiling From Baseline Bone Marrow.|Terminated||Phase 4|1|Actual|Novartis||1||The trial was terminated due to low enrollment.|f||||t|f|f||||||||2017-10-15 05:35:16.557972|2017-10-15 05:35:16.557972
NCT02506101|ClinicalTrials.gov processed this data on October 13, 2017|2015-07-21|2016-10-17|||July 2015||2015-07-01|October 2016|2016-10-01|July 2017|Anticipated|2017-07-01|January 2017|Anticipated|2017-01-01||Interventional|||Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo|Randomized, Split-Body, Single-Blinded Clinical Trial of Narrow Band-Ultraviolet B (NB-UVB) Treatment for Vitiligo|Terminated||Phase 4|2|Actual|Johns Hopkins University||2||"The study was terminated due to lack of enrollment and staff availability to administer   treatment."|f||||f||||||||||2017-10-15 05:37:10.149475|2017-10-15 05:37:10.149475
NCT02151383|ClinicalTrials.gov processed this data on October 13, 2017|2014-05-28|2017-05-24|||September 5, 2014|Actual|2014-09-05|May 2017|2017-05-01|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|RELAX-PEDS-PK||Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure|Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure|Terminated||Phase 2|18|Actual|Novartis||1||Study was terminated based on results from pivotal adult AHF study CRLX030A2301|f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
NCT02071706|ClinicalTrials.gov processed this data on October 13, 2017|2014-02-23|2014-12-01|||January 2014||2014-01-01|December 2014|2014-12-01|August 2014|Actual|2014-08-01|August 2014|Actual|2014-08-01||Interventional|PET/MR_ZURICH||Clinical Evaluation of an Integrated PET/MRI System|Clinical Evaluation of an Integrated PET/MRI System|Terminated||N/A|56|Actual|GE Healthcare||1||"study terminated: the sponsor believes sufficient data has been collected to support regulatory   submissions."|f||||f||||||||||2017-10-15 05:42:56.990941|2017-10-15 05:42:56.990941
NCT02047500|ClinicalTrials.gov processed this data on October 13, 2017|2014-01-24|2016-06-09|||January 2014||2014-01-01|June 2016|2016-06-01|May 2016|Actual|2016-05-01|September 2015|Actual|2015-09-01||Interventional|||Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer|An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma|Terminated||Phase 1|19|Actual|EMD Serono||1||"The trial has been terminated earlier following the company decision to discontinue the   clinical development of Evofosfamide"|f||||||||||||||2017-10-15 05:43:18.738992|2017-10-15 05:43:18.738992
NCT02014649|ClinicalTrials.gov processed this data on October 13, 2017|2013-11-24|2016-03-22||2015-09-17|November 2013||2013-11-01|March 2016|2016-03-01|May 2014|Actual|2014-05-01|April 2014|Actual|2014-04-01||Interventional|FROSTY||Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza|Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B|Terminated||Phase 1/Phase 2|15|Actual|Aviragen Therapeutics||2||Study was terminated as per BARDA decision to terminate contract.|f||||t||||||||||2017-10-15 05:43:50.684343|2017-10-15 05:43:50.684343
NCT01876251|ClinicalTrials.gov processed this data on October 13, 2017|2013-06-10|2017-03-24|||November 2013||2013-11-01|January 2016|2016-01-01|December 2015|Actual|2015-12-01|December 2015|Actual|2015-12-01||Interventional|||A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer|Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer|Terminated||Phase 1|30|Actual|Pfizer||1||"The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014   development. There were no safety/efficacy concerns behind the decision."|f||||f||||||||||2017-10-15 05:45:46.266474|2017-10-15 05:45:46.266474
NCT01777256|ClinicalTrials.gov processed this data on October 13, 2017|2013-01-24|2017-04-25|||March 1, 2013||2013-03-01|April 2017|2017-04-01|March 31, 2014|Actual|2014-03-31|March 1, 2014|Actual|2014-03-01||Interventional|||An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184|An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus|Terminated||Phase 2|51|Actual|GlaxoSmithKline||5||"This study met a protocol defined futility criterion and will be terminated following   completion of the Follow Up Visit on the last subject randomised."|f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2017-10-15 05:47:23.533368|2017-10-15 05:47:23.533368
NCT01682148|ClinicalTrials.gov processed this data on October 13, 2017|2012-09-06|2015-04-28|||September 2012||2012-09-01|April 2015|2015-04-01|March 2015|Actual|2015-03-01|March 2015|Actual|2015-03-01||Interventional|NMJ||Neuro Muscular Junction Study|A Phase III Prospective, Multi-center, Randomised, Evaluator-blinded Study to Compare Neuromuscular Junction (NMJ) Targeted Technique for Dysport® Injections in Upper Limb Spasticity Post Stroke or Traumatic Brain Injury to the Technique Used in Current Clinical Practice|Terminated||Phase 3|101|Actual|Ipsen||2||The study was terminated early due to slow recruitment.|f||||f||||||||||2017-10-15 05:48:58.022721|2017-10-15 05:48:58.022721
NCT01570192|ClinicalTrials.gov processed this data on October 13, 2017|2012-03-22|2017-09-01|2016-12-22|2016-03-15|September 2010||2010-09-01|September 2017|2017-09-01|April 2015|Actual|2015-04-01|April 2015|Actual|2015-04-01||Interventional||Number of patients enrolled in the study and who had a baseline BAL.|Clinical Trials to Reduce the Risk of Antimicrobial Resistance|Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation|Terminated||Phase 2|43|Actual|University of Florida||2||NIAID terminated the study due to low subject enrollment|f||||t|t|f||||||||2017-10-15 05:50:40.101428|2017-10-15 05:50:40.101428
NCT01480245|ClinicalTrials.gov processed this data on October 13, 2017|2011-11-23|2017-03-21|||September 2011||2011-09-01|March 2017|2017-03-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy|An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of GSK2402968 in Subjects With Duchenne Muscular Dystrophy|Terminated||Phase 3|233|Actual|GlaxoSmithKline||3||"The study was formally terminated given that GSK is not submitting an application for   regulatory approval for drisapersen in Duchenne Muscular Dystrophy."|f||||f||||||||||2017-10-15 05:51:52.302532|2017-10-15 05:51:52.302532
NCT01465516|ClinicalTrials.gov processed this data on October 13, 2017|2011-11-02|2015-06-27|||November 2011||2011-11-01|June 2015|2015-06-01|December 2013|Actual|2013-12-01|December 2013|Actual|2013-12-01||Observational|||Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir|Response Guided Therapy (RGT) for Boceprevir Combined With Peginterferon Alpha-2b Plus Ribavirin in Naïve Hispanic Patients With Genotype 1 Hepatitis C Infection|Terminated||N/A|105|Actual|Arrowhead Regional Medical Center|||1|"The study was terminated and recruitment was capped because of the new changes in hepatitis C   market"|f||||f||||||Samples With DNA|"     Blood   "|||2017-10-15 05:52:05.838209|2017-10-15 05:52:05.838209
NCT01452516|ClinicalTrials.gov processed this data on October 13, 2017|2011-09-02|2016-11-07||2014-10-28|July 2010||2010-07-01|November 2016|2016-11-01|September 2013|Actual|2013-09-01|September 2013|Actual|2013-09-01||Interventional|||Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions|A Prospective, Multi-Center, Nonrandomized Study to Assess Lumbar Fusion Using Interbody Cages With Autograft in Conjunction With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive|Terminated||N/A|28|Actual|Pioneer Surgical Technology, Inc.||1||Study was terminated due to slow accrual rate.|f||||f||||||||No||2017-10-15 05:52:17.296877|2017-10-15 05:52:17.296877
NCT01428440|ClinicalTrials.gov processed this data on October 13, 2017|2011-08-25|2017-01-11|||December 2009||2009-12-01|January 2017|2017-01-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional|||PET Study to Study Tumour Apoptosis|A Positron Emission Tomography (PET) Study to Evaluate 18FML10 as an Imaging Agent for Tumour Apoptosis|Terminated||Phase 2|7|Actual|GlaxoSmithKline||1||"The study was terminated early as the results did not support study objectives and were not as   significant as expected."|f||||f||||||||||2017-10-15 05:52:35.472602|2017-10-15 05:52:35.472602
NCT01331499|ClinicalTrials.gov processed this data on October 13, 2017|2011-04-06|2012-06-06|||April 2011||2011-04-01|June 2012|2012-06-01|April 2013|Anticipated|2013-04-01|December 2012|Anticipated|2012-12-01||Interventional|||Salient Aquamantys Spine Trial|A Post-Market, Prospective, Multicenter, Randomized Trial Comparing the Use of Standard of Care Blood Sparing Techniques With and Without the Aquamantys System to Facilitate Hemostasis in Subjects Undergoing Multi-level Spinal Fusions|Terminated||Phase 4|12|Actual|Salient Surgical Technologies||2||Study terminated due to Medtronic acquisition|f||||f||||||||||2017-10-15 05:54:00.944772|2017-10-15 05:54:00.944772
NCT01279187|ClinicalTrials.gov processed this data on October 13, 2017|2011-01-18|2016-04-20|||February 2011||2011-02-01|April 2016|2016-04-01|November 2015|Actual|2015-11-01|March 2015|Actual|2015-03-01||Interventional|||The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone|The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone|Terminated||Phase 2|28|Actual|University of Michigan||2||Study was terminated due to patient complications unrelated to study drugs|f||||f||||||||No||2017-10-15 05:54:52.27437|2017-10-15 05:54:52.27437
NCT01257542|ClinicalTrials.gov processed this data on October 13, 2017|2010-12-07|2012-08-21|2012-08-21|2012-02-15|December 2010||2010-12-01|August 2012|2012-08-01|March 2011|Actual|2011-03-01|March 2011|Actual|2011-03-01||Interventional|||Acute Cough Study In Children|A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose, Pilot Study To Evaluate Efficacy Of Dextromethorphan Hydrobromide On Acute Cough In A Pediatric Population|Terminated||Phase 4|140|Actual|Pfizer|Due to methodological issues during study conduct, the study was terminated after only less than 50% of the targeted enrollment was achieved.|2||See termination reason in detailed description.|f||||f||||||||||2017-10-15 05:55:24.728294|2017-10-15 05:55:24.728294
NCT01232556|ClinicalTrials.gov processed this data on October 13, 2017|2010-10-27|2014-05-29||2014-05-29|April 2011||2011-04-01|May 2014|2014-05-01|March 2014|Actual|2014-03-01|March 2014|Actual|2014-03-01||Interventional|||A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy|An Open-Label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin Administered In Combination With Rituximab Compared To Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who Are Not Candidates For Intensive High-Dose Chemotherapy|Terminated||Phase 3|340|Actual|Pfizer||2||"The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected safety   issues were identified."|f||||t||||||||||2017-10-15 05:55:50.099363|2017-10-15 05:55:50.099363
NCT01179191|ClinicalTrials.gov processed this data on October 13, 2017|2010-07-30|2012-10-09|2012-07-30|2012-04-05|August 2010||2010-08-01|October 2012|2012-10-01|April 2011|Actual|2011-04-01|April 2011|Actual|2011-04-01||Interventional|ConvERT||Conversion to Embeda With Rescue Trial|A Multi-Center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, With Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion|Terminated||Phase 4|684|Actual|Pfizer|The study was prematurely terminated due to drug supply issues.|1||See termination reason in detailed description.|f||||f||||||||||2017-10-15 05:56:45.621761|2017-10-15 05:56:45.621761
NCT01164098|ClinicalTrials.gov processed this data on October 13, 2017|2010-07-15|2017-08-25||2017-08-16|February 2012||2012-02-01|August 2017|2017-08-01|October 2016|Actual|2016-10-01|October 2016|Actual|2016-10-01||Interventional|||Rituximab to Prevent Recurrence of Proteinuria|The Use of Rituximab to Prevent Recurrence of Proteinuria in Patients Receiving Kidney Transplant for FSGS|Terminated||Phase 3|43|Actual|University of Miami||2||Voluntarily terminated by PI due to lack of feasibility.|f||||f||||||||||2017-10-15 05:57:03.359029|2017-10-15 05:57:03.359029
NCT01038856|ClinicalTrials.gov processed this data on October 13, 2017|2009-12-22|2014-05-19|||December 2009||2009-12-01|May 2014|2014-05-01|February 2014|Actual|2014-02-01|December 2012|Actual|2012-12-01||Interventional|||Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera|Phase II Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera|Terminated||Phase 2|6|Actual|University of Oklahoma||1||The study was terminated by the sponsor|f||||t||||||||||2017-10-15 05:59:00.489638|2017-10-15 05:59:00.489638
NCT00961207|ClinicalTrials.gov processed this data on October 13, 2017|2009-08-17|2013-10-24|||August 2009||2009-08-01|October 2013|2013-10-01|September 2012|Actual|2012-09-01|July 2012|Actual|2012-07-01||Interventional|||Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients|Study of Triple Blockade of the Renin Angiotensin Aldosterone System (RAAS) in Diabetic (Type 1&2) Proteinuric Patients With (ACE-, ARB, DRI)|Terminated||Phase 4|2|Actual|John H. Stroger Hospital||2||Altitude trial which used similar drugs was terminated due to increased ADR.|f||||t||||||||||2017-10-15 06:00:30.054801|2017-10-15 06:00:30.054801
NCT00944216|ClinicalTrials.gov processed this data on October 13, 2017|2009-07-21|2010-01-19|||June 2009||2009-06-01|July 2009|2009-07-01|January 2010||2010-01-01|January 2010|Anticipated|2010-01-01||Interventional|||Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study|Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study|Terminated||Phase 4|10|Anticipated|Wright State University||1||terminated due to administrative reasons.|f||||t||||||||||2017-10-15 06:00:46.46305|2017-10-15 06:00:46.46305
NCT00927784|ClinicalTrials.gov processed this data on October 13, 2017|2009-06-23|2013-05-15|||August 2009||2009-08-01|May 2013|2013-05-01|February 2011|Actual|2011-02-01|May 2010|Actual|2010-05-01||Interventional|||Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD|The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Bridge to Transplant Patients|Terminated||Phase 2|10|Actual|Icahn School of Medicine at Mount Sinai||2||The enrollment has been terminated by the NHLBI for administrative reasons.|f||||t||||||||||2017-10-15 06:01:02.58694|2017-10-15 06:01:02.58694
NCT00920556|ClinicalTrials.gov processed this data on October 13, 2017|2009-06-12|2016-11-30|||March 2009||2009-03-01|November 2016|2016-11-01|November 2010|Actual|2010-11-01|November 2010|Actual|2010-11-01||Interventional|||A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma|A Phase II, Open-Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma|Terminated||Phase 2|24|Actual|GlaxoSmithKline||1||Study terminated.24 subjects enrolled;provided adequate data for decision making.|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2017-10-15 06:01:10.498245|2017-10-15 06:01:10.498245
NCT00806351|ClinicalTrials.gov processed this data on October 13, 2017|2008-11-26|2012-11-20|2012-11-20|2012-10-11|August 2009||2009-08-01|November 2012|2012-11-01|October 2011|Actual|2011-10-01|October 2011|Actual|2011-10-01||Interventional|||An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System|Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection|Terminated||Phase 3|21|Actual|Pfizer|Study prematurely terminated due to slow enrollment, not due to safety issues. Meaningful interpretation and comparison of treatment outcomes with caspofungin was difficult due to low number of participants (n=3) with confirmed Candida infection.|2||"The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not   terminate due to any safety issues or concerns."|f||||t||||||||||2017-10-15 06:03:08.552216|2017-10-15 06:03:08.552216
NCT00796445|ClinicalTrials.gov processed this data on October 13, 2017|2008-11-21|2016-09-29||2012-11-16|December 2008||2008-12-01|September 2016|2016-09-01|January 2016|Actual|2016-01-01|September 2015|Actual|2015-09-01||Interventional|||A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor|GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma|Terminated||Phase 3|1351|Actual|GlaxoSmithKline||2||"The study was terminated early following assessment of the two co-primary endpoints showing the   lack of efficacy of the study product."|f||||||||||||||2017-10-15 06:03:20.100848|2017-10-15 06:03:20.100848
NCT00745823|ClinicalTrials.gov processed this data on October 13, 2017|2008-09-02|2017-02-14|2012-03-06|2011-09-29|September 2008||2008-09-01|February 2017|2017-02-01|May 2011|Actual|2011-05-01|October 2010|Actual|2010-10-01||Interventional|||A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)|A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients|Terminated||Phase 3|775|Actual|Merck Sharp & Dohme Corp.|The study was terminated before the 96-week efficacy analysis. Adverse event data were collected for the entire treatment period up to a maximum of Week 108, which defines the Overall Study period.|2||"Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg   once daily versus raltegravir 400 mg twice daily"|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
NCT00738972|ClinicalTrials.gov processed this data on October 13, 2017|2008-08-19|2013-08-17|2013-07-20|2011-08-16|January 2008||2008-01-01|August 2013|2013-08-01|August 2010|Actual|2010-08-01|August 2010|Actual|2010-08-01||Interventional|||Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)|Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients.|Terminated||Phase 3|12|Actual|Fundación Lindavista del Corazón AC|This study was terminated early and due to sample size it was not possible to perform further statistical analyses.|4||"Study terminated early due to sample size, not possible to perform further statistical   analysis."|f||||||||||||||2017-10-15 06:04:17.466651|2017-10-15 06:04:17.466651
NCT00706446|ClinicalTrials.gov processed this data on October 13, 2017|2008-06-25|2017-05-05|2017-03-17|2012-05-17|June 2008||2008-06-01|May 2017|2017-05-01|September 2011|Actual|2011-09-01|June 2010|Actual|2010-06-01||Interventional|GABLE||The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations|Genotype Stratified Treatment With Anticholinergic vs. Beta-agonist (Long Acting) and Exacerbations (GABLE)|Terminated||N/A|255|Actual|Brigham and Women's Hospital||6||Funding was terminated|f||||f||||||||No||2017-10-15 06:04:50.70349|2017-10-15 06:04:50.70349
NCT00706238|ClinicalTrials.gov processed this data on October 13, 2017|2008-06-25|2014-06-19||2011-12-20|September 2008||2008-09-01|June 2014|2014-06-01|January 2011|Actual|2011-01-01|January 2011|Actual|2011-01-01||Interventional|||MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma|Study of GSK1203486A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma|Terminated||Phase 2|6|Actual|GlaxoSmithKline||1||"The study was terminated early due to difficulties in recruiting subjects, not following   concerns for the safety or absence of clinical activity in patients."|f||||||||||||||2017-10-15 06:04:51.608684|2017-10-15 06:04:51.608684
NCT00631137|ClinicalTrials.gov processed this data on October 13, 2017|2008-03-06|2008-09-29|||January 2008||2008-01-01|March 2008|2008-03-01||||September 2008|Anticipated|2008-09-01||Interventional|||Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men Receiving Glucocorticoids for Newly Diagnosed High-Grade Glioma|A Randomized, Controlled Comparative Trial to Determine if Testosterone Gel Prevents Steroid Related Weakness in Brain Cancer Patients|Terminated||N/A|60|Anticipated|National Cancer Institute (NCI)||||Study terminated due to low accrual.|f||||||||||||||2017-10-15 06:06:01.202002|2017-10-15 06:06:01.202002
NCT00591162|ClinicalTrials.gov processed this data on October 13, 2017|2007-12-26|2014-06-05|||October 1992||1992-10-01|June 2014|2014-06-01|June 2008|Actual|2008-06-01|June 2008|Actual|2008-06-01||Interventional|||Bone Disease in Severely Burned Children|Bone Disease in Severely Burned Children|Terminated||Phase 2/Phase 3|254|Actual|The University of Texas Medical Branch, Galveston||1||terminated due to PI lab/duties affected by natural disaster.|f||||f||||||||||2017-10-15 06:06:43.192905|2017-10-15 06:06:43.192905
NCT00585208|ClinicalTrials.gov processed this data on October 13, 2017|2007-12-20|2013-05-08|||December 2007||2007-12-01|May 2013|2013-05-01|December 2010|Actual|2010-12-01|September 2010|Actual|2010-09-01||Interventional|||Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance|A Randomized, Double-Blind, Placebo-Controlled Study of Add-On Ramelteon in Ambulatory Bipolar I Disorder With Clinically Significant Sleep Disturbance|Terminated||Phase 3|21|Actual|Lindner Center of HOPE||2||sponsor terminated study|f||||f||||||||||2017-10-15 06:06:48.903128|2017-10-15 06:06:48.903128
NCT00488774|ClinicalTrials.gov processed this data on October 13, 2017|2007-06-18|2013-04-29|2013-04-29|2009-12-03|August 2007||2007-08-01|April 2013|2013-04-01|May 2009|Actual|2009-05-01|May 2009|Actual|2009-05-01||Interventional|||An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis|A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis|Terminated||Phase 2/Phase 3|291|Actual|Janssen Research & Development, LLC|Data collection was not considered complete for primary outcome measure because study was terminated prematurely.|4||Protocol was cancelled by company based on overall efficacy, no safety concern|f||||t||||||||||2017-10-15 06:08:29.422492|2017-10-15 06:08:29.422492
NCT00480025|ClinicalTrials.gov processed this data on October 13, 2017|2007-05-29|2015-11-19||2013-08-22|October 2007||2007-10-01|November 2015|2015-11-01|September 2014|Actual|2014-09-01|December 2013|Actual|2013-12-01||Interventional|||GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer|GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer|Terminated||Phase 3|2278|Actual|GlaxoSmithKline||2||"The study was terminated following assessment of the lack of efficacy of the study product by   the Independent Data monitoring Committee for the study."|f||||||||||||||2017-10-15 06:08:37.207688|2017-10-15 06:08:37.207688
NCT00455897|ClinicalTrials.gov processed this data on October 13, 2017|2007-04-02|2012-10-23|||December 2006||2006-12-01|October 2012|2012-10-01|July 2011|Actual|2011-07-01|July 2011|Actual|2011-07-01||Interventional|||CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma|Phase II Trial of CHOP-Rituximab Augmented With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma|Terminated||Phase 2|5|Actual|Massachusetts General Hospital||1||Accrual was too slow. Trial terminated|f||||||||||||||2017-10-15 06:09:05.939161|2017-10-15 06:09:05.939161
NCT00366080|ClinicalTrials.gov processed this data on October 13, 2017|2006-08-17|2017-03-09||2009-07-22|November 2006||2006-11-01|March 2017|2017-03-01|January 2008|Actual|2008-01-01|January 2008|Actual|2008-01-01||Interventional|||Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy|An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy.|Terminated||Phase 2|69|Actual|GlaxoSmithKline||||Study was terminated based on the interim results of a futility test.|f||||f||||||||||2017-10-15 06:10:26.237327|2017-10-15 06:10:26.237327
NCT00375752|ClinicalTrials.gov processed this data on October 13, 2017|2006-09-11|2017-06-06|2012-03-30|2011-12-09|June 1, 2006|Actual|2006-06-01|June 2017|2017-06-01|December 16, 2010|Actual|2010-12-16|December 16, 2010|Actual|2010-12-16||Interventional|FEMZONE||Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer|Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks)|Terminated||Phase 4|168|Actual|Novartis|Study terminated after 178 patients screened and 168 randomized, due to insufficient recruitment rate (no safety issues decided the reason to terminate study). LPLV for study was on 13-DEC-2010. LPLV of the 5-year follow-up period was on 03-FEB-2016.|2|||f||||f||||||||Undecided||2017-10-15 06:10:16.479227|2017-10-15 06:10:16.479227
NCT00303303|ClinicalTrials.gov processed this data on October 13, 2017|2006-03-14|2008-07-16|||April 2005||2005-04-01|July 2008|2008-07-01|May 2008|Actual|2008-05-01|May 2008|Actual|2008-05-01||Interventional|||The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations|The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations|Terminated||Phase 4|25|Anticipated|Carolinas Healthcare System||3||Study terminated due to declining enrollment; data analysis proceeding.|f||||t||||||||||2017-10-15 06:11:15.691118|2017-10-15 06:11:15.691118
NCT00217217|ClinicalTrials.gov processed this data on October 13, 2017|2005-09-15|2012-03-13|||September 2004||2004-09-01|March 2012|2012-03-01|January 2012|Actual|2012-01-01|December 2011|Actual|2011-12-01||Interventional|||Low Field Magnetic Stimulation Treatment for Bipolar Depression|Low Field Magnetic Stimulation in Bipolar Depression|Terminated||Phase 3|13|Actual|Mclean Hospital||2||Study was terminated for lack of recruitment.|f||||t||||||||||2017-10-15 06:12:23.196781|2017-10-15 06:12:23.196781
NCT00880048|ClinicalTrials.gov processed this data on October 13, 2017|2009-04-09|2017-09-12|2017-08-09|2012-02-23|March 11, 2009|Actual|2009-03-11|August 2017|2017-08-01|June 21, 2010|Actual|2010-06-21|June 21, 2010|Actual|2010-06-21||Interventional|Orvepitant MDD||A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|Terminated||Phase 2|343|Actual|GlaxoSmithKline|The study was terminated early upon the recommendation of an Independent Data Monitoring Committee. At the time the trial was terminated 343 participants had been randomized, compared to a target of 348 participants.|3||To allow assessment of isolated events of seizure during program|f||||t||||||||||2017-10-16 04:12:20.277388|2017-10-16 04:12:20.277388
NCT02810873|ClinicalTrials.gov processed this data on October 16, 2017|2016-06-08|2017-08-22|||September 2008||2008-09-01|August 2017|2017-08-01|July 2012|Actual|2012-07-01|May 2012|Actual|2012-05-01||Interventional|||Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer|PET Imaging of Breast Cancer Using Oncogene Expression|Terminated||N/A|20|Actual|Thomas Jefferson University||1||Study terminated by PI|f||||t||t|f|||||||2017-10-17 04:24:46.671898|2017-10-17 04:24:46.671898
NCT02377466|ClinicalTrials.gov processed this data on October 16, 2017|2015-02-26|2017-10-12|||February 29, 2016|Actual|2016-02-29|October 2017|2017-10-01|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|NEWBORN-1||A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor|Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor|Terminated||Phase 3|19|Actual|GlaxoSmithKline||2||Asset terminated by PIB|f||||t||||||||||2017-10-17 04:25:51.317301|2017-10-17 04:25:51.317301
NCT01847885|ClinicalTrials.gov processed this data on October 16, 2017|2013-04-23|2017-10-12|2017-09-07||April 2013||2013-04-01|October 2017|2017-10-01|November 14, 2016|Actual|2016-11-14|August 21, 2015|Actual|2015-08-21||Interventional||The full analysis set includes all randomized patients who continued to meet all eligibility criteria prior to the time of lead placement.|Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System|A Randomized, Double-Blinded, Placebo-Control Multicenter Pivotal Study of the Smartpatch Peripheral Nerve Stimulation (PNS) System for the Treatment of Chronic Post-Stroke Shoulder Pain|Completed||N/A|88|Actual|SPR Therapeutics, LLC|This study included a pre-planned interim analysis for sample size re-estimation. The study was suspended because the treatment effect (both groups experienced clinically significant reductions in pain) required a sample size more than 90 subjects.|2|||f||||t||||||||||2017-10-17 04:26:38.49725|2017-10-17 04:26:38.49725
